Document:

EX-10.11

 Exhibit 10.11 

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE VIVIDION THERAPEUTICS, INC. HAS DETERMINED THAT
IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT VIVIDION THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. 
 Execution Copy 

Collaboration, Option and License Agreement 

This Agreement is entered into with effect as of the Effective Date (as defined below) 

by and between 
 F. Hoffmann-La Roche Ltd 
 with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland
(“Roche Basel”) 
 and 
 Hoffmann-La Roche Inc. 
 with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey
07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”) 
 on the one hand 

and 
 Vividion Therapeutics, Inc. 

with an office and place of business at 5820 Nancy Ridge Drive, San Diego, CA 92121, USA (“Vividion”) 

on the other hand. 
  

 Table of Contents 

 

					
	 1. Definitions
	  	 	2	 
	 1.1 Accounting Standard
	  	 	2	 
	 1.2 Affiliate
	  	 	2	 
	 1.3 Agreement
	  	 	2	 
	 1.4 Agreement Term
	  	 	2	 
	 1.5 Applicable Law
	  	 	2	 
	 1.6 Business Day
	  	 	2	 
	 1.7 Calendar Quarter
	  	 	2	 
	 1.8 Calendar Year
	  	 	3	 
	 1.9 CCS
	  	 	3	 
	 1.10 CCS Criteria
	  	 	3	 
	 1.11 CCS Data Package
	  	 	3	 
	 1.12 Change of Control
	  	 	3	 
	 1.13 Change of Control Group
	  	 	3	 
	 1.14 Clinical Plan
	  	 	3	 
	 1.15 Clinical Study
	  	 	3	 
	 1.16 Collaboration
	  	 	3	 
	 1.17 Collaboration Plan
	  	 	4	 
	 1.18 Collaboration Target
	  	 	4	 
	 1.19 Collaboration Term
	  	 	4	 
	 1.20 Combination Product
	  	 	4	 
	 1.21 Commercially Reasonable Efforts
	  	 	4	 
	 1.22 Companion Diagnostic
	  	 	5	 
	 1.23 Completion
	  	 	5	 
	 1.24 Composition of Matter Claim
	  	 	5	 
	 1.25 Compound
	  	 	5	 
	 1.26 Compulsory Sublicense Compensation
	  	 	5	 
	 1.27 Confidential Information
	  	 	5	 
	 1.28 Continuation Election Notice
	  	 	6	 
	 1.29 Control
	  	 	6	 
	 1.30 Covalent Degrader
	  	 	6	 
	 1.31 Covalent Degrader Target
	  	 	6	 
	 1.32 Covalent Inhibitor
	  	 	6	 
	 1.33 Covalent Inhibitor Target
	  	 	7	 
	 1.34 Cover
	  	 	7	 
	 1.35 CRO
	  	 	7	 
	 1.36 “Delivery Date”
	  	 	7	 
	 1.37 Derivative
	  	 	7	 
	 1.38 Development
	  	 	7	 
	 1.39 Development Cost
	  	 	7	 
	 1.40 Development Plan
	  	 	8	 
	 1.41 Directed To
	  	 	8	 
	 1.42 E3 Ligase
	  	 	8	 
	 1.43 E3 Ligase Engager
	  	 	8	 
	 1.44 E3 Module
	  	 	8	 
	 1.45 E3 Module Data Package
	  	 	8	 
	 1.46 Effective Date
	  	 	8	 
	 1.47 Entry into GLP Tox
	  	 	8	 
	 1.48 EU
	  	 	8	 
	 1.49 Excluded Claim
	  	 	8	 

  
 -ii- 

					
	 1.50 Excluded E3 Ligases
	  	 	9	 
	 1.51 Expert
	  	 	9	 
	 1.52 FDA
	  	 	9	 
	 1.53 FDCA
	  	 	9	 
	 1.54 Field
	  	 	9	 
	 1.55 Filing
	  	 	9	 
	 1.56 Financial Appendix
	  	 	9	 
	 1.57 First Commercial Sale
	  	 	9	 
	 1.58 Generic Product
	  	 	9	 
	 1.59 GLP Tox Study
	  	 	10	 
	 1.60 Handle
	  	 	10	 
	 1.61 Hit
	  	 	10	 
	 1.62 HSR
	  	 	10	 
	 1.63 HSR Filing
	  	 	10	 
	 1.64 ICD-10
	  	 	10	 
	 1.65 IFRS
	  	 	10	 
	 1.66 IND
	  	 	11	 
	 1.67 Indication
	  	 	11	 
	 1.68 Initiation
	  	 	11	 
	 1.69 Insolvency Event
	  	 	11	 
	 1.70 Invention
	  	 	11	 
	 1.71 Joint Know-How
	  	 	11	 
	 1.72 Joint Patents
	  	 	11	 
	 1.73 JOT
	  	 	12	 
	 1.74 JRC
	  	 	12	 
	 1.75 JDC
	  	 	12	 
	 1.76 Know-How
	  	 	12	 
	 1.77 Licensed Program
	  	 	12	 
	 1.78 Major Market
	  	 	12	 
	 1.79 Net Sales
	  	 	12	 
	 1.80 Nominated Program
	  	 	13	 
	 1.81 Option Right
	  	 	13	 
	 1.82 Option Data Package
	  	 	13	 
	 1.83 Option Exercise Date
	  	 	13	 
	 1.84 Option Exercise Notice
	  	 	13	 
	 1.85 Option Period
	  	 	13	 
	 1.86 Party
	  	 	13	 
	 1.87 Patented E3 Module Product
	  	 	13	 
	 1.88 Patents
	  	 	13	 
	 1.89 Pharmacovigilance Agreement
	  	 	14	 
	 1.90 PoC Costs
	  	 	14	 
	 1.91 PoC Study
	  	 	14	 
	 1.92 PoC Data Package
	  	 	14	 
	 1.93 Phase I Study
	  	 	14	 
	 1.94 Phase II Study
	  	 	14	 
	 1.95 Phase III Study
	  	 	14	 
	 1.96 Phase IV Study
	  	 	14	 
	 1.97 Pivotal Study
	  	 	15	 
	 1.98 Product
	  	 	15	 
	 1.99 Product Specific Claim
	  	 	15	 
	 1.100 Product Specific Patent
	  	 	15	 

  
 -iii- 

					
	 1.101 Profit and Loss Sharing
	  	 	15	 
	 1.102 Program
	  	 	15	 
	 1.103 Preclinical Plan
	  	 	15	 
	 1.104 Regulatory Approval
	  	 	16	 
	 1.105 Regulatory Authority
	  	 	16	 
	 1.106 Reserved Programs
	  	 	16	 
	 1.107 Roche Group
	  	 	16	 
	 1.108 Roche Know-How
	  	 	16	 
	 1.109 Roche Patent
	  	 	16	 
	 1.110 Roche PoC Product
	  	 	16	 
	 1.111 Roche Program
	  	 	17	 
	 1.112 Roche Target Ligand
	  	 	17	 
	 1.113 Royalty Term
	  	 	17	 
	 1.114 Sales
	  	 	17	 
	 1.115 Selection Effective Date
	  	 	18	 
	 1.116 Shared Product
	  	 	18	 
	 1.117 Sublicensee
	  	 	18	 
	 1.118 Target
	  	 	18	 
	 1.119 Territory
	  	 	18	 
	 1.120 Third Party
	  	 	18	 
	 1.121 Transfer Activities
	  	 	19	 
	 1.122 US
	  	 	19	 
	 1.123 US$
	  	 	19	 
	 1.124 Validated Hit
	  	 	19	 
	 1.125 Validated Hit Data Package
	  	 	19	 
	 1.126 Valid Claim
	  	 	19	 
	 1.127 Vividion Core Platform Technology
	  	 	19	 
	 1.128 Vividion CRG Technology
	  	 	19	 
	 1.129 Vividion E3 Know-How
	  	 	19	 
	 1.130 Vividion E3 Patents
	  	 	20	 
	 1.131 Vividion E3 Technology
	  	 	20	 
	 1.132 Vividion Know-How
	  	 	20	 
	 1.133 Vividion Patents
	  	 	20	 
	 1.134 Vividion Program
	  	 	20	 
	 1.135 Additional Definitions
	  	 	21	 
	 2. Collaboration
	  	 	24	 
	 2.1 Conduct and Scope of the Collaboration
	  	 	24	 
	 2.2 Collaboration Plan
	  	 	25	 
	 2.3 Target Nomination
	  	 	25	 
	 2.4 Target Gatekeeping Process
	  	 	26	 
	 2.5 Program Nomination
	  	 	28	 
	 2.6 Duration
	  	 	32	 
	 2.7 Cost
	  	 	33	 
	 2.8 Progress Reports
	  	 	33	 
	 2.9 Records
	  	 	33	 
	 2.10 Materials
	  	 	34	 
	 3. Roche Program and Vividion Program
	  	 	34	 
	 3.1 Roche Program
	  	 	34	 
	 3.2 Vividion Program
	  	 	34	 
	 4. Option Rights
	  	 	38	 
	 4.1 Roche Option for a Vividion Program
	  	 	38	 

  
 -iv- 

					
	 4.2 Vividion Option for Optioned Roche Program
	  	 	38	 
	 4.3 Roche PoC Option for a Vividion PoC Program
	  	 	41	 
	 4.4 Vividion Sharing Option
	  	 	41	 
	 4.5 E3 Module Option
	  	 	42	 
	 4.6 Option Not Exercised
	  	 	43	 
	 4.7 Information Sharing for Option Rights
	  	 	45	 
	 4.8 Completion of Incomplete Data Packages
	  	 	46	 
	 4.9 Inspection Right
	  	 	46	 
	 4.10 Transfer following Option Right Exercise
	  	 	46	 
	 5. Licenses
	  	 	46	 
	 5.1 Research License
	  	 	46	 
	 5.2 Commercial License
	  	 	46	 
	 5.3 Sublicense
	  	 	48	 
	 5.4 Excluded Affiliates
	  	 	50	 
	 5.5 Cysteine Reactive Groups
	  	 	50	 
	 6. Exclusivity
	  	 	51	 
	 6.1 Collaboration Term; Term of Vividion Activities
	  	 	51	 
	 6.2 Roche Programs; Optioned Roche Program
	  	 	51	 
	 6.3 Roche PoC Program; Shared Program
	  	 	51	 
	 6.4 Scope of Exclusivity
	  	 	51	 
	 6.5 Outside End Date for Roche Programs
	  	 	52	 
	 7. Diligence
	  	 	52	 
	 8. Governance
	  	 	52	 
	 8.1 Joint Research Committee
	  	 	52	 
	 8.2 JDC
	  	 	55	 
	 8.3 Information Exchange
	  	 	57	 
	 8.4 Subcommittees
	  	 	57	 
	 8.5 Joint Operational Teams
	  	 	57	 
	 8.6 Alliance Director
	  	 	58	 
	 8.7 Limitations of Authority
	  	 	58	 
	 8.8 Expenses
	  	 	58	 
	 8.9 Withdrawal
	  	 	58	 
	 9. Development
	  	 	58	 
	 9.1 Roche Responsibility
	  	 	58	 
	 9.2 Updates
	  	 	58	 
	 9.3 Payments to Roche for Shared Products
	  	 	59	 
	 9.4 Development Plan Amendments
	  	 	59	 
	 9.5 Development Cost Opt-Out
	  	 	59	 
	 10. Manufacture and Supply
	  	 	60	 
	 10.1 Pre-clinical and Clinical Supply of Products and
Shared Products
	  	 	60	 
	 10.2 Commercial Supply of Product
	  	 	61	 
	 10.3 Shipment
	  	 	61	 
	 10.4 Manufacturing Transfer
	  	 	61	 
	 11. Regulatory
	  	 	61	 
	 11.1 Responsibility
	  	 	61	 
	 11.2 Pharmacovigilance Agreement
	  	 	63	 
	 12. Commercialization
	  	 	63	 
	 12.1 Responsibility
	  	 	63	 
	 12.2 Updates to Vividion
	  	 	63	 
	 12.3 Termination of Profit and Loss Sharing by Vividion
	  	 	64	 
	 12.4 Conversion of Profit and Loss Sharing
	  	 	64	 

  
 -v- 

					
	 12.5 Launch Costs for Shared Product
	  	 	64	 
	 12.6 Medical Affairs
	  	 	65	 
	 13. Payment
	  	 	65	 
	 13.1 Initiation Payment
	  	 	65	 
	 13.2 Collaboration Term Extension Fee
	  	 	65	 
	 13.3 Roche E3 Module Payment
	  	 	65	 
	 13.4 Fees for Roche Programs
	  	 	66	 
	 13.5 Nomination Fee for Vividion Programs
	  	 	66	 
	 13.6 Fee for Optioned Roche Programs if Vividion does not exercise the Vividion Option
	  	 	66	 
	 13.7 Fees for Vividion PoC Programs
	  	 	66	 
	 13.8 Development Event Payments for Roche Programs and Optioned Roche Programs
	  	 	67	 
	 13.9 Development Milestones for Roche PoC Products
	  	 	68	 
	 13.10 Development Milestones for Shared Products
	  	 	68	 
	 13.11 Sales Based Events
	  	 	69	 
	 13.12 Royalty Payments
	  	 	72	 
	 13.13 Profit and Loss Sharing for Shared Products in the US
	  	 	76	 
	 13.14 Single Royalty.
	  	 	77	 
	 13.15 Disclosure of Payments
	  	 	77	 
	 13.16 Know-How Payments
	  	 	77	 
	 13.17 Different Products
	  	 	77	 
	 14. Accounting and reporting
	  	 	77	 
	 14.1 Timing of Payments
	  	 	77	 
	 14.2 Late Payment
	  	 	78	 
	 14.3 Method of Payment
	  	 	78	 
	 14.4 Currency Conversion
	  	 	78	 
	 14.5 Blocked Currency
	  	 	78	 
	 14.6 Non-Refundable and
Non-Creditable
	  	 	78	 
	 14.7 Reporting
	  	 	78	 
	 15. Taxes
	  	 	79	 
	 15.1 Withholding Taxes
	  	 	79	 
	 16. Auditing
	  	 	79	 
	 16.1 Right to Audit
	  	 	79	 
	 16.2 Audit Reports
	  	 	80	 
	 16.3 Over-or Underpayment
	  	 	80	 
	 17. Intellectual Property
	  	 	80	 
	 17.1 Ownership of Inventions
	  	 	80	 
	 17.2 German Statute on Employee’s Inventions
	  	 	81	 
	 17.3 Trademarks and Labeling
	  	 	82	 
	 17.4 Handling of Patents
	  	 	82	 
	 17.5 Handling of Product Specific Patents
	  	 	82	 
	 17.6 Patent Coordination Team
	  	 	85	 
	 17.7 Unified Patent Court (Europe)
	  	 	85	 
	 17.8 CREATE Act
	  	 	85	 
	 17.9 Infringement
	  	 	86	 
	 17.10 Defense
	  	 	87	 
	 17.11 Common Interest Disclosures
	  	 	88	 
	 17.12 Hatch-Waxman
	  	 	88	 
	 17.13 Patent Term Extensions
	  	 	89	 
	 18. Representations and Warranties
	  	 	89	 

  
 -vi- 

					
	 18.1 Vividion Representations and Warranties
	  	 	89	 
	 18.2 Roche Representations and Warranties.
	  	 	91	 
	 18.3 No Other Representations and Warranties
	  	 	92	 
	 19. Indemnification
	  	 	92	 
	 19.1 Indemnification by Roche
	  	 	92	 
	 19.2 Indemnification by Vividion
	  	 	92	 
	 19.3 Procedure
	  	 	93	 
	 20. Liability
	  	 	93	 
	 20.1 Limitation of Liability
	  	 	93	 
	 21. Obligation Not to Disclose Confidential Information
	  	 	93	 
	 21.1 Non-Use and
Non-Disclosure
	  	 	93	 
	 21.2 Permitted Disclosure
	  	 	93	 
	 21.3 Press Releases
	  	 	93	 
	 21.4 Publications
	  	 	94	 
	 21.5 Commercial Considerations
	  	 	95	 
	 22. Term and Termination
	  	 	96	 
	 22.2 Termination
	  	 	97	 
	 22.3 Consequences of Termination
	  	 	100	 
	 22.4 Survival
	  	 	108	 
	 23. Bankruptcy
	  	 	108	 
	 24. Miscellaneous
	  	 	108	 
	 24.1 Governing Law
	  	 	108	 
	 24.2 Disputes
	  	 	109	 
	 24.3 Arbitration
	  	 	109	 
	 24.4 Expedited Resolution
	  	 	111	 
	 24.5 Assignment
	  	 	112	 
	 24.6 Debarment
	  	 	112	 
	 24.7 Independent Contractor
	  	 	112	 
	 24.8 Unenforceable Provisions and Severability
	  	 	113	 
	 24.9 Waiver
	  	 	113	 
	 24.10 Force Majeure
	  	 	113	 
	 24.11 Interpretation
	  	 	113	 
	 24.12 Waiver of Rule of Construction
	  	 	114	 
	 24.13 Entire Understanding
	  	 	114	 
	 24.14 Amendments
	  	 	114	 
	 24.15 Invoices
	  	 	115	 
	 24.16 Notice
	  	 	115	 

  

  
 -vii- 

 Collaboration, Option and License Agreement 

WHEREAS, Vividion has expertise in proteome wide small molecule discovery approaches building on a proprietary library of small molecules designed to bind
covalently in a selective manner to target proteins; 
 WHEREAS, Vividion is applying its expertise to discover Covalent Inhibitors (as defined below) and
Covalent Degraders (as defined below) based on newly characterized E3 Ligases (as defined below); 
 WHEREAS, Roche has expertise in the research,
development, manufacturing and commercialization of pharmaceutical drugs, including small molecules, in a broad range of disease areas including oncology and immunology; 

WHEREAS, the Parties (as defined below) will combine their respective expertise by entering into a broad collaboration to discover, research and develop small
molecules against targets in oncology and immunology selected by Roche; 
 WHEREAS, for Covalent Inhibitors, the Parties will collaborate under a mutually
agreed Collaboration Plan (as defined below) to identify and validate screening hits and subsequently to validating such hits, Roche will select and the Parties will select programs, either as Roche Programs or as Vividion Programs (each as defined
below); 
 WHEREAS, for Covalent Degraders, Vividion will use its technology to identify and characterize E3 Ligases and identify selective covalent binders
to such ligases. Roche will provide molecules binding to target proteins; under a mutually agreed Collaboration Plan, Vividion will combine ligase binders and Roche’s target binders into Covalent Degraders and validate such molecules in-vitro; and following proof of in-vitro degradation, Roche will nominate and the Parties will select programs, either as Roche Programs or as Vividion Programs; 

WHEREAS, with regard to Vividion Programs, Vividion has the right to perform pre-clinical GLP-Tox study development activities and early clinical development up to proof-of-concept; 

WHEREAS, Roche is responsible for the development of products arising from Roche Programs, and from Vividion Programs after exercising its option rights, as
well as commercialization of such products worldwide and Vividion has certain rights to share worldwide development costs and has certain commercialization rights in the United States for Vividion Programs for which Roche has exercised its option;

 NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
  

	1.	 Definitions 

As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 

 

	1.1	 Accounting Standard 

The term “Accounting Standard” shall mean with respect to a given Party, its Affiliate, or its Sublicensee, either (a) IFRS or (b) United
States generally accepted accounting principles (GAAP), in either case, as currently used at the applicable time by, and as consistently applied by, such applicable Party or its Affiliate or Sublicensee. 

 

	1.2	 Affiliate 

The term “Affiliate” shall mean any individual, corporation, association or other business entity that directly or indirectly controls, is controlled
by, or is under common control with the entity in question, for so long as such control exists. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect ownership of more than fifty percent
(>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution,
regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“Chugai”) and/or its subsidiaries (if any) shall not be deemed as Affiliates of Roche
unless Roche provides written notice to Vividion of its desire to include Chugai and/or its respective subsidiaries (as applicable) as Affiliate(s) of Roche. 
  

	1.3	 Agreement 

The term “Agreement” shall mean this document including any and all appendices and amendments to it as may be added and/or amended from time to time
in accordance with the provisions of this Agreement. 
  

	1.4	 Agreement Term 

The term “Agreement Term” shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided
in Article 22, expiring on the date when no royalty or other payment obligations under this Agreement are or will become due. 
  

	1.5	 Applicable Law 

The term “Applicable Law” shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including
without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same is applicable to the performance by the Parties of their respective
obligations under this Agreement. 
  

	1.6	 Business Day 

The term “Business Day” shall mean 9:00 am to 5:00 pm local time on a day other than a Saturday, Sunday or bank or other public or federal holiday in
Switzerland or in the US. 
  

	1.7	 Calendar Quarter 

The term “Calendar Quarter” shall mean each period of three (3) consecutive calendar months, ending March 31, June 30,
September 30, and December 31. 

  
 - 2 - 

	1.8	 Calendar Year 

The term “Calendar Year” shall mean the period of time beginning on January 1 and ending December 31, except for the first year which shall
begin on the Effective Date and end on December 31. 
  

	1.9	 CCS 

The term “CCS” shall mean Clinical Candidate Selection for a selected Collaboration Target as defined in the Preclinical Plan. 

 

	1.10	 CCS Criteria 

The term “CCS Criteria” shall mean the criteria set forth in Appendix 1.10 of this Agreement that constitute guidance for clinical candidate
selection unless such criteria are modified by the JRC. 
  

	1.11	 CCS Data Package 

The term “CCS Data Package” shall mean, with respect to a Program, the set of documents, records, and reports listed in Appendix 1.82, as may be
modified by the JRC, and to be provided by Vividion pursuant to Section 4.1. 
  

	1.12	 Change of Control 

The term “Change of Control” shall mean, with respect to a Party: (a) the acquisition by any Third Party of beneficial ownership of fifty
percent (50%) or more of the then outstanding common shares or voting power of such Party, other than acquisitions by employee benefit plans sponsored or maintained by such Party; (b) the consummation of a business combination involving such
Party, unless, following such business combination, the stockholders of such Party immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (50%) of the then outstanding common shares or voting
power of the entity resulting from such business combination; or (c) the sale of all or substantially all of such Party’s assets or business relating to the subject matter of the Agreement. Notwithstanding the foregoing, the selling or
issuing of securities for financing purposes, including pursuant to one or more public offerings of securities, shall not constitute a Change of Control. 
  

	1.13	 Change of Control Group 

The term “Change of Control Group” shall mean with respect to a Party, the person or entity, or group of persons or entities, that is the acquirer
of, or a successor to, a Party in connection with a Change of Control, together with Affiliates of such persons or entities that are not Affiliates of such Party immediately prior to the completion of such Change of Control of such Party. 

 

	1.14	 Clinical Plan 

The term “Clinical Plan” shall mean, on a Vividion PoC
Program-by-Vividion PoC Program basis, a plan describing, and a budget for, non-clinical and clinical research and development
activities under a Vividion PoC Program to be conducted after the expiry of the Preclinical Plan (i.e. for all activities after Completion of GLP Tox Study) until delivery of the PoC Data Package. 

 

	1.15	 Clinical Study 

The term “Clinical Study” shall mean a Phase I Study, Phase II Study, Phase III Study, PoC Study (as defined in the PoC Data Package), Pivotal Study,
as applicable. 
  

	1.16	 Collaboration 

The term “Collaboration” shall mean the activities of the Parties under the Collaboration Plan as described in Article 2. 

  
 - 3 - 

	1.17	 Collaboration Plan 

The term “Collaboration Plan” shall mean a plan describing the efforts to be undertaken during the Collaboration Term (i) up to Program
Nomination for Compounds and (ii) up to exercise of the respective E3 Module Option, as updated from time to time by the JRC. The initial Collaboration Plan is attached as Appendix 1.17. 

 

	1.18	 Collaboration Target 

The term “Collaboration Target” shall mean any Covalent Degrader Target and/or Covalent Inhibitor Target. The Collaboration Targets as of the
Effective Date are listed in Appendix 1.18 (as may be updated pursuant to this Agreement, the “Collaboration Target Appendix”). 
  

	1.19	 Collaboration Term 

The term “Collaboration Term” shall mean the period beginning upon the Effective Date and ending on the earlier of (a) thirty nine
(39) months, unless extended pursuant to Section 2.6, and (b) termination of this Agreement. 
  

	1.20	 Combination Product 

The term “Combination Product” shall mean 
  

	a)	 a single pharmaceutical formulation containing as its active ingredients both a Compound and one or more other
therapeutically or prophylactically active ingredients, 

  

	b)	 a combination therapy comprised of a Compound and one or more other therapeutically or prophylactically active
products, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price, or 

  

	c)	 a combination therapy comprised of a Compound and a Companion Diagnostic, priced and sold in a single package
containing such multiple products or packaged separately but sold together for a single price, 

 in each case, including all dosage forms,
formulations, presentations, line extensions, and package configurations. Such other therapeutically and prophylactically active ingredients and Companion Diagnostic under a), b) and c) referred to above shall be referred to as “Other
Components”. All references to Product and Shared Product in this Agreement shall be deemed to include Combination Product. For clarity, a Component is not an Other Component. 

 

	1.21	 Commercially Reasonable Efforts 

The term “Commercially Reasonable Efforts” shall mean [***] 

  
 - 4 - 

	1.22	 Companion Diagnostic 

The term “Companion Diagnostic” shall mean any product that is used for predicting and/or monitoring the response of a human being to treatment with
a Product (e.g. device, compound, kit, biomarker or service that contains a component that is used to detect or quantify the presence or amount of an analyte in body or tissue that affects the pathogens of the disease). 

 

	1.23	 Completion 

The term “Completion” shall mean the availability of the final study report. 

 

	1.24	 Composition of Matter Claim 

The term “Composition of Matter Claim” shall mean, [***]. 
  

	1.25	 Compound 

The term “Compound” shall mean any (i) Covalent Inhibitor or Covalent Degrader, as applicable, discovered, identified or designed, conceived or
reduced to practice by or on behalf of the Parties under the Collaboration Plan, under the Preclinical Plan or under the Clinical Plan, including any [***] (“Original Compound”) and (ii) Derivative. 

 

	1.26	 Compulsory Sublicense Compensation 

The term “Compulsory Sublicense Compensation” shall mean, for a given country or region in the Territory and a Product or Shared Product being
commercialized by Roche, the compensation paid to Roche by a Third Party (a “Compulsory Sublicensee”) under or in connection with a license or sublicense of Patents granted to the Compulsory Sublicensee (the “Compulsory
Sublicense”) through the order, decree or grant of a governmental authority having competent jurisdiction in such country or region (other than pursuant to an infringement or misappropriation action with respect to any Patent or Know-How), authorizing such Third Party to manufacture, use, sell, offer for sale, import or export such Product or Shared Product in such country or region. 

 

	1.27	 Confidential Information 

The term “Confidential Information” shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or
its Affiliates (“Receiving Party”). Confidential Information shall not include any information, data or know-how that: 
  

	 	(i)	 was generally available to the public at the time of disclosure, or becomes available to the public after
disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates, 

  

	 	(ii)	 can be evidenced by written records to have been already rightfully known to the Receiving Party or its
Affiliates prior to its receipt from the Disclosing Party to the extent the Receiving Party is permitted to use and disclose such information, data or know-how, 

 

	 	(iii)	 is obtained at any time lawfully from a Third Party under circumstances, to the extent the Receiving Party is
permitted to use and disclose such information, data or know-how, 

  

	 	(iv)	 is developed independently by the Receiving Party or its Affiliates as evidenced by written

  

	 	(v)	 records other than through knowledge of or reference to Confidential Information , or 

 

	 	(vi)	 is approved in writing by the Disclosing Party for release by the Receiving Party. The terms of this Agreement
shall be considered Confidential Information of the Parties. 

  
 - 5 - 

	1.28	 Continuation Election Notice 

The term “Continuation Election Notice” shall mean the notice Vividion provides to Roche under Section 22.3.1 describing
(i) Vividion’s bona fide intentions to continue ongoing development and commercialization of the applicable Product(s) and Shared Product(s) and (ii) Vividion’s request for Roche’s continuation of activities during
the termination period and/or transfer of the data, material and information relating to the applicable Product(s) and Shared Product(s) in accordance with Section 22.3.1. 

 

	1.29	 Control 

The term “Control” shall mean (as an adjective or as a verb including conjugations and variations such as “Controls” “Controlled”
or “Controlling”) (a) with respect to Patents and/or intangible Know-How, the possession by a Party or its Affiliate of the ability to grant a license or sublicense of such Patents and/or Know-How without violating the terms of any agreement or arrangement between such Party or its Affiliate and any Third Party and (b) with respect to proprietary materials, the possession by a Party or its
Affiliate of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party or its Affiliate and any Third Party. In the case of information or
tangible materials, “Control” requires possession thereof by a Party or its Affiliate or, if such information or tangible materials are in the possession of any other party, the ability of a Party to reasonably access and obtain such
information or tangible materials from such party. Notwithstanding the foregoing, unless the Parties otherwise mutually agree, the Patents and Know-How Controlled by a Party shall exclude any Patents or Know-How that are in-licensed or acquired by such Party except to the extent such Party incorporates such Patents or Know-How into a
Validated Hit or Compound or Product or Shared Product, as applicable, after such in-license or acquisition. 
  

	1.30	 Covalent Degrader 

The term “Covalent Degrader” shall mean a small molecule comprised of a moiety covalently binding to a specific E3 Ligase and chemically linked,
optionally via a Linker, to a Roche Target Ligand binding to the Covalent Degrader Target and leading to degradation of such Covalent Degrader Target. A (i) [***] or (ii) [***], (iii) [***] or (iv) [***], each of clause (ii), (iii) and
(iv) provided by Vividion under the Agreement, shall be a component (“Component”). The term “Linker” shall mean one or more groups of atoms that connects an E3 Ligase Engager to a Roche Target Ligand or target
ligand, respectively. 
 For clarity, [***]. 
  

	1.31	 Covalent Degrader Target 

The term “Covalent Degrader Target” shall mean any Target listed as such in the Collaboration Target Appendix and any Target designated as a
Collaboration Target pursuant to Section 2.3.2 for which Roche provides Roche Target Ligand(s), as such Collaboration Targets may be replaced in accordance with Section 2.3.2. The Covalent Degrader Targets as of the Effective Date are
listed as such in the Collaboration Target Appendix. 
  

	1.32	 Covalent Inhibitor 

The term “Covalent Inhibitor” shall mean a small molecule covalently binding to a Covalent Inhibitor Target leading to a substantially reduced
activity or complete inhibition of the activity of the Covalent Inhibitor Target. 

  
 - 6 - 

	1.33	 Covalent Inhibitor Target 

The term “Covalent Inhibitor Target” shall mean the Targets listed as such in the Collaboration Target Appendix, as may be replaced in accordance
with Section 2.3.1. 
  

	1.34	 Cover 

The term “Cover” shall mean (as an adjective or as a verb including conjugations and variations such as “Covered,” “Coverage” or
“Covering”) that the making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product would infringe a Valid Claim in the absence of a license under or ownership in the Patents to
which such Valid Claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular Valid Claim shall be made on a
country-by-country basis. 
  

	1.35	 CRO 

The term “CRO” shall mean a contract research organization or a contract manufacturing organization. A list of Roche approved CROs is attached as
Appendix 1.35, as such appendix may be amended or restated from time to time in accordance with the terms of this Agreement. 
  

	1.36	 “Delivery Date” 

The term “Delivery Date” shall mean the date of delivery of a Data Package, as set forth in Section 4.8. 

 

	1.37	 Derivative 

The term “Derivative” shall mean, with respect to a Compound, any compound or molecule made by or on behalf of Roche (or any of its Affiliates or
Sublicensees) or Vividion (or any of its Affiliates or (sub)licensees) that is (i) [***] such Compound [***] and (ii) [***] as such Compound. For avoidance of doubt, (a) [***] and (b) [***]. 

 

	1.38	 Development 

The term “Development” (as an adjective or as a verb including conjugations and variations such as “Developing”) shall mean, on a Program-by-Program or Shared Product-by-Shared Product basis, all activities relating to the
research, evaluation and preclinical testing of Products for such Program or Shared Products, and all clinical drug development activities, manufacturing for GLP Tox Studies and Clinical Studies, pre-marketing
activities and related research, including: conducting GLP Tox Studies, toxicology, process and drug product (dosage form) development for manufacturing, statistical analysis and report writing, Clinical Studies for the purpose of obtaining or
maintaining Regulatory Approval (including Pivotal Studies, post-marketing studies intended to support Regulatory Approval, including Phase IV Studies), and regulatory affairs related to all of the foregoing. 

 

	1.39	 Development Cost 

The term “Development Costs” shall mean the cost of Developing a Product for a Program or a Shared Product, as further defined in the Financial
Appendix. The “Development Costs” for a Shared Program shall mean those Development Costs for activities conducted after exercise of the Roche PoC Option for a Shared Product pursuant to Section 4.3. 

  
 - 7 - 

	1.40	 Development Plan 

The term “Development Plan” shall mean, on a Shared Product-by-Shared
Product basis, a plan describing non-clinical and clinical Development activities of Roche after the exercise of the Roche PoC Option for such Shared Product and the budget of Allowable Development Expenses
for the conduct of such activities (as further described in the Financial Appendix). 
  

	1.41	 Directed To 

The term “Directed To” shall mean designed to bind to a Collaboration Target or an E3 Ligase, as applicable, even if incidentally or indirectly,
targeting, binding to or modulating significantly the function or activity of another Target (including another Collaboration Target) or an E3 Ligase (including another E3 Ligase). 

 

	1.42	 E3 Ligase 

The term “E3 Ligase” shall mean a protein or member of a multi-protein complex that recruits or contains an ubiquitin conjugating enzyme (E2),
selectively recognizes a protein substrate, and assists or directly catalyzes the transfer of ubiquitin to the protein substrate. Vividion has characterized as of the Effective Date [***] (“Initial Vividion E3 Ligase”). E3 Ligase
shall not include Excluded E3 Ligases. 
  

	1.43	 E3 Ligase Engager 

The term “E3 Ligase Engager” shall mean [***], to a target-binding ligand. 
  

	1.44	 E3 Module 

The term “E3 Module” shall mean a module that contains (i) [***] and (ii) [***] and optionally (iii) [***]. 

 

	1.45	 E3 Module Data Package 

The term “E3 Module Data Package” shall mean the set of documents, records, and reports listed in Appendix 1.82 provided by Vividion pursuant to
Section 4.5. 
  

	1.46	 Effective Date 

The term “Effective Date” shall mean April 3, 2020. 
  

	1.47	 Entry into GLP Tox 

The term “Entry into GLP Tox” shall mean the date that an animal is first dosed with the Product or Shared Product in a GLP Tox Study. 

 

	1.48	 EU 

The term “EU” shall mean the European Union and all its then-current member countries but including in any case France, Germany, Italy, Spain and the
United Kingdom regardless of whether they are then-current member countries. 
  

	1.49	 Excluded Claim 

The term “Excluded Claim” shall mean a dispute, controversy or claim between the Parties that concerns (a) the validity or infringement, scope,
enforceability or inventorship of a patent, trademark or copyright, or (b) any antitrust, anti-monopoly or competition Applicable Law, whether or not statutory. 

  
 - 8 - 

	1.50	 Excluded E3 Ligases 

The term “Excluded E3 Ligases” shall mean (i) E3 Ligases that, at the Effective Date, are [***], and (ii) E3 Ligases [***]. 

 

	1.51	 Expert 

The term “Expert” shall mean a person with no less than ten (10) years of pharmaceutical industry experience and expertise having occupied at
least one position within a large pharmaceutical company and one position with a private biopharmaceutical company relating to the area the matter relates to (e.g. development for development matters, financial related to financial matters, etc.)
but excluding any current or former employee or consultant of either Party or their respective Affiliates. Such person shall be fluent in the English language. 
  

	1.52	 FDA 

The term “FDA” shall mean the Food and Drug Administration of the United States of America, or its successor. 

 

	1.53	 FDCA 

The term “FDCA” shall mean the Food, Drug and Cosmetics Act. 
  

	1.54	 Field 

The term “Field” shall mean [***]. 
  

	1.55	 Filing 

The term “Filing” shall mean the filing of an application with the FDA for Regulatory Approval as defined in the FDCA and applicable regulations, or
the equivalent application to the equivalent agency in any other country or group of countries, the official approval of which is required before any lawful commercial sale or marketing of Products and Shared Products. 

 

	1.56	 Financial Appendix 

The term “Financial Appendix” shall mean the document in Appendix 1.56, which describes the Development Cost Share and the Profit and Loss Sharing.

  

	1.57	 First Commercial Sale 

The term “First Commercial Sale” shall mean, on a country-by-country
basis, for a given Product or Shared Product, the first invoiced sale of such Product or a Shared Product to a Third Party by the Roche Group or a Sublicensee following the receipt of any Regulatory Approval required for the sale of such Product or
Shared Product, or if no such Regulatory Approval is required, the date of the first invoiced sale of a Product or Shared Product to a Third Party by the Roche Group or Sublicensee in such country. 

 

	1.58	 Generic Product 

The term “Generic Product” shall mean, with respect to a particular Product or Shared Product and on a country-by-country basis, a generic pharmaceutical product that is marketed for sale by a Third Party (other than a Sublicensee) not licensed, supplied or otherwise permitted or authorized by Roche or is
Affiliates or Sublicensee (other than Hatch-Waxman settlements under which Roche, its Affiliates and Sublicensees do not receive payment) and that (i) in the US, is approved under 21 U.S.C. 505(j) and has an “AB” rating with respect
to the Product or Shared Product (or the equivalent of such statute if amended), or (ii) in countries of the EU, is authorized 

  
 - 9 - 

 to be placed on the market in accordance with Article 10(1)(a)(iii) of Directive 2001/83/EC (or the
equivalent of such statute if amended), or (iii) in countries of the Territory other than the US or countries of the EU, a generic version of the Product or Shared Product that (x) contains the same active pharmaceutical ingredient as the
Compound in the Product and (y) is approved by an expedited process that relies in whole or in part on safety and efficacy data generated for the first approval of the Product or Shared Product and (z) has the same or substantially the
same labeling as the Product or Shared Product for at least one indication of the Product or Shared Product, as applicable. 
  

	1.59	 GLP Tox Study 

The term “GLP Tox Study” shall mean a toxicology study of the relationship between dose and its effects on the exposed animal, where (i) the
study is to be conducted in accordance with GLP standards and (ii) the study has been designed in expectation that the results may support establishment of a safe starting dose of the Product and Shared Product in Clinical Studies. 

 

	1.60	 Handle 

The term “Handle” shall mean drafting, filing, prosecuting (including grants, lapse, revocation, surrender, invalidation, interferences, reissue, re-examination, post-grant reviews, inter-parties reviews, derivation proceedings and opposition proceedings), maintaining and abandoning. 
  

	1.61	 Hit 

The term “Hit” shall mean a Compound Directed To a Collaboration Target that is not a Validated Hit, but that has a [***]. A Hit is [***]. 

 

	1.62	 HSR 

The term “HSR” shall mean the Hart-Scott-Rodino Antitrust Improvements Act and the rules and regulations promulgated thereunder, or any successor
statute, rules and regulations thereto. 
  

	1.63	 HSR Filing 

The term “HSR Filing” shall mean (i) filings by the Parties with the FTC and the Antitrust Division of the DOJ of a Notification and Report Form
for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth in this Agreement, together with all required documentary attachments thereto; or (ii) equivalent filings with relevant foreign
authorities. 
  

	1.64	 ICD-10 

The term “ICD-10” shall mean the Tenth Revision of the International Classifications of Diseases and Related
Health Problems, as may be revised or amended from time to time, or a successor classification. 
  

	1.65	 IFRS 

The term “IFRS” shall mean International Financial Reporting Standards. 

  
 - 10 - 

	1.66	 IND 

The term “IND” shall mean an application as defined in the FDCA and applicable regulations promulgated by the FDA, or the equivalent application to
the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of the Compounds and/or Products and Shared Products in humans. 

 

	1.67	 Indication 

The term “Indication” shall mean a disease (a) for which the Product or Shared Product is indicated for treatment and (b) that is described
in the Product label or Shared Product label as required by the Regulatory Approval granted by the applicable Regulatory Authority. An Indication is distinct from another Indication if (i) the diseases associated with such Indications are
listed in two different blocks of the ICD-10 and (ii) the efficacy of such Product or Shared Product in such Indications was established, in whole or in part, in one or more separate Clinical Studies.

 The term “Oncology Indication” shall mean any Indication in the field of oncology (including immuno-oncology). One Oncology Indication
is distinguished from another Oncology Indication by the organ or tumor type that is impacted, e.g. breast versus prostate versus liver, and not by distinctions in treatment, e.g. first line metastatic versus second line metastatic. 

 

	1.68	 Initiation 

The term “Initiation” shall mean the date that a human is first dosed with the Product, Roche PoC Product or Shared Product in a Clinical Study
approved or permitted by the respective Regulatory Authority. 
  

	1.69	 Insolvency Event 

The term “Insolvency Event” shall mean circumstances under which a Party (i) has a receiver or similar officer appointed over all or a material
part of its assets or undertaking; (ii) passes a resolution for winding-up of all of its business (other than a winding-up for the purpose of, or in connection
with, any solvent amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration of such a wind-up (or any equivalent order in any jurisdiction); (iii)
enters into any composition or arrangement with its creditors (other than relating to a solvent restructuring or financing); or (iv) ceases to carry on business. 
  

	1.70	 Invention 

The term “Invention” shall mean an invention that is conceived and reduced to practice in connection with any activity carried out under the
Collaboration Plan, a Preclinical Plan, a Clinical Plan, a Development Plan or a Program pursuant to this Agreement. Under this definition, an Invention may be made by personnel of Vividion solely or jointly with a Third Party (a “Vividion
Invention”), by personnel of the Roche Group solely or jointly with a Third Party (a “Roche Invention”), or jointly by personnel of Vividion and personnel of the Roche Group with or without a Third Party (a “Joint
Invention”). 
  

	1.71	 Joint Know-How 

The term “Joint Know-How” shall mean Know-How that is made jointly by
employees of Vividion and the Roche Group, with or without a Third Party in connection with any activity carried out under the Collaboration Plan, a Preclinical Plan, a Clinical Plan, a Development Plan or Program pursuant to this Agreement. 

 

	1.72	 Joint Patents 

The term “Joint Patents” shall mean all Patents Covering a Joint Invention. 

  
 - 11 - 

	1.73	 JOT 

The term “JOT” shall mean a joint operating team described in Section 8.5. 

 

	1.74	 JRC 

The term “JRC” shall mean the joint research committee described in Section 8.1. 

 

	1.75	 JDC 

The term “JDC” shall mean the joint development committee described in Section 8.2. 

 

	1.76	 Know-How 

The term “Know-How” shall mean data, knowledge and information, including Materials, samples, chemical
manufacturing data, toxicological data, pharmacological data, preclinical and clinical data, assays, platforms, formulations, specifications, quality control testing data, that are confidential. 

 

	1.77	 Licensed Program 

The term “Licensed Program” shall mean Roche’s and its Affiliates’ and Sublicensees’ program for the development and commercialization
of Compounds and Products for any Roche Program or any Vividion Program or Vividion PoC Program for which Roche exercised its Option Right pursuant to Section 4.1 or 4.3. 
  

	1.78	 Major Market 

The term “Major Market” shall mean each of the [***]. 
  

	1.79	 Net Sales 

The term “Net Sales” shall mean, [***][***][***]. 
  

	1.80	 Nominated Program 

The term “Nominated Program” shall mean a program that is nominated based on a Validated Hit Data Package for a Collaboration Target in accordance
with Section 2.5.1. All Hits and Validated Hits (including additional Hits and Validated Hits resulting from screens Vividion conducts against such Collaboration Target during the Collaboration Term) Directed To the Collaboration Target shall
be one Nominated Program, provided that, with respect to Covalent Degraders, such Hits are Directed To the same E3 Ligase and have the same Roche Target Ligand. A Nominated Program can be selected as Roche Program, Vividion Program or allocated as
Reserved Program as described in Section 2.5.4, 2.5.5 and 2.5.6. 
  

	1.81	 Option Right 

The term “Option Right” shall mean the Roche Option, the Roche PoC Option, and the E3 Module Option granted to Roche in Article 4 of this Agreement.

  

	1.82	 Option Data Package 

The term “Option Data Package” shall mean the (i) CCS Data Package, (ii) E3 Module Data Package, and/or (iii) the PoC Data Package,
each as outlined in Appendix 1.82. 
  

	1.83	 Option Exercise Date 

The term “Option Exercise Date” shall mean the date of Vividion’s receipt of the Option Exercise Notice. 

  
 - 12 - 

	1.84	 Option Exercise Notice 

The term “Option Exercise Notice” shall mean the written notice a Party delivers to the other Party to exercise its Option Right. 

 

	1.85	 Option Period 

The term “Option Period” shall mean the Roche Option Period, Roche PoC Option Period and the E3 Module Option Period. 

 

	1.86	 Party 

The term “Party” shall mean Vividion or Roche, as the case may be, and “Parties” shall mean Vividion and Roche collectively. 

 

	1.87	 Patented E3 Module Product 

The term “Patented E3 Module Product” shall mean any product that [***]. An “E3 Ligase Blocking Claim” shall mean, [***]. 

 

	1.88	 Patents 

The term “Patents” shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on
such patent application, and further including any 

  
 - 13 - 

 substitution, extension or supplementary protection certificate, reissue, reexamination, renewal,
divisional, continuation or continuation-in-part of any of the foregoing. 
  

	1.89	 Pharmacovigilance Agreement 

The term “Pharmacovigilance Agreement” shall mean an agreement entered into by the Parties to set forth the responsibilities and obligations of the
Parties with respect to the procedures and timeframes for compliance with Applicable Laws pertaining to the exchange and reporting of safety information for the Product or Shared Product and its related activities. 

 

	1.90	 PoC Costs 

The term “PoC Costs” shall mean Allowable PoC Expenses as further defined in the Financial Appendix. 

 

	1.91	 PoC Study 

The term “PoC Study” shall mean, for a given Vividion PoC Program, a proof of concept Clinical Study that is designed to meet the parameters for a
“PoC Study” established in the Clinical Plan for such Vividion PoC Program. For the avoidance of doubt, such parameters for a “PoC Study” in the Clinical Plan shall be parameters for how such a Clinical Study is to be designed
and not target results to be achieved or outcome of such Clinical Study. 
  

	1.92	 PoC Data Package 

The term “PoC Data Package” shall mean the set of documents, records, and reports described in Appendix 1.82 with respect to a PoC Study set forth in
Section 1.91 provided by Vividion to Roche for a Vividion PoC Program pursuant to Section 4.3. 
  

	1.93	 Phase I Study 

The term “Phase I Study” shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA),
as amended from time to time, and the foreign equivalent thereof. 
  

	1.94	 Phase II Study 

The term “Phase II Study” shall mean a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a
preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof. 

 

	1.95	 Phase III Study 

The term “Phase III Study” shall mean a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe
and effective for use in humans in a manner sufficient to support an application for Regulatory Approval to market such product for use in patients having the disease or condition being studied (or subset thereof) as described in 21 C.F.R. §
312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof. 
  

	1.96	 Phase IV Study 

The term “Phase IV Study” shall mean a human clinical study commenced after Regulatory Approval of the pharmaceutical product to accumulate evidence
about the efficacy and/or safety of the Product or the Shared Product, which shall not include any Post-Approval Commitment Study. The term “Post-Approval Commitment Study” shall mean any human clinical study for a Shared Product
conducted after marketing authorization of such Product or Shared Product has been obtained from the FDA at the request of or requirement of the FDA. 

  
 - 14 - 

	1.97	 Pivotal Study 

The term “Pivotal Study” shall mean, with respect to any Product or Shared Product, a Clinical Study that at the time of Initiation (or any later
expansion of patient enrollment, if applicable), is expected to be the basis for Regulatory Approval of such Product or Shared Product, including any Phase III Study. 
  

	1.98	 Product 

The term “Product” shall mean any product, including without limitation any Combination Product, containing a Compound as a pharmaceutically active
agent, in whatever finished forms, formulations or dosages. 
  

	1.99	 Product Specific Claim 

The term “Product Specific Claim” means, with respect to one or more Products within a Program, a claim of a Patent that (i) is a [***] or
(ii) Covers [***]. As used in the preceding sentence, a Product Specific Claim Covering the applicable Compounds [***], when the Compound is (i) [***] or (ii) [***]. 
  

	1.100	 Product Specific Patent 

The term “Product Specific Patent” shall mean, with respect to a Program, a Vividion Patent that contains Product Specific Claims. 

 

	1.101	 Profit and Loss Sharing 

The term “Profit and Loss Sharing” shall have the meaning given such term in Section 13.13. 

 

	1.102	 Program 

The term “Program” shall mean the activities of the Parties under a Roche Program, Vividion Program, Optioned Roche Program, Vividion PoC Program,
Roche PoC Program or Shared Program, as applicable. A Program includes all Validated Hits, Hits, and Compounds, in each case Directed To the Collaboration Target (to the extent, with respect to Covalent Degraders, such Validated Hits, Hits and
Compounds are Directed To the same E3 Ligase and have the same Roche Target Ligand). 
  

	1.103	 Preclinical Plan 

The term “Preclinical Plan” shall mean, on a Nominated
Program-by-Nominated Program basis, a plan describing preclinical research activities (i) for a Vividion Program from the date a program is a Nominated Program
until delivery of the CCS Data Package and (ii) for a Vividion PoC Program from the date that CCS is reached until Completion of the GLP Tox Study. The Preclinical Plan for activities described in (ii) shall also include a budget for such
activities. 

  
 - 15 - 

	1.104	 Regulatory Approval 

The term “Regulatory Approval” shall mean any approvals (including pricing and reimbursement approvals), licenses, registrations or authorizations by
a Regulatory Authority, necessary for the sale of a Product or Shared Product in the Field in a regulatory jurisdiction in the Territory. 
  

	1.105	 Regulatory Authority 

The term “Regulatory Authority” shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the
European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of regulatory approval for the Product or the
Shared Product. 
  

	1.106	 Reserved Programs 

The term “Reserved Programs” shall mean all Nominated Programs that are not initially selected pursuant to Section 2.5.4 as a Roche Programs or
a Vividion Program. 
  

	1.107	 Roche Group 

The term “Roche Group” shall mean collectively Roche and its Affiliates. 
  

	1.108	 Roche Know-How 

The term “Roche Know-How” shall mean all Know-How that Roche Controls
as of the Effective Date or during the Agreement Term, (a) to the extent reasonably necessary for the manufacture, development, use, or commercialization of a Compound, a Product or a Shared Product and (b) incorporated into a Compound, a
Product or a Shared Product by Roche or used by Roche in the conduct of such Program. For clarity, the Roche Know-How does not include any Know-How pertaining to an
Other Component that is included in a Combination Product, unless reasonably necessary for the manufacture, development, use, or commercialization of a Compound independent of the Other Component. 

 

	1.109	 Roche Patent 

The term “Roche Patents” shall mean all Patents Covering a Product or a Shared Product that Roche Controls as of the Effective Date or during the
Agreement Term to the extent (a) Covering the manufacture, development, use, composition or commercialization of a Compound, a Product or a Shared Product and (b) the subject matter Covered by such Patents is incorporated into a Compound,
a Product or a Shared Product by Roche or practiced by Roche in the conduct of such Program, For clarity, the Roche Patents do not include any Patents to the extent it Covers an Other Component that is included in a Combination Product, unless
reasonably necessary for the manufacture, development, use, or commercialization of a Product or Shared Product independent of the Other Component. 
  

	1.110	 Roche PoC Product 

The term “Roche PoC Product” shall mean any product, including without limitation any Combination Product, containing a Compound of a Vividion PoC
Program for which Vividion has not exercised the Vividion Sharing Option pursuant to Section 4.4.as pharmaceutically active agent, in whatever finished forms, formulations or dosages. 

Unless specifically referred to as Roche PoC Product in Sections 4.6.3, 6 and 13, a Roche PoC Product is a Product and all references to Product shall include
a Roche PoC Product. For clarity, unless expressly specified otherwise, references to Product in this Article 1 shall include Roche PoC Product even if the applicable defined term is used in Sections 4.6.3, 6 and 13. 

  
 - 16 - 

	1.111	 Roche Program 

The term “Roche Program” shall mean a program for the development and commercialization of Compounds and Products for a Nominated Program that is
selected as a “Roche Program” pursuant to Section 2.5.4 or 2.5.6, where Roche is responsible for activities after selection as Nominated Program pursuant to Section 3.1. 

 

	1.112	 Roche Target Ligand 

The term “Roche Target Ligand” shall mean [***] Controlled by Roche that (i) [***] and (ii) [***]. 

 

	1.113	 Royalty Term 

The term “Royalty Term” shall mean, with respect to a Product or a Shared Product and for a given country, the period of time commencing on the date
of First Commercial Sale of the Product or a Shared Product in such country and ending on the later of the date that is (a) [***] years after the date of the First Commercial Sale of the Product or the Shared Product in such country, or (b) the
expiration of the last to expire [***] in such country Covering [***] of such Product or Shared Product. 
  

	1.114	 Sales 

The term “Sales” shall mean, for a Product or a Shared Product or a Patented E3 Module Product in a particular period, the sum of the amounts in
clauses of (i) and (ii): 
 (i) the amount stated in [***]. This amount reflects the gross invoice price at which such Product, [***]. 

By way of example, the [***] deductions taken in accordance with such Accounting Standard as of the Effective Date include items such as the following: 

(a) [***]; 
 (b) [***]; 

(c) [***]; 
 (d) [***]; and 

(e) [***]. 

  
 - 17 - 

 For purposes of clarity, [***] shall be excluded from “Sales”. 

(ii) for Sublicensees that are not Roche Affiliates (and excluding Compulsory Sublicensees), the sales amounts reported to Roche and its Affiliates in
accordance with the sublicensee contractual terms and their then-currently used Accounting Standards (“Sublicensee Sales”) provided that Roche or its Affiliate obtains material royalties (other than those paid or to be paid to
Vividion under this Agreement) calculated based on such reported sales (and in cases where Roche or its Affiliate does not obtain such other material royalties, such sublicensee contractual terms for reporting of sales shall be reasonably similar to
those terms customarily used in drug discovery, development or commercialization licensing contracts in which Roche obtains a material royalty on sales). For the purpose of clarity, any such Sublicensee sales as reported to Roche in accordance with
Compulsory Sublicense agreements shall be excluded from the sales amount. 
  

	1.115	 Selection Effective Date 

The term “Selection Effective Date” for each Roche Program selection pursuant to Section 2.5 and Option Right exercised by Roche pursuant to
Sections 4.1 through 4.5, shall mean (i) if Roche determines that a HSR filing is necessary with respect to such Roche Program selection or Option Right exercise, as applicable, the second Business Day immediately following the later of:
(a) the date upon which any applicable waiting periods under the HSR Act expire or terminate early or (b) the date upon which all requests to the Parties by the United States Federal Trade Commission (the “FTC”) or the
United States Department of Justice (the “DOJ”), as the case may be, have been satisfactorily met and no objection on the part of the FTC or DOJ remains; and (ii) if Roche determines that a HSR Filing is not necessary with
respect to such Roche Program selection or Option Right exercise, as applicable, the date of such Roche Program selection or Option Exercise Date for such Option Right. 
  

	1.116	 Shared Product 

The term “Shared Product” shall mean any product, including without limitation any Combination Product, containing a Compound of a Vividion PoC
Program for which Vividion has exercised the Vividion Sharing Option pursuant to Section 4.4as pharmaceutically active agent, in whatever finished forms, formulations or dosages. For clarity, the term Product includes Shared Product. 

 

	1.117	 Sublicensee 

The term “Sublicensee” shall mean an entity to which Roche has licensed rights (through one or multiple tiers), to any Compound, Product or
Bifunctional Degrader Compound other than through a Compulsory Sublicense under this Agreement. 
  

	1.118	 Target 

The term “Target” shall mean a protein identified by its UniProt accession number, including all splice variants, mutants and natural variants
identified by such UniProt accession number. 
  

	1.119	 Territory 

The term “Territory” shall mean all countries of the world. 
  

	1.120	 Third Party 

The term “Third Party” shall mean a person or entity other than (i) Vividion or any of its Affiliates or (ii) a member of the Roche Group.

  
 - 18 - 

	1.121	 Transfer Activities 

The term “Transfer Activities” shall mean the transfer from Vividion to Roche of the data, Materials,
Know-How, documentation and other items in Vividion’s Control (including through its Affiliates), and reasonable technical assistance, in each case, to the extent reasonably necessary for Roche to
continue development of the Original Compounds, along with such other commercially reasonable actions which may be conducted by Vividion to effectuate transfer of responsibilities, in each case in accordance with and as described in the applicable
Transfer Plans. The term “Transfer Plan” shall mean a plan for the Transfer Activities. Each Transfer Plan may consist of multiple sections applicable for relevant functions (e.g. regulatory, clinical, safety, manufacturing,
clinical). The JRC will establish and oversee the Parties’ activities under each Transfer Plan. 
  

	1.122	 US 

The term “US” shall mean the United States of America and its territories and possessions. 

 

	1.123	 US$ 

The term “US$” shall mean US dollars. 
  

	1.124	 Validated Hit 

The term “Validated Hit” shall mean [***]. 
  

	1.125	 Validated Hit Data Package 

The term “Validated Hit Data Package” shall mean the set of documents, records, and reports listed in Appendix 1.82 provided by Vividion pursuant to
Section 2.5. For clarity, such documents, record and reports are intended to enable a Party to assess whether the Validated Hit criteria set forth in the Collaboration Plan (“Validated Hit Criteria”) are met by a Hit, but such
Validated Hit Data Package shall not be required to evidence that Validated Hit Criteria have been achieved. 
  

	1.126	 Valid Claim 

The term “Valid Claim” shall mean, as applicable, a claim in any (i) unexpired and issued Patents that has not been disclaimed, revoked or held
invalid by a final non-appealable decision of a court of competent jurisdiction or government agency or (ii) pending patent application within the Patents in any country of the Territory that (a) is
on file with the applicable patent office and (b) which application has been on file with the applicable patent office for no more than [***] years from the earliest date to which the patent application claims its earliest priority. 

 

	1.127	 Vividion Core Platform Technology 

The term “Vividion Core Platform Technology” means Vividion’s screening library, screening reagents, and screening methods, including but not
limited to Vividion’s methods, reagents and intellectual property rights related to the discovery and characterization of Compounds. For clarity, the Vividion Core Platform Technology does not include Original Compounds. 

 

	1.128	 Vividion CRG Technology 

The term “Vividion CRG Technology” shall mean any Know-How or invention conceived, developed or made by or on
behalf of Roche or its Affiliates in performance of any activity that is not permitted by Section 5.5, if any. 
  

	1.129	 Vividion E3 Know-How 

The term “Vividion E3 Know-How” shall mean, with respect to an E3 Module, the
Know-How that Vividion Controls at the Effective Date or during the Collaboration Term, in each case to the extent 

  
 - 19 - 

 reasonably necessary for use of the E3 Ligase Engagers for such E3 Module for the generation of Bifunctional
Degrader Compounds and the manufacture, development, use, or commercialization of such an E3 Ligase Engager in a Bifunctional Degrader Compound. For clarity, the Vividion E3 Know-How does not include any Know-How comprising Vividion Core Platform Technology. 
  

	1.130	 Vividion E3 Patents 

The term “Vividion E3 Patents” shall mean, with respect to an E3 Module, the Patents (including a Composition of Matter Claim of a Vividion E3
Patent) that Vividion Controls at the Effective Date or during the Collaboration Term, in each case to the extent Covering the manufacture, development, use, composition or commercialization of an E3 Ligase Engager of such E3 Module in a
Bifunctional Degrader Compound. For clarity, the Vividion E3 Patents do not include any Patents to the extent Covering Vividion Core Platform Technology. 
  

	1.131	 Vividion E3 Technology 

The term “Vividion E3 Technology” shall mean any Know-How or invention conceived, developed or made by or on
behalf of Roche or its Affiliates during the Collaboration Term in each case using Vividion’s Confidential Information, to the extent pertaining to an E3 Ligase, E3 Ligase Engager or E3 Module. 

 

	1.132	 Vividion Know-How 

The term “Vividion Know-How” shall mean, with respect to a Program, the
Know-How that Vividion Controls at the Effective Date or during the Collaboration Term, to the extent (a) reasonably necessary for the manufacture, development, use, or commercialization of a Compound, a
Product or a Shared Product for such Program and (b) incorporated into a Compound, a Product or a Shared Product by Vividion or used by Vividion in the conduct of such Program. For clarity, the Vividion
Know-How does not include any (i) Know-How pertaining to an Other Component that is included in a Combination Product, unless reasonably necessary for the
manufacture, development, use, or commercialization of a Compound independent of the Other Component or (ii) Know-How comprising Vividion Core Platform Technology. 

 

	1.133	 Vividion Patents 

The term “Vividion Patents” shall mean, with respect to a Program, the Patents that Vividion Controls at the Effective Date or during the Agreement
Term to the extent (a) Covering the manufacture, development, use, composition or commercialization of a Compound, a Product or a Shared Product for such Program and (b) the subject matter Covered by such Patents is incorporated into a
Compound, a Product or a Shared Product by Vividion or practiced by Vividion in the conduct of such Program. For clarity, the Vividion Patents do not include any (i) Patents to the extent it Covers the manufacture, development, use, composition
or commercialization of an Other Component that is included in a Combination Product or (ii) Patents to the extent Covering Vividion Core Platform Technology. The term “Vividion Base Patents” shall mean the Patents listed in
Appendix 1.133. 
  

	1.134	 Vividion Program 

The term “Vividion Program” shall mean a program for development of Compounds under a Nominated Program that has been selected as a “Vividion
Program” pursuant to Section 2.5.4, 2.5.5 or 2.5.6 where Vividion conducts the pre-clinical activities from the date the program is a Nominated Program up to delivery of the CCS Data Package, as
described in the Preclinical Plan for such Vividion Program. 

  
 - 20 - 

	1.135	 Additional Definitions 

Each of the following definitions is set forth in the Section of this Agreement indicated below: 

 

			
	 Definition
	  	Section
	 Accounting Period
	  	14.1
	 Achievement of PoC
	  	4.6.2(ii)
	 Achievement of Roche PoC
	  	22.3.1(e)(ii)
	 Acquired Party
	  	22.2.3
	 Alliance Director
	  	8.6
	 Arbitral Tribunal
	  	24.3.1
	 Bankruptcy Code
	  	23
	 Breaching Party
	  	22.2.1
	 Bifunctional Degrader Compound
	  	5.2.3
	 CD Target Replacement Period
	  	2.3.2
	 Chugai
	  	1.2
	 Clinical Plan Budget
	  	3.2.3
	 Co-Exclusive
	  	5.2.3
	 Collaboration End Date
	  	2.6.3
	 Collaboratoin Target Appendix
	  	1.18
	 Collaboration Target Inhibitor
	  	6.4
	 Commercialization Transition Period
	  	22.3.4.1
	 Competing Products
	  	22.2.3
	 Component
	  	1.30
	 Compulsory Sublicense Share Percentage
	  	13.12.7
	 Compulsory Sublicense
	  	1.26
	 Compulsory Sublicensee
	  	1.26
	 Covalent Inhibitor Target Replacement Period
	  	2.3.1
	 Cysteine Reactive Groups
	  	5.5
	 Data Package
	  	4.8
	 Decision Period
	  	17.9
	 Declined Nomination Notice
	  	2.5.1
	 Delivery Date
	  	4.8
	 Development Cost Opt-Out
	  	9.4
	 Development Cost Sharing
	  	9.3
	 Disclosing Party
	  	1.27
	 Disputed Breach Notice
	  	22.3.1
	 Disputing Party
	  	24.3.1
	 DOJ
	  	1.115
	 E3 Field
	  	5.2.3
	 E3 Ligase Blocking Claim
	  	1.87
	 E3 Module Option
	  	4.5.1
	 E3 Module Option Period
	  	4.5.1
	 E3 Royalty Term
	  	13.12.2(g)
	 Excess Development Cost Notice
	  	9.4
	 Excess Development Opt-Out
	  	9.4
	 Excess Launch Costs
	  	12.5

  
 - 21 - 

			
	 Excess PoC Costs
	  	3.2.3
	 Excluded Target
	  	2.4.4
	 Expert Committee
	  	24.4.1
	 Expert Committee Dispute
	  	24.4
	 Expert Resolution Notice
	  	24.4.1
	 Flatiron
	  	5.4
	 FMI
	  	5.4
	 Force Majeure
	  	24.10
	 FTC
	  	1.115
	 FTO
	  	17.6
	 H-W Suit Notice
	  	17.12
	 ICC
	  	24.3.1
	 Indemnified Party
	  	19.3
	 Indemnifying Party
	  	19.3
	 Indirect Taxes
	  	15.1
	 Infringement
	  	17.9
	 Initial Budget
	  	9.4
	 Initial Commercialization Plan
	  	12.5
	 Initial Vividion E3 Ligase
	  	1.42
	 Initiating Party
	  	17.9
	 Joint Invention
	  	1.70
	 JOT
	  	8.5
	 Latest Enrollment Date
	  	22.3.4.1(ii)
	 Linker
	  	1.30
	 Manufacturing Transfer
	  	10.4
	 Members
	  	8.1.1
	 Merger of Equals
	  	22.2.3.1(a)
	 Minimum Transfer Payment
	  	22.3.4.4(c)
	 New Covalent Degrader Information
	  	2.3.2
	 Nomination Date
	  	2.5.1
	 Non-Acquired Party
	  	22.2.3
	 Non-Breaching Party
	  	22.2.1
	 Oncology Indication
	  	1.67
	 Optioned Roche Program
	  	4.1
	 Original Compound
	  	1.25
	 Other Components
	  	1.20
	 Other E3 Module
	  	4.5.1
	 Other Product
	  	6.4(a)
	 PII/Samples
	  	22.3.4.4(b)
	 Patent Challenge
	  	22.2.5
	 Patent Term Extensions
	  	17.13
	 Payment Currency
	  	14.3
	 Peremptory Notice Period
	  	22.2.1
	 PoC Cost Sharing
	  	3.2.3
	 Post-Approval Commitment Study
	  	1.96
	 Preclinical Plan Budget
	  	3.2.3
	 Prior Roche PoC Costs
	  	4.2.2
	 Profit and Loss Sharing
	  	13.13

  
 - 22 - 

			
	 Program Nomination
	  	2.5.1
	 Proposed Target Nomination Notice
	  	2.5.1.1
	 Publishing Notice
	  	21.4(b)
	 Publishing Party
	  	21.4(b)
	 Receiving Party
	  	1.27
	 Redacted Agreement
	  	21.5
	 Register
	  	17.7
	 Regulatory Materials
	  	11.1.1
	 Relative Commercial Value
	  	13.12.3
	 Reservation Period
	  	2.5.7
	 Reserved Program
	  	2.5.4
	 Reserved Program Research Activities
	  	2.5.7
	 Roche
	  	cover page
	 Roche Basel
	  	cover page
	 Roche Cysteine Reactive Group
	  	5.5
	 Roche Indemnitees
	  	19.2
	 Roche Invention
	  	1.70
	 Roche Option
	  	4.1
	 Roche Option Period
	  	4.1
	 Roche PoC Clinical Plan
	  	4.2.2
	 Roce PoC Data Package
	  	4.2.2(c)(v)
	 Roche PoC Option
	  	4.3
	 Roche PoC Option Period
	  	4.3
	 Roche PoC Program
	  	4.3
	 Roche Program Nominatino Fee
	  	13.5.1
	 Roche Switch
	  	4.2.1
	 Roche Transfer Activities
	  	22.3.4.4(c)
	 Roche US
	  	cover page
	 RTL Criteria
	  	2.3.2
	 RTL Product
	  	4.6.2(iii)
	 Scripps License
	  	18.1.11
	 Senior Officers
	  	24.2
	 Settlement
	  	17.9
	 Shared Program
	  	4.4
	 Sole Vividion License Agreement
	  	4.6.3
	 Sole Vividion Program
	  	4.6.2
	 Sole Vividion Program Effective Date
	  	4.6.2
	 SPCs
	  	17.13
	 Sublicensee Sales
	  	1.114(ii)
	 Suit Notice
	  	17.9
	 Target Identification Information
	  	2.4.1
	 Target Nomination Notice
	  	2.5.1.1
	 Target Replacement Notice
	  	2.3.3
	 Target Reviewer
	  	2.4.1
	 Terminated Portion
	  	22.3.1
	 then current and available Validated Hit Data Package
	  	2.6.3
	 Third Party Claim
	  	19.1
	 Threshold Development Costs
	  	9.4

  
 - 23 - 

			
	 Threshold Launch Cost
	  	12.5
	 Tractability Assessment
	  	2.4.4(d)
	 Transfer Plan
	  	1.121
	 Validated Hit Criteria
	  	1.125
	 Vividion
	  	cover page
	 Vividion Base Patents
	  	1.133
	 Vividion CC Patents
	  	17.5.1
	 Vividion Draft Clinical Plan
	  	3.2.2.1
	 Vividion Draft Preclinical Plan
	  	3.2.2.1
	 Vividion Indemnitees
	  	19.1
	 Vividion Invention
	  	1.70
	 Vividion Option
	  	4.2.1
	 Vividion-Originated Transfer Activities
	  	22.3.4.4(c)
	 Vividion PoC Program
	  	4.2.1
	 Vividion PoC Program Opt-Out
	  	3.2.2.4
	 Vividion Program Nomination Fee
	  	13.5
	 Vividion Program Opt-Out
	  	3.2.1.4
	 Vividion Selection Period
	  	2.5.4
	 Vividion Sharing Option
	  	4.4
	 Vividion Switch
	  	4.2.1
	 WIP Collaboration Program
	  	2.6.2
	 WIP Plan
	  	2.6.2
	 WIP Term
	  	2.6.2
	 Withdrawal Notice
	  	8.9
	 Withholding Taxes
	  	15.1
	 work exclusively with Roche
	  	6.4

  

	2.	 Collaboration 

 

	2.1	 Conduct and Scope of the Collaboration 

Roche and Vividion shall use Commercially Reasonable Efforts to conduct the Collaboration pursuant to the mutually agreed Collaboration Plan, as it may be
amended in accordance with this Agreement. The activities conducted in connection with the Collaboration will be overseen by the JRC. 
 The Parties will
conduct the Collaboration aiming to identify and develop Covalent Inhibitors for [***] oncology and [***] immunology Collaboration Targets as well as to identify and develop Covalent Degraders for up to [***] Collaboration Targets as covered by the
Collaboration Plan. The initial [***] Covalent Inhibitor Targets as well as the initial [***] Covalent Degrader Targets are listed in the Collaboration Target Appendix. 

Roche will provide Roche Target Ligands to Vividion that meet the RTL Criteria for the Covalent Degrader Targets within [***] days after the applicable
Covalent Degrader Target becomes a Collaboration Target. Together with each Roche Target Ligand, Roche shall provide to Vividion information related to such Roche Target Ligand as is reasonably necessary or useful for Vividion to verify it meets the
RTL Criteria or for Vividion to perform the activities under the Collaboration Plan with such Roche Target Ligand, including the chemical structure thereof and the complete therapeutic rationale for progressing such Collaboration Target and Roche
Target Ligand under this Agreement. 

  
 - 24 - 

 Under the Collaboration Plan, Vividion shall use Commercially Reasonable Efforts (within the bandwidth
specified in the Collaboration Plan) to progress each Collaboration Target nominated within [***] months after the Effective Date to Validated Hit stage, it being understood that, as guided by the JRC, certain Collaboration Targets, or Compound
constructs Directed To a Collaboration Target, may be deprioritized in favor of Collaboration Targets or Compound constructs that continue to be progressed. Subject to Section 2.6.2, Vividion shall conduct at its own cost its activities under
the Collaboration Plan for such Collaboration Target. 
 Under the Collaboration, Vividion will also use Commercially Reasonable Efforts (within the
bandwidth specified in the Collaboration Plan) to identify and characterize novel E3 Modules, and will similarly use those E3 Modules to develop Covalent Degraders against Covalent Degrader Targets, all as described in the Collaboration Plan. 

 

	2.2	 Collaboration Plan 

The Parties will use Commercially Reasonable Efforts to conduct the Collaboration under the Collaboration Plan attached to the Agreement, as it may be amended
in accordance with this Section 2.2 and Section 8.1. Unless decided otherwise by the JRC, the Collaboration Plan sets forth (i) the scope of the Collaboration and the bandwidth that will be used to conduct the activities contemplated
within the scope of the Collaboration, including the responsibilities of each Party and (ii) specific objectives, which objectives will be updated or amended, as appropriate, by the JRC as research progresses. The JRC shall review the
Collaboration Plan on an ongoing basis and may update the Collaboration Plan. Any such updates shall be reflected in written amendments to the Collaboration Plan. 
  

	2.3	 Target Nomination 

 

	2.3.1	 Covalent Inhibitor Targets 

As of the Effective Date, there are [***] Covalent Inhibitor Targets, [***] of which are Collaboration Targets considered for use in oncology, and
[...***... of which are Collaboration Targets considered for use in immunology. 
 Roche shall have the right to replace any of such Covalent
Inhibitor Targets for oncology without any payments to Vividion, at any time after [***] months of the Effective Date but prior to [***] months after the Effective Date (“Covalent Inhibitor Target Replacement Period”), provided that
no Validated Hit has been identified for such Collaboration Target. The replacement Target must be available pursuant to Section 2.4 below, must be a Target for oncology and may not itself be later replaced pursuant to this Section 2.3.1.
Such replacement is subject to Section 2.4 (Target Gatekeeping Process) and Section 2.3.3. The replaced Target will be deleted from the Collaboration Target Appendix. 

 

	2.3.2	 Covalent Degrader Targets 

The initial Covalent Degrader Targets as of the Effective Date are listed in the Collaboration Target Appendix. In addition, prior to [***] months after the
Effective Date, Roche shall have the right to nominate Covalent Degrader Targets up to a total of [***] Covalent Degrader Targets (including the initial Covalent Degrader Targets) subject to (i) availability pursuant to Section 2.4 and
(ii) Roche providing Vividion a Roche Target Ligand meeting the following criteria with respect to the corresponding Covalent Degrader Target (“RTL Criteria”): 

A Roche Target Ligand must (a) [***] (b) [***], 

  
 - 25 - 

 (c) [***], and (d) not be subject to Third Party obligation on Roche or its Affiliates or otherwise, to
Roche’s knowledge at the time of delivery to Vividion (without an obligation to conduct a freedom to operate analysis), Covered By Patents owned or controlled by a Third Party. In case either of the Parties presents evidence that one of the
criteria of (a) through (d) is not met, the Parties shall discuss whether to include such Roche Target Ligand, and Vividion shall have the right to reject a Roche Target Ligand if one (1) or more of the foregoing criteria (a)-(d) is not
met with respect to such Roche Target Ligand. Promptly, after such rejection, Roche shall notify Vividion of whether a replacement Roche Target Ligand meeting the RTL Criteria will be provided (in which case Roche shall promptly provide such Roche
Target Ligand) or whether the Covalent Degrader Target shall no longer be considered a Collaboration Target. 
 Roche shall have the right to replace
(without any payment to Vividion) any of the Covalent Degrader Targets at any time from the earlier of (i) once a Roche Target Ligand to such Covalent Degrader Target has been rejected by Vividion, and (ii) after [***] months of the
Effective Date but within [***] months after the Effective Date (“CD Target Replacement Period”), provided that no work has been initiated (as described in the Collaboration Plan) with respect to such Covalent Degrader Target under
the Collaboration Plan in case of (ii) above and the reason for such replacement is Roche becoming aware of new information regarding such Covalent Degrader Target since such Covalent Degrader Target became a Collaboration Target under this
Agreement (“New Covalent Degrader Target Information”). The replacement Target must be (once it is a Collaboration Target) a Covalent Degrader Target and may not itself be later replaced pursuant to this Section 2.3.2. Such
replacement is subject to Section 2.4 (Target Gatekeeping Process) and Section 2.3.3. Once such replacement Target has been confirmed to not be an Excluded Target in accordance with Section 2.4, Roche shall provide to Vividion a Roche
Target Ligand meeting the RTL Criteria and thereafter such Target shall be a Covalent Degrader Target. 
  

	2.3.3	 Replacement Process 

To exercise such right to replace a Collaboration Target described in Sections 2.3.1 and 2.3.2, Roche shall, within the Covalent Inhibitor Target Replacement
Period or Covalent Degrader Target Replacement Period, as the case may be, provide written notice (“Target Replacement Notice”) to Vividion of such replacement identifying the Collaboration Target to be replaced (and if it is a
Covalent Degrader Target, the New Covalent Degrader Target Information) and either identifying the Target (including the UniProt accession number thereof) that is to replace such Collaboration Target or notice that it will be providing the identity
thereof to a Target Reviewer pursuant to 2.4.1. 
  

	2.4	 Target Gatekeeping Process 

 

	2.4.1	 Target Reviewer 

If Roche desires to nominate a Target or replace a Collaboration Target, Roche shall provide notice to Vividion of its intent (but not disclose the identity of
the new Target). Within [***] Business Days after such notification, Vividion shall provide an independent reviewer mutually agreed to by the Parties in accordance with Section 2.4.2 (the “Target Reviewer”) with an updated list
of Excluded Targets pursuant to Section 2.4.4. Within [***] Business Days thereafter, Roche shall provide to the Target Reviewer the Target that Roche proposes to become a Collaboration Target, together with its UniProt accession number and
other information requested by such Target Reviewer to the extent reasonably required to identify such Target and 

  
 - 26 - 

 determine whether it is an Excluded Target (“Target Identification Information”). Within
[***] Business Days thereafter, the Target Reviewer shall notify both Parties whether or not the proposed Target is an Excluded Target and if it is not an Excluded Target, the identity of such Target. If the proposed Target is not an Excluded
Target, then such Target shall be considered a Collaboration Target and in case the Target replaces a previous Collaboration Target, the replaced Target shall no longer be considered a Collaboration Target. Promptly after the Target Reviewer has
indicated that the proposed Target is not an Excluded Target, the Collaboration Target Appendix shall be updated. If the proposed Target is an Excluded Target, then such Target may only be added by mutual agreement of the Parties. 

 

	2.4.2	 Target Reviewer 

Within [***] days of the Effective Date, Roche and Vividion shall agree upon the Third Party who will serve as the Target Reviewer. Such Target Reviewer shall
be a mutually agreed law firm with patent prosecution expertise and shall enter into a mutually agreed joint representation agreement with both Roche and Vividion that (i) includes both Roche and Vividion as clients, and (ii) prohibits the
Target Reviewer from sharing with the Parties any information related to the proposed Target or Excluded Target, other than identifying to the Parties the information set forth in Section 2.4.1 to be provided by the Target Reviewer. The Parties
shall share [***] all fees and expenses of the Target Reviewer in accordance with such joint representation agreement. 
  

	2.4.3	 Expedited Process 

For purposes of the designation of any particular Target as a Collaboration Target, the Parties may agree to not utilize the Target Reviewer under Sections
2.4.1 (Target Reviewer) and 2.4.2 (Target Reviewer). Upon such agreement, instead, the Alliance Director from Roche shall make such request to the Alliance Director from Vividion, and the Alliance Director from Vividion shall confirm whether or not
the proposed Target is an Excluded Target. If the proposed Target is not an Excluded Target, then such Target shall be considered a Collaboration Target, and in case the Target replaces a previous Collaboration Target the replaced Target shall no
longer be considered a Collaboration Target. If the proposed Target is an Excluded Target, then such Target may only be added by mutual agreement of the Parties. If the Target is added as Collaboration Target, the Collaboration Target Appendix shall
be updated. 
  

	2.4.4	 Excluded Target 

“Excluded Target” means any Target nominated by Roche under this Section 2.4 that: 

(a) Is subject to an agreement with a Third Party under which Vividion has granted or is obligated to grant an exclusive license to a Third Party (or option
for an exclusive license), is contractually restricted from, or grants rights otherwise inconsistent with, granting to Roche the rights herein, or would be obligated to pay royalties or other amounts to the Third Party by reason of including such
Target hereunder; 
 (b) Vividion is in active negotiations [***] with respect to an arrangement described in clause (a) above; 

(c) Is the subject of a then current Vividion program, [***]; 

(d) Is one of up to [***] priority actionable Targets in Tractability Assessment as described in an actionable hit list provided to the Target Reviewer. For
purposes of the foregoing “Tractability Assessment” means that Vividion has [***] 

  
 - 27 - 

 [***]: 
 (e)
One of [***] Targets on Vividion’s highest priority active screening list. Such [***] Targets shall be those selected by Vividion from Targets [***]. 

In case Vividion claims that a Target proposed by Roche as a Collaboration Target is an Excluded Target, upon Roche’s request Vividion shall provide
written records to the Target Reviewer to demonstrate that the the clauses (a), (b), (c), (d) and/or (e) applies. 
  

	2.5	 Program Nomination 

 

	2.5.1	 Nomination 

In addition to the progress reports for a Collaboration Target pursuant to Section 2.8, Vividion shall provide Roche with the Validated Hit Data Package
for [***] Directed To a Collaboration Target for which it completed during the Collaboration Term (and thereafter prior to [***] month after expiration of the WIP Term with respect to WIP Collaboration Targets for which a WIP Plan was agreed) the
activities for such Compound(s) required to generate the documents, records, and reports required to be included in such Validated Hit Data Package and Roche shall confirm in writing the receipt of the complete Validated Hit Data Package. 

On a Collaboration Target-by-Collaboration Target basis, upon the availability
of a Validated Hit Data Package during the Collaboration Term (and thereafter prior to [***] after expiration of the WIP Term with respect to WIP Collaboration Targets for which a WIP Collaboration Plan was agreed), the JRC shall discuss the
Validated Hit for such Collaboration Target as basis for selecting Nominated Programs. Subject to Section 2.5.1.1, Roche shall decide whether such Validated Hit shall be nominated as a “Nominated Program” (“Program
Nomination”) by providing written notice thereof to Vividion within [***] days of the Delivery Date of a Validated Hit Data Package for a Collaboration Target (the date of Vividion’s receipt of such notice, the “Nomination
Date”). If Roche does not provide such written notice indicating that the Validated Hit is a Nominated Program within such period, or Roche provides Vividion notice that such Validated Hit is not a Nominated Program (“Declined
Nomination Notice”), then: 
  

	 	2.5.1.1	 If Vividion provides notice (a “Proposed Target Nomination Notice”) to Roche within [***] days after
its receipt of the Declined Nomination Notice (or expiration of the [***]-day period described above in which Roche can nominate such Collaboration Target as a Nominated Program) that it will select such
Collaboration Target and Validated Hit as the subject of a Vividion Program, then within [***] Business Days after receipt of such Proposed Target Nomination Notice, Roche shall either: (i) provide notice to Vividion that Roche will pay the
Vividion Program Nomination Fee for such Collaboration Target (“Target Nomination Notice”), in which case such Collaboration Target shall be a Nominated Program and deemed selected as a Vividion Program pursuant to Section 2.5.4 as of
the date Vividion provided the Proposed Target Nomination Notice (provided however, such Vividion Program shall not be considered a Vividion Program for determining whether Vividion has selected and has ongoing [***] Vividion Programs for purposes
of Section 2.5.5 and shall not count towards, or be subject to, the maximum of [***] Vividion Programs that 

  
 - 28 - 

	 	can be selected as Vividion Programs for purposes of Sections 2.5.4, 2.5.6 and 2.5.7) and the date of Vividion’s receipt of such notice shall be deemed the Nomination Date or (ii) provide notice to
Vividion that it is not paying the Vividion Program Nomination Fee, in which case thereafter, Vividion shall have the right to continue the development and commercialization of compounds and products with respect to such Collaboration Target as
a Sole Vividion Program pursuant to Section 4.6.2 independently of Roche and this Agreement and such Collaboration Target shall no longer be a Collaboration Target. If Vividion initiates the development of a Sole Vividion Program, the Parties
shall either negotiate the Sole Vividion License Agreement pursuant to Section 4.6.2 or add such program to the at that time existing Sole Vividion License Agreement to document the license granted to Vividion pursuant to
Section 4.6.2 for such Sole Vividion Program (for clarity, unless and until such a Sole Vividion License Agreement is entered into for (or amended to include) such program, the license and other terms of Section 4.6.2 shall be applicable).

  

	 	2.5.1.2	 If Vividion does not provide a Proposed Target Nomination Notice or Vividion does not initiate the development
of a Sole Vividion Program, then such Collaboration Target and Validated Hit shall not be a Nominated Program and thereafter, at Vividion’s discretion, Vividion may continue activities with respect to such Collaboration Target during the
Collaboration Term to identify additional Validated Hits and propose Validated Hit Data Packages to Roche and the JRC for potential nomination as a Nominated Program. 

 

	2.5.2	 Distinct Nominated Programs for Different E3 Ligases or Different Roche Target Ligands With respect to Covalent
Degrader Targets, if two Validated Hit Data Packages exist for a given Collaboration Target, [***] then those two Validated Hit Data Packages, if nominated, would result in two Nominated Programs. 

 

	2.5.3	 Replacement of Nominated Programs for Different E3 Ligases or Different Roche Target Ligands

 If a second Covalent Degrader directed against the same Covalent Degrader Target but a different E3 Ligase becomes a Nominated Program
within [***] months of nomination of the first Covalent Degrader against the same Covalent Degrader Target, to the extent such first Nominated Program is a Roche Program or Vividion Program, if a Party requests, then the JRC may decide to replace
such first Nominated Program with such second Nominated Program with no additional Roche Program Nomination Fee or Vividion Program Nomination Fee, as applicable. A Party so requesting such replacement shall provide the other Party written notice of
such replacement within [***] days after the Nomination Date for such second Nominated Program. After such a replacement, Roche shall no longer have any rights or options with respect to such first Nominated Program or Compounds Directed To both the
applicable Collaboration Target and E3 Ligase for such first Nominated Program. 
 For clarity, a Nominated Program that is neither selected as a Roche
Program or Vividion Program nor replaced pursuant to this Section 2.5.3, shall be deemed a Reserved Program and Section 6 (Exclusivity) shall apply. 

  
 - 29 - 

	2.5.4	 Nominated Program Selection 

Nominated Programs shall be selected by the Parties within [***] days after its nomination and according to the following procedure and recorded in the minutes
of the relevant JRC meeting: 
 For each Nominated Program, other than for the Collaboration Target [***], Vividion has the first choice of selecting such
Nominated Program as a Vividion Program, if at the time of the Nomination Date for such Nominated Program there are less than [***] concurrent Vividion Programs (not counting any Vividion Programs deemed selected by Vividion pursuant to
Section 2.5.1.1). 
 Vividion shall make such selection by providing written notice thereof to Roche within [***] days after its Nomination Date
(“Vividion Selection Period”). 
 For each Nominated Program that Vividion has not selected as a Vividion Program, Roche may decide, at its
discretion, whether to select such Nominated Program as a Roche Program by providing written notice to Vividion within [***] days after expiration of the Vividion Selection Period (or, if earlier, after Vividion provides written notice to Roche that
it is not selecting such Nominated Program as a Vividion Program). 
 Notwithstanding the second paragraph of this Section 2.5.4, as long as Vividion
has at least [***] concurrent Vividion Programs (not counting any Vividion Programs deemed selected by Vividion pursuant to Section 2.5.1.1), Roche has the first choice of selecting such Nominated Program (other than for the Collaboration
Target [***]) as a Roche Program, such selection to be made by providing written notice thereof to Vividion within [***] days after its Nomination Date. 

Roche shall have the first right to select any Nominated Program for the Collaboration Target [***] as a Roche Program by providing written notice thereof to
Vividion within [***] days after its Nomination Date. If Roche does not so select such Nominated Program as a Roche Program, Vividion shall have the right to select such Nominated Program as a Vividion Program by providing written notice thereof to
Roche within [***] days after expiration of Roche’s [***] day selection period. 
 Vividion shall have the first right to select any Nominated Program
for the Collaboration Target [***] as a Vividion Program by providing written notice thereof to Roche within [***] days after its Nomination Date. If Vividion does not so select such Nominated Program as a Vividion Program, Roche shall have the
right to select such Nominated Program as a Roche Program by providing written notice thereof to Vividion within [***] days after expiration of Vividion’s [***] day selection period. 

A Nominated Program that is not initially selected as described above by the respective Party (or JRC) as a Vividion Program or a Roche Program is a
“Reserved Program” as of the date of the expiry of the last applicable selection period. 
  

	2.5.5	 Vividion Obligation to Select Vividion Program 

If within [***] months of the Effective Date, Vividion has not yet selected the first Vividion Program, Vividion must select at least [***]. 

  
 - 30 - 

 If within [***] months after the Effective Date, Vividion has not yet selected the second Vividion Program,
Vividion must select the second Vividion Program from one of the Reserved Programs as soon as there is at least [***] Reserved Program available; provided that Vividion shall not be obligated to select a second Vividion Program if at the time there
are [***] Reserved Programs available and there is not at least [***]. 
 If, during the Collaboration Term, a Vividion Program is discontinued pursuant to
Section 3.2.1.4 and less than [***] Vividion Programs (or Programs resulting from Vividion Programs) remain, then Vividion shall select a new Vividion Program from the Reserved Programs, provided that at least [***] is available. 

 

	2.5.6	 Selection from Reserved Programs 

During the Reservation Period, Vividion and Roche shall have the right, on a first come-first serve basis (as evidenced by a written notice to the other
Party), at their respective discretion to select additional Vividion Programs (up to a total of [***] concurrent Vividion Programs (not counting any [***]) during the Collaboration Term, and for any number of Vividion Programs after the
Collaboration Term) or Roche Programs from Reserved Programs. 
  

	2.5.7	 Reservation Period for Reserved Programs 

On a Reserved Program-by-Reserved Program basis, the Parties may select such
Program pursuant to Section 2.5.6, for the period of time beginning on the date a Nominated Program has become a Reserved Program and ending on the later of (i) expiration of the Collaboration Term and (ii) the anniversary set forth
in the table below of its Nomination Date, based on the number of Reserved Programs that exist as of [***] months after the expiration of the Collaboration Term (the “Reservation Period”) 

 

			
	 # of Reserved Programs as of expiration of Collaboration Term
[***]
	  	Anniversary of Nomination Date
	 [***]
	  	[***] Anniversary
	 [***]
	  	[***] Anniversary

 Notwithstanding the foregoing, (a) if by the expiration of the Collaboration Term, Roche has not initiated at least [***]
Roche Programs, then the Reservation Period for all Reserved Programs shall end upon the expiration of the Collaboration Term (or, with respect to WIP Collaboration Programs not selected as a Roche Program or Vividion Program pursuant to
Section 2.5.4, the Reservation Period shall be deemed expired upon expiration of the last applicable selection period in Section 2.5.4), or (b) if Roche does not select at least [***] Roche Programs from the Reserved Programs in each
successive [***] month period following expiration of the Collaboration Term then the Reservation Period for the respective Reserved Program shall terminate upon Vividion’s generation of a hit (i.e., a compound (that is not a Compound) meeting
the [***] criteria in the definition of Hit) from an independently performed screen by Vividion outside the Agreement and Directed To the Collaboration Target of such Reserved Program (“Reserved Program Research Activities”). 

For example, if at the end of the Collaboration Term, Roche has initiated at least [***] Roche Programs and there exists [***] Reserved Programs (with
Nomination Dates of [***] months after the Effective Date, respectively), then the Reservation Period for such Reserved Programs shall be 

  
 - 31 - 

	 	-	 [***]; 

provided however, if Roche has not selected at least [***] Reserved Programs as Roche Programs within the [***] month period immediately following expiration
of the Collaboration Term, and Vividion has started Reserved Program Research Activities for the [***] Reserved Program, then the Reservation Period for the corresponding Collaboration Target shall end upon such start of Reserved Program Research
Activities. 
 Following the Reservation Period for a Reserved Program, if neither Party has selected such Reserved Program as Vividion Program or Roche
Program, respectively, within its Reservation Period such Reserved Program shall be abandoned and Section 4.6.2 shall apply. 
  

	2.6	 Duration 

  

	2.6.1	 Collaboration Term Extensions. The Collaboration shall commence on the Effective Date and shall continue until
the end of the Collaboration Term. The Parties may mutually agree to extend the Collaboration Term (e.g. for additional Targets in different disease areas) twice for a [***] extension, each extension to be agreed no later than [***] prior to the end
of the then current Collaboration Term. 

  

	2.6.2	 Work-in-Progress. [***] months
prior to the expiration of the Collaboration Term (or as otherwise mutually agreed by the Parties), Vividion shall report to the JRC the status of its activities with respect to Collaboration Targets for which Vividion has not yet delivered a
Validated Hit Data Package. The JRC shall mutually agree which activities can be progressed under the Collaboration such that a Validated Hit Data Package can be completed within [***] months after the expiration of the Collaboration Term
(“WIP Term”), along with a proposed plan (including budget) for the conduct of activities, if any, to be conducted during the [***] months after the expiration of the Collaboration Term (“WIP Plan”). The activities
included in the WIP Plan shall be designed to be (i) completed within the WIP Term within the bandwidth specified in the Collaboration Plan (e.g., if for a Collaboration Target it would take more than [***] months after expiry of the
Collaboration Term to complete activities to generate a Validated Hit Data Package, then such Collaboration Target would not be worked on under the WIP Plan) and (ii) not reliant on obtaining certain results or technical success in order to be
completed within such period. Vividion shall use Commercially Reasonable Effort to conduct such activities during the WIP Term in accordance with the JRC approved WIP Plan, and [***] all costs and expenses (including [***]) incurred by Vividion for
such activities conducted after expiry of the Collaboration Term. Roche shall pay to Vividion its share of such costs and expenses within [***] days of completion of the WIP Term and receipt of an invoice therefor. Any Collaboration Target for which
a Validated Hit Data Package is provided to Roche under the WIP Plan (“WIP Collaboration Program”) shall then be eligible to become a Nominated Program pursuant to Section 2.5.1. 

 

	2.6.3	 For any Collaboration Target for which Vividion has not provided a Validated Hit Data Package prior to
(a) the end of the Collaboration Term for Collaboration Target not subject to the WIP Plan or (b) [***] months after expiration of the Collaboration Term with respect to Collaboration Targets subject to the WIP Plan, (such expiration of the
Collaboration Term, or [***] months thereafter, as applicable for a particular 

  
 - 32 - 

	 	Collaboration Target, the “Collaboration End Date”) Roche shall have the right to nominate a Nominated Program for such Collaboration Target to the extent a Hit Directed To such Collaboration Target has
been identified in the Collaboration, and such Nominated Program shall include other Hits Directed To such Collaboration Target (provided that with respect to Covalent Degraders such Hits are Directed To the same E3 Ligase and use the same Roche
Target Ligand). If Roche is interested in potentially exercising such right with respect to a Collaboration Target, Roche shall provide written notice to Vividion, within [***] Business Days after the applicable Collaboration End Date, of the
Collaboration Targets for which it is so interested and thereafter Vividion shall promptly provide Roche with the information and data then in Vividion’s Control that would be included in the Validated Hit Data Package (the “then
current and available Validated Hit Data Package”) on at least the most advanced Hit for such Collaboration Target (for clarity, Vividion shall not be obligated to conduct additional activities after the applicable Collaboration End Date to
generate any such data or information). Roche shall exercise such right to nominate a Nominated Program for such a Collaboration Target by providing written notice within [***] days after the applicable Collaboration End Date and the delivery to
Roche of the then current and available Validated Hit Data Package. Such Nominated Program shall be deemed selected as a Roche Program pursuant to Section 2.5.4 (i.e., Roche may not exercise such right to make such Nominated Program a Reserved
Program) and the Roche Program Nomination Fee shall be payable pursuant to Section 13.4.1 with respect to such Roche Program. 

  

	2.7	 Cost 

Each Party shall be responsible for its own costs in the conduct of the Collaboration Plan other than as set forth in Section 2.6.2. 

 

	2.8	 Progress Reports 

At least quarterly during the Collaboration Term, Vividion shall prepare and provide to the JRC a written report (which may be in the form of a slide
presentation) summarizing the progress of the work performed by Vividion in the course of the Collaboration during the preceding Calendar Quarter. 
 Through
the JRC, Roche may request that Vividion provides more detailed information and data regarding the updates earlier provided, and Vividion shall promptly provide the requesting Party with information and data to the extent identified in the
Collaboration Plan to be exchanged between the Parties as is reasonably available and Controlled by Vividion. Promptly upon expiration of the Collaboration Term, Vividion shall provide a final written report (which may be in the form of a slide
presentation) summarizing its activities under the Collaboration Plan and results thereof, to the extent not previously summarized in an earlier report. Upon Vividion’s request, to the extent Roche conducts activities under the Collaboration,
Roche shall provide similar reports and updates. Vividion shall not be obligated under this Agreement to disclose to Roche any information comprising [***]. 
  

	2.9	 Records 

Each Party shall maintain records of the Collaboration (or cause such records to be maintained) in sufficient detail and in good scientific manner as will
properly reflect all work done and results achieved by or on behalf of such Party in the performance of the Collaboration. All laboratory notebooks (which may be in the form of an electronic database) shall be maintained for no less than the term of
any Patents issuing therefrom. 

  
 - 33 - 

	2.10	 Materials 

Each Party will as a matter of course as described in the Collaboration Plan, the Preclinical Plan or the Clinical Plan upon the other Party’s reasonable
written request, furnish to each other samples of Materials which constitute Know-How in such Party’s Control and are necessary for the other Party to carry out its responsibilities under the
Collaboration Plan. 
 Each Party will use such Materials only pursuant to the Collaboration Plan, the Preclinical Plan, the Clinical Plan or otherwise in
accordance with this Agreement or to exercise the rights granted to such Party pursuant to Section 4.6.2 or Section 5. Except with the prior written consent of the other Party, the Party receiving any such Materials will not distribute or
otherwise allow the release of Materials to any Third Party, except for subcontracting or to Sublicensees in each case as permitted hereunder. 
  

	3.	 Roche Program and Vividion Program 

 

	3.1	 Roche Program 

Upon nomination as a Roche Program pursuant to Section 2.5, Roche shall be solely responsible, at Roche’s cost and using Commercially Reasonable
Efforts, to research, develop and commercialize Compounds and Products of such Roche Program. Roche will provide updates to Vividion pursuant to Section 9.2 (Development Updates) and Section 12.2 (Commercialization Updates). 

 

	3.2	 Vividion Program 

 

	3.2.1	 Conduct of a Vividion Program 

 

	 	3.2.1.1	 Preclinical Plan; Conduct 

Upon nomination as a Vividion Program pursuant to Section 2.5, Vividion shall within [***] days submit to the JRC for approval a Preclinical Plan of
activities up to delivery of the CCS Data Package for such Vividion Program. Either Party may propose amendments to the Preclinical Plan from time-to-time. Any such
amendments shall be subject to the approval by the JRC as set forth in Section 8.1. 
 Vividion shall, using Commercially Reasonable Efforts, be solely
responsible, at [***] sole expense, for the development of Compounds until delivery of the CCS Data Package for such Vividion Program. The activities for a Vividion Program are described in a Preclinical Plan. 

 

	 	3.2.1.2	 CCS Criteria; CCS Data Package 

For each Vividion Program, after [***] months after selection as a Vividion Program (or such earlier time the JRC determines) the JRC shall review the CCS
Criteria and required contents of the CCS Data Package to be delivered by Vividion for such Vividion Program and consider whether they should be amended for such particular Vividion Program. Any such amendment to the CCS Criteria and the required
contents of the CCS Data Package shall be applicable for the particular Vividion Program under consideration and shall require the approval of the JRC. For clarity, the CCS Data Package would be established with the aim of providing information to
evaluate whether the CCS Criteria have been achieved and shall not be required to contain information demonstrating that the CCS Criteria have been achieved. 

  
 - 34 - 

 Vividion shall provide the CCS Data Package to the JRC promptly after completion of the activities for such
Vividion Program required to generate the documents, records, and reports required to be included in such CCS Data Package. 
  

	 	3.2.1.3	 Roche Activities 

Roche shall, as set forth in the Preclinical Plan, provide expertise to support advancements of Vividion Programs, such as information on useful cell lines
and animal models and such information provided by Roche shall be considered Roche Know-How. 
  

	 	3.2.1.4	 Termination; Extension 

The JRC (by consensus only, with no escalation) may decide to terminate a Vividion Program, after which (a) if such termination is during the
Collaboration Term, the Collaboration Target for such Vividion Program shall remain a Collaboration Target during the Collaboration Term and, at Vividion’s discretion, Vividion may continue activities under the Collaboration with respect to
such Collaboration Target during the Collaboration Term to identify additional Validated Hits and propose Validated Hit Data Packages to Roche and the JRC for potential nomination as a Nominated Program, or (b) if such termination is after the
Collaboration Term, the Collaboration Target for such Vividion Program shall cease to be a Collaboration Target, the Roche Option for such Vividion Program shall terminate and any rights granted by Roche to Vividion under this Agreement with respect
to any Roche Target Ligand for such Collaboration Target shall terminate. 
 In addition, with respect to each Vividion Program, Vividion shall have the
right beginning [***] months after such Vividion Program was selected as a Vividion Program pursuant to Section 2.5.4 or 2.5.6 to discontinue Vividion’s conduct of the Vividion Program on [***] months’ advance notice (a
“Vividion Program Opt-Out”), which notice, for clarity may be provided as early as [***] months after such Vividion Program was selected as a Vividion Program. During such [***] month notice
period, as requested by Roche, the Parties shall confer through the JRC regarding the progress made and results of the Vividion Program up to such point and if further requested by Roche prior to expiration of such [***] month period the
discontinuation of such Vividion Program shall be escalated to the Senior Officers for discussion for [***] Business Days. The effective date of such Vividion Program Opt-Out shall be the expiration of such
[***] month period, unless Roche requests escalation to the Senior Officers, in which case the effective date shall be the expiration of such [***] Business Day period, in each case to the extent Vividion does not withdraw such notice of a Vividion
Program Opt-Out by notice thereof within such periods. After a Vividion Program Opt-Out, Roche shall have the right to exercise its Roche Option in accordance with
Section 4.1, provided however if Roche exercises its Roche Option for such Vividion Program such Program shall be deemed a Roche Program rather than an Optioned Roche Program (e.g., Roche pays the milestones and royalties for a Roche Program
rather than the milestones and royalties for an Optioned Roche Program); provided that Roche shall pay [***] US Dollars ($[***]) upon [***] instead of a [***] US Dollars ($[***]) option exercise fee under Section 13.6. 

  
 - 35 - 

	3.2.2	 Vividion PoC Program 

 

	 	3.2.2.1	 Preparation of Preclinical Plans and Clinical Plans and exercise of the Vividion PoC Option

 Upon Roche’s exercise of its Option Right for a Vividion Program pursuant to Section 4.1 and in anticipation of
Vividion’s exercise of the Vividion Option pursuant to Section 4.2, (other than in the case of (i) a Vividion Program Opt-Out or (ii) in the case Vividion does not have a Vividion Option or
(iii) provides notice to Roche that it is not exercising the Vividion Option for such Optioned Roche Program), Vividion shall at the latest [***] Business Days after Roche’s exercise of its Option Right for a Vividion Program pursuant to
Section 4.1 submit for approval (i) to the JRC a Preclinical Plan for activities up to Completion of the GLP Tox Study (“Vividion Draft Preclinical Plan”), and (ii) to the JDC a Clinical Plan for activities after the
GLP Tox Study up to Completion of the PoC Study (“Vividion Draft Clinical Plan”). The JRC and JDC (as applicable) shall meet promptly after submission of the Vividion Draft Preclinical Plan and Vividion Draft Clinical Plan to
discuss such draft plans and establish the Preclinical Plan for activities up to Completion of the GLP Tox Study and the Clinical Plan, as applicable. The Option Period for the Vividion Option for the respective Vividion Program shall be tolled
until the final Preclinical Plan and Clinical Plan (including budgets therefor) have been established pursuant to Section 8. 
 The Vividion Draft
Clinical Plan and Clinical Plan shall include an estimated number of subjects to be dosed with the applicable Product under such plan. 
 The Clinical Plan
shall be updated and submitted for JDC approval upon Completion of the GLP Tox Study and whenever considered necessary by the JDC. 
  

	 	3.2.2.2	 Conduct of a Vividion PoC Program 

Vividion shall be solely responsible for the development, manufacture and supply of Compounds under such Vividion PoC Program and shall use Commercially
Reasonable Efforts to conduct its activities under the Preclinical Plan and the Clinical Plan. 
  

	 	3.2.2.3	 Termination of a Vividion PoC Program 

The JRC (prior to Completion of the GLP Tox Study) or JDC (after Completion of the GLP Tox Study), in each case solely by consensus, may decide to terminate a
Vividion PoC Program, after which Vividion shall promptly wind-down its activities under such Vividion PoC Program, the costs of which shall be shared [***] pursuant to PoC Cost Sharing, and the Collaboration Target for such Vividion PoC Program
shall cease to be a Collaboration Target, the Roche PoC Option for such Vividion PoC Program shall terminate and any rights granted by Roche to Vividion under this Agreement with respect to any Roche Target Ligand for such Collaboration Target shall
terminate. 
  

	 	3.2.2.4	 Vividion PoC Program Opt-Out 

With respect to each Vividion PoC Program, Vividion shall have the right to discontinue its conduct of a Vividion PoC Program (“Vividion PoC Program Opt-Out”) by providing written notice to Roche prior to [***] days after the JDC has approved the Clinical Plan as first updated after Completion of the GLP Tox Study for such Vividion PoC Program. The
following shall apply upon delivery of such notice: 
  

	(a)	 Roche shall have the right to exercise its Roche PoC Option in accordance with Section 4.3, provided
however if Roche exercises its Roche PoC Option for such Vividion PoC 

  
 - 36 - 

	 	Program such Program shall be deemed an Optioned Roche Program rather than a Roche PoC Program (e.g., Roche pays a $[***] fee under Section 13.6 upon exercise of the Option Right instead of a $[***]
option exercise fee under Section 13.7, and Roche pays the milestones and royalties for an Optioned Roche Program rather than the milestones and royalties for a Roche PoC Program). 

 

	(b)	 If Roche so exercises the Roche PoC Option in such event, the Parties shall promptly determine a plan for the
prompt transition of the continued conduct of such Vividion PoC Program by Roche as an Optioned Roche Program. 

  

	(c)	 If Roche does not exercise the Roche PoC Option following a Vividion PoC Program
Opt-Out, Vividion shall promptly wind-down its activities under such Vividion PoC Program, the costs of which shall be shared [***] by the Parties pursuant to PoC Cost Sharing. 

 

	3.2.3	 PoC Cost Sharing 

For each Vividion PoC Program, the Parties shall [***] share PoC Costs incurred by Vividion for the conduct of activities under the Preclinical Plan (to the
extent incurred after provision of the applicable CCS Data Package) and Clinical Plan for a Vividion PoC Program, including for GLP-Tox Studies and the PoC Studies up to delivery of the PoC Data Package as
described in the Financial Appendix (“PoC Cost Sharing”). If PoC Costs are exceeding [***] US Dollars ($[***]) for such program (all such costs in excess of $[***], the “Excess PoC Costs”), then at Vividion’s
election Roche shall reimburse Vividion for all Excess PoC Costs (subject to the paragraph below). For clarity, Vividion shall decide to either pay [***] percent ([***]%) of Excess PoC Costs or no Excess PoC Costs, and shall not elect a different
proportion of Excess PoC Costs. 
 The Preclinical Plan and Clinical Plan (and any amendment thereto) approved by the JRC or JDC, as applicable, by
consensus (or by Roche exercising its final decision making authority) shall include a budget of PoC Costs for the conduct of the activities under such Preclinical Plan or Clinical Plan, as applicable (respectively, the “Preclinical Plan
Budget” and “Clinical Plan Budget”). To the extent Roche amends the Preclinical Plan or Clinical Plan by exercising its final decision making authority to add additional activities, the budget in such plan for such
additional activities shall be determined in the same manner and using the same assumptions as the budget set forth in the initial Preclinical Plan and Clinical Plan (e.g., the same costs per patient assumption should be used). The Parties shall
share [***] PoC Costs incurred in excess of the Preclinical Plan Budget and Clinical Plan Budget, subject to Roche reimbursing all Excess PoC Costs, if applicable. 

Following Roche’s exercise of the Roche PoC Option for such Vividion PoC Program, if Vividion exercises its Vividion Sharing Option and Vividion has
elected to have Roche reimburse all Excess PoC Costs, Vividion shall pay to Roche [***] percent ([***]%) of such Excess PoC Costs by means of offsetting such amount from the Option Exercise Fee pursuant to Section 13.7.1 and, if necessary, the
next corresponding future milestone payments for such Program. Vividion may, in its discretion from time-to-time elect to prepay any portion of such then-outstanding
amounts upon written notice to Roche. 
 (b) If Roche does not exercise its Roche PoC Option for a Vividion PoC Program or if Vividion does not exercise its
Vividion Sharing Option, then Vividion shall not be obligated to repay Roche any of the Excess PoC Costs. 

  
 - 37 - 

	3.2.4	 Progress Reports 

Vividion shall prepare and provide to the JRC or the JDC, as applicable, a detailed written report (which may be in the form of a slide presentation)
summarizing the progress of the work performed by Vividion for a Vividion Program or a Vividion PoC Program, as applicable, during the preceding Calendar Quarter. Through the JRC or JDC, as applicable, Roche may request that Vividion provides more
detailed information and data regarding the updates earlier provided, and Vividion shall promptly provide Roche with information and data generated under the Preclinical Plan or Clinical Plan Controlled by Vividion. 

 

	3.2.5	 Records 

Vividion shall maintain records of its activities under each Vividion Program or Vividion PoC Program, as applicable, (or cause such records to be maintained)
in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of Vividion in the performance of the Preclinical Plan or the Clinical Plan, as applicable. All laboratory notebooks
(which may be in the form of an electronic database) shall be maintained for no less than the term of any Patents issuing therefrom. 
  

	4.	 Option Rights 

 

	4.1	 Roche Option for a Vividion Program 

With respect to each Vividion Program, Roche shall have the exclusive option right at the Delivery Date of the CCS Data Package (or upon a Vividion Program Opt-Out, if earlier) to obtain the exclusive license set forth in Section 5.2.1.2 for such Vividion Program to which the option pertains (“Roche Option”). 

Roche shall have the right to exercise the Roche Option for a Vividion Program by providing notice thereof to Vividion within the Roche Option Period for such
Vividion Program, even if not all CCS Criteria are met. 
 The term “Roche Option Period” shall mean, with respect to a Vividion Program,
the period starting on the Delivery Date of the CCS Data Package for a Compound of such Vividion Program (or, if earlier, the effective date of a Vividion Program Opt-Out for such Vividion Program) and ending
[***] months thereafter. 
 If Roche exercises the Roche Option for a Vividion Program by providing an Option Exercise Notice within the Roche Option
Period, Roche shall have on the Selection Effective Date the exclusive license set forth in Section 5.2.1.2 (unless Vividion exercises the Vividion Option for such Vividion Program) and such Vividion Program is deemed an Optioned Roche Program
(“Optioned Roche Program”) and no longer a Vividion Program. 
  

	4.2	 Vividion Option for Optioned Roche Program 

 

	4.2.1	 Vividion Option, Vividion Switch and Roche Switch 

Subject to the Roche Switch and the Vividion Switch, for the second Optioned Roche Program and fourth Optioned Roche Program, Vividion shall have the
exclusive option right to develop such Optioned Roche Program until delivery of the PoC Data Package (“Vividion Option”). 
 Notwithstanding
the foregoing, (a) subject to the Vividion Switch, Roche shall have a one-time right to declare that the Vividion Option shall be applicable to the [***] (the “Roche Switch”) by 

  
 - 38 - 

 providing to Vividion written notice thereof together with the Option Exercise Notice for the first Optioned
Roche Program and (b) Vividion shall have a one-time right (i) if Roche exercises the Roche Switch, to declare that the Vividion Option shall be applicable either to the [***] by providing written
notice thereof to Roche within [***] days after its receipt of notice from Roche of the Roche Switch and (ii) if Roche does not exercise the Roche Switch, to declare that the Vividion Option shall be applicable to the [***] by providing to
Roche written notice thereof within [***] days after receipt of the Option Exercise Notice for the second Optioned Roche Program ((i) or (ii) as applicable, the “Vividion Switch”). 

For illustration, the following scenarios for Vividion Options are possible 
  

			
	 Scenario
	  	 Vividion Option

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	[***]
	 [***]
	  	 [***]

 For clarity, the [***]. 

Vividion must exercise the Vividion Option by providing written notice thereof to Roche within [***] days after the initial Preclinical Plan and initial
Clinical Plan (including the budgets) for the Program is approved by the JRC (or established by Roche by exercising its final decision making authority). If Vividion exercises the Vividion Option, such Optioned Roche Program is converted to and
shall be referred to as a “Vividion PoC Program” and Roche shall have the Roche PoC Option pursuant to Section 4.3. 
 Notwithstanding
anything to the contrary, any Nominated Program for the Collaboration Target [***], regardless of when and in what order such Program becomes an Optioned Roche Program. Such Program becoming an Optioned Roche Program (or a Vividion PoC Program)
shall not affect whether Vividion has the Vividion Option for other Optioned Roche Programs (i.e., the determination of whether an Optioned Roche Program is the [***] for purposes of determining whether Vividion shall have the Vividion Option shall
be determined without taking into consideration any Optioned Roche Program for the Collaboration Target [***]), provided however that Vividion shall not have the right to exercise more than [***] Vividion Options (including [***]), unless there have
been at least [***] Optioned Roche Programs that have not converted into a Vividion PoC Program. 
  

	4.2.2	 PoC Opt-In after GLP Tox 

If Vividion does not exercise the Vividion Option for an Optioned Roche Program after providing a Vividion Draft Preclinical Plan and Vividion Draft Clinical
Plan for such Optioned Roche Program pursuant to Section 3.2.2, the following shall apply: 

  
 - 39 - 

 (a) Upon Completion of the GLP Tox Study for such Optioned Roche Program, Roche shall provide Vividion its
plan and budget for the conduct of clinical research and development activities Roche plans to conduct through the Completion of the last Clinical Study prior to a Pivotal Study for Compounds and Products for such Optioned Roche Program, which plan
shall be prepared by Roche in good faith and conform to the plan and budget that Roche uses internally for planning and budgeting purposes (a “Roche PoC Clinical Plan”). Roche shall provide an updated Roche PoC
Clinical Plan if Roche’s internal plans change prior to Initiation of the first Clinical Study under such Optioned Roche Program. 
 (b) Together with
the Roche PoC Clinical Plan, Roche shall provide to Vividion an accounting of Development Costs incurred by Roche for such Optioned Roche Program since exercise of the Roche Option for such Optioned Roche Program (“Prior Roche PoC
Costs”). 
 (c) Vividion shall have the right, by providing written notice within [***] days after its receipt of a Roche PoC Clinical Plan, to opt
in to sharing Roche’s PoC Costs (mutatis mutandis) incurred in accordance with such Roche PoC Clinical Plan. If Vividion so opts in, then: 

(i) Vividion shall pay Roche [***] percent ([***]%) of the Prior Roche PoC Costs for such Optioned Roche Program within [***] months after
providing such notice to so opt-in. 
 (ii) Roche shall conduct the activities under and in
accordance with the Roche PoC Clinical Plan, as may be amended, and the Clinical Plan, as may be amended; 
 (iii) the Parties shall share
[***] the PoC Costs (mutatis mutandis) incurred by Roche for the conduct of activities under the Roche PoC Clinical Plan, as may be amended (subject to Vividion’s decision whether or not to share Excess PoC Costs pursuant to
Section 3.2.3) 
 (iv) Roche shall provide Vividion progress reports and information and data pursuant to Section 3.2.4 and
Section 4.7 mutatis mutandis; 
 (v) Upon completion of the Clinical Study(ies) in such Roche PoC Clinical Plan, Roche shall
submit to Vividion a data package (“Roche PoC Data Package”) containing the set of documents, reports, records and reports that would be required in a PoC Data Package had Vividion conducted activities under a Clinical Plan for
such Optioned Roche Program; 
 (vi) Such Optioned Roche Program shall thereafter be deemed a Roche PoC Program for purposes of determining
milestones and royalties payable on Products for such Program and Roche shall pay to Vividion [***] US Dollars ($[***]) if Vividion exercises its Vividion Sharing Option or [***] US Dollars ($[***]) if Vividion does not exercises its Vividion
Sharing Option (i.e., the difference between the option exercise fee for exercising the Roche PoC Option and the option exercise fee for exercising the Roche Option) upon [***] for a Product for such Program; and 

  
 - 40 - 

 (vii) Vividion shall have the right to exercise its Vividion Sharing Option with respect to
such Program as if such Program was a Roche PoC Program, provided that it may exercise such Vividion Sharing Option within [***] days after the later of Roche providing the Roche PoC Data Package and Roche providing Vividion the initial
Development Plan for such Program (after delivery of the draft Development Plan). Roche shall deliver to the JDC for review a draft Development Plan for such Program within [***] months after providing the Roche PoC Data Package.
Such Development Plan shall be prepared by Roche in good faith and conform to the plan and budget that Roche uses internally for planning and budgeting purposes. 
  

	4.3	 Roche PoC Option for a Vividion PoC Program 

With respect to each Vividion PoC Program, Roche shall have the exclusive option right to obtain the exclusive license set forth in Section 5.2.1.3 for
such Vividion PoC Program to which the option pertains (“Roche PoC Option”). Together with the delivery of the PoC Data Package, Vividion shall declare its non-binding intent to exercise the
Vividion Sharing Option pursuant to Section 4.4. 
 Within three [***] after either (i) the Delivery Date of the PoC Data Package for a Compound
of a Vividion PoC Program or (ii) notice of the Vividion PoC Program Opt-Out for such Vividion PoC Program (“Roche PoC Option Period”), Roche shall have the right to exercise the Roche
PoC Option for such Vividion PoC Program by providing to Vividion written notice thereof within the Roche PoC Option Period. For clarity, the PoC Data Package for a Compound of a Vividion PoC Program may be delivered by Vividion and Roche may also
exercise the Roche PoC Option thereafter during the Roche PoC Option Period, even if not all PoC Criteria are met. 
 If Vividion has declared its intent
(e.g., by communication at the JDC or, as requested by Roche, by written notice to Roche) to exercise the Vividion Sharing Option for a Vividion PoC Program, then together with the Option Exercise Notice of the Roche PoC Option for such Vividion PoC
Program, Roche shall deliver to the JDC for review and discussion an initial Development Plan, which shall include a budget for the Allowable Development Expenses as described in the Financial Appendix. Such Development Plan shall be prepared by
Roche in good faith and conform to the plan and budget that Roche uses internally for planning and budgeting purposes. 
 If Roche exercises the Roche PoC
Option for a Vividion PoC Program within the Roche PoC Option Period, such Vividion PoC Program is deemed a Roche PoC Program and Roche shall have on the Selection Effective Date the license set forth in Section 5.2.1.3 (“Roche PoC
Program”), in each case unless Vividion exercises the Vividion Sharing Option. 
  

	4.4	 Vividion Sharing Option 

With respect to the first Product developed under each Vividion PoC Program, Vividion shall have the right to participate in (i) the Development Cost
Sharing as set forth in Section 9.3, and (ii) the Profit and Loss Sharing in the US (“Vividion Sharing Option”), provided however that Vividion can only exercise its Vividion Sharing Option with respect to a Vividion PoC
Program once for (i) and (ii) and not individually (i) or (ii). 
 Vividion may exercise a Vividion Sharing Option by providing notice to Roche
thereof within [***] days after the Option Exercise Notice (and JDC approval of the initial Development Plan) for the Roche PoC Option. Such first Product shall be considered a Shared Product and the program 

  
 - 41 - 

 therefor a “Shared Program” and any other Product under the Vividion PoC Program shall be
considered a Roche PoC Product and the milestones and royalties for a Roche PoC Product under the respective Licensed Program shall apply. 
 [***]. 

 

	4.5	 E3 Module Option 

 

	4.5.1	 E3 Module Option 

With respect to each E3 Module, excluding those directed to Excluded E3 Ligases, for which Vividion delivers an E3 Module Data Package, during the
Collaboration Term, Roche shall have the exclusive option right during the Collaboration Term to obtain the license as set forth in Section 5.2.3 to which the option pertains (“E3 Module Option”). 

Roche has the right to exercise an E3 Module Option within [***] months after the Delivery Date of the respective E3 Module Data Package (“E3 Module
Option Period”), unless mutually extended by agreement of the Parties, by providing an Option Exercise Notice to Vividion within such E3 Module Option Period. 

If (i) Roche conducts research or development on a compound that (a) is not a Compound for which it has a license under Section 5.2.1 or 5.2.2,
(b) comprised of a moiety directed to the E3 Ligase of such E3 Module, and (c) such compound also binds to a Covalent Degrader Target for which Vividion has provided Roche a Validated Hit Data Package, and (ii) [***] occurs with respect to such
compound meeting all of the criteria of (i) within [***] years after Roche’s exercise of the E3 Module Option for such E3 Module (such compound, “Other E3 Compound”), then Roche shall provide notice to Vividion upon [***]
for such Other E3 Compound and in addition to any amounts owed with respect to exercise of the E3 Module Option, Roche shall pay to Vividion [***] US Dollars ($[***]) upon such [***] and the amounts set forth in Sections 13.8, 13.11.1 and 13.12
shall be due with respect to any product containing such Other E3 Compound (or a Derivative (mutatis mutandis) thereof) as would be due for a Product under a Roche Program. 

 

	4.5.2	 Initial Vividion E3 Ligase 

Notwithstanding Sections 4.5.1 and 5.2.3: 
  

	 	4.5.2.1	 [***]; 

  

	 	4.5.2.2	 [***]; 

[***]; 
  

	 	4.5.2.3	 [***]; 

  

	 	4.5.2.4	 If Roche exercises the E3 Module Option, Roche shall have on the Selection Effective Date the license set forth
in Section 5.2.3 for the applicable E3 Module. 

  

	4.6	 Option Not Exercised 

 

	4.6.1	 Consequences 

	 	

  
 - 42 - 

 If a Party does not exercise an Option Right under this Section 4 within the respective Option Period,
then the Option Right will automatically expire and the Party not exercising the Option Right will no longer have any rights hereunder thereto, subject to this Section 4.6. 

 

	4.6.2	 Sole Vividion Programs 

If Roche does not exercise the Roche Option for a Vividion Program or the Roche PoC Option for a Vividion PoC Program, then (a) the Roche Option for such
Vividion Program or Vividion PoC Program, as applicable, will automatically terminate, and such Vividion Program or Vividion PoC Program, as applicable, shall cease to be a Vividion Program or Vividion PoC Program, respectively, (b) (unless there is
another Nominated Program for a Covalent Degrader Target either utilizing a different E3 Ligase or a different Roche Target Ligand) the Collaboration Target for such Program shall cease to be a Collaboration Target and (c) Vividion shall have
the right to research, develop, register, use, make, have made, import, export, market, distribute, and sell compounds and products (including Compounds and Products), in each case Directed To the Collaboration Target for such Vividion Program or
Vividion PoC Program (“Sole Vividion Program”), subject to the remainder of this Section 4.6.2. For clarity, if for a Collaboration Target Vividion provides a Proposed Target Nomination Notice pursuant to Section 2.5.1.1
and Roche does not provide a Target Nomination Notice then clauses (b) and (c) above and the remainder of this Section 4.6.2 shall be applicable to such Collaboration Target. 

With respect to Sole Vividion Program(s): 

Effective upon such Program becoming a Sole Vividion Program (“Sole Vividion Program Effective Date”): 

 

	 	(i)	 Roche grants (subject to HSR Filing if Vividion determines an HSR Filing is necessary) to Vividion an
exclusive, sublicensable (through multiple tiers) license under Roche Patents existing as of the grant of the license (including any Patents claiming priority to or common priority with such Roche Patents) and Roche
Know-How actually disclosed to Vividion under the Agreement, including Roche’s interest in the Joint Patents to the extent reasonably necessary to allow Vividion, its Affiliates or (sub)licensees to
research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold compounds and
products, in case of a Covalent Degrader, containing such Roche Target Ligand (or Derivatives thereof and Section 1.37 shall apply mutatis mutandis), 

  
 - 43 - 

	 	in each case Directed To the Target (i.e., the former Collaboration Target) for such Sole Vividion Program, in the Field in the Territory; and 

 

	 	(ii)	 With respect to Covalent Degraders, Vividion shall pay a royalty on worldwide annual Net Sales of RTL Products
sold by Vividion, its Affiliates or sublicensees as follows: 

  

							
	 Tier of calendar

year Net Sales in million US$
	  	Roche does not
exercise Roche
Option for a Vividion
Program - Percent
(%) of annual Net
Sales	 	Roche does not
exercise Roche PoC
Option for a Vividion
PoC Program and
No Achievement of
PoC—Percent (%) of
annual Net
Sales	 	Roche does not exercise
Roche PoC Option for a
Vividion PoC Program and
Achievement of PoC -
Percent (%) of annual
Net
Sales
	£ [***]	  	[***]	 	[***]	 	[***]
	 > [***] and £ [***]
	  	[***]	 	[***]	 	[***]
	 > [***]
	  	[***]	 	[***]	 	[***]

 The term “Achievement of PoC” shall mean, with respect to a Vividion PoC Program, achieving
[***] in the conduct of such Vividion PoC Program. For clarity, if no Clinical Study having [***] has been Completed within such Vividion PoC Program then Achievement of PoC has not occurred. 

 

	 	(iii)	 With respect to Covalent Inhibitors, Vividion shall pay a flat royalty on worldwide annual Net Sales of RTL
Products sold by Vividion, its Affiliates or sublicensees as follows: 

  

					
	 Roche does not exercise Roche

Option for a Vividion Program—Percent (%) of annual
Net

Sales
	  	Roche does not exercise
Roche PoC Option for a
Vividion Program and No
Achievement of PoC -
Percent (%) of annual
Net Sales	 	Roche does not exercise Roche
PoC Option for a Vividion
PoC Program
andPoC Achievement of PoC -
Percent (%) of annual
Net
Sales
	 [***]
	  	[***]	 	[***]

 For purposes of this Section 4.6.2, the definition of “Sales” and “Net Sales,” and
Sections 13.12.1, 13.12.3 through 13.12.8, 14.1, 14.7 and 16 shall [***] and, solely for such purpose, each reference in each such Section (and any related definitions) to (a) Roche shall be deemed to be a reference to Vividion, and (b) a
Sublicensee shall be deemed to be a reference to a licensee or sublicensee of Vividion or its Affiliates of an RTL Product. 
 “RTL
Product” shall mean any Product that either (A) contains the Roche Target Ligand or (B) is Covered by a composition of matter claim (Section 1.24 shall apply mutatis mutandis) of a Roche Patent or of a Joint Patent licensed
to Vividion pursuant to clause (i) above in this Section 4.6.2. 

  
 - 44 - 

	 	(iv)	 Vividion shall use Commercially Reasonable Efforts (with references to Roche in the definition thereof deemed
to be references to Vividion) to develop and commercialize the Sole Vividion Programs for Covalent Degrader Targets. Vividion shall be deemed to use Commercially Reasonable Efforts with respect to a given Sole Vividion Program when at least one
product is developed and commercialized within such Sole Vividion Program within at least one indication. The Sole Vividion License Agreement shall include the right of Roche to terminate the Vividion Sole License Agreement for a product for a
Covalent Degrader Target, if Vividion is not developing or commercializing a product for such Covalent Degrader Target. 

  

	 	(v)	 If Roche wishes to partner with Vividion on a Sole Vividion Program or a compound under the Sole Vividion
Program, Roche shall inform Vividion and if the Parties agree the Parties will discuss in good faith if they wish to enter into discussions for a potential transaction relating to a Sole Vividion Program (or a compound of a Sole Vividion Program).

  

	4.6.3	 Within [***] days after the Sole Vividion Program Effective Date, the Parties shall discuss in good faith a
license agreement that contains the terms of Section 4.6.2 and other customary terms for the Sole Vividion Program in question and potential other Sole Vividion Programs to document the rights and obligations herein with respect to such Sole
Vividion Program (“Sole Vividion License Agreement”). For clarity, unless and until such a Sole Vividion License Agreement is entered into for (or amended to include) a Sole Vividion Program, Section 4.6.2 (and other terms and
conditions of the Agreement) shall be applicable. 

  

	4.6.4	 Vividion Sharing Option 

If Vividion does not exercise the Vividion Sharing Option, the Product is not a Shared Product but a Roche PoC Product and the milestones and royalties for a
Roche PoC Product shall apply. 
  

	4.6.5	 E3 Module Option 

If Roche does not exercise the E3 Module Option for an E3 Module within the E3 Module Option Period, Roche shall not have any rights to such E3 Module and
Vividion and its Affiliates shall be free to use, grant rights to or disclose (including the structure of) such E3 Module (or components thereof or corresponding E3 Ligase or E3 Ligase Engagers) for any purpose and authorize Third Parties to do the
same. 
  

	4.7	 Information Sharing for Option Rights 

In addition to any data and information sharing through the JRC and JDC, as applicable, after the receipt of the respective Option Data Package and for the
remainder of the Option Period with respect to such Option Data Package, (i) Roche shall have the right to perform reasonable due diligence with respect to such Option Data Package and the applicable Compounds and Products and Shared Products,
and (ii) representatives of Roche shall have the opportunity to ask questions of and receive answers from representatives of Vividion related to the work that has been conducted and the data that have been generated with respect to such Option
Data Package and the applicable Compounds and Products and Shared Products. Vividion shall respond to Roche’s inquiries in a timely fashion and shall promptly provide requested information regarding such Compounds and Products and Shared
Products within the Vividion Patent Rights and Know-How for Roche to evaluate such Option Data Package. 

  
 - 45 - 

	4.8	 Completion of Incomplete Data Packages 

Promptly upon delivery of an Option Data Package or Validated Hit Data Package (each, a “Data Package”), Roche shall review such Data Package
for completeness and if such Data Package is not complete it shall prepare and provide to Vividion a list identifying all items missing from such Data Package within [***] Business Days of Vividion’s delivery of such Data Package. To the extent
the Data Package is not complete and Roche delivers such list of missing items within such time period pursuant to this Section 4.8, the “Delivery Date” for such Data Package shall mean the date Vividion
re-delivers an updated version of such Data Package with such missing items and otherwise the “Delivery Date” shall mean the original date Vividion delivered the Data Package to Roche. If
there is a dispute about whether a Data Package is complete, such dispute shall be resolved pursuant to Section 24.4(Expedited Resolution). 
  

	4.9	 Inspection Right 

With respect to each Vividion Program and Vividion PoC Program, upon Roche’s reasonable request, Roche shall have the right, one time prior to exercising
its Option Right to (i) conduct an inspection (including a cGMP audit, as appropriate) of Vividion’s manufacturing site at Vividion and (ii) participate with Vividion in any inspection (including a cGMP audit) that Vividion conducts
of Vividion’s manufacturing sites at a CRO’s facility, for the Compound, subject to confidentiality obligations. The Parties shall reasonably cooperate to schedule such inspection consistent with Vividion’s right to conduct such
inspections of a CRO’s facility. To the extent that Vividion does not have the right to permit Roche to participate in such inspection, Vividion shall cooperate in good faith to exercise its right to conduct an inspection of such facility in a
manner sufficient to Roche. 
  

	4.10	 Transfer following Option Right Exercise 

Following an Option Right exercise (other than exercise of the Roche Option if Vividion exercises its Vividion Option), the JRC or JDC, as applicable, will
establish a Transfer Plan and the Parties will conduct the Transfer Activities with respect to the Compound(s) for which the Option Right has been exercised. 
  

	5.	 Licenses 

  

	5.1	 Research License 

Each Party grants to the other Party during the Collaboration Term a non-exclusive right and license under Know-How and Patent Rights Controlled by such Party (i.e., Vividion Patents and Vividion Know-How or Roche Patents and Roche Know-How,
respectively) solely to enable the other Party to perform the activities assigned to it under the Collaboration Plan, the Preclinical Plan and the Clinical Plan under this Agreement, but excluding Vividion Core Platform Technology. 

 

	5.2	 Commercial License 

 

	5.2.1	 License to Products 

  

	 	5.2.1.1	 Roche Program 

With respect to each Roche Program, upon selection of such Roche Program as a Roche Program pursuant to Section 2.5.4 or 2.5.6 and on the Selection
Effective Date, Vividion hereby grants Roche, with respect to such Roche Program, an exclusive (even as to Vividion) license under the Vividion Patents and Vividion Know-How and its interest in the Joint
Patents and Joint Know-How, in each case for such Roche Program, including the right to sublicense through multiple tiers solely as provided in Sections 5.3.1 and 5.3.2, to research, have researched,

  
 - 46 - 

 
develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and
have sold Compounds and Products, in each case Directed To the Collaboration Target for such Roche Program, in the Field in the Territory. 
  

	 	5.2.1.2	 Optioned Roche Program 

With respect to each Optioned Roche Program, Vividion hereby grants Roche, with respect to such Optioned Roche Program and on the Selection Effective Date, an
exclusive (even as to Vividion) license under the Vividion Patents and Vividion Know-How and its interest in the Joint Patents and Joint Know-How, in each case for such
Optioned Roche Program, including the right to sublicense solely as provided in Sections 5.3.1 and 5.3.2, to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported,
export, have exported, market, have marketed, distribute, have distributed, sell and have sold Compounds and Products, in each case Directed To the Collaboration Target for such Optioned Roche Program, in the Field in the Territory. 

 

	 	5.2.1.3	 Roche PoC Product 

With respect to each Roche PoC Product, Vividion hereby grants Roche, with respect to such Roche PoC Product and on the Selection Effective Date an exclusive
license (even as to Vividion), under the Vividion Patents and the Vividion Know-How and its interest in the Joint Patents and Joint Know-How, in each case for such Roche
PoC Product, including the right to sublicense solely as provided in Sections 5.3.1 and 5.3.2, to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have
exported, market, have marketed, distribute, have distributed, sell and have sold Compounds and Products, in each case Directed To the Collaboration Target for such Roche PoC Product, in the Field in the Territory. 

 

	5.2.2	 License to Shared Products 

With respect to each Shared Product, Vividion hereby grants Roche, with respect to such Shared Product and on the Selection Effective Date, an exclusive
license (even as to Vividion), under the Vividion Patents and the Vividion Know-How and its interest in the Joint Patents and Joint Know-How, in each case for such
Shared Product, including the right to sublicense solely as provided in Sections 5.3.1 and 5.3.2, to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have
exported, market, have marketed, distribute, have distributed, sell and have sold Compounds and Shared Products, in each case Directed To the Collaboration Target for such Shared Product in the Field in the Territory. 

 

	5.2.3	 E3 Module License 

With respect to each E3 Module, upon Roche’s exercise of the E3 Module Option for a given E3 Module and on the Selection Effective Date, Vividion grants
Roche a Co-Exclusive license under the Vividion E3 Patents and Vividion E3 Know-How, and its interest in the Joint Patents and Joint
Know-How, to use such E3 Modules for [***] (“E3 Field”). Roche shall have the right to grant sublicenses with regards to Bifunctional Degrader Compound developed in whole or in part by Roche
or its Affiliate (but not the E3 Module or components thereof separately from such Bifunctional Degrader Compounds) solely as provided in Section 5.3.1 and 5.3.2, to research, have researched, develop, have developed, register, have registered,
use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and 

  
 - 47 - 

 
have sold Bifunctional Degrader Compounds discovered by Roche or its Affiliates in the Field in the Territory. Notwithstanding the foregoing, no right or license is granted to Roche
hereunder with respect to any E3 Ligase Engager that is first discovered, identified or acquired by Vividion or its Affiliate after the end of the Collaboration Term. 

“Bifunctional Degrader Compound” shall mean, with respect to an E3 Module, [***]. 

“Co-Exclusive” for purposes of the foregoing license means, on an E3 Ligase Engager-by-E3 Ligase Engager basis, that until the earlier of [***], Vividion shall not grant a license to a Third Party to use such E3 Ligase Engager for such E3 Module in
the E3 Field separately from a Bifunctional Degrader Compound developed in whole or in part by Vividion or its Affiliates. For clarity, Vividion and its Affiliates shall have the right to (i) use and exploit such E3 Ligase Engager for such E3
Module in the E3 Field and (ii) to authorize Third Parties to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed,
distribute, have distributed, sell and have sold Bifunctional Degrader Compounds discovered by Vividion or its Affiliates in the Field in the Territory. This Section 5.2.3 does not restrict Vividion or its Affiliates from using or exploiting an
E3 Module outside the E3 Field or authorizing a Third Party to do so. 
  

	5.2.4	 No Other Rights 

Except for the rights expressly granted under this Agreement, no right, title, or interest is granted hereunder by implication, estoppel, reliance, or
otherwise, by a Party to the other Party, and all property rights not specifically granted herein are reserved to the owner thereof. For clarity, the Parties agree that nothing in Section 4.6.2 or this Article 5 shall be deemed to grant to the
other Party a right or license to (i) any active pharmaceutical ingredient other than the Compounds and Products in each case that are Directed To (a) in the case of Roche, the Collaboration Target of a Roche Program or Directed To a
Collaboration Target for which Roche has exercised an Option Right or (b) in the case of Vividion, the Collaboration Target for a Sole Vividion Program, and which in each case of this clause (i) are not Directed To any other Target
(except, in the case of a Covalent Degrader, the corresponding E3 Ligase), or (ii) any targeting or binding moiety other than an E3 Ligase Engager within an E3 Module for which Roche exercised the E3 Module Option (i.e., those E3 Ligase
Engagers identified in the corresponding E3 Module Data Package). Nothing in this Agreement grants Roche any rights to any Know-How or Patents that are licensed to Vividion under the Scripps License. 

 

	5.3	 Sublicense 

  

	5.3.1	 Right to Sublicense to its Affiliates 

Roche and Vividion shall have the right to grant sublicenses to its Affiliates (through multiple tiers), and, with respect to Roche, to Chugai if Chugai is an
Affiliate under this Agreement, under its rights granted under Section 5.2 without prior approval of the other Party. If a Party grants such a sublicense, such Party shall ensure that all of the applicable terms and conditions of this Agreement
shall apply to the Affiliate to the same extent as they apply to such Party for all purposes. Such Party assumes full responsibility for the performance of all obligations and 

  
 - 48 - 

 observance of all terms so imposed on such Affiliate and shall itself account to such Party for all payments
due under this Agreement by reason of such sublicense. 
  

	5.3.2	 Right to Sublicense to Third Parties 

 

	 	5.3.2.1	 Roche Programs. Roche and its Affiliates shall have the right to grant written sublicenses to non-Affiliate entities (through multiple tiers) under its rights granted under Section 5.2.1.1 without prior approval of Vividion. 

 

	 	5.3.2.2	 Optioned Roche Programs; Roche PoC Programs; Shared Programs. Prior to the first Commercial Sale of a
respective Product for an Optioned Roche Program, Roche PoC Program or Shared Product, as applicable, Roche and its Affiliates shall have the right to grant to a Third Party rights, including under its rights granted under Sections 5.2.1.2, 5.2.1.3
and 5.2.2, to develop or commercialize Compounds and Products only if Vividion has declined its interest to develop and commercialize such Compounds or Products, such decline to be made within [***] days after receipt of Roche’s notice
specifying its intent to sublicense by providing notice to Roche that Vividion would not provide a Continuation Election Notice if Roche terminated this Agreement with respect to such Optioned Roche Program, Roche PoC Program or Shared Program, as
applicable, on a worldwide basis. The foregoing shall not prevent Roche from granting a Third Party the right to use Compounds and Products developed wholly by Roche and supplied by Roche to the Third Party solely for the purpose of conducting a
Clinical Study on a Combination Product that includes such Compound and/or Product and such Third Party’s own product. After First Commercial Sale of a Product for an Optioned Roche Program, Roche PoC Program or Shared Product, Roche shall only
grant to a Third Party rights to Commercialize a Product for an Optioned Roche Program, Roche PoC Program or Shared Product in a Major Market with Vividion’s prior written consent, such consent to be withheld only if Vividion would pursue
development and commercialization of a Product for such Optioned Roche Program or Roche PoC Program or Shared Product (i.e., it would provide a Continuation Election Notice if Roche terminated this Agreement with respect to such Optioned Roche
Program, Roche PoC Program or Shared Program for such Major Market); provided however the foregoing shall not prevent Roche from granting Third Parties sublicenses outside the Major Markets pursuant to the terms of this Section 5.3 and to co-promote a Product for an Optioned Roche Program, Roche PoC Program or a Shared Product in a Major Market as long as Roche books all sales of such Product or Shared Product in the Major Market.

  

	 	5.3.2.3	 Applicable to all Sublicensees. Roche shall ensure that each Sublicensee is bound by (and each grant of a
sublicense or other right to a Product, Compound or Bifunctional Degrader Compound is pursuant to) a written agreement consistent with, and subject to, the terms and conditions of the Agreement. Roche shall be responsible for the performance of any
Sublicensee and the payment of all amounts due hereunder, and for all other obligations of its Sublicensees under the Agreement as if such obligations were those of Roche. The grant of any such sublicense or rights under any Compound or Product
shall not relieve Roche of its obligations under this Agreement, except to the extent they are satisfactorily performed by any such Sublicensee(s). Roche shall provide Vividion notice promptly after the signature of an agreement with a Sublicensee
(or amendment or termination thereof) informing Vividion of the identity of the Sublicensee and a summary of the rights granted to such 

  
 - 49 - 

	 	Sublicensee with respect to Compounds, Products or Bifunctional Degrader Compound. 

  

	5.3.3	 Right to Subcontract 

Each Party shall have the right to subcontract the work performed by it under this Agreement without prior approval of the other Party. 

The JRC and the JDC, as applicable, shall discuss the use by Vividion of CROs for the performance of a Clinical Study and Vividion shall use a CRO recommended
by the JRC or JDC, as applicable, that is either listed in Appendix 1.35 or otherwise approved by Roche (such approval not be unreasonably withheld, conditioned or delayed). Roche shall have the right to update the list of CROs set forth on Appendix
1.35 by informing the JRC or JDC, as applicable, in the event that Roche determines in good faith using Roche’s compliance criteria that such CRO is incapable of or unsuitable for performing activities under this Agreement, provided that Roche
may not delete any CROs from the list on Appendix 1.35 if any activities are being conducted or expected to be conducted by such CRO(s) pursuant to a written agreement at the time of such update and Vividion shall use Commercially Reasonable Efforts
to change the CRO if Roche deleted such CRO from the Appendix 1.35. At the request of Vividion, Roche shall explain at the JRC or JDC, as applicable, the basis for its determination to delete any CRO. 

Each subcontract shall be consistent with the term and conditions of this Agreement. The subcontracting Party shall remain responsible, at its cost, for and
shall ensure that each subcontractor complies with the terms and conditions of this Agreement. 
  

	5.4	 Excluded Affiliates 

Notwithstanding anything to the contrary in this Section 5.4 or elsewhere in this Agreement, no licenses or rights are granted to Vividion under any
information, data, proprietary materials and/or other intellectual property rights whether or not patentable that are owned or controlled by [***], such data, information, proprietary materials and/or other intellectual property rights shall not be
excluded from licenses or rights granted to Vividion as a result of this Section 5.4. 
  

	5.5	 Cysteine Reactive Groups 

Vividion owns certain Cysteine Reactive Groups and Know-How pertaining thereto. Vividion shall not disclose Cysteine
Reactive Groups and Know-How pertaining thereto, unless requested by Roche or otherwise required under this Agreement. If information on the structure of a molecule containing a Cysteine Reactive Group (other
than a Roche Cysteine Reactive Group) is disclosed to Roche in connection with the Collaboration, a Program or an E3 Module, Roche shall not generate, develop or otherwise use other covalently reacting compounds containing such Cysteine Reactive
Group other than for Compounds and Products under the licenses granted under this Article 5 for a time period that is the shorter of (i) a [***] months from the date of disclosure, or (ii) until the publication of the structure of the
Cysteine Reactive Group and a description of its use as an electrophile for the purpose of reacting with a cysteine thiol on a Target. The term “Cysteine Reactive Groups” shall mean [***]. The term “Roche Cysteine Reactive
Group” shall mean [***]. 
  

	6.	 Exclusivity 

  

	6.1	 Collaboration Term; Term of Vividion Activities 

With respect to a given Collaboration Target, Vividion shall work exclusively with Roche (i) [***] and/or (ii) [***]. 

  
 - 50 - 

	6.2	 Roche Programs; Optioned Roche Program 

For each Roche Program, or Optioned Roche Program, Vividion shall continue to work exclusively with Roche with respect to the Collaboration Target for such
Roche Program or Optioned Roche Program, respectively, [***], as applicable (subject to Section 6.5). 
  

	6.3	 Roche PoC Program; Shared Program 

For each Roche PoC Program or Shared Program, Vividion shall continue to work exclusively with Roche with respect to the Collaboration Target for such Roche
PoC Program or Shared Program, respectively, until [***]. 
  

	6.4	 Scope of Exclusivity 

For purposes of the foregoing, to “work exclusively with Roche” means that Vividion shall not develop or commercialize a small molecule that
is [***] (a “Collaboration Target Inhibitor”). Notwithstanding the foregoing: 
 (a) Vividion shall not be restricted from
(i) conducting development activities with a product that is not a Collaboration Target Inhibitor (“Other Product”), in combination with a Third Party agent that is a Collaboration Target Inhibitor, or (ii) promoting,
distributing, marketing, obtaining Regulatory Approval for or selling an Other Product for use in combination with a Collaboration Target Inhibitor sold by a Third Party; provided, in each such case, that Vividion does not receive any payments from
a Third Party with respect to sales of such Collaboration Target Inhibitor, and Vividion does not have the right to otherwise research, develop or commercialize such Collaboration Target Inhibitor, in each case during the applicable exclusivity
period under Sections 6.1 to 6.3 above; 
 (b) For clarity, it is understood that Vividion conducts proteome wide screening and as such may
continue to conduct screens that may include Collaboration Targets during the exclusivity period under Sections 6.1 to 6.3 above and such activities shall not constitute a breach of Sections 6.1 to 6.3 so long as Vividion does not otherwise
research, develop or commercialize a Collaboration Target Inhibitor and such screens are not conducted specifically for the purpose of identifying Collaboration Target Inhibitors for a Collaboration Target during the exclusivity period under
Sections 6.1 to 6.3. 
 (c) For clarity, the restrictions in this Article 6 shall not be deemed to apply to Sole Vividion Programs or
Collaboration Targets replaced pursuant to Section 2.3. 

  
 - 51 - 

	6.5	 Outside End Date for Roche Programs 

Without limiting Article 7, if Entry into GLP Tox is not achieved by Roche for a Roche Program by [***] years after such Program is selected as a Roche Program
pursuant to Section 2.5, then the restrictions in Section 6.2 shall terminate with respect to the Collaboration Target of such Roche Program. Roche shall have the right to ask Vividion for an extension of the [***] year period, after which
such extension shall be discussed in good faith by the Parties. 
  

	7.	 Diligence 

Roche and Vividion shall use Commercially Reasonable Efforts to perform their respective activities contemplated by this Agreement, including the Collaboration
Plan, the Preclinical Plan and the Clinical Plan in a timely manner. Each Party shall have sufficient FTEs experienced in the type of research or other activities to be undertaken in conducting efforts under the Collaboration Plan, the Preclinical
Plan and the Clinical Plan. 
 Vividion shall use Commercial Reasonable Efforts for [***]. 

Roche shall use Commercially Reasonable Efforts to pursue further development and commercialization of Compounds and Products and Shared Products in the Field
in the Territory with respect to each Program for which it has exercised its Option Right or has a license under Section 5.2.1.1. Roche shall be deemed to use Commercially Reasonable Efforts with respect to Compounds and Products within a given
Program if it develops and commercializes [***]. 
 Without limiting the foregoing, following exercise of the Roche Option or Roche PoC Option for a
Vividion Program or Vividion PoC Program, the following shall apply with respect to such Program on a Program-by-Program basis until First Commercial Sale of a Product
for such Program: 
 If, prior to the First Commercial Sale of the first Product in a Roche Program, Optioned Roche Program or Roche PoC Program,
Roche’s updates to Vividion through the JRC, the JDC or pursuant to Section 9.2 either do not show [***], then Vividion shall have the right to terminate this Agreement for such Program and Section 22.3 shall apply as if Vividion
terminated this Agreement for such Program pursuant to Section 22.2.1. 
  

	8.	 Governance 

  

	8.1	 Joint Research Committee 

Within [***] days after the Effective Date of this Agreement, the Parties shall establish a JRC to oversee the activities under the Collaboration Plan(s) and
Preclinical Plan(s). 
  

	8.1.1	 Members 

The JRC shall be composed of six (6) persons (“Members”). Roche and Vividion each shall be entitled to appoint three (3) Members
with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [***]
days prior to the next scheduled meeting of the JRC. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend
part or the whole JRC meeting with prior 

  
 - 52 - 

 notification to the JRC. The Alliance Director of each Party shall attend the JRC meetings as permanent
participant. One JRC representative from a Party shall chair the JRC on a rotating annual Calendar Year basis, with the initial chairperson to be from Vividion. 
  

	8.1.2	 Responsibilities of the JRC 

The JRC shall have the responsibility and authority to: 
  

	 	a)	 establish and approve the Collaboration Plan updates, the Preclinical Plan(s), and the WIP Plan(s);

  

	 	b)	 revise and approve any revisions to the Collaboration Plan, Preclinical Plan(s), and the WIP Plan(s);

  

	 	c)	 review and oversee the execution of the Collaboration Plan(s) and the Preclinical Plan(s);

  

	 	d)	 establish and revise the Transfer Plans; 

 

	 	e)	 establish and amend the CCS Criteria and required contents of the CCS Data Package for Vividion Programs;

  

	 	f)	 nominate and replace Targets through the Alliance Director (to the extent provided in Sections 2.3 and 2.4
above); 

  

	 	g)	 confirm Validated Hits meet the Validated Hit Criteria; 

 

	 	h)	 replace Nominated Programs for Different E3 Ligases or Different Roche Target Ligands (to the extent provided
in Section 2.5.3); 

  

	 	i)	 propose to the Parties to terminate Vividion Programs and Vividion PoC Programs (as provided in Sections
3.2.1.4 and 3.2.2); 

  

	 	j)	 review of progress reports; 

 

	 	k)	 establish and set expectations and mandates for JOT (if any); 

 

	 	l)	 create or disband JOT as deemed appropriate; 

 

	 	m)	 oversee the JOTs (if any); recommend action items to each Party’s respective decision making bodies;

  

	 	n)	 perform the other functions that are expressly delegated to the JRC in this Agreement and

  

	 	o)	 attempt to resolve any disputes by consensus. 

The JRC shall have no responsibility and authority other than that expressly set forth in this Agreement, unless mutually agreed by the Parties in writing.

  

	8.1.3	 Meetings 

The Chairperson or his/her delegate will be responsible for sending invitations and agendas for all JRC meetings to all Members at least [***] days before the
next scheduled meeting of the JRC. The venue for the meetings shall be agreed by the JRC. The JRC shall hold meetings at least once per Calendar Quarter, either in person or by tele-/video-conference, and in any case as frequently as the Members of
the JRC may agree shall be necessary. 
  

	8.1.4	 Minutes 

The Chairperson will be responsible for designating a Member to record in reasonable detail and circulate draft minutes of JRC meetings to all members of the
JRC for comment and review within [***] days after the relevant meeting. The Members of the JRC shall have [***] days to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to
all Members of the JRC for approval within [***] days of the relevant meeting. 

  
 - 53 - 

	8.1.5	 Decisions 

  

	 	8.1.5.1	 Decision Making Authority 

The JRC shall decide matters within its responsibilities set forth in Section 8.1.2. 

 

	 	8.1.5.2	 Consensus; Good Faith 

The Members of the JRC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JRC. The Parties
shall endeavor to make decisions by consensus. 
  

	 	8.1.5.3	 Failure to Reach Consensus without Escalation 

If the JRC is unable to decide a matter by consensus, then 

	a)	 Roche shall have the final say regarding: 

- [***]; 
  

	b)	 Vividion shall have the final say regarding: 

- [***]; 
 - [***]; 

- [***]; 
 and c) neither Party shall have the final say on a
decision of the JRC with respect to the following matters, and such matters shall not be escalated to Senior Officers or subject to determination pursuant Section 24.4 (Expedited Resolution): 

-[***] 
  

	8.1.6	 Escalation 

If the JRC is unable to decide by consensus on any matter within its authority (other than those covered under Section 8.1.5.3), including but not limited
to changes of CCS Criteria, achievement of CCS, replacement of Vividion Programs pursuant to Section 2.5.3, then either Party may refer such matter to the Senior Officers, who together shall use reasonable and good faith efforts to reach a
decision by consensus within [***] Business Days after the date such matter is referred to them. Any such decision shall be exercised in good faith and shall constitute a decision of the JRC. If the Senior Officers are not able to reach a decision
within [***] Business Days, then except as described in Section 8.1.7 such matter will be determined in accordance with Section 24.4 (Expedited Resolution) and such determination shall constitute the decision (or approval, as applicable)
of the JRC. 
  

	8.1.7	 Failure to Reach Consensus after Escalation 

If the JRC is unable to decide a matter by consensus and after escalation to Senior Officers, then 

 

	a)	 Roche shall have the final say regarding 

[***] 

  
 - 54 - 

	b)	 Vividion shall have the final say regarding 

[***]. 
  

	8.1.8	 Lifetime 

The JRC shall continue for the Collaboration Term. Thereafter, the JRC shall end with respect to each Collaboration Target, at the completion of the activities
under the Preclinical Plan under the Agreement for such Collaboration Target (or expiration of the Roche Option for such Collaboration Target if earlier), provided that for a Vividion PoC Program, the JRC shall remain in place until Completion of
the GLP-Tox Study. 
  

	8.2	 JDC 

Upon Roche’s exercise of a Roche Option for the first Vividion Program and in anticipation of Vividion’s exercise of the Vividion Option (other than
in the case of a Vividion Program Opt-Out or in the case Vividion does not have a Vividion Option or provides notice to Roche that it is not exercising the Vividion Option for such Optioned Roche Program), the
Parties shall establish a JDC to establish the Clinical Plan and to oversee the activities (i) under the Vividion PoC Programs from Completion of the GLP-Tox Study onwards with respect to a Product and
(ii) of a Shared Product. 
  

	8.2.1	 Members 

The JDC shall be composed of six (6) persons (“Members”). Roche and Vividion each shall be entitled to appoint three (3) Members with
appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [***] days
prior to the next scheduled meeting of the JDC. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part
or the whole JDC meeting with prior notification to the JDC. The Alliance Director of each party shall attend the JDC meetings as permanent participant. One JDC representative from a Party shall chair the JRC on a rotating annual Calendar Year
basis, with the initial chairperson to be from Vividion. 
  

	8.2.2	 Responsibilities of the JDC 

The JDC shall have the responsibility and authority to: 
  

	a)	 approve the Clinical Plan (s) (including Clinical Plan Budget); 

 

	b)	 revise and approve any revisions to the Clinical Plan (s) (including the Clinical Plan Budget), including as
updated after Completion of GLP Tox Study; 

  

	c)	 review and oversee the execution of the Clinical Plan; 

 

	d)	 establishing and amending the PoC criteria; 

 

	e)	 identify appropriate resources necessary to conduct the Clinical Plan; 

 

	f)	 propose to the Parties to terminate a Vividion PoC Program (as provided in Section 3.2.2.3)

  

	g)	 establish, revise and implement the Transfer Plans; 

 

	h)	 monitor the development of the Compounds of the Vividion PoC Programs in the Field; 

 

	i)	 monitor the manufacturing and supply of the Compounds, including Manufacturing Transfer; 

 

	j)	 review the Development Plan for each Shared Product and any revisions thereof; 

 

	k)	 review the progress reports; 

  
 - 55 - 

	l)	 share information regarding the Development activities under the Development Plan for each Shared Product;

  

	m)	 establish and set expectations and mandates for JOT; 

 

	n)	 create or disband JOT as deemed appropriate; 

 

	o)	 oversee the JOTs; 

  

	p)	 recommend action items to each Party’s respective decision making bodies; 

 

	q)	 perform the other functions that are expressly delegated to the JDC in this Agreement and

  

	r)	 attempt to resolve any disputes by consensus. 

The JDC shall have no responsibility and authority other than that expressly set forth in this Section, unless mutually agreed by the Parties in writing. 

 

	8.2.3	 Meetings 

The Chairperson or his/her delegate will be responsible for sending invitations and agendas for all JDC meetings to all Members at least [***] days before the
next scheduled meeting of the JDC. The venue for the meetings shall be agreed by the JDC. The JDC shall hold meetings at least quarterly while there is any Vividion PoC Program ongoing and otherwise twice per Calendar Year, either in person or by
tele-/video-conference, and in any case as frequently as the Members of the JRC may agree shall be necessary. The Alliance Director of each Party may attend the JDC meetings as a permanent participant. 

 

	8.2.4	 Minutes 

The Chairperson will be responsible for designating a Member to record in reasonable detail and circulate draft minutes of JDC meetings to all members of the
JDC for comment and review within [***] days after the relevant meeting. The Members of the JRC shall have [***] days to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to
all Members of the JDC for approval within [***] days of the relevant meeting. 
  

	8.2.5	 Decisions 

  

	 	8.2.5.1	 Decision Making Authority 

The JDC shall decide matters within its responsibilities set forth in Section 8.2.2. 

 

	 	8.2.5.2	 Consensus; Good Faith 

The Members of the JDC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JDC. The Parties
shall endeavor to make decisions by consensus. 
  

	 	8.2.5.3	 Failure to Reach Consensus without Escalation 

If the JDC is unable to decide a matter by consensus, then Roche shall have the final say (without escalation) regarding: 

 

	a)	 [***]; 

and Vividion shall have the final say regarding [***]. 

  
 - 56 - 

 Neither Party shall have the final say on a decision of the JDC with respect to the following matters, and
such matters shall not be escalated to Senior Officers or subject to determination pursuant Section 24.4 (Expedited Resolution): 
 -[***] 

 

	8.2.6	 Escalation 

If the JDC is unable to decide a matter within its authority (other than under Section 8.2.5.3) by consensus, then such matter shall be referred to the
Senior Officers for resolution, who together shall use reasonable and good faith efforts to reach a decision by consensus within [***] Business Days after the date such matter is referred to them. If the Parties still fail to reach a decision within
such [***] Business Days, then such matter shall be determined in accordance with Section 24.4 (Expedited Resolution) and such determination shall constitute the decision (or approval, as applicable) of the JDC. 

 

	8.2.7	 Lifetime 

The JDC shall end, on a Vividion PoC Program-by-Vividion PoC Program basis, at
the delivery of the PoC Data Package for such Vividion PoC Program provided that in the case Vividion exercises the Vividion Sharing Option for a Vividion PoC Program the JDC shall remain in place until the discontinuation of Development of the
Shared Product. 
 If Vividion does not exercise the first Vividion Option for the Optioned Roche Program after the initial Clinical Plan for the Program is
approved by the JDC, the JDC shall end for such Program, provided that the JDC shall be reestablished, if Vividion exercises its option pursuant to Section 4.2.2. 
  

	8.3	 Information Exchange 

Vividion and Roche shall exchange the information in relation to its activities under this Agreement through the JRC and JDC, as applicable. The JRC and the
JDC may determine other routes of information exchange. 
  

	8.4	 Subcommittees 

The JRC and the JDC does not have the right to establish sub-committees. 

 

	8.5	 Joint Operational Teams 

The JRC and the JDC have the authority to establish joint operational teams (“JOT”) as necessary to prepare plans and to perform activities
within the scope of such committee’s responsibility and authority for the applicable Program. JOTs shall not have decision making authority except to the extent delegated by the respective committee as applicable. Any disagreement between the
members of Roche and Vividion on a JOT shall be referred to the applicable committee that formed the JOT for resolution. 
 Each JOT shall perform such
activities as decided by the respective committee. Each JOT shall consist of the members designated by each Party (with each Party having equal number of members, unless otherwise agreed) and each member shall have the expertise and knowledge
sufficient to perform assigned activity. 
 The Parties will establish a joint patent coordination team. 

  
 - 57 - 

	8.6	 Alliance Director 

Each Party shall appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each,
an “Alliance Director”). The Alliance Directors shall be permanent participants of the JRC and JDC meetings (but not members of the JRC and JDC) and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate
resolution of potential and pending issues and potential disputes to enable the JRC or JDC to reach consensus and avert escalation of such issues or potential disputes. 
  

	8.7	 Limitations of Authority 

The JRC or JDC shall have no authority to amend or waive any terms of this Agreement, nor to increase or substantially modify the nature of the required
effort, expenses or activities of a Party under the Collaboration Plan. For clarity, the JRC and JDC shall not have decision-making authority with respect to the conduct of Sole Vividion Programs. 

 

	8.8	 Expenses 

Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JRC or JDC. 

 

	8.9	 Withdrawal 

Notwithstanding the foregoing, at any time after the earlier of [***] years after the Effective Date and completion of Vividion’s activities pursuant to
the Collaboration Plan and for any reason, Vividion shall have the right to withdraw from participation in the JRC, JDC and any or all of the JOTs with respect to one or more Collaboration Targets upon notice to Roche referencing this
Section 8.9, which notice shall be effective immediately upon receipt (“Withdrawal Notice”). Following the issuance of a Withdrawal Notice and subject to this Section 8.9, the Parties will amend the respective decision
making and disclosure rights and obligations enumerated in this Agreement to preserve the Parties’ respective decision making and disclosure rights and obligations in the absence of participation through such JRC, JDC and/or JOTs. 

 

	9.	 Development 

  

	9.1	 Roche Responsibility 

Other than Vividion’s development responsibilities for a Vividion PoC Program pursuant to Section 3.2, Roche, at its sole cost and discretion
(subject to cost sharing under the Vividion Sharing Option pursuant to Section 4.4), shall use Commercially Reasonable Efforts to develop Compounds and Products and Shared Products for Licensed Programs. 

Roche shall use Commercially Reasonable Efforts to conduct the activities for a Shared Product under and in accordance with the Development Plan for such
Shared Product. 
 Roche shall submit to the JDC for review any amendment to the Development Plan for a Shared Product after Vividion exercises the Vividion
Sharing Option for such Shared Product. 
  

	9.2	 Updates 

Roche shall provide a written summary report (which may be in the format of a slide deck) to Vividion to update Vividion with a summary based on information
Roche provides to its internal management as to development progress and plans for each Product (other than Shared Products prior to the disbandment of the JDC for such Shared Product) under a Licensed Program, which report shall include, without
limiting the foregoing, a summary in reasonable detail of available results, plans and activities for further development of such Product. Such report shall be provided [***] until Completion of a Pivotal Study for such Licensed Program and annually
thereafter. 

  
 - 58 - 

	9.3	 Payments to Roche for Shared Products 

If Vividion exercises its Vividion Sharing Option with respect to one or more Vividion PoC Programs, then, subject to Section 9.4, Vividion will be
responsible for sharing Allowable Development Expenses for the applicable Shared Product incurred in accordance with the Development Plan, on a Shared Product-by-Shared
Product basis, as defined in the Financial Appendix (“Development Cost Sharing”). 
  

	9.4	 Development Plan Amendments 

If, for a Shared Product, for whatever reason Allowable Development Expenses exceed or are budgeted to exceed [***] US Dollars ($[***]) over the initial budget
of Allowable Development Expenses set forth in the initial Development Plan for such Shared Product (“Initial Budget” and $[***] over such Initial Budget the “Threshold Development Costs”), Vividion shall, for such
Shared Product, have the option to (a) elect to have Roche bear all Allowable Development Expenses in excess of the Threshold Development Costs (“Excess Development Opt-Out”) or
(b) elect for the Development Cost Opt-Out to occur for such Shared Product as described in Section 9.5, in either case of (a) or (b) by providing written notice to Roche within [***] days of
receiving written notice from Roche of such excess Allowable Development Costs exceeding or budgeted to exceed the Threshold Development Costs (“Excess Development Cost Notice”). If upon providing an Excess Development Cost Notice
Vividion does not exercise the Development Cost Opt-Out for the applicable Shared Product within such [***] days notice period, Vividion may thereafter exercise the Excess Development Opt-Out or Development Cost Opt-Out effective as of the following Calendar Quarter (or sooner at Vividion’s election upon and to the extent there is an amendment to the
Development Plan leading to an increase of the budget for Allowable Development Expenses and affecting the budget for the Calendar Quarter in which such exercise is made). Once exercised, the Excess Development
Opt-Out may not be reversed for such Shared Product. 
 If Vividion exercises its Excess Development Opt-Out with regards to (a) above, then Roche shall have the right recoup an amount equal to [***] percent ([***]%) of the Allowable Development Expenses incurred in excess of such Threshold Development Costs
in connection with such Excess Development Opt-Out by offsetting this amount against any payments owed to Vividion for the applicable Shared Product (i.e., any milestone payments or royalties in any country,
and profits from the Profit and Loss Sharing), provided that if after [***] years after the First Commercial Sale of such Shared Product in a Major Market, Roche may [***] under this Agreement. For clarity, Vividion shall continue to be responsible
for sharing Allowable Development Expenses according to Section 9.3 that do not exceed the Threshold Development Costs unless it exercises a Development Cost Opt-Out. Vividion may in its discretion from time-to-time elect to pre-pay any portion of the then-outstanding recoupable Allowable Development Expenses upon written notice to
Roche. 
 The Development Plan for a Shared Product is prepared and executed in accordance with Roche’s internal procedures. 

 

	9.5	 Development Cost Opt-Out 

Vividion may, upon written notice to Roche, opt out of sharing of Allowable Development Expenses for a Shared Product (“Development Cost Opt-Out”), in which case (a) Vividion shall not share in additional Allowable Development Expenses for such Shared Product, (b) Vividion shall not participate in the Profit and Loss Sharing for
such Shared Product and shall, instead, receive royalties and milestones for such Shared Product as if it were a: 

  
 - 59 - 

	 	(i)	 Roche PoC Product pursuant to Section 13.9, 13.11 and 13.12.2 if such
opt-out occurs [***]; 

  

	 	(ii)	 Roche PoC Product pursuant to Section 13.9, 13.11 and 13.12.2 if such
opt-out occurs prior to the [***]; or 

  

	 	(iii)	 Shared Product for which there is not Profit and Loss Sharing pursuant to Section 13.10, 13.11 and 13.12.2
if such opt-out occurs after [***]; 

 and (c) Roche shall no longer be required to obtain
JDC approval of the Development Plan. Such Development Cost Opt-Out shall become effective: (X) immediately upon Vividion’s notice if received within [***] days after receipt of an Excess Cost
Development Notice and effective as of the following Calendar Quarter if received thereafter (or sooner at Vividion’s election upon and to the extent there is an amendment to the Development Plan leading to an increase of the budget for
Allowable Development Expenses and affecting the budget for the Calendar Quarter in which such exercise is made) (and in such case, Vividion shall not be obligated to share Cost Overruns incurred prior to the Excess Development Cost Notice to the
extent they are in excess of the Threshold Development Costs) and otherwise (Y) on January 1 of a Calendar Year if Vividion’s notice of such Development Cost Opt-Out is provided on or prior to
June 30 of the prior Calendar Year and on June 30 of a Calendar Year if Vividion’s notice of such Development Cost Opt-Out is provided from between July 1 and December 31 of the prior
Calendar Year. 
  

	10.	 Manufacture and Supply 

 

	10.1	 Pre-clinical and Clinical Supply of Products and Shared Products

  

	10.1.1	 Roche Responsibility 

Subject to Section 10.1.2 Roche shall use Commercially Reasonable Efforts to manufacture and supply Compound and Product for pre-clinical and clinical use for Licensed Programs, at its own cost. 
 Roche shall use Commercially Reasonable Efforts
to manufacture and supply Shared Products for non-clinical and clinical use, subject to the Development Cost Share as defined in the Financial Appendix. 

 

	10.1.2	 Manufacture and Supply by Vividion 

Vividion shall use Commercially Reasonable Efforts to manufacture and supply compounds of a program prior to being a Nominated Program at its own cost. 

  
 - 60 - 

 Vividion shall use Commercially Reasonable Efforts to manufacture and supply Compounds and Products under
Vividion Programs and Vividion PoC Programs at its own cost, provided that the cost for the Vividion PoC Programs shall be shared as PoC Cost as defined in the Financial Appendix. 

 

	10.2	 Commercial Supply of Product 

Roche shall use Commercially Reasonable Efforts to manufacture and supply Products and Shared Products for commercial use in the Territory, either by itself or
through Third Parties, for Licensed Programs at its own cost (subject to Vividion’s Development Cost Share and Profit and Loss Share for Shared Products). 
  

	10.3	 Shipment 

Unless otherwise specified in this Agreement or as agreed to by the Parties, the following shall apply to all shipments that a Party or a Party’s
designees are to provide to the other Party: in case of shipment to Roche: shipped DAP Roche Basel or Roche’s designee (Incoterms 2010). 
 In case of
shipment to Vividion: shipped DAP Vividion San Diego or Vividion’s designee (Incoterms 2010). 
  

	10.4	 Manufacturing Transfer 

Roche shall have the right, but not obligation, to request a manufacturing transfer as soon as feasible after exercising the Roche Option for a given Licensed
Program. Within [***] months upon such request of Roche, Vividion shall use Commercially Reasonable Efforts to complete the transfer of all its Vividion Know-How for such Licensed Program reasonably necessary
for the manufacture of the Compound in question with the goal of enabling Roche and/or its designated contract manufacturing organization to manufacture such Compound under such Program, (“Manufacturing Transfer”). 

In case of Manufacturing Transfer of a Licensed Program prior to the Initiation of the first Phase I Study of such Licensed Program, the Parties shall plan
for a transfer at the latest [***] after the Option Exercise Date. 
 The Parties will agree in good faith on a Manufacturing Transfer protocol defining the
scope and conditions of transfer. The Manufacturing Transfer shall be included in the Transfer Plan. 
 Each Party shall bear its own costs for the
Manufacturing Transfer (in case of transfer from Roche to Vividion, this Section 10.4 shall apply mutatis mutandis), provided that if a Party requests transfer to such Party from a Third Party contract manufacturer included in Appendix
1.35 such Party shall be responsible for amounts owed to such Third Party to conduct such transfer. 
  

	11.	 Regulatory 

  

	11.1	 Responsibility 

 

	11.1.1	 Vividion PoC Program 

Prior to Roche’s exercise of the Roche PoC Option, Vividion (i) shall be responsible [***] (in consultation with Roche as described below) for all
regulatory affairs relating to the Vividion PoC Programs and (ii) shall lead all interactions with applicable Regulatory Authorities for the Vividion PoC Programs, each until exercise of the Roche PoC Option. 

  
 - 61 - 

 During such time (a) Vividion shall file and own all INDs for a Vividion PoC Program, (b) Roche
shall have the right to have one (1) representative attend (as a non-participatory observer) material regulatory meetings (including
face-to-face meetings and, to the extent scheduled, phone calls) with Regulatory Authorities for the Product for a Vividion PoC Program to the extent permitted by
Applicable Law; Vividion shall give notice of any such meeting within [***] Business Days after Vividion first receives notice of the scheduling of such meeting; Roche may have a reasonable number of representatives participate in any preparatory pre-meetings held prior to such a Regulatory Authority meeting, (c) Vividion will consult with Roche on its material communications with and material submissions by Vividion to any Regulatory Authority
(“Regulatory Materials”) for the Vividion PoC Program, including all IND submissions, IND amendments, Regulatory Authority meeting requests and Regulatory Authority advice (including scientific advisory packages) as follows:
(i) Vividion shall provide copies of draft Regulatory Authority meetings requests, Regulatory Authority advice (including scientific advisory packages) and any other material submissions and communications (including written summaries of
material oral communications proposed or conducted by or on behalf of Vividion) with any Regulatory Authority pertaining to the Compound or Product sufficiently in advance, where reasonable, for Roche to comment on any such Regulatory Materials or
communications with any Regulatory Authority, and (ii) Vividion shall give due consideration in good faith to any comments provided by Roche in relation to such Regulatory Materials or communications with any Regulatory Authority. Material
communications include all formal communications or communications that impact the PoC Study. 
 The following in this Section 11.1.1 shall be part of
the Transfer Activities after exercise of the Roche PoC Option for a Vividion PoC Program, specifically with respect to regulatory affairs. All such Transfer Activities shall commence in accordance with the timeline in the Transfer Plan or as
otherwise reasonably practical to facilitate Roche’s preparation for continued development of the Compound. 
 After Roche’s reasonable request
(unless not allowed by Applicable Law), in accordance with the Transfer Plan, Vividion shall, to the extent it has the right to, transfer sponsorship of the existing INDs for the applicable Vividion PoC Program to the Roche Affiliate designated by
Roche, and the Parties will cooperate to draft and execute the necessary documents required to effect such transfer. Prior to the IND transfer, Vividion shall provide to Roche copies of all material correspondence with the Regulatory Authorities, to
the extent not previously provided. For all completed study reports, Vividion shall provide reasonably necessary documentation in its Control to confirm data reliability, as required by Article 43 of the Japanese Pharmaceutical Affairs Law
Enforcement Regulations and related notifications, including original author signatures, raw data lists, GLP and Good Clinical Practice compliance information. All documentation will be provided in English. 

After Roche’s reasonable request in accordance with the Transfer Plan, Vividion shall transfer to Roche all relevant historical clinical safety data for
the applicable Product for the applicable Vividion PoC Program. 
  

	11.1.2	 Roche Responsibility 

Subject to Section 11.1.3, after the exercise of its Option Right for a Licensed Program: (a) Roche shall be solely responsible [***] for all
regulatory affairs related to Compounds and Products and Shared Products in the Territory for the applicable Licensed Program including the preparation and filing of applications for Regulatory Approval as well as any or all governmental approvals
required to develop, have developed, make, have made, use, 

  
 - 62 - 

 have used, manufacture, have manufactured, import, have imported, sell and have sold Products and Shared
Products for such Licensed Program, (b) Roche shall be responsible for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with regulatory agencies, for all Products in all countries in the Territory for
the applicable Licensed Program and (c) Roche or its Affiliates shall own and file in their discretion (subject to the terms and conditions of this Agreement) all regulatory filings and Regulatory Approvals for all Products and Shared Products
in all countries of the Territory for the applicable Licensed Program. 
  

	11.1.3	 Shared Programs 

For each Shared Product and for as long as Vividion is sharing Allowable Development Expenses for such Shared Product as described in the Financial Appendix:
(a) Vividion shall have the right to have one (1) representative attend (as a non-participatory observer) material regulatory meetings for [***] Major Markets (including face-to-face meetings and, to the extent scheduled, phone calls) with Regulatory Authorities for the Shared Product to the extent (i) permitted by Applicable Law and
(ii) such attendance is not jeopardizing communication of Roche with such Regulatory Authorities, as discussed in good faith between the Parties; Roche shall give notice of any such meeting within [***] Business Days after Roche first receives
notice of the scheduling of such meeting; Vividion may have a reasonable number of representatives participate in any preparatory pre-meetings held prior to such a Regulatory Authority meeting, and
(b) Roche will consult with Vividion on its material communications with and material Regulatory Materials submitted by Roche to any Regulatory Authority in a Major Market for the Shared Product, including all IND submissions, IND amendments,
Regulatory Authority meeting requests and Regulatory Authority advice (including scientific advisory packages) as follows: (i) Roche shall provide copies of draft Regulatory Authority meetings requests, Regulatory Authority advice (including
scientific advisory packages) and any other material submissions and communications (including written summaries of material oral communications proposed or conducted by or on behalf of Roche) with any Regulatory Authority pertaining to the
Compounds or Shared Product sufficiently in advance, where reasonable, for Vividion to comment on any such Regulatory Materials or communications with any Regulatory Authority, and (ii) Roche shall give due consideration in good faith to any
comments provided by Vividion in relation to such Regulatory Materials or communications with any Regulatory Authority. Material communications include all formal communications or communications that substantively impact any Clinical Study
conducted under the Development Plan. 
  

	11.2	 Pharmacovigilance Agreement 

The Parties shall execute separate Pharmacovigilance Agreement(s) specifying the procedure for the information exchange of the adverse events that may occur
during the development for Licensed Programs if necessary for the respective Licensed Products and each such agreement will be in place prior to the first patient being dosed in the first Clinical Study of a Product in the Territory. 

 

	12.	 Commercialization 

 

	12.1	 Responsibility 

Roche, at its own expense, shall have sole responsibility and decision making authority (subject to the terms and conditions of this Agreement, including
Article 6) for the marketing, promotion, sale, booking of sales, and distribution of Products and Shared Products in the Territory for Licensed Programs. 

  
 - 63 - 

	12.2	 Updates to Vividion 

Upon request of Vividion, Roche shall update Vividion regarding the commercialization of the Products in the Territory in the Field by Roche, its Affiliates
and Sublicensees including plans and activities in preparation of launch in the Major Markets and in Japan. If Vividion requests an update, Roche shall provide a summary in reasonable detail, in writing (in the format of a slide deck) and/or through
a meeting (face to face/ tele-presence/videoconference or telephone). Vividion shall not request an update more frequently than [***] per Calendar Year. 

Upon request of Vividion, Roche shall update Vividion regarding the commercialization of the Shared Products in the Territory in the Field by Roche, its
Affiliates and Sublicensees including plans and activities in preparation of launch in the Major Markets and in Japan. If Vividion requests an update, Roche shall provide a summary in reasonable detail, in writing (in the format of a slide deck)
and/or through a meeting (face to face/ tele-presence/videoconference or telephone). Vividion shall not request an update more frequently than [***] per Calendar Year. 
  

	12.3	 Termination of Profit and Loss Sharing by Vividion 

Subject to Section 9.5, Vividion shall have the right to opt-out of the Profit and Loss Sharing. Vividion’s opt-out right shall be exercisable at any time. 
 In such case, (i) the Profit and Loss Sharing under this Agreement
shall terminate with respect to such Shared Product, (ii) Vividion shall continue to share the Allowable Development Expenses for such Shared Product (unless it exercised its Development Cost Opt-Out),
and (iii) Roche shall pay to Vividion milestones pursuant to Section 13.10 and 13.11 and royalties pursuant to Section 13.12 for such Shared Product as a Shared Product with no Profit and Loss Sharing. 

 

	12.4	 Conversion of Profit and Loss Sharing 

On a Shared Product-by-Shared Product basis, upon Roche’s request after
the earlier of (i) the [***] and (ii) cessation of all marketing, detailing and other promotional activity in the United States for such Shared Product, the Parties shall negotiate in good faith royalty rate(s) Roche shall pay to Vividion
instead of Vividion participating in Profit and Loss Sharing for such Shared Product and the duration Roche shall pay such royalty. If the Parties are not able to agree on such terms, then upon either Party’s request, such matter shall be
resolved by Expedited Resolution pursuant to Section 24.4. 
  

	12.5	 Launch Costs for Shared Product 

For a given Shared Product, [***] months prior to the anticipated first Regulatory Approval of the Shared Product in the United States Roche shall provide
Vividion an initial commercialization plan for the United States for such Shared Product, including the corresponding initial budget for Launch Costs (as defined in the Financial Appendix), the amount of actual Launch Costs incurred by Roche prior
to delivery of such plan to Vividion, and the then current Net Sales forecast for the period Roche has forecasted at such time (the “Initial Commercialization Plan”). The Initial Commercialization Plan shall conform to the plan
Roche uses for internal planning and budgeting purposes at Roche. Vividion shall not be obligated to share any Launch Costs incurred by Roche prior to [***] months after Roche provides the Initial Commercialization Plan to Vividion unless Vividion
does not opt-out of Profit and Loss Sharing pursuant to Section 12.3 within such [***] months period. If Vividion does not opt-out of Profit and Loss Sharing within
such [***] month period, then Vividion shall promptly reimburse Roche for fifty percent (50%) of such Launch Costs incurred during such [***] month period in accordance with the budget in the Initial Commercialization Plan and 50% of the actual
Launch Costs incurred by Roche for the Shared Product prior to providing the Initial Commercialization Plan to Vividion, as reported in the Initial Commercialization Plan. 

  
 - 64 - 

 If Launch Costs prior to First Commercial Sale of a Shared Product exceed [***] percent ([***]%) of such
initial budget in the Initial Commercialization Plan (“Threshold Launch Costs”), then upon Vividion’s request, Roche shall bear the remaining Launch Costs incurred in excess of the Threshold Launch Costs (such amounts, the
“Excess Launch Costs”), provided that in such case Roche shall be permitted to recoup an amount equal to [***] percent ([***]%) of the Excess Launch Costs by offsetting such amounts against future profit and milestone payments due
for such Shared Product, provided that if after [***] years after the First Commercial Sale of such Shared Product in the United States it is reasonably determined that the future payments owed Vividion for such Shared Product will not be sufficient
for Roche to recoup all such amounts, Roche may offset unrecouped amounts against payments owed to Vividion for other Products or Shared Products under this Agreement. Vividion may in its discretion from time-to-time elect to pre-pay any portion of the then-outstanding recoupable Excess Launch Cost upon written notice to Roche. 

 

	12.6	 Medical Affairs 

Roche and its Affiliates shall have the sole right and responsibility to conduct and make decisions regarding medical affairs activities with respect to all
Products and Shared Products for Licensed Programs. 
 The Medical Affairs cost in the US for a Shared Product shall be shared as defined in the Financial
Appendix. 
 With respect to a Shared Product, Vividion’s Sales Representatives shall be supported by Roche’s or its Affiliate’s Medical
Affairs personnel. 
  

	13.	 Payment 

  

	13.1	 Initiation Payment 

Within [***] Business Days after the Effective Date and receipt of an invoice from Vividion, Roche shall pay to Vividion One Hundred Thirty Five Million US
Dollars (135’000’000 USD). 
  

	13.2	 Collaboration Term Extension Fee 

Within [***] days after the first extension of the Collaboration Term pursuant to Section 2.6, Roche shall pay Vividion an extension fee of [***] US
Dollars ([***] USD) for the first one-year extension of the Collaboration Term. 
 Within [***] days after the
second extension of the Collaboration Term pursuant to Section 2.6, Roche shall pay Vividion an extension fee of [***] US Dollars ([***] USD) for the second one-year extension of the Collaboration Term.

  

	13.3	 Roche E3 Module Payment 

 

	13.3.1	 For the first [***] E3 Modules 

Together with each of first [***] times Roche exercises an E3 Module Option, Roche shall pay Vividion [***] US Dollars ([***] USD). 

  
 - 65 - 

	13.3.2	 For the [***] E3 Module and [***] E3 Module 

Together with each of the [***] and [***] times Roche exercises an E3 Module Option, Roche shall pay Vividion [***] US Dollars ([***] USD). 

 

	13.4	 Fees for Roche Programs 

 

	13.4.1	 Nomination Fee for Roche Programs 

Upon each selection pursuant to Section 2.5 of a Nominated Program as a Roche Program, Roche shall pay Vividion [***] US Dollars ([***] USD), except with
respect to a Roche Program for the Collaboration Target [***] for which Roche shall pay Vividion [***] US Dollars ([***] USD) ( “Roche Program Nomination Fee”). 

 

	13.4.2	 Fee upon Entry into [***] of a Roche Program: 

Roche shall pay Vividion [***] US Dollars ([***] USD) upon the first [***] for the first Product under each Roche Program. Roche shall provide Vividion written
notice of each such entry within [***] Business Days thereof. 
  

	13.5	 Nomination Fee for Vividion Programs 

Upon each selection pursuant to Section 2.5 of a Nominated Program as a Vividion Program, Roche shall pay Vividion [***] US Dollars ($[***] USD), except
with respect to a Vividion Program for the Collaboration Target [***] for which Roche shall pay Vividion [***] US Dollars ([***] USD) (“Vividion Program Nomination Fee”). If a Vividion Program is nominated pursuant to
Section 2.5.5 to replace a Vividion Program that is discontinued within [***] months after initiation of the Preclinical Plan for such Vividion Program, then no payment is due for such nomination under this Section 13.5 (unless such
Vividion Program so nominated is for the Collaboration Target [***] and the Vividion Program being replaced is not, in which case Roche shall pay [***] US Dollars ([***] USD) (i.e., the difference between the Vividion Program Nomination Fee for a
[***] Vividion Program and for a Vividion Program not for [***])). For clarity, if a Vividion Program is nominated pursuant to Section 2.5.5 to replace a Vividion Program that is discontinued after such [***] month time period then a payment
shall be due under this Section 13.5 for such nomination regardless of how many Vividion Programs exist. 
  

	13.6	 Fee for Optioned Roche Programs if Vividion does not exercise the Vividion Option 

Upon each exercise of the Roche Option for a Vividion Program and provided that Vividion has not exercised the Vividion Option for such Vividion Program
pursuant to Section 4.2, Roche shall pay Vividion [***] US Dollars ([***] USD). 
  

	13.7	 Fees for Vividion PoC Programs 

 

	13.7.1	 Option Exercise fee 

Roche shall (i) within [***] days after expiry of the notice period during which Vividion may exercise the Vividion Sharing Option (Section 4.4 Vividion
Sharing Option) (or, if earlier, receipt of notice from Vividion that it is not exercising the Vividion Sharing Option), if applicable, or (ii) within [***] after exercise of the Roche PoC Option for a Vividion PoC Program, pay Vividion either
of the following amounts for each exercise of a Roche PoC Option: 
 (a) pay Vividion [***] US Dollars ([***] USD) upon each exercise of the Roche PoC Option
for a Vividion PoC Program, if Vividion exercises the Vividion Sharing Option for such Vividion PoC Program; or 

  
 - 66 - 

 (b) [***] US Dollars ([***] USD) upon each exercise of the Roche PoC Option for a Vividion PoC Program if
Vividion does not exercise the Vividion Sharing Option for such Vividion PoC Program. 
  

	13.8	 Development Event Payments for Roche Programs and Optioned Roche Programs 

Roche shall pay Vividion the milestone payment amounts below upon the achievement of the corresponding development event with respect to a Product for each
Roche Program up to a total of [***][***] US Dollars ([***] USD) per Roche Program and for each Optioned Roche Program up to a total of [***] US Dollars ([***] USD) per Optioned Roche Program, as applicable, as follows: 

 

											
	 Milestone #
	  	Development Event	 	Roche Program
Milestone Payment
(numbers
represent million USD)	 	Optioned Roche Program Milestone Payment (numbers represent million
USD)
	 	[***]	 	[***]	 	[***]
	 1
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 2
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 3
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 4
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 5
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 6
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 7
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 8
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 9
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 10
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 11
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 12
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	  
	 	  
	 	  
	 	  
	 	  

		  	Total	 	[***]	 	[***]	 	[***]	 	[***]
		  	  
	 	  
	 	  
	 	  
	 	  

 Each development event milestone payment under this Section 13.8 shall be paid only once for a given Roche Program or
Optioned Roche Program and is payable the first time a Product of 

  
 - 67 - 

 such Roche Program or Optioned Roche Program, as applicable, reaches such development event, regardless of
the number of times such events are reached for the given Product or for a given Roche Program or Optioned Roche Program or Indication (for example for Optioned Roche Programs, the milestone payment for achievement of a development event for a [***]
Indication or [***] Indication shall be due regardless of whether the Product that achieves such development event is the same as the Product that achieved such development event for the [***] Indication). 

If, with respect to a particular Roche Program or Optioned Roche Program, the development event for [***]. 

 

	13.9	 Development Milestones for Roche PoC Products 

Roche shall pay Vividion the milestone payment amounts below of up to a total of [***] US Dollars ([***] USD) for each Roche PoC Program upon achievements of
the corresponding development event with respect to a Roche PoC Product for each Roche PoC Program, as follows: 
  

									
	 Milestone #
	  	Development
Event	 	Roche PoC Product Milestone Payment
	 	[First Indication] (numbers
represent million
USD)	 	[Second Indication] (numbers
represent million USD)	 	[Third Indication] (numbers
represent million USD)
	 1
	  	[***]	 	[***]	 	[***]	 	[***]
	 2
	  	[***]	 	[***]	 	[***]	 	[***]
	 3
	  	[***]	 	[***]	 	[***]	 	[***]
	 4
	  	[***]	 	[***]	 	[***]	 	[***]
	 5
	  	[***]	 	[***]	 	[***]	 	[***]
	 6
	  	[***]	 	[***]	 	[***]	 	[***]
	 7
	  	[***]	 	[***]	 	[***]	 	[***]
	 8
	  	[***]U]	 	[***]	 	[***]	 	[***]
	 9
	  	[***]	 	[***]	 	[***]	 	[***]
		  	  
	 	  
	 	  
	 	  

		  	Total	 	[***]	 	[***]	 	[***]
		  	  
	 	  
	 	  
	 	  

  
 - 68 - 

 Each development event milestone payment under this Section 13.9 shall be paid only once for a given
Roche PoC Program and is payable the first time a Roche PoC Product for such Roche PoC Program reaches such development event, regardless of the number of times such events are reached for the given Roche PoC Product or for a given Roche PoC
Program. 
  

	13.10	 Development Milestones for Shared Products 

Roche shall pay Vividion the milestone payment amounts below upon the achievements of the corresponding development event with respect to a Shared Product for
each Shared Program up to a total of (i) [***] US Dollars ([***] USD) with respect to a Shared Product for each Shared Program with Development Cost Sharing and Profit and Loss Sharing and (ii) [***]d] US Dollars ([***] USD) for each Shared Program
with Development Cost Sharing and no Profit and Loss Sharing, as follows: 
  

											
	 [***]
	  	[***]	 	[***]	 	[***]
	 	[***]	 	[***]	 	[***]
	 1
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 2
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 3
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 4
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 5
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 6
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 7
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 8
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 9
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	  
	 	  
	 	  
	 	  
	 	  

		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	  
	 	  
	 	  
	 	  
	 	  

 Each development event milestone payment under this Section 13.10 shall be paid only once for a given Shared Program and
is payable the first time a Shared Product for such Shared Program reaches such development event, regardless of the number of times such events are reached for the given Shared Product or for a given Shared Program. 

  
 - 69 - 

	13.11	 Sales Based Events 

 

	13.11.1	 Products for Roche Programs 

For a Product of each Roche Program, Roche shall pay to Vividion up to a total of [***] US Dollars ([***] USD) by payment of the milestone payment amounts
below upon Calendar Year Net Sales of a Product of a Roche Program in the Territory exceeding the corresponding threshold listed below: 
  

					
	 [***]
	  	[***]	 
	 [***] [***]
	  	 	[***]	 
	 [***] [***]
	  	 	[***]	 
	 [***] [***]
	  	 	[***]	 
		  	  
	  
	 
	 [***]
	  	 	[***]	 
		  	  
	  
	 

  

	13.11.2	 Products for Optioned Roche Programs 

For a Product of each Optioned Roche Program, Roche shall pay to Vividion up to a total of [***] US Dollars ([***] USD) by payment of the milestone payment
amounts below upon Calendar Year Net Sales of a Product of an Optioned Roche Program in the Territory exceeding the corresponding threshold listed below: 
  

					
	 [***]
	  	[***]	 
	 [***] [***]
	  	 	[***]	 
	 [***] [***]
	  	 	[***]	 
	 v [***]
	  	 	[***]	 
		  	  
	  
	 
	 Total
	  	 	[***]	 
		  	  
	  
	 

  

	13.11.3	 Roche PoC Products and Shared Products without Profit and Loss Sharing 

For a Roche PoC Product of each Roche PoC Product and a Shared Product of each Shared Program without Profit and Loss Sharing, Roche shall pay to Vividion up
to a total of [***][***] US Dollars ([***] USD) by payment of the milestone payment amounts below upon Calendar Year Net Sales of (i) a Roche PoC Product for such Roche PoC Program or (ii) a Shared Product for such Shared Program without
Profit and Loss Sharing, exceeding the corresponding threshold listed below: 
  

									
	 [***]
	  	[***]	 	  	[***]	 
		  				  	 	[***]	 
	 [***] [***]
	  	 	[***]	 	  	 	[***]	 
	 [***] [***]
	  	 	[***]	 	  	 	[***]	 
	 [***] [***]o]
	  	 	[***]	 	  	 	[***]	 
		  	  
	  
	 	  	  
	  
	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
		  	  
	  
	 	  	  
	  
	 

  
 - 70 - 

	13.11.4	 Shared Products (with Profit and Loss Sharing) in the Territory outside the US 

For a Shared Product for each Shared Program with Profit and Loss Sharing, Roche shall pay to Vividion up to a total of [***] US Dollars ([***] USD) by payment
of the milestone payment amounts below upon Calendar Year Net Sales of a Shared Product for such Shared Program in the Territory outside the US exceeding the corresponding threshold listed below: 

 

					
	 [***]
	  	[***]	 
	 [***] [***]
	  	 	[***]	 
	 [***] [***]
	  	 	[***]	 
	 [***] [***]
	  	 	[***]	 
		  	  
	  
	 
	 [***]
	  	 	[***]	 
		  	  
	  
	 

  

	13.11.5	 Sales Event Payments only Once 

Each of the sales based event payments under Section 13.11 shall be paid no more than once during the Royalty Term for each Licensed Program, and is
payable the first time a Product or Roche PoC Product or Shared Product for such Licensed Program reaches such sales based event, regardless of the number of times such events are reached for a given Product, Roche PoC Product or Shared Product or
for a given Licensed Program, and irrespective of whether or not the previous sales based event payment was triggered by the same or by a different Product or Roche PoC Product or Shared Product, and shall be due within [***] days after the end of
the Calendar Quarter in which the event first occurs for the applicable Licensed Program, and shall be non-refundable. 

  
 - 71 - 

	13.11.6	 No Valid Claim 

For the purpose of this Section 13.11.6, if no [***] of a Roche Patent or a Vividion Patent of a Product or a PoC Product or a Shared Product exists in a
given country, then with respect to Calendar Year Net Sales Threshold calculation for purposes of this Section 13.11, the Net Sales in such country for such Product or PoC Product or Shared Product shall be reduced by [***] percent ([***]%).

  

	13.12	 Royalty Payments 

 

	13.12.1	 Royalty Term 

On a Product-by-Product basis, a Roche PoC
Product-by Roche PoC Product basis and a Shared Product-by-Shared Product basis (other than Shared Products in the United States
for which there is Profit and Loss Sharing), Roche shall pay to Vividion royalties on Net Sales of Products or Roche PoC Products or Shared Products during the Royalty Term. Thereafter, the licenses granted to Roche shall be fully paid up,
irrevocable and royalty-free with respect to such Product, Roche PoC Product or Shared Product, as applicable, for the applicable country. 
  

	13.12.2	 Royalty Rates 

The following royalty rates shall apply to the respective tiers of aggregate Calendar Year Net Sales of a Product or a Roche PoC Product or a Shared Product in
the applicable area of the Territory (i.e., in the US or outside the US when so specified and otherwise worldwide), on an incremental basis, as follows: 
  

	a)	 For Products of Roche Programs: 

 

					
	 [***]
	  	[***]	 
	 £[***]
	  	 	[***]	 
	 >[***] and £ [***]
	  	 	[***]	 
	 >[***]
	  	 	[***]	 

 For example, if Net Sales of a Product for a given Roche Program for a given Calendar Year worldwide, are US$ [***], then
royalties owed to Vividion on such Net Sales of such Product for that Calendar Year shall equal [***] US dollars (US$ [***]) calculated as follows: 
 [***]
= US$[***] royalty payment 
  

	b)	 For Products of Optioned Roche Programs: 

 

					
	 [***]
	  	[***]	 
	 £[***]
	  	 	[***]	 
	 >[***] and £ [***]
	  	 	[***]	 
	 >[***]
	  	 	[***]	 

  
 - 72 - 

 For example, if Net Sales of a Product for a given Optioned Roche Program for a given Calendar Year
worldwide, are US$ [***], then royalties owed to Vividion on such Net Sales of such Product for that Calendar Year shall equal [***] US dollars (US$ [***]) calculated as follows: 

[***] = US$[***] royalty payment 
  

	c)	 

For Roche PoC Products in the Territory outside the US 
  

			
	 [***]
	  	[***]
	£ [***]	  	[***]%
	 > [***] and £ [***]
	  	[***]%
	 > [***]
	  	[***]%

 For example, if Net Sales of a Roche PoC Product in the Territory outside US for a given Calendar Year, are US$[***], then
royalties owed to Vividion on such Net Sales of such Roche PoC Product for that Calendar Year shall equal [***] US Dollars (US$ [***]) calculated as follows: 

[***] = US$[***] royalty payment 
  

	d)	 For Roche PoC Products in the US 

 

			
	 [***]
	  	[***]
	£[***]	  	[***]%
	 >[***] and £[***]
	  	[***]%
	 >[***]
	  	[***]%

 For example, if Net Sales of a Roche PoC Product in the US for a given Calendar Year are US$[***], then royalties owed to
Vividion on such Net Sales of such Roche PoC Product for that Calendar Year shall equal [***] US Dollars (US$ [***]) calculated as follows: 
 [***] =
US$[***] royalty payment 
  

	 	e)	 For Shared Products in the Territory outside the US: 

  
 - 73 - 

					
	 [***]
	  	[***]	  	[***]
	£[***]	  	[***]%	  	[***]%
	>[***] and £[***]	  	[***]%	  	[***]%
	>[***]	  	[***]%	  	 [***]%

 f) For Shared Products in the US 
  

									
	 [***]
	  	[***]	 	  	[***]	 
	 £[***]
	  	 	[***]	 	  	 	[***]%	 
	 >[***] and £[***]
	  	 	[***]	 	  	 	[***]%	 
	 >[***]
	  	 	[***]	 	  	 	[***]%	 

 g) Royalty on Patented E3 Module Products 

On a Patented E3 Module Product-by-Patented E3 Module Product, Roche shall pay
to Vividion royalties on Net Sales of Patented E3 Module Products within the corresponding tier of Calendar Year Net Sales during the E3 Royalty Term, as follows: 
  

					
	 [***]
	  	[***]	 
	 £[***]
	  	 	[***]%	 
	 >[***] and £[***]
	  	 	[***]%	 
	 >[***]
	  	 	[***]%	 

 The term “E3 Royalty Term” shall mean with respect to a Patented E3 Module Product and for a given country,
the period of time commencing on the date of First Commercial Sale of the Patented E3 Module Product in such country and ending on the date of the expiration of [***]. 

For purposes of this Section 13.12.2 (g), a Patented E3 Module Product shall be deemed a different Patented E3 Module Product from another Patented E3
Module Product only if it contains a different active pharmaceutical ingredient. 

  
 - 74 - 

 After the expiry of the E3 Royalty Term, the license granted to Roche in Section 5.2.3 shall be fully
paid up, irrevocable and royalty-free with respect to such Patented E3 Module Product. 
 For clarity, no payment shall be made under this
Section 13.12.2 (g) for a Patented E3 Module Product if Roche already pays royalties under this Section 13 for such Patented E3 Module Product as a Product, Roche PoC Product or Shared Product. 

For the purpose of calculating royalties of a Product or a Roche PoC Product or a Shared Product or a Patented E3 Module Product, Calendar Year Net Sales and
the royalty rates shall be subject to the following adjustments, as applicable: 
  

	13.12.3	 Combination Product 

If Roche, its Affiliates or Sublicensees intend to sell a Combination Product, then the Parties shall meet approximately [***] prior to the anticipated First
Commercial Sale of such Combination Product in the Territory to negotiate in good faith and agree to an appropriate adjustment to Net Sales to reflect the relative commercial value contributed by the components of the Combination Product (the
“Relative Commercial Value”). If, after such good faith negotiations not to exceed [***] days, the Parties cannot agree to an appropriate adjustment, the dispute shall be initially referred to the executive officers of the Parties
in accordance with Section 24.2. 
 If the Parties are unable to agree on the Relative Commercial Value within [***] days of such referral, then the
Relative Commercial Value shall be determined pursuant to Section 24.4. 
  

	13.12.4	 No Valid Claim 

If no [***] of a Roche Patent or a Vividion Patent of a Product, a Roche PoC Product or a Shared Product exists in a given country, then the royalties in such
country for such Product or Roche PoC Product or Shared Product shall be reduced by [***] percent ([***]%) during the period that no such [***] exists. 
  

	13.12.5	 Generic Product 

Upon the first entry in a given country of a Generic Product, the royalties in such country for such Product or Roche PoC Product or Shared Product or Patented
E3 Module Product shall be reduced as follows: 
 (i) If in any Calendar Quarter at any time after entry of a Generic Product there has been a decline of the
Sales of the applicable Product or Roche PoC Product or Shared Product or Patented E3 Module Product in such country greater than [***] percent ([***]%) of the level of the Sales of such Product or Roche PoC Product or Shared Product or Patented E3
Module Product achieved in the average of the four Calendar Quarters immediately prior to such entry, then the royalty payments due to Vividion for such Product or Roche PoC Product or Shared Product or Patented E3 Module Product in such country
shall be reduced by [***] percent ([***]%) for such Calendar Quarter and, subject to the paragraph (ii) below, such reduction in royalty payments shall continue for all following Calendar Quarters of the Royalty Term. 

(ii) If in any Calendar Quarter at any time after entry of a Generic Product there has been a decline of the Sales of the applicable Product or Roche PoC
Product or Shared Product or Patented E3 Module Product in such country greater than [***] percent ([***]%) of the level of the Sales of such Product or Roche PoC Product or Shared Product achieved in the average of the four Calendar Quarters
immediately prior to such entry, then the royalty payments due to Vividion for such Product or Roche PoC Product or Shared Product or Patented E3 Module Product in such country shall be reduced by [***] percent ([***]%) for such Calendar Quarter and
such reduction in royalty payments shall continue for all remaining Calendar Quarters of the Royalty Term. 

  
 - 75 - 

	13.12.6	 Third Party Payments 

Unless otherwise agreed, Vividion shall be responsible, at its cost, for payments to Third Parties relating to the (i) Vividion Patents and
(ii) Vividion Know-How, (iii) Vividion Core Platform Technology and (iv) E3 Ligase Engager per se in the E3 Module from which such Patented E3 Module Product was created or claiming the use of
such E3 Ligase Engager per se to bind to the E3 Ligase in such E3 Module, on the manufacture or sale of a Product, a Roche PoC Product, a Shared Product or a Patented E3 Module Product (including in case of Profit and Loss Sharing in the US) to the
extent owed by Vividion under an agreement between such Third Party and Vividion. Unless otherwise agreed, Roche shall be responsible for payments to Third Parties relating to the Roche Target Ligands, each on a sale of a Product, a Roche PoC
Product, a Shared Product or a Patented E3 Module Product. 
 If Roche is obligated to pay a royalty to a Third Party on the sale of a Product, Roche PoC
Product or Shared Product in a particular country (other than Shared Products sold in the US for which there is Profit and Loss Sharing) in consideration for a license to Third Party patents containing a Composition of Matter Claim of the Original
Compound, in each case that would be infringed by the sale of such Product or a Roche PoC Product or Shared Product, then Roche shall be permitted to offset [***] percent ([***]%) of any such royalty due to such Third Party against royalties owed by
Roche to Vividion for the sale of such Product, Roche PoC Product or Shared Product in such country. 
  

	13.12.7	 Apportionment of Compulsory Sublicensee Consideration 

Compulsory Sublicense Compensation received by the Roche Group from a Compulsory Sublicensee during the Royalty Term shall be shared with Vividion at a rate of
[***] percent ([***]%) (the “Compulsory Sublicense Share Percentage”). 
 On a Product-by-Product and Shared Product-by-Shared Product basis, within [***] days after the end of each Calendar Year, Roche
shall pay to Vividion the Compulsory Sublicense Compensation under a given country or region of the Territory multiplied by the Compulsory Sublicense Share Percentage and shall report to Vividion the total Compulsory Sublicense Compensation received
by a Roche Group with respect to each such Product or Shared Product and the calculation of the share of such Compulsory Sublicense Compensation payable to Vividion. For clarity, any sales or payments by Compulsory Sublicensees under a Compulsory
Sublicense shall not be considered as Net Sales and shall not give rise to any royalty payment under Section 13.12.2 of this Agreement. 
  

	13.12.8	 Royalty Floor 

In no event shall the royalty paid to Vividion for Net Sales of any Product, Roche PoC Product, Shared Product or Patented E3 Module Product in any country for
a Calendar Quarter be reduced pursuant to Section 13.12.4, 13.12.5 and 13.12.6 from the applicable royalty rates set forth in Section 13.12.2 above by more than an amount equal to [***] percent ([***]%) of the royalties that would be
otherwise due for Net Sales of such Product, Roche PoC Product, Shared Product or Patented E3 Module Product in such country for such Calendar Quarter per the applicable royalty rates in Section 13.12.2. 

  
 - 76 - 

 For clarity, Roche may carry forward any amounts not utilized as a result of the maximum deduction cap in
this Section to future accounting periods until any amounts not utilized are fully deducted. 
  

	13.13	 Profit and Loss Sharing for Shared Products in the US 

With respect to each Shared Product, for which Vividion has not opted out pursuant to Section 12.3, Vividion shall share fifty percent (50%) profit and
loss in the US with Roche US or any other Roche Affiliate that shares profit and loss for such Shared Product in the US (“Profit and Loss Sharing”) for each Shared Product as set forth in the Financial Appendix. Profit and Loss
Sharing starts with the initiation of any commercial activities in the US as defined in the Financial Appendix and expires on the date as further described in Section 12.4 (Conversion of Profit and Loss Sharing). 

The Financial Appendix covers reporting, payment and accounting procedures that the Parties shall follow in determining and Profit and Loss Sharing for a
Shared Product. 
  

	13.14	 Single Royalty. 

No more than one stream of royalty payments shall be due under this Section 13 with respect to sales of any one particular Product, Roche PoC Product or
Shared Product. For the avoidance of doubt, multiple royalties shall not be payable because the sale of a particular Product, Roche PoC Product or Shared Product is Covered by more than one (1) Valid Claim in the country on which such Product,
Roche PoC Product and Shared Product is sold. 
  

	13.15	 Disclosure of Payments 

Each Party acknowledges that the other Party may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as
may be required under Applicable Law, including the US Sunshine Act. 
  

	13.16	 Know-How Payments 

The amounts owing under this Agreement are attributable independently but concurrently to the Patents licensed to Roche hereunder, as well as the grant of
other rights and undertakings of Vividion in this Agreement (including rights to know-how and the restrictions on Vividion’s activities in Section 6). However, if it is determined in a legal
proceeding with respect to this Agreement that amounts to be paid hereunder with respect to Products, Roche PoC Products or Shared Products not Covered by an issued and unexpired patent of Vividion must be subject to a reduction to be valid and
enforceable, then such amounts shall be reduced by the minimum amount necessary to make such payment obligations valid and enforceable. 
  

	13.17	 Different Products 

For purposes of this Article 13, a Product, Roche PoC Product or Shared Product shall be deemed a different Product, Roche PoC Product or Shared Product,
respectively, from another Product, Roche PoC Product or Shared Product only if it contains a different Compound. 
  

	14.	 Accounting and reporting 

 

	14.1	 Timing of Payments 

All payments under Sections 13.3 to 13.10 and 22.2.3.1 shall be made within [***] days after receipt of the relevant Option Exercise Notice or the event,
as applicable, and after receipt of an invoice by Roche. 

  
 - 77 - 

 With respect to each milestone payment set forth in Sections 13.8 through 13.10, Roche shall provide
Vividion written notice of the achievement of the event triggering such milestone payment within [***] Business Days following such achievement. With respect to each milestone payment set forth in Section 13.11, Roche shall provide Vividion
written notice of the achievement of the event triggering such milestone payment within [***] Business Days following such achievement. 
 Roche shall
calculate royalties on Net Sales quarterly as of March 31, June 30, September 30 and December 31 (each being the last day of an “Accounting Period”) and shall pay royalties on Net Sales within [***] days after
the end of each Accounting Period in which such Net Sales occur. 
  

	14.2	 Late Payment 

Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at
[***] percentage points above the average [***], as reported by Reuters from time to time, calculated on the number of days such payment is overdue. 
  

	14.3	 Method of Payment 

Royalties on Net Sales and all other amounts payable by Roche or Vividion hereunder shall be paid by Roche or Vividion, as applicable, in US Dollars (the
“Payment Currency”) to account(s) designated by the other Party. 
  

	14.4	 Currency Conversion 

When calculating the Sales of any Product or Shared Product that occur in currencies other than the Payment Currency or losses or Allowable Development
Expenses to be shared by Vividion incurred by Roche in currencies other than the Payment Currency, Roche shall convert the amount of such sales, losses or Allowable Development Expenses into Swiss Francs and then into the Payment Currency using
Roche’s then-current internal foreign currency translation method and rates actually used on a consistent basis in preparing its audited financial statements (which is, at the Effective Date, YTD average rate as reported by Reuters). When
calculating PoC Costs to be shared by Roche that are incurred by Vividion in currencies other than the Payment Currency, Vividion shall convert the amount expressed in a foreign currency into the Paying Currency using its standard conversion
methodology consistent with its Accounting Standards. 
  

	14.5	 Blocked Currency 

In a given country, if by reason of Applicable Law (for example governmental restrictions on foreign exchange trade) the local currency is blocked and cannot
be removed from such country, Roche will notify Vividion in writing and 
 (a) Vividion will have the right to receive the applicable royalties of Net Sales
in such country in local currency by deposit in a local bank designated by Vividion, or 
 (b) if such local currency payment is not allowed by reason of
Applicable Law or if otherwise requested by Vividion, then the royalties related to such Net Sales in such country shall continue to be accrued and shall continue to be reported, but such royalties will not be paid until the sales proceeds related
to such Net Sales may be removed from such country. At such time as Roche, its Affiliates or their Sublicensees, as the case may be, is able to remove the sales proceeds related to such Net Sales from such country, Roche shall also pay such accrued
royalties in Payment Currency using the actual exchange rate which is used to remove such sales proceeds from such country. 

  
 - 78 - 

	14.6	 Non-Refundable and
Non-Creditable 

 Except as expressly set forth in this Agreement, all payments under Sections
13.1 through 13.12 are non-refundable and non-creditable. 
  

	14.7	 Reporting 

With each payment, Roche shall provide Vividion in writing for the relevant Calendar Quarter on a US and Territory outside the US basis, Product-by-Product basis and Shared-Product-by-Shared Product basis the following information:

  

	(a)	 Sales in Swiss Francs; 

 

	(b)	 Deductions from Sales to calculate Net Sales 

 

	(c)	 Net Sales in Swiss Francs; 

 

	(d)	 adjustments made pursuant to Sections 13.12.3, 13.12.4, 13.12.5 or 13.12.6; 

 

	(e)	 exchange rate used for the conversion of Net Sales from the currency in which the sales occurred to Swiss
Francs and from Swiss Francs to the Payment Currency pursuant to Section 14.4; 

  

	(f)	 Total royalties due to Vividion with respect to such Net Sales and the royalty rate applied.

  

	15.	 Taxes 

  

	15.1	 Withholding Taxes 

The Party receiving any payment from the other Party under this Agreement shall pay all net income or franchise taxes imposed on such Party’s income
arising as a result of any payments accruing or made to such Party under this Agreement. All amounts of payments stated in this Agreement exclude any applicable indirect taxes, including, but not limited to, value added taxes, sales taxes, and use
taxes (collectively, “Indirect Taxes”). The Party preparing an invoice for any payment under this Agreement shall separately state any applicable Indirect Taxes, which shall be paid by the Party making the payment. Each Party agrees
to reasonably assist the other Party (upon request) in claiming exemption from, or a recovery of, any applicable Indirect Tax, and in minimizing the amount of any applicable Indirect Tax. 

If provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges in the nature of a tax (other than
Indirect Taxes) with respect to any royalty or other amount payable under this Agreement (“Withholding Taxes”) to the Party receiving any payment from the other Party under this Agreement, then the Party making such payment shall
promptly pay such Withholding Tax for and on behalf of the payment receiving Party to the proper governmental authority, and shall promptly furnish the payment receiving Party with receipt of payment. The Party making such payment shall be entitled
to deduct any such Withholding Tax actually paid from the royalty or other payment due the payment receiving Party or be promptly reimbursed by the payment receiving Party if no further payments are due to them. Each Party agrees to reasonably
assist the other Party (upon request) in claiming exemption from, or a reduction in, such deductions or withholdings of any Withholding Taxes under an applicable double taxation or similar agreement or treaty from time to time in force and in
minimizing the amount required to be so withheld or deducted or claiming a refund thereof, including, but not limited to, by requesting any applicable form, certification, or other information from the other Party that may reduce or eliminate any
such Withholding Tax (i) prior to making a relevant payment or type of payment and (ii) at any time thereafter when any such form, certification or other information is required to be updated or supplemented. 

  
 - 79 - 

 Notwithstanding the foregoing, if Roche assigns or otherwise transfers this Agreement, or any rights or
obligations hereunder, and as a result of such assignment or other transfer, the amount of the Withholding Tax exceeds the amount of Withholding Tax that would have applied had such assignment or transfer not occurred, then Roche shall pay Vividion
such additional amounts so that the net amount received by Vividion after the imposition of such Withholding Tax is the same as what Vividion would have received had such assignment or other transfer not occurred. 

 

	16.	 Auditing 

  

	16.1	 Right to Audit 

Each Party shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may
be necessary for the purpose of calculating or determining amounts payable under this Agreement, with respect to Roche including all Allowable Development Expenses and Shared Profit and Loss (as defined in the Financial Appendix) and with respect to
Vividion including the PoC Costs. Such books of accounts shall be kept at their principal place of business. At the expense of the auditing Party, the auditing Party shall have the right to engage an internationally recognized independent public
accountant reasonably acceptable to the other Party to perform, on behalf of the auditing Party, an audit of the relevant books and records of the other Party and its Affiliates that are deemed necessary by the independent public accountant to
report on Net Sales of Products and Shared Products (and with respect to Vividion for Vividion PoC Programs) or otherwise calculate or determine the amounts payable hereunder, for the period or periods requested by Vividion and the correctness of
any financial report or payments made under this Agreement. In addition, Vividion shall have the right to audit, through the auditor, selected Third Party agreements executed by Roche (in the [***] year period prior to the audit) for the sole
purpose of confirming that the concept of gross to net deduction of sales in Section 1.79 is consistent with the concept used by Roche for other Third Party collaborations. 

Upon timely request and at least [***] working days’ prior written notice from the auditing Party, such audit shall be conducted for those countries the
auditing Party has specifically requested, during regular business hours in such a manner as to not unnecessarily interfere with audited Party’s normal business activities. Such audit shall be limited to results in the [***] Calendar Years
prior to audit notification, and if the auditing Party requests an audit for a given Calendar Year, no additional audits may be conducted for the audited countries in the Territory for such Calendar Year, except with respect to any audit for cause.

 Such audit without cause shall not be performed more frequently than [***] per Calendar Year nor more frequently than once with respect to records
covering any specific period of time. 
 All books of account and records herein referred to shall be used only for the purpose of verifying financial
reports and payments provided hereunder, including royalty and other payment statements, and shall be treated as the respective Party’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than
[***] year after completion of an audit hereof, if an audit has been requested; nor more than [***] years from the end of the Calendar Year to which each shall pertain. 
  

	16.2	 Audit Reports 

The auditors shall only state factual findings in the audit reports and shall not interpret the agreement. The auditors shall share all draft audit findings
with Roche and Vividion before sharing such findings with the auditing Party and before the final audit report is issued. The final audit report shall be shared with the audited Party at the same time it is shared with the auditing Party. 

  
 - 80 - 

	16.3	 Over-or Underpayment 

If the audit reveals an overpayment, the Party overpaid shall reimburse the other Party for the amount of the overpayment within [thirty [***]. If the audit
reveals an underpayment, the underpaying Party shall make up such underpayment within [***] days. The audited Party shall pay for the audit costs if the underpayment exceeds [***] percent ([***]%) of the aggregate amount of payments owed with regard
to the books and records subject to the audit. Section 14.2 shall apply to this Section 16.3. 
  

	17.	 Intellectual Property 

 

	17.1	 Ownership of Inventions 

As between the Parties, each Party shall remain owner of its Patents and Know-How that the Party Controls prior to the
Effective Date of this Agreement or that it develops independently of the activities under this Agreement. 
 Roche hereby grants to Vividion a worldwide, non-exclusive, irrevocable, fully-paid up license, with the right to grant and authorize sublicenses, to make, use, sell, offer to sell, import and otherwise exploit for any purpose Vividion E3 Technology; in each
case including all intellectual property rights therein Controlled by Roche, subject to the exclusive license granted to Roche under Section 5.2.1, 5.2.2, 5.2.3. 

Notwithstanding anything to the contrary, Vividion shall own inventions and resulting Patents to the extent comprising or directed to Vividion CRG Technology,
if any, and Roche hereby assigns to Vividion all of Roche’s right, title and interest in and to Vividion CRG Technology, if any. 
 Roche shall
promptly disclose to Vividion any Vividion E3 Technology and Vividion CRG Technology (if any) upon creation thereof and provide Vividion with any information and materials pertaining thereto to the extent necessary to exploit any such Vividion E3
Technology and Vividion CRG Technology. 
 Vividion shall own all Vividion Inventions, Roche shall own all Roche Inventions, and Vividion and Roche shall
jointly own all Joint Inventions. Vividion and Roche each shall require all of its personnel to assign all inventions related to Products and Shared Products made by them to Roche and Vividion, as the case may be. In case of a Joint Invention, the
Parties shall discuss in good faith the assignment of any Patent claiming such Joint Invention to one Party and an appropriate license of such Patent to the other Party. 

Inventorship for Inventions (including Patents and Know-How) first made during the course of the performance of
activities under this Agreement will be determined in accordance with United States patent laws for determining inventorship. Vividion and Roche each shall require all of its employees, consultants and contractors to assign all Inventions conceived
by them to Roche and/or Vividion, to the extent required by this Agreement. 
 Subject to the terms of this Agreement, including the licenses granted under
Sections 5.1 and 5.2, each Party shall have an equal, undivided interest in any Joint Invention, and any Patent filed on such Joint Invention, without obligation to account to the other for the practice, license or other exploitation thereof or to
seek consent of the other Party for such activities and each Party hereby waives any right it may have under the laws of any jurisdiction to require any such consent or accounting. 

  
 - 81 - 

 With respect to Know-How (other than Inventions), Vividion shall own
such Know-How made by employees of Vividion solely or jointly with a Third Party, Roche shall own such Know-How made by employees of the Roche Group solely or jointly
with a Third Party. 
 Except as specifically set forth herein, this Agreement shall not be construed as (i) giving any of the Parties any license,
right, title, interest in or ownership to the Confidential Information; (ii) granting any license or right under any intellectual property rights; or (iii) representing any commitment by either Party to enter into any additional agreement,
by implication or otherwise. 
  

	17.2	 German Statute on Employee’s Inventions 

In accordance with the German Statute on Employees’ Inventions, each Party agrees to claim the unlimited use of any Invention conceived, reduced to
practice, developed, made or created in the performance of, or as a result of, any Collaboration Plan, Preclinical Plan, and Clinical Plan by employees of any German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling
the obligations towards their employees under the German Statute of Employee’s Inventions. 
  

	17.3	 Trademarks and Labeling 

Roche shall own all trademarks used on or in connection with Products and Shared Products for Licensed Programs in the Territory, and shall, at its sole cost,
be responsible for procurement, maintenance, enforcement and defense of all such trademarks used on or in connection with such Products and Shared Products in the Territory. Other than as agreed by the other Party, a Party shall not use any
trademark or housemark owned or controlled by such Party. 
 Roche shall have the right to obtain the International
Non-proprietary Name (INN) from the World Health Organization and the US Adopted Name (USAN) from the US adopted Names Council (USANC) as the generic name(s) for the Products and Shared Products, in each case
that are within a Licensed Program. 
 To the extent permitted by Applicable Law, all packaging and labeling for a Shared Product shall display that the
Shared Product has been “licensed from Vividion.” 
  

	17.4	 Handling of Patents 

Except as set forth in Section 17.5, Vividion shall, at [***] expense and discretion, Handle Vividion Patents and Vividion E3 Patents. 

Subject to the terms of Section 17.5, (i) each Party shall, at [***] expense and discretion, Handle the Patents claiming an Invention solely owned by
such Party and (ii) neither Party shall Handle any Patent claiming a Joint Invention unless the Parties agree in advance in writing with respect to the Handling and enforcement of any such Patent. 

 

	17.5	 Handling of Product Specific Patents 

 

	17.5.1	 For each Collaboration Target, beginning at the Effective Date and ending on selection of the applicable
Collaboration Target as a Roche Program or Vividion Program, Vividion shall (a) consult with Roche with respect to the general strategy of Handling any Product Specific Patent and Vividion Patents, and (b) consult with Roche in due time
reasonably before filing substantive changes in Composition of Matter Claims and before the grant of any Product Specific Patent or Vividion Patents that would Cover a Compound intended for a Roche Program or Vividion Program, in order to allow
Roche to request filing of continuations, continuation-in-part and/or divisional patent application (where possible) for

  
 - 82 - 

	 	
Composition of Matter Claims Covering a Compound within such Program that Vividion did not obtain, and reasonably prior to any deadline for filing any such Product Specific Patent in each country
or region in order to allow Roche to request filing in such countries or regions, which comments and requests Vividion will consider in good faith, provided that any such review and comment by Roche shall be conducted by an external patent law firm
selected by Roche at [***] expense and such external patent law firm shall not share any Vividion Confidential Information or chemical structures with Roche until such information is submitted by Vividion to Roche in a Validated Hit Data Package.
For each Collaboration Target, beginning on the Effective Date and, if Roche does not exercise the applicable Option Right prior to expiration of the applicable Option Period, ending on the expiration of the applicable Option Period, at Roche’s
request, Vividion shall, where and when reasonable (as discussed in the Patent Coordination Team, subject to the limitations on sharing Vividion Confidential Information and chemical structures as described in the preceding sentence), Handle
Vividion Patents in such a way to obtain Vividion Patents that have claims related only to Compounds or Components that are specific to such Compounds, in each case within the applicable Program, and to the Collaboration Target, provided that in no
event would Vividion be obligated to, for any Patent filed as of the Effective Date and any Patent claiming priority to such Patent filed as of the Effective Date (w) seek a divisional Patent application that is not supported by a unity
objection, restriction requirement or the equivalent, (x) take any action in violation of applicable patent law, (y) Handle any Patent application that would have an adverse impact on any other Vividion Patent or other Patent within the
applicable Patent family or (z) Handle any such other Vividion Patent or such other Patent in a manner that has an adverse impact on such other Vividion Patent or such other Patent. The term “Vividion CC Patents” shall mean the
Vividion Patents that result from the Handling of the Vividion Patents pursuant to the preceding sentence of this Section 17.5.1 that have claims related only to Compounds or Components that are specific to such Compounds, in each case within
the applicable Program, and to the Collaboration Target. 

  

	17.5.2	 Beginning on selection of a Nominated Program as a Roche Program or Vividion Program, Vividion shall, through
the Patent Coordination Team (and no longer via an external patent law firm), (a) consult with Roche with respect to the general strategy of Handling any Product Specific Patent, in each case within such Program, and (b) consult with Roche in
due time reasonably before filing substantive changes in Product Specific Patents and before the grant of any Product Specific Patent in order to allow Roche to request filing of continuations, continuation-in-part and/or divisional patent application (where possible) for Product Specific Patents Covering a Compound within such Program that Vividion did not obtain, and reasonably prior to any
deadline for filing any such Product Specific Patent in each country or region in order to allow Roche to request filing in such countries or regions, which comments and requests Vividion will consider in good faith. 

 

	17.5.3	 Beginning on selection of a Nominated Program as a Roche Program or Vividion Program and, if Roche does not
exercise the applicable Option Right prior to expiration of the applicable Option Period, ending on the expiration of the applicable Option Period: 

  

	    	 Vividion shall, at Roche’s request with respect to Original Compound(s) within such Program and [***]
expense, file one or more Product Specific Patents with respect to such Original Compound. Vividion shall provide Roche with a draft of each such intended application for a Product Specific Patent reasonably well in advance of filing such
application to give Roche a reasonable opportunity to review and comment on any such application proposed to be filed before a patent office. Vividion shall consider in good 

  
 - 83 - 

	 	
faith Roche’s comments thereon. Promptly after filing each such Product Specific Patent, Vividion shall provide Roche a copy of such Product Specific Patent as filed, together with
notice of its filing date and serial number. After such Product Specific Patent is so filed, the Handling of such Product Specific Patent shall be subject to the terms below of this Section17.5.3, and the terms of Sections 17.5.5 and 17.5.6.

  

	  	 Vividion shall Handle such patent filings at [***] expense until Roche exercises the applicable Option Right.
The Parties shall agree in the Patent Coordination Team prior to start of substantive prosecution (at the latest within [***] days after receipt of ISR/WOISA or 1st office action from a national Patent Office) on a general strategy of Handling such
Product Specific Patent. Thereafter until Roche exercises the applicable Option Right, Vividion shall consult with Roche in due time reasonably before substantive changes in subject matter or claims and before the grant of any Product Specific
Patent in order to allow Roche to request filing of continuations, continuation-in-part and/or divisional patent application (where possible) for matter that Vividion
did not obtain, and reasonably prior to any deadline for filing any such Product Specific Patent in each country or region in order to allow Roche to request filing in such countries or regions, which comments and requests Vividion shall consider in
good faith, provided that Vividion shall follow any request to file a new continuation, continuation-in-part and/or divisional application for Product Specific Patents
having only Product Specific Claims that Vividion did not obtain or in any country or region in which Vividion has not filed such Product Specific Patents, provided that in no event shall Vividion be required to, for any Patent filed as of the
Effective Date, and any Patent claiming priority to a Patent filed as of the Effective Date, (w) seek a divisional Patent application that is not supported by a unity objection, restriction requirement or the equivalent, (x) take any
action in violation of applicable patent law, (y) Handle any Patent application that would have an adverse impact on any other Vividion Patent or other Patent within the applicable Patent family or (z) Handle any such other Vividion Patent
or such other Patent in a manner that has an adverse impact on such other Vividion Patent or such other Patent. Vividion shall furnish information on filing particulars for such Product Specific Patents in every country, copies of material
communications to and from each Patent Office, copies of claims as pending and granted for any Product Specific Patent and copies of filing documents of any child application. 

 

	  	 If Roche does not exercise its Option Right with respect to a Program prior to expiration of the applicable
Option Period, then Vividion shall thereafter bear all patent cost for the respective Product Specific Patents related to such Program and have the sole right to Handle such Product Specific Patents at its discretion. 

 

	17.5.4	 For each Licensed Program following Roche’s exercise of the Option Right with respect thereto and after
the initial filing of such Product Specific Patent by Vividion pursuant to the terms of Section 17.5.3: 

  

	  	 Roche shall, at [***] expense, Handle such Product Specific Patent, provided that in no event shall Roche
Handle such Product Specific Patent in a manner to cause it to include any claims that are not Product Specific Claims. Notwithstanding anything to the contrary, if either Party identifies a claim in a Product Specific Patent that is not a Product
Specific Claim, then such Party shall notify the other Party thereof and, if Roche is Handling such Product Specific Patent, Roche shall Handle such Product Specific Claim in accordance with Vividion’s instructions. 

  
 - 84 - 

	  	 The Parties shall agree in the Patent Coordination Team prior to start of substantive prosecution (at the
latest within [***] days after the earlier of receipt of ISR/WOISA or 1st office action from a national patent office) on a general strategy of Handling such Product Specific Patent. Thereafter, Roche shall consult with Vividion in due time
reasonably before substantive changes in subject matter or claims and before the grant of any Product Specific Patent in order to allow Vividion to request filing of continuations,
continuation-in-part and/or divisional patent application (where possible) for matter that Roche did not obtain, and reasonably prior to any deadline for filing any such
Product Specific Patent in each country or region in order to allow Vividion to request filing in such countries or regions, which comments and requests Roche shall consider in good faith. Roche shall furnish information on filing particulars in
every country, copies of material communications to and from each Patent Office, copies of claims as pending and granted for any Product Specific Patent and copies of filing documents of any child application. 

 

	17.5.5	 If Roche determines in its sole discretion to: (i) abandon or cease Handling of any Product Specific
Patent in any jurisdiction, or (ii) to abandon any subject matter or claims in any Product Specific Patent, then Roche will provide Vividion written notice of such determination as soon as possible but in due time reasonably before any deadline
for taking action to avoid abandonment (or other loss of rights) and will provide Vividion with the opportunity to Handle, at [***] expense, such Product Specific Patent in such jurisdiction or, in the case of subject matter or claims, to file, at
[***] expense, such subject matter or claims through a divisional or continuation Patent (or foreign equivalent thereof) of such Product Specific Patent and thereafter such Patent (and any continuation or divisional thereof) shall still be a Product
Specific Patent. 

  

	17.5.6	 Each Party will reasonably cooperate with and assist each other in the Handling of Product Specific Patents,
including making scientists and scientific records reasonably available and using its reasonable efforts to have documents signed as necessary for the Handling of such Product Specific Patents. All communications between the Parties relating to the
Handling of Patents pursuant to this Section 17.5, and Sections 17.6 and 17.7 shall be considered Confidential Information. Communication by email is deemed sufficient. 

 

	17.6	 Patent Coordination Team 

Where the Parties need to consult with each other on the Handling of Patents, the Parties shall establish a patent coordination team and shall adopt procedures
for interacting on patent matters. Such procedures shall include a general filing strategy for Compounds, including Components, and shall be subject to the limitations on sharing Vividion Confidential Information and chemical structures as described
in the first sentence of Section 17.5.1. 
 At the request of either Party, the Patent Coordination Team shall discuss the conduct of any freedom-to-operate assessment (“FTO”) that may be performed with respect to a Licensed Program. 

 

	17.7	 Unified Patent Court (Europe) 

With respect to any Product Specific Patent following Roche’s exercise of the Option Right with respect to the applicable Licensed Program, at any time
prior to the end of the “transitional period” as such term is used in Article 83 of the Agreement on a Unified Patent Court between the 

  
 - 85 - 

 participating Member States of the European Union, for a given relevant EU Patent, Roche may request in
writing that Vividion either (i) opt out from the exclusive competence of the Unified Patent Court or (ii) if applicable, withdraw a previously-registered opt-out, and Vividion shall notify the
Registry, pay any such registry fee and take such other action as may be necessary to effect the opt-out or opt-out withdrawal (“Register”). With
respect to any such Product Specific Patent following exercise of the Option Right for the applicable Licensed Program, Vividion shall Register within [***] days of receipt of Roche’s written request, or such other time parameters specified by
Roche. 
  

	17.8	 CREATE Act 

It is the intention of the Parties that this Agreement is a “joint research agreement” as that phrase is defined in 35 USC §103(c)(3). 

 

	17.9	 Infringement 

Following Roche’s exercise of its Option Right with respect to a Licensed Program, each Party shall promptly provide written notice to the other Party
during the Agreement Term of any known infringement or suspected infringement by a Third Party of the applicable Product Specific Patents by a product Directed To the Collaboration Target for the Licensed Program (“Infringement”),
and shall provide the other Party with all evidence in its possession supporting such infringement. 
 Within [***] days after Roche provides or receives
such written notice (“Decision Period”), Roche, in its sole discretion, shall decide whether or not to initiate a suit or take action in the Territory to remedy such Infringement and shall notify Vividion of its decision in writing
(“Suit Notice”). 
 If Roche decides to bring such suit or take such action, once Roche provides Suit Notice, Roche may immediately
commence such suit or take such action. In the event that Roche (i) does not in writing advise Vividion within the Decision Period that Roche will commence suit or take action, or (ii) fails to commence suit or take action within a
reasonable time after providing Suit Notice, Vividion shall thereafter have the right (subject to Roche’s written consent, not to be unreasonably withheld) to commence such suit or take such action in the Territory to remedy such Infringement
and shall provide written notice to Roche of any such suit commenced or action taken by Vividion. 
 On a country-by-country basis: 
 (i) For Roche Programs where (a) there is not sufficient support available for
filing of a Product Specific Patent prior to the Nomination Date of the Roche Program or (b) Roche does not request Vividion to file a Product Specific Patent pursuant to Section 17.5.3 or (c) Roche abandons or ceases Handling such
Product Specific Patent pursuant to Section 17.5.5, should one or more Vividion CC Patents or Roche Patents exist: 
 Roche shall not have the right to
enforce any Vividion Patent other than the applicable Vividion CC Patent that Cover the applicable Product within the Licensed Program, provided that at Roche’s request and only with Vividion’s prior written consent, Roche may initiate a
suit to enforce a Vividion Patent against a Third Party to remedy infringement by such Third Party of such Vividion Patent for such Product by a product Directed To the Collaboration Target for such Product. Upon such consent, such infringement
shall be considered an Infringement under this Section 17.9; and 
 (ii) Should one or more Product Specific Patent or Vividion CC Patent exist: 

  
 - 86 - 

 Roche shall not have the right to enforce any Vividion Patent other than the applicable Vividion CC Patent
that Cover the applicable Product within the Licensed Program, provided that at Roche’s request and only with Vividion’s prior written consent, Roche may initiate a suit to enforce a Vividion Patent against a Third Party to remedy
infringement by such Third Party of such Vividion Patent for such Product by a product Directed To the Collaboration Target for such Product. Upon such consent, such infringement shall be considered an Infringement under this Section 17.9; 

(iii) Should no Product Specific Patent or Vividion CC Patent or, with respect to Roche Programs described in clause (i) above, Roche Patent exist, Roche
shall, after Vividion’s prior consent that shall not unreasonably be withheld, have the right to enforce a Vividion Patent that Covers the applicable Component or Compound for the applicable Product within the Licensed Program against a Third
Party to remedy infringement by such Third Party of such a Vividion Patent by a product Directed To the Collaboration Target for such Product. Without limiting the reasons for which Vividion may withhold its consent, it shall not be unreasonable for
Vividion to withhold its consent (A) if Vividion has initiated (or plans to initiate within [***] days) enforcement of a Vividion Patent against such product, (B) if one or more further Vividion Patents Covers such product and Vividion
would allow Roche to enforce any such further Vividion Patents, (C) if such enforcement action would put such Vividion Patent at unreasonable risk of an adverse impact or (D) if the applicable Product contains a Derivative and a Roche
Patent Covering such Product exists. Upon such consent, such infringement shall be considered Infringement under this Section 17.9. 
 Upon written
request, the Party bringing suit or taking action to remedy such Infringement (“Initiating Party”) shall keep the other Party informed of the status of any such suit or action and shall provide the other Party with copies, to the
extent the Initiating Party is lawfully permitted to do so, of all substantive documents or communications filed in such suit or action. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action. 

The Initiating Party shall, except as provided below, pay all expenses of the suit or action, including the Initiating Party’s attorneys’ fees and
court costs. Unless otherwise agreed by the Parties, and subject to the Parties’ respective obligations under Article 19, all monies recovered upon the final judgment or settlement of any action described in this Section 17.9 for all
Products other than Shared Products shall be used as follows: 
 (a) First, to reimburse the Initiating Party for its costs associated with such action and,
if any remains that was not previously reimbursed, to the other Party for any advisory counsel fees and costs; and 
 (b) Second, the balance, if any, shall
be allocated [***] percent ([***]%) to the Initiating Party, and [***] percent ([***]%) to the other Party. 
 If the Initiating Party believes it is
reasonably necessary or desirable to obtain an effective remedy, upon written request, the other Party agrees to be joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation
is required as the result of its being a named party to the suit or action. At the Initiating Party’s written request, the other Party shall offer reasonable assistance to the Initiating Party in connection therewith at no charge to the
Initiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance. The other Party shall have the
right to participate and be represented in any such suit or action by its own counsel at its own expense. 
 The Initiating Party may settle, consent
judgment or otherwise voluntarily dispose of the suit or action (“Settlement”) without the written consent of the other Party but only if such Settlement can be achieved without adversely affecting the other Party (including any of
its Patents). If a Settlement could adversely affect the other Party, then the written consent of the other Party would be required, which consent shall not be unreasonably withheld. 

  
 - 87 - 

 For any patent that is a Roche Patent, Roche, in its sole discretion, shall decide whether or not to
initiate such suit or action in the Territory. Roche shall have full discretion as to how it wishes to handle such suit and may reach Settlement and retain all damages, settlement fees or other consideration under any terms and conditions it desires
and retain whatever. Only if a Settlement could adversely affect Vividion shall the written consent of Vividion be required, which consent shall not be unreasonably withheld. 
  

	17.10	 Defense 

Subject to the indemnity obligations under Article 19, if an action for infringement is commenced or alleged against either Party, its licensees or its
sublicensees related to a Party’s (or such Party’s licensee’s or sublicensee’s) conduct of the Collaboration within the scope of the Collaboration Plan, the Preclinical Plan, the Clinical Plan or the discovery, development,
manufacture, use or sale of a Product or Shared Product, then such Party shall notify the other Party thereof and such Party shall have the right (but not the obligation) to defend such action at its own expense, and the other Party shall assist and
cooperate with such Party, at such Party’s expense, to the extent necessary in the defense of such suit. Unless the Parties otherwise agree and subject to the indemnity obligations under Article 19, such Party shall have the right to settle the
suit or consent to an adverse judgment thereto, in its sole discretion, so long as such settlement or adverse judgment does not adversely affect the rights of the other Party or its Affiliates (including any Patents Controlled by any of them).
Subject to the indemnity obligations under Article 19, Roche shall assume full responsibility for the payment of any award for damages, or any amount due pursuant to any settlement entered into by it with such Third Party. 

 

	17.11	 Common Interest Disclosures 

With regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology
owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of the Collaboration Plan, the Preclinical Plan(s), the
Clinical Plan(s), and/or Compounds and/or Products and/or Shared Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual
property rights relating to the conduct of the Collaboration Plan, the Preclinical Plan(s), the Clinical Plan(s), Compounds and/or Products. Accordingly, the Parties agree that all such information and Materials obtained by Vividion and Roche from
each other pursuant to this Article 17 will be used solely for purposes of the Parties’ common legal interests with respect to Handling, enforcement and defense of intellectual property rights pursuant to the terms of this Article 17. All such
information and Materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and Materials, neither Party
intends to waive or limit any privilege or immunity that may apply to the shared information and Materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party’s prior
written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any other Party. Notwithstanding the foregoing, neither Party’s attorney represents the other Party. 

 

	17.12	 Hatch-Waxman 

Following Roche’s exercise of its Option Right with respect to a Licensed Program, with respect to any identification of Patents to Regulatory Authorities
for a Product within such Licensed Program as required or allowed for listing in the FDA’s Orange Book in the United States or foreign equivalents outside of the United States: (i) Roche will have the sole right to make any such 

  
 - 88 - 

 decision to list any Product Specific Patent or any Vividion CC Patent for such Product and
(ii) Vividion will have the sole right to make any such decision with respect to any Vividion Patents other than Product Specific Patents and Vividion CC Patents for any product, provided that Roche shall have the right to list any Vividion CC
Patents for such Product with Vividion’s prior written consent. 
 Notwithstanding anything herein to the contrary, should a Party receive a
certification for a Product or Shared Product within a Licensed Program pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417, known as the Hatch-Waxman Act), as
amended, or its equivalent in a country other than the US, then such Party shall immediately provide the other Party with a copy of such certification. Roche shall have [***] days from date on which it receives or provides a copy of such
certification to provide written notice to Vividion (“H-W Suit Notice”) whether Roche will bring suit, at [***] expense, within a [***] day period from the date of such certification, and in
any case at least [***] Business Days prior to which any further delay in bringing such suit would limit or compromise the remedies available in connection with such certification. Should such [***] day period expire without Roche bringing suit or
providing such H-W Suit Notice, then Vividion shall be free to immediately bring suit in its name. 
  

	17.13	 Patent Term Extensions 

The Parties shall use Commercially Reasonable Efforts to obtain all available patent term extensions, adjustments or restorations, or supplementary protection
certificates with respect to Product Specific Patents directed to Products within a Licensed Program (“SPCs”, and together with patent term extensions, adjustments and restorations, “Patent Term Extensions”).
Vividion shall execute such authorizations and other documents and take such other actions as may be reasonably requested by Roche to obtain such Patent Term Extensions, including designating Roche as its agent for such purpose as provided in 35 USC
§ 156. All filings for such Patent Term Extensions shall be made by Roche; provided, that in the event that Roche elects not to file for a Patent Term Extension, Roche shall (a) promptly inform Vividion of its intention not to file and
(b) grant Vividion the right to file for such Patent Term Extension. Each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. The
Parties shall cooperate with each other in gaining patent term restorations, extensions and/or SPCs wherever applicable to such Product Specific Patents. 
  

	18.	 Representations and Warranties 

 

	18.1	 Vividion Representations and Warranties 

 

	  	 Vividion represents and warrants that: 

 

	 	18.1.1.1	 Safety Data 

Vividion has disclosed to Roche and will promptly disclose to Roche (i) the results of all preclinical testing and human clinical testing of Products or
Shared Products in its possession or control and (ii) all information in its possession or control that are the subject of a Validated Hit Data Package, CCS Data Package, or PoC Data Package, in its Control, concerning side effects, injury,
toxicity or sensitivity reaction and incidents or severity thereof with respect to Products and Shared Products. 

  
 - 89 - 

	18.1.1.2	 Third Party Patents 

As of the Effective Date, Vividion has no knowledge of the existence of any patent or patent application owned by or licensed to any Third Party that would
prevent Roche from making, having made, using, offering for sale, selling or importing Products and Shared Products in the Territory. 
  

	18.1.1.3	 Ownership of Vividion Base Patents. 

As of the Effective Date, Vividion is the sole and exclusive owner of the Vividion Base Patents. No other parties have any right, title or interest in or to
the Vividion Base Patents. The Vividion Base Patents are free and clear of all liens, claims, security interests and other encumbrances of any kind or nature. Vividion has not granted any licenses to the Vividion Base Patents to any Third Party, nor
has Vividion effectuated any prior transfer, sale or assignment of any part of the Vividion Patents. 
  

	18.1.1.4	 Inventors 

Vividion has obtained the assignment of, or an exclusive license under, all interest and all rights or licenses thereunder with respect to the Vividion Base
Patents necessary to grant the licenses granted hereunder. All of Vividion’s employees, officers and consultants have, prior to such individual’s performance of any activities under this Agreement on behalf of Vividion, executed agreements
requiring assignment to Vividion of all Inventions made by such individuals in performance of such activities. 
  

	18.1.1.5	 Grants 

To the best of Vividion’s knowledge and belief as of the Effective Date, Vividion has the lawful right to grant Roche and its Affiliates the rights and
licenses described in this Agreement. 
  

	18.1.1.6	 Authorization 

As of the Effective Date, the execution, delivery and performance of this Agreement by Vividion and all instruments and documents to be delivered by Vividion
hereunder: (i) are within the corporate power of Vividion; (ii) have been duly authorized by all necessary or proper corporate action; (iii) are not in contravention of any provision of the certificate of formation or limited
liability company agreement of Vividion; (iv) to the knowledge of Vividion, will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture,
mortgage, deed of trust, lease, agreement, or other instrument to which Vividion is a party or by which Vividion or any of its property is bound, which violation would have an adverse effect on the financial condition of Vividion or on the ability
of Vividion to perform its obligations hereunder; and (vi) do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained
previously (other than approvals required under the HSR Act, Regulatory Approvals required for the sale of Products and Shared Products and filings with Regulatory Authorities required in connection with Products and Shared Products). 

 

	18.1.1.7	 Validity of Patents. 

As of the Effective Date, Vividion is not in possession of information that would render invalid and/or unenforceable any claims that are in any of the
Vividion Base Patents. Vividion is aware that information had been cited in the prosecution of Vividion Base Patents which information Vividion would not consider to reasonably be render invalid and/or unenforceable any claims that are in any of the
Vividion Base Patents. Vividion has no knowledge of any inventorship disputes concerning any Vividion Base Patents. 

  
 - 90 - 

	18.1.1.8	 Ownership and Validity of Know-How 

Vividion’s Know-How is legitimately in the possession of Vividion and has not been misappropriated from any Third
Party. Vividion has taken reasonable measures to protect the confidentiality of its Know-How. 
  

	18.1.1.9	 No Claims 

As of the Effective Date, there are no claims or investigations (other than with respect to the Parties’ HSR filings), pending or, to its knowledge,
threatened against Vividion or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect Vividion’s ability to
perform its obligations hereunder. 
  

	18.1.1.10	 No Conflict 

To Vividion’s knowledge as of the Effective Date, neither Vividion nor any of its Affiliates is or will be under any obligation to any person, contractual
or otherwise, that is conflicting with the terms of this Agreement. 
  

	18.1.1.11	 Scripps License 

The activities by Vividion under this Agreement are not Covered by Patents, or require use of any Know-How, licensed to
Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016 (“Scripps License”). Vividion will not use in the Collaboration and/or incorporate any such Know-How or technology Covered by such Patents into a Compound or Product. 
  

	18.2	 Roche Representations and Warranties. 

 

	  	 Roche represents and warrants that: 

 

	18.2.1	 Authorization 

As of the Effective Date, the execution, delivery and performance of this Agreement by Roche and all instruments and documents to be delivered by Roche
hereunder: (i) are within the corporate power of Roche; (ii) have been duly authorized by all necessary or proper corporate action; (iii) are not in contravention of any provision of the certificate of formation or limited liability
company agreement of Roche; (iv) to the knowledge of Roche, will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of
trust, lease, agreement, or other instrument to which Roche is a party or by which Roche or any of its property is bound, which violation would have an adverse effect on the financial condition of Roche or on the ability of Roche to perform its
obligations hereunder; and (vi) do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals
required under the HSR Act, Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with Products). 
  

	18.2.2	 Inventors 

All Roche employees, officers and consultants have executed agreements requiring assignment to Roche of all Inventions made by such individuals during the
course of and as a result of their association with Roche. 

  
 - 91 - 

	18.2.3	 Grants 

To Roche’s knowledge as of the Effective Date, Roche has the lawful right to grant Vividion and its Affiliates the rights and licenses described in this
Agreement. 
  

	18.2.4	 No conflict 

To Roche’s knowledge as of the Effective Date, neither Roche nor any of its Affiliates is or will be under any obligation to any person, contractual or
otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of Roche’s obligations hereunder. 
  

	18.2.5	 Ownership and Validity of Know-How 

Roche’s Know-How is legitimately in the possession of Roche and has not been misappropriated from any Third Party.
Roche has taken reasonable measures to protect the confidentiality of its Know-How. 
  

	18.2.6	 No Claims 

As of the Effective Date, there are no claims or investigations (other than with respect to the Parties’ HSR filings), pending or, to its knowledge,
threatened against Roche or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect Roche’s ability to perform
its obligations hereunder. 
  

	18.3	 No Other Representations and Warranties 

EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF PRODUCTS AND SHARED PRODUCTS. 
  

	19.	 Indemnification 

 

	19.1	 Indemnification by Roche 

Roche shall indemnify, hold harmless and defend Vividion, Vividion’s Affiliates and their directors, officers, employees and agents (“Vividion
Indemnitees”) from and against any and all losses, expenses, cost of defense (including without limitation reasonable attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) that Vividion Indemnitees
become legally obligated to pay arising from any claim, demand, suit, proceeding or cause of action brought by a Third Party (each a “Third Party Claim”) against a Vividion Indemnitee because of [***]. 

  
 - 92 - 

	19.2	 Indemnification by Vividion 

Vividion shall indemnify, hold harmless and defend Roche, Roche’s Affiliates and their directors, officers, employees and agents (“Roche
Indemnitees”) from and against any and all losses, expenses, cost of defense (including without limitation reasonable attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) that Roche Indemnitees
become legally obligated to pay arising from a Third Party Claim because of [***]. 
  

	19.3	 Procedure 

In the event of a claim by a Third Party against a Party entitled to indemnification under this Agreement (“Indemnified Party”), the
Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and, subject to the terms of this Section 19.3, solely manage and control, at its
sole expense, the defense of the claim and its settlement. At the Indemnifying Party’s request and expense, the Indemnified Party shall cooperate with the Indemnifying Party and may, at the Indemnified Party’s option and expense, be
represented in any such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The
Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 

 

	20.	 Liability 

  

	20.1	 Limitation of Liability 

Neither Party is providing a guarantee or warranty that it will successfully discover, develop or commercialize any Compound or Product and, so long as such
Party complies with its obligations under Article 7, it shall not be liable to the other Party as a result of failure or delay to discover, develop and/or commercialize a Compound or Product, as applicable, including but not limited to, a) a delay
in timelines, or b) delay or failure to recruit patients, or c) a change in its respective study protocols, or d) failure to obtain regulatory approval for the Compound or Product as applicable. 

EXCEPT WITH RESPECT TO INDEMNIFICATION UNDER ARTICLE 19, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER. 
  

	21.	 Obligation Not to Disclose Confidential Information 

 

	21.1	 Non-Use and Non-Disclosure

 During the Agreement Term and for ten (10) years thereafter, a Receiving Party shall (i) treat Confidential Information
provided by Disclosing Party as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third Parties, without the Disclosing Party’s prior written
consent, and (iii) not use such 

  
 - 93 - 

 Confidential Information other than for exercising its rights or fulfilling its obligations under this
Agreement. 
  

	21.2	 Permitted Disclosure 

Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 21.1, the Parties recognize the need for certain exceptions to this obligation that are specifically set forth below with respect to press releases in Section 21.3 and certain commercial considerations in Section 21.5. 

 

	21.3	 Press Releases 

Vividion may issue the press release attached as Appendix 21.3, and following such press release, Vividion shall have the right to make any additional public
statement that is consistent with the contents of such press release or other press release issued or approved by Roche. 
 Roche shall issue press releases
in accordance with its internal policy that typically Roche does not issue a second press release until a Phase II Study has been completed for a Compound. Roche shall provide Vividion with a copy of any draft press release related to the activities
contemplated by this Agreement at least [***] weeks prior to its intended publication for Vividion’s review. Vividion may provide Roche with suggested modification to the draft press release. Roche shall in good faith consider Vividion’s
suggestions in issuing its press release. 
 Roche shall have the right to make any additional public statement that is consistent with the contents of an
earlier press release. 
 Except as provided above, Vividion shall only issue press releases related to the activities contemplated by this Agreement that
either (i) have been approved by Roche (such approval not to be unreasonably withheld); (ii) are required to be issued by Vividion as a matter of law or are required for compliance with the rules of any stock exchange and Vividion has a
competent legal opinion to that effect; or (iii) related to activities under Sole Vividion Programs. In all circumstances requiring approval by Roche, Vividion shall provide Roche with a draft press release at least two (2) weeks prior to
its intended publication for Roche’s review. During such period, Roche shall (i) approve the draft press release and permit Vividion to issue the press release, (ii) contact Vividion to discuss modification to the draft press release,
or (iii) contact Vividion and disapprove the press release. If Roche so asks for modification, then Vividion shall either make such modification or work with Roche to arrive at a press release that Roche approves. If Vividion issues a press
release without Roche’s approval, then Vividion must obtain a competent legal opinion that the release was required to be issued by Vividion as a matter of law or are required for compliance with the rules of any stock exchange. 

To ensure communication alignment, responses (if any) to inquiries by media or other Third Parties after issuance of a permitted press release by a Party
shall consist solely of the press release language or shall follow the response guidelines that may be mutually developed by the Parties, except to the extent required by Applicable Law, a Regulatory Authority or the rules of any stock exchange.

  

	21.4	 Publications 

During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of the other Party’s Confidential Information
relating to a Compound, Product, E3 Ligase, E3 Ligase Engager or E3 Module in any publication or presentation: 

  
 - 94 - 

	a)	 Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and
published in accordance with their internal guidelines and Applicable Law. Each Party, in accordance with its internal policies and procedures and Applicable Law, shall have the right to publish all studies, clinical trials and results thereof
conducted by such Party on the clinical trial registries that are maintained by or on behalf of such Party. Neither Party shall publish any studies, clinical trials or results thereof conducted by the other Party on its clinical trial registry,
provided however, that the clinical trial registry maintained by the Party conducting such clinical trial may be accessed via a link from the other Party’s clinical trial registry. 

 

	b)	 A Party (“Publishing Party”) shall provide the other Party with a copy of any such proposed
publication or presentation at least [***] days prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential
Information of the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies (“Publishing
Notice”) the Publishing Party in writing, within [***] days after receipt of the copy of the proposed publication or presentation that such publication or presentation in its reasonable judgment (i) contains an invention owned by the
other Party, for which the other Party reasonably desires to obtain patent protection or (ii) could be expected to have an adverse effect on the commercial value of any Confidential Information of the other Party, the Publishing Party shall
prevent such publication or presentation or delay such publication or presentation for a mutually agreeable period of time. In the case of any such inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and
filing of a patent application(s) on such invention, and in no event less than [***] days from the date of the Publishing Notice. In the case of any such Confidential Information of the other Party, the Publishing Party shall not include such
Confidential Information in such publication or presentation if the other Party requests it to be removed. 

  

	c)	 Without limiting the foregoing, with respect to E3 Modules for which Roche exercises the E3 Module Option that
include an E3 Ligase discovered in performance of the Collaboration Plan, each Party shall provide notice to the other Party promptly after disclosure of the sequence of any novel E3 Ligase or the chemical structure(s) of E3 Ligase Engager(s)
associated with such E3 Module in any application for a Patent or otherwise to any patent office, during the period beginning on such exercise until the sequence and/or chemical structure(s) are otherwise publicly disclosed, as the case may be.

  

	21.5	 Commercial Considerations 

Nothing in this Agreement shall prevent a Receiving Party or its Affiliates from disclosing Confidential Information of the Disclosing Party and the existence
and terms of this Agreement to (i) governmental agencies to the extent required or desirable to secure government approval for the development, manufacture or commercialization of a Product in the Territory; provided that such Confidential
Information will be disclosed only to the extent reasonably necessary to do so, and where permitted, subject to confidential treatment, (ii) Third Parties acting on behalf of the Receiving Party, to the extent reasonably necessary for the
Receiving Party to perform its obligations or exercise its rights under this Agreement, (iii) Third Parties requesting Clinical Study data information (in accordance with the Receiving Party’s then-current data sharing policy), (iv) Third
Parties to the extent reasonably necessary to market the Products and Shared Products in the Territory, (v) its Affiliates, consultants, CROs, service providers, licensees or Sublicensees, 

  
 - 95 - 

 and its and their directors, officers, employees, agents or advisors (including accountants, attorneys,
consultants, bankers, financial advisors and members of advisory boards) who reasonably require Confidential Information, and (vi) any bona fide potential or actual sources of debt or equity financing or parties to a merger, acquisition,
royalty factoring or similar transaction (including attorneys, accountants, consultants, bankers or financial advisors of the foregoing) who reasonably require such Confidential Information as part of their due diligence investigations, in each case
(ii)-(vi), who are informed of the confidential nature of such information and are bound by obligations of non-use, non-disclosure and confidentiality with respect to
such Confidential Information. 
 The Receiving Party may use and disclose Confidential Information of the Disclosing Party to the extent that such
Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Law, including the rules and regulations of the U.S. Securities and Exchange Commission (or equivalent foreign agency) or a securities exchange on
which its or its Affiliate’s securities are listed (or to which an application for listing has been submitted), or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to
the Disclosing Party, such Confidential Information is disclosed only to the extent reasonably necessary to do so and, to the extent practicable, takes reasonable and lawful actions to minimize the degree of such disclosure. 

The Parties acknowledge that either or both Parties may be obligated to make a filing (including to file a copy of this Agreement) with the U.S. Securities
and Exchange Commission (or equivalent foreign agency) or a governmental authority. Each Party will be entitled to make such a required filing, provided that it will (a) submit in connection with such filing the redacted copy of this Agreement
that considers the comments of the other Party in good faith (the “Redacted Agreement”), (b) request, and use commercially reasonable efforts consistent with Applicable Laws to obtain, confidential treatment of all terms redacted
from this Agreement, as reflected in the Redacted Agreement, and (c) if the U.S. Securities and Exchange Commission (or equivalent foreign agency) or a governmental authority requests any changes to the redactions set forth in the Redacted
Agreement, use commercially reasonable efforts consistent with Applicable Laws to support the redactions in the Redacted Agreement as originally filed (provided that a Party will not be required to make such efforts to support such redactions more
than once). Each Party will be responsible for its own legal and other external costs in connection with any such filing, registration or notification. 
  

	22.	 Term and Termination 

 

	22.1.1	 Commencement and Term 

This Agreement shall commence upon the Effective Date and continue for the Agreement Term. 

 

	22.1.2	 HSR Filings 

Prior to any Roche Program nomination pursuant to Section 2.5 and Option Right exercise by Roche pursuant to Sections 4.1 through 4.5, Roche shall notify
Vividion in writing whether an HSR Filing is required or not with respect to such Roche Program nomination or Option Right exercise. If Roche notifies Vividion that an HSR Filing is required, then each Party will, as soon as practicable but not
later than [***] Business Days following the date of Roche’s written notification, make any required filings with the FTC and the DOJ required under HSR Act, and/or similar required filings with equivalent foreign authorities, with respect to
the applicable exercise of a Option Right or selection of a Roche Program. The Parties will reasonably cooperate with one another to the extent necessary in the preparation and execution of all such documents that are required to be filed pursuant
to any HSR Filing. Each Party will be responsible for its own 

  
 - 96 - 

 costs and expenses associated with any such HSR Filing. With respect to any HSR Filing, the Parties will
each use best efforts to ensure that any applicable waiting period under the applicable Antitrust Law expires or is terminated as soon as practicable and to obtain any necessary approval or consents under HSR at the earliest possible date after the
date of filing. If the Parties make an HSR Filing to report any Option Right exercise or Roche Program selection, then the applicable Option Right or Roche Program selection shall terminate: (i) immediately if the FTC or the DOJ, or an
equivalent authority in the European Union or in the United Kingdom, obtains a preliminary injunction under the applicable antitrust laws against the Parties to enjoin the transactions contemplated exercise of any Option Right or any Roche Program
selection, as applicable, or (ii) at the election of either Party, immediately upon written notice to the other Party, in the event that the Selection Effective Date shall not have occurred on or prior to [***] days after the effective date of
the HSR Filing. In the event of such termination, the Option Right exercise or Roche Program selection, as applicable, shall be of no force and effect and Section 4.6 shall apply such that the applicable Program becomes a Sole Vividion Program.
Nothing in this Agreement shall require or be deemed to require either Party to commit to any divestitures or licenses or agree to hold separate any assets or agree to any similar arrangements or commit to conduct its business in a specified manner,
in each case as a condition to obtaining antitrust clearance for the transactions (including any Roche Program selection or Roche Option exercise) contemplated hereunder. 
  

	22.2	 Termination 

  

	22.2.1	 Termination for Breach 

A Party (“Non-Breaching Party”) shall have the right to terminate this Agreement in its entirety, on a
Program-by-Program basis or on a Product-by-Product basis and Shared Product-by-Shared Product basis in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach, and the Program, the Product or Shared Product in which the
Non-Breaching Party intends to have this Agreement terminate. The Breaching Party shall have a period of ninety (90) days after such written notice is provided (“Peremptory Notice
Period”) to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party’s request for termination, this Agreement shall
terminate in its entirety or with respect to such applicable Program, Products or Shared Products effective as of the expiration of the Peremptory Notice Period. Notwithstanding the foregoing, if the Breaching Party, in good faith, disputes whether
such breach occurred or has not been cured, it will so notify the Non-Breaching Party, and the Peremptory Notice Period shall be tolled until such time that the dispute is resolved pursuant to
Section 24.3 or that the Arbitral Tribunal determines that such tolling shall not continue, whichever is earlier. Following the cessation of such tolling, the Breaching Party may have the remainder of the Peremptory Notice Period to cure such
breach. If the Breaching Party so disputes whether such breach occurred or has not been cured and the Arbitral Tribunal determines that such tolling shall not continue, this Agreement shall not be terminated for such breach until such time as such
dispute has been resolved pursuant to Section 24.3. 
  

	22.2.2	 Insolvency 

A Party shall have the right to terminate this Agreement upon ninety (90) days prior written notice, if the other Party incurs an Insolvency Event;
provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed
within ninety (90) days after the filing thereof. 

  
 - 97 - 

	22.2.3	 Effects of Change of Control 

If there is a Change of Control, then the Party experiencing such Change of Control (“Acquired Party”) shall provide written notice to the
other Party (“Non-Acquired Party”) promptly after completion of such Change of Control and in any event within [***] days after completion of such Change of Control. 

Following the closing of such Change of Control, the Acquired Party and the Change of Control Group shall adopt in writing reasonable procedures to prevent
the disclosure of the Non-Acquired Party’s Confidential Information beyond the Acquired Party’s and the Change of Control Group’s personnel who need to know such Confidential Information for the
purpose of fulfilling the Acquired Party’s obligations, and exercising the Acquired Party’s licenses and other rights under this Agreement. 

Notwithstanding anything to the contrary, following a Change of Control of a Party, the following shall not be deemed to be Controlled by such Party:
(i) any Patent, Know-How or materials owned or licensed by any member of the Change of Control Group immediately prior to such Change of Control and (ii) any Patent,
Know-How or materials that any member of the Change of Control Group develops following the Change of Control without use of or reference to any Confidential Information of the other Party. 

With respect to any Change of Control of Vividion, the obligations set forth in Article 6 shall not apply to any activities conducted by or on behalf of a
member of the Change of Control Group with respect to programs existing as of the date of such Change of Control or initiated thereafter, provided that such programs do not use any proprietary non-public
Vividion Know-How. 
 If Vividion acquires rights to any compounds, products or programs that would be prohibited by
the provisions of Article 6 (such compounds, products or programs, a “Competing Products”) pursuant to an acquisition or an in-license of Competing Products, such acquisition and/or in-license, and the development and commercialization of such Competing Product thereafter, shall not constitute a breach of Article 6 if Vividion (i) (a) notifies Roche of such acquisition or in-license, (b) divests or out-licenses to a Third Party on an exclusive basis or otherwise terminates rights or ceases all development and commercialization activities
with respect to such Competing Product within [***] months of such acquisition, and (c) during the pendency of such divestment or out-license, segregates such Competing Product from its activities under
this Agreement or (ii) segregates such Competing Product from its activities under this Agreement for the applicable period during which such activities would be prohibited under Article 6. 

 

	22.2.3.1	 Effects of Change of Control of Vividion 

If a Change of Control of Vividion occurs, then Roche may, at its election within [***] months after receipt of written notice from Vividion of such Change of
Control, either (i) continue as usual but set up measures to protect sensitive information according to its internal practices as reasonably agreed by the Parties, as appropriate; or (ii) any or all of the following: 

 

	 	(a)	 continue the Collaboration through the Collaboration Term and, other than in the case of a Merger of Equals,
nominate all Nominated Programs as Roche Programs (to the extent not previously selected as a Vividion Program), where “Merger of Equals” means a Change of Control in which stockholders of Vividion immediately prior to such Change of
Control (x) beneficially own directly or indirectly more than [***] percent ([***]%) of the then outstanding common shares or voting power of the entity resulting from such Change of Control or (y) have the power to appoint the majority of
the board of directors of such resulting entity (e.g., including a “merger of equals” of Vividion into another private company or a reverse acquisition of Vividion into a company that is publicly listed on a major national or international
securities exchange); 

  
 - 98 - 

	 	(b)	 convert all Vividion Programs to Roche Programs, provided that for each converted Program: (i) upon such
conversion, Roche shall pay Vividion [***] Dollars ([***] USD), (ii) upon the earlier of the first [***] of a Product within such Program or the first payment of any milestone under Section 13.8 with respect to any Product for such Program,
Roche shall pay Vividion [***] Dollars ([***] USD), (iii) the development and sales based events and corresponding milestone payments applicable to an Optioned Roche Program under Section 13.8 and Section 13.11.2 shall apply to such
Products in lieu of the development and sales based events and corresponding milestone payments applicable to a Roche Program under Section 13.8 and Section 13.11.1 and (iv) the royalties applicable to an Optioned Roche Program under
Section 13.12.2(b) shall apply to such Products in lieu of royalties applicable to a Roche Program under Section 13.12.2(a); and 

  

	 	(c)	 convert all Vividion PoC Programs to Roche Programs, provided that for each converted Program: (i) upon
such conversion, Roche shall pay Vividion [***] Dollars ([***] USD), (ii) upon the earlier of the first [***] of a Product within each such Program or the first payment of any milestone under Section 13.9 with respect to any such Product, Roche
shall pay Vividion [***] Dollars ([***] USD); (iii) the development and sales based events and corresponding milestone payments applicable to Roche PoC Products under Section 13.9 shall apply to such Products in lieu of the development and
sales based events and corresponding milestone payments applicable to Roche Programs under Section 13.8; and (iv) the royalties applicable to Roche PoC Program under Section 13.12.2(c) and (d) shall apply to such Products in lieu
of royalties applicable to a Roche Program under Section 13.12.2(a); 

  

	 	(d)	 solely with respect to the Programs converted pursuant to subclause (b) or (c) above, terminate the JRC
upon expiry of the Collaboration Term, unless there is a WIP Plan, in which case the JRC may be terminated upon completion of activities under the WIP Plan; or 

 

	 	(e)	 solely with respect to the Programs converted pursuant to subclause (b) or (c) above, terminate the JDC
and include the US in the updates pursuant to Sections 9.2 and 12.2. 

  

	22.2.4	 Termination by Roche without a Cause 

Roche shall have the right to terminate this Agreement at any time as a whole, on a
country-by-country, Product-by-Product or on a Program-by-Program basis upon (a) ninety (90) day prior written notice before First Commercial Sale of a Product or Shared Product within the terminated Program(s) or (b) upon a one hundred and
eighty (180) day prior written notice after the First Commercial Sale of a Product or Shared Product within the terminated Program(s), as the case may be. The effective date of termination under this Section 22.2.4 shall be the date ninety
(90) days (or one hundred and eighty (180) days (as the case may be)) after Roche provides such written notice to Vividion. 
  

	22.2.5	 Termination by Vividion for Patent Challenge 

  
 - 99 - 

 Vividion may terminate this Agreement upon notice to Roche in the event that a member of the Roche Group, a
Third Party designated by such member or a Sublicensee, takes any action, directly or indirectly, or knowingly provides financial or other assistance, including legal or technical advice, directly or indirectly, to any Third Party, to invalidate or
challenge the validity, enforceability, or otherwise oppose, any Vividion Patents or Vividion E3 Patents in any court or tribunal or any patent office in a jurisdiction, or in any arbitration proceeding, including in connection with an opposition
proceeding, re-examination or post-grant proceeding within the scope of the licenses granted hereunder (or in the case of a Sublicensee, within the scope of the sublicense granted to such Sublicensee)
(“Patent Challenge”). In addition, Roche shall reimburse Vividion for any amounts that become due to a Third Party by Vividion as a result of such action or assistance by such member. 

Notwithstanding the foregoing, Vividion shall not have a right to terminate this Agreement pursuant to this Section 22.2.5 where (a) the Patent
Challenge is made by Roche or its Affiliates or Sublicensees in defense of any legal proceeding, administrative proceeding, or arbitration brought by Vividion or any of its Affiliates, licensors, or sublicensees asserting infringement against Roche
or any of its Affiliates or Sublicensees of any Vividion Patents or Vividion E3 Patents, (b) the Patent Challenge was brought by a Sublicensee of Roche and Roche promptly and in any event within five (5) Business Days terminated the
Sublicense with such Sublicensee, or (c) the Patent Challenge originates from a dispute or challenge brought by a non-Sublicensee Third Party that subsequently becomes an Affiliate of Roche, provided that
such dispute or challenge was commenced at least thirty (30) days prior to the signing of the agreement (e.g., purchase agreement or merger agreement) pursuant to which such Third Party becomes an Affiliate of Roche and that Roche causes such
Third Party to rescind and terminate the Patent Challenge within thirty (30) days after such Third Party becomes an Affiliate of Roche. 
  

	22.3	 Consequences of Termination 

 

	22.3.1	 Termination by Vividion for Breach by Roche or Roche Patent Challenge, or Roche Insolvency Event or by Roche
without Cause 

 Except as set forth in Section 22.4, upon any termination by Vividion pursuant to Sections 22.2.1, 22.2.2, or 22.2.5
or by Roche pursuant to Section 22.2.4, (i) the rights and licenses granted by Vividion to Roche and, by Roche to Vividion under this Agreement shall terminate in their entirety or on a Program-by-Program and country-by-country and
Product-by-Product and Shared Product-by-Shared Product basis, as applicable, (such
Programs, countries, Products and Shared Products so terminated, the “Terminated Portion”) and (ii) such terminated Programs, Collaboration Targets that are the subject of such Programs, Products and Shared Products shall cease
to be Licensed Programs, Collaboration Targets, Products and Shared Products as applicable under this Agreement, in each case on the effective date of termination. Notwithstanding anything to the contrary in this Agreement, (A) if this
Agreement, or portion thereof, is terminated under Section 22.2.4 with respect to a country, (x) Vividion’s obligations under Article 6 with respect to any Collaboration Target for any Program, Product or Shared Product within the
scope of such termination shall cease upon the effective date of termination and (y) the exclusivity of the rights and license granted by Vividion to Roche under Section 5.2 (except with respect to the rights and licenses granted to Roche
to market, have marketed, sell and have sold Compounds and Products in countries outside of the Terminated Portion) shall be subject to the right of Vividion (and its licensees or sublicensees) to research, develop and manufacture Products or Shared
Products within the scope of such termination anywhere in the world for commercialization of such Products or Shared Products in such terminated country, and (B) if this Agreement is terminated under Sections 22.2.1 or 22.2.4 with respect to a
Product, Vividion’s obligations under Article 6 with respect to any Collaboration Target for such terminated Product shall cease upon the effective date of termination. 

  
 - 100 - 

 If Vividion desires to continue development and/or commercialization of the Product or Shared Product within
the Terminated Portion, Vividion shall give a Continuation Election Notice to Roche within [***] days after the notice of termination. If Roche receives such a timely Continuation Election Notice, and to the extent requested by Vividion: 

 

	a)	 After the effective date of termination, Roche shall, to the extent Roche has the right to do so, assign and
transfer to Vividion all regulatory filings and approvals, all final pre-clinical and clinical study reports and clinical study protocols, and all data, including clinical data, in Roche’s possession and
control related to the Terminated Portion necessary or useful for Vividion to conduct development, manufacturing and commercialization activities with respect to the Terminated Portion. All data shall be transferred in the form and format in which
it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to Vividion. Roche hereby grants
to Vividion a right of reference to all such regulatory filings and approvals, and, within [***] Business Days request from Vividion, shall provide the applicable Regulatory Authority a letter confirming the foregoing right of reference and take any
other such action as reasonably necessary for Vividion or its designee to exercise such right of reference or obtain the benefit of such regulatory filings and approvals. For avoidance of doubt, the foregoing provision shall apply to regulatory
filings and approvals, reports, protocols, and data collected in or for countries outside of the Terminated Portion that are necessary or useful to conduct development, manufacturing and commercialization activities (and obtain Regulatory Approvals)
with respect to the Terminated Portion. 

  

	b)	 Vividion shall have the right to disclose such filings, approvals and data to (i) governmental agencies of
the country to the extent required or desirable to secure government approval for the conduct of development, manufacturing or commercialization activities with respect to the Terminated Portion, (ii) Third Parties acting on behalf of Vividion,
its Affiliates or licensees, to the extent reasonably necessary for the conduct of development, manufacture, or commercialization activities with respect to the Terminated Portion, and (iii) Third Parties to the extent reasonably necessary for
marketing activities with respect to the Terminated Portion. 

  

	c)	 Vividion shall have an exclusive, transferable, sublicensable (through multiple tiers), irrevocable license,
which shall be subject to the termination stage-dependent royalties below under the Roche Patents and Roche Know-How, including Roche’s interest in the Joint Patents and Joint Know-How, solely to the extent necessary to allow Vividion, its Affiliates or licensees to develop, manufacture, have manufactured, use, export, and import the applicable Compounds, Product(s) and Shared Product(s)
in all countries and to offer to sell, sell, and promote, the applicable Compounds, Product(s) and Shared Product(s) in the country(ies) within the Terminated Portion, provided that to the extent the foregoing license includes any then-existing
licenses that Roche has with a Third Party for which such grant would be prohibited, such license shall not be granted to Vividion or its Affiliates until Roche obtains such right, which Roche shall use commercially reasonable efforts to do, and if
a member of the Roche Group would incur financial obligations to a Third Party as a result of Vividion exercising such license, Roche shall disclose such terms to Vividion and Vividion shall have the option to include the applicable rights upon
assumption of the financial obligations with respect thereto. 

  
 - 101 - 

	d)	 Effective upon the effective date of termination, Roche hereby assigns and shall cause to be assigned and
transferred to Vividion (i) any trademarks and promotional materials specific to one or more Products or Shared Products that Roche or any of its Affiliates used in connection with Product(s) or Shared Product(s), and (ii) all rights to
all Internet domain names incorporating the applicable Product or Shared Product trademark(s) or any variation or part of such Product or Shared Product trademark(s) as its URL address or any part of such address. It is understood that such
assignment shall not include the name of Roche or any of its Affiliates, nor the corporate logo, service mark, trade dress or trademark that is not specific to the Products or Shared Product, which was created or acquired and used by Roche or any of
its Affiliates independently of this Agreement for purposes other than the Products or Shared Products. 

  

	e)	 With respect to any terminated Products or Shared Product, Vividion shall pay Roche a royalty on all net sales
(as determined by reasonable accounting methods) of such Product(s) and Shared Products by Vividion, its Affiliates or licensees, to the extent provided in Section 4.6.2 (mutatis mutandis) with respect to such Products and Shared
Products: 

  

	 	i.	 With respect to Covalent Degraders, Vividion shall pay a royalty on worldwide annual net sales of terminated
Products and Shared Products sold by Vividion, its Affiliates or sublicensees as follows: 

  

											
	 [***]
	  	[***]	 	[***] 	 	[***] 	 	[***] 	 	[***]
		  		 		 	[***]	 		 	
	 £[***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 >[***]

and £[***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 >[***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

	 	ii.	 With respect to Covalent Inhibitors, Vividion shall pay a royalty on worldwide annual net sales of terminated
Products and Shared Products sold by Vividion, its Affiliates or sublicensees as follows: 

  

									
	 [***] 
	  	[***]	 	[***] 	 	[***] 	 	[***] 
		  		 	[***]	 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]

 The term “[***]” shall mean, with respect to a Product or Shared Product, [***]. 

 

	22.3.2	 Termination by Roche for Breach by Vividion or for Vividion Insolvency 

Upon any termination by Roche for breach by Vividion or Vividion’s Insolvency, the rights and licenses granted by one Party to the other Party under this
Agreement shall terminate in their entirety or with respect to the applicable Products and Shared Products, on the effective date of termination. Regardless of whether or not Roche has terminated the Agreement, Vividion shall compensate damages
caused by such Vividion’s breach, to the extent Roche is entitled to such damages under Applicable Law. For clarity, this Section 22.3.2 does not apply to any rights and licenses to Vividion under the Sole Vividion Programs and
Section 4.6.2 shall survive termination for any reason. 

  
 - 102 - 

	22.3.3	 Sublicensees 

Irrespective of anything to the contrary in this Agreement, following termination of this Agreement: 

 

	(a)	 any Compulsory Sublicense shall remain in full force and effect if required by Applicable Law and the sharing
of Compulsory Sublicense Compensation pursuant to Section 13.12.7 shall remain in full force and effect, and 

  

	(b)	 in its entirety or for a Program, Product or Shared Product, sublicenses granted under Section 5.3 of this
Agreement and other rights granted by Roche to a Sublicensee to Products or Shared Products (and any further sublicenses or grants of rights thereunder) shall terminate to the same extent this Agreement terminates (e.g., in its entirety if this
Agreement is terminated in its entirety or for a Program, Product or Shared Product, if this Agreement is terminated with respect to a Program, Product or Shared Product). 

 

	22.3.4	 Other Obligations 

  

	 	22.3.4.1	 Obligations Related to Ongoing Activities 

If Vividion does not provide timely Continuation Election Notice, then Roche (a) shall have the right to cancel all ongoing obligations and (b) shall
complete all non-cancellable obligations at [***] expense. 
 If Vividion provides such timely Continuation Election
Notice, then from the date of notice of termination until the effective date of termination, Roche shall continue activities, including preparatory activities, ongoing as of the date of notice of termination. However, Roche shall not be obliged to
initiate any new activities not ongoing at the date of notice of termination, other than as expressly stated in Sections 22.3 or Section 22.4. 

  
 - 103 - 

 After the effective date of termination, Roche shall have no obligation to perform and/or complete any
activities or to make any payments for performing or completing any activities under this Agreement, except as expressly stated in this Section 22.3 or Section 22.4. 

Notwithstanding the foregoing, in case of termination by Vividion under Section 22.2.1, 22.2.2, or 22.2.5 or by Roche under Section 22.2.4, to the
extent requested by Vividion: 
 (a) Roche shall complete any Clinical Studies related to the Product(s) and Shared Product(s) that are being
conducted by Roche for the Product(s) and Shared Product(s) and are ongoing as of the effective date of termination; provided, however, that 
  

	 	(i)	 either Vividion or Roche in their reasonable judgment have not concluded that completing any such Clinical
Studies presents an unreasonable risk to patient safety; 

  

	 	(ii)	 Roche shall continue to recruit or enroll additional patients until (a) for Shared Products, [***] months
after the effective date of termination according to Development Cost Sharing and (b) for all other Products, [***] month after the effective date of termination at Roche’s cost (“Latest Enrollment Date”); and

  

	 	(iii)	 [***] shall reimburse [***] for [***] that arise after Latest Enrollment Date in completing such Clinical
Studies; and 

  

	 	(iv)	 Roche shall promptly transition to Vividion or its designee such Clinical Studies and the activities related to
or supporting such Clinical Studies; and Roche shall assign the related agreements, to the extent such agreements have not expired on its own terms or been cancelled independent of and prior the notice of termination of the applicable Product or
Shared Product within the Terminated Portion and are assignable without Roche paying any consideration not reimbursed by Vividion or commencing litigation in order to effect an assignment of any such agreement provided that Roche shall use
commercially reasonable efforts to assign to Vividion such related agreements that were not so cancelled that require such unreimbursed consideration or litigation to effect such assignment. 

(b) With respect to any Vividion PoC Program conducted by Vividion, PoC Cost Sharing shall continue for the conduct of the Clinical Plan and
Roche shall reimburse [***] percent ([***]%) of Excess PoC Costs; provided however if Roche terminates this Agreement pursuant to Section 22.2.4 and Vividion determines to wind-down a Clinical Study under a Clinical Plan in effect at the time
of such termination then Roche shall be responsible for [***] percent ([***]%) of the PoC Costs for such Clinical Study to so wind-down such Clinical Study. Section 4.6.2 shall apply. 

If this Agreement is terminated after the First Commercial Sale of a Product or Shared Product within the Terminated Portion and Vividion provided a timely
Continuation Election Notice, the Parties shall enable a smooth transition during the termination period and to complete the transition as soon as possible after the effective date of termination. Roche, its Affiliates and its Sublicensees shall
continue to fulfill orders for such Products or Shared Products through their respective then-existing distribution network of internal and external distributors of such Products 

  
 - 104 - 

 or Shared Products, in accordance with the terms and conditions of this Agreement, in each country for which
Regulatory Approval therefor has been obtained, for up to [***] months after the effective date of termination (“Commercialization Transition Period”); provided, that Roche, its Affiliates and its Sublicensees shall cease any such
activities being conducted pursuant to this paragraph, or any portion thereof, upon [***] days’ notice by Vividion requesting that such activities (or portion thereof) be ceased. Any such Products or Shared Products sold or disposed of by
Roche, its Affiliates or its Sublicensees during the Commercialization Transition Period shall be subject to applicable payment obligations under Article 13. Any reasonable,
out-of-pocket, documented costs incurred by Roche or its Affiliates in accordance with such plan for the transition of Roche’s activities shall be reimbursed by
Vividion for Products and for Shared Products, provided that any costs for activities in the US with respect to a Shared Product that is subject to Profit and Loss Sharing immediately prior to the effective date of such termination shall continue to
be allocated pursuant to the Financial Appendix until such transition is complete. 
  

	 	22.3.4.2	 Obligations Related to Manufacturing 

 

	a)	 Clinical Supplies 

In the case of termination by Vividion according to Section 22.2.1, 22.2.2, or 22.2.5 or by Roche under Section 22.2.4, if Vividion
elects to develop Product(s), Roche shall, to the extent requested by Vividion, transfer all existing and available clinical material to Vividion at Roche’s fully burdened manufacturing cost. Roche shall have no obligation to perform any
additional activities concerning the clinical supplies (e.g. retesting, analyses). Vividion shall assume all liability for the use of such material by Vividion. Roche will inform Vividion about the applicable specifications of such material and if
such material was manufactured and handled in accordance with cGMP. 
  

	b)	 Commercial Supplies 

In the case of termination by Vividion according to Section 22.2.1, 22.2.2, or 22.2.5 or by Roche under Section 22.2.4, if a Product
or Shared Product is marketed in any country of Territory or if Roche or its Affiliates manufactured a Product or Shared Product (or component thereof or other materials used in the manufacture of a Product or Shared Product) on the date of the
notice of termination of this Agreement and Vividion provided a Continuation Election Notice, the Parties shall coordinate in good faith a smooth and fast transition of the commercial manufacturing and supply to Vividion or a designee of Vividion.
To the extent requested by Vividion, Roche shall manufacture and supply reasonable amounts of such Product or Shared Product, including components and other materials used to manufacture such Product or Shared Product, to Vividion for up to [***]
months from the effective date of the termination of this Agreement at a price to be agreed by the Parties in good faith, but in no event exceeding (i) Roche‘s cost [***], or (ii) Roche‘s [***] plus
mark-up of [***] percent ([***]%), if [***], as calculated on a consistent basis according to its then current accounting procedures. Vividion shall use Commercially Reasonable Efforts to take over the
manufacturing as soon as possible after the effective date of termination. 

  
 - 105 - 

	c)	 Manufacturing and Supply Agreements 

Upon Vividion’s request, Roche shall assign to Vividion Roche’s agreement(s) with its Third Party manufacturer for terminated
Products, Shared Products and placebo thereof (including any component thereof or other materials used in the manufacture thereof), to the extent such agreements are assignable under the terms thereof, or, the portion of the master agreements
pertaining to the Product are assignable under the terms thereof if the applicable Product is manufactured under a master agreement such Third Party manufactures products other than the applicable Product for Roche. To the extent such an agreement
or portion of a master agreement is not assignable, Roche shall use reasonable efforts to facilitate Vividion’s direct contact with and supply from such Third Party manufacturer of such Products, Shared Products and placebo thereof, including,
at Vividion’s reasonable request, reasonably cooperating with Vividion to establish supply from such Third Party (e.g., by providing such Third Party with letters confirming Vividion’s rights to such supply and the related data and
information as provided in this Agreement) and using reasonable efforts to obtain the Third Party manufacturer’s agreement to assign the applicable agreement or portion of a master agreement to Vividion or Vividion’s designee. For
avoidance of doubt, Roche does not guarantee that Vividion will obtain assignment of any such agreement or portion of a master agreement where such agreement or work order is not assignable on its terms, and Roche will not seek assignment of a
portion of a master agreement where Roche concludes that such assignment would have negative effects on the master agreement. 
  

	 	22.3.4.3	 Ancillary Agreements 

Unless otherwise agreed by the Parties, the termination of this Agreement shall cause the automatic termination of the ancillary agreements, if any, related
hereto. 
  

	 	22.3.4.4	 Limitations on Grant-Backs; Transfer Expenses 

For purposes of clarity, irrespective of anything to the contrary in this Agreement: 
  

	a)	 All transfers and licenses from Roche to Vividion (or other obligations of Roche) under Section 22.3 are
solely with respect to Product(s) and Shared Product(s) and not an Other Component that is an active ingredient of such Product(s) or Shared Product(s). If this Agreement is terminated with respect to a Product or Shared Product that is a
Combination Product, and the Other Component is a generic non-proprietary active ingredient or the Combination Product is a single pharmaceutical formulation containing as its active ingredients both a
Compound and one or more other therapeutically or prophylactically active ingredients that is commercially available and not subject to Third Party obligations, then the Parties shall, at Vividion’s request, negotiate in good faith the
continuing availability of such other active ingredient. If any such arrangement is not mutually agreed within [***] days after Vividion’s request, then such arrangement shall be determined pursuant to the terms of Section 24.4.

  

	b)	 In connection with research studies, clinical trials or other activities associated with the development and
commercialization of Products and Shared Products, Roche may have collected (i) personally identifiable information about individual human subjects and/or (ii) human biological samples (collectively, “PII/Samples”). Legal
and contractual restrictions may apply to such PII/Samples, provided that Roche uses the same standard processes for Products and Shared Products Roche uses for its other products. Roche shall have no obligation to transfer such PII/Samples unless
necessary for the continued development of the Product and Shared Product, in which case it shall so transfer such PII/Samples at Vividion’s request, provided that Roche shall not be obliged to transfer any PII/Samples that Roche determines in
good faith and upon advice of its legal counsel would be prohibited by Applicable Law to be transferred to Vividion or would subject Roche to liability by reason of Applicable Law, contractual restrictions or insufficient patient consent. If Roche
transfers any such PII/Samples, Vividion shall use such PII/Samples for the sole purpose of developing and commercializing the Product and Shared Product, and Vividion shall be responsible for the

  
 - 106 - 

	 	correct use of the PII/Samples in line with the applicable informed consent forms (including but not limited to potential re-consenting of the patients at Vividion’s costs).

  

	c)	 Vividion shall promptly reimburse Roche for all reasonable out-of-pocket costs and expenses incurred by or on behalf of Roche for transfer activities from Roche to Vividion under Sections 22.3.1 and 22.3.4 (“Roche Transfer Activities”); however
transfer activities corresponding to the return of material remains, data, reports, records, documents, regulatory filings and Regulatory Approvals originally provided by Vividion to Roche no less than [***] years from the effective date of
termination (“Vividion-Originated Transfer Activities”) shall be returned to Vividion free of charge. 

If Vividion desires Roche Transfer Activities other than Vividion Originated Transfer Activities, Vividion shall make a payment to Roche of
[***] US Dollars (US$ [***]) if such Roche Transfer Activities apply to at least one (1) Program for which Clinical Studies have been Initiated and otherwise [***] US Dollars (US$ [***]) (“Minimum Transfer Payment”). The
Minimum Transfer Payment shall be non-refundable, but shall be fully creditable against Vividion’s reimbursement for the Roche Transfer Activities and for supply of Products and Shared Products (or
components thereof). Roche shall be under no obligation to provide Roche Transfer Activities (beyond than Vividion-Originated Transfer Activities) prior to receipt of the Minimum Transfer Payment or if the Minimum Transfer Payment is received after
the effective date of the termination. 
  

	c)	 Unless otherwise agreed to by the Parties, transfer of physical materials that are required under Roche
Transfer Activities shall be delivered, at Roche’s option, FCA international courier near location where materials stored at time of transfer (Incoterms 2010) or CPT Vividion or Vividion’s designee (Incoterms 2010). 

 

	 	22.3.4.5	 Royalty and Payment Obligations 

Termination of this Agreement by a Party, for any reason, shall not release any Party from any obligation to pay royalties (in case of Roche) or make any
payments to the other Party that are payable or have accrued prior to the effective date of termination (irrespective of the payment due date). Termination of this Agreement by a Party, for any reason, will release all Parties from any obligation to
pay royalties (in case of Roche) or make any payments to the other Party that did not become payable or accrue prior to the effective date of termination (irrespective of the payment due date) unless arising from sale of Product or Shared Products
pursuant to the terms of this Section 22.3 or the Financial Appendix or any activities of any Party, its Affiliates or Sublicensees with respect to any compound or product that would have been a Compound or Product or a Shared Product if this
Agreement had not been terminated. 
  

	 	22.3.5	 Support of the Transition 

Each Party agrees, and agrees on behalf of its Affiliates, to reasonably cooperate with the other Party, its Affiliates and its designee(s) to facilitate a
smooth, orderly and prompt transition of the program and activities with respect to Products and Shared Products in the Terminated Portion, including any ongoing development, manufacturing and commercialization of such Products and Shared Products
to Vividion or its designee(s). 

  
 - 107 - 

	22.4	 Survival 

Article 1 (Definitions, to the extent necessary to interpret this Agreement), Section 2.9 (Records) (with respect to records held by Roche for the time
period set forth therein), Section 2.10 (Materials) (with respect to the restrictions on use, distribution and release of Materials), Section 4.6.2 (Sole Vividion Programs) (for all countries irrespective of any termination with respect to
a country), Section 4.5.1 (E3 Module Option) (with respect to Roche’s payment obligations), Section 5.2.4 (No Other Rights), Section 5.3.2.3 (Applicable to all Sublicensees) (to the extent the terms of this Agreement survive
termination or expiration of this Agreement), Section 5.3.3 (Right to Subcontract) (to the extent the terms of this Agreement survive termination or expiration of this Agreement), Section 5.5 (Cysteine Reactive Groups), Articles 13, 14 and
16 (Payment, Accounting and Reporting, and Auditing), Section 22.2.3.1 (Effects of Change of Control of Vividion) and the Financial Appendix (each of Articles 13, 14, 16, Section 22.2.3.1 and the Financial Appendix, to the extent payment
obligations under this Agreement exist at the time of termination irrespective of the payment due date and with respect to payments owed by a Party or its Affiliates or Sublicensee’s activities following termination with respect to any compound
or product that would have been a Compound, Product or Shared Product if this Agreement had not been terminated), Article 15 (Taxes), Section 17.1 (Ownership of Inventions), Section 17.2 (German Statute on Employee’s Inventions),
Section 17.4 (Handling of Patents), Section 17.8 (CREATE Act), Section 17.11 (Common Interest Disclosures), Section 18.3 (No Other Representations or Warranties), Article 19 (Indemnification), Article 21 (Obligation Not to
Disclose Confidential Information) (solely with respect each Party’s rights and obligations pertaining to Confidential Information and disclosures required by Applicable Law, a Regulatory Authority, or the rules of any stock exchange),
Section 22.3 (Consequences of Termination), Section 22.4 (Survival), Section 24.1 (Governing Law) and Section 24.3 (Arbitration)—Section 24.16 (Notice) shall survive any expiration or termination of this Agreement for
any reason. 
 If this Agreement is terminated with respect to a Terminated Portion and not in its entirety, then following such termination, the provisions
of this Agreement specified above shall remain in effect with respect to such Terminated Portion (to the extent such provisions would survive and apply in the event this Agreement expires or is terminated in its entirety), and all provisions not
surviving in accordance with the foregoing shall terminate upon termination of this Agreement with respect to such Terminated Portion and be of no further force and effect. For purposes of clarity, all provisions of this Agreement shall remain in
effect with respect to any Program, Compound, Product, Shared Product or country that is not within the Terminated Portion. 
  

	23.	 Bankruptcy 

All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by a Party to the other Party are, and shall otherwise be deemed
to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that
each Party, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the continued performance of its obligations under this
Agreement. 
  

	24.	 Miscellaneous 

 

	24.1	 Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of New York, U.S.A. without reference to its conflict of laws principles, and
shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

  
 - 108 - 

 Notwithstanding anything to the contrary in this Agreement, issues regarding the scope, construction,
validity and/or enforceability of any Patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions have issued the Patents in question. 

 

	24.2	 Disputes 

Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the respective
executive officers of the Parties designated below or their designees (“Senior Officers”), for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: 

For Vividion: CEO 
 For Roche:
Head of Pharma Partnering 
  

	24.3	 Arbitration 

  

	24.3.1	 Initiation of Arbitration 

Except for an Excluded Claim, should the Parties fail to agree within [***] months after a dispute has first arisen, it shall be finally settled by arbitration
in accordance with the Rules of the International Chamber of Commerce (“ICC”) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The place of arbitration shall be New York, US.
The language to be used shall be English. 
 If a Party asserted to be in breach of this Agreement (the “Disputing Party”) disagrees in
good faith as to the occurrence of the asserted breach, the Disputing Party shall provide written notice (a “Disputed Breach Notice”) to the non-breaching Party prior to expiration of the
applicable Peremptory Notice Period and thereafter such dispute shall be resolved in accordance with Section 24.2 above first and, failing agreement by the executive officers of the Parties within [***] days of the Disputed Breach Notice, then
such dispute shall be resolved in accordance with this Section 24.3. In such event, the Peremptory Notice Period for such alleged breach shall begin to be tolled as of the date of the Disputed Breach Notice. Within [***] days following the
appointment of the Arbitral Tribunal pursuant to this Section 24.3, the Arbitral Tribunal shall make a determination as to whether such Peremptory Notice Period shall continue to be tolled until such time as the dispute regarding such asserted
breach has become finally settled or determined. The Arbitral Tribunal shall make such determination based on the totality of the circumstances, including the likelihood of a final determination of material breach and the relative hardship on the
Parties of continuing or ending such tolling. If the Arbitral Tribunal determines that such tolling shall continue, the non-breaching Party shall not have the right to terminate this Agreement with respect to
the disputed breach unless and until it has been finally determined in accordance with this Section 24.3 that the claimed breach is actually a material breach of this Agreement and the breaching Party fails to cure such breach within the time
period remaining in the applicable Peremptory Notice Period as of the date of such determination. 
  

	24.3.2	 Arbitrators 

Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the request for arbitration within [***] days of being requested
to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within [***] days of being requested to do so, the other Party shall request the ICC Court to make such appointment. 

The arbitrators nominated by the Parties shall, within [***] days from the appointment of the arbitrator nominated in the answer to the request for
arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the panel of arbitrators (“Arbitral Tribunal”). Should such procedure not result in an appointment within the
[***] day time limit, either Party shall be free to request the ICC Court to appoint the third arbitrator. 

  
 - 109 - 

 Where there is more than one claimant and/or more than one respondent, the multiple claimants or respondents
shall jointly appoint one arbitrator. 
 If any Party-appointed arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall
be appointed in accordance with the arrangements provided for in this clause. 
 New York shall be the seat of the arbitration. The arbitrators shall, in
rendering any decision hereunder, apply the substantive law set forth in Section 24.1 without regard to conflict of laws provisions. The Parties have agreed that English Rules of Evidence, and in particular common law discovery or disclosure,
shall not apply to any arbitration under this clause. A request to produce documents by the Parties shall be considered by the Arbitral Tribunal according to Rules of the ICC. 

The language of the arbitration shall be English. Documents submitted in the arbitration (the originals of which are not in English) shall be submitted
together with an English translation. 
  

	24.3.3	 Decisions; Timing of Decisions 

The arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than
[***] months from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing shall be made and, upon request, shall be made available to each Party. 

Notwithstanding the above, in the case of JRC and JDC disputes that are not finally resolved pursuant to Section 8.1.6 or 8.2.6, the arbitrators shall
render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than [***] months from the date on which the arbitrators were appointed to the dispute. 

The time periods set forth in the ICC Arbitration Rules shall be followed; provided however that the arbitrators may modify such time periods as reasonably
necessary to render a written opinion in accordance with this Section 24.3.3. 
 The Arbitral Tribunal is empowered to award any remedy allowed by law,
including money damages, prejudgment interest and attorneys’ fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief. 

This Agreement does not preclude either Party seeking conservatory or interim measures from any court of competent jurisdiction including, without limitation,
the courts having jurisdiction by reason of either Party’s domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim measures.
Conservatory or interim measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures. 

In the event that any issue shall arise which is not clearly provided for in this Section 24.3, the matter shall be resolved in accordance with the ICC
Arbitration Rules. 
 Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard
each Party’s Confidential Information. Except as 

  
 - 110 - 

 required by law or in a proceeding to enforce the award of the Arbitral Tribunal, neither Party shall make
(or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award,
shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise required by Applicable Law. 

Notwithstanding anything to the contrary in this Agreement, any Excluded Claim with respect to Patents will be determined in a court of competent jurisdiction
under the local patent laws of the jurisdictions having issued the Patents in question. 
  

	24.4	 Expedited Resolution 

Any dispute stated in this Agreement to be resolved pursuant to this Section 24.4 (“Expert Committee Dispute”) shall be resolved as
follows: 
  

	24.4.1	 Escalation 

Any Expert Committee Dispute shall first be escalated for resolution by the Senior Officers pursuant to the terms of Section 24.2 (to the extent not
previously escalated to the Senior Officers pursuant to Section 8.1 or 8.2). If the Parties do not reach a mutually acceptable resolution to an Expert Committee Dispute within [***] Business Days (either pursuant to Section 24.2 or
Sections 8.1 or 8.2), then upon written notice by either Party (an “Expert Resolution Notice”), the Expert Committee Dispute shall be resolved by a final, binding determination by an independent committee of three (3) experts
(“Expert Committee”) in the manner described below. 
  

	24.4.2	 Expedited Resolution 

Each Party shall appoint one (1) Expert for the Expert Committee within [***] Calendar Days after the date of the Expert Resolution Notice under this
Section 24.4. The two (2) Experts shall appoint the third Expert within [***] days after the date the second Expert has been appointed. If the first two (2) Experts are unable to mutually agree upon the third Expert within such [***]
days, then the third Expert shall be an arbitrator appointed by JAMS, which arbitrator need not have the experience of an Expert. Once the Expert Committee has been selected, the Expert Committee shall conduct the arbitration as a
“baseball” type of binding arbitration; accordingly, notwithstanding the rules of JAMS, each Party shall provide the Expert Committee and the other Party with a written report outlining its position. The report must clearly provide and
identify the Party’s position with respect to the disputed matter, as may be modified by such Party in accordance with procedures established by the Expert Committee. The Expert Committee may fashion such detailed procedures as the Expert
considers appropriate to implement this intent. After receiving both Parties’ reports, the Expert Committee shall select one Party’s proposed positions as their decision, and shall not have the authority to render any substantive decision
other than to select the proposal submitted by either Vividion or Roche. The Expert Committee shall have no discretion or authority with respect to modifying the positions of the Parties. The Expert Committees decision shall be final and binding on
the Parties (and shall be considered to be the decision of the Parties on the matter for the purposes of resolving such dispute) and may be enforced in any court of competent jurisdiction. 

 

	24.4.3	 JAMS Supervision 

In the event the third Expert is a JAMS arbitrator selected by JAMS as provided in Section 24.4.2 above, the matter shall be conducted as a binding
“baseball arbitration” in accordance with JAMS procedures, as modified by this Section 24.4 (including that the arbitrator shall adopt as his or her decision the position of one Party or the other, as described in
Section 24.4.2). 

  
 - 111 - 

	24.4.4	 Costs 

The Parties agree that they shall share [***] the costs and fees of the Expert Committee in connection with any proceeding under this Section 24.4,
including the cost of the arbitration filing and hearing fees, the cost of the independent expert retained by the arbitrator and the cost of the arbitrator and administrative fees of JAMS if applicable. Each Party shall bear its own costs and
attorneys’ and witnesses’ fees and associated costs and expenses incurred in connection with any proceeding under this Section 24.4. 
  

	24.4.5	 Timetable for Completion 

The Parties shall use, and shall direct the Expert Committee to use, diligent efforts to resolve any Expert Committee Dispute within [***] after the selection
of the third Expert, or if resolution within [***] days is not reasonably achievable, as determined by the Expert Committee, then as soon thereafter as is reasonably practicable. 

 

	24.5	 Assignment 

Neither Party may assign its rights or obligations under this Agreement absent the prior written consent of the other Party, except (i) to any of its
Affiliates, (ii) in the context of a merger, acquisition, sale or other transaction involving all or substantially all of the assets of the Party seeking to assign, or (iii) in connection with a royalty factoring transaction, in which case
such Party in its sole discretion may assign its rights and obligations under this Agreement, and the other Party shall reasonably cooperate in connection with such assignment. Any permitted assignment shall be binding on the successors of the
assigning Party. Any purported assignment in violation of this Section 24.5 will be void and of no force and effect. 
  

	24.6	 Debarment 

Each Party represents and warrants that neither it, its Affiliates, nor their employees have ever been debarred under 21 U.S.C. §335a, disqualified under
21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C. §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program,
or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party, its Affiliates or their employees receives notice of debarment, suspension, sanction, exclusion,
ineligibility or disqualification under the above-referenced statutes, such Party shall immediately notify the other Party in writing and the other Party shall have the right, but not the obligation, to terminate this Agreement for breach,
effective, at the other Party’s option, immediately or at a specified future date. 
  

	24.7	 Independent Contractor 

No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner
whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and not- withstanding any other provision of this
Agreement to the contrary, each Party’s legal relationship to the other Party under this Agreement shall be that of independent contractor, and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint
venture, employment, franchise, agency or fiduciary relationship between the Parties, provided that if Roche and Vividion begin Profit and Loss Sharing, the Parties shall cooperate in good faith at that time to evaluate the U.S. tax status of such
arrangement. 

  
 - 112 - 

	24.8	 Unenforceable Provisions and Severability 

If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and
enforceable provisions mutually agreed by the Parties that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement will remain in full force and effect, provided that the material
interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 
  

	24.9	 Waiver 

The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will neither
constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute
a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	24.10	 Force Majeure 

Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in
fulfilling or performing any term of this Agreement (other than for the payment pursuant to Section 13.1) to the extent, and for so long as, such failure or delay is caused by or results from events beyond the reasonable control of the affected
Party not caused by the fault or negligence of such Party or its Affiliates or Sublicensees, which may include, but are not limited to, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil
commotions, strikes, lockouts or other labor disturbances, fire, floods, earthquakes, epidemics, pandemics or other acts of God or acts, omissions or delays in acting by any governmental authority (except to the extent such delay results from the
breach by the affected Party or any of its Affiliates or Sublicensees of any term or condition of this Agreement) (“Force Majeure”); provided that the affected Party gives the other Party prompt (and in any event within [***] days)
written notice of any such Force Majeure and the cessation thereof; and provided further that the affected Party promptly undertakes and continues to use Commercially Reasonable Efforts to cure such failure or delay resulting from the Force Majeure
as soon as practicable and to mitigate its effects and promptly resumes performance whenever such Force Majeure removed. If a Force Majeure persists for more than [***] days, the Parties will negotiate in good faith any modifications of the terms of
this Agreement that may be necessary to arrive at an equitable solution, unless the Party giving such notice has set out a reasonable timeframe and plan to resolve the effects of such force majeure and executes such plan within such timeframe. 

Notwithstanding the foregoing, the Parties shall not be obliged to negotiate any modification of the terms of this Agreement due to COVID-19 within the first [***] months after the Effective Date. 
  

	24.11	 Interpretation 

Except where the context expressly requires otherwise: 
  

	(a)	 the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of
the singular shall be deemed to include the plural (and vice versa), 

  

	(b)	 the words “include”, “includes” and “including” shall be deemed to be followed by
the phrase “without limitation”, 

  

	(c)	 the word “will” shall be construed to have the same meaning and effect as the word “shall”,

  
 - 113 - 

	(d)	 any definition of or reference to any agreement, instrument or other document herein shall be construed as
referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), 

 

	(e)	 any reference herein to any Party or Third Party or person shall be construed to include the Party’s or
Third Party’s or person’s permitted successors and assigns, 

  

	(f)	 the words “herein”, “hereof” and “hereunder”, and words of similar import, shall
be construed to refer to this Agreement in its entirety and not to any particular provision hereof, 

  

	(g)	 all references herein to Articles, Sections or Appendices shall be construed to refer to Articles, Sections or
Appendices of this Agreement, and references to this Agreement include all Appendices hereto, 

  

	(h)	 references to any specific law, rule or regulation, or article, section or other division thereof, shall be
deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and 

  

	(i)	 the term “or” may be interpreted in the inclusive sense commonly associated with the term
“and/or”. 

  

	24.12	 Waiver of Rule of Construction 

Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of
construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply. 
  

	24.13	 Entire Understanding 

This Agreement contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior
agreements, understandings and arrangements, whether written or oral, including the Non-Disclosure Agreement between the Vividion and Roche US dated February 28, 2019. 

 

	24.14	 Amendments 

No amendments of the terms and conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties. 

  
 - 114 - 

	24.15	 Invoices 

All invoices that are required or permitted hereunder shall be in writing and sent at the following address or such other address as the other Party may later
provide: 
 by Vividion to Roche: 

F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 

Grenzacherstrasse 124 
 4070 Basel

 Switzerland 
 Attn: Name of
the then current Alliance Director of Roche 
 By Roche to Vividion: 

Vividion Therapeutics, Inc. 
 5820
Nancy Ridge Drive 
 San Diego, CA 92121 

USA 
 Attn: Controller 

 

	24.16	 Notice 

All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by
personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 

 

			
	 if to Vividion, to:
	  	Vividion Therapeutics, Inc.
		  	Attn: CEO
		  	5820 Nancy Ridge Drive
		  	San Diego, CA 92121
		  	USA
		  	Facsimile No.:
		
	 if to Roche, to:
	  	F. Hoffmann-La Roche Ltd
		  	Grenzacherstrasse 124
		  	4070 Basel
		  	Switzerland
		  	Attn: Legal Department
		
	 and:
	  	Hoffmann-La Roche Inc.
		  	150 Clove Road
		  	Suite 8
		  	Little Falls, New Jersey 07424
		  	U.S.A.
		  	Attn. Corporate Secretary

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 [Signature Page Follows] 

  
 - 115 - 

 IN WITNESS WHEREOF, the Parties have entered Into this Agreement as of the Effective Date. 

 

			
	Vividion Therapeutics, Inc.
	
	/s/ G. Diego Miralles
	Name:	 	G. Diego Miralles
	Title:	 	Chief Executive Officer

  

											
	F. Hoffmann-La Roche Ltd	 	                    	  		  	                    
				
	 /s/ Vikas Kabra
	 		  	 /s/ Dr. Melanie Wick
	  	
	Name:	  	Vikas Kabra	 		  	Name:	  	Dr. Melanie Wick	  	
	Title:	  	Head of Transaction Excellence	 		  	Title:	  	Legal Counsel	  	

  

			
	Hoffman-La Rocha Inc.
	
	/s/ John P. Parise
	Name:	 	John P. Parise
	Title:	 	Authorized Signatory

  
 - 116 - 

 List of Appendices to Collaboration, Option and License Agreement 

 

			
	 Appendix 1.10
	  	 CCS Criteria

		
	 Appendix 1.17
	  	 Collaboration Plan

		
	 Appendix 1.18
	  	 Collaboration Target Appendix

		
	 Appendix 1.35
	  	 Approved CROs

		
	 Appendix 1.56
	  	 Financial Appendix

		
	 Appendix 1.82
	  	 CCS Data Package / E3 Module Data Package / PoC Data Package / Validated Hit Data
Package

		
	 Appendix 1.133
	  	 Vividion Base Patents

		
	 Appendix 21.3
	  	 Form of Press Release

 Appendix 1.10 

CCS Criteria 

 Appendix 1.17 

Collaboration Plan 

 Appendix 1.18 

Collaboration Target Appendix 

[***] 

 Appendix 1.35 

Approved CROs 

 Appendix 1.56 

Financial Appendix 
 This Appendix
(“Financial Appendix”) to the Collaboration, Option and License Agreement between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel,
Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche
US”; Roche Basel and Roche US together referred to as “Roche”), on the one hand, and Vividion, Inc., with an office and place of business at 5820 Nancy Ridge Drive, San Diego, CA 92121, U.S.A.
(“Vividion”), on the other hand, effective as of April 3, 2020 (the “Agreement”) addresses certain financial definitions and related principles of reporting and reconciliation to be followed in determining on a
Vividion PoC Program-by-Vividion PoC Program basis with respect to each Vividion PoC Program and on a Shared Product-by-Shared-Shared Product basis (but not for any Compounds or Products, under Roche Programs, Optioned Roche Programs), and for the purposes of this Appendix and the Agreement only, the sharing of
(a) costs pertaining to the Development of Compounds and Products under Vividion PoC Programs and/or Shared Products for the Territory, as applicable, and (b) Shared Profits and Losses for Shared Products in the US, each (a) and (b)
as set forth in the Agreement and this Appendix 1. 
 Terms not defined in this Financial Appendix shall have the meanings set forth in the body of the
Agreement to which this Financial Appendix is attached. 
 For each Vividion PoC Program or Shared Product and on a Vividion PoC Program-by-Vividion PoC Program or Shared Product-by-Shared Product basis, the following
processes and definitions shall be utilized to calculate, and reimburse or share, as applicable, such Allowable Expense and Shared Profits and Losses (for Shared Products only) between the Parties. 

1) Definitions: 
 “Accounting
Standards” Shall have the meaning set forth in the Agreement. 
 “Allowable Expenses” shall mean (Subject to Section 2(d) of
this Financial Appendix) 
 (a) with respect to a Shared Product the following items: 

 

	 	(i)	 [***] (“Allowable Development Expenses”) 

 

	 	(ii)	 [***] ((“Allowable Commercialization Expenses)”; 

(b) with respect to a Vividion PoC Program the following items: [***] (“Allowable PoC Expenses” 

“Applicable Product” shall mean either a) [***] or b) [***] as applicable 

 “Applicable Cost Sharing Ratio” shall mean 

 

	 	a)	 [***] cost share between Roche and Vividion for Allowable PoC Expenses under a Vividion PoC Program. For
clarity, this includes all costs actually incurred before Completion of the PoC Data Package. 

  

	 	b)	 [***] cost share between Roche and Vividion for Allowable Development Expenses for Shared Products actually
incurred after exercise of the Roche PoC Option for such Shared Product. 

  

	 	c)	 [***] share between Roche and Vividion of Shared Profits and Losses for a Shared Product in the US.

 “Commercialization” shall mean all activities undertaken for the commercial manufacture, marketing, promotion
(including advertising, education, Detailing, and medical affairs activities), any other offering for sale, distribution and sale of a Product. Commercialization includes commercial activities in preparation for First Commercial Sale of Product.
“Commercialize” has a correlative meaning. 
 “Cost of Manufacture” shall mean, with respect to an Applicable Product: 

 

	(a)	 In case a Party(or its Affiliates) itself Manufactures such Applicable Product the cost (as defined in
the manufacturing Party’s Accounting Standards consistently applied) to Manufacture such Applicable Product, including (i) [***]; (ii) [***]; and (iii) [***] and (iv) [***]; and 

 

	(b)	 In case a Party uses a Third Party to Manufacture such Applicable Product (each a “Third Party
Manufacturer”), the sum of (i) [***] and (ii) [***]. 

  

	(c)	 [***]. 

For clarity, the Cost of Manufacture will exclude (x) [***], (y) [***] and (z) [***]. Cost of Manufacture shall be determined and allocated to an Applicable
Product in accordance with the Accounting Standards, consistently applied by the Manufacturing Party. Roche shall only include types of costs and expenses in the Cost of Manufacture to the same extent Roche includes such types of costs and expenses
for purposes of determining the Costs of Manufacturing (or similar amounts) that are shared with each other Third Party partner with which Roche or its Affiliates 

  
 - 139 - 

 shares manufacturing costs. Further, Cost of Manufacture shall exclude [***]. 

“Development Costs” shall mean with respect to an Applicable Product, the following costs actually paid or accrued (i) [***]; and (ii) [***];
in each case ((i) and (ii), above, and (a) – (f), below), to the extent reasonable, documented and actually paid or accrued by or on behalf of a Party or any of its Affiliates in performing its obligations under and in accordance with the
Preclinical Plan, Clinical Plan or Development Plan for such Applicable Product or the Vividion PoC Program as applicable, including the budget set forth therein and that are recorded as an expense in accordance with the Accounting Standards of such
Party as applicable and consistently applied. 
 For clarity and without limitation, Development Costs for an Applicable Product shall include the following
for the Territory: 
  

	(a)	 [***]; 

  

	(b)	 [***]; 

  

	(c)	 [***]; 

  

	(d)	 [***]; 

  

	(e)	 [***]; 

  

	(f)	 [***]; and 

  

	(g)	 [***]. 

For clarity, Development Costs for Applicable Product shall exclude [***]. 

Fixed SG&A Expense” shall mean the amount calculated by [***], starting on [***] and is representative of the costs and expenses from
the Program associated with [***]. Roche shall not deduct from Sales in determining the Shared Profits and Losses any costs or expenses that Roche in accordance with its Accounting Standards, consistently applied, accounts for as selling, marketing,
distribution or general and administrative costs. 

  
 - 140 - 

 Fixed SG&A Percentage” shall mean with respect to a Shared Product [***] percent ([***]%).

 “FTE” shall mean the equivalent of the work of one (1) employee engaged full time for one (1) Calendar Year that is carried
out by employees or individual contract personnel (which, for purposes of clarity, shall exclude contract research organizations) based on 1,880 hours per Calendar Year excluding vacations and holidays, or such other period as may be prescribed by
Applicable Law, on a country-by-country basis. Overtime, work on weekends, holidays and the like will not be counted with any multiplier (e.g., double time) toward the
number of hours that are used to calculate the FTE contribution. For the avoidance of doubt, no individual shall count as more than one (1) FTE for any year. 

“FTE Costs” shall mean an amount equal to the product of the applicable standard internal FTE rate (for employees or contract personnel, as
applicable) and the number of FTEs performing the applicable activity under and in accordance with the applicable Pre-clinical Plan, Clinical Plan and Development Plan for the Territory. The applicable FTE
rate for each activity shall be consistent for each Party’s internal FTE rate as consistently applied across such Party’s respective functions, provided that for Roche such FTE rate for a particular function in a particular country shall
be no higher than the FTE rate Roche uses for such function for such country for purposes of determining FTE Costs (or similar costs) that are shared with any other Third Party with which Roche or its Affiliates have executed agreements over the
prior three years from the Effective Date and shares FTE Costs (or similar costs). The Parties intend the FTE rate to be fully burdened and include (i) personnel costs (e.g. compensation, benefits, travel, supervision, supplies, material,
training, telephone) and (ii) that portion of overhead specifically identifiable and directly allocable to such FTE, including items such as costs that relate to that Party’s supervisory, occupancy, facility and equipment, as calculated
according to and consistent with each Party’s internal policies and the Accounting Standards. 
 “Launch Costs” shall mean, with
respect to a Shared Product, those [***] (in each case to the extent reasonable, documented and actually paid or accrued by or on behalf of a Party or any of its Affiliates in performing its obligations under and in accordance with the
commercialization plan for such Shared Product for the US, including the budget set forth therein) that are specifically identifiable or reasonably allocable to launching such Shared Product in the US, and solely to the extent incurred prior to
[***] including any such costs for: 
  

	(a)	 [***]; 

  

	(b)	 [***]; 

  

	(c)	 [***]; 

  

	(d)	 [***]; 

  

	(e)	 [***]; 

  

	(f)	 [***]; 

  

	(g)	 [***]; 

  

	(h)	 [***]; 

  

	(i)	 [***]; 

  

	(j)	 [***]; 

  

	(k)	 [***]; 

  

	(l)	 [***]; 

  
 - 141 - 

	(m)	 [***]; 

	(n)	 [***]; and 

	(o)	 [***]. 

For clarity, Launch Costs shall exclude any amount included in [***]. 

“Manufacture” means all operations in the manufacture, receipt, incoming inspections, storage and handling of materials, manufacture,
processing, formulation, filling, packaging, labeling, warehousing, quality control testing (including in-process release and stability testing), shipping and release of Applicable Products. 

“Medical Affairs Activities” shall mean, with respect to a Shared Product, the coordination of medical information requests and field based
medical scientific liaisons in the US with respect to such Shared Product, including activities of medical scientific liaisons, activities involving key opinion leaders, and the provision of medical information services, in each case, in the US and
with respect to such Shared Product. 
 “Other Income” shall mean any payment or income received by Roche or its Affiliate from a Third
Party that is attributable to [***]. 
 “Other Operating Expense” shall mean, with respect to an Applicable Product, those [***] (in each
case to the extent reasonable, documented and actually paid or accrued by or on behalf of a Party or its Affiliates in performing its obligations under and in accordance with the Preclinical Plan, Clinical Plan or Development Plan in the Territory
or Commercialization in the US for such Shared Product, including the budget set forth therein) or not part of the primary business activity, but is considered as income or expense generated from operations limited to the following, in each case
((a) – (l)), only as and to the extent such items (i) [***] and (ii) [***]: 
 Development in the Territory: 

 

	(a)	 [***]; 

	(b)	 [***]; 

	(c)	 [***]; 

Commercialization in the US: 

  
 - 142 - 

	(d)	 [***]; 

  

	(e)	 [***]; 

  

	(f)	 [***]; 

“Out of Pocket Costs” shall mean documented, direct expenses actually paid or accrued by either Party or its Affiliates to Third Parties for
[***] to the extent specifically identifiable and incurred to [***] such Applicable Product, including any such payments to contract personnel (including contractors, consultants, CROs and subcontractors). For clarity, Out of Pocket Costs do not
include [***]. 
 “Party” shall mean Vividion or Roche. 

“PoC Cost Sharing” shall mean on a Vividion PoC
Program-by-Vidion PoC Program basis, the sharing of Development Costs of all activities under [***] and Cost of Manufacture for [***] at the Applicable Cost Sharing
Ratio. 
 “Regulatory Expense” shall mean, with respect to a Shared Product, those [***] (in each case to the extent reasonable, documented
and actually paid or accrued by or on behalf of a Party or any of its Affiliates in performing its obligations under and in accordance with the Development Plan for such Shared Product including the budget set forth therein) that are specifically
identifiable or reasonably allocable to regulatory activities undertaken with respect to the [***], including any such expenses and costs incurred for regulatory activities in connection with [***] and otherwise undertaken pursuant to the Agreement
for the Development for the Territory of such Shared Products. For clarity, Regulatory Expenses excludes [***] and any item addressed in any of subsections (a) through (e) of the definition of Development Costs. For a Vividion PoC Program
“Regulatory Expenses” shall mean [***] that are specifically identifiable or reasonably allocable to regulatory activities undertaken with respect to [***] of a Vividion PoC Program through Completion of the PoC Data Package.

 “Shared Profits and Losses” shall mean, with respect to a Shared Product for a given period, the sum of [***], as applicable, for such
Shared Product and such period in the US minus [***] for such Shared Product and such period. 
  

	2)	 Principles of Reporting and Sharing 

 

	 	a)	 Vividion PoC Program: The quarterly actuals and estimates for a Vividion PoC Program 

  
 - 143 - 

 in the Territory with respect to Allowable PoC Expenses will be presented in the following
format with the categories as defined in this Section 2 of this Appendix below: 
  

	
	Reporting Item
	
	[***]
	
	[***]
	
	[***]
	
	[***]

  

	 	b)	 Shared Product: The quarterly actuals and estimates for a Shared Product, for the US (including Development
Costs for the Territory) will be presented in the following format (as to all Shared Products, as applicable, and also on a Shared Product-by-Shared Product basis), with
the categories as defined in this Section 2 of this Appendix below: 

  

Development Expenses 
  

	
	Reporting Item
	
	[***]
	
	[***]
	
	[***]
	
	[***]

 Shared Profits and Losses 
  

	
	Reporting Item
	
	[***]
	
	[***]
	
	[***]
	
	[***]
	
	[***]
	
	[***]
	
	[***]

 After the First Commercial Sale of a Shared Product in the US, [***] and amounts for items listed in clauses (d), (e) and
(f) in the definition of Other Operating Expenses shall be [***]. 
  

	 	c)	 The Shared Profits and Losses and Allowable Expenses will then be reconciled at the Applicable Cost Sharing
Ratio on a line item-by-line item basis. It is the intention of the Parties that the interpretation of the definitions set forth in this Financial Appendix will be
consistent with the Accounting Standards, as consistently applied by the respective Party to the extent consistent with the express terms and conditions in the Financial Appendix. 

  
 - 144 - 

 Further, the Parties agree that no individual cost or expense will be counted more than once
in the determination of Allowable Expenses or Shared Profits and Losses (or any component thereof).For the avoidance of doubt, income and withholding taxes imposed either of the Parties or their Affiliates hereunder will not be included in the
calculation of Shared Profit and Losses. 
  

	 	d)	 Notwithstanding anything to the contrary, if any Clinical Studies or other Development activities are conducted
under the Development Plan that involve the use of a product of a Party or its Affiliate, other than the Applicable Product, as part of a Combination Product or otherwise (e.g. as a comparator or as an induction therapy), [***] shall supply such
other product for purposes of such study or activity at the manufacturing cost thereof (calculated in the same manner as Cost of Manufacture) 

  

	3)	 Mechanics and Timing of Reconciliation and Payment 

 

	 	1)	 Development Costs and Shared Profits and Losses Reconciliation for a Vividion PoC Program or Shared
Product: For each Vividion PoC Program or Shared Product commencing with [***] and continuing thereafter [***], no later than [***] days after the end of each such Calendar Quarter, each Party shall submit a report setting forth the actual
Allowable Expenses or Shared Profits and Losses it incurred in such Calendar Quarter for such Vividion PoC Program or Shared Product (each, an “Interim Report”). 

 

	 	2)	 Each Party shall have [***] days after the delivery of the other Party’s Interim Report to review and ask
questions with regard to the other Party’s Allowable Expenses for Vividion PoC Programs and Shared Products and Profits and Losses for Shared Products. Within [***] days following the end of such Calendar Quarter, each Party shall update such
report to reflect the final amount of Allowable Expenses and/or Shared Profit and Losses for Shared Products incurred by such Party in such Calendar Quarter (each, a “Final Financial Report”); provided that if there are any
Allowable Expenses and/or Shared Profit and Losses incurred in such Calendar Quarter that a Party is unable to timely include in such Final Financial Report, then such amount shall be included and reconciled in the Final Financial Report in a future
Calendar Quarter. Each such report shall specify in reasonable detail costs incurred and shall include reasonably detailed supporting information. 

  

	 	3)	 Payment: Within [***] days after receipt of each such Final Financial Report, the Parties, shall confer and
agree in writing on whether a reconciliation payment is due from one Party to the other Party, and if so, the amount of such reconciliation payment, so that the Parties’ Allowable Expenses and/or Shared Profit and Losses for each Vividion PoC
Program or Shared Product are shared at the Applicable Cost Sharing Ratio in accordance 

  
 - 145 - 

	 	
with this Agreement and an invoice shall be issued to the Party owing such reconciliation payment. The Party required to pay such reconciliation payment shall make such payment to the other Party
within [***] days after the receipt of such invoice; provided, however, that in the event of any disagreement with respect to the calculation of such reconciliation payment, any undisputed portion of such reconciliation payment shall be paid in
accordance with the foregoing timetable and any additional amount determined to be due shall be paid within [***] Business Days after the date on which the Parties, using good faith efforts, resolve such dispute. For clarity, such reconciliation
process and payments shall take into consideration Allowable Expenses that Roche is responsible for bearing in excess of the Applicable Cost Sharing Ratio (and the repayment of such amounts, as applicable) pursuant to Section 3.2.3,
Section 4.2.2, Section 9.4 and Section 12.5. 

 4. Plans and Budgets 

a) For each Vividion PoC Program, the Preclinical Plan for activities after exercise of the Vividion Sharing Option for such Vividion PoC Program and the
Clinical Plan shall include a Calendar Quarterly budget of Allowable PoC Expenses through Completion of the PoC Study for such Vividion PoC Program. Such budget for the Clinical Plan shall be the Clinical Plan Budget established in accordance with
Section 3.2.3 of the Agreement. 
 b) For each Shared Product: 

(i) The initial Development Plan for such Shared Product shall include an Annual Calendar budget of Allowable Development Expenses for the following [***]
Calendar Years. The Development Plan shall be updated annually no later than [***] of each Calendar Year such that the Development Plan includes such a budget for the following [***] Calendar Years. Unless otherwise agreed by the JDC the budget for
the first Calendar Year of an updated Development Plan shall not provide for aggregate expenses greater than the budget included for such Calendar Year in the Development Plan in effect as of January 1 of the prior year. 

(ii) If on a Calendar Quarter by Calendar Quarter basis the Allowable Development Expenses are in excess of the amounts allocated in the budget as provided as
part of the Development Plan, then: 
  

	 	a)	 The costs will be shared jointly if the Parties approve such excess Allowable Development Expenses. The
approval shall not be unreasonably withheld to the extent the Allowable Development Expenses in excess of the approved budget were not within the reasonable control of the Party (or Party’s Affiliate) incurring such expense. The Party
responsible for the overrun will promptly give written notice to the other Party of such anticipated cost overrun (“Cost Overrun”) including an explanation. 

 

	 	b)	 If the Cost Overrun exceeds [***] percent ([***]%), such excess Allowable Development Expenses shall be carried
forward to the subsequent Calendar Quarter to the extent the total Allowable Development Expenses incurred by such Party and its Affiliates as of the end of such subsequent Calendar Quarter are less than [***] percent ([***]%) of the aggregate
Allowable Development Expenses allocated to such Party under the relevant budget for such Calendar Quarter. If the excess can not be absorbed in the same Calendar 

  
 - 146 - 

	 	Year it will be carried forward to the following Calendar Year and the same mechanism as above applies. 

If the Cost Overrun (after completion of the Development Plan) are not offset through the foregoing mechanism or pursuant to Section 9.4
of the Agreement then any remaining Cost Overrun may be offset against subsequent milestones and if necessary with the Shared Profits or Losses and royalties through Section 3 of the Financial Appendix for such Shared Product;
provided that if after [***] years after the First Commercial Sale of such Shared Product in the United States it is reasonably determined that the future payments owed Vividion for such Shared Product will not be sufficient for Roche to recoup all
such amounts, Roche may offset unrecouped amounts against payments owed to Vividion for other Products or Shared Products under the Agreement. 

  
 - 147 - 

 Appendix 1.133 

CCS Data Package / E3 Module Data Package / PoC Data Package / Validated Hit Data Package 

 Appendix 1.133 

Vividion Base Patents 

 Appendix 21.3 

Form of Press Release 

 AMENDMENT No. 1 TO COLLABORATION, OPTION AND LICENSE AGREEMENT 

This Amendment No.1 to the Collaboration, Option and License Agreement (“Amendment”), effective September 9, 2020 (“Amendment
Effective Date”), is by and between Vividion Therapeutics, Inc. with an office and place of business at 5820 Nancy Ridge Drive, San Diego, CA 92121, USA (“Vividion”), F. Hoffmann-La
Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, 8th Floor, Room 850, Little
Falls, New Jersey 07424, U.S.A. (“Roche”). 
 WHEREAS, Roche and Vividion are Parties to a Collaboration, Option and
License Agreement effective April 3, 2020 (“Agreement”); and 
 WHEREAS, the Parties wish to add [***] as [***]
Covalent Inhibitor Target for oncology to the Collaboration (“[***] Collaboration Target”); 
 WHEREAS, Roche and
Vividion desire to amend the Agreement; 
 NOW, THEREFORE, the Parties agree as follows: 

 

	A.	 The Collaboration Target Appendix 1.18 shall be replaced by the Collaboration Target Appendix 1.18 attached to
this Amendment No. 1. 

  

	B.	 A new Section 2.11 shall be added to the Agreement as follows: 

“The Collaboration with respect to the [***] Collaboration Target shall be limited to identifying and developing Covalent Inhibitors for
the [***] Collaboration Target that are Collaboration [***] Covalent Inhibitors (as defined below) and only Compounds that are a Collaboration [***] Covalent Inhibitor shall be considered Hits or Validated Hits for the [***] Collaboration Target.
Roche does not obtain under the Agreement any option, license or other rights to any Covalent Inhibitor with respect to the [***] Collaboration Target that is not a Collaboration [***] Covalent Inhibitor. Accordingly, Vividion shall not be obligated
to provide Roche any information or results, including a Validated Hit Data Package, for any Covalent Inhibitor with respect to the [***] Collaboration Target that is not a Collaboration [***] Covalent Inhibitor, and (ii) for purposes of the
definition of ‘Vividion Know-How’, ‘Vividion Patents’ and ‘Product Specific Claims’ for Programs for the [***] Collaboration Target and for purposes of Section 5.2 of the
Agreement with respect to the [***] Collaboration Target, the term “Compound” does not include compounds that are not Collaboration [***] Covalent Inhibitors and the terms “Product” and “Shared Product” do not include
any product that includes a Covalent Inhibitor that is not a Collaboration [***] Covalent Inhibitor. 
 ‘Collaboration
[***] Covalent Inhibitors’ means any compound that is a Covalent Inhibitor with respect to the [***] Collaboration Target and is shown to meet both of the following characteristics: 

  
 1 

	(a)	 the compound does not covalently bind to the Vividion [***]; and 

 

	(b)	 the compound binds selectively, relative to the wild-type protein of the [***] Collaboration Target, to forms
of the [***] Collaboration Target with a point mutation [***] (i.e., [***]), [***] (i.e., [***]) or [***] (i.e., [***]) with at least a [***] higher potency for the mutant form over the wild-type form, as measured by the ratio of concentration to
achieve [***]% inhibition ([***]), as assessed by a cell-based assay of downstream signaling activation in isogenic cell lines (i.e., [***]) as outlined in Appendix A. 

‘Vividion [***] Cysteine Residue’ means that cysteine residue on the [***] Collaboration Target identified by
Vividion as the `Vividion [***] Cysteine Residue` and disclosed to the Target Reviewer. Promptly upon the joint representation agreement among the Target Reviewer, Roche and Vividion being entered into under Section 2.4.2 of the Agreement,
Vividion shall disclose to the Target Reviewer the cysteine residue that is the Vividion [***] Cysteine Residue. Vividion shall not be obligated to disclose the Vividion [***] Cysteine Residue to Roche and the joint representation agreement with the
Target Reviewer shall prohibit the Target Reviewer from disclosing the Vividion [***] Cysteine Residue to Roche. 
 The Parties agree it is
important to clarify and resolve any disputes regarding whether a compound is or is not a Collaboration [***] Covalent Inhibitor quickly and in good faith. Accordingly, any dispute about whether a compound is a Collaboration [***] Covalent Inhibitor
shall be resolved pursuant to Section 24.4 of the Agreement. If at any time there is not consensus between the Parties about whether a compound is or is not a Collaboration [***] Covalent Inhibitor either Party may submit an Expert Resolution
Notice for such matter to be determined pursuant to Section 24.4 of the Agreement. 
 Vividion shall not be restricted by the Agreement,
including under Articles 5 and 6 of the Agreement, from conducting activities involving the [***] Collaboration Target, alone or with Affiliates or Third Parties, in connection with the research, development or commercialization of compounds other
than Collaboration [***] Covalent Inhibitors, or authorizing Affiliates or Third Parties to conduct such activities. Accordingly, (i) for purposes of Article 6 of the Agreement, to ‘work exclusively with Roche’ with respect to the
[***] Collaboration Target means that Vividion shall not develop or commercialize a Collaboration [***] Covalent Inhibitor that is Directed To, and the primary mechanism of action of which is mediated by modulating the activity of or degrading, the
[***] Collaboration Target and (ii) for purposes of Section 6.4, the term ‘Collaboration Target Inhibitor’, with respect to the [***] Collaboration Target, shall not include any compound that is not a Collaboration [***] Covalent
Inhibitor.” 

  
 2 

	C.	 A new Section 5.6. shall be added to the Agreement as follows: 

“Roche hereby grants to Vividion a perpetual, irrevocable, non-exclusive, royalty-free, and fully paid-up license, for all internal research purposes with respect to the [***] Collaboration Target (other than for a Compound that is a Collaboration [***] Covalent Inhibitor), under [***] Know-How that is actually disclosed by Roche to Vividion under this Agreement. For clarity, as used in the foregoing, internal research purposes shall include the research, development and commercialization of
compounds and products Directed To the [***] Collaboration Target (other than a Compound that is a Collaboration [***] Covalent Inhibitor), including in connection with or as a result of a bona fide collaboration or a product developed in whole or
in part by Vividion, and Vividion shall have the right to use and disclose such Know-How for such purposes. The foregoing license for internal research purposes shall not include or constitute a license or
other grant by Roche to practice any Patent. ‘[***] Know-How’ means any Know-How that pertains to the structure, biological function or other
aspects of the [***] Collaboration Target per se and the Know-How that pertains to the Know-How per se described in Appendix A.” 

 

	D.	 Roche shall transfer to Vividion aliquots of each cell line listed in Appendix A promptly after execution of
this Amendment No.1 and thereafter from time-to- time to the extent reasonably requested by Vividion. 

  

	E.	 The Agreement shall remain in full force and effect except solely to the extent expressly modified by this
Amendment No.1. All references contained in the Agreement shall be deemed to include the provisions of this Amendment No. 1. This Amendment No.1 may be executed in multiple counterparts, each of which shall be deemed an original, but both of which
together will constitute one and the same instrument. 

  
 3 

 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be executed by
their duly authorized representatives. 
  

			
	Vividion Therapeutics, Inc.
		
	By:	 	 /s/ Fred Aslan

	Name:	 	Fred Aslan
	Title:	 	President

  

									
	F. Hoffmann-La Roche Ltd	 		 		 	
					
	By:	 	 /s/ Juergen May
	 		 	By:	 	 /s/ Melanie Wick

	Name:	 	Dr. Juergen May	 		 	Name:	 	Dr. Melanie Wick
	Title:	 	Global Business Development Director	 		 	Title:	 	Legal Counsel

  

			
	Hoffmann-La Roche Inc.
		
	By:	 	 /s/ John P. Parise

	Name:	 	John P. Parise
	Title:	 	Authorized Signatory

  
 4 

 Collaboration Target Appendix 1.18 

  
 5 

 Appendix A 

Cell lines and assays to be utilized to determine mutant selectivity of [***] inhibitors 

[***] 

  
 6 

 AMENDMENT No. 2 TO COLLABORATION, OPTION AND LICENSE AGREEMENT 

This Amendment No.2 to the Collaboration, Option and License Agreement (“Amendment”), effective April 20, 2021 (“Amendment
Effective Date”), is by and between Vividion Therapeutics, Inc. with an office and place of business at 5820 Nancy Ridge Drive, San Diego, CA 92121, USA (“Vividion”), F. Hoffmann-La
Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, 8th Floor, Room 850, Little
Falls, New Jersey 07424, U.S.A. (“Roche”). 
 WHEREAS, Roche and Vividion are Parties to a Collaboration, Option and
License Agreement effective April 3, 2020 (“Agreement”); and 
 WHEREAS, the Parties executed an Amendment No 1 to the
Agreement on September 9, 2020; 
 WHEREAS, Roche wishes to transfer certain cell lines to Vividion; 

WHEREAS, Vividion wishes to modify a Roche Target Ligand ([***]) under the Agreement; 

WHEREAS, Roche and Vividion desire to amend the Agreement; 

NOW, THEREFORE, the Parties agree as follows: 
  

	 	A.	 Appendix A (as defined in Amendment No. 1) shall be deleted and replaced by Appendix A attached to this
Amendment No. 2. All future changes to Appendix A will be captured in the JRC minutes and the updated Appendix A (as defined in Amendment No.1) shall be attached to the respective JRC minutes. 

 

	 	B.	 The current Appendix 1.18 is attached to this Amendment No 2. All future changes to Appendix 1.18 pursuant to
Section 2.3 and Section 2.4 of the Agreement shall be captured in the JRC minutes and the updated Appendix 1.18 shall be attached to the respective JRC minutes. 

 

	 	C.	 a. The following shall be added to Section 2.1 of the Agreement. 

“[***]”-series (exemplified as e.g. [***]) and “[***]” (exemplified as e.g. [***]) is a Roche Target Ligand provided by
Roche to Vividion under the Agreement. Vividion wishes to modify this [***] Roche Target Ligand and/or generate a de novo design starting from such [***] Roche Target Ligand (“Modified [***] Roche Target Ligand”). 

b. The following shall be added to Section 17.1. 

  
 1 

 “Roche shall, independently of inventorship, solely own inventions and resulting
Patents to the extent comprising or directed to the [***] Modified Target Ligand, if any, and Vividion hereby assigns to Roche all of Vividion’s right, title and interest in and to the [***] Modified Roche Target Ligand, if any. 

 

	 	D.	 The Agreement shall remain in full force and effect except solely to the extent expressly modified by this
Amendment No. 2. All references contained in the Agreement and Amendment No. 2 shall be deemed to include the provisions of this Amendment No. 2. This Amendment No. 2 may be executed in multiple counterparts, each of which shall
be deemed an original, but both of which together will constitute one and the same instrument. 

 [Signatures on the
following page] 

  
 2 

 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 2 to be executed by their duly
authorized representatives. 
  

			
	Vividion Therapeutics, Inc.
		
	By:	 	 /s/ Jean Bemis

	Name:	 	Jean Bemis
	Title:	 	Head of Alliance Management

  

									
	F. Hoffmann-La Roche Ltd	 		 		 	
					
	By:	 	 /s/ Seda Larsen
	 		 	By:	 	 /s/ Melanie Wick

	Name:	 	Seda Larsen	 		 	Name:	 	Dr. Melanie Wick
	Title:	 	Global Alliance & Asset Management Director	 		 	Title:	 	Legal Counsel

  

			
	F. Hoffmann-La Roche Inc.
		
	By:	 	 /s/ John P. Paries

	Name:	 	John P. Parise
	Title:	 	Authorized Signatory

  
 3 

 Appendix A 

  
 4 

 Collaboration Target Appendix 1.18 

[***] 

  
 5EX-10.12

 Exhibit 10.12 

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***],HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE VIVIDION THERAPEUTICS, INC. HAS DETERMINED THAT
IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT VIVIDION THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. 
 EXECUTION VERSION

 MASTER RESEARCH AND COLLABORATION AGREEMENT 

by and between 
 VIVIDION
THERAPEUTICS, INC. 
 and 

CELGENE CORPORATION 
 Dated as of
March 1, 2018 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 ARTICLE I
	 	DEFINITIONS	  	 	1	 
			
	 ARTICLE II
	 	COLLABORATION; PRE-OPT-IN EXERCISE DEVELOPMENT	  	 	20	 
			
	 ARTICLE III
	 	OPT-IN RIGHTS EXERCISE; DEVELOPMENT & COMMERCIALIZATION AGREEMENTS	  	 	33	 
			
	 ARTICLE IV
	 	GOVERNANCE	  	 	38	 
			
	 ARTICLE V
	 	LICENSES; EXCLUSIVITY	  	 	48	 
			
	 ARTICLE VI
	 	FINANCIAL TERMS	  	 	53	 
			
	 ARTICLE VII
	 	INTELLECTUAL PROPERTY	  	 	59	 
			
	 ARTICLE VIII
	 	CONFIDENTIALITY	  	 	62	 
			
	 ARTICLE IX
	 	REPRESENTATIONS AND WARRANTIES	  	 	68	 
			
	 ARTICLE X
	 	INDEMNIFICATION; INSURANCE	  	 	73	 
			
	 ARTICLE XI
	 	TERM AND TERMINATION	  	 	75	 
			
	 ARTICLE XII
	 	MISCELLANEOUS	  	 	79	 

  
 - i - 

			
	 LIST OF APPENDICES

		
	 Appendix A-1
	 	Form of US Co-Development and Co-Commercialization Agreement
		
	 Appendix A-2
	 	Form of Global Co-Development and Co-Commercialization Agreement
		
	 Appendix B-1
	 	Form of License Agreement
		
	 Appendix B-2
	 	Form of E3 Ligase Binder Program License Agreement
		
	 Appendix C
	 	Form of CCB Program MTA
		
	 Appendix D
	 	Form of Common Interest Agreement
		
	 Appendix E
	 	Form of Press Release
		
	 Appendix F
	 	Form of E3 Ligase Binder Program MTA
	
	LIST OF SCHEDULES
		
	 Schedule 1.1.32
	 	Data
		
	 Schedule 1.1.34
	 	Deal E3 Ligases
		
	 Schedule 1.1.35
	 	Deal Targets
		
	 Schedule 1.1.56
	 	Functional Phenotypic Assay Similarity Criteria
		
	 Schedule 1.1.91
	 	Publication Guidelines
		
	 Schedule 9.2.9
	 	Vividion Patents

  

  
 - ii - 

 MASTER RESEARCH AND COLLABORATION AGREEMENT 

This Master Research and Collaboration Agreement (this “Agreement”) is entered into as of March 1, 2018 (the
“Effective Date”) by and between Vividion Therapeutics, Inc., a Delaware corporation (“Vividion”) and Celgene Corporation, a Delaware corporation (“Celgene”). Celgene and Vividion are each referred
to herein by name or as a “Party”, or, collectively, as the “Parties.” 
 RECITALS 

WHEREAS, Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using
its proprietary chemical proteomics platform for drug and target discovery; 
 WHEREAS, Celgene is engaged in the research,
development and commercialization of therapeutic products to treat various diseases and conditions, including for the treatment of cancer and diseases and conditions of the immune system; 

WHEREAS, the Parties intend to collaborate on the research and development of therapies for the treatment of cancer and diseases and
conditions of the immune system; 
 WHEREAS, Vividion may conduct certain research and development activities to identify
therapeutics directed against certain targets, and Celgene will obtain exclusive opt-in rights to enter into one or more separate Development & Commercialization Agreements (as defined below) with
respect to such therapeutics, as further described herein; 
 WHEREAS, upon each exercise of such
opt-in rights, the Parties shall enter into a separate Development & Commercialization Agreement, on the terms and subject to the conditions set forth herein; 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I 

DEFINITIONS 
 1.1
Terms. 
 1.1.1 “Accounting Standards” means (a) GAAP (United States Generally Accepted Accounting Principles);
or (b) IFRS (International Financial Reporting Standards), in either case, consistently applied. 
 1.1.2 “Affiliate”
means, as to any Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with such Person, as the case may be, for so long as such control exists. As used in this Section 1.1.2,
“control” means: (a) to possess, directly or indirectly, the power to direct the management and policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate
governance; or (b) direct or indirect beneficial ownership of at least fifty percent (50%) (or such 

 lesser percentage that is the maximum allowed to be owned by a foreign Person in a particular jurisdiction
and is sufficient to grant the holder of such voting stock or interest the power to direct the management and policies of such entity) of the voting share capital in a Person. For purposes of this Agreement and any Development &
Commercialization Agreement, neither Celgene nor Vividion shall be deemed an Affiliate of the other Party. 
 1.1.3 “Antitrust
Law” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the “HSR Act”), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade
Commission Act, as amended, and any other Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade, in the following jurisdictions: the United States,
all states and territories thereof, Australia, Brazil, Canada, the countries that are officially recognized as member states of the European Union from time to time (the “EU”), the United Kingdom, the Republic of Korea, Japan,
Mexico, Taiwan, and any other jurisdiction that Celgene or Vividion, in its good faith judgment, determines requires a pre-merger notification filing prior to consummation of the transactions contemplated by
the Development & Commercialization Agreements in accordance with Section 3.2 of this Agreement. 
 1.1.4 “beneficial
owner,” “beneficially owns,” “beneficial ownership” and terms of similar import used in this Agreement shall, with respect to a Person, have the meaning set forth in Rule
13d-3 under the Securities Exchange Act of 1934, as amended (a) assuming the full conversion into, and exercise and exchange for, shares of common stock, other voting stock or any securities exercisable
for common stock or other voting stock beneficially owned by such Person and (b) determined without regard for the number of days in which such Person has the right to acquire such beneficial ownership. 

1.1.5 “Business Day” means a day other than a Saturday or Sunday or any other day on which commercial banks in San Diego,
California or Summit, New Jersey are authorized or required by applicable Law to close. 
 1.1.6 “Calendar Quarter” means a
calendar quarter ending on the last day of March, June, September or December; provided, however, that (a) the first Calendar Quarter shall begin on the Effective Date and end on the last day of March, 2018, and (b) the final
Calendar Quarter shall end on the last day of the Term. 
 1.1.7 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31; provided, however, that (a) the first Calendar Year shall begin on the Effective Date and end on December 31, 2018, and (b) the final Calendar Year shall end
on the last day of the Term. 
 1.1.8 “CCB Program” means a program comprising Development activities by or on behalf of
Celgene or any of its Affiliates for the Development of a CCB LDD Directed against a specific Deal Target following CCB Determination for the applicable Target Ligand(s) pursuant to Section 2.4.1. For the avoidance of doubt, “CCB
Program” excludes all Lapsed Programs. 
 1.1.9 “CCB Program MTA” means a material transfer agreement, in the form of
material transfer agreement attached hereto as Appendix C, entered into by the Parties in accordance with Section 2.4.2. 

  
 - 2 - 

 1.1.10 “Celgene Cereblon Binder LDD” or “CCB LDD” means
each LDD Developed by or on behalf of Celgene or any of its Affiliates that is Directed against one or more Deal Targets and intended for use in the Field that contains both (a) a Target Ligand identified, synthesized, discovered, acquired
(whether or not pursuant to a license), Developed or Controlled by or on behalf of Vividion or, subject to Section 12.4.2, any of its Affiliates prior to or during the Research Term which is Directed against one or more Deal Targets and
licensed to Celgene under a CCB Program MTA, and (b) one or more E3 Ligase Binders Controlled by Celgene that is(are) Directed against Cereblon. 

1.1.11 “Celgene Collaboration Intellectual Property” means any Patents or Know-How, or
Celgene’s or its Affiliates’ interest therein, that are discovered, developed, generated or invented by or on behalf of Celgene or any of its Affiliates through the use of Vividion Know-How, Joint
Collaboration Know-How or materials disclosed or transferred by Vividion to Celgene in the conduct of the Collaboration during the Opt-In Term and are necessary or
useful for the Development, Manufacture or Commercialization of any Program Compound(s) or Program Product(s); but excluding any Celgene CCB Program IP and Joint Collaboration IP. 

1.1.12 “Celgene Intellectual Property” means Celgene Know-How and Celgene Patents,
collectively. 
 1.1.13 “Celgene Know-How” means any
Know-How that is (a) Controlled by Celgene as of the Effective Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of any Program Compound(s) or
Program Product(s); and (c) contributed by Celgene, in Celgene’s sole discretion, to the Collaboration, as evidenced by written notice from Celgene to Vividion; but excluding (i) Celgene Collaboration Intellectual
Property and (ii) any Celgene CCB Program IP. 
 1.1.14 “Celgene Lead Shared Program” means the Shared US Program or
any Shared Global Program for which Celgene will be the “Lead U.S. Party” (as defined in Appendix A-1 or Appendix A-2, as applicable),
subject to the terms and conditions of the applicable Co-Development and Co-Commercialization Agreement. 

1.1.15 “Celgene Patents” means any Patents that (a) are Controlled by Celgene as of the Effective Date or during the
Term; (b) Cover the Development, Manufacture or Commercialization of any Program Compound(s) or Program Product(s) (including the composition of matter, manufacture or any use thereof); and (c) are contributed by Celgene, in Celgene’s
sole discretion, to the Collaboration, as evidenced by written notice from Celgene to Vividion; but excluding (i) Celgene Collaboration Intellectual Property and (ii) any Celgene CCB Program IP. 

1.1.16 “Cereblon” means the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination of target proteins and is referenced by the UNiProtKB:Q96SW2. 

1.1.17 “Cereblon Binder Product” means, with respect to each E3 Ligase Binder Ligand that is Directed to Cereblon, any product
that includes in its chemical structure such E3 

  
 - 3 - 

 
Ligase Binder Ligand or any portion of such E3 Ligase Binder Ligand; but excluding any product that includes in its chemical structure (a) any LDD identified in any information
which may be provided to Celgene under Section 1.1.32 or Summary provided by Vividion to Celgene prior to the end of the Research Term (each, a “Pre-Existing Vividion Cereblon LDD”) or
(b) any CCB LDD that is Developed by Celgene prior to the end of the Research Term (each, a “Pre-Existing Celgene Cereblon LDD”). 

1.1.18 “Cereblon Binder Program” means all E3 Ligase Binder Ligands that bind or otherwise associate with Cereblon. 

1.1.19 “Change of Control” of a Party means any of the following, in a single transaction or a series of related transactions:
(a) the sale or disposition of all or substantially all of the assets of such Party to a Third Party, (b) the direct or indirect acquisition by a Third Party (other than an employee benefit plan (or related trust) sponsored or maintained
by such Party or any of its Affiliates) of beneficial ownership of more than fifty percent (50%) of the then-outstanding common shares or voting power of such Party or any direct or indirect entity which holds, directly or indirectly, beneficial
ownership of more than fifty percent (50%) of the then-outstanding common shares or voting power of such Party (a “Parent Entity”), or (c) the merger or consolidation of such Party or any Parent Entity with or into a Third
Party, unless, following such merger or consolidation, the stockholders of such Party or Parent Entity immediately prior to such merger or consolidation beneficially own directly or indirectly more than fifty percent (50%) of the then-outstanding
common shares or voting power of the entity resulting from such merger or consolidation. 
 1.1.20 “Chemistry, Manufacturing and
Controls” or “CMC” means the part of pharmaceutical development that is directed to the Development and Manufacture of products, the specifications therefor, and other parameters which indicate that the finished drug or
biologic product and the manufacturing process are consistent and controlled, in each case, as specified by the FDA or other applicable Regulatory Authorities in the chemistry, manufacturing and controls section of an IND or other regulatory filing
in the United States, or the equivalent section of regulatory filings made outside of the United States. 
 1.1.21 “Claims”
means any and all suits, claims, actions, proceedings or demands brought by a Third Party. 
 1.1.22 “Commercialization” or
“Commercialize” means any activities directed to using, marketing, promoting, distributing, importing, offering to sell or selling a product, after or in expectation of receipt of Regulatory Approval for such product (but
excluding Development). 
 1.1.23 “Commercially Reasonable Efforts” means, with respect to the performing Party under
this Agreement or any Development & Commercialization Agreement, the carrying out of obligations of such Party in a diligent, expeditious and sustained manner with efforts that are consistent with the efforts used by a biopharmaceutical
company of similar size and market capitalization as such Party in the exercise of its commercially reasonable business practices relating to an exercise of a right or performance of an obligation under this Agreement or any applicable
Development & Commercialization Agreement, including the Development, Manufacture and Commercialization of a pharmaceutical or biologic compound or product, as 

  
 - 4 - 

 applicable, at a similar stage in its research, development or commercial life as the relevant Program
Compound(s) or Program Product(s), and that has commercial and market potential similar to the relevant Program Compound(s) or Program Product(s), taking into account issues of intellectual property coverage, safety and efficacy, stage of
development, product profile, competitiveness of the marketplace, proprietary position, regulatory exclusivity, anticipated or approved labeling, present and future market and commercial potential, the likelihood of receipt of Regulatory Approval
and other regulatory requirements, profitability (including pricing and reimbursement status achieved or likely to be achieved), amounts payable to licensors of patent or other intellectual property rights, legal issues, Manufacturing, difficulty in
Manufacturing the Program Compound(s) or Program Product(s) and alternative Third Party products in the marketplace of the Program Compound(s) or Program Product(s) to be marketed. 

1.1.24 “Companion Diagnostic” means a biomarker or diagnostic test that is developed by or on behalf of a Party or jointly by
the Parties in the course of the Collaboration as a companion diagnostic for use with a Program Compound or Program Product in accordance with the Regulatory Approval(s) therefor to generate a result for the purposes of diagnosing a disease or
condition, or to facilitate the application of the Program Compound or Program Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a specific patient
will contract a disease or condition or to predict which patients are suitable candidates for a specific form of therapy using the Program Compound or Program Product. 

1.1.25 “Compound” means a chemical entity (including any salt, fluorinated derivative, free acid, free base, clathrate,
solvate, hydrate, hemihydrate, anhydride, ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate,
complex or mixture of such chemical entity, each a “Related Compound”) identified, synthesized, discovered, acquired (whether or not pursuant to a license), Developed or Controlled by or on behalf of Vividion or, subject to
Section 12.4.2, any of its Affiliates, whether or not in the conduct of the Collaboration. For clarity, an LDD identified, synthesized, discovered, acquired (whether or not pursuant to a license), Developed or Controlled by or on behalf of
Vividion or, subject to Section 12.4.2, any of its Affiliates shall always be a Compound for purposes of this Agreement and any applicable Development & Commercialization Agreement. 

1.1.26 “Confidential Information” means, subject to Sections 8.1(a), 8.1(b), 8.1(c) and 8.1(d) (a) all confidential or
proprietary information relating to any Program Target(s), Program Compound(s) or Program Product(s), including information in the Data Packages, and (b) all other confidential or proprietary documents, technology, Know-How or other information (whether or not patentable) actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement, any CCB Program MTA or the
Confidentiality Agreement, including information regarding a Party’s technology, products, business information or objectives and reports under Section 2.8, and all proprietary biological materials of a Party. 

1.1.27 “Confidentiality Agreement” means the Confidentiality Agreement between Vividion and Celgene, dated as of
January 5, 2017. 

  
 - 5 - 

 1.1.28 “Continuation Program” means a Program that Celgene designates as a
Continuation Program in accordance with Section 2.6.1 and under which Vividion may continue to carry out Development activities directed to the identification and nomination of Development Candidates after the end of the Research Term. 

1.1.29 “Control” or “Controlled” means, with respect to any
(a) Know-How or other information or materials, (b) compound, or (c) intellectual property right, the possession (whether by license (other than a license granted under this Agreement) or
ownership) by a Party of the ability to grant to the other Party access or a license, as provided herein, without violating the terms of any agreement with any Third Party existing as of the Effective Date or thereafter during the Term.
Notwithstanding the foregoing, for the purpose of defining whether intellectual property, Patents, Know-How or Confidential Information is Controlled by a Party, if such intellectual property, Patents, Know-How or Confidential Information is first acquired, licensed or otherwise made available to such Party after the Effective Date, or the effective date of the applicable Development & Commercialization
Agreement, as applicable, and if the use, practice or exploitation thereof by or on behalf of the other Party, its Affiliates or sublicensees would require the first Party to pay any amounts to the Third Party from which the first Party acquired,
licensed or otherwise obtained such intellectual property, Patents, Know-How or Confidential Information (“Additional Amounts”), such intellectual property, Patents, Know-How or Confidential Information shall be deemed to be Controlled by the first Party only if the other Party agrees to pay (if necessary) and does in fact pay all Additional Amounts with respect to such other
Party’s use of or license to such intellectual property, Patents, Know-How or Confidential Information to the extent specified in this Agreement or the applicable Development & Commercialization
Agreement. 
 1.1.30 “Cover,” “Covering” or “Covered” means that, with respect to a
product or technology and a Patent, but for ownership of or a license under such Patent, the Development, Manufacture, Commercialization or other use of such product or practice of such technology by a Person would infringe a claim of such Patent
or, with respect to a claim included in any patent application, would infringe such claim if such patent application were to issue as a patent. 

1.1.31 “Damages” means all claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs (including
reasonable legal expenses, costs of litigation and reasonable attorney’s fees), or judgments, whether for money or equitable relief, of any kind and is not limited to matters asserted by Third Parties against a Party, but includes claims,
threatened claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney’s fees) or judgments incurred or sustained by a Party in the absence of Third Party
claims; provided that no Party shall be liable to hold harmless or indemnify the Vividion Indemnified Parties or Celgene Indemnified Parties, as applicable, for any claims, threatened claims, damages, losses, suits, proceedings,
liabilities, costs or judgments for punitive or exemplary damages, except to the extent the Party seeking indemnification is actually liable to a Third Party for such punitive or exemplary damages in connection with a Claim by such Third Party. 

1.1.32 “Data Package” means, on a
Program-by-Program basis, a data package prepared for each applicable Program in accordance with the terms and conditions of this Agreement (including Schedule 1.1.32)
by Vividion for Celgene upon [***]. 

  
 - 6 - 

 1.1.33 “Data Verification Date” means, with respect to a Data Package, the
date that is [***] days after the date of receipt by Celgene of such Data Package; provided, however, that, if Celgene requests additional reasonable information and clarifications during such original [***] day period, then
such Data Verification Date will be automatically extended (as necessary) until the later of (a) [***] days following receipt by Celgene (or any designee) of such additional reasonable information and clarifications and (b) the end of such
original [***] day period. 
 1.1.34 “Deal E3 Ligase” means any E3 Ligase included on Schedule 1.1.34, as may be amended
from time to time in accordance with Section 2.2; but excluding all Excluded Targets and Cereblon. 
 1.1.35 “Deal
Target” means any Target included on Schedule 1.1.35, as may be amended from time to time pursuant to Section 2.2; but excluding all Excluded Targets. 

1.1.36 “Deal Target Program” means a program comprising Development activities by or on behalf of Vividion or any of its
Affiliates for (a) Program Compound(s) or Program Product(s) Directed against a specific Deal Target, [***]. 
 1.1.37
“Defense” means any actions brought to defend a Patent against a challenge to such Patent, including without limitation interferences, oppositions, reexaminations, inter partes reviews, covered business method reviews or
post-grant reviews, but excluding any actions included within Prosecution. “Defend” will have the correlative meaning. 

1.1.38 “Develop” or “Development” means discovery, research, preclinical,
non-clinical and clinical development activities, including activities relating to screening, assays, test method development and stability testing, toxicology, pharmacology, formulation, quality
assurance/quality control development, clinical trials (including Phase IV clinical trials), technology transfer, statistical analysis, process development and scale-up, pharmacokinetic studies, data
collection and management, report writing and other pre-Regulatory Approval activities. 
 1.1.39
“Development & Commercialization Agreement” means an agreement, in the form attached hereto as Appendix A-1 (“US
Co-Development and Co-Commercialization Agreement”), in the form attached hereto as Appendix A-2 (“Global
Co-Development and Co-Commercialization Agreement”), in the form attached hereto as Appendix B-1
(“License Agreement”) or the form attached hereto as Appendix B-2 (“E3 Ligase Binder Program License Agreement”), as applicable, entered into by the Parties in accordance with
this Agreement. As used herein, the US Co-Development and Co-Commercialization Agreement and the Global Co-Development and
Co-Commercialization Agreement(s) are referred to, collectively, as the “Co-Development and Co-Commercialization
Agreements”. 

  
 - 7 - 

 1.1.40 “Development Candidate” means, on a
Program-by-Program basis, a Program Compound in such Program that is (a) Developed by or on behalf of Vividion or, subject to Section 12.4.2, any of its
Affiliates prior to or after the Effective Date until expiration of the Opt-In Term and (b) nominated by either Vividion or Celgene in accordance with Section 2.3.2 or Section 2.4.3 and, solely
with respect to Program Compounds nominated in accordance with Section 2.3.2, has been determined or deemed, as applicable, to meet the development candidate criteria which may be developed by the JSC (the “Development Candidate
Criteria”) pursuant to Section 2.3.3. 
 1.1.41 “Directed” means, with respect to a Compound (including a
Licensed Product or a Shared Product), that such Compound binds or otherwise associates with either (a) [***] and/or (ii) [***] or (b) a [***]. 

1.1.42 “Distinct Product” means, solely with respect to any [***], following Regulatory Approval in the United States for the
first (1st) Program Product in such Program (the “Initially-Approved Product”), any other Program Product in such Program (i.e., other than the Initially-Approved Product) that receives Regulatory Approval in the United States with
a product label with an entirely separate and non-overlapping Indication from the Indication contained in the then-existing product label for the Initially-Approved Product (based upon distinct substantiating
evidence obtained from Functional Phenotypic Assay Similarity Criteria results for the Compound(s) included in each such Program Product demonstrating utility in distinct Indications where the later-approved Program Product could not be substituted
for the Initially-Approved Product for the same Indication) (each such later-approved Product, an “Other Distinct Product”); it being understood and agreed that, for clarity, if the foregoing conditions are met, each
Initially-Approved Product and Other Distinct Product in the same Program shall be deemed to be “Distinct Products” for purposes of this Agreement and any Development & Commercialization Agreement, as applicable. 

1.1.43 “Dollars” or “$” means the legal tender of the United States. 

1.1.44 “E3 Ligase” means ***. 

1.1.45 “E3 Ligase Binder” means any ligand which binds or otherwise associates with an E3 Ligase. 

“E3 Ligase Program” means a program comprising Development activities by or on behalf of Vividion or any of its Affiliates for
(a) [***] or (b) [***]. For clarity, an “E3 Ligase Program” shall [***]. 
 1.1.46 “E3 Ligase Binder
Program” means, [***]. 
 1.1.47 “E3 Ligase Binder Ligand” means all E3 Ligase Binders [***]; it being understood
and agreed that “E3 Ligase Binder Ligand” shall in all cases exclude [***]. 

  
 - 8 - 

 1.1.48 “E3 Ligase Binder Product” means, with respect to each E3 Ligase
Binder Ligand Directed to a given E3 Ligase, any product that [***]; provided, however, that, “E3 Ligase Binder Product” shall exclude any product that [***] 

1.1.49 “Excluded Target” means any Deal Target or Deal E3 Ligase which Celgene elects to remove from the Collaboration, or
that the Parties mutually agree to remove from the Collaboration, pursuant to Section 2.2. 
 1.1.50 “Executive
Officers” means Celgene’s head of research (or the officer or employee of Celgene then serving in a substantially equivalent capacity) or his or her designee and Vividion’s Chief Executive Officer (or the officer or employee of
Vividion then serving in a substantially equivalent capacity) or his or her designee; provided that any such designee must have decision-making authority on behalf of the applicable Party. 

  
 - 9 - 

 1.1.51 “FDA” means the United States Food and Drug Administration, or any
successor agency thereof. 
 1.1.52 “FDCA” means the United States Federal Food, Drug, and Cosmetic Act, and the regulations
promulgated thereunder, each as amended from time to time. 
 1.1.53 “Field” means the diagnosis, prevention, palliation or
treatment of diseases in humans or animals. 
 1.1.54 “Functional Target Ligand” means, on a Deal Target-by-Deal Target basis, any Target Ligand which the JRC determines has functional activity against such Deal Target in accordance with Section 4.3.2(l). 

1.1.55 “Functional Phenotypic Assay Similarity Criteria” means, with respect to any Deal E3 Ligase or Cereblon, the functional
phenotypic assay similarity testing criteria set forth on Schedule 1.1.56. 
 1.1.56 “Good Clinical Practices” or
“GCP” means the ethical and scientific quality standards for designing, conducting, recording, and reporting trials that involve the participation of human subjects as are required by applicable Regulatory Authorities or Law in the
relevant jurisdiction. In the United States, GCP shall be based on Good Clinical Practices established through FDA guidances (including Guideline for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6)), and, outside the
United States, GCP shall be based on Guideline for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6). 
 1.1.57
“Good Laboratory Practices” or “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards
in jurisdictions outside the United States, as they may be updated from time to time). 
 1.1.58 “Good Manufacturing
Practices” or “GMP” means all applicable standards relating to manufacturing practices for fine chemicals, intermediates, bulk products or finished pharmaceutical products, including (a) all applicable requirements
detailed in the FDA’s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211 and “The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal
Products”, as each may be amended from time to time, and (b) all applicable Laws promulgated by any Governmental Authority having jurisdiction over the Manufacture of any Product. 

1.1.59 “Governmental Authority” means any: (a) nation, principality, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division,
subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multinational organization or body; or
(e) individual, entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature. 

  
 - 10 - 

 1.1.60 “IND” means any Investigational New Drug application, filed with the
FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any supplements or amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s) outside the United States (such
as a Clinical Trial Application (“CTA”) in the countries that are officially recognized as member states of the EU). 

1.1.61 “IND Acceptance” means, with respect to any applicable Program Compound, the complete submission and first acceptance
by either the FDA or the European Medicines Agency (“EMA”) of an IND for such Program Compound. 
 1.1.62 “IND-Enabling Studies” means studies that are required to meet the requirements for filing an IND with a Regulatory Authority, including ADME (absorption, distribution, metabolism, and excretion) and GLP
(good laboratory practice) toxicology studies, or studies required for the preparation of the CMC (chemistry, manufacturing, and controls) section of such IND, including but not limited to studies relating to analytical methods and purity analysis,
and formulation and Manufacturing development studies, all as necessary to obtain the permission of such Regulatory Authority to begin human clinical testing. 

1.1.63 “IND Filing” means the filing of an IND with the FDA or the EMA for a Program Compound. 

1.1.64 “Indication” means any human disease, condition or syndrome, or sign or symptom of, or associated with, a human
disease, condition or syndrome in a particular target patient population; it being understood that references to Indications with regard to Distinct Products shall be based upon entirely different diseases or condition (including but not limited to
cancers arising from different tissues) in particular target patient populations (and, for the avoidance of doubt, different line therapies for the same disease or condition, such as (for example) first line treatment for a disease or condition as
compared to second line treatment for such same disease or condition, shall not be deemed to be a different Indication and therefore such different line therapies shall not be Distinct Products with respect to one another). 

1.1.65 “Inventions” means all inventions, whether or not patentable, that are discovered, developed, generated or invented by
or on behalf of any Party or any of its respective Affiliates or both Parties or any of their respective Affiliates, whether solely or jointly with any Third Party, in the course of activities performed under this Agreement or any CCB Program MTA or
Development & Commercialization Agreement, as applicable. 
 1.1.66 “Joint Collaboration IP” means, collectively:

 (a) “Joint Collaboration Know-How,” which means all Know-How, including physical embodiments of Program Compound(s), Program Product(s) and Companion Diagnostics, that is discovered, developed, generated or invented by or on behalf of both Parties or any of their
respective Affiliates, whether solely or jointly with any Third Party, pursuant to the conduct of activities under the Collaboration at any time during the Term; and 

(b) “Joint Collaboration Patents,” which means Patents that Cover any Joint Collaboration
Know-How; 

  
 - 11 - 

 
provided that, “Joint Collaboration Know-How” shall exclude all Know How [***], “Joint Collaboration
Patents” shall exclude all Patents [***] and “Joint Collaboration IP” shall exclude all Celgene CCB Program IP. 

1.1.67 “Know-How” means any tangible or intangible trade secrets, know-how, expertise, discoveries, inventions, information, data or materials, including ideas, concepts, formulas, methods, procedures, designs, technologies, compositions, plans, applications, technical data,
assays, manufacturing information or data, samples, chemical and biological materials and all derivatives, modifications and improvements thereof. 

1.1.68 “Law” means any law, statute, rule, regulation, ordinance or other pronouncement having the effect of law, of any
federal, national, multinational, state, provincial, county, city or other political subdivision, as from time to time enacted, repealed or amended, including Good Clinical Practices and adverse event reporting requirements, guidance from the
International Conference on Harmonization or other generally accepted conventions, the FDCA and similar laws and regulations in countries outside the United States, and all other rules, regulations and requirements of the FDA and other applicable
Regulatory Authorities. 
 1.1.69 “LDD” means a ligand directed degrading molecule which: (a) *** (“Selected
Target”) and (ii) *** and (b) ***. LDDs may also include a Linker, including where the Linker is ***. For purposes of determining the Program Target for any Program that involves a Selected Target described in clause (a)(i) above, in the
case where the Selected Target described in clause (a)(i) above is a Deal E3 Ligase or Cereblon, such Deal E3 Ligase or Cereblon shall be considered the Program Target. 

1.1.70 “Licensed Product” means a Program Product that is the subject of a Licensed Program. 

1.1.71 “Licensed Program” means a Program (a) for which the Parties have entered into a License Agreement pursuant to
ARTICLE III or (b) for which Celgene has exercised its Opt-In Right and for which the Parties are required to enter into a License Agreement pursuant to Section 3.1.2. 

1.1.72 “Linker” means any chemical composition that chemically connects both (a) a first Target Ligand and (b) a
second Target Ligand. 
 1.1.73 “Manufacture” or “Manufacturing” means, as applicable, all activities
associated with the production, manufacture, processing, filling, packaging, labeling, shipping and storage of a drug substance or drug product, or any components thereof, including process and formulation development, process validation, stability
testing, manufacturing scale-up, preclinical, clinical and commercial manufacture and analytical methods development and validation, product characterization, quality assurance and quality control development,
testing and release. 

  
 - 12 - 

 1.1.74 “Opt-In Exercise Notice”
means, on a Program-by-Program basis, the written notice provided to Vividion by Celgene pursuant to Section 3.1.2, such notice constituting Celgene’s exercise
of its Opt-In Right with respect to such Program to convert it into a Licensed Program or Shared Program, as applicable. 

1.1.75 “Opt-In Term” means the period commencing on the Effective Date and ending on
the later of (a) the expiration of the Research Term or (b) the expiration of the last-to-expire Opt-In Exercise Window
for any Program. 
 1.1.76 “Patent” means any (a) patent or patent application anywhere in the world,
(b) divisional, continuation, continuation in-part thereof or any other patent application claiming priority, or entitled to claim priority, directly or indirectly to (i) any such patent or patent
application or (ii) any patent or patent application from which such patent or patent application claims, or is entitled to claim, direct or indirect priority, and (c) patent issuing on any of the foregoing anywhere in the world, together
with any registration, reissue, re-examination, patent of addition, renewal, patent term extension, supplemental protection certificate, or extension of any of the foregoing anywhere in the world. 

1.1.77 “Patent Officers” means Celgene’s Vice President of Intellectual Property and Chief Patent Counsel (or the officer
or employee of Celgene then serving in a substantially equivalent capacity) or his or her designee and Vividion’s Head of Legal (or the officer or employee of Vividion then serving in a substantially equivalent capacity) or his or her designee;
provided that any such designee must have decision-making authority on behalf of the applicable Party. 
 1.1.78
“Person” means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.

 1.1.79 “Phase I Study” means a human clinical trial of a product, the principal purpose of which is a preliminary
determination of safety, tolerability and pharmacokinetics in study subjects where potential pharmacological activity may be determined or a similar clinical study prescribed by any applicable Regulatory Authority, from time to time, pursuant to
applicable Law or otherwise, including for example the trials referred to in 21 C.F.R. §312.21(a), as amended (or the non-United States equivalent thereof). 

1.1.80 “Phase II Study” means a human clinical trial intended to explore a variety of doses, dose response, and duration of
effect, and to generate evidence of clinical safety and effectiveness for a particular indication or indications in a target patient population, or a similar clinical study prescribed by any applicable Regulatory Authority, from time to time,
pursuant to applicable Law or otherwise, including for example the trials referred to in 21 C.F.R. §312.21(b), as amended (or the non-United States equivalent thereof). 

1.1.81 “Phase III Study” means a human clinical trial of a product in any country that would satisfy the requirements of 21
C.F.R. §312.21(c), as amended (or the non-United States equivalent thereof) and is intended to (a) establish that the product is safe and efficacious for its intended use, (b) define
contraindications, warnings, precautions and adverse reactions that are associated with the product in the dosage range to be prescribed, and (c) support Regulatory Approval for such product. 

  
 - 13 - 

 1.1.82 “Pivotal Clinical Trial” means a human clinical trial of a product
on a sufficient number of subjects that satisfies both of the following ((a) and (b)): 
  

	 	(a)	 such trial is designed to establish (with one or more other Pivotal Clinical Trials, if applicable) that such
product has an acceptable safety and efficacy profile for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support
Regulatory Approval of such product, or a similar clinical study prescribed by the FDA or EMA; and 

  

	 	(b)	 such trial is a registration trial designed to be sufficient (with one or more other Pivotal Clinical Trials,
if applicable) to support the filing of an application for a Regulatory Approval for such product in the U.S. or another country or some or all of an extra-national territory, as evidenced by (i) an agreement with or statement from the FDA or
the EMA on a Special Protocol Assessment or equivalent, or (ii) other guidance or minutes issued by the FDA or EMA, for such registration trial. 

1.1.83 “Pre-Exercise Development” means, with respect to a Program, the first
advancement of a Development Candidate of such Program through [***]. Notwithstanding the foregoing or anything to the contrary herein or in any applicable Development & Commercialization Agreement, as to (a) any CCB Program as to
which Celgene elects to enter into a CCB Program MTA or (b) any other Program for which Celgene elects to exercise its Opt-In Right prior to [***], Pre-Exercise
Development shall be deemed to have been completed with respect to such Program, and Vividion shall have no further responsibility for Development with respect to such Program hereunder, except as expressly provided under the applicable
Development & Commercialization Agreement, following such entry into a CCB Program MTA or early exercise of the Opt-In Right, as applicable, by Celgene with respect to such Program. 

1.1.84 “Program” means (a) a CCB Program, (b) a Vividion Cereblon Program, (c) an E3 Ligase Program or
(d) a Deal Target Program, as applicable (for clarity, including any such Program that is a Continuation Program), as further described in Section 2.1.3; but excluding all Lapsed Programs. 

1.1.85 “Program Compound” means any Compound Directed against a Program Target. 

1.1.86 “Program Product” means a product that contains as an active ingredient a Program Compound, in all forms,
presentations, and formulations (including all manners of delivery and dosage). 

  
 - 14 - 

 1.1.87 “Program Target” means (a) any Deal Target, (b) solely to
the extent that it is the subject of an E3 Ligase Program, any Deal E3 Ligase or (c) Cereblon; it being understood and agreed that “Program Target” shall exclude all Excluded Targets. 

1.1.88 “Prosecution” or “Prosecute” means the filing, preparation, prosecution and maintenance of Patents,
including any and all pre-grant proceedings before any patent authority, such as interferences. 

1.1.89 “Publication” means any publication in a scientific journal, any scientific abstract to be presented to any audience,
any presentation at any scientific conference, including slides and texts of oral or other public presentations, any other scientific presentation and any other oral, written or electronic scientific disclosure directed to any audience that pertains
to any Program Target(s), Program Compound(s) or Program Product(s), or the use of any of the foregoing, or the data or results from any work under any Program. 

1.1.90 “Publication Guidelines” means the criteria for Publication set forth on Schedule 1.1.91. 

1.1.91 “Regulatory Approval” means all approvals of each applicable Regulatory Authority necessary for the commercial
marketing and sale of a product for a particular indication in a country (including separate Regulatory Authority pricing or reimbursement approvals whether or not legally required in order to sell the product in such country, it being understood
that, as of the Effective Date, no such Regulatory Authority pricing or reimbursement approval requirement is applicable in the United States). 

1.1.92 “Regulatory Authority” means a federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing or sale (including pricing and reimbursement approval) of a product in a country or territory. 

1.1.93 “Research Term” means the period commencing on the Effective Date and, unless earlier terminated in accordance with
this Agreement, if Celgene does not exercise its option to extend the Research Term pursuant to Section 2.1.2, ending on the fourth (4th) anniversary of the Effective Date, or, if Celgene
exercises its option to extend the Research Term pursuant to Section 2.1.2, ending on the sixth (6th) anniversary of the Effective Date. 

1.1.94 “Shared Global Program” means a Program (a) for which the Parties have entered into a Global Co-Development and Co-Commercialization Agreement pursuant to ARTICLE III or (b) for which Celgene has exercised its Opt-In Right
and for which the Parties are required to enter into a Global Co-Development and Co-Commercialization Agreement pursuant to Section 3.1.2, in each case ((a) and
(b)) pursuant to which Operating Profits or Losses (as defined in Appendix A-2) in the Territory are allocated fifty percent (50%) to Celgene and fifty percent (50%) to Vividion. 

1.1.95 “Shared Product” means a Program Product that is the subject of a Shared Program pursuant to a Co-Development and Co-Commercialization Agreement. 
 1.1.96
“Shared Program” means the Shared US Program or a Shared Global Program. 

  
 - 15 - 

 1.1.97 “Shared US Program” means a Program (a) for which the Parties
have entered into the US Co-Development and Co-Commercialization Agreement pursuant to ARTICLE III or (b) for which Celgene has exercised its Opt-In Right and for which the Parties are required to enter into a US Co-Development and Co-Commercialization Agreement pursuant to
Section 3.1.2, in each case ((a) and (b)) pursuant to which (x) Operating Profits or Losses for U.S. Administration (each as defined in Appendix A-1) are allocated fifty percent (50%) to
Celgene and fifty percent (50%) to Vividion, (y) Celgene will be the “Lead Party” (as defined in Appendix A-1) worldwide and (z) there is no sharing of Operating Profits or
Losses outside the United States (but Celgene is obligated to pay certain royalties and milestones as provided in such US Co-Development and Co-Commercialization
Agreement). 
 1.1.98 “Summary” means, on a
Program-by-Program basis, a summary of all relevant data (including chemical structures) with respect to the applicable Program (including any applicable Related
Compounds) that would have been included in an IND Filing, together with the applicable IP Information, all as existing as of the end of the Research Term or Continuation Term, as applicable. 

1.1.99 “Summary Verification Date” means, with respect to the Summary, the date that is [***] days after the date of receipt
by Celgene of such Summary; provided, however, that, (i) if Celgene requests additional reasonable information and clarifications during such original [***] day period, then such Summary Verification Date will be automatically
extended (as necessary) until the later of (a) [***] days following receipt by Celgene (or any designee) of such additional reasonable information and clarifications and (b) the end of such original [***] day period and (ii) if any Program
included in the Summary does not include any Program Compound that has been determined or deemed to satisfy the Development Candidate Criteria, then (A) if the Parties mutually agree, or the Scientific Panel determines, that any Program
Compound in such Program satisfies the Development Candidate Criteria pursuant to Section 2.3.3(b), then, solely with respect to such Program, the Summary Verification Date will be automatically extended until [***] days following such
agreement or determination and (B) if the Parties mutually agree, or the Scientific Panel determines, that no Program Compound in such Program satisfies the Development Candidate Criteria pursuant to Section 2.3.3(b), then the Summary
Verification Date with respect to such Program will end on the date of such determination or determination. 
 1.1.100
“Target” means a protein or polypeptide (including, for the avoidance of doubt, any E3 Ligase), including all variants thereof and any specific protein that is identified by a GenBank protein accession number or by its amino acid
sequence and coded by a genetic locus. 
 1.1.101 “Target Ligand” means a ligand which binds or otherwise associates with a
Target (including, for the avoidance of doubt, any E3 Ligase Binder). 
 1.1.102 “Territory” means worldwide. 

1.1.103 “Third Party” means any Person other than Vividion or Celgene or each Party’s respective Affiliates. 

  
 - 16 - 

 1.1.104 “United States” or “U.S.” means the United States
of America and all of its territories and possessions, including Puerto Rico. 
 1.1.105 “Vividion Cereblon Program” means a
program comprising Development activities by or on behalf of Vividion or any of its Affiliates for Program Compound(s) or Program Product(s) (including, for the avoidance of doubt, any LDD(s)) Controlled by Vividion that is(are) Directed against
Cereblon; but excluding all Deal Target Programs. For the avoidance of doubt, “Vividion Cereblon Program” excludes all Lapsed Programs. 

1.1.106 “Vividion Intellectual Property” means Vividion Know-How and Vividion Patents,
collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016.

 1.1.107 “Vividion Know-How” means any
Know-How that is (a) Controlled by Vividion as of the Effective Date or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of any Linker, Target
Ligand, Program Compound or Program Product; but excluding any Know-How licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of
January 6, 2016. 
 1.1.108 “Vividion Lead Shared Program” means a Shared Global Program for which Vividion will be the
“Lead U.S. Party” (as defined in Appendix A-2), subject to the terms and conditions of the applicable Global Co-Development and Co-Commercialization Agreement. 
 1.1.109 “Vividion Patents” means any and all Patents
that (a) are Controlled by Vividion as of the Effective Date or during the Term, and (b) Cover the Development, Manufacture or Commercialization of any Linker, Target Ligand, Program Compound or Program Product (including the composition
of matter, manufacture or any use thereof); but excluding any Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. 

1.2 Additional Definitions. Each of the following terms has the meaning described in the corresponding section of this Agreement
indicated below: 
  

			
	DEFINITION:	  	SECTION:
	Academic Essential Provisions	  	5.2.2(b)
	Acquirer Program	  	5.2.2(d)(ii)
	Additional Amounts	  	1.1.29
	Agreement	  	Preamble
	Alliance Manager	  	4.7
	Annual Net Sales	  	Appendix B-2
	Antitrust Clearance Date	  	3.2.2
	Bankruptcy Code	  	5.1.7
	Binder Program Access Term	  	2.14.2
	Binder Program Product	  	1.1.49
	Binder Royalty Term	  	6.6.4(b)

  
 - 17 - 

			
	DEFINITION	  	SECTION
	CCB DC Nomination Date	  	2.4.3
	CCB Determination	  	2.4.1
	CCB MTA Election Notice	  	2.4.2
	CCB Program Development Fee	  	6.4
	Celgene	  	Preamble
	Celgene CCB MTA Election	  	2.4.2
	Celgene CCB Program IP	  	7.1.3
	Celgene Indemnified Parties	  	10.2.1
	Celgene Independent Product	  	5.1.1
	Closed Target	  	2.2.1(b)
	Closed Target Notice	  	2.2.1(b)
	Co-Development and Co-Commercialization Agreement	  	1.1.39
	Collaboration	  	2.1
	Committee	  	4.1.1
	Competitive Program	  	5.2.2(c)
	Continuation Term Period	  	2.6.2
	control	  	1.1.2
	Cooperating Party	  	8.3.2(c)
	CTA	  	1.1.61
	Cure Period	  	11.3.1
	Defend	  	1.1.37
	Development Candidate Criteria	  	1.1.40
	Disclosing Party	  	8.1
	Dispute	  	12.1
	DOJ	  	3.2.2
	E3 Ligase Binder Program License Agreement	  	1.1.39
	E3 Ligase Binder Program Assets	  	9.3.3
	E3 Ligase Binder Program MTA	  	2.14.2
	Effective Date	  	Preamble
	Electronic Delivery	  	12.14
	EMA	  	1.1.62
	EU	  	1.1.3
	First Program	  	3.1.1(a)
	force majeure event	  	12.5
	FTC	  	3.2.2
	Global Co-Development and Co-Commercialization Agreement	  	1.1.39
	HSR Act	  	1.1.3
	HSR/Antitrust Filing	  	3.2.2
	Implementation Date	  	3.2.2
	Indirect Taxes	  	6.9.1(a)
	Initially-Approved Product	  	1.1.42
	IP Information	  	Schedule 1.1.32

  
 - 18 - 

			
	DEFINITION	  	SECTION
	JCC	  	4.1.1
	JDC	  	4.1.1
	JPC	  	4.1.1
	JRC	  	4.1.1
	JSC	  	4.1.1
	Lapsed Program	  	2.13.1
	License Agreement	  	1.1.39
	Limited Information	  	2.2.1(b)
	Listed E3 Ligands	  	2.14.1
	Material Breach	  	11.3.1
	Material Receiving Party	  	2.12.1
	Materials	  	2.12.1
	Opt-In Exercise Window	  	3.1.1
	Opt-In Right	  	3.1.1
	Other Distinct Product	  	1.1.42
	Parent Entity	  	1.1.19
	Party or Parties	  	Preamble
	Payee Party	  	6.9.1(a)
	Paying Party	  	6.9.1(a)
	Pre-Existing Celgene Cereblon LDD	  	1.1.17
	Pre-Existing Vividion Cereblon LDD	  	1.1.17
	Pre-Existing Vividion E3 LDD	  	1.1.49
	Program Assets	  	9.3.2
	Purpose	  	2.12.1
	Qualified Scientist	  	2.3.3
	Receiving Party	  	8.1
	Redacted Version	  	8.3.2(a)
	Related Compound	  	1.1.25
	Requesting Party	  	8.3.2(c)
	Research Plan	  	2.1.1
	Research Term Extension Fee	  	6.3
	Scientific Panel	  	2.3.3
	SEC	  	8.3.2(a)
	Selected Target	  	1.1.70
	Separate Program	  	2.3.4(b)
	Subcommittee	  	4.1.2
	Summary Fee	  	2.6.1(b)
	Term	  	11.1
	Third Party License	  	7.5.2
	Transferring Party	  	2.12.1
	US Co-Development and Co-Commercialization Agreement	  	1.1.39
	Valid E3 Ligase Claim	  	6.6.4(b)
	Vividion	  	Preamble

			
	Vividion Indemnified Parties	  	10.1.1
	Vividion Opt-Out Notice	  	3.1.1(d)

  
 - 19 - 

 ARTICLE II 

COLLABORATION; PRE-OPT-IN EXERCISE DEVELOPMENT 

2.1 Scope and Collaboration Overview. Subject to the terms and conditions of this Agreement, during the Research Term:
(a) Vividion (i) may conduct discovery activities to identify Program Compounds (including related Target Ligands) for Programs, (ii) may nominate Program Compounds from Programs as Development Candidates pursuant to the terms and
conditions of this Agreement, and (iii) as to Development Candidates in Programs, may conduct Pre-Exercise Development and (b) Celgene may conduct Development under any CCB Program MTA, if
applicable. The activities conducted pursuant to this ARTICLE II, as well as activities conducted pursuant to Development & Commercialization Agreements following Celgene’s exercise of its Opt-In
Rights, together, shall be the “Collaboration”. 
 2.1.1 Vividion Responsibility for Research and Pre-Opt-In Exercise Development. Subject to the terms and conditions of this Agreement, commencing on the Effective Date and during the Research Term, on a Program-by-Program basis, Vividion may, in its discretion, conduct Development activities with respect to each Program with the goal of identifying Program Compounds and
Developing and progressing such Program Compounds in Programs through Pre-Exercise Development. During the Research Term, Vividion shall have sole discretion regarding which Programs it selects to progress and
the Development activities performed thereunder (if any). The Parties understand and agree that Vividion (a) may, in its sole discretion, conduct Pre-Exercise Development (including for any Continuation
Program, if applicable) and (b) shall offer Celgene the opportunity to obtain rights to each applicable Program through the exercise of Celgene’s Opt-In Rights in accordance with ARTICLE III. Each
Program may be conducted pursuant to a research plan (which Vividion may prepare and submit (including in the form of slides, provided that Vividion provides additional written clarifying information if Celgene so requests) to the JRC, and which may
be amended from time to time by the JRC pursuant to ARTICLE IV) setting forth the activities to be conducted by Vividion and its Affiliates (and, with Celgene’s prior written consent, Celgene and its Affiliates) with respect to such Program
during the Opt-In Term (each such research plan, a “Research Plan”). Any failure to include any Development activities directed against a Program Target and Program Compounds in a Research
Plan shall not, in any way, exclude such activities from constituting a Program or prevent Celgene from exercising an Opt-In Right with respect to such Program under this Agreement. Vividion may decide to
cease activities under any Program it conducts prior to the exercise of the Opt-In Right by Celgene with respect to such Program at any time (and, for clarity, no such cessation of activity shall in any way
affect Celgene’s rights to exercise such Opt-In Right under this Agreement). 
 2.1.2
Extension of Research Term. Celgene may, at its election, extend the Research Term for a two (2) year extension period (to run consecutively after the end of the then-current Research Term) by giving notice to Vividion of such election
at least [***] days prior to the expiration of the then-existing Research Term and by paying the Research Term Extension Fee as set forth in Section 6.3. 

  
 - 20 - 

 2.1.3 Programs. Each Program shall include, subject to Sections 2.3.4 and 2.4, and
with respect to the Program Target that is the subject of such Program, all Program Products Controlled by Vividion during the Research Term that are Directed against such Program Target and Development activities conducted by the Parties with
respect to such Program Products; provided, however, that, for purposes of this Section 2.1.3, (a) [***]. Following any exercise by Celgene of its Opt-In Right with respect to a Program,
such Program shall be referred to as a “Licensed Program” (where the applicable Development & Commercialization Agreement is a License Agreement), or a “Shared Program” (where the applicable
Development & Commercialization Agreement is a Co-Development and Co-Commercialization Agreement). For clarity (and subject to this Section 2.1.3 regarding
Cereblon Programs and to Section 2.3.4(b) regarding “Separate Programs”), if two (2) or more Program Products are each Directed against the same applicable Program Target (based upon the same Functional Phenotypic Assay
Similarity Criteria, all subject to Section 2.3.4), then each such Program Product shall be deemed part of the same applicable Program for purposes of this Agreement and any applicable Development & Commercialization Agreement. 

2.2 Target and E3 Ligase Identification, Substitution and Additions. 

2.2.1 Target Identification. 

(a) During the Research Term, Vividion may discuss with Celgene, on a regular basis at JRC meetings, additional Targets as potential Program
Targets identified by Vividion in the course of its ongoing research activities in the Field as well as discuss with Celgene material developments in or new data or information in Vividion’s possession and Control relating to previously
identified Targets; provided that Vividion shall not have any obligation to discuss with Celgene any developments, data or information relating to Programs that have reverted to Vividion pursuant to Section 2.4.4 or
Section 2.13. 
 (b) Notwithstanding anything to the contrary contained herein, Celgene shall always be entitled to inform Vividion
that it wishes to remove a Target as a Program Target and that such Target shall be considered an Excluded Target. Notwithstanding anything to the contrary contained herein, Celgene shall be entitled to designate, in a written notice
(“Closed Target Notice”) to Vividion, any Program Target for which Celgene wishes to receive only specified or no additional information or to have a Third Party designee reasonably acceptable to Vividion receive and review
information relating to such Program Target in place of Celgene (any such designated Target, a “Closed Target”); it being understood and agreed that Celgene shall be entitled to modify (i) the designation of any Closed Target
such that the corresponding Program Target is no longer a Closed Target, and (ii) the information restrictions and recipients then-imposed with respect to such Closed Target. In each initial Closed Target Notice and in any 

  
 - 21 - 

 
subsequent modifications to such Closed Target Notice, Celgene shall include (x) the identity of the corresponding Closed Target, (y) a detailed written description of the limited
information, if any, that Celgene wishes to receive for such Closed Target (such limited information the “Limited Information”), and (z) the identity and address of Celgene’s designee (if any) that Celgene wishes to
receive the Limited Information. 
 2.2.2 Substitution Rights. If, at any time during the Research Term, the JSC unanimously so
agrees, (a) any Deal Target may be substituted with a different Target or (b) any Deal E3 Ligase may be substituted with a different E3 Ligase and, for clarity, the new Deal Target or Deal E3 Ligase, as applicable, shall be added to
Schedule 1.1.34 or Schedule 1.1.35, as applicable, and the former Deal Target or Deal E3 Ligase, as applicable, shall become an “Excluded Target”. 

2.3 Identification of Program Compounds; Nomination and Designation of Development Candidates. 

2.3.1 Compound Identification. During the Research Term, Vividion may notify Celgene, on a regular basis at JRC meetings (and make
relevant information available to the JRC), of Program Compounds that both (a) are Developed or otherwise identified by or on behalf of Vividion in the course of its ongoing research activities in the Field and (b) based upon confirmed
screening hits then to date, are demonstrated to be Directed against one or more Program Targets, and Vividion may include the identity of such Program Compounds and any associated Program Target(s) in the meeting minutes for the applicable JRC
meeting(s). No failure by Vividion to identify or the JSC to approve any Development activities by and on behalf of Vividion and its Affiliates directed to a Program Target and Program Compounds in the Field may prevent such Development activities
from being deemed a “Program” (and, accordingly, Celgene may have an Opt-In Right for any such Program under this Agreement). 

2.3.2 Nomination of Development Candidates. Based upon the Development Candidate Criteria and the results of Development activities with
respect to a Program (but excluding any CCB Program), Vividion may nominate a Program Compound Directed against the Program Target that is the subject of such Program as a Development Candidate, by providing written notification thereof to Celgene
and the JSC. In addition, following a Change of Control with respect to Vividion, Celgene may propose to nominate a Program Compound Directed against any Program Target as a Development Candidate, by providing written notification thereof to
Vividion and the JSC. 
 2.3.3 Designation of Development Candidates. 

(a) Following nomination of a Program Compound that is a CCB LDD as a Development Candidate by Celgene, the JSC shall discuss and review, and
Celgene shall in its sole discretion determine, whether such Program Compound meets the Development Candidate Criteria. During the Research Term or, pursuant to Section 2.3.3(b), at the end of the Research Term, following nomination of a
Program Compound that is not a CCB LDD as a Development Candidate, the JRC shall determine, or, in the event that the JRC is unable to unanimously agree, the JSC shall determine, whether such Program Compound meets the Development Candidate Criteria
as follows: (i) any such determination by the JRC or JSC, as applicable, must be 

  
 - 22 - 

 unanimous; or (ii) in the event that neither the JRC nor the JSC unanimously agree that such Program
Compound meets the Development Candidate Criteria, then the Parties agree to submit such matter to a panel of three Qualified Scientists (each and every such panel of three Qualified Scientists, a “Scientific Panel”) appointed as
provided in this Section 2.3.3 to determine whether or not such Program Compound meets the Development Candidate Criteria, all in accordance with the procedures provided in this Section 2.3.3; it being understood and agreed that, in
connection with any review and determination by the Scientific Panel, the Scientific Panel will render a decision that is consistent with the Development Candidate Criteria. Within [***] days following any such request for a Scientific Panel, each
of Vividion and Celgene shall nominate a Qualified Scientist to participate on the applicable Scientific Panel and, if the Parties are unable to agree upon a third Qualified Scientist for such Scientific Panel within [***] days following any such
request for a Scientific Panel, then the initial two Qualified Scientists shall select such third Qualified Scientist (and, in the event the first two Qualified Scientists are unable to agree upon a third Qualified Scientist within [***] days
following any request by a Scientific Panel, each of the first two Qualified Scientists shall submit the name of one Qualified Scientist whose name shall be selected by lot by the CEO of Vividion). Each Scientific Panel shall act as follows:
(x) each Qualified Scientist (and the Scientific Panel as a whole) shall act as an expert and not as an arbitrator; (y) each decision of the Scientific Panel shall be by majority vote of the three Qualified Scientists; and (z) the
decision of the Scientific Panel is, in the absence of fraud or manifest error, final and binding on the Parties. The costs of the Scientific Panel shall be shared equally by Vividion and Celgene. For purposes of this Agreement, a “Qualified
Scientist” shall mean any scientist (A) with at least [***] years of applicable pharmaceutical industry experience, (B) solely in the case of the third Qualified Scientist selected by the initial two Qualified Scientists, who has
not worked for or been engaged by any Party in the [***] year period immediately prior to the formation of the applicable Scientific Panel, and (C) who does not own more than [***] percent ([***]%) of the outstanding equity in any Party. The
Parties agree that, if such Scientific Panel determines that such Program Compound meets the Development Candidate Criteria, then such Program Compound shall be deemed a Development Candidate. Conversely, if such Scientific Panel determines that
such Program Compound does not meet the Development Candidate Criteria, then such Program Compound shall remain eligible for nomination as a Development Candidate during the Research Term. Upon the proposed nomination of a Program Compound as a
Development Candidate by Celgene pursuant to Section 2.3.2, or Celgene’s written confirmation to Vividion within [***] days following receipt of the written notification of nomination (or a Scientific Panel’s determination) that a
Program Compound is a Development Candidate, such Program Compound shall be deemed to satisfy the Development Candidate Criteria (whether or not the Development Candidate Criteria have actually been satisfied). Vividion shall use reasonable efforts
to respond to requests from the JSC and Celgene for additional reasonable information regarding each nominated Development Candidate. 
 (b)
If any Summary includes a Program for which no Program Compound has been determined or deemed to satisfy the Development Candidate Criteria pursuant to this Section 2.3, the Parties shall discuss in good faith for a period of [***] days after
Celgene’s receipt of such Summary whether any Program Compound in such Program satisfies the Development Candidate Criteria. In the event that, within such [***] day period, the Parties are unable to mutually identify a Program Compound in such
Program that satisfies the Development Candidate Criteria, then the Parties agree to submit such matter to a Scientific Panel appointed as provided in this Section 2.3.3 to determine whether or not any Program Compound 

  
 - 23 - 

 in such Program satisfies the Development Candidate Criteria, all in accordance with the procedures provided
in this Section 2.3.3. If such Scientific Panel determines that a Program Compound in such Program satisfies the Development Candidate Criteria, then such Program Compound shall be deemed a Development Candidate, and otherwise, if the
Scientific Panel determines that no Program Compound in such Program satisfies the Development Candidate Criteria, then no Program Compound in such Program will be deemed a Development Candidate. 

2.3.4 Distinct Products and Separate Programs. Solely with respect to [***], the following shall apply: 

(a) Distinct Products. If at the time of the [***] Regulatory Approval in the United States for any Program Compound in any specific
applicable Program, Vividion wishes to determine whether or not Distinct Products exist under such Program, then Vividion shall issue a notice to Celgene that it believes there are Distinct Products under such Program. The Parties shall discuss in
good faith for a period of [***] days whether or not such Distinct Products exist under such Program, and, for the avoidance of doubt, the Parties agree that no Party may unilaterally determine that Distinct Products exist under such Program. In the
event that Celgene does not agree in writing within such [***] day period that such Program contains Distinct Products, Vividion may issue a written notice to Celgene requesting the independent evaluation described in Section 2.3.4(c). This
Section 2.3.4(a) shall survive any termination or expiration of this Agreement and remain in effect for the duration of any applicable Development & Commercialization Agreement. Each Distinct Product shall separately be subject to the
applicable payment provisions for Distinct Products set forth in each applicable Development & Commercialization Agreement. 
 (b)
Separate Programs. Prior to the earlier of (i) [***] or (ii) [***], if Vividion reasonably believes that [***] Program Compounds in such Program would be approved under different product labels for distinct Indications if such Program
Compounds were to receive Regulatory Approval in the United States (based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results for each such Program Compound demonstrating utility in distinct
Indications where one Program Compound could not be substituted by another Program Compound for such distinct Indication(s)), then Vividion may deliver written notice thereof to Celgene and thereafter the Parties shall discuss in good faith for a
period of [***] days whether or not such Program should be split into [***] separate Programs (with each such Program Compound assigned to a distinct separate Program) (each, a “Separate Program”). If Celgene does not agree in
writing within such [***] day period that such Program should be split into [***] Separate Programs, then Vividion shall have the right to submit such Program Compounds to the independent evaluation described in Section 2.3.4(c) to determine or
confirm based upon then-current good scientific practice and understanding, data generated, and the proposed discovery and development research plan with respect to the applicable Program, whether or not each such Program Compound in such Program
would be approved under different product labels with distinct Indications if such Program Compounds were to receive Regulatory Approval in the United States. If so agreed upon by Celgene or determined or confirmed under Section 2.3.4(c), then
such Program shall be split into [***] Separate Programs (with each applicable Program Compound assigned to a distinct Separate Program), notwithstanding that 

  
 - 24 - 

 each such Program Compound is Directed against the same Program Target. After the earlier of (i) [***] or
(ii) [***], where Vividion reasonably believes [***] Products were Developed under such Program, such determination shall no longer be subject to the “Separate Program” determination set forth in this Section 2.3.4(b) and will instead
be subject solely to the “Distinct Product” determination mechanism provided in Section 2.3.4(a). 
 (c) Scientific
Panel. In the event that either of the Parties wishes to have a Scientific Panel appointed as provided in Section 2.3.3 to determine (i) the existence or the number of Distinct Products in any single Program, or (ii) whether a
Program should be split into Separate Programs, then the Parties agree to the procedure as provided in this Section 2.3.4(c). If such Scientific Panel determines that [***] Distinct Products exist in a single Program, or that a single Program
should be split into [***] Separate Programs, as provided in this Section 2.3.4, as applicable, then there shall be, for purposes of this Agreement and any applicable Development & Commercialization Agreement the number of Distinct
Products and Separate Programs determined by the Scientific Panel. If such Scientific Panel determines that there are not Distinct Products in such single Program or that a single Program should not be split into Separate Programs, then the
applicable Program shall be deemed to consist of only one Program or contain only one Program Product, as applicable. This Section 2.3.4(c) shall survive any termination or expiration of this Agreement until there are no longer any
Development & Commercialization Agreements in force and effect. 
 (d) The Parties understand and agree that, on a Program-by-Program basis, in no event shall a Party be entitled to request that a Scientific Panel review whether (i) any two (2) or more Distinct Products exist
under such Program or (ii) such Program should be split into two (2) or more Separate Programs pursuant to this Section 2.3.4 if (x) a Scientific Panel has previously rendered a decision as to whether or not Distinct Products
exist under such Program or such Program should be split into Separate Programs, as applicable, or (y) such Program has been determined to contain Distinct Products in accordance with Section 2.3.4(a) or has been split into Separate
Programs in accordance with Section 2.3.4(b), as applicable. 
 2.4 CCB Programs. 

2.4.1 Development of Target Ligands. During the Research Term, the Parties may discuss, through the JSC, whether any Target Ligand(s)
Directed against a Deal Target should be evaluated and further Developed by Celgene under a CCB Program MTA. In the event that the JSC unanimously agrees that Celgene may evaluate and further Develop one or more Target Ligands Directed against a
specified Deal Target (any such determination, a “CCB Determination”), Celgene shall have the right, but not the obligation, to enter into a CCB Program MTA for such Target Ligand(s) and Deal Target in accordance with this
Section 2.4. 
 2.4.2 Celgene CCB MTA Election. On a CCB
Program-by-CCB Program basis, Vividion hereby grants to Celgene an exclusive right, exercisable at any time during the Research Term following a CCB Determination for
such CCB Program and subject to Celgene’s obligation to pay the CCB Program Development Fee for such CCB Program pursuant to Section 6.4, to enter into a CCB Program MTA for such Program (the “Celgene CCB MTA Election”).
Celgene shall have the right, but not the obligation, to exercise its Celgene CCB MTA Election for a CCB 

  
 - 25 - 

 Program in its sole discretion by delivering written notice of such exercise (the “CCB MTA Election
Notice”) to Vividion. Within [***] Business Days following delivery of a CCB MTA Election Notice, each of Celgene (or an Affiliate designated by Celgene) and Vividion agrees to enter into the applicable CCB Program MTA and to update the
exhibits and schedules thereto. 
 2.4.3 Celgene Development of CCB LDDs. Celgene shall have the sole right and responsibility to
Develop a CCB LDD licensed under a CCB Program MTA until Celgene nominates any such CCB LDD as a Development Candidate through written notice to the JSC (the date on which Celgene nominates each such CCB LDD as a Development Candidate, the
applicable “CCB DC Nomination Date”); provided, however, that, if Celgene files any IND for any CCB LDD that Celgene has not previously nominated as a Development Candidate, Celgene shall be deemed to have
nominated such CCB LDD as a Development Candidate, and the date on which Celgene files such IND shall be the CCB DC Nomination Date for the applicable Program. Following any CCB DC Nomination Date and exercise of the applicable Opt-In Right as contemplated by Section 3.1.2 below, Celgene shall have the sole right and responsibility to Develop the applicable CCB Program, and all CCB LDDs thereunder, pursuant to a License Agreement.

 2.4.4 Reversion of Unexercised CCB Programs. For any CCB Program for which Celgene does not exercise its Opt-In Right during the applicable Opt-In Exercise Window, subject to the terms of the applicable CCB Program MTA, the rights granted by Vividion to Celgene with respect to
such CCB Program, if any, shall revert in accordance with the terms of such CCB Program MTA, and such CCB Program shall become a Lapsed Program; provided, however, that any Confidential Information and Materials that relate to a
non-terminated Program may be retained by Celgene. Notwithstanding anything to the contrary contained herein, in no event shall Vividion receive any right or license to the CCB LDD Developed by Celgene under
such CCB Program or any Celgene CCB Program IP. 
 2.4.5 Related Compounds. In the event that the Parties enter into any CCB Program
MTA, the Parties understand and agree that Vividion may continue to Develop Program Compounds under this Agreement Directed against the Deal Target that is the subject of such CCB Program MTA. For clarity, in the event Vividion Develops any Program
Compounds Directed against any Deal Target that is the subject of an executed CCB Program MTA, such Program shall constitute a separate “Program” under the Collaboration. 

2.5 Delivery of Data Package upon [***]. Within [***] days following [***] of the first Program Compound in a Program (excluding any CCB
Program under a CCB Program MTA), Vividion shall provide Celgene with an Data Package for such Program. During the period between Celgene’s receipt of such Data Package and the applicable Data Verification Date, Vividion shall use reasonable
efforts to respond to requests from Celgene for additional reasonable information and clarifications regarding content in the Data Package. In the event Celgene exercises its Opt-In Right for any Program
following [***]. 

  
 - 26 - 

 2.6 Disposition of Programs After the End of the Research Term. 

Summary. No earlier than [***] days prior to the end of the Research Term, Vividion may, in its sole discretion, provide a Summary to Celgene. No later
than [***] days prior to expiration of the Research Term, Celgene may, in its sole discretion, make a one-time, non-refundable,
non-creditable payment of [***] U.S. Dollars ($[***]) to Vividion on a Program-by-Program basis (“Summary Fee”).
Following payment of the Summary Fee, Vividion shall provide Celgene with a Summary as to all remaining Programs on a Program-by-Program basis, excluding (a) any
Program as to which the Parties have entered into a Development & Commercialization Agreement and (b) any CCB Program that is the subject of a
then-in-effect CCB Program MTA. Celgene shall have a period of [***] days following the Summary Verification Date: (i) to exercise its Opt-In Right for any such Program as provided in Section 3.1.2, and (ii) if, but only if, no Program Compound (other than pursuant to a CCB Program that is the subject of a CCB Program MTA) has been
designated a Development Candidate pursuant to Section 2.3 in any Program prior to the end of the Research Term, to elect, in its sole discretion, to designate one (1) such ongoing Program as a Continuation Program, which election Celgene
shall make by giving notice thereof to Vividion prior to the end of such [thirty ***] day period. During the period between Celgene’s receipt of such Summary and Summary Verification Date: (x) Vividion shall use reasonable efforts to
respond to requests from Celgene for additional reasonable information and clarifications regarding content in such Summary; and (y) if Celgene designates a Continuation Program, Vividion shall notify Celgene whether or not it will elect in its
sole discretion to conduct Development activities with the goal of identifying and nominating a Program Compound in such Continuation Program as a Development Candidate. For clarity, if Celgene designates a Continuation Program, then Vividion may
elect in its sole discretion to conduct Development activities with the goal of identifying and nominating a Program Compound in such Continuation Program as a Development Candidate and thereafter Vividion may conduct Development as to such
Continuation Program. The Parties’ respective rights and obligations as to such Continuation Program shall otherwise continue in accordance with this Agreement (substituting “Continuation Term Period” for “Research Term”
with respect thereto). For clarity, in the event that a Separate Program related to such Continuation Program is determined to exist in accordance with Section 2.3.4 during the Continuation Term Period, Celgene also shall have an Opt-In Right with respect to such Separate Program. 
 2.6.1 Treatment of Continuation Program. 

(a) End-of-Continuation Term. If Celgene designates a
Continuation Program in accordance with Section 2.6.1 and Vividion elects in its sole discretion to continue Development with respect to such Continuation Program, then Vividion may conduct such Development at its sole discretion and expense
until the earlier of (i) [***] years after the end of the Research Term or (ii) the later of (A) [***] for such Continuation Program or (B) [***] for any such related Separate Program (such period between the expiration of the Research Term and
the earlier time described in clause (i) and (ii), the “Continuation Term Period”). 
 (b) Summary. No earlier
than [***] days prior to the end of the Continuation Term Period, Vividion may, in its sole discretion, provide a Summary to Celgene. If Celgene designates a Continuation Program in accordance with Section 2.6.1 and Vividion elects

  
 - 27 - 

 
in its sole discretion to continue Development with respect to such Continuation Program, then Vividion may conduct such Development at its sole discretion and expense until the end of the
Continuation Term Period. No later than [***] days prior to expiration of the Continuation Term Period, Celgene may, in its sole discretion, pay the Summary Fee to Vividion. Following payment of the Summary Fee, Vividion shall provide Celgene with a
Summary as to the Continuation Program and any related Separate Program. Celgene shall be entitled to exercise its Opt-In right for such Continuation Program and any such related Separate Program within the
applicable Opt-In Exercise Window as provided in Section 3.1.2. Celgene shall have a period of [***] days following the Summary Verification Date to exercise its
Opt-In Right for any such Programs as provided in Section 3.1.2. During the period between Celgene’s receipt of such Summary and the applicable Summary Verification Date, Vividion shall use
reasonable efforts to respond to requests from Celgene for additional reasonable information and clarifications regarding content in any Summary. For clarity, after the expiration of the Opt-In Exercise Window
for the Continuation Program and any such related Separate Program, Celgene shall no longer have an Opt-In Right with respect to such Continuation Program or such Separate Program(s) and such Program(s) shall
be dropped from the Collaboration. 
 2.6.2 Disposition of Programs Not Designated as the Continuation Program. Following the
expiration of the Research Term, any Program in the Collaboration for which Celgene does not exercise its Opt-In Right following the expiration of the applicable Opt-In
Exercise Window or designate as a Continuation Program in accordance with Section 2.6.1 shall be dropped from the Collaboration and all rights thereto shall revert to Vividion in accordance with Section 2.4.4 or Section 2.13, as
applicable. Notwithstanding anything to the contrary, Vividion shall be entitled to research, develop, manufacture, and commercialize any and all pharmaceutical products outside the scope of the Collaboration. 

2.7 Regulatory Affairs. Subject to the proviso to this sentence, Vividion shall be responsible for and shall control all regulatory
matters relating to each Program until such time that Celgene exercises its Opt-In Right and enters into a Development & Commercialization Agreement for such Program; it being understood and agreed
that Celgene shall be responsible for and control all regulatory matters relating to any CCB Program licensed under a CCB Program MTA. Until such time that Celgene exercises its Opt-In Right and enters into a
Development & Commercialization Agreement with respect to a Program or such Program reverts to Vividion in accordance with Section 2.4.4 or Section 2.13, as applicable, Vividion shall consult with Celgene with respect to
regulatory filing strategy and document preparation, and shall reasonably consider all timely comments made by Celgene with respect thereto. 

2.8 Reports; Results; Testing by the Parties. Each Party shall maintain complete, current and accurate records of all Development
activities conducted by it under the Collaboration, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of such Development activities
in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and clinical trials for Programs in formal written study records according to
applicable Laws, including national and international guidelines such as ICH, GCP, GLP and GMP. Excluding with respect to any CCB Program under a CCB Program MTA, each Party shall have the right to review and copy such records maintained by the
other Party at reasonable times, as reasonably requested by such Party. Except with respect to any CCB Program, 

  
 - 28 - 

 at each meeting of the JRC or the JDC held pursuant to Section 4.8.2, each Party shall provide the
other Party a written progress report summary (which may consist solely of slides) on the status of its activities under each Program during the Research Term, including summaries of data associated with such activities, it being understood that any
Party may reasonably request additional information regarding any such written progress report summary provided by the other Party. 
 2.9
No Representation. No Party makes any representation, warranty or guarantee that the Collaboration will be successful, or that any other particular results will be achieved with respect to the Collaboration, any Program, any Program Target,
any Program Compound, any Development Candidate or any Program Product hereunder. 
 2.10 Subcontracting. Subject to the terms of this
Agreement and any applicable Development & Commercialization Agreement, each Party shall have the right to engage Affiliates or Third Party subcontractors to perform certain of its obligations under this Agreement or any applicable
Development & Commercialization Agreement. Any such Affiliate or subcontractor shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity and
perform such work consistent with the terms of this Agreement and any applicable Development & Commercialization Agreement; provided, however, that any Party engaging an Affiliate or subcontractor hereunder shall remain
fully responsible and obligated for such activities. Unless otherwise agreed by the Parties, each Party will obligate each of its Third Party subcontractors hereunder to agree in writing to assign to such Party ownership of, or grant to such Party
an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to the extent related to Development, Manufacture or
Commercialization with respect to Program Compounds, as applicable; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party inventions to the other Party pursuant to the
applicable provisions of this Agreement and of any applicable Development & Commercialization Agreement (including permitting such other Party to grant further sublicenses). 

2.11 Academic Collaborators. If any Party collaborates with an academic institution or one or more individuals at an academic
institution to perform research on Program Targets or Program Compounds, such Party shall be required to obligate such academic collaborator to agree in writing to grant the same rights specified in Section 2.10 with respect to ownership or
licenses to inventions; it being understood and agreed that, solely in the case of academic collaborations to perform research on Program Targets or Program Compounds which are not reasonably expected by the applicable Party to result in inventions
related to composition of matter or methods of use, in lieu of the rights specified in Section 2.10, it shall be sufficient for such Party to obtain a non-exclusive, worldwide, royalty-free, perpetual
license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses to, any such inventions, which sublicensing rights must permit sublicensing to the other Party pursuant to the
applicable provisions of this Agreement and of any applicable Development & Commercialization Agreement (including permitting such other Party to grant further sublicenses). 

  
 - 29 - 

 2.12 Material Transfer. 

2.12.1 Transfer. On a Program-by-Program basis, during
the Opt-In Term, any Party (the “Transferring Party”) shall transfer, if such Party agrees in writing to make such transfer (such agreement not to be unreasonably withheld) upon reasonable
request by the other Party (the “Material Receiving Party”), certain tangible materials, including such Program’s compositions of matter, cells, cell lines, assays, animal models and any other physical, biological or chemical
material, each to the extent related to Program Products, including physical embodiments of such Program’s Program Products and Diagnostic Products (the “Materials”) for use by the Material Receiving Party in furtherance of its
rights and the conduct of its obligations under this Agreement, as mutually agreed by the Parties and set forth in an appropriate material transfer agreement (the “Purpose”). The Parties agree that the exchanged Materials shall be
used in compliance with applicable Law and the terms and conditions of this Agreement and the applicable material transfer agreement, and shall not be reverse engineered or chemically analyzed, except as required for verification purposes (if
needed). The Parties understand and agree that, notwithstanding anything in this Section 2.12.1 to the contrary, entry into a CCB Program MTA for a CCB Program shall be in accordance with Section 2.4. 

2.12.2 License; Ownership. At the time the Transferring Party provides Materials to the Material Receiving Party as provided herein and
to the extent not separately licensed under this Agreement, the Transferring Party hereby grants to the Material Receiving Party a non-exclusive license under the Patents and
Know-How Controlled by the Transferring Party to use such Materials solely for the Purpose, and such license, upon termination of this Agreement (subject to ARTICLE XI), completion of the Purpose, or
discontinuation of the use of such Materials (whichever occurs first), shall automatically terminate. Except as otherwise provided under this Agreement, all such Materials delivered by the Transferring Party to the Material Receiving Party shall
remain the sole property of the Transferring Party, shall only be used by the Material Receiving Party in furtherance of the Purpose, and shall be returned to the Transferring Party or destroyed, in the Transferring Party’s sole discretion,
upon the termination of this Agreement (subject to ARTICLE XI), the expiration of the Opt-In Exercise Window with respect to any Program to which such Materials solely relate (unless the Opt-In Right is exercised for the Program for which such transfer occurred), or upon the discontinuation of the use of such Materials (whichever occurs first). The Material Receiving Party shall not permit the
Materials to be used by or delivered to or for the benefit of any Third Party without the prior written consent of the Transferring Party except as contemplated by Section 2.10 or Section 2.11. 

2.12.3 No Warranties; Liability. THE MATERIALS SUPPLIED BY THE TRANSFERRING PARTY UNDER THIS SECTION 2.12 ARE SUPPLIED “AS
IS” AND, EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, THE TRANSFERRING PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, OR THAT THE MATERIALS OR USE THEREOF DO NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY. The Material Receiving Party assumes all liability for Damages that may arise from its use, storage or
disposal of the Materials. Except as otherwise set forth in this Agreement, the Transferring Party shall not be liable to the Material Receiving Party for any loss, claim or demand made by the Material Receiving Party, or made against the Material
Receiving Party by any Third Party, due to or arising from the use of the Materials, except to the extent such loss, claim or demand is caused by the gross negligence or willful misconduct of the Transferring Party. 

 

  
 - 30 - 

 2.13 Reversion of Rights. 

2.13.1 Programs. If Section 2.4, Section 2.6.2, Section 2.6.3, Section 3.1.3, Section 3.2.5 or
Section 11.5.1(a) specifies that rights to a Program are to be dropped from the Collaboration, or if a Program’s sole Target becomes an Excluded Target (or, if a Program has multiple Targets, only when all of the Program’s Targets
become Excluded Targets), or if Celgene does not exercise its Opt-In Right with respect to any Program within the applicable Opt-In Exercise Window for such Program
(each such Program, a “Lapsed Program”), then, subject to Section 2.4.4, (a) all rights granted by Vividion to Celgene with respect to such Lapsed Program, if any, shall revert to Vividion, and (b) subject to ARTICLE VIII
and Section 2.4.4, Celgene shall return to Vividion, or destroy, at Vividion’s option, all Confidential Information or Materials provided by Vividion to Celgene in relation to such Lapsed Program; provided, however,
that any Confidential Information or Materials that also relate to a non-terminated Program may be retained by Celgene. 

2.13.2 Reversion License. Effective upon any of the events set forth in Section 2.13.1 with respect to a Lapsed Program, Celgene
hereby grants to Vividion a non-exclusive, non-transferable (except as set forth in Section 2.4.4 or Section 12.4.1), worldwide right and license in the Field
with the right to grant sublicenses, under Celgene’s rights in Celgene Collaboration Intellectual Property and Joint Collaboration IP, to Develop, Manufacture or Commercialize Program Compounds or Program Products under such Lapsed Program;
provided that, for this purpose, “Celgene Collaboration Intellectual Property” means Celgene Collaboration Intellectual Property only to the extent that it is actually used in such Lapsed Program prior to the
applicable reversion set forth in this Section 2.13 and in no case includes any Celgene CCB Program IP; provided further that the foregoing license under this Section 2.13.2 shall be exclusive (even as to Celgene
except as provided in an executed Development & Commercialization Agreement) with respect to the applicable Lapsed Program to the extent of claims within the Patents included in the Celgene Collaboration Intellectual Property and Joint
Collaboration IP that Cover a composition of matter of any Program Compound or Program Product in such Lapsed Program. Vividion shall not owe royalties or milestones with respect to any license in this Section 2.13.2, but Vividion shall be
solely responsible for any payments owed by Celgene to any Third Party licensors of Celgene Collaboration Intellectual Property or Joint Collaboration IP, and shall be responsible for complying with the terms of any license agreements with such
third Party licensors, in either case, directly related to Vividion’s exercise of such licenses. 
 2.13.3 Exercised Programs.
For the avoidance of doubt, none of the reversion events described in this Section 2.13 shall affect Celgene’s rights with respect to (a) any other Program for which Celgene retains Opt-In
Rights (including any Separate Program which includes Program Compounds Directed against the same Program Target as such Lapsed Program), (b) any other Program for which Celgene has delivered an Opt-In
Exercise Notice pursuant to Section 3.1.2, or (c) any specific Linker or Target Ligand associated with the Program Compound in the Lapsed Program, each of which shall continue to be available to the Collaboration for use with any and all
Programs. 

  
 - 31 - 

 2.14 E3 Ligase Binder Programs and Cereblon Binder Programs. 

2.14.1 [***] days prior to the end of the Research Term, Vividion shall, in its sole discretion, seek to prepare a list of E3 Ligase Binder
Ligands, provided that such list only will include E3 Ligase Binder Ligands from Vividion as Vividion shall determine in its sole discretion. All of the E3 Ligase Binder Ligands on such list as prepared pursuant to this Section 2.14.1 shall be
deemed to be “Listed E3 Ligands.” 
 2.14.2 During the period beginning at the end of the Research Term and ending [***]
months after the end of the Research Term (the “Binder Program Access Term”) Celgene shall, in its sole discretion, decide which Listed E3 Ligands, if any, it wishes to test pursuant to a material transfer agreement, in the form of
material transfer agreement attached hereto as Appendix F (each such material transfer agreement, an “E3 Ligase Binder Program MTA”). 

2.14.3 For [***] months following preparation of the list of Listed E3 Ligands, if any, by Vividion in its sole discretion pursuant to
Section 2.14.1, Celgene may test such Listed E3 Ligand in order to determine whether to exclusively license such Listed E3 Ligand and all associated E3 Ligase Binder Products. Prior to the end of such [***] month period Vividion may, in its
sole discretion, offer to Celgene the option to exclusively license the right to Develop, Manufacture and Commercialize such Listed E3 Ligand and all associated E3 Ligase Binder Products (subject, as applicable, to Vividion’s retained right to
Develop, Manufacture and Commercialize any Pre-Existing Vividion E3 LDD that includes in its chemical structure such Listed E3 Ligand or any portion of such Listed E3 Ligand) and Celgene may notify Vividion of
its exercise thereof in writing on or before the end of such [***] month period, all pursuant to the Binder Program License Agreement with respect to such Listed E3 Ligand and associated E3 Ligase Binder Products, and each Party will update the
exhibits and schedules thereto, as applicable. Following the applicable Implementation Date for each Binder Program License Agreement, Celgene shall pay the applicable fees to Vividion set forth in Section 6.6. 

2.15 Reversion of Rights. 

2.15.1 E3 Ligase Binder Ligands. At the end of the Binder Program Access Term, if any E3 Ligase Binder Ligand has not been exclusively
licensed by Celgene, then (a) all rights granted by Vividion to Celgene with respect to such E3 Ligase Binder Ligand, if any, shall revert to Vividion and (b) subject to the applicable E3 Ligase Binder Program MTA, Celgene shall return to
Vividion, or destroy, at Vividion’s option, all Confidential Information or tangible materials provided by Vividion to Celgene in relation to such E3 Ligase Binder Ligand; provided, however, that any Confidential
Information or tangible materials that also relate to an E3 Ligase Binder Ligand that has been exclusively licensed by Celgene pursuant to Section 2.14 may be retained by Celgene. 

2.15.2 Reversion License. Effective upon the event set forth in Section 2.15.1 with respect to an E3 Ligase Binder Ligand, Celgene
hereby grants to Vividion a non-exclusive, worldwide right and license in the Field with the right to grant sublicenses (subject to Section 5.1.4), under Celgene’s rights in Celgene Collaboration
Intellectual Property and Joint Collaboration IP, to Develop, Manufacture or Commercialize Binder Program Products associated with such E3 Ligase Binder Ligand; provided that, for this purpose, “Celgene Collaboration 

  
 - 32 - 

 Intellectual Property” means Celgene Collaboration Intellectual Property only to the extent that it is
actually used in the Development of any such Binder Program Product prior to the applicable reversion set forth in Section 2.15.1; provided further that the foregoing license under this Section 2.15.2 shall be
exclusive (even as to Celgene) with respect to the applicable Binder Program Product(s) to the extent of claims within the Patents included in the Celgene Collaboration Intellectual Property and Joint Collaboration IP that Cover a composition of
matter of any such Binder Program Product. Vividion shall not owe royalties or milestones with respect to any license in this Section 2.15.2, but Vividion shall be solely responsible for any payments owed by Celgene to any Third Party licensors
of Celgene Collaboration Intellectual Property or Joint Collaboration IP, and shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in either case, directly related to Vividion’s exercise
of such licenses. 
 ARTICLE III 

OPT-IN RIGHTS EXERCISE; DEVELOPMENT & COMMERCIALIZATION 

AGREEMENTS 
 3.1 Opt-In Right Grant and Exercise. 
 3.1.1 Opt-In Right
Grant. Subject to the terms and conditions of this Agreement on a Program-by-Program basis, Vividion hereby grants to Celgene an exclusive right with respect to each
Program (each, an “Opt-In Right”), exercisable (in Celgene’s sole discretion) at any time during the period commencing on Celgene’s receipt of a Data Package (subject to
Section 2.5) or Summary (whichever is received earliest) for such Program or, with respect to any CCB Program, the applicable CCB DC Nomination Date, and ending [***] days following (a) with respect to each Vividion Cereblon Program, Deal
Target Program or E3 Ligase Program, the earliest to occur of the Data Verification Date or Summary Verification Date, if any, for such Program, and (b) with respect to any CCB Program, [***] days following the end of the term of the CCB MTA
for the applicable CCB Program (each such period for each Program, as applicable, the “Opt-In Exercise Window”) as follows: 

(a) First Opt-In. Celgene may exercise its Opt-In
Right, at any time during the applicable Opt-In Exercise Window, to enter into a License Agreement with respect to the [***] for which Celgene delivers an Opt-In
Exercise Notice pursuant to Section 3.1.2 (the “First Program”) (including all applicable Program Compounds thereunder specified in such License Agreement) and any related Companion Diagnostics developed therefor, as set forth
in and on the terms and conditions set forth in such License Agreement (and each applicable Program Compound under such First Program specified in such License Agreement shall be deemed a “Licensed Candidate” thereunder and the Program
Target (or, if such Program Compounds are LDDs, the Selected Target) against which such Program Compounds are Directed shall be deemed a “Licensed Target” thereunder). For clarity, in the event that Celgene exercises its Opt-In Right for [***] shall be deemed the “First Program” for purposes of this Section 3.1.1. 

(b) [***] Opt-In Rights. After Celgene has delivered an
Opt-In Exercise Notice for the First Program, with respect to each 

  
 - 33 - 

 
[***] for which Celgene delivers an Opt-In Exercise Notice pursuant to Section 3.1.2, Vividion hereby grants (subject to Section 3.1.1(d) below)
to Celgene an Opt-In Right, exercisable at any time during the applicable Opt-In Exercise Window, to enter into: 

(i) With respect to the [***] for which Celgene exercises its Opt-In Right after the First Program,
which Program shall be a Shared US Program, a US Co-Development and Co-Commercialization Agreement with respect to such Program (including all applicable Program
Compounds thereunder specified in the US Co-Development and Co-Commercialization Agreement) and any related Companion Diagnostics developed therefor, as set forth in and
on the terms and conditions set forth in the US Co-Development and Co-Commercialization Agreement (and each applicable Program Compound specified in the US Co-Development and Co-Commercialization Agreement shall be deemed a “Co-Co Candidate” thereunder and the Program Target (or,
if such Program Compounds are LDDs, the Selected Target) against which such Program Compounds are Directed shall be deemed a “Co-Co Target” thereunder); or 

(ii) With respect to the [***] for which Celgene exercises its Opt-In Right, which Program shall be a
Shared Global Program, a Global Co-Development and Co-Commercialization Agreement with respect to such Program (including all applicable Program Compounds thereunder
specified in such Global Co-Development and Co-Commercialization Agreement) and any related Companion Diagnostics developed therefor, as set forth in and on the terms
and conditions set forth in the Global Co-Development and Co-Commercialization Agreement (and each applicable Program Compound specified in such Global Co-Development and Co-Commercialization Agreement shall be deemed a “Co-Co Candidate” thereunder and the Program Target (or,
if such Program Compounds are LDDs, the Selected Target) against which such Program Compounds are Directed shall be deemed a “Co-Co Target” thereunder). The first Shared Global Program shall be a
[***]. Thereafter, the designation of the “Lead U.S. Party” (as defined in Appendix A-2) for each subsequent Shared Global Program, as applicable, shall [***] with respect to each subsequent
Shared Global Program. By way of example, the [***]. 
 (c) [***] Opt-In Rights. With respect
to each [***], Vividion hereby grants to Celgene an exclusive Opt-In Right, exercisable at any time during the applicable Opt-In Exercise Window, to enter into a License
Agreement with respect to such [***], as applicable, (including all applicable [***] thereunder) and any related Companion Diagnostics developed therefor, as set forth in and on the terms and conditions set forth in the applicable License Agreement
and [***] (and each applicable Program Compound under such [***], as applicable, specified in such License Agreement shall be deemed a “Licensed Compound” thereunder and the Program Target (or, if such Program Compounds are LDDs, the
Selected Target) against which such Program Compounds are Directed shall be deemed a “Licensed Target” thereunder). 

  
 - 34 - 

 (d) Vividion Opt-Out. Notwithstanding
Section 3.1.1(b), Vividion shall have the right to elect to opt out of its Development, Manufacturing and Commercialization rights and the sharing of Development Costs (as defined in Appendix A-1
or Appendix A-2, as applicable) and Operating Profits or Losses (as defined in Appendix A-1 or Appendix A-2,
as applicable) under any Co-Development and Co-Commercialization Agreement by written notice to Celgene within [***] days of receipt of Celgene’s Opt-In Exercise Notice for the applicable Program (such notice, the “Vividion Opt-Out Notice”) or, if Celgene has exercised its
Opt-In Right prior to IND Filing for such Program, within [***] days of receipt of such Opt-In Exercise Notice. If Vividion provides a Vividion Opt-Out Notice for any applicable Program, the Parties shall instead enter into a License Agreement for such Program. For purposes of clarity, after delivery of a Vividion
Opt-Out Notice, Celgene shall be responsible for all costs and expenses for the applicable Program in accordance with the terms and conditions of the License Agreement and Vividion shall not have any option or
right to buy back into any co-Development or co-Commercialization rights with respect to such Program. 

3.1.2 Opt-In Exercise. Celgene shall have the right, but not the obligation, to exercise its Opt-In Right for a Program by delivering an Opt-In Exercise Notice to Vividion within the applicable Opt-In Exercise Window. Upon such
exercise, the applicable Program shall become a “Licensed Program” or “Shared Program” as provided in this Section 3.1. Within [***] days following each Opt-In Exercise Notice
delivery, Celgene (or an Affiliate designated by Celgene) and Vividion and each Affiliate of Vividion that holds Vividion Intellectual Property relating to the applicable Program will enter into the applicable Development &
Commercialization Agreement as set forth in Section 3.1.1, and each Party will update the exhibits and schedules thereto, as applicable, including to identify the Program Compound(s) and Program Target that are the subject of such
Development & Commercialization Agreement. Following the applicable Implementation Date for each Development & Commercialization Agreement, (a) Celgene shall pay the applicable fees set forth in such Development &
Commercialization Agreement in accordance therewith and (b) Vividion shall no longer have any obligation to provide Celgene with any Data Package or Summary (provided that, in the case of the Summary, Celgene has paid the Summary Fee) for the
Program that is the subject of such Development & Commercialization Agreement, and all requests from Celgene for data relating to such Program shall be governed by the terms of such Development & Commercialization Agreement. 

3.1.3 Expiration of Opt-In Exercise Windows. If Celgene does not exercise an Opt-In Right prior to the expiration of the applicable Opt-In Exercise Window, then the corresponding Program shall be dropped from the Collaboration in accordance with
Section 2.4.4 or Section 2.13, as applicable, and shall no longer be subject to Celgene’s rights under this Agreement, including ARTICLE V and all rights thereto shall revert to Vividion in accordance with Section 2.4.4 or
Section 2.13, as applicable. 
 3.2 Government Approvals. 

3.2.1 Efforts. Each of Vividion and Celgene will use its commercially reasonable good faith efforts to eliminate any concern on the part
of any Governmental Authority regarding 

  
 - 35 - 

 
the legality of any proposed Development & Commercialization Agreement including, if required by Governmental Authorities, promptly taking all steps to remove any and all impediments to
consummation of the transactions contemplated by the Development & Commercialization Agreements, including obtaining government antitrust clearance, cooperating in good faith with any Governmental Authority investigation, promptly producing
any documents and information and providing witness testimony if requested by a Governmental Authority. Notwithstanding anything to the contrary in this Agreement or any Development & Commercialization Agreement, this Section 3.2 and
the term “commercially reasonable good faith efforts” do not require that any Party (a) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other
disposition of any capital stock, assets, rights, products or businesses of Vividion, Celgene or their respective Affiliates, (b) agree to any restrictions on the businesses of Vividion, Celgene or their respective Affiliates, or (c) pay
any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise have the effect of
preventing or delaying the transactions contemplated by the applicable Development & Commercialization Agreement(s). 
 3.2.2
HSR/Antitrust Filings. Each of Vividion and Celgene will, within [***] Business Days after the execution of any relevant Development & Commercialization Agreement (or such later time as may be agreed to in writing by the Parties)
file with the U.S. Federal Trade Commission (“FTC”) and the Antitrust Division of the U.S. Department of Justice (“DOJ”) any HSR/Antitrust Filing required of it under the HSR Act and, as soon as practicable, file
with the appropriate Governmental Authority any other HSR/Antitrust Filing required of it under any other Antitrust Law as determined in the reasonable opinion of any Party with respect to the transactions contemplated by such Development &
Commercialization Agreement. The Parties shall cooperate with one another to the extent necessary in the preparation of any such HSR/Antitrust Filing. Each Party shall be responsible for its own costs, expenses and filing fees associated with any
HSR/Antitrust Filing; provided, however, that the Parties shall equally share all fees (other than penalties that may be incurred as a result of actions or omissions on the part of a Party, which penalties shall be the sole
financial responsibility of such Party), required to be paid to any Governmental Authority in connection with making any such HSR/Antitrust Filing. In the event that the Parties make an HSR/Antitrust Filing under this Section 3.2, the relevant
Development & Commercialization Agreement shall terminate (a) at the election of any Party, immediately upon notice to the other Party, in the event that the FTC, DOJ or other Governmental Authority obtains a preliminary injunction or
final order under Antitrust Law enjoining the transactions contemplated by such Development & Commercialization Agreement, or (b) at the election of any Party, immediately upon notice to the other Party, in the event that the Antitrust
Clearance Date shall not have occurred on or prior to [***)] days after the effective date of the last HSR/Antitrust Filing submitted to a Governmental Authority in relation to such Development & Commercialization Agreement. Notwithstanding
anything to the contrary contained herein, except for the terms and conditions of this Section 3.2, none of the terms and conditions contained in any Development & Commercialization Agreement shall be effective until the
“Implementation Date,” which is agreed and understood to mean the later of (i) the execution date of such Development & Commercialization Agreement, (ii) if a determination is made pursuant to this
Section 3.2 that an HSR/Antitrust Filing is not required to be made under any Antitrust Law for such Development & Commercialization Agreement, the date of such determination, or (iii) if a determination is made pursuant to this
Section 3.2 that an HSR/Antitrust Filing is required to be 

  
 - 36 - 

 made under any Antitrust Law for such Development & Commercialization Agreement, the applicable
Antitrust Clearance Date. As used herein: (x) “Antitrust Clearance Date” means the earliest date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act and any comparable waiting periods as
required under any other Antitrust Law, in each case with respect to the transactions contemplated by the relevant Development & Commercialization Agreement have expired or have been terminated; and (y) “HSR/Antitrust
Filing” means (i) a filing by Vividion and Celgene with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act), together with all required documentary
attachments thereto or (ii) any comparable filing by Vividion or Celgene required under any other Antitrust Law, in each case ((i) and (ii)) with respect to the transactions contemplated by any applicable Development &
Commercialization Agreement(s). 
 3.2.3 Information Exchange. Each of Vividion and Celgene will, in connection with any HSR/Antitrust
Filing, (a) reasonably cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party; (b) keep the
other Party or its counsel informed of any communication received by such Party from, or given by such Party to, the FTC, the DOJ or any other U.S. or other Governmental Authority and of any communication received or given in connection with any
proceeding by a private party, in each case regarding the transactions contemplated by any Development & Commercialization Agreement; (c) consult with each other in advance of any meeting or conference with the FTC, the DOJ or any
other Governmental Authority or, in connection with any proceeding by a private party, with any other Person, and to the extent permitted by the FTC, the DOJ or such other Governmental Authority or other Person, give the Parties or their counsel the
opportunity to attend and participate in such meetings and conferences; and (d) to the extent practicable, permit the other Party or its counsel to review in advance any submission, filing or communication (and documents submitted therewith)
intended to be given by it to the FTC, the DOJ or any other Governmental Authority; provided that materials may be redacted to remove references concerning the valuation of the business of Vividion or other sensitive information.
Vividion and Celgene, as each deems advisable and necessary, may reasonably designate any competitively sensitive material to be provided to the other under this Section 3.2.3 as “Antitrust Counsel Only Material.” Such materials and
the information contained therein shall be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in
advance from the source of the materials (Vividion or Celgene, as the case may be) or its legal counsel. 
 3.2.4 Assistance Unrelated to
Antitrust Law. Subject to this Section 3.2, Vividion and Celgene shall cooperate and use all reasonable efforts to make all other registrations, filings and applications, to give all notices and to obtain as soon as practicable all
governmental or other consents, transfers, approvals, orders, qualifications, authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. 

3.2.5 No Further Obligations. If any Development & Commercialization Agreement is terminated pursuant to this Section 3.2,
then, notwithstanding any provision in this Agreement to the contrary, no Party shall have any further obligation to the other Party with respect 

  
 - 37 - 

 
to the subject matter of such Development & Commercialization Agreement; provided that, prior to termination of such Development & Commercialization Agreement
pursuant to this Section 3.2, Celgene shall instead be permitted to assign such Development & Commercialization Agreement or any rights or obligations related thereto to any Third Party if required to comply with any Antitrust Law;
provided further that, in any event of termination of the applicable Development & Commercialization Agreement pursuant to this Section 3.2, rights to the applicable Program shall revert to Vividion in accordance
with Section 2.4.4 or Section 2.13, as applicable. 
 ARTICLE IV 

GOVERNANCE 
 4.1
General. 
 4.1.1 Governance Committees. The Parties shall establish (a) a Joint Steering Committee
(“JSC”) to oversee and coordinate the overall conduct of all Programs hereunder; (b) a Joint Research Committee (“JRC”) to oversee and coordinate discovery, research and
pre-clinical Development activities with respect to each Program until nomination of a Development Candidate for such Program; (c) a Joint Development Committee (“JDC”) for each Program
as to which a Development Candidate has been nominated and designated and for which Celgene retains an Opt-In Right; (d) a Joint Commercialization Committee (“JCC”) to oversee
Commercialization activities under a Development & Commercialization Agreement; and (e) a Joint Patent Committee (“JPC”) to oversee Patent Prosecution and enforcement (the JSC, the JRC, the JDC, the JCC and the JPC
shall each be referred to as a “Committee”). Each Committee shall have decision-making authority with respect to the matters within its purview to the extent expressly and as more specifically provided herein; it being understood
and agreed that (i) notwithstanding anything to the contrary contained herein, on a Program-by-Program basis, from and after the date that Vividion provides a
Vividion Opt-Out Notice, the Committees shall no longer have any decision-making authority with respect to such Program, but shall continue to function for information sharing purposes until the applicable
Vividion Opt-Out Date (each as defined in Appendix A-1 or Appendix A-2, as applicable) and (ii) with respect
to any Program that is subject to an executed License Agreement, no Committee shall have any review or decision-making authority. 
 4.1.2
From time to time, each Committee may establish subcommittees to oversee particular projects or activities, as it deems necessary or advisable (each, a “Subcommittee”). Each Subcommittee shall consist of such number of members as
the applicable Committee determines is appropriate from time to time. Such members shall be individuals with expertise and responsibilities in the relevant areas such as high-throughput screening, protein homeostasis,
non-clinical development, pharmacology, clinical development, Patents, process sciences, Manufacturing, quality, regulatory affairs, product Development or product Commercialization, as applicable, to the
stage of the project or activity. Such Subcommittees shall operate under the same principles as are set forth in this ARTICLE IV for the Committee forming such Subcommittee. 

4.1.3 Execution of Co-Development and Co-Commercialization
Agreement. On a Program-by-Program basis, upon execution of the applicable Co-Development and
Co-Commercialization Agreement for such Program, such Program and matters related thereto shall continue to be within the purview of the applicable Committee, in accordance with and pursuant to the terms of
the applicable Co-Development and Co-Commercialization Agreement. 
  

  
 - 38 - 

 4.2 Joint Steering Committee. 

4.2.1 Establishment. Within [***] days following the Effective Date, Vividion and Celgene shall establish the JSC. The JSC shall have
oversight over each Program, subject to Sections 4.10 and 4.11. 
 4.2.2 Duties. The JSC shall: 

(a) manage the strategic direction of the Collaboration; 

(b) oversee implementation of the Collaboration in accordance with this Agreement and each
Co-Development and Co-Commercialization Agreement; 
 (c)
review and monitor progress of the Collaboration and serve as a forum for exchanging information and facilitating discussions regarding the conduct of the Collaboration; 

(d) oversee all Programs (excluding any CCB Program under a CCB Program MTA) and related matters within the responsibilities of the Committees
hereunder; 
 (e) manage the substitution and addition of Program Targets in accordance with Section 2.2; 

(f) discuss and determine appropriate measures to take in view of Third Party rights; 

(g) serve as a forum for dispute resolution in accordance with Section 4.10 with respect to matters that are not resolved at the JRC,
JDC, JCC or JPC; and 
 (h) perform such other duties as are specifically assigned to the JSC under this Agreement or any Co-Development and Co-Commercialization Agreement. 
 4.3 Joint
Research Committee. 
 4.3.1 Establishment. Within [***] days following the Effective Date, Vividion and Celgene shall establish
the JRC. The JRC shall have oversight over each Program until a Development Candidate has been nominated and designated for such Program, subject to Sections 4.10 and 4.11. 

4.3.2 Duties. The JRC shall: 

(a) review and approve any initial Research Plans (if any) proposed by Vividion and amendments to such Research Plan(s); 

(b) discuss the inclusion of Program Compounds in the Collaboration in accordance with Section 2.3.1; 

 

  
 - 39 - 

 (c) oversee, review and provide strategic guidance to the Parties with respect to the
conduct of each Program (excluding any CCB Program under a CCB Program MTA), including the prioritization of Programs; 
 (d) review and,
solely as set forth in Section 2.3.3, approve whether a Program Compound has met the criteria for a Development Candidate in accordance with Section 2.3.3; 

(e) in conjunction with the JDC, approve for which Indication(s) in the Field the first IND should be filed for Program Compounds or
Development Candidates of Programs; 
 (f) in conjunction with the JDC, discuss additional Indications for Development of Program Compounds
or Development Candidates of Programs; 
 (g) oversee and coordinate the Parties’ activities with respect to the IND-enabling activities and Manufacture of pre-clinical and clinical supply of Program Compounds and Program Products (to the extent the JDC has not yet been formed); 

(h) in conjunction with the JDC, provide a forum for the Parties (i) to discuss the objectives of each Program; and (ii) to exchange
and review scientific information and data relating to the activities being conducted under each Program; 
 (i) provide a forum for the
Parties to identify and discuss which Programs Celgene may wish to identify for early Opt-In Right exercise by Celgene; 

(j) discuss and attempt to resolve any disputes in the JRC; 

(k) in conjunction with the JDC, provide strategic guidance, and coordinate efforts between the Parties, with respect to any Publications and,
by mutual agreement, approve requests for Publication, from any Party, according to the Publication Guidelines and Section 8.4 hereof; 

(l) determine whether, on a Deal Target Program-by-Deal Target
Program basis, any Target Ligand has functional activity; and 
 (m) perform such other duties as are specifically assigned to the JRC under
this Agreement. 
 4.3.3 Dissolution. The JRC shall be dissolved and its activities and authority terminated upon the end of the Opt-In Term. 
 4.4 Joint Development Committee. 

4.4.1 Establishment. Within [***] days following Vividion’s first identification of a Program Compound as a Development Candidate
pursuant to Section 2.3.2 or 

  
 - 40 - 

 
[***], Vividion and Celgene shall establish the JDC. The JDC shall have oversight over Development activities with respect to each Program and as to which Celgene retains an Opt-In Right hereunder or that has become a Shared Program. 
 4.4.2 Duties Prior to Opt-In Right Exercise by Celgene. The JDC shall: 
 (a) Review and approve the applicable Development
plans for each Program and any proposed updates or amendments to such Development plans, and propose revisions to each of such Development plans as needed; 

(b) review and approve the content of any IND for a Program Product and oversee, review and coordinate the studies required for the
preparation of the CMC section of an IND for filing with Regulatory Authorities for the Program Products, including studies relating to analytical methods and purity analysis; 

(c) provide a forum for the Parties to share information with respect to the Development of Program Compounds and Program Products, including
reviewing and commenting on updates on such Development; 
 (d) provide a forum for the Parties to discuss whether to conduct additional
Development activities for a Related Compound (other than the designated Development Candidate for a Program or a Program Compound for a Continuation Program) for a Program; 

(e) in conjunction with the JRC, approve for which Indication(s) in the Field the first IND should be filed for Program Compounds or
Development Candidates of Programs; 
 (f) in conjunction with the JRC, discuss additional Indications for Development of Program Compounds
or Development Candidates of Programs; 
 (g) in conjunction with the JRC, oversee, review and coordinate process research and development
activities (including Manufacturing and formulation development activities); 
 (h) in conjunction with the JRC, oversee and coordinate the
Parties’ activities with respect to the Manufacture of pre-clinical and clinical supply of Program Compounds and Program Products; 

(i) oversee the initial development of any biomarkers; 

(j) in conjunction with the JRC, provide strategic guidance, and coordinate efforts between the Parties, with respect to any Publications and,
by mutual agreement, approve requests for Publication, from any Party, according to the Publication Guidelines and Section 8.4 hereof; 

(k) discuss and attempt to resolve any disputes in the JDC; and 

  
 - 41 - 

 (l) perform such other duties as are specifically assigned to the JDC under this Agreement
or any Development & Commercialization Agreement. 
 4.4.3 Duties Post Opt-In Right
Exercise by Celgene. The JDC shall, solely with respect to any Shared Program under an executed Co-Development and Co-Commercialization Agreement: 

(a) review and recommend to the JSC approval of the initial Development Plan (as provided in the applicable
Co-Development and Co-Commercialization Agreement) and any proposed updates or amendments to the Development Plan (and applicable Development Budget) (each as defined in
Appendix A-1 or Appendix A-2, as applicable) as needed; 

(b) oversee, review, coordinate and provide strategic guidance to the Parties on the Development of the
Co-Co Candidates and Shared Products (each as defined in Appendix A-1 or Appendix A-2, as applicable), including
assigning activities to be performed by each Party, subject to the provisions of the applicable Co-Development and Co-Commercialization Agreement; 

(c) review and coordinate the Parties’ Development activities under the applicable Co-Development
and Co-Commercialization Agreement; 
 (d) subject to and within the parameters of each Development
Plan (i) oversee the implementation of the Development Plan (including evaluation of clinical trial protocols and review of the conduct of clinical trials conducted pursuant to the Development Plan); and (ii) oversee and approve the
overall strategy and positioning of all material submissions and filings with the applicable Regulatory Authorities; 
 (e) oversee the
Development of any Companion Diagnostics, including the Development of any biomarkers; 
 (f) oversee and review (in conjunction with the
JCC) formulation and Manufacturing development studies, together with associated regulatory activities; 
 (g) oversee and review the
Parties’ activities with respect to Manufacturing of Co-Co Candidates and Shared Products for Development purposes, including in conjunction with the JCC,
pre-clinical and clinical supply; 
 (h) develop and approve a publication plan for any Publications
made prior to the First Commercial Sale (as defined in Appendix A-1 or Appendix A-2, as applicable) of a Shared Product; 

(i) discuss and attempt to resolve any disputes in the JDC; and 

(j) perform such other duties as are specifically assigned to the JDC under the applicable
Co-Development & Co-Commercialization Agreement. 

  
 - 42 - 

 4.5 Joint Commercialization Committee. No later than the earlier of (a) the date
upon which the Parties commence the [***] under a Co-Development and Co-Commercialization Agreement, or (b) the date upon which the Parties commence the [***] under
a Co-Development and Co-Commercialization Agreement, or within [***] days after request by any Party if requested by any Party earlier, the Parties shall establish the
JCC. The Parties intend that the JCC shall have the responsibility for overseeing the Commercialization of Shared Products under the Collaboration pursuant to the terms of each Co-Development and Co-Commercialization Agreement. 
 4.5.1 Meetings. The first scheduled meeting of the JCC shall
be held no later than [***] days after establishment of the JCC unless otherwise agreed by the Parties. After the first scheduled meeting of the JCC until the JCC is disbanded, the JCC shall meet in person or telephonically at least once each
Calendar Quarter, as further provided in Section 4.8. The JCC shall disband upon the expiration or termination of all Co-Development and Co-Commercialization
Agreements. Each Party will bear all expenses it incurs in regard to participating in all meetings of the JCC, including all travel and living expenses. 

4.5.2 Duties. The JCC shall, with respect to each Co-Development and Co-Commercialization Agreement: 
 (a) approve the initial Commercialization Plan (as defined in
Appendix A-1 or Appendix A-2, as applicable) for each Shared Product and, each year thereafter, shall review and approve the Commercialization Plan for the
then-current Calendar Year and the next succeeding Calendar Year; 
 (b) oversee implementation of the Commercialization Plan; 

(c) review and coordinate the Commercialization activities of Celgene and Vividion with respect to Shared Products, including pre-launch and post-launch activities in the United States; 
 (d) review and comment on approaches and
plans proposed by the applicable Lead Party in the relevant portion of the Territory (each as defined in Appendix A-1 or Appendix A-2, as applicable) for
pricing for Shared Products, including pricing of Shared Products included in bundles of products sold to purchasers, in the relevant portion of the Territory; 

(e) discuss any branding or co-branding matters; 

(f) establish target numbers regarding reach and frequency of sales performance; 

(g) oversee and coordinate the commercial supply of Program Compounds and Program Products; 

(h) discuss and attempt to resolve any disputes in the JCC; and 

(i) perform such other responsibilities as may be set forth in the applicable Co-Development and
Co-Commercialization Agreement or mutually agreed by the Parties from time to time. 

  
 - 43 - 

 
For purposes of clarity, the JCC shall not have any authority beyond the specific matters set forth in this Section 4.5. In any case where a matter within the JCC’s authority arises,
the JCC shall convene a meeting and consider such matter as soon as reasonably practicable, but in no event later than [***] days after the matter is first brought to the JCC’s attention (or, if earlier, at the next regularly scheduled JCC
meeting). 
 4.6 Joint Patent Committee. 

4.6.1 Establishment. The initial member of the JPC for each Party will be determined by each Party, respectively, within [***] days
after the Effective Date. The Parties intend that the JPC shall have the responsibility for sharing information and coordinating Patent Prosecution matters involving Vividion Patents, Celgene Patents, Patents included in the Celgene Collaboration
Intellectual Property and Joint Collaboration Patents. 
 4.6.2 Duties. The JPC shall: 

(a) discuss the current status of all Vividion Patents, Celgene Patents, Patents included in the Celgene Collaboration Intellectual Property
and Joint Collaboration Patents; 
 (b) discuss filing and claiming strategies involving any Vividion Patents, Celgene Patents, Patents
included in the Celgene Collaboration Intellectual Property or Joint Collaboration Patents, whether existing as of the Effective Date or filed after the Effective Date; 

(c) coordinate the timing and conduct of transfer of the Parties’ responsibilities under each
Co-Development and Co-Commercialization Agreement with respect to Prosecution; 

(d) coordinate the Parties’ respective activities in preparation for potential litigation involving the assertion of any Vividion
Patents, Celgene Patents, Patents included in the Celgene Collaboration Intellectual Property or Joint Collaboration Patents; 
 (e) discuss
and attempt to resolve any disputes in the JPC; and 
 (f) perform such other duties as are specifically assigned to the JPC under this
Agreement or any Co-Development and Co-Commercialization Agreement. 

4.7 Alliance Managers. Each Party shall appoint one designated representative to serve as an alliance manager (“Alliance
Manager”) with responsibility for being the primary point of contact between the Parties with respect to the Collaboration. The Alliance Managers shall attend JSC, JRC, JDC, JCC and JPC meetings, as necessary, as non-voting observers. Nothing herein shall prohibit a Party from appointing its Alliance Manager as a member of one or more Committees. 

4.8 General Committee Membership and Procedures. 

  
 - 44 - 

 4.8.1 Committee Membership. Each Committee shall each be composed of three
(3) representatives from each of Celgene and Vividion (provided that the JPC shall be composed of one (1) representative from each of Celgene and Vividion), each of which representatives shall be of the seniority and
experience appropriate for service on the applicable Committee in light of the functions, responsibilities and authority of such Committee and the status of Development of the Program Products being pursued hereunder from time to time. Each Party
may replace any of its representatives on any Committee at any time with prior written notice to the other Party; provided that such replacement meets this standard. Each Committee shall appoint a chairperson from among its members,
with the chairperson for the JSC, JRC and JDC being a representative from Vividion. The JSC shall appoint the chairpersons for the JCC and the JPC. Within [***] days following each Committee meeting, the chairperson of the applicable Committee shall
circulate to all Committee members a draft of the minutes of such meeting. The Committee shall then approve, by mutual agreement, such minutes within [***] days following circulation. 

4.8.2 Committee Meetings. 

(a) The JSC and JRC shall hold an initial joint meeting within [***] days after the Effective Date or as otherwise agreed by the Parties. The
JDC shall meet at the time the JDC is formed in accordance with Section 4.4.1. Thereafter, each Committee shall meet at least once every Calendar Quarter, unless the respective Committee members otherwise agree. All Committee meetings shall be
conducted in person or, for two of such meetings each year, by teleconference, unless otherwise determined by the applicable Committee. 

(b) Unless otherwise agreed by the Parties, all in-person meetings for each Committee shall be held on
an alternating basis between Vividion’s facilities in San Diego, California (or such future location as Vividion’s facilities may move to) and Celgene’s facilities in Summit, New Jersey, Seattle, Washington, San Francisco, California
or San Diego, California, as determined by Celgene (or such future location as Celgene’s facilities may move to). A reasonable number of other representatives of a Party may attend any Committee meeting as
non-voting observers; provided that such additional representatives are under obligations of confidentiality and non-use applicable to the Confidential
Information of the other Party that are at least as stringent as those set forth in ARTICLE VIII; and provided further that the Parties, reasonably in advance of the applicable Committee meeting, approve the list of non-voting observers to attend such meeting. Each Party shall be responsible for all of its own personnel and travel costs and expenses relating to participation in Committee meetings. 

4.9 Responsibilities under Specific Agreements. Following the execution of a Development & Commercialization Agreement for a
given Program: 
 4.9.1 License Agreement. After the Parties have entered into a License Agreement to govern the further Development
and Commercialization of Licensed Products under a specified Program, no Committee shall have any review or decision-making authority with respect to such Licensed Products. 

4.9.2 Co-Development and Co-Commercialization Agreement.
After the Parties have entered into a Co-Development and Co-Commercialization Agreement to govern the further Development and Commercialization of Shared Products for a
specified Program, the Committees other than the JRC shall continue to have review and oversight of the Development, Manufacture and Commercialization of such Shared Products as set forth in this Agreement and the applicable Co-Development and Co-Commercialization Agreement. 
  

  
 - 45 - 

 4.10 Decision-Making. 

4.10.1 Committee; Referral to JSC and to Patent or Executive Officers. All decisions of a Committee shall be made by unanimous vote,
with each Party’s Representatives collectively having one (1) vote, and shall be set forth in minutes approved by both Parties. Upon [***] Business Days prior written notice, any Party may convene a special meeting of a Committee for the
purpose of resolving any failure to reach agreement on a matter within the scope of the authority and responsibility of such Committee. No Committee shall have the authority to resolve any dispute involving the breach or alleged breach of this
Agreement and shall not have any power to amend, modify or waive the terms of this Agreement (including any amendment of the Development Candidate Criteria), any Development & Commercialization Agreement or any other agreement between the
Parties, or to alter, increase, expand or waive compliance by a Party with a Party’s obligations under this Agreement or any Development & Commercialization Agreement. If the JRC, JDC, JCC or JPC is unable to reach agreement on any
matter so referred to it for resolution by one or both Parties within [***] Business Days after the matter is so referred to it, such matter shall be referred to the JSC for resolution. If the JSC is unable to reach agreement on any matter within
[***] Business Days after the matter is referred to it or first considered by it, such matter shall be referred to the Executive Officers for resolution; provided, however, that, with respect to matters within the scope of the
authority and responsibility of the JPC, such matters shall be referred to the Patent Officers. 
 4.10.2 Decision-Making Authority.
If the matter is not resolved by the Executive Officers or Patent Officers, as applicable, after discussions between such Executive Officers or Patent Officers, as applicable, within [***] Business Days after referral to the Executive Officers or
Patent Officers, as applicable, then, on a Program-by-Program basis, subject to Section 4.11 and except as otherwise provided herein (a) Vividion’s
Executive Officer or Patent Officer, as applicable, shall have the right to decide the unresolved matter as to each Program (other than a CCB Program after execution of the applicable CCB Program MTA) with respect to which the Parties have not
executed a Development & Commercialization Agreement, (b) the right to decide the unresolved matter as to any Program with respect to which the Parties have executed a Development & Commercialization Agreement shall be as set
forth in such Development & Commercialization Agreement and (c) the right to decide the unresolved matter as to each CCB Program after execution of the applicable CCB Program MTA shall be as provided in the CCB Program MTA. 

4.10.3 Notwithstanding the foregoing, no Party shall have the right to finally resolve a dispute pursuant to Section 4.10.2: 

(i) in a manner that excuses such Party from any of its obligations specifically enumerated under this Agreement or any Development &
Commercialization Agreement; 

  
 - 46 - 

 (ii) in a manner that negates any consent rights or other rights specifically allocated to
the other Party under this Agreement or any Development & Commercialization Agreement; 
 (iii) to resolve any dispute involving
the breach or alleged breach of this Agreement or any Development & Commercialization Agreement; 
 (iv) to resolve a matter if the
provisions of this Agreement or any Development & Commercialization Agreement specify that unanimous or mutual agreement of the Parties or a Committee, or consent of the other Party, is required for such matter (including for clarity the
substitution or addition of any Deal Targets or Deal E3 Ligases pursuant to Section 2.2); 
 (v) to resolve a matter submitted to a
Scientific Panel for resolution, in accordance with terms of this Agreement or any Development & Commercialization Agreement; 

(vi) in a manner that would require the other Party to perform any act that is inconsistent with any Law; 

(vii) to determine whether or not a milestone event has been achieved under a Development & Commercialization Agreement; or 

(viii) otherwise expand a Party’s rights or reduce or increase a Party’s obligations under this Agreement or any
Development & Commercialization Agreement. 
 4.11 Scope of Governance. Notwithstanding the creation of each of the
Committees, each Party shall retain the rights, powers and discretion granted to it under this Agreement (including, in the case of Celgene, Celgene’s right to Develop a CCB Program pursuant to Section 2.4, to designate a Continuation
Program pursuant to Section 2.6.1, and to elect whether to exercise Opt-In Rights pursuant to Section 3.1), and no Committee shall be delegated or vested with rights, powers or discretion unless such
delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. The Parties understand and agree that issues to be formally decided by a particular Committee are only those specific issues that are expressly
provided in this Agreement or any Co-Development and Co-Commercialization Agreement to be decided by such Committee, as applicable. 

4.12 Vividion Right to Discontinue Participation. Notwithstanding anything in this ARTICLE IV to the contrary, Vividion shall have the
right to discontinue its participation in, and to not appoint members to, any Committee or any subcommittee or project team upon [***] days prior written notice to Celgene if, but only if, at all relevant times during the Research Term Vividion
shall have selected one or more independent Third Parties who will at all relevant times during the Research Term act as a representative on the JSC in place of Vividion’s representative (provided that such Third Party is not a
competitor to Celgene), subject to Celgene’s prior written consent, such consent not to be unreasonably withheld, and such Third Party representatives shall constitute Vividion’s members on such Committee. Any such independent Third Party
representatives designated by Vividion pursuant to the immediately preceding sentence shall have the same authority as Vividion for purposes of this ARTICLE IV. In the event Vividion elects to have a Third Party act as a representative on the JSC in
place of Vividion’s representative pursuant 

  
 - 47 - 

 to this Section 4.12, the Parties understand and agree that Celgene shall not have sole decision-making
authority or control of the JSC. If, at any time, following issuance of such a notice, Vividion wishes to resume participation in any Committee or Subcommittee, Vividion shall notify Celgene in writing and, thereafter, Vividion’s
representatives to such Committee or Subcommittee shall be entitled to attend any subsequent meeting of such Committee or Subcommittee and to participate in the activities of, and decision-making by, such Committee or Subcommittee as provided in
this ARTICLE IV as if such notice had not been issued by Vividion pursuant to this Section 4.12. If Vividion discontinues participation in, or does not appoint members (including a Third Party representative as provided above) to, any Committee
or any Subcommittee or project team, (a) it shall not be a breach of this Agreement; (b) no consideration shall be required to be returned; (c) unless and until such members are appointed, Celgene may unilaterally discharge the roles
of such Committee, Subcommittee or project team, as applicable, for which members were not appointed, including making in Celgene’s sole discretion all decisions of such Committee, Subcommittee, or project team, including decisions requiring
mutual agreement; provided that Celgene shall not unilaterally discharge the roles of such Committee, Subcommittee or project team, as applicable, as permitted under this ARTICLE IV unless Vividion has not appointed any members within
[***] days after Celgene has completed its appointment of its members; and (d) Vividion shall abide by all decisions made by Celgene on behalf of the applicable Committee, Subcommittee, or project team and shall continue to perform its
obligations hereunder. If Vividion thereafter appoints members to a Committee, Subcommittee or project team, Celgene shall no longer have the unilateral right to discharge the role of such Committee, Subcommittee or project team, as applicable, and
the applicable Committee, Subcommittee or project team, as applicable, shall be re-formed. 
 ARTICLE
V 
 LICENSES; EXCLUSIVITY 

5.1 Licenses. 
 5.1.1
License to Vividion. On a Program-by-Program basis, commencing on the Effective Date and extending until expiration of (a) the earlier of (i) expiration
of the Research Term and (ii) the Opt-In Term or (b) solely with respect to a Continuation Program, the Continuation Term Period, subject to the terms and on the conditions set forth in this
Agreement, Celgene hereby grants and shall cause (within [***] days after the Effective Date) its Affiliates to grant to Vividion a non-exclusive, worldwide, royalty-free right and license, with the right to
grant sublicenses (subject to Section 5.1.4), under the Celgene Intellectual Property, Celgene Collaboration Intellectual Property and Celgene’s interest in the Joint Collaboration IP, solely to permit Vividion to perform its obligations
under the Research Plan for each Program that is subject to an Opt-In Right exercisable by Celgene under Section 3.1 to Develop or Manufacture, for purposes of such Program, Program Compounds or Program
Products during the Opt-In Term. With respect to Celgene Intellectual Property, Celgene Collaboration Intellectual Property or Joint Collaboration IP that also Covers the manufacture, use, offer for sale, sale
or importation of any pharmaceutical product or compound owned or otherwise Controlled by Celgene (each, a “Celgene Independent Product”), such license granted in this Section 5.1.1 shall not include a license to make,
manufacture, use, offer for sale, sell or import such Celgene Independent Product, except as mutually agreed in writing between the Parties. 

  
 - 48 - 

 5.1.2 License to Celgene. 

(a) On a Program-by-Program basis, commencing on the Effective
Date until the expiration of the Opt-In Term, subject to the terms and on the conditions set forth in this Agreement, Vividion hereby grants to Celgene a non-exclusive,
worldwide, royalty-free right and license, with the right to grant sublicenses (subject to Section 5.1.4), under the Vividion Intellectual Property and Vividion’s interest in the Joint Collaboration IP, solely to permit Celgene to Develop
CCB Programs and to perform its obligations under the Research Plan for each Program that is subject to an Opt-In Right exercisable by Celgene under Section 3.1 to Develop or Manufacture, for purposes of
such Program, Program Compounds or Program Products during the Opt-In Term. 
 5.1.3 Additional
Licenses. Each Development & Commercialization Agreement will specify additional licenses for the Development, Manufacture or Commercialization of Licensed Candidates, Licensed Products, Co-Co
Candidates and Shared Products (each as defined in Appendix A-1, Appendix A-2, Appendix B-1 or Appendix B-2, as applicable) for the Programs that are subject to such agreement. 
 5.1.4 Sublicenses.
Vividion shall have the right to grant sublicenses under the rights granted to it under Section 5.1.1 to its Affiliates and Third Party contractors, and Celgene shall have the right to grant sublicenses under the rights granted to it under
Section 5.1.2 to its Affiliates and Third Party contractors. Each such sublicense granted by any Party shall be subject to and consistent with the terms and conditions of this Agreement, and each Party shall provide the other Party with an
unredacted copy of such sublicense. 
 5.1.5 Rights Retained by the Parties. For purposes of clarity, each Party retains all rights
under Know-How and Patents Controlled by such Party not expressly granted to the other Party pursuant to this Agreement. 

5.1.6 No Implied Licenses. Except as explicitly set forth in this Agreement, no Party shall be deemed by estoppel, implication or
otherwise to have granted the other Party any license or other right to any intellectual property of such Party. 
 5.1.7
Section 365(n) of the Bankruptcy Code. All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as
defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any
Bankruptcy Code, such Party shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than:
(a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under the Agreement, or (b) if not delivered under clause (a), upon the rejection of this
Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. As used
herein, “Bankruptcy Code” means the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over a Party or its assets. 
  

  
 - 49 - 

 5.1.8 America Invents Act (“AIA”). Notwithstanding anything to the contrary
in this ARTICLE V, no Party will have the right to make an election under 35 USC § 102(b)(2)(C) or 35 USC § 102(c) when exercising its rights under this ARTICLE V without the prior written consent of the other Party, which will not be
unreasonably withheld, conditioned or delayed. With respect to any such permitted election, the Parties will use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support
thereof. The Parties acknowledge and agree that this Agreement or any Development & Commercialization Agreement is deemed a “joint research agreement” as defined in 35 USC § 100(h). Notwithstanding the foregoing, the other
Party’s consent under this Section 5.1.8 will not be required in connection with filing a terminal disclaimer to overcome an obviousness-type double patenting rejection in any patent application claiming a Program Compound, Development
Candidate, Program Product, or uses thereof and for which an election under 35 USC § 102(b)(2)(C) or 35 USC § 102(c) has been made, provided that the Parties shall first agree on terms and conditions under which the Patent
subject to such terminal disclaimer and the Patent over which such Patent is terminally disclaimed are not separately enforced, as set forth in 37 CFR § 1.321(d)(3). 

5.1.9 Recording. If Celgene deems it necessary or desirable to register or record this Agreement or any Development &
Commercialization Agreement or evidence of this Agreement or any Development & Commercialization Agreement with any patent office or other appropriate Governmental Authority in one or more jurisdictions in the Territory, Vividion will
reasonably cooperate to execute and deliver to Celgene any documents accurately reflecting or evidencing this Agreement or any Development & Commercialization Agreement that are necessary or desirable, in Celgene’s reasonable judgment,
to complete such registration or recordation, provided that the Parties first mutually agree on the contents of such documents. Celgene will reimburse Vividion for all reasonable out-of-pocket costs, including attorneys’ fees, incurred by Vividion in complying with the provisions of this Section 5.1.9 within thirty [***] after receipt of an invoice therefor. 

5.2 Exclusivity. 
 Vividion. During
the Research Term and, if applicable, the Continuation Term Period, Vividion and its Affiliates shall not (except as otherwise expressly permitted in this Agreement or any Development & Commercialization Agreement): (a) [***] or (b) [***];
provided, however, that (y) [***] and (z) [***]. The Parties understand and agree that Vividion shall be entitled to research, develop, manufacture, and commercialize pharmaceutical products outside the scope of this Collaboration.

 5.2.1 Certain Exceptions to Exclusivity. 

(a) Incidental Discoveries. Vividion shall be deemed not to be, directly or indirectly (whether such activities are conducted
internally or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions of this Section 5.2 

  
 - 50 - 

 
as a result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a therapeutic modality resulting from such research program or discovery effort)
that has as its specified and primary goal, as evidenced by laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to Develop compounds that are not within the prohibitions set forth in this Section 5.2. 

(b) Academic Collaborations. Notwithstanding the provisions of Section 5.2.1, Vividion shall be permitted to perform any of the
activities that would otherwise be prohibited under Section 5.2.1 if such activities are (i) the subject of an existing agreement between Vividion and an academic institution or academic collaborator entered into prior to the Effective
Date, provided that Vividion shall not be permitted to amend any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the Effective Date with respect to
(A) ownership and licenses of pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of activities under such agreement,
(B) rights regarding publication of the results arising pursuant to the conduct of activities under such agreement, and (C) confidentiality obligations (collectively, (A) through (C), the “Academic Essential
Provisions”), or (ii) the subject of a new agreement entered into between Vividion and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic Essential Provisions consistent
with the terms and conditions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the Effective Date; provided that, if any Academic Essential Provisions of an amendment
described in (i) or an agreement described in (ii) would not be consistent with the Academic Essential Provisions of the agreements between Vividion and an academic institution or academic collaborator entered into prior to the Effective
Date, Vividion shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of Celgene. 

(c) Competitive Programs. Section 5.2.1 shall not apply if, during the Term, Vividion or any of its Affiliates (other than in a
Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this Section 5.2 by Vividion or its
Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, if Vividion is engaged in a Competitive Program, then Vividion shall, within [***] days after the date of such
merger, consolidation or acquisition, notify Celgene 

  
 - 51 - 

 
that it intends to either: (i) terminate, or cause its relevant Affiliate to terminate, the Competitive Program or (ii) divest, or cause its relevant Affiliate to divest, whether by
license or otherwise, the Competitive Program. If Vividion notifies Celgene within such [***] day period that it intends to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, Vividion or its relevant Affiliate, shall
(A) terminate such Competitive Program as quickly as possible, and in any event within [***] days (unless applicable Law requires a longer termination period) after Vividion delivers such notice to Celgene; and (B) confirm to Celgene when
such termination has been completed, and Vividion’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period shall not constitute a breach of Vividion’s exclusivity obligations under
Section 5.2.1. If Vividion notifies Celgene within such [***] day period that it intends to divest such Competitive Program, Vividion or its relevant Affiliate shall use all reasonable efforts to effect such divestiture as quickly as possible,
and in any event within [***] days after Vividion delivers such notice to Celgene, and shall confirm to Celgene when such divestiture has been completed. If Vividion or its relevant Affiliate fails to complete such divestiture within such [***] day
period, but has used reasonable efforts to effect such divestiture within such [***] day period, then, unless otherwise required by applicable Law, such [***)] day period shall be extended for such additional reasonable period thereafter as is
necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided, however, that such additional [***] day period shall be extended for such period as is necessary to obtain
any governmental or regulatory approvals required to complete such divestiture if Vividion or its relevant Affiliate is using good faith efforts to obtain such approvals. The continuation by Vividion of the Competitive Program during such
divestiture period shall not constitute a breach of Vividion’s exclusivity obligations under 5.2.1. 
 (d) Certain Permitted
Activities. 
 (i) The restrictions set forth in Section 5.2.1 shall not be deemed to prevent any Party or its respective
Affiliates from (A) fulfilling its obligations under this Agreement, or (B) engaging any subcontractors in accordance with Section 2.10 or academic collaborators in accordance with Section 5.2.2(b). 

(ii) If a Change of Control occurs with respect to Vividion with a Third Party and the Third Party already is conducting or is planning to
conduct activities that would cause Vividion or an Affiliate to violate Section 5.2.1 (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such initiation or
continuation will not constitute a violation of Section 5.2.1; provided that (A) none of the Vividion Intellectual Property or Joint Collaboration IP will be used in any Acquirer Program, (B) none of the other Patents or
Know-How licensed by any Party to the other Party pursuant to this Agreement will be used in any Acquirer Program, (C) no Confidential Information of Celgene will be used in any such Acquirer Program, and
(D) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program, including by the maintenance of separate lab notebooks and records (password-protected
to the extent kept on a computer network) and the use of separate personnel working on each of the activities under this Agreement, and the activities covered under such Acquirer Program (except that this requirement shall not apply to personnel who
have senior research management roles and not project level research roles, provided such personnel in senior research management roles are not directly involved in the
day-to-day activities under such Acquirer Program). 

  
 - 52 - 

 ARTICLE VI 

FINANCIAL TERMS 
 6.1
Upfront Payment. In consideration for the rights granted to Celgene under this Agreement, Celgene will make a one-time, non-refundable, non-creditable upfront payment of Ninety-Five Million U.S. Dollars ($95,000,000) to Vividion within ten (10) Business Days after the Effective Date. 

6.2 Equity Purchase Agreement. Celgene will purchase preferred stock of Vividion on the terms and pursuant to the conditions of the
Series A-3 Preferred Stock Purchase Agreement dated as of the Effective Date by and between Vividion and Celgene. 

6.3 Research Term Extension Fee. Celgene may elect, in its sole discretion, to extend the Research Term pursuant to Section 2.1.2
by making a non-refundable payment to Vividion of [***] Dollars ($[***]) for such two (2) year extension (the “Research Term Extension Fee”) within [***] days after receipt of
Vividion’s invoice therefor, in which case the Research Term will end on the sixth (6th) anniversary of the Effective Date. 
 6.4
CCB Program Fee. On a CCB Program-by-CCB Program basis, in consideration for the right to enter into a CCB Program MTA with respect to such CCB Program, upon
exercise of the Celgene CCB MTA Election with respect to such CCB Program in accordance with Section 2.4, Celgene shall, within [***] Business Days after entry into each such CCB Program MTA, pay to Vividion a
one-time, non-refundable, non-creditable payment equalling [***] U.S. Dollars ($[***]) (each, a “CCB Program Development
Fee”). 
 6.5 Opt-In Right Fees. 

6.5.1 Deal Target Programs, E3 Ligase Programs and Vividion Cereblon Programs. Upon exercise of its
Opt-In Right for a Deal Target Program, E3 Ligase Program or Vividion Cereblon Program, Celgene shall, within [***] Business Days after the Implementation Date of the applicable Development &
Commercialization Agreement for such Program, pay to Vividion a one-time, non-refundable, non-creditable payment of
(a) where the Parties are entering into a License Agreement for such Program, [***] U.S. Dollars ($[***]) or (b) where the Parties are entering into a Co-Development and Co-Commercialization Agreement for such Program, [***] U.S. Dollars ($[***]). 
 6.5.2 CCB Programs.
Upon exercise of its Opt-In Right for a CCB Program, Celgene shall, within [***] Business Days after the Implementation Date of the applicable License Agreement for such Program, pay to Vividion a one-time, non-refundable, non-creditable payment of [***] U.S. Dollars ($[***]). 

6.6 Binder Program Payments. If Vividion elects, in its sole discretion, to present any Listed E3 Ligands to Celgene, then the following
shall apply: 

  
 - 53 - 

 6.6.1 Fees. Upon exercise of its right to exclusively license the right to Develop,
Manufacture and Commercialize a given Listed E3 Ligand and all associated Binder Program Products pursuant to Section 2.14.3, Celgene shall, within [***] Business Days after the Implementation Date of the applicable Binder Program License
Agreement for such Listed E3 Ligand, pay to Vividion a one-time, non-refundable, non-creditable payment of [***] U.S. Dollars
($[***]). 
 6.6.2 Development Milestones. If Celgene exclusively licenses the right to Develop, Manufacture and Commercialize a
Listed E3 Ligand and all associated E3 Ligase Binder Products pursuant to Section 2.14.3, then Celgene shall pay Vividion the following one-time amounts after the first achievement by or on behalf of
Celgene or its Affiliates or sublicensees of the corresponding development and regulatory milestone events set forth below with respect to each Binder Program Product associated with the applicable Listed E3 Ligand. Notwithstanding anything to the
contrary contained herein, [***]. 
  

			
	Milestones	  	 Payment

(in US
Dollars)

	 (1) [***]
	  	$[***]
	 (2) [***]
	  	$[***]
	 (3) [***]
	  	$[***]
	 (4) [***]
	  	$[***]

 (i) Each milestone payment under this Section 6.6.2 shall be made within [***] days after the
achievement of the applicable milestone by Celgene or any of its Affiliates or sublicensees. 
 (ii) For clarity, the milestone payments set
forth in the table above in this Section 6.6.2 (to the extent payable) shall be paid only once with respect to each Binder Program Product, regardless of the number of Indications for which the milestone event may be achieved for such Binder
Program Product. 

  
 - 54 - 

 6.6.3 Sales Milestones. If Celgene exclusively licenses the right to Develop,
Manufacture and Commercialize a Listed E3 Ligand and all associated E3 Ligase Binder Products pursuant to Section 2.14.3, then Celgene shall make a non-refundable,
non-creditable, one-time payment of [***] US Dollars ($[***]) to Vividion within [***] days following the end of the Calendar Quarter in which aggregate Annual Net Sales
of any Binder Program Product associated with the applicable Listed E3 Ligand in the Territory first exceed [***] U.S. Dollars ($[***]). For clarity, the milestone payment set forth in this Section 6.6.3 shall be paid only once for each
applicable Binder Program Product. 
 6.6.4 Royalties. 

(a) Binder Program Products. If Celgene exclusively licenses the right to Develop, Manufacture and Commercialize a Listed E3 Ligand and
all associated E3 Ligase Binder Products pursuant to Section 2.14.3, then Celgene shall pay to Vividion royalties on worldwide Annual Net Sales of such licensed Binder Program Products, on a Binder Program Product-by-Binder Program Product basis, as set forth below: 
  

			
	Per Binder Program Product Worldwide Annual Net Sales	  	Royalty Rate
	Portion of Annual Net Sales of such Binder Program Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%
		
	Portion of Annual Net Sales of such Binder Program Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).	  	[***]%
		
	Portion of Annual Net Sales of such Binder Program Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

 provided, however, that the royalty rates set forth in the table above shall each be reduced by [***]
percent ([***]%) (e.g., [***]% shall become [***]%) for a given Binder Program Product if, prior to the [***] for such Binder Program Product, Celgene pays to Vividion [***] U.S. Dollars ($[***]). 

Each royalty rate set forth in the table above will apply only to that portion of the worldwide Annual Net Sales of a given Binder Program Product in the
Territory during a given Calendar Year that falls within the indicated portion. For example, if worldwide Annual Net Sales of a given Binder Program Product by Celgene and its Affiliates and sublicensees were $[***], then (provided that the royalty
rates have not been reduced as described in the preceding paragraph) the royalties payable with respect to such worldwide Annual Net Sales would be: 

  
 - 55 - 

 ($[***] x [***]%) + ($[***] x [***]%) = $[***]. 

(b) Binder Royalty Term. Subject to the penultimate sentence of this Section 6.6.4(b), royalties payable under this
Section 6.6.4 shall be paid by Celgene on a Binder Program Product-by-Binder Program Product and
country-by-country basis from the date of First Commercial Sale of each Binder Program Product in a country with respect to which royalty payments are due, until the
last to expire of any Valid E3 Ligase Claim of any Vividion Patents, Celgene License Collaboration Patents or Joint Patents Covering such Binder Program Product in such country(each such term with respect to a Binder Program Product and a country, a
“Binder Royalty Term”). Notwithstanding anything to the contrary contained herein, [***]. As used herein, “Valid E3 Ligase Claim” shall mean (i) a claim, as in existence as of the end of the Research Term, Covering
the [***] the E3 Ligase Binder Ligand of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with
respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) a claim, as in existence as of the end of
the Research Term, Covering the [***] the E3 Ligase Binder Ligand, of any patent application filed by a Person in good faith that has not been cancelled, withdrawn or abandoned, nor been pending for more than [***] years from the earliest filing
date to which such patent application or claim is entitled.***Expiration of Binder Royalty Term. Upon the expiration of the Binder Royalty Term with respect to a Binder Program Product in a country, the license granted by Vividion to Celgene
in the applicable Binder Program License Agreement shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Binder Program Product in such country. 

(c) Royalty Reduction for Generic Competition. If, on a Binder Program
Product-by-Binder Program Product, country-by-country and Calendar Quarter-by-Calendar Quarter basis, (i) a Generic Product(s) has a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%) or
(ii) a Generic Product(s) has a market share of more than [***] percent ([***]%); then, subject to Section 6.6.4(f), the royalties payable with respect to Annual Net Sales of such Binder Program Product pursuant to Section 6.6.4(a) in
such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies, respectively, of the royalties otherwise payable pursuant to
Section 6.6.4(a). Market share shall be based on the aggregate market in such country of such Binder Program Product and all applicable Generic Products (based on sales of units of such Binder Program Product and such Generic Product(s) in the
aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

  
 - 56 - 

 (d) Deduction for Third Party Payments. In the event that royalties are payable by
Celgene to Vividion with respect to any Binder Program Product in any country under this Section 6.6.4, then, subject to Section 6.6.4(f), Celgene shall have the right to deduct a maximum of [***] percent ([***]%) of any royalties or other
amounts actually paid by Celgene to a Third Party with respect to any license obtained with respect to such Binder Program Product in such country, but only to the extent that the Patents or Know-How licensed
under such other license are necessary for the Development, Manufacture or Commercialization of such Binder Program Product in such country, from royalty payments otherwise due and payable by Celgene to Vividion under this Section 6.6.4 with
respect to such Binder Program Product in such country, on a Binder Program Product-by-Binder Program Product and country-by-country basis. 
 (e) Cumulative Effect of Royalty Reductions. In no event shall
the royalty reductions described in this Section 6.6.4, alone or together, reduce the royalties payable by Celgene for a Binder Program Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts
otherwise payable by Celgene for such Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth
above in this Section 6.6.4(f), to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully
deducted, in all cases subject to the limitation set forth above in this Section 6.6.4(f). 
 6.7 Development Costs and Manufacturing
Costs. As between the Parties, except as expressly set forth herein or otherwise agreed by the Parties, (a) Vividion shall be solely responsible, on a
Program-by-Program basis, for any and all costs and expenses it incurs in connection with the conduct of Development and Manufacturing activities for such Program that
occur before Celgene exercises the Opt-In Right for such Program and (b) Celgene shall be solely responsible, on a CCB
Program-by-CCB Program basis, for any and all costs and expenses it incurs under a CCB Program MTA in connection with the conduct of Development and Manufacturing
activities for such CCB Program that occur before Celgene exercises the Opt-In Right for such CCB Program, after which the costs of further Development, Manufacturing and Commercialization activities, for the
applicable Products shall be borne by the Parties in accordance with the applicable Development & Commercialization Agreement. 

6.8 Financial Records. Vividion shall keep, and shall require its Affiliates to keep, complete and accurate books and records containing
all data reasonably required for the calculation and verification of amounts payable by Celgene under this ARTICLE VI in accordance with applicable Accounting Standards. Vividion shall keep, and shall require its Affiliates to keep, such books and
records for at least [***] years following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing and maintaining such
records. 

  
 - 57 - 

 6.9 Tax Matters. 

6.9.1 Withholding Taxes. 

(a) Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement such taxes as are required to be
deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will: (i) deduct those taxes from such payment, (ii) timely remit the taxes to
the proper taxing authority, and (iii) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee Party”) on a timely basis following that tax payment; provided, however,
that, before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction or withholding (and such notice, which shall set forth in reasonable detail the authority,
basis and method of calculation for the proposed deduction or withholding, shall be given a reasonable period of time before such deduction or withholding is required, in order for such Payee Party to obtain reduction of or relief from such
deduction or withholding). Each Party agrees to cooperate with the other Party in claiming refunds of, or reductions in, such deductions or withholdings under any applicable Law or treaty to ensure that any amounts required to be withheld pursuant
to this Section 6.9.1(a) are reduced to the fullest extent permitted by applicable Law. In addition, the Parties shall co-operate to minimize value added tax, sales and use tax, consumption and other
similar taxes (“Indirect Taxes”) in connection with this Agreement, as applicable. 
 (b) Tax Documentation. Each
Party has provided a properly completed and duly executed IRS Form W-9 or applicable Form W-8 to the other Party. Each Party and any other recipient of payments under
this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Party or as required by applicable Law, such other properly completed and duly executed documentation (for example, IRS Forms W-8 or W-9) as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made
without (or at a reduced rate of) withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 

6.9.2 Tax Cooperation. Upon request, each Party shall use Commercially Reasonable Efforts to cooperate with the other Party to mitigate,
reduce or eliminate adverse tax consequences to such other Party from changes in applicable Law, the use of present or future Affiliates of any Party to engage in transactions described in or contemplated by this Agreement, or from other activities
or transactions described in or contemplated by this Agreement. 
 6.10 Payments; Currency Exchange. Payments of all amounts payable
under this ARTICLE VI shall be made directly by Celgene to the bank account designated in writing by Vividion. Unless otherwise expressly stated in this Agreement, all amounts specified in, and all payments made under, this Agreement shall be in
United States Dollars. Conversion of sales recorded in local currencies to Dollars shall be performed in a manner consistent with Celgene’s normal practices used to prepare its audited financial statements for internal and external reporting
purposes. For clarity, Celgene sets currency transaction rates for the month on the last Business Day of the prior calendar month. Vividion has the right to verify that the exchange rates used by Celgene for a given month are within the trading
range of the last Business Day of the prior calendar month. 

  
 - 58 - 

 6.11 Late Payments. Celgene shall pay interest to Vividion on the aggregate amount of
any payments that are not paid on or before the date such payments are due under this Agreement at a rate per annum equal to the lesser of (x) [***], or (y) [***]; provided that, [***]. 

ARTICLE VII 
 INTELLECTUAL
PROPERTY 
 7.1 Ownership of Inventions. 

7.1.1 Inventions. Inventorship of Inventions shall be determined by application of U.S. patent law pertaining to inventorship, and
ownership shall follow inventorship. 
 7.1.2 Background IP. As between the Parties, each Party will retain all right, title and
interest in and to all Patents and Know-How Controlled by such Party (a) as of the Effective Date, and (b) during the Term that do not Cover Inventions and are not
Know-How arising in the course of the conduct of Collaboration activities, except, in each case, to the extent that any such rights are expressly licensed by one Party to the other Party under this Agreement
or any Development & Commercialization Agreement. 
 7.1.3 CCB Programs. As further set forth in the CCB Program MTA and
notwithstanding anything contained herein to the contrary, [***] shall solely own all Inventions and intellectual property rights therein, including any Patents or Know-How, that are discovered, developed,
generated or invented by or on behalf of [***], whether or not through the use of [***]. For clarity, the Parties understand and agree that the [***] shall be [***]. 

7.1.4 Joint Collaboration IP. Subject to Sections 7.1.1, 7.1.2, and 7.1.3, both Parties shall jointly own all Inventions and
intellectual property rights therein that are Joint Collaboration IP, such that each Party has an undivided one-half (1/2) interest in such Joint Collaboration IP, and, subject to any licenses granted by one
Party to the other under this Agreement or any Development & Commercialization Agreement, with no duty of accounting to the other Party and no requirement to obtain consent from the other Party in connection with any licenses granted by any
Party to Third Parties with respect to such Joint Collaboration IP. Enforcement of such Joint Collaboration IP shall be controlled by Section 7.4 or as otherwise agreed by the Parties in writing. To the extent necessary in any jurisdiction to
effect the foregoing, each Party hereby grants to the other Party a non-exclusive, royalty-free, fully-paid, worldwide license, with the right to grant sublicenses, to practice such Joint Collaboration IP for
any and all purposes, subject to any licenses granted by one Party to the other under this Agreement or any Development & Commercialization Agreement. 

  
 - 59 - 

 7.2 Prosecution of Patents. 

7.2.1 As between the Parties, the Party that owns or Controls (for the avoidance of doubt, other than by way of a license granted under this
Agreement) a Patent relating to a Program, unless otherwise explicitly provided under a Development & Commercialization Agreement, shall have the sole right (but not the obligation) to Prosecute such Patent, at such Party’s expense,
except that Vividion, unless otherwise explicitly provided under a Development & Commercialization Agreement, shall have the first right (but not the obligation) to Prosecute all Vividion Patents and Joint Collaboration Patents, at [***].
For any Vividion Patent that is first filed after the Effective Date (and except as otherwise mutually agreed), Vividion will not include in such Vividion Patent any claim directly claiming any Celgene Independent Product of which Vividion is aware
in advance that is Directed to [***], including methods of using a Program Compound in combination with any such Celgene Independent Product Directed to [***]. Notwithstanding anything in this Section 7.2.1 to the contrary, [***] shall have
final decision-making authority as to representations made to any patent office worldwide with respect to any Celgene Independent Products Directed to [***] or any Patents owned or otherwise controlled by Celgene claiming, Covering, or related to
such Celgene Independent Product; it being understood and agreed that, prior to [***] making any representations to any patent office worldwide with respect to any Celgene Independent Products Directed to [***] or any Patents owned or otherwise
controlled by Celgene claiming, Covering, or related to such Celgene Independent Product, [***] will provide such representations to [***] for its review. 

7.2.2 Until the earlier of (a) Celgene’s exercise of its Opt-In Right and entry into a
Development & Commercialization Agreement for a given Program or (b) the expiration of the Opt-In Exercise Window for such Program, Vividion shall, with respect to any Vividion Patent or Joint
Collaboration Patent related to such Program, (x) keep Celgene informed, via the JPC, as to material developments with respect to the Prosecution of such Vividion Patent or Joint Collaboration Patent, including by providing copies of all
substantive office actions or any other substantive documents in connection with such Vividion Patent or Joint Collaboration Patent that Vividion receives from any patent office, and (y) provide Celgene with a reasonable opportunity to comment
substantively on the Prosecution of such Vividion Patent or Joint Collaboration Patents prior to taking material actions (including the filing of initial applications) with respect to such Vividion Patent or Joint Collaboration Patent, and will in
good faith consider any comments made by and actions recommended by Celgene with respect thereto, provided that Celgene does so promptly and consistently with any applicable filing deadlines. Notwithstanding anything in this
Section 7.2.2 to the contrary, [***] shall have final decision-making authority as to representations made to any patent office worldwide with respect to any Celgene Independent Products Directed to [***] or [***], provided,
however, that [***] shall be responsible for any such costs associated with [***] enforcing this final decision-making authority pursuant to this Section 7.2.2. If, during the Term, 

  
 - 60 - 

 Vividion in any country in the Territory decides not to Prosecute and Maintain any Vividion Patent or Joint
Collaboration Patent, or intends to allow such Vividion Patent or Joint Collaboration Patent to lapse or become abandoned without having first filed a substitute, it shall notify and consult with Celgene of such decision or intention at least [***]
Business Days prior to the date upon which the subject matter of such Vividion Patent or Joint Collaboration Patent shall become unpatentable or shall lapse or become abandoned, and, subject to the rights of any owner of such Vividion Patent or
Joint Collaboration Patent in the case of any in-licensed Patents or Patents to which Vividion has an option to obtain a license, Celgene shall thereupon have the right (but not the obligation) to assume the
Prosecution and Maintenance thereof at Celgene’s own expense with counsel of its choice. 
 7.3 Defense of Claims Brought by Third
Parties. If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization of any Program Compound or Program Product infringes or misappropriates the intellectual property rights of any Third
Party, such Party shall promptly notify the other Party in writing. Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the Development & Commercialization Agreement for the
applicable Program (in each case, if applicable). 
 7.4 Enforcement and Defense of Patents. As between the Parties, the Party that
owns or Controls (for the avoidance of doubt, other than by way of the license granted under this Agreement) a Patent relating to a Program, and Vividion with respect to any Joint Collaboration Patent, unless otherwise explicitly provided under a
Development & Commercialization Agreement, shall have the sole right, but not the obligation, to institute, prosecute, and control any action or proceeding with respect to any infringement or Defense of such Patent, by counsel of its own
choice, in such Party’s own name and under such Party’s direction, control and expense. Notwithstanding anything in this Section 7.4 to the contrary, [***] shall have final decision-making authority as to representations made in any
proceedings under this Section 7.4 with respect to any Celgene Independent Products or Celgene CCB Program IP. 
 7.5 Third Party
Licenses. 
 7.5.1 Notice. On a Program-by-Program
basis, if, at any time during the Term, any Party reasonably determines that a license to any Third Party intellectual property rights is necessary or useful for the Development, Manufacture or Commercialization of any Program Compound or Program
Product that is the subject of Development or Manufacturing efforts under this Agreement (and that is the subject of an Opt-In Right), then such Party will promptly provide written notice thereof to the other
Party. 
 7.5.2 Pre-Opt-In Right. Prior to entry by
Celgene into a CCB Program MTA or the exercise of an Opt-In Right, on a Program-by-Program basis, Vividion shall have the right,
but not the obligation, at its sole discretion, to determine whether Vividion wishes to obtain one or more licenses, on commercially reasonable terms, from one or more Third Parties for the Development, Manufacture or Commercialization of any
Program Compound or Program Product that is the subject of such Program (a “Third Party License”) or take other appropriate measures in view of such Third Party rights. In each case, Vividion shall have the right to take such
actions as it deems appropriate with respect to such Third Party rights. 

  
 - 61 - 

 7.5.3
Post-Opt-In Right. On a Program-by-Program basis, following the exercise of the Opt-In Right for such Program, the rights and obligations of the Parties with respect to obtaining licenses from Third Parties or taking other appropriate measures in view of such Third Party rights shall be as set
forth in the Development & Commercialization Agreement for such Program. 
 7.5.4 Costs. Unless otherwise allocated in a
Development & Commercialization Agreement or agreed by the Parties in writing, the costs associated with negotiating and obtaining rights under any Third Party License obtained under this Section 7.5 shall be borne by the Party that
exercises its right to obtain such Third Party License, and the costs (including upfront, milestone, royalty and other payments) associated with exercising rights under any Third Party License obtained under this Section 7.5 shall be borne by
the Party exercising such rights pursuant to Section 7.5.2 or 7.5.3, as applicable. 
 7.6 Common Interest Agreement. The Parties
shall enter into the common interest agreement attached hereto as Appendix D on the Effective Date. 
 ARTICLE VIII 

CONFIDENTIALITY 
 8.1
Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its
Affiliates shall (x) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a
reasonable degree of effort, (y) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (z) not use such Confidential
Information for any purpose except those permitted by this Agreement or any Development & Commercialization Agreement (it being understood that this clause (z) shall not create or imply any rights or licenses not expressly granted
under this Agreement). No Confidential Information of the Disclosing Party or any of its Affiliates shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights
explicitly granted to the Receiving Party under this Agreement or a Development & Commercialization Agreement. “Confidential Information” shall exclude any information that: 

(a) was known by the Receiving Party or any of its Affiliates prior to its date of disclosure to the Receiving Party by or on behalf of the
Disclosing Party or any of its Affiliates, as established by written evidence; or 
 (b) is lawfully disclosed to the Receiving Party or any
of its Affiliates by sources other than the Disclosing Party or any of its Affiliates rightfully in possession of the Confidential Information; or 

(c) is or becomes published or generally known to the public through no fault or omission on the part of the Receiving Party or any of its
Affiliates or (sub)licensees; or 

  
 - 62 - 

 (d) is independently developed by or for the Receiving Party or any of its Affiliates
without reference to or reliance upon such Confidential Information, as established by written records. 
 8.2 Permitted Disclosure.
The Receiving Party may provide the Disclosing Party’s or any of the Disclosing Party’s Affiliates’ Confidential Information: 

(a) to the Receiving Party’s respective employees, consultants and advisors, and to the employees, consultants and advisors of such
Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement or any Development & Commercialization Agreement and have an obligation
to treat such information and materials as confidential under obligations of confidentiality and non-use no less stringent than those set forth in this ARTICLE VIII; 

(b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in order to seek or obtain approval to conduct clinical
trials or to gain Regulatory Approval with respect to any Program Compound(s) or Program Product(s), as contemplated by this Agreement or any Development & Commercialization Agreement; provided that such disclosure may be made
only following reasonable notice to the Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or approvals; or 

(c) if such disclosure is required by judicial order or applicable Law or to defend or prosecute litigation or arbitration; provided
that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such requirement, cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect
the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its applicable Affiliate(s)’) Confidential Information that the Receiving Party is legally required to furnish. 

8.3 Publicity; Terms of this Agreement; Non-Use of Names. 

8.3.1 Except as required by judicial order or applicable Law (in which case, Section 8.3.2 must be complied with) or as explicitly
permitted by this ARTICLE VIII, no Party shall make any public announcement concerning this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such
public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would like to make the public announcement (or, in extraordinary circumstances, such shorter period as required
to comply with applicable Law). Notwithstanding the foregoing, the Parties agree that Vividion may issue the press release attached hereto as Appendix E within [***] Business Days after the Effective Date. No Party shall use the name,
trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, any Party
may issue a press release or public announcement or make such other disclosure relating to this Agreement if the content of such press release, public announcement or disclosure (a) (i) does not consist of financial information and has
previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates, (ii) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or
(iii) if applicable as provided in Section 8.3.2, is contained in the Redacted Version of this Agreement, and (b) is material to the event or purpose for which the new press release or public announcement is made. 

  
 - 63 - 

 8.3.2 Notwithstanding the terms of this ARTICLE VIII: 

(a) Any Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the reasonable opinion of
such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other Governmental Authority. Notwithstanding the foregoing, before disclosing this
Agreement or any of the terms hereof pursuant to this Section 8.3.2, the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all exhibits and schedules) with
respect to any filings with the U.S. Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which securities issued by a Party or a
Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other Party, and the Parties
will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(b) Notwithstanding Section 8.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of
its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary
in the following instances: 
 (i) subject to Section 8.3.2(a), complying with applicable Laws (including the rules and regulations of
the SEC or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(ii) disclosure, solely on a “need to know basis,” to (A) Affiliates, subcontractors, advisors (including attorneys and
accountants), (B) subject to Section 8.3.2(b)(iii), investment bankers, and (C) in each case of (A) and (B) such Affiliates’, subcontractors’, advisors’ and investment bankers’, and each of the Parties’,
respective directors, employees, contractors and agents; provided that, in all cases of (A), (B) and (C), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this ARTICLE VIII (provided, however, that, in the case of prospective
investment bankers, the term of confidentiality may be [***] from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt, will not permit use of such Confidential
Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential
Information pursuant to this Section 8.3.2(b)(ii) or Section 8.3.2(b)(iii) to treat such Confidential Information as required under this ARTICLE VIII; and 

  
 - 64 - 

 (iii) in the case of any disclosure of this Agreement, or any executed
Development & Commercialization Agreement, to any actual or potential acquirer, assignee, licensee, licensor, investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted
Version, in each case, which version shall be agreed upon by the Parties in good faith (and, if Vividion does not then have securities listed or authorized for trading on the London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock
Market or any other stock exchange, the Parties hereby agree to prepare a Redacted Version promptly in good faith which redacts information as contemplated by this Agreement); it being understood and agreed that, in connection with a proposed Change
of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is in the final round of negotiations with such Third Party regarding
execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement or such Development & Commercialization Agreement, as applicable,
to such Third Party; provided that a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under obligations
of confidentiality not to disclose the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such licensors and
lenders. 
 (c) The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results and significant
developments regarding the Programs and other activities in connection with this Agreement and each Development & Commercialization Agreement that may include information that is not otherwise permitted to be disclosed under this ARTICLE
VIII, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and regulatory process, commercialization activities and the like. In addition to the
initial press release described in Section 8.3.1, a Party (the “Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the Development and regulatory process and
Commercialization activities, and in such event it shall first notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business Days in
advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with
as much advance notice as possible under the circumstances if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement
without such prior review by the other Party if (i) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the issuing Party and (ii) such press release
or public announcement does not materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the
Cooperating Party may have regarding the proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles to be observed in such
disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding
the Requesting Party’s business. 

  
 - 65 - 

 8.4 Publications. The Parties agree that decisions regarding the timing and content
of Publications shall be subject to the oversight and approval of the JDC and, as applicable, JRC, and no Party nor its Affiliates shall have the right to make Publications pertaining to any Program Compound(s), Program Product(s) or Program
Target(s) except as provided herein. If a Party or its Affiliates desire to make a Publication, such Party must comply with the following procedure: 

8.4.1 The publishing Party shall provide the JDC and, as applicable, JRC and the non-publishing Party
with an advance copy of the proposed Publication, and the JDC and, as applicable, JRC shall then have [***] days prior to submission for any Publication ([***] days in the case of an abstract or oral presentation) in which to determine whether the
Publication meets the Publication Guidelines and may be published and under what conditions, including (a) delaying sufficiently long to permit the timely preparation and filing of a patent application or (b) specifying changes the JDC or,
as applicable, JRC reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or license, including under this Agreement) in whole or in part to the non-publishing Party. 
 8.4.2 In addition, if the non-publishing
Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the
non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential Information of the
non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

8.4.3 Each Party shall have the right to present its Publications approved pursuant to this Section 8.4.3 at scientific conferences,
including at any conferences in any country in the world, subject to any conditions imposed by the JDC or, as applicable, JRC in its approval. 

8.4.4 Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Vividion Intellectual Property
that Vividion has licensed from a Third Party, its licensor(s) may have retained the right to publish certain information, and nothing in this Section 8.4.4 is intended to restrict the exercise of such rights; provided that, to
the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under its agreements with such Third Parties, exercise such rights after consultation with Celgene. 

8.4.5 Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Celgene Intellectual Property
or Celgene CCB Program IP that Celgene has licensed from a Third Party, its licensor(s) may have retained the right to publish certain information, and nothing in this Section 8.4.5 is intended to restrict the exercise of such rights;
provided that, to the extent that Celgene has the right to review and comment on any such publications, Celgene shall, to the extent permissible under its agreements with such Third Parties, exercise such rights after consultation with
Vividion. 
 8.4.6 For purposes of convenience, the JDC or, as applicable, JRC may delegate its responsibilities under this
Section 8.4.6 to one or more representatives of Vividion and Celgene. 

  
 - 66 - 

 8.4.7 Notwithstanding anything to the contrary in this Section 8.4, (a) upon
Celgene’s exercise of its Opt-In Right with respect to a Program, the publication provisions set forth in the applicable Development & Commercialization Agreement shall apply to such Program and
this Section 8.4 shall cease to apply to such Program and (b) the restrictions described in this Section 8.4 shall not apply to any Excluded Targets or Lapsed Programs. 

8.5 Term. All obligations under Sections 8.1, 8.2, 8.3 and 8.6 shall survive termination or expiration of this Agreement and shall
expire [***] years following termination or expiration of this Agreement. 
 8.6 Return of Confidential Information. 

8.6.1 Upon the expiration or termination of this Agreement, the Receiving Party shall return to the Disclosing Party all Confidential
Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: 

(a) any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of
the Disclosing Party or any of its Affiliates; and 
 (b) any Confidential Information of the Disclosing Party or any of its Affiliates (and
all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 
 8.6.2
Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies
and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any requested destruction of
Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

8.6.3 Nothing in this Section 8.6 shall require the alteration, modification, deletion or destruction of archival tapes or other
electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under
this ARTICLE VIII with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

8.6.4 Notwithstanding the foregoing, 

(a) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this ARTICLE VIII; and 
 (b) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents: 

  
 - 67 - 

 (i) to the extent reasonably required (A) to exercise the rights and licenses of the
Receiving Party expressly surviving expiration or termination of this Agreement; or (B) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(ii) to the extent it is impracticable to do so without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving Party shall
continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE VIII. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES 

9.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the Effective Date,
that: 
 9.1.1 Authority. It is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its
formation and has full corporate power and authority to enter into this Agreement or any applicable Development & Commercialization Agreement, and to carry out the provisions hereof or thereof, as applicable. 

9.1.2 Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement or any applicable Development & Commercialization Agreement, and the performance of its obligations hereunder or
thereunder, as applicable, have been obtained. 
 9.1.3 No Conflict. Notwithstanding anything to the contrary in this Agreement, the
execution and delivery of this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (a) do not and will not conflict with or
violate any requirement of applicable Laws existing as of the Effective Date and (b) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to
which it is a party or by which it or any of its Affiliates is bound, existing as of the Effective Date. 
 9.1.4 Enforceability. This
Agreement has been duly executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

9.1.5 Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in
the Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 

  
 - 68 - 

 9.2 Additional Vividion Representations. Vividion represents, warrants and covenants
to Celgene, as of the Effective Date, as follows: 
 9.2.1 Vividion possesses sufficient rights, authorizations and consents necessary to
grant all rights and licenses it purports to grant to Celgene with respect to the Vividion Intellectual Property under this Agreement. 

9.2.2 Vividion has not used, and during the Term will not knowingly use, any Know-How in a Program
conducted by Vividion that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder or under any Development &
Commercialization Agreement. 
 9.2.3 Vividion has not granted, and during the Term Vividion will not grant, any right or license to any
Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder or under any Development & Commercialization
Agreement. 
 9.2.4 There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings
or governmental investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion
to consummate the transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or any Program Target or Program
Compound. 
 9.2.5 To Vividion’s knowledge, the practice of the Vividion Intellectual Property as contemplated under this Agreement does
not (a) infringe any claims of any Patents of any Third Party or (b) misappropriate any Know-How of any Third Party. 

9.2.6 None of (a) the Vividion Patents owned by Vividion or both Controlled by and Prosecuted by Vividion and (b) to Vividion’s
knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination, opposition, interference or litigation proceedings. 

9.2.7 There is no agreement with any Third Party to which Vividion or any of its Affiliates is a party pursuant to which Vividion Controls any
Vividion Patent that is necessary or, to Vividion’s reasonable belief as of the Effective Date, reasonably useful to Develop, Manufacture or Commercialize any Program Compounds. 

9.2.8 Neither Vividion nor any of its Affiliates has granted any liens or security interests on the Vividion Intellectual Property and the
Vividion Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind, except in each case with respect to licenses, covenants not to sue, immunities from
suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration. 

9.2.9 Schedule 9.2.9 contains a complete and accurate list of all Patents owned by Vividion or its Affiliates as of the Effective Date
that are included in the Patents licensed 

  
 - 69 - 

 
hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 9.2.9, Vividion and its Affiliates do not own any Patent that
is necessary or, to Vividion’s reasonable belief as of the Effective Date, reasonably useful to Develop, Manufacture or Commercialize any Program Compounds. 

9.2.10 Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance of
this Agreement. 
 9.3 Covenants. 

9.3.1 Mutual Covenants. Each Party hereby covenants to the other Party that: 

(a) all employees of such Party or its Affiliates or Third Party subcontractors working under this Agreement, or any Development &
Commercialization Agreement, as applicable, will be under appropriate confidentiality provisions at least as protective as those contained in this Agreement, or any Development & Commercialization Agreement, as applicable, and, to the
extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; 

(b) to its knowledge, such Party will not (i) employ or use, nor hire or use any contractor or consultant that employs or uses, any
individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any Regulatory Authority outside the United States) or (ii) employ any
individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in each of subclauses (i) and (ii) in the conduct of its activities
under this Agreement or any Development & Commercialization Agreement, as applicable; 
 (c) neither such Party nor any of its
Affiliates shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder or
under any Development & Commercialization Agreement; 
 (d) such Party and its Affiliates shall perform their activities pursuant
to this Agreement or any Development & Commercialization Agreement, as applicable, in compliance (and shall ensure compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP, as
applicable, and with respect to the Development, Manufacturing and Commercialization activities hereunder; 
 (e) the Parties agree and
acknowledge that (A) the terms of this Agreement and (B) the terms of the License Agreement are not intended to give rise to, and shall not be treated by the Parties as giving rise to, in whole or in part, a partnership for U.S. federal
(or applicable state or local) income tax purposes, or for any other purposes, except as expressly provided in the Co-Development and Co-Commercialization Agreements. No
Party shall take any position, or cause or permit any of its Affiliates, to take any position inconsistent with this Section 9.3.1(e) for such purposes (including with respect to filing U.S. federal income tax returns and in the course of any
audit, review or litigation), unless otherwise required by applicable Law; and 

  
 - 70 - 

 (f) notwithstanding anything to the contrary in this Agreement, the License Agreements or
the Co-Development and Co-Commercialization Agreements, including the use therein of the term “option” (or any derivation thereof), the Parties agree and
acknowledge that the Opt-In Rights are not intended to be treated, and shall not be treated by the Parties, as options for U.S. federal (or applicable state or local) income tax purposes, and no Party shall
take any position, or cause or permit any of its Affiliates to take any position, inconsistent with this Section 9.3.1(f) for tax purposes (including with respect to filing U.S. federal income tax returns and in the course of any audit, review
or litigation), unless otherwise required by applicable Law. 
 9.3.2 Vividion Covenants During
Opt-In Term. Except to the extent expressly permitted under ARTICLE V or Section 12.4, on a Program-by-Program basis,
during the Opt-In Term, neither Vividion nor its Affiliates will, other than to an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign,
transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including
any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, any assets specifically related to such Program, including with respect to the applicable Program Compound(s), Program Product(s) and
then-identified Companion Diagnostic(s), or pre-clinical study or Clinical Trial results or other data specifically related to such Program, or any intellectual property specifically related to any of the
foregoing (with respect to each Program, the “Program Assets”) Controlled by Vividion, except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this
Agreement or any applicable Development & Commercialization Agreement with respect to such Program, (b) license or grant to any Third Party, or agree to license or grant to any Third Party, any rights to any Program Assets Controlled
by Vividion of such Program if such license or grant would fundamentally frustrate the purpose of this Agreement or any applicable Development & Commercialization Agreement with respect to such Program, or (c) disclose any Confidential
Information relating to the Program Assets Controlled by Vividion of such Program to any Third Party if such disclosure would fundamentally frustrate the purpose of this Agreement with respect to such Program. Vividion or its Affiliates shall have
the right to assign, transfer, convey or dispose of any assets specifically related to such Program to any Affiliate of Vividion, to the extent permitted by Section 12.4. 

9.3.3 Vividion Covenants During Binder Program Access Term. Except to the extent expressly permitted under Section 12.4, on an E3
Ligase Binder Program-by-E3 Ligase Binder Program basis, during the Binder Program Access Term, neither Vividion nor its Affiliates will, other than to an Affiliate of
Vividion who agrees in writing to be bound by the terms and conditions of this Agreement or, solely with respect to Pre-Existing Vividion E3 LDDs or Pre-Existing
Vividion Cereblon LDDs as a whole and not with respect to the E3 Ligase Binder Ligand individually, in the context of Developing, Manufacturing or Commercializing any applicable Pre-Existing Vividion E3 LDD or
Pre-Existing Vividion Cereblon LDD: 
 (a) assign, transfer, convey, encumber (including any liens
or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any
licenses, which are the subject of subsection (b), below) or dispose of, any assets specifically related to the E3 Ligase Binder Ligand(s) that are the subject of such E3 

  
 - 71 - 

 Ligase Binder Program, or pre-clinical study or Clinical Trial
results or other data specifically related to such E3 Ligase Binder Ligand(s), or any intellectual property specifically related to any of the foregoing (with respect to each E3 Ligase Binder Program, the “E3 Ligase Binder Program
Assets”) Controlled by Vividion, except to the extent such assignment, transfer, conveyance, encumbrance or disposition was made or occurs in the ordinary course of business and would not fundamentally frustrate the purpose of this
Agreement or any applicable E3 Ligase Binder Program License Agreement with respect to such E3 Ligase Binder Program; 
 (b) license or
grant to any Third Party, or agree to license or grant to any Third Party, any rights to any E3 Ligase Binder Program Assets Controlled by Vividion of such E3 Ligase Binder Program except to the extent such license was made or occurs in the ordinary
course of business and would not fundamentally frustrate the purpose of this Agreement or any applicable E3 Ligase Binder Program License Agreement with respect to such E3 Ligase Binder Program; or 

(c) disclose any Confidential Information relating to the E3 Ligase Binder Program Assets Controlled by Vividion of such E3 Ligase Binder
Program to any Third Party except to the extent such disclosure was made or occurs in the ordinary course of business and would not fundamentally frustrate the purpose of this Agreement or any applicable E3 Ligase Binder Program License Agreement
with respect to such E3 Ligase Binder Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to such E3 Ligase Binder Program to any Affiliate of Vividion, to the extent
permitted by Section 12.4. 
 9.3.4 Vividion Covenant During Term and Binder Program Access Term. Except as contemplated by this
Agreement, if the Parties enter into a Development & Commercialization Agreement for a non-LDD Co-Co Candidate or
non-LDD Licensed Candidate, as applicable, which includes any E3 Ligase Binders, then Vividion covenants and agrees (on behalf of itself and its Affiliates) that it shall not (by itself or with any Third
Party) use, Develop, or otherwise Commercialize the exact chemical matter of such E3 Ligase Binder (or any portion thereof other than the binding moiety of such E3 Ligase Binder) in any Compound, other than in the
Co-Co Candidates, Licensed Candidates or Program Compounds. 
 9.4 Disclaimer. Except as
otherwise expressly set forth in this Agreement or any executed Development & Commercialization Agreement, NO PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY
PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party
disclaims any warranties with regards to: (a) the success of any study or test, including any Program, commenced under this Agreement; (b) the safety or usefulness for any purpose of the technology or materials, including any Program
Compound, Program Product or Companion Diagnostic, it provides or discovers under this Agreement; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology
it provides or licenses to the other Party under this Agreement. 

  
 - 72 - 

 ARTICLE X 

INDEMNIFICATION; INSURANCE 

10.1 By Celgene. 
 10.1.1
Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless Vividion and its Affiliates and their respective directors, officers, employees and agents (the “Vividion Indemnified Parties”) from and
against any Damages arising out of any Claim relating to: 
 (a) any breach by Celgene of any of its representations, warranties or
obligations pursuant to this Agreement; or 
 (b) the gross negligence or willful misconduct of Celgene. 

10.1.2 In the event of any such Claim against any Vividion Indemnified Party by any Third Party, Vividion shall promptly, and in any event
within [***] Business Days, notify Celgene in writing of the Claim. Celgene shall have the right, exercisable by notice to Vividion within [***] Business Days after receipt of notice from Vividion of the Claim, to assume direction and control of the
defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Celgene agrees to pay all Damages relating to such matter, as evidenced in a written confirmation
delivered by Celgene to Vividion) with counsel selected by Celgene and reasonably acceptable to Vividion; provided that the failure to provide timely notice of a Claim shall not limit a Vividion Indemnified Party’s right for
indemnification hereunder except to the extent such failure results in actual prejudice to Celgene. The Vividion Indemnified Parties shall cooperate with Celgene and may, at their option and expense, be separately represented in any such action or
proceeding. Celgene shall not be liable for any litigation costs or expenses incurred by the Vividion Indemnified Parties without Celgene’s prior written authorization. In addition, Celgene shall not be responsible for the indemnification or
defense of any Vividion Indemnified Party to the extent arising from any negligent or intentional misconduct by any Vividion Indemnified Party or the breach by Vividion of any representation, obligation or warranty under this Agreement, or any
Claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 10.1. 

10.2 By Vividion. 
 10.2.1
Vividion agrees, at Vividion’s cost and expense, to defend, indemnify and hold harmless Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and
against any Damages arising out of any Claim relating to: 
 (a) any breach by Vividion of any of its representations, warranties or
obligations pursuant to this Agreement; 
 (b) the gross negligence or willful misconduct of Vividion; or 

  
 - 73 - 

 (c) the Development, Manufacture, Commercialization, use, sale or other disposition by
Vividion, its Affiliates, licensees (other than Celgene) or sublicensees (other than Celgene) of any Program Compound(s) or Program Product(s) that have reverted to Vividion pursuant to this Agreement. 

10.2.2 In the event of any such Claim against any Celgene Indemnified Party by any Third Party, Celgene shall promptly, and in any event within
[***] Business Days, notify Vividion in writing of the Claim. Vividion shall have the right, exercisable by notice to Celgene within [***] Business Days after receipt of notice from Celgene of the Claim, to assume direction and control of the
defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Vividion agrees to pay all Damages relating to such matter, as evidenced in a written confirmation
delivered by Vividion to Celgene) with counsel selected by Vividion and reasonably acceptable to Celgene; provided that the failure to provide timely notice of a Claim shall not limit a Celgene Indemnified Party’s right for
indemnification hereunder except to the extent such failure results in actual prejudice to Vividion. The Celgene Indemnified Parties shall cooperate with Vividion and may, at their option and expense, be separately represented in any such action or
proceeding. Vividion shall not be liable for any litigation costs or expenses incurred by the Celgene Indemnified Parties without Vividion’s prior written authorization. In addition, Vividion shall not be responsible for the indemnification or
defense of any Celgene Indemnified Party to the extent arising from any negligent or intentional misconduct by any Celgene Indemnified Party or the breach by Celgene of any representation, obligation or warranty under this Agreement, or any Claims
compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 10.2. 

10.3 Indemnification Following Exercise of an Opt-In Right. The Development &
Commercialization Agreements provide separately for each Party’s indemnification obligations with respect to each Program Compound and Program Product that is the subject of such agreement. 

10.4 Joint Defendants. Subject to any applicable Development & Commercialization Agreement, if any suit is brought against any
Party relating in any way to any Program Compound(s) or Program Product(s), and it is not clear from the allegations in the complaint or the known facts surrounding the allegations in the complaint as to whether a Claim exists for which there is a
right of indemnification pursuant to Section 10.1 or 10.2 above, then Vividion shall be responsible for controlling the defense of such suit in the first instance. During such period that Vividion is controlling such defense, with regard to the
costs of such defense, including attorneys’ fees, Celgene and Vividion each shall be responsible for fifty percent (50%) of all such costs. No settlement, consent judgment or other voluntary final disposition of any such suit may be entered
into without the prior written consent of Celgene, which consent shall not be unreasonably withheld or delayed. If, at any time in the course of such suit, it becomes apparent from discovery or otherwise that a Claim exists for which indemnification
may be obtained in accordance with Section 10.1 or 10.2, then the indemnification provisions of either Section 10.1 or 10.2, whichever is applicable, shall become applicable and govern further proceedings in the suit, and the Party
determined to be responsible shall reimburse the other Party for all prior costs incurred by such other Party for which indemnification should have been obtained in accordance with Section 10.1 or 10.2. 

  
 - 74 - 

 10.5 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF ARTICLE V OR ARTICLE
VIII, OR A PARTY’S LIABILITY PURSUANT TO ARTICLE III, SECTION 10.1, SECTION 10.2 OR SECTION 10.4, NO PARTY NOR ITS RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR
REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 
 10.6 Insurance. Vividion, beginning on [***] shall maintain
commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least $[***] per claim and annual aggregate. Vividion shall furnish to Celgene a certificate
of insurance evidencing such coverage. If such coverage is modified or cancelled, Vividion shall notify Celgene and promptly provide Celgene with a new certificate of insurance evidencing that Vividion’s coverage meets the requirements of this
Section 10.6. 
 ARTICLE XI 

TERM AND TERMINATION 
 11.1
Term; Expiration. Unless earlier terminated in accordance with this ARTICLE XI, the term of this Agreement (the “Term”) shall commence as of the Effective Date and remain in force until the later of (a) the expiration of
the last-to-expire of the following (i) the Opt-In Term, (ii) the Research Term, and (iii) the Continuation Term
Period; and (b) if one or more Opt-In Rights is exercised, the termination or expiration of the last to expire Development & Commercialization Agreement executed with respect to any Program
hereunder. 
 11.2 Termination for Convenience. Celgene may terminate this Agreement in its entirety (provided that
there are no Programs that are subject to any surviving Development & Commercialization Agreements) or with respect to one or more Programs (provided that such Program(s) are not subject to any surviving Development &
Commercialization Agreements) upon ninety (90) days’ prior written notice to Vividion hereunder at any time; provided that Celgene shall not have the right to terminate this Agreement until six (6) months following the
Effective Date (it being understood and agreed that Celgene shall be entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). For
the avoidance of doubt, any such termination of any particular Program(s) pursuant to this Section 11.2 shall not terminate any other Program(s). 

11.3 Termination for Breach. 

11.3.1 Material Breach. Subject to the other terms of this Agreement, this Agreement and the rights granted herein may be terminated by
either Vividion or Celgene (a) on a Program-by-Program basis prior to Celgene’s exercise of its Opt-In Right for such
Program, for the material breach of this Agreement in a manner that fundamentally frustrates the transactions 

  
 - 75 - 

 contemplated by this Agreement taken as a whole (each, a “Material Breach”) by the other
Party of this Agreement with respect to such Program, or (b) on a Program-by-Program basis after Celgene’s exercise of its
Opt-In Right for such Program, if all Development & Commercialization Agreements for such Program are terminated for Material Breach by a Party; provided in each of (a) or (b) that the breaching
Party has not cured such breach within ninety (90) days after the date of written notice to the breaching Party of such breach (or thirty (30) days in the case of a breach as a result of non-payment
of any amounts due under this Agreement or a Development & Commercialization Agreement, as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement with respect to a given Program, pursuant to this Section 11.3.1 with respect to such Program. For clarity, but subject to Section 11.3.2,
the Cure Period for any allegation made in good faith as to a Material Breach under this Agreement with respect to a given Program for events described in subsections (a) or (b) of this Section 11.3.1 will run from the date that written
notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement with respect to a given Program under this Section 11.3.1 shall become effective at the
end of the Cure Period, unless the breaching Party has cured any such breach or default prior to the expiration of such Cure Period, or, if such breach is not susceptible to cure within the Cure Period, then the
non-breaching Party’s right of termination shall be suspended only if and for so long as the breaching Party has provided to the non-breaching Party a written plan
that is reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five (225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. For
the avoidance of doubt, termination of any particular Program(s) pursuant to this Section 11.3.1 shall not terminate (i) this Agreement with respect to any other Program(s) or (ii) any Development & Commercialization
Agreement for any other Program. The Parties understand and agree that the totality of this Agreement with respect to a given Program, and the totality of the circumstances with respect to this Agreement with respect to a given Program, will be
taken into account and assessed as a whole for purposes of determining whether a breach is material under this Agreement with respect to a given Program. 

11.3.2 Disagreement as to Material Breach. If the Parties reasonably and in good faith disagree as to whether there has been a Material
Breach pursuant to either subsections (a) or (b) of Section 11.3.1, then subject to Section 12.1: (a) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within thirty
(30) days following such notice of alleged Material Breach for resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter, whether or
not a Material Breach has occurred pursuant to subsections (a) or (b) of Section 11.3.1, as applicable; (b) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement (provided that if such dispute relates to payment, the Cure
Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts), (c) it is understood and agreed that, during the pendency of such dispute, all of the terms and conditions of this Agreement shall
remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and (d) if it is finally and conclusively determined that the breaching Party committed such Material Breach, then the breaching Party
shall have the right to cure such Material Breach after such determination within the Cure Period. 

  
 - 76 - 

 11.3.3 If the Executive Officers are unable to resolve a dispute within such ten
(10) Business Day period after it is referred to them, the matter will be resolved as provided in Section 12.1. 
 11.4
Termination for Insolvency. To the extent permitted by Law, this Agreement may be terminated by either Vividion or Celgene upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to,
or upon an assignment of a substantial portion of the assets for the benefit of creditors by, the other Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding, such right to
terminate shall only become effective if the non-terminating Party consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days after the filing
thereof. 
 11.5 Effects of Termination. 

11.5.1 Termination by Vividion Pursuant to Section 11.3 or 11.4, or by Celgene pursuant to
Section 11.2. In the event of termination of this Agreement in part with respect to any one or more Programs, or in its entirety, as applicable, (i) by Vividion pursuant to any of Sections 11.3 or 11.4, or (ii) by
Celgene pursuant to Section 11.2, notwithstanding anything contained in this Agreement to the contrary, upon the effective date of such termination: 

(a) subject to Sections 2.4.4, 11.5.1(c), 11.5.1(d) and 11.6, all rights (including all Opt-In Rights
granted to Celgene hereunder) and licenses granted herein to Celgene by Vividion with respect to any such terminated Program shall terminate, Celgene shall cease any and all Development, Manufacture and Commercialization activities under this
Agreement (if any) with respect to each terminated Program and Program Compounds within such terminated Program, each such terminated Program shall be dropped from the Collaboration, any and all rights in such terminated Program and Program
Compounds granted by Vividion to Celgene shall revert to Vividion, and the provisions of Section 2.4.4 or Section 2.13, as applicable, shall apply with respect to such terminated Program; 

(b) Vividion shall have no further obligations to Celgene under this Agreement with respect to any terminated Program, subject to
Section 11.6; 
 (c) all Development & Commercialization Agreements previously entered into by the Parties for Programs for
which Celgene exercised its Opt-In Right that have not been terminated shall continue in full force, in accordance with the terms and conditions of such Development & Commercialization Agreements;

 (d) subject to Section 2.4.4, each Party shall return or destroy all Confidential Information of the other Party with respect to any
terminated Programs and Program Compounds within such terminated Programs being Developed, Manufactured or Commercialized under this Agreement, as required by ARTICLE VIII; and 

(e) Section 11.6 shall apply. 

11.5.2 Termination by Celgene Pursuant to Section 11.3 or 11.4. In the event of termination of this Agreement with
respect to any one or more Programs conducted hereunder or 

  
 - 77 - 

 
in its entirety by Celgene pursuant to Sections 11.3 or 11.4, notwithstanding anything contained in this Agreement to the contrary, upon the effective date of such termination: 

(a) subject to Sections 2.4.4, 11.5.2(c), 11.5.2(e) and 11.6, all rights and licenses granted herein to Vividion by Celgene with respect to
any such terminated Programs and Program Compounds within such terminated Programs shall terminate; 
 (b) subject to Sections 11.5.2(d) and
11.6, Vividion shall have no further obligations to Celgene under this Agreement with respect to any terminated Program; 
 (c) all
Development & Commercialization Agreements previously entered into by the Parties for Programs that have not been terminated shall continue in full force, in accordance with the terms and conditions of such Development &
Commercialization Agreements, as applicable; 
 (d) with respect to any terminated Program that is a Program for which Pre-Exercise Development has not been completed as of the effective date of termination, Vividion may provide Celgene with a Summary in its sole discretion or shall provide Celgene with a Summary following
Celgene’s payment of the Summary Fee to Vividion for such Program as is reasonable under the circumstances, and Celgene shall have the right to exercise, within thirty (30) days after the Summary Verification Date, an Opt-In Right with respect to such Program to enter into a Development & Commercialization Agreement for such Program (subject to payment by Celgene of the applicable
Opt-In Right fee set forth in Section 6.5); 
 (e) subject to Section 2.4.4, each Party
shall return or destroy all Confidential Information of the other Party with respect to any terminated Programs and Program Compounds within the terminated Programs being Developed, Manufactured or Commercialized under this Agreement, as required by
ARTICLE VIII; and 
 (f) Section 11.6 shall apply. 

11.6 Surviving Provisions. 

11.6.1 Accrued Liabilities. Except as otherwise specifically provided herein, termination of this Agreement shall not relieve the
Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude any Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of
this Agreement nor prejudice any Party’s right to obtain performance of any obligation which accrued hereunder prior to the effective date of such termination. In addition, termination of this Agreement shall not terminate provisions which
provide by their respective terms for obligations or undertakings following the expiration of the term of this Agreement. 
 11.6.2
Survival. The rights and obligations of the Parties set forth in the following Sections and Articles shall survive the expiration or termination of this Agreement, in addition to those other terms and conditions that are expressly stated to
survive termination or expiration of this Agreement (or by their context are intended to survive): Sections 2.4.4, 2.9, 2.12.3, 2.13, 2.14., 2.15, 3.1.3, 5.1.5, 5.1.6, 5.1.7, 5.1.8, 6.6 (solely for purposes of any executed E3 Ligase Binder Program
License Agreement), 7.1, 8.5, 8.6, 9.4, 10.1, 10.2, 10.3, 10.4, 10.5, 11.5, 11.6 and 12.2-12.16. 
  

  
 - 78 - 

 11.6.3 Equitable Relief. Termination of this Agreement shall be in addition to, and
shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive Damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for
the termination. 
 11.6.4 Relationship to Other Agreements. Termination of this Agreement with respect to a Program shall not affect
in any way the terms or provisions of any then-existing executed Development & Commercialization Agreement for any other Program. 

ARTICLE XII 
 MISCELLANEOUS

 12.1 Dispute Resolution. Except for any disagreements that are within the authority of the JSC as provided in ARTICLE IV
(which disagreements shall be resolved in accordance with Section 4.10), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement (each, a
“Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this Section 12.1 after discussions between the Executive
Officers within [***] Business Days after referring such dispute to the Executive Officers, any Party may, at its sole discretion, seek resolution of such matter in accordance with Section 12.2. 

12.2 Submission to Court for Resolution. Subject to Section 12.1, the Parties hereby irrevocably and unconditionally consent to the
exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit or
proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom)
arising out of or relating to this Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has
been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 12.6 shall be effective service of process for any action, suit or
proceeding brought against it under this Agreement in any such court. Notwithstanding anything to the contrary in this Section 12.2, each Party shall have the right to institute judicial proceedings against the other Party or anyone acting by,
through or under such other Party, in any court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific performance, injunction or similar equitable relief. 

12.3 Governing Law. This Agreement and all questions regarding its validity or interpretation, or the performance or breach of this
Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

  
 - 79 - 

 12.4 Assignment. 

12.4.1 Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the
Parties (whether by operation of law or otherwise) without the prior written consent of the other Parties, except (a) Celgene may, without Vividion’s written consent, assign this Agreement and its rights and obligations hereunder in whole
or in part to an Affiliate of Celgene (or by an Affiliate of Celgene to another Affiliate of Celgene or to Celgene) in whole in in part, and (b) either Party may, without the other Party’s written consent, assign this Agreement and its
rights and obligations hereunder in whole or in part to a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the subject matter
of this Agreement relates; provided that, (i) in the case described in clause (a), Celgene shall remain responsible for the performance of Celgene’s obligations under this Agreement and Celgene shall guarantee the performance
of its obligations hereunder by such assignee; and (ii) in the case described in clause (b), the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement, and the assigning Party will remain
responsible for the performance by its assignee of this Agreement or any obligations hereunder so assigned. Any purported assignment in violation of this Section 12.4.1 will be void. The terms and conditions of this Agreement shall be binding
upon, and shall inure to the benefit of, the Parties and their respective successors and permitted assigns. 
 12.4.2 Change of
Control. Notwithstanding anything to the contrary in this Agreement, with respect to any technology or intellectual property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any
Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of any Party, such technology and intellectual property rights shall not be included in the technology and intellectual property rights licensed to any
other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant Party to this Agreement or any Affiliate of a Party immediately before such Change of Control) prior to such transaction, or to the extent such
technology or intellectual property rights are developed outside the scope of activities conducted with respect to the Collaboration, any Program, any Program Compounds or Program Products, or any related Companion Diagnostics. The Vividion
Intellectual Property and the Celgene Intellectual Property and Celgene CCB Program IP shall exclude any technology or intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the
Collaboration, any Program, or any Program Compounds or Program Products, or any related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement. 

12.4.3 All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit of the
successors, heirs, administrators and permitted assigns of the Parties. In the event of any assignment by a Party of its rights and obligations under this Agreement, such Party shall remain primarily liable to the other Party for the performance
thereof. Any purported assignment in violation of this Section 12.4 will be null and void ab initio. 
 12.5 Force
Majeure. If the performance of any part of this Agreement by a Party is prevented, restricted, interfered with or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial
condition, negligence or fault), 

  
 - 80 - 

 
including fire, earthquake, flood, embargo, power shortage or failure, acts of war or terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or
restrictions, acts of God (for the purposes of this Agreement, a “force majeure event”), such Party shall, upon giving written notice to the other Party, be excused from such performance to the extent of such
prevention, restriction, interference or delay; provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue
performance with the utmost dispatch whenever such causes are removed. 
 12.6 Notices. Unless otherwise agreed by the Parties or
specified in this Agreement, all notices required or permitted to be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested
and postage prepaid); (c) sent by express courier service providing evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of
providing notice described in clauses (a), (b) or (c) above), to the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 

 

					
		 	 To Vividion:
 Vividion Therapeutics, Inc.

3565 General Atomics Ct., Suite 100
 San Diego, CA 92121

Attention: Chief Executive Officer
 Telephone: 
	  	 To Celgene:
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Senior Vice President Business
 Development

Telephone: 
 Facsimile: 

			
		 	 With a copy to:
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Legal Department

Telephone: 
	  	 With a copy to:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Legal Department

Telephone: 
 Facsimile: 

			
		 	 And
  

WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Steven D. Barrett
 Telephone: 

Facsimile: 
	  	 And
  

Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone: 
 Facsimile: 

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

  
 - 81 - 

 12.7 Waiver. Except as otherwise expressly provided in this Agreement, any term of
this Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of any Party at any time to require performance of any provision of this Agreement shall in
no manner affect such Party’s rights at a later time to thereafter enforce such provision. No waiver by any Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or
term or of another condition or term. 
 12.8 Severability. If any provision of this Agreement should be invalid, illegal or
unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in
full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal or
unenforceable provision of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed that
the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 12.9 Entire
Agreement. This Agreement (including the Schedules and Appendices attached hereto, including the form of each Development & Commercialization Agreement and CCB Program MTA) constitutes the entire agreement between the Parties relating
to its subject matter, and supersedes all prior and contemporaneous agreements, representations or understandings, either written or oral, between the Parties with respect to such subject matter, including the Confidentiality Agreement. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties relating to the subject matter hereof other than as set forth herein. 

12.10 Modification. No modification, amendment or addition to this Agreement, or any provision hereof, shall be effective unless reduced
to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an
agreement in writing and signed by a duly authorized representative of each Party. 
 12.11 Independent Contractors; No Intended Third
Party Beneficiaries. Nothing contained in this Agreement is intended or shall be deemed or construed to create any relationship of employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an
independent contractor. No Party shall assume, either directly or indirectly, any liability of or for the other Party. No Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of,
the other Party, nor to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, except for the indemnitees identified in Sections 10.1 and 10.2. 

12.12 Interpretation; Construction. The captions to the several Articles and Sections of this Agreement are included only for
convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, 

  
 - 82 - 

 
unless the context requires otherwise, (a) the words “including,” “include,” “includes,” “such as” and “e.g.” shall be deemed to be
followed by the phrase “without limitation” or like expression, whether or not followed by the same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter
pronouns and expressions shall be interchangeable; (d) the words “herein” or “hereunder” relate to this Agreement; (e) the word “or” is used in the inclusive sense that is typically associated with the phrase
“and/or”; (f) the word “will” shall be construed to have the same meaning and effect as the word “shall”; (g) all references to “dollars” or “$” herein shall mean U.S. Dollars; and (h) a
capitalized term not defined herein but reflecting a different part of speech from that of a capitalized term which is defined herein shall be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel
in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which
drafted such terms and provisions. 
 12.13 Performance by Affiliates. A Party may perform any obligation this Agreement imposes on
such Party through any of such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

12.14 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an original, and both of
which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic
Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party hereto
shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or defense with respect to the formation of
a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

12.15 Equitable Relief. Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief,
including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at
law or equity. 
 12.16 Further Assurances. Each Party shall execute, acknowledge and deliver such further instruments, and do all
such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Signature Page Follows] 

  
 - 83 - 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Master Research and Collaboration Agreement to be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	CELGENE CORPORATION
		
	By:	 	/s/ Mark J. Alles
		 	Name: Mark J. Alles
		 	Title:   Chief Executive Officer

 [Signature Page to Master Research and Collaboration Agreement] 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Master Research and Collaboration Agreement to be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	VIVIDION THERAPEUTICS, INC.
		
	By:	 	/s/ Diego Miralles
		 	Name: Diego Miralles, M.D.
		 	Title: Chief Executive Officer

 [Signature Page to Master Research and Collaboration Agreement] 

 APPENDIX A-1 

FORM OF US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

  
 [Appendix A-1]-1 

 EXECUTION VERSION 

EXHIBIT A-1 

FORM OF US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

 US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

 by and between 
 VIVIDION
THERAPEUTICS, INC. 
 and 

CELGENE CORPORATION 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	ARTICLE I	  	DEFINITIONS	  	 	1	
			
	ARTICLE II	  	GOVERNANCE; COLLABORATION	  	 	14	
			
	ARTICLE III	  	DEVELOPMENT	  	 	20	
			
	ARTICLE IV	  	MANUFACTURE AND SUPPLY	  	 	27	
			
	ARTICLE V	  	REGULATORY MATTERS	  	 	28	
			
	ARTICLE VI	  	COMMERCIALIZATION	  	 	30	
			
	ARTICLE VII	  	DILIGENCE	  	 	36	
			
	ARTICLE VIII	  	GRANT OF RIGHTS; EXCLUSIVITY	  	 	37	
			
	ARTICLE IX	  	FINANCIAL PROVISIONS	  	 	48	
			
	ARTICLE X	  	INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS	  	 	58	
			
	ARTICLE XI	  	CONFIDENTIALITY	  	 	67	
			
	ARTICLE XII	  	REPRESENTATIONS AND WARRANTIES	  	 	73	
			
	ARTICLE XIII	  	INDEMNIFICATION; PRODUCT LIABILITIES	  	 	78	
			
	ARTICLE XIV	  	TERM AND TERMINATION	  	 	83	
			
	ARTICLE XV	  	MISCELLANEOUS	  	 	93	

  
 i 

 Exhibits 
  

			
	Exhibit A	  	Co-Co Target and Co-Co Candidate(s)
		
	Exhibit B	  	Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents (as of the Execution Date)
		
	Exhibit C	  	Existing Third Party Agreements
		  	Exhibit D Profit & Loss Share
		
	Exhibit E	  	Partnership Tax Matters
		
	Schedules	  	
		
	Schedule 6.5	  	Minimum Vividion and Celgene Sales Representative Qualifications
		
	Schedule 12.2(i)	  	Patents
		
	Schedule 12.2(j)    	  	Existing Third Party Agreements

  
 ii 

 US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 
 This US Co-Development and Co-Commercialization Agreement (this “Agreement”) is entered into as of [•] (the “Execution Date”), by and between Vividion Therapeutics, Inc., a Delaware corporation
(“Vividion”) and Celgene Corporation, a Delaware corporation (“Celgene”). Celgene and Vividion are each referred to herein by name or as a “Party”, or, collectively, as the
“Parties”. 
 INTRODUCTION 
  

	1.	 Vividion and Celgene are parties to the Master Research and Collaboration Agreement, dated as of March 1,
2018 (the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Vividion has discovered and has been developing the Co-Co Candidate(s) identified on Exhibit A, each of which the Parties believe to be Directed against the Co-Co Target identified on Exhibit A.

  

	3.	 Pursuant to the terms of the Master Agreement, upon exercise by Celgene of its
Opt-In Right (as defined in the Master Agreement) with respect to the Shared US Program (as defined in the Master Agreement), the Parties shall enter into this Agreement with respect to such Shared US Program.

  

	4.	 Pursuant to this Agreement, Vividion grants to Celgene (a) under a license, exclusive rights in
(i) the ROW Territory with respect to the development and commercialization of the Shared Products for such Program and (ii) the Territory with respect to the manufacture of the Shared Products for such Program, and (b) under a co-development and co-commercialization structure, co-exclusive rights in the US Territory with respect to the development and
commercialization of the Shared Products, on the terms and subject to the conditions set forth herein. 

 NOW, THEREFORE,
in consideration of the respective representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Vividion and Celgene hereby agree as follows:

 Article I 

Definitions 
 When used in
this Agreement, each of the following terms shall have the meanings set forth in this Article I. Terms used but not defined herein shall have the meaning set forth in the Master Agreement. 

Section 1.1 “Annual Net Sales” means, [***]. 

 Section 1.2 “Calendar Quarter” means a calendar quarter ending on the
last day of March, June, September or December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the last day of the calendar quarter during which the Effective Date occurs. 

Section 1.3 “Calendar Year” means a period of time commencing on January 1 and ending on the following December 31;
provided, however, that the first Calendar Year shall begin on the Effective Date and end on December 31 of the calendar year during which the Effective Date occurs. 

Section 1.4 “Celgene Co-Co Collaboration Intellectual Property” means Celgene Co-Co Collaboration Know-How and Celgene Co-Co Collaboration Patents, collectively. 

Section 1.5 “Celgene Co-Co Collaboration
Know-How” means, collectively, (a) Know-How within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that was discovered,
developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Know-How (as defined in the
Master Agreement) that was discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Know-How Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Know-How and Joint Inventions), in each case that
is necessary or useful for the Development, Manufacture or Commercialization of any Shared Products. 
 Section 1.6 “Celgene Co-Co Collaboration Patents” means, collectively, (a) Patents within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that Cover
Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Patents (as
defined in the Master Agreement) that Cover Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Patents Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Patents and Joint Patents), in each case that are necessary or
useful for the Development, Manufacture or Commercialization of any Shared Products. Celgene Co-Co Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.7 “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively. 
 Section 1.8 “Celgene Know-How” means any Know-How that is (a) Controlled by Celgene as of the Execution Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products; and
(c) contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Know-How. 
 Section 1.9 “Celgene Patents” means any Patents that (a) are
Controlled by Celgene as of the Execution Date or during the Term; (b) Cover the Shared Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from
Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Patents. Celgene Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

  
 2 

 Section 1.10 “Clinical Trial” means a Phase I Study, a Phase II Study,
a Phase III Study, a Pivotal Clinical Trial, a Phase IV Study or a combination of any of the foregoing studies. 
 Section 1.11
“Code” means the United States Internal Revenue Code of 1986, as amended. 
 Section 1.12 “Co-Co Candidate” means (a) any Program Compound that is listed on Exhibit A and (b) to the extent Directed against the Co-Co Target, any salt,
fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates, anhydride, ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug,
isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of any such Program Compound identified in the foregoing clause (a) or in this clause (b). 

Section 1.13 “Co-Co Collaboration Intellectual Property” means Co-Co Collaboration Know-How and Co-Co Collaboration Patents, collectively. 

Section 1.14 “Co-Co Collaboration
Know-How” means any Know-How or interest therein that is discovered, developed, generated or invented on or after the Execution Date, either (a) solely by
or on behalf of Celgene or its Affiliates, (b) solely by or on behalf of Vividion or its Affiliates or (c) jointly by or on behalf of Persons described in the foregoing clauses (a) and (b), in the conduct of the Collaboration
activities pursuant to this Agreement, including Joint Co-Co Know-How and Joint Inventions. 

Section 1.15 “Co-Co Collaboration Patents” means any Patents or interest therein
that: (a) result from the conduct of the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date, (c) are Controlled solely by Celgene or Vividion or Controlled jointly by any of such Persons
and (d) Cover Co-Co Collaboration Know-How, including Joint Co-Co Patents and Joint Patents. 

Section 1.16 “Co-Co Target” means the Program Target set forth as the “Co-Co Target” on Exhibit A; it being understood and agreed that (i) in the case of Co-Co Candidates in a Deal Target Program described in clause
(b) of Section 1.1.36 of the Master Agreement, the “Co-Co Target” shall be the Selected Target and (ii) in the case of Co-Co Candidates
in an E3 Ligase Program described in clause (b) of Section 1.1.46 of the Master Agreement, the “Co-Co Target” shall be the Selected Target. 

Section 1.17 “Collaboration” means the activities performed or to be performed by a Party or Parties, as the case may
be, relating to the Development, Manufacture or Commercialization of the Shared Products under this Agreement or the Master Agreement, including in the exercise of any license granted under this Agreement or the Master Agreement relating to the
Shared Products. 

  
 3 

 Section 1.18 “Companion Diagnostic” means a biomarker or diagnostic
test that is developed by or on behalf of a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Shared Product in accordance with the Regulatory Approval(s) therefor to generate a result for
the purposes of diagnosing a disease or condition, or to facilitate the application of any Shared Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a
specific patient will contract a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy using a Shared Product. 

Section 1.19 “Confidential Information” means, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), (a) all
confidential or proprietary information relating to the Collaboration, and (b) all other confidential or proprietary documents, technology, Know-How or other information (whether or not patentable)
actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement or the Master Agreement relating to the Shared Products and all proprietary biological materials of a Party. 

Section 1.20 “Data” means any and all research data, results, pharmacology data, medicinal chemistry data, preclinical
data, market research, clinical data (including investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, safety and other electronic databases), in any and all forms, including files, reports, raw data,
source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the like, in each case directed to, or used in, the Development, Manufacture or
Commercialization of the Shared Products. 
 Section 1.21 “Development Plan” means a development plan and the related
Development Budget approved by the JSC, as amended from time to time pursuant to Section 3.2(a). 
 Section 1.22 “Direct
Cost” means, with respect to certain activities hereunder, [***]. 
 Section 1.23 “Effective Date” means the
date on or after the Execution Date that is the Implementation Date (as defined in the Master Agreement) with respect to this Agreement. 

Section 1.24 “Executive Officers” means Celgene’s Chief Executive Officer (or the officer or employee of Celgene
then serving in a substantially equivalent capacity) or his designee and Vividion’s Chief Executive Officer (or the officer or employee of Vividion then serving in a substantially equivalent capacity) or his designee; provided
that any such designee must have decision-making authority on behalf of the applicable Party. 
 Section 1.25 “Existing
Third Party Agreement” means any agreement listed on Exhibit C to this Agreement. 
 Section 1.26
“Field” means the diagnosis, prevention, palliation or treatment of diseases in humans or animals. 

  
 4 

 Section 1.27 “First Commercial Sale” means the first commercial sale
of a Shared Product by Celgene, its Affiliates or Licensee Partners in a country in an arms’ length transaction to a Third Party following receipt of applicable Regulatory Approval of such product in such country. Sales for test marketing or
Clinical Trial purposes shall not constitute a First Commercial Sale. 
 Section 1.28 “FTE” means the equivalent of
the work of one (1) full-time employee of a Party or its Affiliates for one (1) year (consisting of 1840 hours per year) in directly conducting Development, Manufacturing or Commercialization activities hereunder. Any Party’s employee
who devotes fewer than 1840 hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, calculated by dividing the actual number of hours worked by such employee on such
activities by 1840. Any employee who devotes more than 1840 hours per year on the applicable activities shall be treated as one (1) FTE. For the avoidance of doubt, FTE shall not include the work of general corporate or administrative
personnel, except for the portion of such personnel’s work time actually spent on conducting scientific, technical or commercial activities directly related to the Development, Manufacture or Commercialization of Shared Products. 

Section 1.29 “FTE Rate” means, during the Term: (a) with respect to Development activities, $[***] per FTE and
(b) with respect to Commercialization activities, $[***] per FTE. On January 1, 2019 and on January 1st of each subsequent Calendar Year, the foregoing rate shall be increased for the Calendar Year then commencing by [***]. As used in this
definition, [***]. The FTE Rate includes the applicable employee’s wages, bonuses, Incentive Compensation, equity incentive compensation, employer paid taxes, benefits, perks and other forms of compensation that would otherwise be considered
the cost of an employee. 
 Section 1.30 “Generic Competition” means, with respect to a Shared Product in a given
country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.31 “Generic Product” means, as to a Shared Product, in any country, any pharmaceutical product sold by a Third
Party not authorized by or on behalf of Celgene, its Affiliates or Licensee Partners, that (a) contains, as an active pharmaceutical ingredient, the same Co-Co Candidate contained in the applicable Shared
Product, (b) is approved by the applicable Regulatory Authority in such country for one or more of the same Indications as the applicable Shared Product; and (c) is AB rated in the United States or is comparably rated in any jurisdiction
outside the United States (including pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001) with respect to the applicable Shared Product. 

Section 1.32 “IIT” means any investigator initiated Clinical Trial sponsored and conducted by an investigator at a
research institution for which a Party or its Affiliate provides drug supplies. 

  
 5 

 Section 1.33 “Joint Co-Co IP”
means, collectively: 
 “Joint Co-Co
Know-How” which means all Know-How, including physical embodiments of Shared Product(s) and Companion Diagnostic(s), that is discovered, developed, generated or
invented by or on behalf of both Parties or their respective Affiliates, whether solely or jointly with any Third Party, pursuant to the conduct of activities under the Collaboration at any time during the Term, including Joint Inventions; and 

“Joint Co-Co Patents” which means Patents that: (a) result from the conduct of
the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date, and (c) Cover any Joint Co-Co Know-How, including Joint
Patents. 
 Section 1.34 “Licensee Partner” means any Third Party to whom a Party or any of its Affiliates or any
other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Shared Products in the Field under rights to Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration Intellectual Property or Joint Co-Co IP, as the case may be,
granted to such Party or Affiliate hereunder, in each case excluding (a) Third Party Contractors and (b) wholesale distributors or any other Third Party that purchases any Shared Product in an
arm’s-length transaction, where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize any Shared Product except for a limited sublicense to the extent required to enable
such Third Party to perform final packaging for such Shared Product for local distribution. 
 Section 1.35 “Major
Market” means each of the US Territory, France, Germany, Italy, Spain, the United Kingdom, and Japan. 
 Section 1.36
“Manufacturing Technology” means copies of all Celgene Know-How, Vividion Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co-Co Collaboration Know-How or Joint Co-Co
Know-How, as applicable, which are necessary or useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Shared Products, including specifications, assays, batch records,
quality control data, and transportation and storage requirements. 
 Section 1.37 “Manufacturing Transition Costs”
means the Direct Costs associated with the transfer by Vividion, following the Effective Date, of responsibility for Manufacturing and CMC activities to Celgene or a Third Party selected by Celgene, including [***]. 

Section 1.38 “NDA” means an application submitted to a Regulatory Authority for the marketing approval of a Shared
Product, including (a) a New Drug Application (as such capitalized term is used in C.F.R Title 21) filed with FDA or any successor applications or procedures, (b) a foreign equivalent of a US New Drug Application or any successor
applications or procedures, including a Marketing Authorization Application in the European Union, and (c) all supplements and amendments that may be filed with respect to the foregoing. 

  
 6 

 Section 1.39 “Net Sales” means, with respect to any Shared Product,
the gross amounts invoiced by Celgene, its Affiliates and Licensee Partners (each, a “Selling Party”) to Third Parties (that are not Licensee Partners) for sales or other commercial dispositions of such Shared Product, less the
following deductions actually incurred, allowed, paid, accrued or specifically allocated in its financial statements and calculated in accordance with the Accounting Standards as consistently applied, for: 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; and 

  

	 	(f)	 [***]. 

There should be no double counting in determining the foregoing deductions from gross amounts invoiced to calculate “Net Sales” hereunder.
The calculations set forth in this definition shall be determined in accordance with Accounting Standards consistently applied. 
 If non-monetary consideration is received by a Selling Party for any Shared Product in the relevant country, Net Sales will be [***]. Notwithstanding the foregoing, Net Sales 

shall [***]. 

  
 7 

 Net Sales shall be determined on, [***], the [***] by a Selling Party or any of its Affiliates or
(sub)licensees to a non-(sub)licensee Third Party. 
 If a Shared Product is sold as part of a Combination Product
(as defined below), Net Sales will be the product of (i) [***] and (ii) the fraction (A/(A+B)), where: 
 “A” is [***]; and 

“B” is [***]. 
 If “A” or “B”
cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated as above, but [***]. 

As used in this definition of “Net Sales,” “Combination Product” means a Shared Product that contains one or more additional
active ingredients (whether co-formulated or co-packaged) that are neither Co-Co Candidates nor generic or other non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall be deemed not to be “active ingredients.” 

Section 1.40 “Out-of-Pocket Costs”
means, with respect to certain activities hereunder, [***]. 
 Section 1.41 “Partnership Agreement” means an agreement
pursuant to which a Party or its Affiliate provides funding to a Third Party to research and develop pharmaceutical compounds or products and which may include the grant of an option for such Party or Affiliate to obtain rights to, but not (in the
absence of the exercise of such option) a license to Commercialize or other rights to Commercialize, such pharmaceutical compounds or products. 

Section 1.42 “Phase IV Study” means a human clinical trial of a product which is (a) conducted to satisfy a
requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has been obtained from an appropriate Regulatory Authority for enhancing marketing or
scientific knowledge of an approved Indication. 

  
 8 

 Section 1.43 “Product Liabilities” means all losses, damages, fees,
costs and other liabilities incurred by a Party, its Affiliate(s) or its Licensee Partner(s) and resulting from or relating to the use of a Shared Product in a human (including clinical trials or Commercialization) in the Territory incurred after
the Effective Date. For the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party, its Affiliate(s), or its Licensee Partner(s) and all
losses, damages, fees and costs associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of any Shared Product. 

Section 1.44 “Regulatory Documentation” means, with respect to the Collaboration, all INDs, NDAs and other regulatory
applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug dossiers, master files (including Drug Master Files, as
defined in 21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials relating to Development or Regulatory Approval of the
Shared Products, or required to Manufacture, distribute or sell the Shared Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls data, batch records, safety and efficacy, and any safety
database. 
 Section 1.45 “Regulatory Exclusivity” means, with respect to a Shared Product in a country, that the
Shared Product has been granted (a) data exclusivity afforded approved drug products pursuant to Section 505(c), 505(j), or 505A of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or their equivalent in
a country other than the United States, (b) market exclusivity pursuant to the orphan drug provisions governing approved drugs designated for rare diseases or conditions under Sections 526 and 527 of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (c) any other data exclusivity or market exclusivity pursuant to any future Law. 

Section 1.46 “Right of Reference or Use” means a “Right of Reference or Use” as that term is defined in
21 C.F.R. §314.3(b), and any non-United States equivalents. 
 Section 1.47 “ROW
Administration” means administration of Shared Products to a patient when such patient is located in the ROW Territory. 

Section 1.48 “ROW Territory” means all countries in the world other than the US Territory. 

Section 1.49 “Shared Product” means (a) a Co-Co Candidate or (b) any
product that contains a Co-Co Candidate as an active ingredient. 
 Section 1.50
“Shared Product Data” means all relevant Data included in the Know-How Controlled by either Party in relation to Shared Products or Companion Diagnostics for use in the Field either:
(a) as of the Execution Date; or (b) generated from activities conducted by or on behalf of a Party under the Development Plan or that otherwise specifically relates to Shared Products or Companion Diagnostics and in each case is necessary
or useful for applications for Regulatory Approval, or Regulatory Approvals, for Shared Products in the Field and in the Territory. 

  
 9 

 Section 1.51 “Shared Program” means the Program that is the subject of
this Agreement. Section 1.52 “Territory” means the US Territory and the ROW Territory. 
 Section 1.52
“Third Party Agreement” means (a) each Existing Third Party Agreement and (b) each Subsequent Third Party Agreement. 

Section 1.53 “Third Party Rights” means, with respect to a Party, any rights of, and any limitations, restrictions or
obligations imposed by, Third Parties pursuant to any Third Party Agreements. 
 Section 1.54 “U.S. Administration”
means administration of Shared Products to a patient when such patient is located in the US Territory. 
 Section 1.55 “US
Territory” means the United States of America, including its territories, possessions and Puerto Rico. 
 Section 1.56
“Valid Claim” means (a) a claim of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be
taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or
subject matter of a claim thereof filed by a Person in good faith that has not been cancelled, withdrawn or abandoned, nor been pending for more than six (6) years from the earliest filing date to which such patent application or claim is
entitled. 
 Section 1.57 “Vividion Co-Co Collaboration Intellectual Property”
means the Co-Co Collaboration Intellectual Property Controlled by Vividion. 
 Section 1.58
“Vividion Co-Co Collaboration Know-How” means the Co-Co Collaboration
Know-How Controlled by Vividion (including Vividion’s interest in the Joint Co-Co Know-How and Joint Inventions). 

Section 1.59 “Vividion Co-Co Collaboration Patents” means the Co-Co Collaboration Patents Controlled by Vividion (including Vividion’s interest in the Joint Co-Co Patents and Joint Patents). 

Section 1.60 “Vividion Intellectual Property” means Vividion Know-How and
Vividion Patents, collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6,
2016. 

  
 10 

 Section 1.61 “Vividion
Know-How” means any Know-How that is (a) Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Know-How, as defined under the Master Agreement) or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products, but excluding (y) Co-Co Collaboration Know-How and (z) any Know-How licensed to Vividion under the License Agreement by and between
Vividion and The Scripps Research Institute, dated as of January 6, 2016. 
 Section 1.62 “Vividion Patents”
means any Patents that (a) are Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Patents, as defined under the Master Agreement) or during the Term, and (b) Cover, or are useful for, the
Development, Manufacture or Commercialization of the Shared Products (including the composition of matter, manufacture or any use thereof); but excluding (y) Co-Co Collaboration Patents and (z) any
Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. Vividion Patents as of the Execution Date are as set forth on Exhibit B to this Agreement.

 Section 1.63 Additional Definitions. Each of the following definitions is set forth in the section of this Agreement
indicated below: 
  

			
	 DEFINITION
	  	 SECTION

	35 U.S.C. § 102(c) Patent	  	Section 10.7
	Academic Essential Provisions	  	Section 8.6(b)(iii)
	Accounting Standards	  	Master Agreement
	Acquirer Program	  	Section 8.6(b)(v)(D)
	Additional Study	  	Section 3.4
	Additional Study Approval	  	Section 3.4(c)
	Affiliate	  	Master Agreement
	Agreement	  	Preamble
	Allocable Overhead	  	Exhibit D
	Allowable Expenses	  	Exhibit D
	Allowed Indication	  	Section 8.6(b)(viii)
	Antitrust Law	  	Master Agreement
	Audit Team	  	Section 9.9(a)
	Audit Rights Holder	  	Section 9.9(e)
	Auditee	  	Section 9.9(e)
	Bankruptcy Code	  	Section 8.8
	Barred Indication	  	Section 8.6(b)(vii)
	Business Day	  	Master Agreement
	CCB Program MTA	  	Master Agreement
	Celgene	  	Preamble
	Celgene Indemnified Parties	  	Section 13.1(b)
	Celgene Independent Product	  	Master Agreement
	Challenge	  	Section 14.2(d)
	Challenging Party	  	Section 14.2(d)
	Change of Control	  	Master Agreement
	Clinically Develop	  	Section 8.6(a)
	Co-Co Buy-In	  	Section 3.5

  
 11 

			
	 DEFINITION
	  	 SECTION

	Combination Product	  	Section 1.39
	Commercialization/Commercialize	  	Master Agreement
	Commercially Reasonable Efforts	  	Master Agreement
	Competitive Infringement	  	Section 10.3(b)
	Competitive Program	  	Section 8.6(b)(iv)
	Competitive Program Party	  	Section 8.6(b)(iv)
	Control/Controlled	  	Master Agreement
	Cooperating Party	  	Section 11.3(b)(iii)
	Costs of Goods Sold or COGs	  	Exhibit D
	Cover/Covering/Covered	  	Master Agreement
	CPI	  	Section 1.29
	Cure Period	  	Section 14.2(b)(i)
	Damages	  	Master Agreement
	Deemed Buy-In	  	Section 3.4(c)
	Develop/Development	  	Master Agreement
	Development Budget	  	Section 3.2(a)(i)
	Development Cost Share	  	Section 9.1(a)
	Directed	  	Master Agreement
	Disclosing Party	  	Section 11.1
	Dispute	  	Section 15.1
	[Distinct Product	  	Master Agreement]
	[Distinct Product Catch-Up Payments	  	Section 9.2(a)(iv)]
	Distribution Costs	  	Exhibit D
	Earlier Patent	  	Section 10.7
	Electronic Delivery	  	Section 15.16
	Enabling Manufacturing	  	Section 8.6(a)
	Execution Date	  	Preamble
	FDA	  	Master Agreement
	FDCA	  	Master Agreement
	Finance Working Group	  	Section 2.2(f)
	force majeure event	  	Section 15.7
	Functional Phenotypic Assay Similarity Criteria	  	Master Agreement
	Global Safety Database	  	Section 5.3
	Gross Profit	  	Exhibit D
	Incentive Compensation	  	Section 6.5(b)(v)
	IND	  	Master Agreement
	Indemnified Party	  	Section 13.3
	Indemnitor	  	Section 13.3
	Indirect Taxes	  	Section 9.10(b)(i)
	Indication	  	Master Agreement
	Information Request	  	Section 6.5(b)(vii)
	Joint Inventions	  	Section 10.1(c)
	Joint Patents	  	Section 10.1(c)
	Know-How	  	Master Agreement
	Law	  	Master Agreement

  
 12 

			
	 DEFINITION
	  	 SECTION

	Licensed Branding	  	Section 6.6(c)
	Licensing Party	  	Section 8.5(c)
	Lump Sum	  	Section 3.4(c)
	Manufacture/Manufacturing	  	Master Agreement
	Manufacturing Costs	  	Exhibit D
	Marketing Costs	  	Exhibit D
	Master Agreement	  	Introduction
	Material Breach	  	Section 14.2(b)(i)
	Operating Profits or Losses	  	Exhibit D
	Opt-In Right	  	Master Agreement
	Other Operating Income/Expense	  	Exhibit D
	Party or Parties	  	Preamble
	Patent Officers	  	Master Agreement
	Patent Prosecution Expenses	  	Section 10.2(c)
	Patent	  	Master Agreement
	Payee Party	  	Section 9.10(b)(i)
	Paying Party	  	Section 9.10(b)(i)
	Permitted Indication	  	Section 8.6(b)(vii)
	Person	  	Master Agreement
	Pharmacovigilance Agreement	  	Section 5.3
	Pharmacovigilance Expenses	  	Exhibit D
	Phase I Study	  	Master Agreement
	Phase II Study	  	Master Agreement
	Phase III Study	  	Master Agreement
	Pivotal Clinical Trial	  	Master Agreement
	Product Recall Expenses	  	Exhibit D
	Product Trademarks	  	Section 6.6(a)
	Profit & Loss Share	  	Section 9.6(a)
	Program Assets	  	Section 12.4(a)
	Program Compound	  	Master Agreement
	Program Product	  	Master Agreement
	Program Target	  	Master Agreement
	Prosecuting Party	  	Section 10.2(d)(ii)
	Prosecution/Prosecute	  	Master Agreement
	Publication	  	Master Agreement
	Pursuing Party	  	Section 14.2(d)
	Receiving Party	  	Section 11.1
	Redacted Version	  	Section 11.3(b)(i)
	Regulatory Approval	  	Master Agreement
	Regulatory Authority	  	Master Agreement
	Regulatory Interactions	  	Section 5.1(b)
	Regulatory Expenses	  	Exhibit D
	Report	  	Exhibit D
	Requesting Party	  	Section 11.3(b)(iii)
	ROW Development Costs	  	Section 9.1(a)

  
 13 

			
	 DEFINITION
	  	 SECTION

	Royalty Term	  	Section 9.3(b)
	Sales Costs	  	Exhibit D
	Sales Milestone Condition	  	Section 9.2(b)
	SEC	  	Section 11.3(b)(i)
	Selected Target	  	Master Agreement
	Selling Party	  	Section 1.39
	Separate Program	  	Master Agreement
	Separate Program Product	  	Section 8.6(b)(vii)
	Sublicense Revenues	  	Exhibit D
	Subsequent Third Party Agreement	  	Section 9.7(b)
	Term	  	Section 14.1(a)
	Third Party Contractors	  	Section 8.2(a)(ii)
	Third Party Infringement	  	Section 10.3(a)
	Third Party Infringement Action	  	Section 10.4
	Third Party Products Liability Action	  	Section 13.5(a)
	U.S. Commercialization Budget	  	Section 6.2(c)
	U.S. Commercialization Costs	  	Section 6.5(c)
	U.S. Commercialization Plan	  	Section 6.2(a)
	Vividion	  	Preamble
	Vividion Indemnified Parties	  	Section 13.1(a)
	Vividion Opt-Out Notice	  	Section 2.3(a)
	Vividion Opt-Out Date	  	Section 2.3(b)
	Worldwide Development Costs	  	Section 9.1(a)

 Article II 

Governance; Collaboration 

Section 2.1 Certain Interactions with and Effects on the Master Agreement. Upon and after the Effective Date, notwithstanding
anything to the contrary in the Master Agreement: 
 (a) During the Term, the Committees shall remain established as set forth in Article IV
of the Master Agreement to perform the functions set forth therein with respect to the Parties’ activities under this Agreement. 
 (b)
Except as otherwise set forth in this Agreement, all activities regarding Development and Manufacturing of Shared Products shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 

(c) None of the Parties’ activities performed in accordance with this Agreement (including those activities specifically permitted upon
and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 
 Section 2.2 Decision Making.

  
 14 

 (a) Committee Voting. All decisions of a Committee with respect to the Parties’
activities under this Agreement shall be attempted to be made by unanimous vote, with each Party’s representatives collectively having one (1) vote, and each such decision (if made) shall be set forth in minutes approved by both
Parties’ representatives on the Committee. Upon [***] Business Days prior written notice, either Party may convene a special meeting of a Committee for the purpose of resolving any failure to reach agreement on a matter within the scope of the
authority and responsibility of such Committee. No Committee shall have the authority to resolve any dispute involving the breach or alleged breach of this Agreement or to amend or modify this Agreement or the Parties’ respective rights and
obligations hereunder. 
 (b) Referrals from JDC or JCC to JSC. If the JDC or JCC is unable to decide, by unanimous vote, on any
matter so referred to it for resolution by one or both Parties within [***] Business Days after the matter is so referred to it, the chairperson of the JDC or JCC, as applicable, shall refer such matter to the JSC for attempted resolution by
unanimous vote. 
 (c) Referrals from the JSC to Executive Officers. If the JSC is unable to decide, by unanimous vote, on any such
matter referred to it by the JDC or the JCC or on any other matter specified in this Agreement to be decided by the JSC, within [***] Business Days after the matter is referred to it or first considered by it, the chairperson of the JSC shall submit
such matter for attempted resolution by agreement of the Executive Officers. 
 (d) Decision-Making Authority. If the Executive
Officers are unable to resolve any matter referred to them by the chairperson of the JSC within [***] Business Days after the matter is referred to them, then, subject to Section 2.2(g), if the unresolved matter relates to the Development,
Manufacture or Commercialization of the Shared Products, Celgene shall have the right to decide any such unresolved matter that relates to either or both of the US Territory and the ROW Territory; provided, however, that,
Celgene shall give due, good faith consideration to any comments or preferences expressed by Vividion with respect to any such matter that relates to U.S. Administration. For the avoidance of doubt, the JCC will have no right to supervise or direct
the Commercialization of the Shared Products and Companion Diagnostics for ROW Administration and, subject to the terms and conditions of this Agreement and the Master Agreement, Celgene will have sole decision-making authority with respect to such
Commercialization. 
 (e) JPC. If the JPC is unable to decide, by unanimous vote, on any matter within [***] Business Days after the
matter is first raised with the JPC, then the matter will be referred to the Patent Officers for resolution. If such matter is not resolved by the Patent Officers of the Parties within [***] Business Days after the matter was referred to them, then,
subject to Section 2.2(g), the applicable Prosecuting Party (as set forth in Article X) may decide the matter. Notwithstanding the foregoing, but subject to Section 2.2(g), if at any time the Party who has decision-making rights for such
matter under Article X reasonably believes that the delay in decision resulting from such procedure will create a risk that any rights to Know-How or Patents will be lost or otherwise diminished, then such
Party may exercise such decision-making rights immediately, provided that such resolving Party shall give due, good faith consideration to any comments or preferences expressed by the other Party with respect to such matter. 

  
 15 

 (f) Formation of Finance Working Group. Promptly after the Effective Date, Celgene
and Vividion shall establish a joint Finance Working Group (the “Finance Working Group”), which shall report to the JDC with respect to the Development of the Shared Products, to the JCC with respect to the Commercialization of the
Shared Products and to the JSC with respect to the preparation and approval of the Reports and other related financial information in accordance with Exhibit D and the terms and conditions of this Agreement, and operate in coordination with
the various committees. The Finance Working Group shall include individuals from each Party with reasonable expertise in the areas of accounting, cost allocation, budgeting and financial reporting. The Finance Working Group shall be responsible for:
(i) coordinating and conducting the accounting, reporting, reconciliation and other related activities set forth in this Agreement and Exhibit D; (ii) advising and providing support to the JSC and the other committees with respect
to financial, accounting, budgeting, reporting and other issues that may arise in connection with the various plans and corresponding budgets for activities thereunder; (iii) reviewing relevant FTE costs and other costs included in the
Profit & Loss Share incurred by the Parties and their Affiliates hereunder; (iv) recommending for approval by the JSC any changes to reporting procedures; (v) coordinating or performing the budgeting, consolidation, completion and
review of the Reports and other related financial information statements in accordance with the terms and conditions of this Agreement and Exhibit D, including budgeting and calculation of Allowable Expenses not covered in the U.S.
Commercialization Budget; (vi) performing and reviewing calculations for the reconciliation of payments, and controlling and performing such other accounting functions as provided in the terms and conditions of this Agreement and Exhibit
D; (vii) coordinating audits pursuant to Section 9.9, by Third Party audit firms, and discussing and attempting to resolve discrepancies or issues arising from such audits; (viii) performing such other functions as are
specifically delegated to the Finance Working Group in this Agreement or Exhibit D, or as the Parties otherwise agree are appropriate to further the purposes of this Agreement; (ix) working with the JSC and the committees to assist in
financial, budgeting and planning matters, and providing periodic updates to the JSC, JDC and JCC on financial matters relating to this Agreement, and perform such other financial matters as are delegated to it under this Agreement or by the JSC,
JDC and JCC; and (x) making such decisions and determinations as are assigned to it under this Agreement. If the Finance Working Group is unable to decide, by unanimous vote, on any matter so referred to it for resolution by one or both Parties
within [***] Business Days after the matter is so referred to it, the Finance Working Group shall refer such matter to the JCC, JDC or JSC, as applicable, for attempted resolution by unanimous vote. 

(g) Exceptions. 
 (i) This
Section 2.2 is subject to the applicable terms and conditions of Article IV of the Master Agreement. 
 (ii) No Party shall have the
right to finally resolve a dispute pursuant to Section 2.2(d), without agreement of the other Party, in a manner that would impose any obligations on such other Party beyond those for which such other Party is responsible, or diminish such
other Party’s rights, under this Agreement or the then-current Development Plan or Development Budget or U.S. Commercialization Plan or U.S. Commercialization Budget, as applicable, (including by increasing such other Party’s financial
obligations hereunder). 

  
 16 

 (iii) Notwithstanding anything to the contrary contained herein, the Parties understand and
agree that, from and after the date that Vividion provides the Vividion Opt-Out Notice, the Committees shall no longer have any decision-making authority, but shall continue to function for information sharing
purposes until the Vividion Opt-Out Date. 
 (h) All “Confidential Information”
disclosed under the Master Agreement that solely relates to any Shared Product shall, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), be deemed to be Confidential Information disclosed under this Agreement and not the Master Agreement.
All “Confidential Information” disclosed under the Master Agreement that relates to, but does not solely relate to, any Shared Product shall be deemed “Confidential Information” disclosed under the Master Agreement
and also, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), Confidential Information disclosed under this Agreement; provided, however, that any disclosure of such information that is permitted under the Master
Agreement shall not be deemed a breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be deemed a breach of the Master Agreement. 

Section 2.3 Vividion Opt-Out. 

(a) Opt-Out Notice. Without it being a breach of Article VII, Vividion shall have the right to elect to
opt out of its Development, Manufacturing and Commercialization rights and the sharing of Worldwide Development Costs and Operating Profits or Losses under this Agreement by written notice to Celgene (such notice, the “Vividion Opt-Out Notice”); provided, however, that Vividion may not, without consent of Celgene, provide any such notice (x) within [***] months after any Regulatory Authority or the other
Party has provided to any Committee or Vividion any notification under Section 5.4 that a recall, market withdrawal or similar action may be required with respect to any Shared Product in the US Territory or (y) within [***] months after
any Committee or Vividion receives knowledge of any Third Party Products Liability Action in the US Territory. After Vividion provides such Vividion Opt-Out Notice, Celgene shall have sole discretion with
respect to any matters regarding further Development, Manufacturing and Commercialization (including any sales force activities and designation of sales representatives) hereunder, provided that, (i) during the period between such
Vividion Opt-Out Notice and the applicable Vividion Opt-Out Date, Celgene shall use Commercially Reasonable Efforts to continue such activities in accordance with the
plans and budgets therefor in effect as of such Vividion Opt-Out Notice and (ii) after the applicable Vividion Opt-Out Date, Celgene shall use Commercially
Reasonable Efforts to Develop and Commercialize the Shared Products as provided in Article VII. 
 (b)
Opt-Out Date. Vividion’s opt-out shall be effective [***] months after the Vividion Opt-Out Notice is given; provided
that, if Vividion exercises its right to opt-out at any time during the [***] month period prior to the anticipated First Commercial Sale in the US Territory of any Shared Product, then such notice
period shall commence on the date of the Vividion Opt-Out Notice and continue until [***] months after the actual First Commercial Sale of such Shared Product in the US Territory (the “Vividion Opt-Out Date”). 

  
 17 

 (c) Effects of Vividion Opt-Out Notice or Vividion Opt-Out Date. Following the Vividion Opt-Out Notice: 
 (i) the
license and sublicense granted to Vividion under Section 8.1(b) shall terminate effective as of the Vividion Opt-Out Date and all licenses granted by Vividion to Celgene under Section 8.1(a) with
respect to the Shared Product(s) shall convert to exclusive worldwide licenses and otherwise remain in effect; 
 (ii) effective as of the
Vividion Opt-Out Date, the Committees shall not oversee or review any of the matters under this Agreement; 

(iii) neither Party shall have any further obligations under the Development Plan or U.S. Commercialization Plan effective as of the Vividion Opt-Out Date (and such plans, for clarity, shall terminate); 
 (iv) effective as of the Vividion Opt-Out Date, Celgene (but not Vividion) shall continue to have obligations under Section 7.1(b) and Section 7.2, but neither Party shall have any obligations under Section 7.1(a); 

(v) [***] shall be solely responsible for all Worldwide Development Costs, COGS and Allowable Expenses for the Shared Products incurred after
the Vividion Opt-Out Date, except as provided in this Section 2.3(c) and as provided in Section 5.4, Section 13.4 and Section 13.5; 

(vi) effective as of the Vividion Opt-Out Date, Vividion shall cease to conduct any further
Development or Commercialization activities (including marketing activities) with respect to any Shared Products, cease to have any obligations to use Commercially Reasonable Efforts with respect to Article III (Development) and Article VI
(Commercialization), and cease to incur any further Worldwide Development Costs, COGS or Allowable Expenses except as approved by Celgene or as provided in Section 5.4, Section 13.4 and Section 13.5; 

(vii) within [***] days after the Vividion Opt-Out Date, Vividion shall provide to Celgene a
reasonably detailed accounting of all Worldwide Development Costs, COGS and Allowable Expenses incurred by Vividion under the Collaboration prior to the Vividion Opt-Out Date for the purpose of calculating a
final reconciliation of shared costs through the Vividion Opt-Out Date in accordance with Section 9.1 and Section 9.6; 

(viii) within [***] days after the Vividion Opt-Out Notice, Vividion shall provide to Celgene a
reasonably detailed summary of Development and Commercialization activities performed by Vividion under the Collaboration, including any Clinical Trials committed but not yet completed as of such date; 

(ix) within [***] days after the Vividion Opt-Out Date, Vividion shall provide to Celgene an update to
the summary provided pursuant to subsection (viii) above; 
 (x) Vividion shall undertake, and coordinate with Celgene with respect to,
any wind-down or transitional activities reasonably necessary to transfer to Celgene all Development and Commercialization responsibility for the Shared Products throughout the Territory, at [***] sole expense, and Vividion shall use Commercially
Reasonable Efforts to complete such activities before the Vividion Opt-Out Date; provided that the Parties shall 

  
 18 

 
reasonably cooperate in seeking to minimize the costs of such wind-down or transitional activities; provided further that, (A) if Celgene requests that any contracts or agreements that
extend beyond the Vividion Opt-Out Date be terminated, Vividion and Celgene shall share all costs associated with such termination, and, (B) if Celgene requests that any such contract or agreement remain
in effect, Celgene shall be responsible for all costs, expenses, and Product Liabilities incurred under such contract or agreement following the Vividion Opt-Out Date or, if Celgene requests assignment of such
contract or agreement prior to the Vividion Opt-Out Date, incurred following such assignment (whichever is earlier); it being understood and agreed that, notwithstanding anything to the contrary contained
herein, Vividion shall continue to be responsible with Celgene pursuant to the terms and conditions of this Agreement for all costs, expenses and Product Liabilities incurred or otherwise arising prior to the assignment of such contract or agreement
to Celgene (including liability arising following the Vividion Opt-Out Date to the extent based on facts and circumstances first arising prior to such assignment), under such contract or agreement as if no
such Vividion Opt-Out Date had occurred; 
 (xi) effective as of the Vividion Opt-Out Date, each Shared Product shall be subject to the royalty provisions of Section 9.3 from and after the Vividion Opt-Out Date, in lieu of the sharing of Worldwide
Development Costs under Section 9.1 and Operating Profits or Losses under Section 9.6, substituting “Territory” for “ROW Territory” and increasing royalties payable under Section 9.3 (subject to the
terms and conditions of Article IX) as follows: 
  

					
	 Per Shared Product Annual Net Sales in the Territory
	  	Royalty
Rate	 
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in the
aggregate, up to and including [***] U.S. Dollars ($[***]).
	  	 	[***]%	 
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in the
aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).
	  	 	[***]%	 
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in the
aggregate, greater than [***] U.S. Dollars ($[***]).
	  	 	[***]%	 

 (xii) following the Vividion Opt-Out Date, Celgene shall provide to
Vividion an annual written progress report during the Term on the status of its material Development activities with respect to the Shared Program under this Agreement; and 

(xiii) as quickly as reasonably possible, as and to the extent applicable, Vividion shall transition to Celgene (if not previously
transitioned) Vividion’s Prosecution and enforcement responsibilities (if any) with respect to Vividion Patents, Vividion Co-Co Collaboration Patents, Joint Inventions and Joint Co-Co Patents, which transition Vividion shall use Commercially Reasonable Efforts to complete prior to the Vividion Opt-Out Date, and thereafter provide reasonable assistance
to Celgene and cooperation in connection therewith, 

  
 19 

 
including execution of such documents as may be necessary to effect such transition, provided that Vividion shall retain step-in rights (in
the event that Celgene elects not to Prosecute) on Prosecution matters relating to Joint Co-Co Patents, Vividion Patents and Vividion Co-Co Collaboration Patents that
are not Joint Co-Co Patents comparable to Vividion’s step-in rights under Section 10.2(a). 

(d) No Reversion. For purposes of clarity, except as provided in this Agreement, after the Vividion
Opt-Out Date, Celgene shall be responsible for all costs and expenses for the Shared Program and Vividion shall not have any option or right to buy back into any
co-Development or co-Commercialization rights with respect to the Shared Program. 

Article III 
 Development

 Section 3.1 Roles and Responsibilities. 

(a) Roles. 
 (i)
U.S. As of and after the Effective Date, subject to the terms and conditions of this Agreement and applicable provisions of the Master Agreement, the Parties will assume through the Committees joint responsibility for, and control of, the
Development and Commercialization of the Shared Products and Companion Diagnostics for such Shared Products in the Field in the Territory for U.S. Administration, under the Development Plan and the U.S. Commercialization Plan, respectively. Celgene
shall be the Development lead Party, the Commercialization lead Party and the Regulatory lead Party for U.S. Administration. The JDC and JCC, as applicable, will assign to each Party roles and responsibilities for performing the Development and
Commercialization for U.S. Administration consistent with the terms and conditions of this Agreement and the Master Agreement. 
 (ii)
ROW. As of and after the Effective Date, subject to the terms and conditions of this Agreement and applicable provisions of the Master Agreement, Celgene will assume sole responsibility for, and control of, Developing and Commercializing the
Shared Products and Companion Diagnostics in the Field in the Territory for ROW Administration, under the Development Plan, subject to the activities to be performed by the JSC pursuant to the Master Agreement with respect to such Development
activities in the Territory. Celgene shall be the Development lead Party, the Commercialization lead Party and the Regulatory lead Party for ROW Administration. Vividion will reasonably cooperate with Celgene in such Development and
Commercialization activities for ROW Administration in accordance with Section 3.1(c) provided, however, that, if such cooperation will cause Vividion to incur Direct Costs (including Out-of-Pocket Costs), then Celgene shall, within [***] days after receiving any invoice therefor, reimburse such costs to the extent approved in advance by Celgene. 

(b) Diligence. Celgene, directly or through one or more of its Affiliates or (sub)licensees, will use Commercially Reasonable Efforts to
Develop and Commercialize Shared Products in the Field for ROW Administration and otherwise to perform its obligations under the Development Plan for ROW Administration. Each Party, directly or through one or more of its Affiliates or
(sub)licensees, will use Commercially Reasonable Efforts to Develop and Commercialize Shared Products in the Field for U.S. Administration and otherwise perform its obligations under the Development Plan for U.S. Administration. Each Party will
reasonably cooperate with the other Party in performing the foregoing obligations. 

  
 20 

 (c) Assistance. During the Term, each Party will cooperate with the other Party to
provide reasonable assistance requested by such other Party, to facilitate the transfer of Development, Manufacture and Commercialization efforts related to the Shared Products and Companion Diagnostics, including assistance with respect to
regulatory and Clinical Trial transition matters, and the transfer to the other Party of any additional Know-How licensed to such other Party under this Agreement. Such cooperation will include providing the
other Party with reasonable access, in person or by teleconference, to such Party’s personnel involved in the Development and Manufacture of the Shared Products and Companion Diagnostics. Notwithstanding the foregoing provisions of this
Section 3.1(c), if such cooperation occurs after any Vividion Opt-Out Date or pertains primarily to ROW Administration and will cause Vividion to incur Direct Costs (including Out-of-Pocket Costs), then Celgene shall, within [***] days after receiving any invoice therefor, reimburse such costs to the extent approved in advance by Celgene. 

Section 3.2 Development of Shared Products. 

(a) Development Plan. 

(i) Initial Plan. Subject to Section 2.2 and Section 2.3, Development of Shared Products shall be governed by the Development
Plan for each of the US Territory and the ROW Territory that, collectively, describe the Development activities to be undertaken with respect to the Shared Products in the Territory, which shall include an annual budget of Development Costs pursuant
to Section 3.2(b) (“Development Budget”) and anticipated timelines for performance. Promptly after the Effective Date, but in any event within [***] days thereafter, Celgene shall prepare and submit to the JDC for review an
initial global Development Plan for Shared Products, including any activities to be performed by Vividion for U.S. Administration, and such initial global Development Plan for Shared Products shall be subject to review and approval by the JSC. The
JDC will review the required form and contents of the Development Plan (which shall be subject to review and approval by the JSC), and will review each Development Plan in accordance with Section 3.2(c). The Development Plan may be amended from
time to time by the JSC. The Direct Costs of conducting Development activities in both the ROW Territory and the US Territory in relation to a Shared Product shall be reflected in the Development Budget and allocated and paid as set forth in
Section 3.3. 
 (ii) Updates. Following the initial preparation of the Development Plan as set forth in Section 3.2(a)(i),
the JDC will update, and the JSC will review and approve, the Development Plan at least once in each Calendar Year during the Term prior to the grant of Regulatory Approval for the applicable Shared Products, with Celgene proposing the updates for
the Development Plan with respect to Shared Products for U.S. Administration and ROW Administration. In addition, either Party may reasonably request at any time that the JDC consider, and the JSC review and approve, other updates to the Development
Plan for Development activities to support Regulatory Approval on a global basis, including any Additional Study pursuant to Section 3.4. Neither Party (itself or by or through any others, including any Affiliates or (sub)licensees) will take
any material action regarding the Development of the Shared Products unless described in the Development Plan or mutually agreed upon in writing by the Parties or, with respect to Additional Studies, in accordance with Section 3.4, or as
required by applicable Laws or applicable Regulatory Authorities or independent monitoring boards for Clinical Trials. 

  
 21 

 (b) Development Budgets. Promptly after the Effective Date, but in any event within
[***] days thereafter, and concurrently with the preparation of the Development Plan pursuant to Section 3.2(a), Celgene shall prepare and submit to the JDC for review the initial Development Budget, which shall be reviewed and approved by the
JSC. Celgene shall be solely responsible for the preparation of the budget for the Development activities, including all Clinical Trials, to be conducted solely to support Regulatory Approval of Shared Products for ROW Administration. For Worldwide
Development Costs to be incurred from and after the Effective Date, the JSC will review and approve the Development Budget reasonably in advance of the applicable Worldwide Development Costs being incurred (with the intent being to obtain such
approval at least [***] months in advance of such costs being incurred, where practicable). Thereafter, the JDC will update and provide the JSC with a copy of the Development Budget, including the budgeted Worldwide Development Costs, each Calendar
Year at a meeting of the JSC sufficiently in advance of the next Calendar Year so as to provide the Parties with an opportunity to budget accordingly, but in any event no later than November 1st of each Calendar Year during the Term. The JSC will
review and approve any such update or any other amendment to the Development Budget. In addition, either Party may request at any time that the JDC consider, and the JSC approve, other updates to the Development Budget. The Parties understand and
agree that, if Vividion does not elect to participate in an Additional Study as set forth in Section 3.4, Celgene shall have the sole right to amend the Development Budget to account for the Direct Costs of such Additional Study (but, for
clarity, shall not have the right to impose any additional payment obligations on Vividion for expenses related to such Additional Study, unless and until a Co-Co Buy-In
occurs as set forth in Section 3.5, or a Deemed Buy-In occurs pursuant to Section 3.4(c)), after which time any changes to the Development Budget shall be run through the procedures described in this
Section 3.2(b). Subject to this Section 3.2(b) and Sections 3.4 and 3.5, all reasonable Direct Costs (including Out-of-Pocket Costs) arising from either
Party’s conduct of Development with respect to the Shared Program in accordance with the Development Plan and the Development Budget that qualify as Worldwide Development Costs shall be subject to the Development Cost Share. Each Party shall
use Commercially Reasonable Efforts to perform the activities assigned to it in the Development Plan. 
 (c) General Development
Principles. It is the intent of the Parties that Development of the Shared Products will be conducted in accordance with the following principles, except as otherwise mutually agreed by the Parties. The JDC (or the JSC or the Executive Officers
as applicable) shall take into account and attempt to implement the following principles in its decision-making, including preparation, review and approval of any updates to and amendments of the Development Plan: 

(i) Regardless of the specific division of responsibility between the Parties for particular activities at any particular time, the JDC (and
JSC) shall serve as a conduit for sharing information, knowledge and expertise relating to the Development of the Shared Products. 

  
 22 

 (ii) Clinical Development of the Shared Products should be performed according to a single,
integrated global program (with, for the avoidance of doubt, allowance of Additional Studies as provided in Section 3.4). 
 (iii) The
Development Plan should include an allocation of responsibilities between the Parties reasonably determined after taking into consideration each Party’s expertise, capabilities, staffing and available resources to take on such activities. 

(iv) After receipt of Regulatory Approval of a Shared Product in any Major Market, the Development Plan should (absent special circumstances
or significant changes in circumstances) include pursuit of Regulatory Approval for such Shared Product in the other Major Markets and such other countries as Celgene deems appropriate (in accordance with Section 3.1(a)). 

(d) Coordination and Reports. Each Party shall coordinate with, and keep the JDC informed with respect to, activities assigned to such
Party under the Development Plan, including the conduct of any applicable Clinical Trials. Each Party shall provide the JDC with regular quarterly written reports on such Party’s Development activities relating to the Collaboration, including a
summary of results, information, and data generated, any activities planned with respect to Development going forward (including, for example, updates regarding regulatory matters and Development activities for the next Calendar Quarter), challenges
anticipated and updates regarding intellectual property issues (including a disclosure of Co-Co Collaboration Intellectual Property discovered, developed, generated or invented since the last written report)
relating to the Collaboration. Such written reports may be discussed by telephone or video-conference, or may be provided at each JDC meeting; provided that, reasonably in advance of the meeting of the JDC, the Party providing the
written report will deliver to the JDC an agenda setting forth what will be discussed during the meeting. The Party receiving such written report shall have the right to reasonably request, and to receive in a timely manner at or after the JDC
meeting, clarifications and answers to questions with respect to such reports. 
 Section 3.3 Development Costs. The Parties
will share all Worldwide Development Costs incurred from and after the Effective Date in accordance with Section 9.1. 

Section 3.4 Additional Development Activities. If, following the Effective Date, Celgene wishes (i) to conduct a Clinical
Trial (including to repeat any Clinical Trial previously conducted under the Development Plan that failed to meet its primary endpoints) of Shared Products not contemplated by the Development Plan, (ii) to Develop Shared Products in a country
in the Territory for any Indication in the Field other than an Indication for which such Shared Products are being Developed pursuant to the Development Plan, (iii) to Develop a dosage form or formulation of Shared Products in a country in the
Territory other than that being studied in the Development Plan, or (iv) to conduct any other Clinical Trial of a Shared Product in the Field in a country, including any Clinical Trial or study that is not otherwise set forth in the Development
Plan, or any Clinical Trial that Celgene believes may have utility to support Regulatory Approval on a global basis (each such study or activity in (i)-(iv) not already included in the then-current Development Plan, an “Additional
Study”), then Parties understand and agree that this Section 3.4 shall apply and, accordingly, (A) Celgene shall first provide the proposed trial design and protocol for such Additional Study to the JSC for review and approval as
to the clinical and regulatory 

  
 23 

 
aspects of such Additional Study, and shall incorporate reasonable comments from the JSC into such Additional Study design and protocol, and (B) following such review by the JSC, Celgene
shall provide the final proposed design and projected costs of such Additional Study to the JSC. In any such case the following shall apply: 

(a) If Vividion, through its members of the JSC, agrees to co-fund such Additional Study or
subsequently elects to exercise a Co-Co Buy-In pursuant to Section 3.5, the Parties shall amend the Development Plan and the Development Budget to include such
Additional Study, and the Direct Costs of such Additional Study that constitute Worldwide Development Costs shall be included for the purpose of calculating the Development Cost Share in accordance with Section 9.1. 

(b) If Vividion does not wish to include costs incurred with respect to such proposed Additional Study within the Worldwide Development Costs
subject to the Development Cost Share, but Vividion has no material objection to such Additional Study, Celgene may proceed with such Additional Study and would be solely responsible for the conduct and costs of such study, subject to
Section 3.4(c) and Section 3.5. 
 (c) For any Additional Study that Vividion does not wish to
co-fund, to include in the Worldwide Development Costs subject to the Development Cost Share, or to exercise a Co-Co Buy-In with
respect to such Additional Study pursuant to Section 3.5 prior to the initiation of (A) a Pivotal Clinical Trial or (B) a Phase III Study of such Shared Product for the Indication, formulation, dosage form or other attribute of such
Shared Product that was the subject of such Additional Study, if the data from such Additional Study thereafter is included as primary efficacy data (and not solely safety data) in the Regulatory Approval in the US Territory for such Indication,
formulation, dosage form or other attribute of such Shared Product or informs a reimbursement decision in the US Territory (each, an “Additional Study Approval”), then Vividion shall be deemed to have elected to buy in to such
Additional Study (a “Deemed Buy-In”), and shall pay to Celgene for such Additional Study a lump sum payment (“Lump Sum”) equal to [***] percent ([***]%) of the Direct Costs
that otherwise would have been apportioned to Vividion as Worldwide Development Costs had Vividion originally opted-in, to conduct such Additional Study prior to the Deemed
Buy-In. For example, [***]. Vividion shall pay to Celgene the Deemed Buy-In amounts set forth in this Section 3.4(c) within [***] days after Celgene
notifies Vividion in writing that Celgene has received Additional Study Approval in the US Territory. 
 (d) If Vividion elects to co-fund an Additional Study, or elects to exercise a Co-Co Buy-In pursuant to Section 3.5, or is subject to a Deemed Buy-In as set forth in Section 3.4(c), then following Vividion’s decision to co-fund, or following such Co-Co Buy-In, or Deemed Buy-In, as applicable, all data resulting from such Additional Study (including any Shared Product Data) shall be available for use by Vividion (i) in
connection with Shared Products in the Field for U.S. Administration, and (ii) in the Territory to perform activities allocated to Vividion in the Development Plan or otherwise as set forth in this Agreement. 

  
 24 

 (e) For clarity, the costs of any such Additional Study shall never be included in the
Worldwide Development Cost or be subject to the Development Cost Share pursuant to Section 9.1 (and Vividion shall have no rights to any Shared Product Data arising from any such Additional Study) unless and until (i) Vividion agrees to
pay such costs pursuant to Section 3.4(a); (ii) a Co-Co Buy-In occurs pursuant to Section 3.5; or (iii) a Deemed
Buy-In occurs pursuant to Section 3.4(c). 
 Section 3.5
Buy-In Right. Notwithstanding Section 3.4(b) above, and subject to Section 3.4(c), at any time prior to the initiation of the earlier of (a) a Pivotal Clinical Trial or (b) a Phase
III Study of an applicable Shared Product for the Indication, formulation, dosage form or other attribute of such Shared Product that was the subject of an Additional Study which Vividion declined previously to
co-fund or for which a Deemed Buy-In has not yet occurred, Vividion shall have the right to elect by written notice to Celgene to include within the Worldwide
Development Costs to be subject to the Development Cost Share any Additional Study for Shared Products for which Vividion declined previously to co-fund and for which a Deemed
Buy-In has not yet occurred (the “Co-Co Buy-In”). In such case, (x) the Parties shall include within the
Worldwide Development Costs subject to the Development Cost Share, from the day of such notice onward, [***], and (y) Vividion shall reimburse Celgene an amount equal to [***] percent ([***]%) of the Direct Costs that otherwise would have been
apportioned to Vividion, if Vividion had originally opted-in, to conduct such Additional Study prior to the Co-Co Buy-In. For
example, [***]. Upon any such Co-Co Buy-In, the Parties shall have the rights with respect to such Clinical Trial or studies and the data arising therefrom as
set forth in Section 3.4(d) and Section 3.6. If Vividion elects a Co-Co Buy-In, it shall pay to Celgene the Co-Co Buy-In amounts set forth in subsection (y) within [***] days after Vividion notifies Celgene in writing that Vividion is exercising its right to effect the Co-Co Buy-In pursuant to this Section 3.5 and, for clarity, from and after any Co-Co Buy-In, the ongoing Direct Costs incurred for such
Additional Study that constitute Worldwide Development Costs shall be subject to the Development Cost Share. 
 Section 3.6 Rights
to Use Shared Product Data. 
 (a) Each Party, in a given country for Development or Commercialization of Shared Products in such
country, shall keep accurate records of all Shared Product Data generated as a result of all activity by or on behalf of such Party in performing Development and Commercialization in relation to Shared Products and Companion Diagnostics, including
any data generated pursuant to the Party’s activities under Section 3.4. Except as provided in Section 3.4(e), each Party shall provide the other Party with copies of all such Shared Product Data Controlled by the Party during the
Term that is necessary for or reasonably related to the Development and Commercialization of Shared Products and Companion Diagnostics promptly following the generation of such Shared Product Data. Shared Product Data Controlled by Celgene (other
than that to which Vividion does not have rights pursuant to Section 3.4(e)) shall be included in the license grant to Vividion pursuant to Section 8.1(b), and Shared Product Data Controlled by Vividion shall be included in the Vividion Know-How and licensed to Celgene pursuant to Section 8.1(a). 

  
 25 

 (b) Notwithstanding anything to the contrary in this Agreement, each Party shall promptly
provide to the other Party, free of charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party, and that is relevant to or necessary to address issues relating to: (i) the safety of Shared
Products in the Territory, including data that is related to adverse effects experienced with Shared Products, or (ii) all activities relating to CMC regarding Shared Products, and in each of (i) and (ii), that are required to be reported
or made available to Regulatory Authorities in the Territory, when and as such data become available. 
 Section 3.7 Companion
Diagnostics. 
 (a) Development of Companion Diagnostic. The Parties may mutually agree to Develop or Commercialize a Companion
Diagnostic for use with the Shared Products; provided that, in the event the Parties do not agree to jointly Develop or Commercialize a Companion Diagnostic, the JDC may permit a Party to Develop, Manufacture or Commercialize a
Companion Diagnostic for use with Shared Products in the Territory, directly or indirectly through a Third Party Contractor. In such event, all costs and profits with respect to such Development, Manufacturing or Commercialization of the Companion
Diagnostics for U.S. Administration (as Developed, Manufactured and Commercialized in accordance with this Section 3.7(a)) shall, prior to any Vividion Opt-Out date, be shared by the Parties in accordance
with the Development Cost Share or the Profit & Loss Share, as applicable, pursuant to a mechanism agreed to by the Parties at the time the Parties agree or the JDC permits a Party to Develop, Manufacture or Commercialize the applicable
Companion Diagnostic. 
 (b) Separate Obligations. No payments shall be owed by Celgene to Vividion pursuant to Section 9.2 or
Section 9.3 or by either Party pursuant to Section 14.3 with respect to any Companion Diagnostic. Upon termination of this Agreement, or reversion of rights to a Party with respect to the Shared Products, in addition to the effects of such
termination or reversion set forth in Section 14.3, separate transitional activities shall be undertaken with respect to the Companion Diagnostics to ensure that the appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostics shall be transferred to the Party to whom the rights to the Shared Products are transferred to the
same extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Shared Products are transferred. 

(c) No Other Diagnostics. For purposes of clarity, unless otherwise mutually agreed by the Parties, neither Party shall have any right,
under the licenses granted to such Party pursuant to Section 8.1 and notwithstanding the definition of “Field” hereunder, to Develop, Manufacture or Commercialize any biomarker or diagnostic product for use with the Shared
Products, other than a Companion Diagnostic pursuant to this Section 3.7. 

  
 26 

 Section 3.8 Records; Tech Transfer. 

(a) Maintenance of Records. Each Party shall maintain in all material respects, and shall require its Licensee Partners and Third Party
Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted in furtherance of the Collaboration and all results, data and developments made in conducting such activities. Such
records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Each Party shall require the
applicable study sites to maintain original source documents from Clinical Trials of the Shared Products for at least [***] years (or such longer period as is commercially reasonable under the circumstances, taking into account maintenance
requirements under applicable Law) following completion of the Development activities undertaken by such Party or its Licensee Partners or Third Party Contractors; provided that Celgene or Vividion shall be entitled to obtain copies of
such source documents at the end of such [***]-year period. 
 (b) Inspection. Each Party shall have the right, during normal business
hours and upon reasonable notice, to inspect and copy (or request the other Party to copy) all records of the other Party or its Licensee Partners or Third Party Contractors, as applicable, maintained in connection with the work done and results
achieved in the performance of Development activities under the Collaboration, but solely to the extent access to such records is necessary for such Party to exercise its rights under this Agreement. 

(c) Tech Transfer. As soon as reasonably practical after the Effective Date and thereafter upon Celgene’s reasonable request during
the Term, Vividion shall transfer to Celgene, at no cost to Celgene, copies of all Vividion Know-How, Vividion Co-Co Collaboration
Know-How and Vividion’s interest in the Joint Co-Co Know-How related to the Shared Products, to the extent not previously
transferred to Celgene. Upon Vividion’s reasonable request during the Term, Celgene shall transfer to Vividion, at no cost to Vividion, copies of all Celgene Know-How, Celgene Co-Co Collaboration Know-How and Celgene’s interest in the Joint Co-Co Know-How related to
the Shared Products, to the extent not previously transferred to Vividion. In addition, each Party shall provide reasonable assistance, including making its personnel reasonably available for meetings or teleconferences to answer questions and
provide technical support to the other Party with respect to the use of such transferred Know-How in the Development, Manufacture and Commercialization of Shared Products. The costs and expenses incurred by
either Party in connection with such assistance shall, prior to any Vividion Opt-Out Date, constitute Worldwide Development Costs; provided, however, that, to the extent that such
assistance occurs after any Vividion Opt-Out Date or relates primarily to ROW Administration, [***] shall solely bear all such and expenses and shall reimburse [***] for any such costs and expenses incurred
[***] within [***] days after receiving any invoice therefor and to the extent approved in advance by [***]. 
 Article IV 

Manufacture and Supply 

Section 4.1 Generally. Subject to the terms and conditions of this Agreement, Celgene will assume sole responsibility for
Manufacture of the Shared Products and Companion Diagnostics for Development and Commercialization in the Territory for both U.S. Administration and ROW Administration. 

  
 27 

 Section 4.2 Manufacturing Transition Costs. All Manufacturing Costs associated
with Manufacturing Shared Products and Companion Diagnostics (including Manufacturing Transition Costs) for U.S. Administration, excluding Manufacture of Shared Products and Companion Diagnostics for sale for U.S. Administration that are included as
“Cost of Goods Sold” in the Profit & Loss Share, will be included in the calculation of Worldwide Development Costs, and shared by the Parties in accordance with the Development Cost Share. For clarity, any Manufacturing
Costs associated with Manufacturing Shared Products and Companion Diagnostics (and associated CMC activities) that are not included in the Profit & Loss Share (as provided in the immediately preceding sentence), will be included in the
calculation of Worldwide Development Costs (unless such costs are solely for ROW Administration). 
 Article V 

Regulatory Matters 

Section 5.1 Lead Responsibility for Regulatory Interactions. Except as may otherwise be mutually agreed by the Parties or the JSC,
JDC or JCC, as applicable, and subject to oversight by the JSC, JDC or JCC: 
 (a) Lead Responsibility. Celgene shall have lead
responsibility for all Regulatory Interactions with Regulatory Authorities in the US Territory and the ROW Territory for each Shared Product. 

(b) Regulatory Interactions Defined. For purposes of this Agreement, “Regulatory Interactions” means
(i) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory Authorities with respect to the Shared Products and (ii) interfacing,
corresponding and meeting with the Regulatory Authorities with respect to the Shared Products. 
 (c) Regulatory Responsibilities.

 (i) Vividion shall (A) at Celgene’s option, either close or inactivate Vividion’s IND(s) for each Shared Product, or
transfer such IND(s) to Celgene, and (B) with Celgene input, complete all relevant activities related to such IND(s) as required for Celgene to assume regulatory ownership, as applicable, all as soon as practicable (but, in the case of the
transfer of any IND(s), in no event later than [***] days after Celgene’s notice unless otherwise agreed by the Parties); 
 (ii)
Celgene shall be responsible for the preparation and filing of all regulatory filings with respect to any subsequent Development, Manufacturing or Commercialization for Shared Products after such activities described in clause (i) above are
completed; and 
 (iii) Vividion shall provide Celgene with all relevant clinical and non-clinical
data reasonably requested by Celgene or a Regulatory Authority, including CMC, pharmacology and toxicology generated by Vividion with respect to each Shared Product. 

  
 28 

 Section 5.2 Participation Rights. 

(a) Review of Regulatory Documentation. Each Party shall keep the JDC reasonably informed in connection with all Regulatory
Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, Regulatory Approvals, annual reports, including annual safety reports to the respective health authorities, annual re-assessments, and any subsequent variations and changes to labeling, in each case with respect to the Shared Products. Each Party shall respond within a reasonable time frame to all reasonable inquiries by the
other Party with respect to any information provided pursuant to this Section 5.2(a) (and sufficiently promptly for the other Party to provide meaningful input with respect to responses to Regulatory Authorities). 

(b) Participation in Meetings. Vividion shall have the right to have up to two (2) senior, experienced employees reasonably
acceptable to Celgene participate as observers in material or scheduled face-to-face meetings, video conferences and teleconferences with all applicable Regulatory
Authorities relating to any Shared Product, and shall be provided with advance access to Celgene’s material documentation prepared for such meetings. 

(c) Review. Prior to submission of material correspondence to any Regulatory Authority with respect to the Shared Products, Celgene
shall, sufficiently in advance for the other Party to review and comment, provide Vividion any material correspondence with the Regulatory Authority related to such meetings. Celgene shall also provide Vividion with copies of any material
correspondence with Regulatory Authorities relating to Development of, or the process of obtaining Regulatory Approval for, the Shared Products and respond within a reasonable time frame to all reasonable inquiries by Vividion with respect thereto.

 Section 5.3 Global Safety Database; Pharmacovigilance Agreement. At a time to be mutually agreed by the Parties, Celgene
shall establish, hold and maintain a single electronic system for the collection and storage of all safety information for the Shared Products in the Territory (the “Global Safety Database”). Such database shall comply in all
material respects with all Laws reasonably applicable to pharmacovigilance anywhere where the Shared Products are being or have been Developed or Commercialized. Unless the Parties otherwise agree in the Pharmacovigilance Agreement, Celgene shall be
responsible for the Global Safety Database for the Shared Products; provided, that Vividion may hold and maintain a parallel safety database for the Shared Products as needed or required according to applicable Laws. The Parties will use
Commercially Reasonable Efforts to negotiate a pharmacovigilance agreement (the “Pharmacovigilance Agreement”) to govern cooperation among the Parties that will enable each of them to comply with its respective obligations under
applicable Laws and to satisfy its duty of care with respect to the Shared Products, including with regard to ownership of the Global Safety Database, adverse event data collection, analysis and reporting. The Pharmacovigilance Agreement will be
entered among the Parties no later than [***] days following the Effective Date. 
 Section 5.4 Recalls, Market Withdrawals or
Corrective Actions. 
 (a) In the event that any Regulatory Authority issues or requests a recall, market withdrawal or similar action in
connection with a Shared Product in any portion of the Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall, market withdrawal or similar action in any
country in the 

  
 29 

 
Territory, the Party notified of such recall, market withdrawal or similar action, or the Party that desires such recall, market withdrawal or similar action, shall within twenty-four
(24) hours advise the other Party thereof by telephone. Celgene shall, after reasonable consultation with Vividion, decide whether to conduct a recall, market withdrawal or similar action in such country or portion of the Territory and the
manner in which any such recall, market withdrawal or similar action shall be conducted. Each Party will make available to the other Party, upon request, all of such Party’s (and its Affiliates’) pertinent records that such other Party may
reasonably request to assist such other Party in effecting any recall, market withdrawal or similar action. 
 (b) The costs and expenses
incurred before the Vividion Opt-Out Date relating to a recall, market withdrawal or similar action of any Shared Product(s) in the Territory shall be (I) taken into account in determining the Development
Cost Share if incurred prior to First Commercial Sale of the applicable Shared Product in the applicable country, (II) taken into account in determining the Profit & Loss Share if incurred in the US Territory after the First Commercial
Sale of the applicable Shared Product in the US Territory or (III) borne solely by Celgene if incurred in a country in the ROW Territory after the First Commercial Sale of the applicable Shared Product in such country (in each case, as, and to
the extent, provided in Section 9.1, Section 9.6 and Exhibit D). The costs and expenses incurred after the Vividion Opt-Out Date for any recall, market withdrawal or similar action of any
Shared Product(s) in the Territory shall be borne solely by Celgene if and only to the extent (i) such recall, market withdrawal or similar action was caused by the occurrence after the Vividion Opt-Out
Date of the event, incident or circumstance that led to the recall, market withdrawal or similar action and (ii) the event, incident or circumstance and the costs and expenses for such recall, market withdrawal or similar action are not the
subject of an indemnity obligation of Vividion under Section 13.1 or Section 13.2. The costs and expenses incurred after the Vividion Opt-Out Date relating to any recall, market withdrawal or similar
action of any Shared Product(s) in the US Territory shall be borne by the Parties in accordance with the Profit & Loss Share to the extent (A) such recall, market withdrawal or similar action was caused by the occurrence before the
Vividion Opt-Out Date of the event, incident or circumstance that led to the recall, market withdrawal or similar action and (B) such event, incident or circumstance and such costs and expenses are not
the subject of an indemnity obligation of either Party under Section 13.1 or Section 13.2. If Vividion is invoiced for its portion of such costs and expenses incurred after the Vividion Opt-Out Date,
payment is due within [***] days of receipt of invoice. 
 Article VI 

Commercialization 

Section 6.1 Commercialization Responsibilities for Shared Products. 

(a) Responsibility. Subject to the terms and conditions of this Agreement, including Vividion’s rights under Section 6.2,
Celgene will have sole responsibility, and shall be the Commercialization lead Party, for all Commercialization activities for Shared Products for U.S. Administration and ROW Administration. Subject to the terms and conditions of this Agreement,
including this Article VI, Celgene (as the Commercialization lead Party) shall have final decision-making authority with respect to all matters that relate to Commercialization of Shared Products in the Territory, in accordance with
Section 2.2. Vividion (itself or by or through any others, including any Affiliates or (sub)licensees), will not take any action regarding the Commercialization of Shared Products unless (i) described in the U.S. Commercialization Plan or
(ii) otherwise approved by the JCC. 

  
 30 

 (b) Sales. Celgene will book all sales of the Shared Products in the US Territory and the
ROW Territory, and will have the sole responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Shared Products throughout the US Territory and the ROW Territory. 

Section 6.2 U.S. Commercialization Plan. 

(a) Initial U.S. Commercialization Plan. No later than [***] months prior to the anticipated submission of the first NDA for the first
Shared Product for Regulatory Approval from the FDA in the US Territory (as set forth in the Development Plan), Celgene (after good faith consultation with Vividion) will prepare an initial Commercialization plan for the US Territory (the
“U.S. Commercialization Plan”) for Shared Products covering the first [***] years after First Commercial Sale of any Shared Product in the US Territory, and the JCC will review and approve such initial U.S. Commercialization Plan.
Thereafter, Celgene (after good faith consultation with Vividion) will update the U.S. Commercialization Plan (for the current Calendar Year and the [***] succeeding Calendar Years) each Calendar Year, and the JCC will review and approve any such
update or other amendment to the U.S. Commercialization Plan. Either Party may request at any time that the JCC consider and approve other updates to the U.S. Commercialization Plan. 

(b) Additional Terms. In addition: 

(i) The JCC will set the required form and contents of the U.S. Commercialization Plan. The U.S. Commercialization Plan will specify, as
applicable, among other things, the number of sales representatives in the US Territory for each Party, creation of marketing and promotional materials, planning for conferences, the number, type (e.g., first position, second position) and
frequency of details to be conducted by sales representatives for Shared Products in each Calendar Year, the allocation of sales details across geographies between the Parties, sales forecasts, strategies for compensation packages for sales
representatives, Shared Product pricing strategy, strategy for managed care and reimbursement plans. Vividion will have the right to provide up to [***] percent ([***]%) of the total sales representatives and medical science liaisons in the US
Territory, calculated on an FTE basis (with the calculation of costs of engaging such FTEs for purposes of calculating Operating Profits or Losses being based on the FTE Rate), such basis to be used by both Parties for promotion of Shared Products
for U.S. Administration. The U.S. Commercialization Plan will set forth the precise number of Vividion sales representatives and medical science liaisons consistent with the foregoing. 

(ii) The U.S. Commercialization Plan will attempt to provide that marketing activities in the US Territory are distributed equitably (with
respect to geography and prescriber opportunities) between the Parties. 
 (iii) Neither Party (itself or by or through any others,
including any Affiliates or (sub)licensees) will take any material action regarding the Commercialization of Shared Products for U.S. Administration unless described in the U.S. Commercialization Plan or approved by the JCC. 

  
 31 

 (iv) All Commercialization of Shared Products for U.S. Administration will be conducted
pursuant to the overview of the JCC and pursuant to the U.S. Commercialization Plan. 
 (c) U.S. Commercialization Budget. At such times as
the JCC will deem appropriate, and concurrently with the preparation of the initial U.S. Commercialization Plan, Celgene (after good faith consultation with Vividion) will prepare an initial U.S. Commercialization budget for the US Territory (the
“U.S. Commercialization Budget”), and the JCC will review and approve such initial U.S. Commercialization Budget. Thereafter, Celgene (after good faith consultation with Vividion) will update the U.S. Commercialization Budget at
least once in each Calendar Year, (but in any event no later than November 30 of each Calendar Year during the Term) and the JCC will review and approve any such update or any other amendment to the U.S. Commercialization Budget. In addition,
either Party may request at any time that the JCC consider and approve other updates to the U.S. Commercialization Budget. 
 (d)
Additional Terms. In addition: 
 (i) The JCC will set the required form and contents of the U.S. Commercialization Budget. 

(ii) In preparing the U.S. Commercialization Budget, only the Commercialization activities for U.S. Administration will be included; any costs
and expenses for ROW Administration will not be included. 
 Section 6.3 ROW Commercialization; Celgene Reports. For the
avoidance of doubt, and notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that Celgene has the sole right and responsibility for the Commercialization of the Shared Products for the ROW Territory and,
except as expressly set forth in this Agreement, and subject to the terms and conditions of this Agreement and the Master Agreement, nothing will restrict Celgene from taking any action regarding the Commercialization of the Shared Products in the
ROW Territory. At least once during each year during the Term, Celgene shall provide to Vividion, through the JSC, a written progress report on the status of its material Commercialization activities with respect to Shared Products and related
Companion Diagnostics during the applicable year, and Celgene’s plans with respect to Commercialization of Shared Products during the following [***] month period. 

Section 6.4 Acknowledgement. Vividion hereby acknowledges and agrees that (a) it has rights with respect to the
Commercialization of Shared Products for U.S. Administration solely as set forth herein; (b) it will not convey, transfer, license or lease any of its rights or obligations under this Agreement, except as expressly permitted in this Agreement,
including as set forth in Section 8.2, Section 12.4 or Section 15.4. 
 Section 6.5 Commercialization Activities.

  
 32 

 (a) Training. Celgene shall, in the ROW Territory and, pursuant to the overview of
the JCC, in the US Territory (i) direct the training of sales representatives (together with the first line managers who oversee such sales representatives) with respect to Shared Products, and will prepare and implement a training program and
training materials for such sales representatives therefor, and (ii) specify the conduct and content of details (including detail scripts) for the Shared Products. Each Party will cause each of its sales representatives assigned to promote the
Shared Products to attend and complete the training program developed as provided above for the Shared Products to assure a consistent, focused promotional strategy and message as and to the extent consistent with applicable Law. 

(b) Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to
Commercialization of Shared Products: 
 (i) Conduct of Sales Representatives. Each Party will be solely responsible for recruiting,
hiring and maintaining its sales force of sales representatives for promotion of the Shared Products in accordance with its standard procedures, the requirements of this Agreement and the minimum qualifications set forth on Schedule 6.5. Each Party
will be responsible for the activities of its sales representatives, including compliance by its sales representatives with training and detailing requirements. In particular, each Party will provide its sales representatives assigned to promote the
Shared Products in the US Territory and the other Major Markets with the level of oversight, management, direction and sales support with respect to the promotion of Shared Products necessary to effectively and efficiently promote the Shared
Products in accordance with the terms of this Agreement and applicable Law. Each Party agrees that none of its sales representatives involved in the promotion of the Shared Products will have any legal or regulatory disqualifications, bars or
sanctions. If Celgene raises any reasonable concern with Vividion regarding the performance or fitness of any of Vividion’s sales representatives, Vividion will address such concerns in a reasonable manner. 

(ii) Third Party Contract Sales Force. Notwithstanding the foregoing, Vividion will not have the right to use any Third Party contract
sales force to fulfill its activities under this Agreement, except with the prior written consent of Celgene not to be unreasonably withheld or delayed (provided that Celgene may withhold or revoke its consent, with respect to all
Shared Products, for any reason during the [***] months following First Commercial Sale in the US Territory upon reasonable written notice to Vividion). 

(iii) Detailing. The U.S. Commercialization Plan will set forth (A) the precise number of each Party’s sales representatives
for Shared Products in the US Territory, consistent with the foregoing, (B) policies and processes for the creation of marketing and promotional materials, (C) planning for conferences, (D) the number, type (e.g., first position,
second position, etc.) and frequency of details to be conducted by sales representatives for Shared Products in each Calendar Year, (E) the allocation of sales details between the Parties, (F) development of sales forecasts, and
(G) coordinating strategies for compensation packages for sales representatives. 

  
 33 

 (iv) Shortfall. If the Vividion does not initially provide in the US Territory or at
any particular time after the commencement of such detailing does not provide in the US Territory, for any reason, the number of sales representatives specified in the U.S. Commercialization Plan to be provided for the US Territory, then Celgene
will have the right to make up such shortfall using its sales representatives until such time as Vividion is able to provide its agreed upon number of sales representatives and for a period of one hundred eighty (180) days thereafter and, for
clarity, all costs incurred by Celgene related to Celgene’s making up such shortfall shall be included in the calculation of Operating Profits or Losses. 

(v) Cost Calculation. The calculation of costs of engaging sales representatives in the US Territory for purposes of calculating
Operating Profits or Losses shall be based on the FTE Rate, and such FTE Rate shall be used by both Parties for promotion of Shared Products in the US Territory; provided, however, that (A) if the costs of engaging a sales
representative (whether or not as an employee) in the US Territory is (x) above the FTE Rate, the costs shall be capped at the FTE Rate and (y) below the FTE Rate, the actual costs shall be used instead of the FTE Rate; and (B) with
respect to any sales representative who is detailing pharmaceutical products other than Shared Products, the applicable Party shall allocate costs of engaging such sales representative with respect to such pharmaceutical products and Shared Products
based on the weighted Incentive Compensation of such sales representative. For purposes of this Section 6.5(b)(v), “Incentive Compensation” means, with respect to a sales representative, the variable, periodic target
compensation (not including equity compensation) the sales representative earned based on such sales representative’s performance. 

(vi) Promotional Materials. Each Party’s sales representatives assigned to promote the Shared Products in the US Territory will
utilize only promotional materials that have been reviewed by the JCC and approved by Celgene. All detailing activities conducted by each Party’s sales representatives will be consistent in all material respects with the promotional materials
so approved. Each Party will train and instruct their respective sales representatives to make only those statements and claims regarding the Shared Products, including as to efficacy and safety, that are consistent with the Shared Product labeling
and accompanying inserts and the approved promotional materials. For clarity, all marketing and promotional materials used in the US Territory must be approved by Celgene prior to use. 

(vii) Medical Affairs; Information. For Shared Products in the US Territory, the Parties will discuss the implementation of medical and
scientific affairs and programs, including for professional symposia and other educational activities, and medical affairs studies based upon approved protocols, medical information support and medical communications and publishing activities, and
the allocation of each Party to such activities in the US Territory, provided that Celgene, following consultation with the JCC, shall have the final decision-making authority to the conduct of such activities in the US Territory (it
being understood and agreed that [***] shall be permitted to contribute [***] percent ([***]%) of the medical science liaisons on an equitable basis in the US Territory). The Parties acknowledge that in the US Territory each Party may receive
requests for medical information concerning any Shared Product from members of the medical professions and consumers. Celgene will have the exclusive right to respond to questions and requests for information about Shared Products received from
Persons in the Territory that warrant a response beyond the understanding of the sales representatives or that are beyond the scope of the Shared Product labels and inserts (each such request, an “Information Request”) and that are
solely applicable to Shared Products for ROW Administration. Any Information Request that is applicable to Shared Products for U.S. Administration or throughout the Territory shall be referred to the JCC. 

  
 34 

 (viii) Market Access Activities. Celgene, as the Commercialization lead Party, will
have sole authority, in the Territory, following consultation with the JCC, to develop plans for market access activities. For Shared Products in the US Territory, each Party shall have the right to participate in the foregoing activities in
accordance with the U.S. Commercialization Plan, which shall provide for an equitable distribution of such activities between the Parties. The costs related to such market access activities in the US Territory prior to any Vividion Opt-Out Date shall be included, to the extent they constitute Allowable Expenses, in the calculation of Operating Profits or Losses, and the costs related to such market access activities in the ROW Territory and,
after any Vividion Opt-Out Date, the US Territory shall be borne solely by Celgene. 
 (ix)
Reporting. Each Party will provide the JCC with a report, as soon as practicable but in no event later than [***] days following the end of each Calendar Quarter commencing as of the date upon which the first Shared Product has received Regulatory
Approval in the Territory, or at such other time as the JCC deems appropriate, and continuing thereafter for each Calendar Quarter for the remainder of the Term, setting forth the number of details made by its sales representatives of Shared
Products during such Calendar Quarter. Costs and expenses for sales representatives for U.S. Administration prior to any Vividion Opt-Out Date will be charged to the Profit & Loss Share on an FTE Rate
basis consistent with the U.S. Commercialization Budget. Costs and expenses for sales representatives for ROW Administration and, after any Vividion Opt-Out Date, U.S. Administration will be borne solely by
[***]. 
 (x) Records. Each Party will maintain records and otherwise establish procedures to ensure compliance with all applicable Laws and
professional requirements that apply to the promotion and marketing of Shared Products, including compliance with the PhRMA Code on Interactions with Healthcare Professionals. 

(c) Commercialization Costs. During the Term, all Commercialization costs in the US Territory that constitute Allowable Expenses and are
incurred pursuant to the U.S. Commercialization Plan and U.S. Commercialization Budget prior to any Vividion Opt-Out Date (for U.S. Administration only, the “U.S. Commercialization Costs”)
shall be included in the Profit & Loss Share. Subject to the terms and conditions of this Agreement, all Commercialization costs in the ROW Territory and, after any Vivdion Opt-Out Date, the US
Territory shall be borne [***] percent ([***]%) by [***]. 
 Section 6.6 Trademarks. 

(a) Selection of Trademarks. Celgene, following consultation with the JCC and JPC, shall select the trademark(s) to be used in
connection with the marketing and sale of the Shared Products in the Territory (such marks, together with registrations, applications for registration and common law rights therein, collectively, “Product Trademarks”). Any dispute
over the selection of a Product Trademarks shall be presented to the JSC for resolution. The Parties shall adhere to the use of the Product Trademark(s) in their Commercialization of the Shared Products in the Territory hereunder, to the extent
permitted by Law. 

  
 35 

 (b) Ownership. Celgene shall own all Product Trademarks for any Shared Product in the
Territory. Vividion will execute and deliver any further document reasonably requested by Celgene to further document or record such assignment. 

(c) Branding. At such time as the JCC deems appropriate, the Parties shall discuss in good faith any branding or
co-branding of the Shared Products (the “Licensed Branding”), and the Parties will enter into appropriate trademark licensing agreements to achieve the foregoing. For the avoidance of doubt,
nothing in this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s trademarks, tradenames, logos, or other marks (other than Product Trademarks), including use thereof, absent a separate trademark
licensing agreement entered into by the Parties. Notwithstanding the foregoing, subject to any restrictions on the form or content of the Licensed Branding imposed by any Regulatory Authority, unless the Parties mutually agree otherwise in writing,
the Licensed Branding used with respect to Shared Products shall feature the logos of Vividion and Celgene with approximately equal sizing and similar prominence, with Celgene’s name first, on all packaging and materials used for
Commercialization of such Shared Products, to the extent permitted by applicable Law. 
 Article VII 

Diligence 

Section 7.1 Collaboration Activities. 

(a) General. Each Party shall use Commercially Reasonable Efforts to perform all Development, Manufacturing and Commercialization
activities for which such Party is responsible hereunder and, as applicable, shall perform such activities in compliance with the applicable Development Plan or U.S. Commercialization Plan, including any budget(s) and timeframe(s) set forth therein
and including making available those resources set forth in any applicable Development Plan or U.S. Commercialization Plan, and the terms of this Agreement. 

(b) Compliance with Laws. Each Party shall: 

(i) perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and 

(ii) carry out all work done in the course of the Collaboration in compliance with all applicable Laws governing the conduct of such work.

 Section 7.2 Diligence Obligations. In addition to the diligence obligations set forth in , the Parties (directly or through
one or more Affiliates or Licensee Partners) shall, as applicable, use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Shared Products in each of the Major Markets and, following such Regulatory Approval, to
Commercialize such Shared Products in each of the Major Markets. 
 Section 7.3 Day-to-Day Responsibility. Each Party shall be responsible for day-to-day implementation of the Development, Manufacturing
and Commercialization activities for which it (or its Affiliate) has been, or otherwise is, assigned responsibility under this Agreement or, as applicable, the Development Plan or U.S. Commercialization Plan and shall keep the other Party reasonably
informed as to the progress of such activities, as determined by the JDC and JCC. 

  
 36 

 Article VIII 

Grant of Rights; Exclusivity 

Section 8.1 License Grants. Subject to the terms and conditions of this Agreement: 

(a) License Granted to Celgene. During the Term, subject to the terms and the conditions set forth in this Agreement and the Master
Agreement, Vividion hereby grants to Celgene the following licenses: 
 (i) in the Territory, an exclusive (even as to Vividion and its
Affiliates) license, with the right to grant sublicenses (subject to Section 8.2 and Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property
and Vividion’s interest in the Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion Diagnostics for ROW Administration;
provided, however, that, as to Companion Diagnostics, such license grant shall be limited to Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing Companion
Diagnostics for use as companion diagnostics with Shared Products under this Agreement; 
 (ii) in the Territory, a co-exclusive (with Vividion and its Affiliates and (sub)licensees) license, with the right to grant sublicenses (subject to Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and Vividion’s interest in the Manufacturing Technology to Develop, use, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion
Diagnostics for U.S. Administration; provided, however, that, as to Companion Diagnostics, such license grant shall be limited to Developing, using, offering for sale, selling, importing and otherwise Commercializing Companion
Diagnostics for use as companion diagnostics with Shared Products under this Agreement; and 
 (iii) in the Territory, an exclusive (even as
to Vividion and its Affiliates) license, with the right to grant sublicenses (subject to Section 8.2 and Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration
Intellectual Property and Vividion’s interest in the Manufacturing Technology to Manufacture and have Manufactured the Shared Products and Companion Diagnostics for the US Territory; provided, however, that, as to Companion
Diagnostics, such license grant shall be limited to Manufacturing and having Manufactured Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

(b) License Granted to Vividion. During the Term, subject to the terms and on the conditions set forth in this Agreement and the Master
Agreement, Celgene hereby grants to Vividion the following licenses (in addition to the covenant not to sue contained in Section 12.7): 

(i) a non-exclusive, worldwide, royalty-free, fully-paid right and license, with the right to grant
sublicenses (subject to Section 8.3), under the Celgene Co-Co Collaboration Intellectual Property, solely (A) in the event Celgene requests Vividion to perform activities with respect to the Shared
Products or Companion Diagnostics (including pursuant to Section 3.2), and in the event Vividion agrees to perform such activities, in accordance with the terms and conditions of this Agreement and (B) to the extent required to permit
Vividion to conduct such activities (if any); provided, however, that, as to Companion Diagnostics, such license grant shall be limited to performing such activities with respect to Companion Diagnostics for use as companion
diagnostics with Shared Products under this Agreement; and 

  
 37 

 (ii) in the Territory, a co-exclusive (with Celgene
and its Affiliates and (sub)licensees), royalty-free, fully-paid right and license, with the right to grant sublicenses (subject to Section 8.3) under and to the Celgene Co-Co Collaboration Intellectual
Property to offer for sale, sell, import, and otherwise Commercialize the Shared Products and Companion Diagnostics for U.S. Administration; provided, however, that, as to Companion Diagnostics, such license grant shall be
limited to offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

Section 8.2 Sublicense Rights. Subject to Section 8.3, the Parties have the following sublicensing rights. 

(a) Sublicenses to Affiliates and Subcontractors. Each Party shall have the right to grant sublicenses within the scope of the licenses
and sublicense under Section 8.1: 
 (i) to such Party’s Affiliates; and 

(ii) to Third Parties for the purpose of (X) with respect to Celgene, Commercializing, outside of the US Territory, France, Germany,
Italy, Spain and the United Kingdom, any Shared Product or related Companion Diagnostic or (Y) engaging Third Parties as contract research organizations, contract manufacturers, contract sales forces, consultants, academic researchers and the
like (“Third Party Contractors”) in connection with Development, Manufacturing or Commercialization activities throughout the Territory (to the extent such Party is permitted to engage in such activities in any applicable country)
on behalf of such Party or its Affiliates with respect to the Collaboration under this Agreement, subject to the following: 
 (A) unless
otherwise mutually agreed by the Parties, each Party shall require any such Third Party to whom such Party discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of
confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in
compliance with the terms of this Agreement (including approval by the JDC or JCC, as applicable, pursuant to the approved publication plan, and the obligations set forth in Section 11.4, except that Publications by academic collaborators shall
be permitted (without JDC or JCC consent, as applicable) if the academic collaborator (i) provides an advance copy of the proposed Publication (under the same time periods as described in Section 11.4(a)), which must be shared with the
other Party, (ii) agrees to delay such Publication sufficiently long enough to permit the timely preparation and filing of a patent application, and (iii) upon the request of either Party, removes from such Publication any Confidential
Information of such Party); 

  
 38 

 (B) unless otherwise mutually agreed by the Parties, each Party will obligate such Third
Party to agree in writing to assign ownership of, or grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to the
extent related to Development, Manufacturing or Commercialization with respect to the Shared Products in the Field; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party
inventions to the other Party pursuant to Section 8.1 (including permitting such other Party to grant further sublicenses); provided that, in connection with any academic collaborator performing research work with respect to the Co-Co Target or Shared Products that is not reasonably expected by the applicable Party to result in inventions related to composition of matter or methods of use, it shall be sufficient for such Party to obtain a
non¬exclusive, worldwide, royalty-free, perpetual license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses, to, any inventions resulting from such research work,
which sublicensing rights must permit sublicensing to the other Party pursuant to Section 8.1 (including permitting such other Party to grant further sublicenses); 

(C) each Party shall notify the JDC or JCC, as applicable, at a regular meeting of the JDC or JCC, as applicable, of the execution of any such
agreement with any such Third Party and, if requested, shall provide the other Party with a copy of such agreement, which copy may be redacted with respect to matters that do not relate to the Collaboration; and 

(D) unless otherwise mutually agreed by the Parties, each Party will require any such Third Party to grant to the other Party access to all
confidential protocols and data generated by such Third Party’s work with respect to the Shared Products to the same extent as such other Party’s grant of licenses under Section 8.1, and grant the other Party the right to audit the
records of such Third Party. 
 (b) Other Sublicenses. Except as provided in Section 8.2(a), any other sublicense by either Party under
the licenses and sublicenses set forth in Section 8.1 shall require the prior written approval of the other Party. 
 Section 8.3
Sublicense Requirements. Any sublicense granted by a Party pursuant to this Agreement shall be subject to the following: 
 (a) each
sublicense granted hereunder by a Party or its Affiliates shall be consistent with the requirements of this Agreement; 
 (b) any transfer of
rights between a Party and its Affiliates shall not be deemed a sublicense by such Party but shall be deemed a direct license by the other Party to such Party’s Affiliate; it being understood and agreed that such Party shall remain responsible
for the activities of its Affiliate; 
 (c) a Party’s or its Affiliates’ Licensee Partners or Third Party Contractors shall have no
right to grant further sublicenses without the other Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 

  
 39 

 (d) such Party shall be primarily liable for any failure by its Affiliates and Licensee
Partners and Third Party Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement; and 
 (e) such
sublicense must be granted pursuant to a written sublicense agreement and, with respect to any sublicense other than a sublicense by a Party to an Affiliate of such Party, such Party must provide the other Party with a copy of any sublicense
agreement entered into under Section 8.2 above within thirty (30) days after the execution of such sublicense agreement; provided that any such copy may be reasonably redacted to remove any confidential, proprietary or
competitive information, but such copy shall not be redacted to the extent that it impairs the other Party’s ability to ensure compliance with this Agreement. Such sublicense agreement shall be treated as Confidential Information of the
sublicensing Party and no copies are required with respect to sublicense agreements with Third Party Contractors. 
 Section 8.4
Affiliates and Third Party Contractors. Either Party may exercise its rights and perform its obligations hereunder itself or through its Affiliates and (sub)licensees. Each Party shall be primarily liable for any failure by its Affiliates and
(sub)licensees (including Third Party Contractors) to comply with all relevant restrictions, limitations and obligations in this Agreement. If either Party desires to use any Person to conduct any of its Development, Commercialization, Manufacture
or other Collaboration activities hereunder, such Party must comply with the obligations of Section 8.2(a)(ii)(A) through (D), even to the extent no sublicense of rights is granted to such Third Party. 

Section 8.5 Third Party Agreements. 

(a) Acknowledgement. Except as provided in Section 8.5(b) and Section 9.7, each Party acknowledges that Vividion is
responsible for the fulfillment of its obligations under each Existing Third Party Agreement, and each Party is responsible for the fulfillment of its obligations under any Subsequent Third Party Agreement that it enters into, and each Party agrees
to fulfill the same obligations, including any provisions necessary to maintain in effect any rights sublicensed to the other Party hereunder and the exclusive or non-exclusive nature of such rights, as
applicable, subject to the other Party’s compliance with its obligations hereunder. 
 (b) Incorporation of Certain Provisions.
Each Party agrees and acknowledges that Vividion is required to provide to licensors under the Existing Third Party Agreements, and either Party may be required to provide to licensors under any Subsequent Third Party Agreements, periodic reports
relating to the gross sales and Net Sales of Shared Products. Each Party shall keep true and accurate records and books of account, and open such books and records for inspection by such licensors, for a duration of [***] years from the date of
origination of such books or records. Furthermore, each Party acknowledges that the other Party may be required to share certain reports and copies of sublicense agreements provided hereunder with any licensor under an Existing Third Party Agreement
or Subsequent Third Party Agreement, and each Party consents to the sharing of such reports and such copies of such sublicense agreements to the extent required under such Existing Third Party Agreement or Subsequent Third Party Agreement to the
same extent as disclosures are permitted under Section 11.3(b) hereunder; provided that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party Agreement or Subsequent
Third Party Agreement. In addition, 

  
 40 

 
each Party acknowledges that the Prosecution, enforcement and other intellectual property management rights under this Agreement with respect to Patents and other intellectual property licensed
under Existing Third Party Agreements or Subsequent Third Party Agreements shall be subject to the terms and conditions of the applicable Existing Third Party Agreements or Subsequent Third Party Agreements and, in the case of Existing Third Party
Agreements or Subsequent Third Party Agreements in which the licensor is an academic institution, other provisions of such Existing Third Party Agreements or Subsequent Third Party Agreements that are customarily required to be imposed on
sublicensees in academic licenses (in no event to include any exclusivity covenant). 
 (c) Covenants Regarding Third Party
Agreements. Each Party that has entered into an Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement (the “Licensing Party”) agrees that during the Term: 

(i) The Licensing Party shall not modify or amend any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent
Third Party Agreement in any way that adversely affects the other Party’s rights hereunder without the other Party’s prior written consent; 

(ii) The Licensing Party shall not terminate any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third
Party Agreement, in whole or in part, without the other Party’s prior written consent; 
 (iii) Subject to Section 9.7, the
Licensing Party shall be solely responsible for, and shall make, all royalty payments, milestone payments, yearly fees, sublicensee fees, Prosecution fees, and all other payments owed to any licensor under and pursuant to any Existing Third Party
Agreement or Subsequent Third Party Agreement; 
 (iv) The Licensing Party shall not exercise or fail to exercise any of its rights, or fail
to perform any of its obligations, under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement, where such exercise or failure to exercise or perform would adversely affect the other
Party’s rights hereunder, without the prior written consent of the other Party, including rights with respect to including applicable improvements within the licenses granted under such Existing Third Party Agreement or, solely with respect to
the US Territory, Subsequent Third Party Agreement; and, at the reasonable request of the other Party, the Licensing Party shall exercise such rights and make such requests described above as are permitted under such Existing Third Party Agreement
or Subsequent Third Party Agreement; 
 (v) The Licensing Party shall promptly furnish the other Party with copies of all reports and other
communications that the Licensing Party furnishes to any licensor under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement to the extent that such reports relate to this Agreement; 

(vi) The Licensing Party shall promptly furnish the other Party with copies of all reports and other communications that the Licensing Party
receives from any licensor under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement that relate to this Agreement (including notices relating to applicable improvements under such
Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement); 

  
 41 

 (vii) The Licensing Party shall furnish the other Party with copies of all notices received
by the Licensing Party relating to any alleged breach or default by the Licensing Party under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement within [***] Business Days after the
Licensing Party’s receipt thereof; in addition, if the Licensing Party should at any time breach an Existing Third Party Agreement or, solely with respect to the US Territory, subsequent Third Party Agreement or become unable to timely perform
its obligations thereunder, the Licensing Party shall immediately notify the other Party; and 
 (viii) If the Licensing Party cannot or
chooses not to cure or otherwise resolve any alleged breach or default under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement, (A) the Licensing Party shall so notify the other
Party within [***] Business Days of such decision, which shall not be less than [***] Business Days prior to the expiration of the cure period under such Existing Third Party Agreement or Subsequent Third Party Agreement; provided that
the Licensing Party shall use Commercially Reasonable Efforts to cure any such breach or default; and (B) the other Party, in its sole discretion, shall be permitted (but shall not be obligated), on behalf of the Licensing Party, to cure any
breach or default under such Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement in accordance with the terms and conditions of such Existing Third Party Agreement or, solely with respect to
the US Territory, Subsequent Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement; and
(C) if Celgene pays any such licensor any amounts owed by the Licensing Party under such Existing Third Party Agreement, then, provided that such amounts have not arisen as a result of Celgene’s failure to comply with the
terms and conditions of such Existing Third Party Agreement within the categories described in Section 8.5(b) applicable to Celgene as a sublicensee, Celgene may deduct the Licensing Party’s share of such amounts from payments Celgene is
required to make thereafter to the Licensing Party hereunder or, at Celgene’s election, may otherwise seek reimbursement of such amounts from the Licensing Party. 

(d) Survival of Rights Following Termination of Third Party Agreement. The Parties agree that in the event of any termination of any
Existing Third Party Agreement or Subsequent Third Party Agreement with respect to any intellectual property rights licensed to a Party hereunder, such Party shall have any rights available under such Existing Third Party Agreement or Subsequent
Third Party Agreement to become a direct licensee of the Third Party licensor(s) under such Existing Third Party Agreement or Subsequent Third Party Agreement and the Licensing Party shall use Commercially Reasonable Efforts to assist the other
Party in exercising such rights, in each case solely with respect to Shared Products; provided that the other Party has not breached this Agreement, or breached the applicable Third Party Rights under such Existing Third Party
Agreement or Subsequent Third Party Agreement. In addition, notwithstanding the foregoing, in the event of such termination, the other Party may in any event approach any licensor under any Existing Third Party Agreement or Subsequent Third Party
Agreement for a direct license. 

  
 42 

 (e) Termination of Third Party Agreements. The Parties agree that termination,
without both Parties’ prior written consent, of any Existing Third Party Agreement with respect to any Patent or Know-How that is necessary to Develop, Manufacture or Commercialize the Shared Products
shall be deemed a breach of this Agreement by the Licensing Party; provided that (i) if the other Party’s breach of this Agreement results in a breach of any Existing Third Party Agreement, such other Party agrees to use
Commercially Reasonable Efforts to assist the Licensing Party in curing such breach of such Existing Third Party Agreement and (ii) if the other Party’s breach of this Agreement results in a termination of any Existing Third Party
Agreement , such termination of such Existing Third Party Agreement shall not be deemed a breach by the Licensing Party of this Agreement. 

Section 8.6 Exclusivity. 

(a) Exclusivity Obligations. From the Effective Date until the end of the Term, each of the Parties covenants and agrees, solely on
behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program MTA or any other Development &
Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or Commercialization (“Enabling
Manufacturing”) or Commercialize (A) the Co-Co Candidate, (B) any molecule in the Field that is Directed against the Co-Co Target or (C) any
pharmaceutical product (including any Diagnostic Product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Co-Co Target, or (ii) license,
authorize, appoint or otherwise willfully or intentionally enable, whether directly or indirectly, a Third Party to conduct any of the activities described in clause (i). 

(b) Exceptions. 
 (i)
Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly (whether such activities are conducted internally or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions
of Section 8.6(a) as a result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a molecule resulting from such research program or discovery effort) that has as its specified and primary goal,
as evidenced by items such as laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to discover or Develop any compound that is Directed against a target other than the
Co-Co Target. 
 (ii) Celgene Exception. It is agreed and understood by the Parties that,
(A) solely prior to the enrollment of the first patient in the first Phase II Study of the first Shared Product under this Agreement: (x) any Celgene research, Development, discovery, manufacturing and commercialization activities existing
as of the Effective Date or (y) any commercialization activities commenced following the Effective Date, where the applicable compound or product was the subject of ongoing research, Development, discovery, or manufacturing or commercialization
activities as of the Effective Date, whether in either case such activities are 

  
 43 

 
undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators, are expressly excluded from the provisions of this Section 8.6, and
(B) at any time during the Term, Celgene research, discovery, and commercialization activities related to (i) the glutarimide class of drugs, including but not limited to lenalidomide, pomalidomide, and thalidomide; (ii) the
activation or inhibition through direct binding to PDE4 (apremilast); (iii) romidepsin drugs; (iv) Celgene’s cell-based therapies; or (v) any drug or program owned or controlled by Celgene on or before the Effective Date that has
commenced a Phase III Study or has been Commercialized on or before the Effective Date are expressly excluded from the provisions of this Section 8.6. 

(iii) Academic Collaborations. Notwithstanding the provisions of Section 8.6(a), and without limiting Section 8.2(a)(ii),
each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in relation to the Co-Co Target, if such activities are (A) the subject of an
existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, provided that such Party shall not be permitted to amend any such agreement
unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the Master Agreement with respect to (1) ownership and licenses of
pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of activities under such agreement, (2) rights regarding publication of
the results arising pursuant to the conduct of activities under such agreement, and (3) confidentiality obligations (collectively, (1) through (3), the “Academic Essential Provisions”), or (B) the subject of a new
agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic Essential Provisions consistent with the terms and conditions of the agreements between
such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement; provided that, if any Academic Essential Provisions of an amendment described in (A) or an agreement
described in (B) would not be consistent with the Academic Essential Provisions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, such
Party shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of the other Party. 

(iv) Competitive Programs. Section 8.6(a) shall not apply to the applicable Party if, during the Term, such Party or any of its
Affiliates (other than in a Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this
Section 8.6 by such Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a Competitive Program (the
“Competitive Program Party”) shall, within [***] days after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant Affiliate to terminate,
the Competitive Program or (B) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [***] day period that it intends
to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program 

  
 44 

 
as quickly as possible, and in any event within [...***... days (unless applicable Law requires a longer termination period) after the Competitive Program Party delivers such notice to the
other Party; and (Y) confirm to the other Party when such termination has been completed, and the Competitive Program Party’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period
shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). If the Competitive Program Party notifies the other Party within such [***] day period that it intends to divest such
Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable efforts to effect such divestiture as quickly as possible, and in any event within one hundred eighty (180) days after the Competitive Program
Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed. If the Competitive Program Party or its relevant Affiliate fails to complete such divestiture within such [***] day period,
but has used reasonable efforts to effect such divestiture within such [***] day period, then, unless otherwise required by applicable Law, such [***] day period shall be extended for such additional reasonable period thereafter as is necessary to
enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided, however, that such additional [***] day period shall be extended for such period as is necessary to obtain any
governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the
Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). 

(v) Certain Permitted Activities. 

(A) The supply by either Party or its Affiliates of drug for use in any IIT shall not constitute a breach of Section 8.6(a) by such
Party. Each Party shall report to the JSC on a Calendar Quarterly basis all IITs for which it or its Affiliates supply drug and that would otherwise breach Section 8.6(a). For clarity, providing at market price any supply of any biological or
pharmaceutical product owned or controlled by a Party or any of its Affiliates that is then being commercialized without violation of Section 8.6(a) to a Third Party conducting a human Clinical Trial with respect to a compound that is Directed
against the Co-Co Target in the Field for the Territory shall not constitute Development in violation of such Party’s exclusivity obligations under this Section 8.6 as long as neither such Party nor
any of its Affiliates receives any other monetary consideration with respect to any product other than such product that is the subject of such Clinical Trial. 

(B) The entry into any Partnership Agreement by Celgene or its Affiliates, either before or after the Effective Date, and the performance by
Celgene or its Affiliates of any obligations thereunder shall not constitute a breach of Section 8.6(a); provided that any exercise of any options by Celgene or its Affiliates thereunder shall be subject to Section 8.6(a) and
such exercise, in and of itself, shall not be permitted under this Section 8.6(b)(v). 

  
 45 

 (C) The restrictions set forth in Section 8.6(a) shall not be deemed to prevent either
Party or its respective Affiliates from (1) fulfilling its obligations under this Agreement, or (2) engaging any subcontractors in accordance with Section 8.2(a)(ii) of this Agreement. 

(D) If a Change of Control occurs with respect to either Party with a Third Party and the Third Party already is conducting or is planning to
conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such initiation or
continuation will not constitute a violation of Section 8.6(a); provided that (1) none of the Celgene Co-Co Collaboration Intellectual Property, Vividion
Co-Co Collaboration Intellectual Property or Joint Co-Co IP will be used in any Acquirer Program, (2) none of the other Patents or
Know-How licensed by either Party to the other Party pursuant to this Agreement will be used in any Acquirer Program, (3) no Confidential Information of the other Party will be used in any such Acquirer
Program, and (4) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program, including by the maintenance of separate lab notebooks and records
(password-protected to the extent kept on a computer network) and the use of separate personnel working on each of the activities under this Agreement, and the activities covered under such Acquirer Program (except that this requirement shall not
apply to personnel who have senior research management roles and not project level research roles, provided such personnel in senior research management roles are not directly involved in the day-to-day activities under such Acquirer Program). 
 (vi) Clinical Combinations.
Notwithstanding anything to the contrary in this Agreement, for purposes of this Section 8.6, either Party shall, at all times, have the right to conduct clinical Development of Shared Products, alone or with Third Parties, in which the Shared
Products are used in combination with other therapeutic products, and to grant to any such Third Parties the right to use and reference either Party’s regulatory filings for purposes of enabling such Party and such Third Party to include the
relevant use of Shared Products in combination with such other therapeutic product in the approved label for such Shared Products or such other therapeutic product, respectively, provided that neither Party may grant to any such Third
Party the right to sell, offer for sale or otherwise commercially exploit such Shared Products. 
 (vii) Separate Programs under the
Collaboration.1 Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any Program Product in a Separate Program Directed
against the Co-Co Target by or on behalf of Vividion (a “Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement:
(x) such Separate Program Product is no longer subject to Celgene’s Opt-In Right under the Master Agreement and is not the subject of any Development & Commercialization Agreement as a
Licensed Product or Shared Product; and (y) such proposed Separate Program Product demonstrates utility in distinct Indications where such Separate Program Product could not be substituted by any Shared Product for such distinct Indication(s),
based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty (30) days,
as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any of such one or more distinct Indications for which the Separate Program Product 

 

	1 	 Only insert for E3 Ligase Programs. 

  
 46 

 
demonstrates utility, a “Permitted Indication”); and (z) such Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or
Commercialization, or Commercialized by or on behalf of Vividion or its Affiliates for one or more Permitted Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(vii) may be convened at any
time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Vividion covenants and agrees, on behalf of itself and its Affiliates, as a condition to
granting a license or sublicense to Develop, Manufacture or Commercialize such Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Separate Program Product, Vividion shall cause such Third
Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such Separate Program Product in one
or more Permitted Indications. 
 (viii) Non-Collaboration Separate Programs.2 [Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any molecule outside of the Collaboration by or on behalf of either
Party or its Affiliates (a “Non-Collaboration Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement with respect
to such Party or its Affiliates: (x) such Non-Collaboration Separate Program Product is Directed to the Co-Co Target; (y) such
Non-Collaboration Separate Program Product demonstrates utility in distinct Indications where such Non-Collaboration Separate Program Product could not be substituted by
any Shared Product for such distinct Indication(s), based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are
unable to mutually agree within thirty (30) days, as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any such one or more distinct Indications for which the Non-Collaboration Separate Program Product demonstrates utility, an “Allowed Indication”), where such Non-Collaboration Separate Program Product could not be
substituted for any Shared Product for an Allowed Indication; and (z) such Non-Collaboration Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or
Commercialization, or Commercialized by or on behalf of such Party or its Affiliates for one or more Allowed Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(viii) may be convened at
any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Each Party covenants and agrees, on behalf of itself and its Affiliates, as a
condition to granting a license or sublicense to Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such Non-Collaboration Separate Program Product, or otherwise
transferring, assigning, conveying or otherwise granting rights to such Non-Collaboration Separate Program Product, such Party shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree
in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Enabling Manufacture or Commercialize such Non-Collaboration Separate Program Product in one or more Allowed Indications.] 

 
  

	2 	 Only insert for E3 Ligase Programs. 

  
 47 

 Section 8.7 Retained Rights. 

(a) No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and subject to Section 8.6, all rights in and
to the Vividion Intellectual Property, Vividion’s and its Affiliates’ interests in Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP and any
other Patents or Know-How of Vividion and its Affiliates, are hereby retained by Vividion and its Affiliates. Except as expressly provided in Section 8.1, and subject to Section 8.6, all rights in
and to the Celgene Intellectual Property, Celgene’s and its Affiliates’ interests in Celgene Co-Co Collaboration Intellectual Property and any other Patents or
Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 
 (b)
Other Retained Rights. The Parties acknowledge that the licenses granted hereunder are subject to any rights retained by any licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement,
as identified in Exhibit C; provided that, upon Celgene’s reasonable request, Vividion shall cooperate fully in requesting and obtaining any waiver with respect to the requirement, if applicable under such agreements, that
the Shared Products used or sold in the US Territory be manufactured substantially in the US Territory. 
 Section 8.8
Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States
Bankruptcy Code (Title 11, US Code), as amended (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may
fully exercise all of their respective rights and elections under the Bankruptcy Code. The Parties agree that each Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the
Bankruptcy Code or any other provisions of applicable Law outside the US Territory that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy
proceeding by or against a Party under the Bankruptcy Code or analogous provisions of applicable Law outside the US Territory, the Party that is not subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as
appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy
Code. 
 Article IX 

Financial Provisions 

Section 9.1 Sharing of Worldwide Development Costs. Subject to Section 3.4 and Section 3.5: 

(a) During the Term, all reasonable Direct Costs incurred by either Party or its Affiliates in conducting (i) Additional Studies for
which (A) Vividion has agreed to share such costs pursuant to Section 3.4(a); (B) a Co-Co Buy-In has occurred pursuant to Section 3.5; or (C) a
Deemed Buy-In has occurred pursuant to Section 3.4(c) and (ii) Development activities pursuant 

  
 48 

 
to the Development Plan (including Manufacturing related thereto and any Clinical Trials, but excluding any Phase IV Studies conducted following Regulatory Approval) in accordance with terms and
conditions of this Agreement, but excluding Development costs solely for ROW Administration that constitute ROW Development Costs (such costs after exclusion of the costs solely for ROW Administration that constitute ROW Development Costs the
“Worldwide Development Costs”) by the Parties shall be borne [***] percent ([***]%) by [***] and [***] percent ([***]%) by [Vividion] (the “Development Cost Share”) as provided in this Agreement. Pursuant to this
Section 9.1, [***] shall bear [***] percent ([***]%) of any Developments Costs it incurs solely for ROW Administration (“ROW Development Costs”). The Parties shall seek to mutually and reasonably agree, through the JDC, whether
any Development or Manufacturing activities were intended solely for U.S. Administration or ROW Administration or intended to be included in Regulatory Filings for Regulatory Approval on a global basis; provided, however, that,
with respect to any Development or Manufacturing activities that are not designed for a specific territory, such costs shall be presumed to be Worldwide Development Costs. Worldwide Development Costs shall initially be borne by the Party incurring
the applicable costs or expenses, subject to reimbursement in accordance with Section 9.1(b). Notwithstanding the foregoing, the Parties understand and agree that any Direct Costs incurred by either Party or its Affiliates in conducting Phase
IV Studies following Regulatory Approval in the US Territory for U.S. Administration shall be included in the Profit & Loss Share and not in the Development Cost Share; provided, however, that, in the event that any
primary efficacy data (and not solely safety data) from any such Phase IV Study is included in any application for Regulatory Approval in any ROW Territory for any Indication, formulation, dosage form or other attribute of any Shared Product or
informs any reimbursement decision, [***] shall reimburse [***] for [***] percent ([***]%) of the Direct Costs incurred to conduct such Phase IV Study and shared between the Parties in accordance with the Profit & Loss Share within [***]
days following receipt of the first such Regulatory Approval in the ROW Territory. 
 (b) Within [***] days following the end of each
Calendar Quarter, each Party shall provide the other Party a report of actual Worldwide Development Costs incurred by such Party during such Calendar Quarter in accordance with the Development Plan, together with reasonable supporting evidence of
such Worldwide Development Costs. Subject to Section 6.5(b)(v), costs for employees and other persons engaged in Development, Manufacturing or Commercialization activities for U.S. Administration under this Agreement shall be included in the
Worldwide Development Costs on an FTE Rate basis. Each Party shall submit any supporting information or clarifications reasonably requested by the other Party related to such Worldwide Development Costs included in such Party’s report within
[***] days after such Party’s receipt of such request. The Parties, with the assistance of the JDC, shall conduct a reconciliation of Worldwide Development Costs for the subject Calendar Quarter within [***] days after receipt of all such
supporting information, and an invoice shall be issued to the Party (if any) that has not paid for its full share of the Worldwide Development Costs for such Calendar Quarter so that each of the Parties bears its Development Cost Share after giving
effect to such payment for such Calendar Quarter. The paying Party shall pay all amounts payable under any such invoice within [***] days after its receipt of such invoice. 

  
 49 

 Section 9.2 Milestone Payments. 

(a) Development and Regulatory Milestones. Celgene shall pay Vividion the following amounts after the first achievement by or on behalf
of Celgene (or Vividion, solely if Celgene requests (and Vividion, in its sole discretion, subject to Section 2.3, accepts) that Vividion Develop the Shared Product for the applicable development and regulatory milestone events set forth below)
or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the first Shared Product to achieve such milestone events. 

 

					
	 Milestones
	  	Payment
(in US
Dollars)	 
	 (1) [***]
	  	$	[	***] 
	 (2) [***]
	  	$	[	***] 
	 (3) [***]
	  	$	[	***] 

 (i) Each milestone payment under this Section 9.2(a) shall be made within [***] days after the
achievement of the applicable milestone by either Party or any of its Affiliates or Licensee Partners. 
 (ii) Subject to
Section 9.2(a)(iii) [and Section 9.2(a)(iv)] [include as applicable] below, the milestone payments set forth in the table above in this Section 9.2(a) (to the extent payable) shall be paid only once, regardless of the
number of Shared Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

(iii) Solely with respect to Milestone 3 above, [***] percent ([***]%) of the corresponding milestone payment amount shall be paid upon the
second achievement of the applicable milestone event by a Shared Product for a different Indication than the Indication for which such Shared Product first achieved such milestone event. For the avoidance of doubt, each distinct histology shall
qualify as a distinct Indication for purposes of this Section 9.2(a)(iii). For the further avoidance of doubt, if a Shared Product achieves a milestone for an Indication and subsequently achieves the same milestone for an earlier or different
line setting in the same Indication, no milestone payment shall be due for such earlier or different line setting (e.g., if a Shared Product received Regulatory Approval in the European Union as a third line therapy for an Indication, no
milestone payment would be due if such Shared Product later received Regulatory Approval in the European Union as a second line therapy for such Indication). For the further avoidance of doubt, for purposes of this Section 9.2(a)(iii), if a
Shared Product achieves a milestone for an Indication as part of a monotherapy or combination therapy and subsequently achieves the same milestone in the same Indication as part of a combination therapy or monotherapy, respectively, no milestone
payment shall be due for such subsequent milestone. 

  
 50 

 (iv) [Parties to include in execution version solely where the Program under this
Agreement is an E3 Ligase Program] [Solely for purposes of this Section 9.2(a), in the event that the Shared Program produces two (2) or more Distinct Products (as determined pursuant to Section 2.3.4 of the Master Agreement),
the Parties understand and agree that, following Regulatory Approval of the first Shared Product in the United States under this Agreement, each subsequent Distinct Product to receive Regulatory Approval in the United States shall be eligible to
receive the Milestone Payments set forth in the table above and Section 9.2(a)(iii) (the “Distinct Product Catch-Up Payments”). Celgene will make any Distinct Product Catch-Up Payments within [***] days after such Distinct Product receives Regulatory Approval in the United States; provided, however, that, Milestone 3 above shall instead only be payable [***]
days after such Distinct Product receives Regulatory Approval in the European Union. For clarity, in the event that Celgene makes any Distinct Product Catch-Up Payment for a Distinct Product pursuant to this
Section 9.2(a)(iv), Vividion shall be entitled to additionally receive the milestone amounts under Section 9.2(a)(iii) for such Distinct Product if, but only if, such Distinct Product receives Regulatory Approval in the United States for
an additional Indication which is distinct from any of the Indications for which any of the Shared Products have received Regulatory Approval.] 

(b) Sales Milestones. Celgene shall make a one-time sales milestone payment to Vividion of
[***] U.S. Dollars ($[***]) the first time aggregate Annual Net Sales of Shared Products in a given Calendar Year in the ROW Territory exceed [***] U.S. Dollars ($[***]) (the “Sales Milestone Condition”); it being understood and
agreed that (i) Celgene shall notify Vividion of the achievement of such Sales Milestone Condition within [***] days after the end of the applicable Calendar Quarter in which such Sales Milestone Condition is achieved; and (ii) Vividion
shall deliver to Celgene an invoice for such [***] U.S. Dollars ($[***]) payment; and (iii) Celgene shall pay to Vividion such [***] U.S. Dollars ($[***]) payment within [***] days following receipt of such invoice. For clarity, the sales
milestone payment set forth in this Section 9.2(b) (to the extent payable) shall be paid only once, regardless of the number of Shared Products to achieve the applicable milestone event and regardless of the number of Indications for which the
milestone event may be achieved. 
 Section 9.3 Royalties for Shared Products. 

(a) Royalty Rate. On a Shared Product-by-Shared Product
basis, Celgene shall pay Vividion royalties on Annual Net Sales by Celgene, its Affiliates and Licensee Partners in the ROW Territory during the applicable Royalty Term for the applicable Shared Product at the royalty rates set forth below: 

 

			
	 Annual Net Sales in the ROW Territory

(For each Shared Product)
	  	Royalty
Rate
	 Portion of Annual Net Sales of such Shared Product in the ROW Territory by all Selling Parties,
in the aggregate, up to and including [***] U.S. Dollars ($[***]).
	  	[***]%

  
 51 

			
	 Annual Net Sales in the ROW Territory

(For each Shared Product)
	  	Royalty
Rate
	 Portion of Annual Net Sales of such Shared Product in the ROW Territory by all Selling Parties,
in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).
	  	[***]%
	 Portion of Annual Net Sales of such Shared Product in the ROW Territory by all Selling Parties,
in the aggregate, greater than [***] U.S. Dollars ($[***]).
	  	[***]%

 Each royalty rate set forth in the table above will apply only to that portion of the Annual Net Sales of a given Shared
Product in the ROW Territory during a given Calendar Year that falls within the indicated portion. 
 For example, if Annual Net Sales of a
Shared Product in the ROW Territory by Celgene, its Affiliates and Licensee Partners was $[***], the royalties payable with respect to such Annual Net Sales under this Section 9.3, would be [***]. 

(b) Royalty Term. Royalties payable under this Section 9.3 shall be paid by Celgene on a Shared Product-by-Shared Product and country-by-country basis from the date of First Commercial Sale of each Shared Product in a
country with respect to which royalty payments are due, until the latest of: 
 (i) the last to expire of any Valid Claim of Vividion
Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents or Joint Co-Co Patents Covering such Shared
Product in such country; 
 (ii) [***] years following the date of First Commercial Sale in such country; and 

(iii) the expiration of Regulatory Exclusivity for such Shared Product in such country; 

(each such term with respect to a Shared Product and a country, a “Royalty Term”). 

Notwithstanding the foregoing, in the event that the Royalty Term for a Shared Product in a country continues solely due to Section 9.3(b)(ii) above
(i.e., the Shared Product is not Covered by a Valid Claim of Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents or Joint Co-Co Patents in the applicable country, and such Shared Product is not subject to Regulatory Exclusivity in such country) then, in such event, the royalty rate for such Shared Product in such country will be
reduced to [***] percent ([***]%) of the applicable rate in Section 9.3(a) for such Shared Product in such country. 

  
 52 

 Upon the expiration of the Royalty Term with respect to a Shared Product in a country, the license granted
by Vividion to Celgene pursuant to Section 8.1(a) shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Shared Product in such country; provided that,
notwithstanding Section 8.5 or 9.7, Celgene shall assume and be solely responsible (without deduction under Section 9.3(d)) for any amounts payable to Third Party licensors and Celgene shall be responsible for complying with the terms of
any license agreements with such Third Party licensors, in each case, with respect to Celgene’s exercise of such rights as to such Shared Product in such country following the expiration of such Royalty Term. 

(c) Royalty Reduction for Generic Competition. If, on a Shared
Product-by-Shared Product, country-by-country and Calendar
Quarter-by-Calendar Quarter basis, 
 (i) A Generic
Product(s) has a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%); or 
 (ii) A Generic
Product(s) has a market share of more than [***] percent ([***]%); 
 then, subject to Section 9.4, the royalties payable with respect to Annual Net
Sales of such Shared Product pursuant to Section 9.3(a) in such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies,
respectively, of the royalties otherwise payable pursuant to Section 9.3(a). Market share shall be based on the aggregate market in such country of such Shared Product and all applicable Generic Products (based on sales of units of such Shared
Product and such Generic Product(s) in the aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

(d) Royalty Reduction for Third Party Payments. Subject to Section 9.4 and Section 9.7, the amount of any royalties owed by
Celgene to Vividion pursuant to Section 9.3(a) shall be reduced, on a Shared Product-by-Shared Product, country-by-country and Calendar Quarter-by-Calendar Quarter basis, by an amount equal to [***] percent ([***]%) of any payments
pursuant to Section 9.7 that are (i) necessary for ROW Administration of such Shared Product in such country in such Calendar Quarter and (ii) made to a Third Party for each Subsequent Third Party Agreement with respect to such Shared
Product in such country, subject to the effective royalty rate floor set forth in Section 9.4. Celgene may carry over and apply any payments made to a Third Party as described in this Section 9.3(d), which are incurred or accrued in any
Calendar Quarter and are not deducted in such Calendar Quarter due to the effective royalty rate floor set forth in Section 9.4, to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as
practicable and continue applying such reduction on a Calendar Quarterly basis thereafter. Payments for Existing Third Party Agreements shall be borne by Vividion as set forth in the Master Agreement. 

Section 9.4 Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in Section 9.3, alone
or together, reduce the royalties payable by Celgene for a Shared Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts otherwise payable by Celgene for such Shared Product in such country in such
Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth above in this Section 9.4, to any
subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully deducted, in all cases subject to the
limitation set forth above in this Section 9.4. 

  
 53 

 Section 9.5 Payment of Royalties. Celgene shall: (i) within [***] days
following the end of each Calendar Quarter in which a royalty payment accrues, provide to Vividion a report for each country in the ROW Territory in which sales of any Shared Product occurred in the Calendar Quarter covered by such statement,
specifying for such Calendar Quarter: the number of Shared Products sold, the gross sales and Annual Net Sales in each country’s currency; the applicable royalty rate under this Agreement; the royalties payable in each country’s currency,
including an accounting of deductions taken in the calculation of Annual Net Sales in accordance with Celgene’s Accounting Standards; the applicable exchange rate to convert from each country’s currency to U.S. Dollars under
Section 9.11; and the royalty calculation and royalties payable in U.S. Dollars, and (ii) make the royalty payments owed to Vividion hereunder in accordance with such royalty report in arrears, within [***] days from the end of each
Calendar Quarter in which such payment accrues. 
 Section 9.6 Profit & Loss Share. Subject to
Section 2.2: 
 (a) Profit & Loss Share. The Parties will share in (and bear) Operating Profits or Losses
with respect to Shared Product(s) for U.S. Administration as follows: Vividion will bear (and be entitled to) [***] percent ([***]%) of such Operating Profits or Losses, and Celgene will bear (and be entitled to) [***] percent ([***]%) of such
Operating Profits or Losses (collectively, the “Profit & Loss Share”). 
 (b) Quarterly
Reconciliation and Payments. Unless the Parties otherwise agree in advance in writing, reconciliation and payments of the Profit & Loss Share shall be conducted as set forth in Exhibit D. 

Section 9.7 Third Party Payments. After the Effective Date, if Celgene at any time, or, with respect to U.S. Administration,
Vividion before a Vividion Opt-Out Notice, believes that a license under Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, could
be necessary or useful to Develop, Manufacture or Commercialize the Shared Products, then such Party shall notify (A) the JDC if such notice is provided during Development or Manufacturing of Shared Products for Development or (B) the JCC
if such notice is provided during Commercialization of Shared Products, and the following shall apply: 
 (a) If the JDC or JCC, as
applicable, agrees by unanimous vote to obtain such license, and if so, which of the Parties will do so, then the Parties will proceed as determined by the JDC or JCC, as applicable. If the JDC or JCC, as applicable, cannot agree on whether to
obtain such license or which Party will do so, then the matter will be escalated to the JSC for resolution in accordance with Section 2.2; provided that, if the JSC cannot agree on which Party should obtain such license, then
Celgene shall have the sole right, but not the obligation, to obtain such license throughout the Territory. 

  
 54 

 (b) The costs of each license obtained pursuant to Section 9.7(a) (each, a
“Subsequent Third Party Agreement”) paid by Celgene pursuant to any Subsequent Third Party Agreement (i) for ROW Administration shall be applied to reduce royalties payable to Vividion, to the extent provided in
Section 9.3(d), or (ii) prior to any Vividion Opt-Out Date, for U.S. Administration, shall be shared by the Parties in accordance with the Development Cost Share (if incurred prior to First
Commercial Sale of the first Shared Product) or Profit & Loss Share (if incurred after First Commercial Sale of the first Shared Product). Payments for Existing Third Party Agreements shall be borne by Vividion as set forth in the Master
Agreement. 
 (c) For purposes of this Agreement, the Third Party Patents and Third Party Know-How
licensed under a Subsequent Third Party Agreement shall be deemed “Co-Co Collaboration Intellectual Property” of the Party obtaining such license. 

(d) (i) The Party designated to pursue the Subsequent Third Party Agreement shall keep the other Party fully informed of the status of the
negotiations with the applicable Third Party and provide the other Party with copies of all draft agreements; (ii) the other Party may provide comments and suggestions with respect to the negotiation of the agreement with such Third Party, and
the Party seeking the Subsequent Third Party Agreement shall reasonably consider all comments and suggestions reasonably recommended by the other Party; and (iii) the Party seeking the Subsequent Third Party Agreement shall obtain a license
that is sublicensable to the other Party in accordance with the terms of this Agreement (except that any sublicense to Vividion shall only be for the US Territory), treating (unless otherwise agreed by the Parties) the Third Party intellectual
property as Co-Co Collaboration Intellectual Property hereunder and treating the agreement licensing such Third Party intellectual property in the same way as the Existing Third Party Agreements (including as
provided in Section 8.5), except for payment obligations, which will be treated as provided in this Section 9.7. 

Section 9.8 Financial Records. The Parties shall keep, and shall require their respective Affiliates and (sub)licensees to keep,
complete and accurate books and records in accordance with the applicable Accounting Standards. The Parties shall keep, and shall require their respective Affiliates and (sub)licensees to keep, such books and records for at least [***] years
following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing and maintaining such records. With respect to
royalties, such records shall be in sufficient detail to support calculations of royalties due to Vividion. Prior to any Vividion Opt-Out Date, Celgene and Vividion shall also keep, and require their
respective Affiliates and (sub)licensees to keep, complete and accurate records and books of accounts containing all data reasonably required for the calculation and verification of Worldwide Development Costs, including internal FTEs utilized by
either Party, and the Profit & Loss Share. 
 Section 9.9 Audits. 

(a) Audit Team. Each Party may, upon request and at its expense (except as provided for herein), cause an internationally recognized
independent accounting firm selected by it (except one to whom the Auditee has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of the other Party and the correctness of any
payment made or required to be made to or by such Party, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this Agreement, the Audit Team shall enter into an
appropriate confidentiality 

  
 55 

 agreement with the Auditee obligating the Audit Team to be bound by obligations of
confidentiality and restrictions on use of confidential information that are no less restrictive than the obligations set forth in Article XI. 

(b) Limitations. In respect of each audit of the Auditee’s books and records: (i) the Auditee may be audited only once per year,
(ii) no records for any given year for an Auditee may be audited more than once; provided that the Auditee’s records shall still be made available if such records impact another financial year which is being audited, and
(iii) the Audit Rights Holder shall only be entitled to audit books and records of an Auditee from the three (3) Calendar Years prior to the Calendar Year in which the audit request is made. 

(c) Audit Notice. In order to initiate an audit for a particular Calendar Year, the Audit Rights Holder must provide written notice to the
Auditee. The Audit Rights Holder exercising its audit rights shall provide the Auditee with notice of one or more proposed dates of the audit not less than sixty (60) days prior to the first proposed date. The Auditee will reasonably
accommodate the scheduling of such audit. The Auditee shall provide such Audit Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate with such audit. 

(d) Payments. If the audit shows any under-reporting or underpayment, or overcharging or overpayment by any Party, that under-reporting,
underpayment, overpayment or overcharging shall be reported to the Audit Rights Holder and the underpaying or overcharging Party shall remit the applicable underpayment amount or reimburse the applicable overpayment amount (together with interest at
the rate set forth in Section 9.12) to the underpaid or overcharged Party within [***] days after receiving the audit report. Further, if the audit for an annual period shows an under-reporting or underpayment or an overcharge by any Party for
that period in excess of [***] percent ([***]%) of the amounts properly determined, the underpaying or overcharging Party, as the case may be, shall reimburse the applicable underpaid or overcharged Audit Rights Holder conducting the audit, for its
respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [***] days after receiving appropriate
invoices and other support for such audit-related costs. 
 (e) Definitions. For the purposes of the audit rights described herein, an
individual Party subject to an audit in any given year will be referred to as the “Auditee” and the other Party who has certain and respective rights to audit the books and records of the Auditee will be referred to as the
“Audit Rights Holder.” 
 Section 9.10 Tax Matters. 

(a) General. The Parties acknowledge that the rights and obligations imposed on each of them pursuant to this Agreement that relate to the
sharing of profits from the development and commercialization of the Shared Products in the US Territory to the Shared Products and Companion Diagnostics and the collaborative relationship formed between them in connection therewith, gives rise to a
partnership for US federal (and, to the extent applicable, state) income tax purposes (but not for any non-tax or non-US purpose), and the Parties shall act in
accordance with Exhibit E. 

  
 56 

 (b) Withholding and Indirect Taxes. 

(i) Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement (or allocable to another Party pursuant
to Section 1.6 of Exhibit E) such taxes as are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will:
(A) deduct those taxes from such payment, (B) timely remit the taxes to the proper taxing authority, and (C) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee
Party”) on a timely basis following that tax payment; provided, however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction
or withholding (and such notice, which shall set forth in reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding, shall be given at least a reasonable period of time before such deduction or
withholding is required, in order for such Payee Party to obtain reduction of or relief from such deduction or withholding). Each Party agrees to cooperate with the other Parties in claiming refunds or exemptions from, or reductions in, such
deductions or withholdings under any applicable Law or treaty to ensure that any amounts required to be withheld pursuant to this Section 9.10(b)(i) are reduced to the fullest extent permitted by applicable Law. 

(ii) Each Party, for itself and, if applicable, in its capacity as “Tax Matters Partner” of such partnership (as defined in
Exhibit E), agrees to cooperate with the other Party in claiming refunds or exemptions from, or reductions in, any deductions or withholdings, including pursuant to Code Section 1446(f), required to be made by an acquirer of an interest
in the partnership described in Section 9.10(a) and in reducing or eliminating such withholdings to the fullest extent permitted by applicable Law. 

(iii) The Parties shall cooperate to minimize value added tax, sales and use tax, consumption tax and other similar taxes (“Indirect
Taxes”) imposed in connection with this Agreement, as applicable. 
 (iv) Each Party has provided a properly completed and duly
executed IRS Form W-9 or Form W-8, as applicable, to the other Party. Each Party and any other recipient of payments described in this Section 9.10(b) shall provide
to the other Party (including where the other Party is acting in its capacity as Tax Matters Partner (as defined in Exhibit E)), at the time or times reasonably requested by such other Parties or as required by applicable Law, such other
properly completed and duly executed documentation as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made without (or at a reduced rate of)
withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 
 Section 9.11 Currency
Exchange; Blocked Payments; Prohibitions on Payments. 
 (a) Currency Exchange. Unless otherwise expressly stated in this
Agreement, all amounts specified in, and all payments made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts payable under this Agreement, such
conversion shall be performed in a manner consistent with the paying Party’s normal practices used to prepare its audited financial statements 

  
 57 

 for internal and external reporting purposes. For clarity, Celgene sets currency transaction rates for the
month on the last business day of the month prior. Vividion has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month prior. 

(b) Blocked Payments. In the event that, by reason of applicable Law in any country, it becomes impossible or illegal for the paying
Party (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed the other Party hereunder, the paying Party will promptly notify the other Party of the conditions preventing such transfer and such
payments will be deposited in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is designated by the other Party within a period of [***] days, in a
recognized banking institution selected by the paying Party or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to the other Party. 

(c) Prohibitions on Payments. When in any country in the Territory applicable Law prohibits both the transmittal and the deposit of
royalties on sales in such country, royalty payments due on Net Sales shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in effect, all royalties that Celgene would have been under an
obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent allowable. The Parties shall cooperate in good faith to overcome, to the extent reasonably possible, any prohibition described in
this Section 9.11(c) within a reasonable period of time. 
 Section 9.12 Late Payments. Any payments that are not paid on
or before the date such payments are due under this Agreement shall bear interest at an annual rate equal to the lesser of (x) [***], or (y) [***]; provided that, [***]. 

Article X 
 Intellectual
Property Ownership, Protection and Related Matters 
 Section 10.1 Ownership of Inventions. 

(a) Non-Co-Co Collaboration
Know-How. Any Know-How discovered, developed, generated or invented by Celgene or its Affiliates or Vividion or its Affiliates prior to or outside the Collaboration
shall remain the sole property of such Party or its applicable Affiliate(s), except as otherwise agreed by the Parties. 
 (b) Sole
Inventions. All Co-Co Collaboration Know-How discovered, developed, generated or invented solely by employees, agents and consultants of a Party or its Affiliates
shall be owned exclusively by such Party or its applicable Affiliate(s). 

  
 58 

 (c) Joint Inventions. All Co-Co Collaboration
Know-How discovered, developed, generated or invented jointly by employees, agents and consultants of Celgene or its Affiliates, on the one hand, and employees, agents and consultants of Vividion or its
Affiliates, on the other hand, in the conduct of activities under this Agreement (“Joint Inventions” and, any Patents Covering such Joint Inventions, “Joint Patents”) shall be owned jointly on the basis of each
Party (or its applicable Affiliate(s)) having an undivided interest without a duty to account to the other Party (or its applicable Affiliate(s)) and shall be deemed to be Controlled by each Party. Each Party shall have the right to use such Joint
Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell or otherwise transfer its interest in such Joint Inventions to its Affiliates or a Third Party, in each case without the consent of the other Party or its
applicable Affiliate(s) (and, to the extent that applicable Law requires the consent of the other Party or its applicable Affiliate(s), this Section 10.1(c) shall constitute such consent), so long as such use, sale, license or transfer is
subject to Section 8.6 and the licenses granted pursuant to this Agreement and is otherwise consistent with this Agreement. 
 (d)
Notice. Each Party agrees to provide, at the request of the other Party and no more than once per Calendar Quarter, reports disclosing to the other Party all Co-Co Collaboration Intellectual Property
discovered, developed, generated or invented by employees, agents and consultants of such Party and all Vividion Intellectual Property and Celgene Intellectual Property that becomes subject to this Agreement, which disclosures may be made in
connection with the updates made in accordance with Section 3.2(d). 
 (e) Inventorship. For purposes of determining ownership
hereunder, the determination of inventorship shall be made in accordance with United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually
acceptable independent patent counsel not regularly employed by either Party to resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(f) Further Actions and Assignments. Each Party shall take all further actions and execute all assignments requested by the other Party
and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 
 Section 10.2
Prosecution of Patents. Subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Vividion Patents, Vividion
Co-Co Collaboration Patents, Celgene Patents or Celgene Co-Co Collaboration Patents, the following provisions shall apply with respect to the Vividion Patents, Celgene
Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the
Territory: 
 (a) General. Subject to the provisions of Section 10.2(f) and coordination with the JPC, Celgene shall have the
initial right and option to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the Territory. In the event that Celgene declines to Prosecute such Patents, it shall give Vividion reasonable notice to this effect, sufficiently in advance to permit Vividion to
undertake such Prosecution in any applicable country without a loss of rights, and thereafter Vividion may, upon written notice to Celgene and receipt of Celgene’s prior written consent (not to be unreasonably withheld), Prosecute such
Patents in the owning Party(ies)’s name(s) subject to coordination with the JPC. 

  
 59 

 (b) Celgene. Celgene shall have the sole right and option to Prosecute the Celgene
Patents. 
 (c) Costs and Expenses. All costs and expenses in Prosecuting Vividion Patents, Vividion
Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents (collectively,
“Patent Prosecution Expenses”) (i) in the US Territory, shall be shared equally by the Parties (to the extent incurred in the US Territory prior to the First Commercial Sale of the first Shared Product in the US Territory) or be
included as Commercialization expenses as part of the Profit & Loss (if incurred after First Commercial Sale of the first Shared Product in in the US Territory) and (ii) in the ROW Territory, shall be borne by solely [***];
provided, however, that, (A) in the event of a Vividion Opt-Out Date, all such Patent Prosecution Expenses incurred by [***] following the Vividion
Opt-Out Date shall be borne solely by [***] and (B) all such Patent Prosecution Expenses paid to a Third Party in connection with an Existing Third Party Agreement shall be borne as set forth in the
Master Agreement. 
 (d) Strategy; Failure of JPC to Agree; Diligence and Cooperation. 

(i) The JPC shall attempt to agree upon a strategy (which may be updated from time to time) for Prosecution of Vividion Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents, including the scope and
priority of the claims to be pursued within such Patents and to maximize the value of such Patents, on a global basis. As part of such strategy, the JPC shall discuss and consider in good faith filing separate Patents that include claims that Cover
Shared Products specifically or generically and claims that Cover only other compounds. Any failure by the JPC to agree by unanimous vote with respect to such strategy or any other Prosecution matter will be attempted to be resolved as specified in
Section 2.2(e), and if such attempt fails, then the Prosecuting Party may resolve such matter. The Prosecuting Party with respect to any such Patent shall follow such strategy in connection with all Prosecution of such Patent unless the JPC
approves of a divergence from such strategy (with any failure by the JPC to agree by unanimous vote to be resolved in accordance with Section 2.2(e) and the foregoing sentence). 

(ii) The Party authorized to conduct prosecution pursuant to Section 10.2(a) or Section 10.2(b) at the relevant time (as applicable,
the “Prosecuting Party”) shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including
in-house patent counsel as well as outside patent counsel) for the Prosecution of the Patents subject to Section 10.2(a) and Section 10.2(b). Each Party agrees to cooperate with the other with
respect to the Prosecution of such Patents pursuant to this Section 10.2, including (X) executing all such documents and instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake
any Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a) and Section 10.2(b) and (Y) giving consideration to the proper scope of Patents. In addition, Vividion
agrees that, if it is the non-Prosecuting Party, then Vividion, from time to time at the direction of the Prosecuting Party, shall Prosecute the Patents together with its external Patent counsel. The
Prosecuting Party shall: 

  
 60 

 (A) use Commercially Reasonable Efforts to regularly provide the JPC in advance with
reasonable information relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and
copies of drafts of filings and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with sufficient time for the non-Prosecuting party to provide meaningful input; 
 (B) use Commercially Reasonable Efforts to consider
in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 

(C) use Commercially Reasonable Efforts to Prosecute additional claims substantially similar to those suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 

(D) consult with the JPC and non-Prosecuting Party before taking any action that would have a material
adverse impact on the scope of claims within the Vividion Patents, Celgene Co-Co Collaboration Patents or Vividion Co-Co Collaboration Patents (including the Joint Co-Co Patents and Joint Patents), as applicable. 
 (iii) The applicable Prosecuting Party, in
consultation with the JPC, shall determine the countries in which Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents
(including Joint Co-Co Patents and Joint Patents) shall be Prosecuted. 
 (iv) The Prosecuting Party
may abandon the subject matter of a claim in a Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent in
response to an office action from the applicable patent office if, in the Prosecuting Party’s reasonable judgment after consultation with the non-Prosecuting Party, such Patent requires such abandonment;
provided, however, that, prior to such abandonment, if feasible, the Parties will cooperate to file divisional or continuation applications to separate such claim. The Prosecuting Party agrees not to otherwise abandon any
Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent without filing a divisional or continuation
application in respect thereof unless it provides the non-Prosecuting Party with reasonable notice to this effect, sufficiently in advance to permit the non-Prosecuting
Party to undertake such Prosecution of such Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent, and
thereafter such non-Prosecuting Party may, upon written notice to the Prosecuting Party and, in the case of Vividion, receipt of Celgene’s prior written consent (not to be unreasonably withheld),
Prosecute such Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent at [***] expense with counsel of
its choice. 

  
 61 

 (e) Third Party Rights. Vividion covenants and agrees that it shall not grant any
Third Party any right to control the Prosecution of the Vividion Patents or Vividion Co-Co Collaboration Patents or to approve or consult with respect to any Patents licensed to Celgene hereunder, in any case,
that is more favorable to the Third Party than the rights granted to Celgene hereunder or that otherwise conflicts with Celgene’s rights hereunder. Celgene covenants and agrees that it shall not grant any Third Party any right to control the
Prosecution of the Celgene Co-Co Collaboration Patents or to approve or consult with respect to the Celgene Co-Co Collaboration Patents licensed to Vividion hereunder,
in any case, that is more favorable to the Third Party than the rights granted to Vividion hereunder or that otherwise conflicts with Vividion’s rights hereunder. 

(f) Third Party Agreements. Each Party acknowledges that, pursuant to an Existing Third Party Agreement or Subsequent Third Party
Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co
Collaboration Patents covered by such agreement, and Vividion or Celgene, as applicable, may have certain rights to assume Prosecution under such agreement. Vividion and Celgene, as applicable, each agrees to keep the other Party fully informed of
these rights, as well as provide to the other Party all information and copies of documents received from the licensor(s) under any such Existing Third Party Agreement or Subsequent Third Party Agreement, or their patent counsel, relating to the
Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents covered by such agreement. To the extent that Vividion or Celgene, as
applicable, is permitted to proceed with Prosecution or provide comments or suggestions to patent documents under an Existing Third Party Agreement or Subsequent Third Party Agreement, then the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party Agreement shall be treated, to the
extent possible, in the same manner as other Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under this Section 10.2,
and Vividion or Celgene, as applicable, shall exercise all such rights with respect to such Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co
Collaboration Patents pursuant to the instructions of the other Party, if the other Party is given the right to act under this Section 10.2 (provided that all such decisions shall be subject to the applicable Prosecuting
Party’s final decision-making authority). 
 Section 10.3 Third Party Infringement and Challenges of Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents. Subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party
Agreement to the extent such agreement applies to the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents, the following
provisions shall apply with respect to the Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents, Joint Co-Co Patents, Joint Patents, Vividion Know-How, Vividion Co-Co Collaboration Know-How, Celgene
Co-Co Collaboration Know-How, Joint Co-Co Know-How and Joint Inventions: 

(a) Notice. Each Party shall immediately provide the other Party with written notice reasonably detailing any (i) known or alleged
infringement of any Vividion Patents, Celgene Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents or Joint Patents,
or known or alleged misappropriation of any Vividion Know-How, Celgene Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co- 

  
 62 

 Co Collaboration Know-How, Joint
Co-Co Know-How or Joint Inventions, by a Third Party, (ii) “patent certification” filed in the US Territory under 21 U.S.C. §355(b)(2) or 21 U.S.C.
§355(j)(2) or similar provisions in other jurisdictions, and (iii) any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any such
intellectual property rights (collectively “Third Party Infringement”). 
 (b) First Right to Initiate Infringement
Actions. Celgene shall have the initial right throughout the US Territory and the sole right in the ROW Territory, but not the obligation, to initiate a suit or take other appropriate action that Celgene believes is reasonably required to
protect the Vividion Intellectual Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or Joint Inventions against any infringement or challenge (including any Third Party Infringement), unauthorized use or misappropriation by a Third Party that relates to a Shared Product in
such part of the Territory, which, in the case of a Companion Diagnostic, shall mean Third Party Infringement, unauthorized use or misappropriation in connection with such Companion Diagnostic in the Field (“Competitive
Infringement”). Celgene shall give Vividion advance notice of Celgene’s intent to file any such suit or take any such action and the reasons therefor, and shall provide Vividion with an opportunity to make suggestions and comments
regarding such suit or action. Thereafter, Celgene shall keep Vividion promptly informed, and shall from time to time consult with Vividion regarding the status of any such suit or action and shall provide Vividion with copies of all material
documents (e.g., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert
reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall
discuss in good faith Celgene’s intended response to a Competitive Infringement. For clarity, Celgene shall have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any
Celgene Independent Products . 
 (c) Preparation to Enforce. After the First Commercial Sale of a Shared Product in the US Territory
or the ROW Territory, as applicable, subject to coordination with the JPC, Celgene shall use reasonable efforts to prepare for the possibility of suit for Competitive Infringement starting [***] years after such First Commercial Sale. 

(d) Step-in Rights. Celgene shall have [***] days after becoming aware of any Competitive
Infringement to elect to so enforce the applicable Patent(s) in the applicable jurisdiction(s) (or settle or otherwise secure the abatement of such Competitive Infringement); provided, however, that (i) such period will be
more than [***] days to the extent applicable Law prevents earlier enforcement of the applicable Patent(s) and provided further that if such period is extended because applicable Law prevents earlier enforcement, Celgene shall have until the date
that is [***] days following the date upon which applicable Law first permits such enforcement proceeding to elect to so enforce the applicable Patent(s), and (ii) Celgene shall have less than [***] days (or, as applicable, less than the [***]
day period described in clause(i)) to elect to so enforce the applicable Patent(s) to the extent that a delay in bringing such enforcement proceeding against such alleged Third Party infringer would limit or compromise the remedies (including
monetary relief and stay of regulatory approval) available against such alleged Third Party infringer. In the event Celgene does not so elect to enforce or settle or 

  
 63 

 otherwise secure the abatement of such Competitive Infringement in the US Territory before the first to
occur of (A) the expiration of the applicable period of time set forth in above, or (B) [***] days before the expiration of any time period under applicable Law, that would, if an enforcement proceeding was not filed within such time period,
limit or compromise the remedies available from such an enforcement proceeding, Celgene will so notify Vividion in writing and in the case where Vividion then desires to commence a suit or take action to enforce the applicable Patent(s) with respect
to such Competitive Infringement in the US Territory, Vividion will, subject to this Section 10.3(d) and Section 10.3(e), thereafter have the right to commence such a suit or take such action to enforce the applicable Patent(s) in the
applicable jurisdiction(s). Vividion shall give Celgene advance notice of Vividion’s intent to file any such suit or take any such action and the reasons therefor and shall provide Celgene with an opportunity to make suggestions and comments
regarding such suit or action. Thereafter, Vividion shall keep Celgene promptly informed and shall from time to time consult with Celgene regarding the status of any such suit or action and shall provide Celgene with copies of all material documents
(e.g., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports,
affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Notwithstanding anything in this Section 10.3 to the contrary:
(x) Celgene shall have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products, (y) if Celgene has a reasonable, good faith concern that
Vividion’s exercise of its backup enforcement or defense rights with respect to any Patent would be detrimental to the overall patent protection of the Shared Products or related Companion Diagnostics, then Vividion shall not be permitted to
enforce or defend such Patent without the prior consent of Celgene, and (z) in no event shall Vividion ever be entitled to enforce or defend any Celgene Intellectual Property. 

(e) Conduct of Action. The Party initiating suit shall have the sole and exclusive right to select counsel for any suit initiated by it
under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate or maintain such suit, the other Party shall join as a party to the suit. If requested
by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party except that the initiating Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The Party initiating suit shall assume and pay all of its own Out-of-Pocket Costs incurred in connection with any litigation or proceedings described in this Section 10.3, including the fees and expenses of the counsel selected by
it, provided that, prior to the Vividion Opt-Out Date, if any, such fees and expenses shall be (i) included in the calculation of Development Costs (if incurred prior to the First Commercial
Sale of the first Shared Product in the US Territory) and (ii) if incurred after the First Commercial Sale of the first Shared Product in the US Territory, shared by the Parties pursuant to the Profit & Loss Share. The other Party
shall have the right to participate and be represented in any such suit by its own counsel at its own expense (which shall not be included in the calculation of the Development Costs or the Profit & Loss Share). 

(f) Costs of Enforcement. Except as otherwise set forth in this Section 10.3 or in this Agreement or the Master Agreement: 

  
 64 

 (i) ROW. Each Party shall bear all of its own internal costs incurred in connection with
its activities under this Section 10.3 that relate to an enforcement proceeding relating to Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual
Property, Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or Joint Inventions in the ROW Territory, and, if Celgene commences an
enforcement proceeding in the ROW Territory, [***] shall bear all external costs and expenses for such action; and 
 (ii) U.S. All Direct
Costs and reasonable and documented external costs and expenses incurred by either Party in pursuing any enforcement proceeding of the Vividion Intellectual Property, Celgene Intellectual Property, Celgene
Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or
Joint Inventions in the US Territory in accordance with this Section 10.3 shall be shared by the Parties in accordance with the Development Share (if incurred prior to the First Commercial Sale of the first Shared Product in the US Territory)
or Profit & Loss Share (if incurred after the First Commercial Sale of the first Shared Product in the US Territory). 
 (g)
Recoveries. Any damages or other monetary awards recovered in any action, suit or proceeding brought under this Section 10.3 shall be shared as follows: 

(i) Initial Allocation. Such damages or other sums recovered shall first be applied to reimburse each Party for all of the costs and expenses
it incurred in connection with such action, and if such recovery is insufficient to cover all such costs and expenses of both Parties, it shall [***]; and 

(ii) Remaining Proceeds. Any remaining proceeds in case of suits with respect to an enforcement proceeding relating to any Shared Product or
Companion Diagnostic under this Section 10.3, shall, (A) with respect to such suits in the ROW Territory, be allocated between the Parties such that the Party bringing suit in accordance with this Section 10.3 retains [***] percent
([***]%) and the other Party retains [***] percent ([***]%) of such amount, and (B) with respect to suits in the US Territory, shall be shared by the Parties in accordance with the Profit & Loss Share or, if obtained on or after the
Vividion Opt-Out Date, the Party bringing suit under this Section 10.3 shall retain [***] percent ([***]%) and the other Party shall retain [***] percent ([***]%) of such amount. 

(h) Third Party Agreements. In the event that (i) a Patent covered by an Existing Third Party Agreement or Subsequent Third Party
Agreement is at issue in an action under this Section 10.3 or Section 10.4, (ii) Vividion or Celgene, as applicable, has a right to enforce or defend, as applicable, the Vividion Patents, Vividion
Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party Agreement, and (iii) Celgene
or Vividion, respectively, desires to enforce or defend, as applicable, such Patent in accordance with the procedures under this Section 10.3 or Section 10.4, as applicable, then Vividion or Celgene, respectively, shall either
(A) obtain the licensor(s)’ consent under such Existing Third Party Agreement or Subsequent Third Party Agreement so that Celgene or Vividion, respectively, may file such an action in its own name or (B) shall undertake such an action
on Celgene’s behalf and at [***] expense or on Vividion’s behalf and at [***] expense, respectively. 

  
 65 

 Section 10.4 Claimed Infringement. Each Party shall promptly notify the other
Party in writing of any allegation by a Third Party that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or misappropriates, or may infringe or misappropriate, the intellectual property rights of
such Third Party. If a Third Party asserts or files against a Party or its Affiliates any claim of infringement or misappropriation of the intellectual property rights of such Third Party or other action relating to alleged infringement or
misappropriation of such intellectual property rights (“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 

(a) Notice and Defense. If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization
of any Shared Product or Companion Diagnostic infringes or misappropriates the intellectual property rights of any Third Party, such Party shall promptly notify the other Party. In any such instance, the Parties shall as soon as practicable
thereafter meet (which may be through the JSC) to discuss in good faith regarding the best response to such notice. With respect to any such claim by a Third Party described in this Section 10.4(a), Celgene shall have the sole right, but not
the obligation, to defend and dispose (including through settlement or license) such claim in the Territory; it being understood and agreed that Vividion shall be entitled to defend itself with respect to any such Third Party claim in the Territory
to the extent that Vividion’s responses and admissions in conducting such defense do not interfere with ability of Celgene to defend such Third Party claim. 

(b) Costs. The costs and expenses incurred by the Parties in connection with defense of any claim described in Section 10.4(a) in
the US Territory shall, prior to any Vividion Opt-Out Date, be shared by the Parties in accordance with the Profit & Loss Share, and with respect to any such claim in the US Territory after any
Vividion Opt-Out Date or in the ROW Territory shall be borne solely Celgene, unless otherwise agreed in writing by the Parties. For clarity, this Section 10.4(b) is intended to address the Parties’
defense costs in such claim, and if as a result of any such defense of such claim, a Party obtains a license under Third Party intellectual property rights, Section 9.7 shall apply to the amounts due to any such Third Party pursuant to such
license. 
 Section 10.5 Patent Term Extensions. The JPC shall, as necessary and appropriate, use reasonable efforts to agree
upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions for Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene
Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents that Cover Shared Products. If the JPC is unable to agree upon which of such Patents should be
extended, and the matter remains unresolved after the procedure described in Section 2.2(e), then Celgene shall have the right to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement or
Subsequent Third Party Agreement to the extent such agreement applies to such Vividion Patent, Vividion Co-Co Collaboration Patent or Celgene Co-Co Collaboration Patent.

 Section 10.6 Patent Marking. Each Party shall comply with the patent marking statutes in each country in which any Shared
Product is Manufactured or Commercialized by or on behalf of a Party or their respective Affiliates or (sub)licensees, as applicable, hereunder. 

  
 66 

 Section 10.7 Application of 35 U.S.C. § 102(c). It is agreed
and acknowledged that this Agreement establishes a qualifying collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C.
§ 102(c). Neither Party shall invoke the provisions of 35 U.S.C. § 102(c), or file this Agreement, in connection with the prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without
the prior written consent of the other Party. In the event that a Party, during the course of prosecuting a patent application claiming a 35 U.S.C. § 102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it
necessary to file a terminal disclaimer to overcome an obviousness type double patenting rejection in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall
coordinate the filing of such terminal disclaimer in good faith, and, to the extent required under 35 U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce 35 U.S.C. § 102(c) Patent
independently from the Earlier Patent. To this end, to the extent required under 35 U.S.C. § 102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to 35
U.S.C. § 102(c) Patent. 
 Article XI 

Confidentiality 

Section 11.1 Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its
Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its Affiliates shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (b) not disclose such Confidential Information to any Third Party without the prior written
consent of the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement, the Master Agreement or any other Development &
Commercialization Agreement (it being understood that this clause (c) shall not create or imply any rights or licenses not expressly granted under this Agreement). No Confidential Information of the Disclosing Party or any of its Affiliates
shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights explicitly granted to the Receiving Party under this Agreement. “Confidential
Information” shall exclude any information that: 
 (a) was known by the Receiving Party or any of its Affiliates prior to its date
of disclosure to the Receiving Party or any of its Affiliates by or on behalf of the Disclosing Party or any of its Affiliates, as established by written evidence; or 

(b) is lawfully disclosed to the Receiving Party or any of its Affiliates by sources other than the Disclosing Party or any of its Affiliates
rightfully in possession of the Confidential Information; or 
 (c) is or becomes published or generally known to the public through no fault
or omission on the part of the Receiving Party or any of its Affiliates or (sub)licensees; or 

  
 67 

 (d) is independently developed by or for the Receiving Party or any of its Affiliates
without reference to or reliance upon such Confidential Information, as established by written records. 
 Section 11.2 Permitted
Disclosure. The Receiving Party may provide the Disclosing Party’s or any of the Disclosing Party’s Affiliates’ Confidential Information: 

(a) to the Receiving Party’s employees, consultants and advisors, and to the employees, consultants and advisors of such Party’s
Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such information and materials as confidential under
obligations of confidentiality and non-use no less stringent than those set forth in this Article XI (provided that legal counsel shall not be required to execute any written confidentiality
agreements); 
 (b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in order to seek or obtain approval to
conduct Clinical Trials or to gain Regulatory Approval with respect to the Shared Products as contemplated by this Agreement; provided that such disclosure may be made only following reasonable notice to the Disclosing Party and to the
extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 
 (c) if such disclosure is required by judicial
order or applicable Law or to defend or prosecute litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such requirement,
cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its applicable Affiliates’) Confidential
Information that the Receiving Party is legally required to furnish. 
 Section 11.3 Publicity; Terms of this Agreement; Non-Use of Names. 
 (a) Public Announcements. Except as required by judicial order or
applicable Law (in which case, Section 11.3(b) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other
Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would like to
make the public announcement (or, in extraordinary circumstances, such shorter period as required to comply with applicable Law). Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or
news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure
relating to this Agreement if the contents of such press release, public announcement or disclosure (i) (A) does not consist of financial information and has previously been made public other than through a breach of this Agreement by the
issuing Party or its Affiliates, (B) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or (C) is contained in the a redacted version of this Agreement, and (ii) is material
to the event or purpose for which the new press release or public announcement is made. 

  
 68 

 (b) Notwithstanding the terms of this Article XI: 

(i) Either Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the reasonable opinion of
such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other Governmental Authority. Notwithstanding the foregoing, before disclosing this
Agreement or any of the terms hereof pursuant to this Section 11.3(b)(i), the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all exhibits and schedules)
with respect to any filings with the US Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which securities issued by a Party or
a Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other Party, and the Parties
will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(ii) Notwithstanding Section 11.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of
its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary
in the following instances: 
 (A) complying with applicable Laws (including the rules and regulations of the SEC or any national securities
exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(B) disclosure, solely on a “need to know basis,” to (1) Affiliates, subcontractors, advisors (including attorneys and
accountants), (2) subject to Section 11.3(b)(ii)(C), investment bankers, and (3) in each case of (1) and (2), such Affiliates’, subcontractors’, advisors’ and investment bankers’, and each of the Parties’,
respective directors, employees, contractors and agents; provided that, in all cases of (1), (2) and (3), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this Article XI (provided, however, that in the case of prospective
investment bankers, the term of confidentiality may be shortened to three (3) years from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt, will not permit use of
such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who
receives Confidential Information pursuant to this Section 11.3(b)(ii)(B) or Section 11.3(b)(ii)(C) to treat such Confidential Information as required under this Article XI; and 

  
 69 

 (C) in the case of any disclosure of this Agreement to any actual or potential acquirer,
assignee, licensee, licensor, investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted Version, in each case, which version shall be agreed upon by the Parties in good faith; it
being understood and agreed that, in connection with a proposed Change of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is
in the final round of negotiations with such Third Party regarding execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement as
applicable, to such Third Party; provided that a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under
obligations of confidentiality not to disclose the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such
licensors and lenders. 
 (iii) The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results
and significant developments regarding the Shared Program and other activities in connection with this Agreement, the Master Agreement and each Development & Commercialization Agreement that may include information that is not otherwise
permitted to be disclosed under this Article XI, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and regulatory process, commercialization
activities and the like. A Party (the “Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory process and commercialization activities,
and in such event it shall first notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business Days in advance of issuing such press
release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as
possible under the circumstances if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement without such prior review by
the other Party if (A) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the issuing Party and (B) such press release or public announcement does not
materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the Cooperating Party may have regarding the
proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles to be observed in such disclosures shall include accuracy,
compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the Requesting Party’s
business. 

  
 70 

 Section 11.4 Publications. The Parties agree that decisions regarding the timing and
content of Publications shall be subject to the oversight and approval of the JDC and JPC and neither Party nor its Affiliates shall have the right to make Publications pertaining to the Collaboration except as provided herein. If a Party or its
Affiliates desire to make a Publication, such Party must comply with the following procedure: 
 (a) JDC Review. The publishing Party
shall provide the JDC and the non-publishing Party with an advance copy of the proposed Publication, and the JDC shall then have [***] days prior to submission for any Publication [***] days in the case of an
abstract or oral presentation) in which to determine whether the Publication may be published and under what conditions, including (i) delaying sufficiently long to permit the timely preparation and filing of a patent application or
(ii) specifying changes the JDC reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or license, including under this Agreement) in whole or in part
to the non-publishing Party. 
 (b) Removal of Confidential Information. In addition, if the non-publishing Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential Information of the
non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c) Scientific Conferences. Each Party shall have the right to present its Publications approved pursuant to this Section 11.4 at
scientific conferences, including at any conferences in any country in the world, subject to any conditions imposed by the JDC in its approval. 

(d) Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to
Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to
restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement,
exercise such rights after consultation with Celgene. 
 (e) Delegation. For purposes of convenience, the JDC may delegate its
responsibilities under this Section 11.4 to one or more representatives of Vividion and Celgene. 
 Section 11.5 Term. All
obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall survive termination or expiration of this Agreement and shall expire five (5) years following termination or expiration of this Agreement. 

Section 11.6 Return of Confidential Information. 

(a) Obligations to Return or Destroy. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the Disclosing
Party all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: 

  
 71 

 (i) any notes, reports or other documents prepared by the Receiving Party or any of its
Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates; and 
 (ii) any Confidential Information
of the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 

(b) Destruction. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential
Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of
its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the
Receiving Party supervising such destruction. 
 (c) Limitation. Nothing in this Section 11.6 shall require the alteration,
modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by
its obligations of confidentiality and other obligations under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d) Exceptions. Notwithstanding the foregoing, 

(i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 
 (ii) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents 

(A) to the extent reasonably required (1) to exercise the rights and licenses of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(B) to the extent it is impracticable to return or destroy such Confidential Information without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving
Party shall continue to be bound by its obligations of confidentiality and other obligations under this Article XI. 

  
 72 

 Article XII 

Representations and Warranties 

Section 12.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the
Execution Date, that: 
 (a) Authority. Each Party is duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as applicable. 

(b) Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder have been obtained, except for authorizations and consents that may be necessary
under Antitrust Law. 
 (c) No Conflict. Notwithstanding anything to the contrary in this Agreement, the execution and delivery of
this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of
applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to which it is a party or by
which it or any of its Affiliates is bound, existing as of the Execution Date. 
 (d) Enforceability. This Agreement has been duly
executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e) Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in the
Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 
 Section 12.2 Additional Vividion
Representations. Vividion represents, warrants and covenants to Celgene, as of the Execution Date, as follows: [Note: The representations and warranties marked by an asterisk (*) below may be qualified by Vividion with a schedule of
exceptions prior to the Execution Date] 
 (a) Vividion has all rights, authorizations and consents necessary to grant all rights and
licenses it purports to grant to Celgene under this Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 

(b) Vividion has not used, and during the Term will not knowingly use, any Know-How in the Shared
Program that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder; it being understood and agreed that, notwithstanding
anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(b) with respect to any Patents or Know-How licensed to Vividion
under the Scripps License is as set forth in Section 12.4(b). 

  
 73 

 (c) Vividion has not granted, and during the Term Vividion will not grant, any right or
license, to any Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d) There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings or governmental
investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion to consummate the
transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or the Co-Co
Target or any Shared Product.* 
 (e) To Vividion’s knowledge, the practice of the Vividion Intellectual Property as contemplated under
this Agreement does not (i) infringe any claims of any Patents of any Third Party (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including
any safe harbor, research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (ii) misappropriate any
Know-How of any Third Party, and, in particular, the practice of the Vividion Intellectual Property by or on behalf of Celgene or any of its Affiliates or Licensee Partners as contemplated under this Agreement
does and will not (A) infringe any claims of any Patents licensed to Vividion pursuant to the License Agreement dated as of January 6, 2016 by and between by The Scripps Research Institute (“Scripps”) and Vividion (the
“Scripps License”) (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including any safe harbor, research exemption, government or
executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (B) misappropriate any Know-How
licensed to Vividion pursuant to the Scripps License; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy for any breach of this Section 12.2(e)
solely with respect to the Scripps License is as set forth in Section 12.4(b).* 
 (f) None of (i) the Vividion Patents owned by
Vividion or both Controlled by and Prosecuted by Vividion and (ii) to Vividion’s knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination,
opposition, interference or litigation proceedings or inter partes reviews, post grant reviews or covered business methods reviews.* 
 (g)
To the knowledge of Vividion, the Vividion Patents Controlled by Vividion or any of its Affiliates pursuant to any Existing Third Party Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing
Third Party Agreements. 

  
 74 

 (h) Vividion has and, to Vividion’s knowledge, the applicable licensor under each
Existing Third Party Agreement has, if applicable, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patents or Know-How licensed thereunder.* Neither Vividion
nor any of its Affiliates has granted any liens or security interests on the Vividion Intellectual Property and the Vividion Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance,
lien or charge of any kind, except in each case with respect to licenses, covenants not to sue, immunities from suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration.

 (i) Schedule 12.2(i) contains a complete and accurate list of all Patents owned or licensed by Vividion or its Affiliates as of the
Execution Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 12.2(i), Vividion and its Affiliates do not own and have not
licensed any Patent that is necessary or, to Vividion’s reasonable belief as of the Execution Date, reasonably useful to Develop, Manufacture or Commercialize any Shared Products; it being understood and agreed that, notwithstanding anything to
the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(i) with respect to any Patents or Know-How licensed to Vividion under the
Scripps License is as set forth in Section 12.4(b). 
 (j) Schedule 12.2(j) sets forth a complete and accurate list of all Existing
Third Party Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Vividion nor, to the knowledge of Vividion, any licensor under
the Existing Third Party Agreements is in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a material obligation under,
the Existing Third Party Agreements.* 
 (k) Except under the Scripps License (solely with respect to royalties for which Vividion shall be
solely responsible) and Existing Third Party Agreements in effect as of the Execution Date, and except as set forth on Schedule 12.2(j), Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the
execution or performance of this Agreement. 
 Section 12.3 Covenants. 

(a) Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i) all employees of such Party or its Affiliates, Licensee Partners or Third Party subcontractors working under this Agreement will be under
appropriate confidentiality obligations at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries,
whether or not patentable, to such Party as the sole owner thereof; 
 (ii) to its knowledge, such Party will not (A) employ or use,
nor hire or use any contractor or consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or 

  
 75 

 subject to a similar sanction by any Regulatory Authority outside the US Territory) or
(B) employ any individual who, or entity that is, the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the US Territory), in each of subclauses (A) and (B) in the conduct of
its activities under this Agreement 
 (iii) neither such Party nor any of its Affiliates shall, during the Term, grant any right or license
to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder; and 

(iv) such Party and its Affiliates shall perform their activities pursuant to this Agreement in compliance (and shall ensure compliance by any
of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP as applicable. 
 (b) Third Party
Agreement Covenants. Vividion hereby covenants to Celgene that Vividion shall maintain the Existing Third Party Agreements and each Party hereby covenants to the other Party that it shall maintain any Subsequent Third Party Agreements to which
it is a Party, and shall not amend or terminate such agreements entered into by such Party, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect the other Party’s rights under this
Agreement. 
 Section 12.4 Vividion Covenants During the Term. 

(a) Except to the extent expressly permitted under Section 15.4, during the Term, neither Vividion nor its Affiliates will, other than to
an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection
(b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, any assets
specifically related to this Agreement, including with respect to any Shared Product(s) and any then-identified Companion Diagnostic(s) developed therefor, or pre-clinical study or Clinical Trial results or
other data specifically related to the Shared Program, or any intellectual property specifically related to any of the foregoing (with respect to the Shared Program, the “Program Assets”) owned or controlled by Vividion at any time,
except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this Agreement with respect to the Shared Program, (b) license or grant to any Third Party, or agree to
license or grant to any Third Party, any rights to any Program Assets owned or controlled by Vividion at any time if such license or grant would fundamentally frustrate the purpose of this Agreement with respect to the Shared Program, or
(c) disclose any Confidential Information relating to the Program Assets owned or controlled by Vividion at any time to any Third Party if such disclosure would fundamentally frustrate the purpose of this Agreement with respect to the Shared
Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to the Shared Program to any Affiliate of Vividion to the extent permitted under Section 15.4. 

  
 76 

 (b) Vividion hereby covenants and agrees, subject to Section 13.3, that it will defend
and hold harmless Celgene and its Affiliates in the Territory from any Damages resulting from any Claims that, as a result of any Development, Manufacturing or Commercialization, including any making, using, selling, offering for sale, or importing,
of any Shared Product, Celgene or any other Selling Party has infringed or misappropriated (i) any Patents or Know-How that (A) are owned jointly or solely by Scripps and/or its employees or
consultants and (B) (I) arose from any Development by or on behalf of Vividion of any Shared Product and/or involved, to the extent provided by Vividion, the use of any Shared Product, Vividion Intellectual Property and/or other Vividion
materials or resources and/or (II) were discovered, developed, generated or invented by any employee or consultant of Scripps in the conduct of activities under a sponsored research or other agreement or any other arrangement (whether formal or
informal) with Vividion and (ii) any Patents or Know-How licensed to Vividion under the Scripps License (any such claims under clauses (i) or (ii) above, the “Scripps Claims”).
Notwithstanding anything to the contrary in this Agreement, in the event of any Scripps Claim, Vividion hereby covenants and agrees to sublicense to Celgene (with the right to sublicense in accordance with Section 8.2 and Section 8.3) any
Patents or Know-How that are the subject of such Scripps Claim, all as reasonably necessary or desirable in order to enable Celgene and its Selling Parties to Develop, Manufacture, Commercialize, make, use,
sell, offer for sale, or import the Shared Product throughout the Territory in accordance with this Agreement without any royalty or other financial obligation on account of such sublicense. 

Section 12.5 Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR
EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success of any study or test commenced under this Agreement; (b) the safety or usefulness for any
purpose of the technology or materials, including any Shared Product or Companion Diagnostic; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it
provides or licenses to the other Party under this Agreement. 
 Section 12.6 Additional Celgene Representations. Celgene
represents and warrants to Vividion, as of the Execution Date that Celgene possesses sufficient rights to enable Celgene to grant all rights and licenses it purports to grant to Vividion under this Agreement as of the Execution Date. 

Section 12.7 Covenant Not to Sue. Celgene (on behalf of itself and its Affiliates and its and their respective successors, assigns
and transfers) covenants not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming
or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves
Vividion or its Affiliates or their respective (sub)licensees (a) Developing, using, Manufacturing or having Manufactured the Shared Products 

  
 77 

 and Companion Diagnostics (solely for use in connection with the Shared Products) in the Territory at the
request of Celgene or (b) offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics (solely for use in connection with the Shared Products) in the US Territory as contemplated by this
Agreement. 
 Article XIII 

Indemnification; Product Liabilities 

Section 13.1 In the US Territory and for U.S. Administration. 

(a) Indemnification by Celgene. Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless Vividion and
its Affiliates and their respective directors, officers, employees and agents (the “Vividion Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Celgene of any of its representations, warranties or obligations under this Agreement with respect to the US Territory or
for U.S. Administration; 
 (ii) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee
Partners or Third Party Contractors in the US Territory for U.S. Administration in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; or 

(iii) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Celgene or any of its Affiliates following
any Vividion Opt-Out Date, including any Product Liability Claims incurred following any Vividion Opt-Out Date (except as contemplated by Section 2.3(c)) in the US
Territory or for U.S. Administration or any personal injury, property damage or other damage in the US Territory or for U.S. Administration, in each case, resulting from any of the foregoing activities described in this Section 13.1(a)(iii);
provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this Section 13.1(a)(iii) from or against any Third Party Damages arising out of or
relating to, directly or indirectly, any Claim in the US Territory or for US Administration brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in his/her capacity as a director, officer,
shareholder or employee of Vividion, as applicable; 
 in each case, provided, however, that, such indemnity shall not apply to the
extent (i) Vividion has an indemnification obligation pursuant to Section 13.1(b) for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

(b) Indemnification by Vividion. Vividion agrees, at Vividion’s cost and expense, to defend, indemnify and hold harmless Celgene and its
Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Vividion of any of its representations, warranties or obligations under this Agreement in the US Territory or for U.S.
Administration (including without limitation pursuant to Section 12.4(b)); 

  
 78 

 (ii) the gross negligence, willful misconduct or violation of Law of Vividion or its
Affiliates, Licensee Partners or Third Party Contractors in the US Territory for U.S. Administration in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any of the matters disclosed by Vividion in a disclosure schedule pursuant to Section 12.2, where the cause of action underlying
such Damages accrued in the US Territory or for U.S. Administration prior to the Execution Date. For the avoidance of doubt, amounts payable under Subsequent Third Party Agreements entered into under Section 9.7 shall be borne by Celgene as set
forth in Section 9.7, and shall not be subject to indemnification under this Section 13.1 but shall be subject to Section 9.3(d); and 

(iv) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Vividion or any of its Affiliates following
the reversion thereof to Vividion pursuant to Section 14.3(a), including any Product Liability Claims in the US Territory or for U.S. Administration or any personal injury, property damage or other damage in the US Territory or for U.S.
Administration, in each case, resulting from any of the foregoing activities described in this Section 13.1(b)(iv); provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the
Celgene Indemnified Parties under this Section 13.1(b)(iv) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim in the US Territory or for US Administration brought against Celgene Indemnified
Parties by any director, officer, shareholder or employee of Celgene acting in his/her capacity as a director, officer, shareholder or employee of Celgene, as applicable; 

in each case, provided, however, that such indemnity shall not apply to the extent (i) Celgene has an indemnification obligation
pursuant to Section 13.1(a) for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

Section 13.2 In the ROW Territory and for ROW Administration. 

(a) Indemnification by Celgene. Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless the Vividion
Indemnified Parties, from and against any Damages arising out of any Claim relating to: 
 (i) any breach by Celgene of any of its
representations, warranties or obligations pursuant to this Agreement with respect to the ROW Territory or for ROW Administration; or 

(ii) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee Partners or Third Party
Contractors in the ROW Territory or for ROW Administration in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Celgene or any of its Affiliates following
any Vividion Opt-Out Date, including any Product Liability Claims incurred following any Vividion Opt-Out Date (except as contemplated by Section 2.3(c)) in the ROW
Territory or for ROW Administration or any personal injury, property damage or other damage in the ROW Territory or for ROW 

  
 79 

 Administration, in each case resulting from any of the foregoing activities described in this
Section 13.2(a)(iii); provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this Section 13.2(a)(iii) from or against any Third Party
Damages arising out of or relating to, directly or indirectly, any Claim in the ROW Territory or for ROW Administration brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in his/her
capacity as a director, officer, shareholder or employee of Vividion, as applicable; it being understood and agreed that this Section 13.2(a)(iii) shall not require Celgene to pay Vividion any amounts that Celgene deducts from royalties paid to
Vividion pursuant to Section 9.3(d) or includes as an expense in, or has previously paid pursuant to, Section 9.1 or Section 9.6, as applicable; 

in each case, provided, however, that, such indemnity shall not apply to the extent Vividion has an indemnification obligation pursuant
to Section 13.2(b) for such Damages. 
 (b) Indemnification by Vividion. Vividion agrees, at Vividion’s cost and expense, to
defend, indemnify and hold harmless the Celgene Indemnified Parties, from and against any Damages arising out of any Claim relating to: 

(i) any breach by Vividion of any of its representations, warranties or obligations pursuant to this Agreement in the ROW Territory or for ROW
Administration (including without limitation pursuant to Section 12.4(b)); 
 (ii) the gross negligence, willful misconduct or
violation of Law of Vividion or its Affiliates in the ROW Territory or for ROW Administration in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any of the matters disclosed by Vividion in a disclosure schedule pursuant to Section 12.2, where the cause of action underlying
such Damages accrued in the ROW Territory or for ROW Administration prior to the Execution Date. For the avoidance of doubt, amounts payable under Subsequent Third Party Agreements entered into under Section 9.7 shall be borne by Celgene as set
forth in Section 9.7, and shall not be subject to indemnification under this Section 13.2 but shall be subject to Section 9.3(d); and 

(iv) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Vividion or any of its Affiliates following
the reversion thereof to Vividion pursuant to Section 14.3(a), including any Product Liability Claims in the ROW Territory or for ROW Administration or any personal injury, property damage or other damage in the ROW Territory or for ROW
Administration, in each case, resulting from any of the foregoing activities described in this Section 13.2(b)(iv); provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the
Celgene Indemnified Parties under this Section 13.2(b)(iv) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim in the ROW Territory or for ROW Administration brought against Celgene
Indemnified Parties by any director, officer, shareholder or employee of Celgene acting in his/her capacity as a director, officer, shareholder or employee of Celgene, as applicable; it being understood and agreed that this Section 13.2(b)(iv)
shall not require Vividion to pay Celgene any amounts that Vividion includes as an expense in, or has previously paid pursuant to, Section 9.1 or Section 9.6, as applicable; 

  
 80 

 in each case, provided, however, that, such indemnity shall not apply to the extent
Celgene has an indemnification obligation pursuant to Section 13.2(a) for such Damages. 
 Section 13.3 Indemnification
Procedures. In the event of any such Claim against any of the Celgene Indemnified Parties or Vividion Indemnified Parties (each, an “Indemnified Party”), as applicable, by any Third Party, such Indemnified Party shall promptly,
and in any event within [***] Business Days, notify the applicable indemnifying Party (the “Indemnitor”) in writing of the Claim. The Indemnitor shall have the right, exercisable by notice to the Indemnified Party within [***]
Business Days after receipt of notice from the Indemnified Party of the Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for
monetary damages and the Indemnitor agrees to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by the Indemnitor to the Indemnified Party) with counsel selected by the Indemnitor and reasonably acceptable to
the Indemnified Party; provided that the failure to provide timely notice of a Claim by a Third Party shall not limit an Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual
prejudice to the Indemnitor. The Indemnified Parties shall cooperate with the Indemnitor and may, at their option and expense, be separately represented in any such action or proceeding. The Indemnitor shall not be liable for any litigation costs or
expenses incurred by the Indemnified Parties without the Indemnitor’s prior written authorization for so long as the Indemnitor controls such litigation. In addition, the Indemnitor shall not be responsible for the indemnification or defense of
any Indemnified Party to the extent arising from any negligent or intentional acts by any Indemnified Party or the breach by such Indemnified Party of any representation, obligation or warranty under this Agreement, or any Claims compromised or
settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Article XIII. 

Section 13.4 Product Liability Costs. Except with respect to such portion (if any) of Product Liabilities that are Claims entitled
to indemnification under Section 13.1 or Section 13.2, the Parties jointly shall be responsible for all Product Liabilities, all Out-of-Pocket Costs and FTE
costs incurred by the controlling Party under Section 13.5 in connection with any litigation or proceeding related to any applicable Third Party Products Liability Action and all
Out-of-Pocket Costs and FTE costs incurred by the non-controlling Party under Section 13.5 at the request of the controlling
Party under Section 13.5, as follows: 
 (a) All such costs and expenses incurred relating to Shared Products distributed prior to the
Vividion Opt-Out Date in (a) the US Territory shall be taken into account in determining the Profit & Loss Share as, and to the extent, provided in Exhibit D and (b) the ROW
Territory, shall be borne by [***]. 
 (b) All such costs and expenses incurred after the Vividion
Opt-Out Date relating to Shared Products shall be borne solely by [***] if and only to the extent such Product Liabilities arose from Shared Products distributed after the Vividion Opt-Out Date. 

  
 81 

 Section 13.5 Conduct of Product Liability Claims. 

(a) Each Party shall promptly notify the other in the event that any Third Party asserts or files any products liability claim or other action
relating to alleged defects in any Shared Product (whether design defects, manufacturing defects or defects in sales or marketing) (“Third Party Products Liability Action”) against such Party. In the event of a Third Party Products
Liability Action against such a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to join or otherwise participate in such legal action with legal counsel selected by the unnamed Party and reasonably
acceptable to the named Party. The Party named in such Third Party Products Liability Action shall have the right to control the defense of the action, but shall notify and keep the unnamed Party apprised in writing of such action and shall consider
and take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action; provided, however, that, in the event of a Vividion
Opt-Out Notice, Celgene shall have the right to control the defense of all Third Party Product Liability Actions after the Vividion Opt-Out Date. In the event of a Third
Party Products Liability Action against both Parties, unless otherwise agreed by the Parties in writing, Celgene shall control the response to such Third Party Products Liability Action. 

(b) The non-controlling Party of a Third Party Products Liability Action shall reasonably cooperate
with the controlling Party in the preparation and formulation of a defense to such Third Party Products Liability Action, and in taking other steps reasonably necessary to respond to such Third Party Products Liability Action. The controlling Party
shall have the right to select its counsel for the defense to such Third Party Products Liability Action, which counsel must be reasonably acceptable to the non-controlling Party. If required under applicable
Law in order for the controlling Party to maintain a suit in response to such Third Party Products Liability Action, the non-controlling Party shall join as a party to the suit. The non-controlling Party shall also have the right to participate and be represented in any such suit on a voluntary basis by its own counsel at [***] expense. The controlling Party shall not settle or compromise any
Third Party Products Liability Action without the consent of the other Party, which consent shall not be unreasonably withheld. 

Section 13.6 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF SECTION 8.6 OR ARTICLE XI, OR A PARTY’S LIABILITY
PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT
OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 

Section 13.7 Insurance. Beginning on the commencement of the first Clinical Trial of a Shared Product and thereafter during the
Term, each Party shall maintain commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least [***] US Dollars ($[***]) per claim and annual
aggregate. Celgene may elect to self-insure all or parts of the limits described above. Within [***] days following written request from the other Party, each Party shall furnish to the other Party a certificate of insurance evidencing such
coverage. If such coverage is modified or cancelled, the insured Party shall notify the other Party and promptly provide such other Party with a new certificate of insurance evidencing that such insured Party’s coverage meets the requirements
of this Section 13.7. 

  
 82 

 Article XIV 

Term and Termination 

Section 14.1 Term; Expiration. 

(a) Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article XIV, shall
remain in effect until it expires as set forth in this Section 14.1(a) (the “Term”). 
 (i) Prior to any Vividion Opt-Out Date: 
 (A) this Agreement shall continue in full force and effect in the US Territory for as
long as the Parties continue to Develop or Commercialize Shared Products in the US Territory or for U.S. Administration; 
 (B) on a Shared Product-by-Shared Product and country-by-country basis in the ROW Territory, this Agreement
shall expire on the date of the expiration of all applicable Royalty Terms with respect to such Shared Product in such country; and 
 (C)
this Agreement shall expire in its entirety with respect to the ROW Territory only upon the expiration of all applicable Royalty Terms in the ROW Territory under this Agreement with respect to all Shared Products in the ROW Territory. 

(ii) In the event of a Vividion Opt-Out Date, this Agreement shall 

expire: 
 (A) on a Shared Product-by-Shared Product and country-by-country basis, upon the expiration of the applicable
Royalty Term with respect to such Shared Product in such country; and 
 (B) in its entirety upon the expiration of all applicable Royalty
Terms under this Agreement with respect to all Shared Products in all countries worldwide. 
 For the avoidance of doubt, this Agreement shall not be
effective until the Effective Date, and this Agreement may be subject to termination prior to the Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Program (as defined in the Master Agreement)
that is the subject of this Agreement shall revert to Vividion in accordance with Section 3.2 of the Master Agreement. 
 (b) Effect
of Expiration. After the expiration of the Term with respect to any Shared Product in any country, the following terms shall apply solely with respect to such Shared Product in such country: 

(i) Licenses after Shared Product Expiration. After expiration of the Term (but not after early termination) with respect to any Shared
Product in a country pursuant to Section 14.1(a)(i)(B) or Section 14.1(a)(ii)(A), Celgene shall have an exclusive, fully-paid, royalty-free, irrevocable, non-terminable, right and license in such
country, with the right to grant sublicenses through multiple tiers, under the Vividion Intellectual Property, Vividion Co-Co 

  
 83 

 Collaboration Intellectual Property and Vividion’s rights in the Joint
Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize such Shared Product and related Companion Diagnostics in the Field in such country;
provided, however, that, following such expiration, notwithstanding anything to the contrary in Section 8.5 or Section 9.7, (A) Celgene shall be solely responsible for all payments owed to any Third Party licensors and
(B) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((A) and (B)) solely with respect to Celgene’s exercise of such rights. 

(ii) Licenses after Expiration of Agreement. After expiration of the Term (but not after early termination) with respect to this
Agreement in the ROW Territory pursuant to Section 14.1(a)(i)(C) or in its entirety pursuant to Section 14.1(a)(ii)(B), Celgene shall have an exclusive, fully-paid, royalty-free, irrevocable,
non-terminable, right and license, with the right to grant sublicenses, under the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and
Vividion’ rights in the Joint Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize Shared Products and Companion Diagnostics in the Field in
the ROW Territory or Territory, respectively; provided, however, that, following such expiration, notwithstanding anything to the contrary in Section 8.5 or Section 9.7, (A) Celgene shall be solely responsible for all
payments owed to any Third Party licensors and (B) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((A) and (B)) solely with respect to Celgene’s exercise of
such rights. 
 Section 14.2 Termination. 

(a) Termination for Convenience. Celgene shall have the right to terminate this Agreement in its entirety for convenience upon ninety
(90) days’ prior written notice to Vividion; provided that Celgene shall not have the right to terminate this Agreement until twelve (12) months following the Effective Date (it being understood and agreed that Celgene
shall be entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

(b) Termination for Material Breach. 

(i) Termination by Either Party for Breach. Subject to Section 14.2(b)(ii) (with respect to a Material Breach by either Party of
its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that fundamentally frustrates the transactions contemplated
by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such Material Breach within ninety (90) days after the date
of written notice to the breaching Party of such breach (or thirty (30) days, in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.2(b)(ii) with respect to a Material
Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section 14.2(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as 

  
 84 

 to a Material Breach under this Agreement will run from the date that written notice was first provided to
the breaching Party by the non-breaching Party. Any such termination of this Agreement under this Section 14.2(b)(i) shall become effective at the end of the Cure Period, unless the breaching Party has
cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within the Cure Period, then, the non-breaching Party’s right of
termination shall be suspended only if and for so long as the breaching Party has provided to the non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable
to the non-breaching Party, and the breaching Party commits to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five
(225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the totality of
the circumstances with respect to this Agreement will be taken into account and assessed as a whole for purposes of determining whether a breach is a Material Breach under this Agreement. 

(ii) Additional Procedures for Termination by either Party for Failure of the Other Party to Use Commercially Reasonable Efforts. If
either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.2(b)(i) for the other Party’s Material Breach of its obligations to use Commercially Reasonable Efforts, it shall provide to such other Party a
written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially Reasonable Efforts,” and shall state the reasons and justification for such termination and
recommending steps which such Party believes the other Party should take to cure such alleged breach. For any such notice of breach by a Party, the Cure Period shall, subject to Section 14.2(b)(iii), be one hundred and eighty (180) days,
and shall become effective in accordance with Section 14.2(b)(i). 
 (iii) Disagreement as to Material Breach. If the Parties
reasonably and in good faith disagree as to whether there has been a Material Breach, then, subject to Section 15.1: (A) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within
thirty (30) days following such notice of alleged Material Breach for resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter,
whether or not a Material Breach has occurred pursuant to this Section 14.2(b); (B) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the
non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement (provided, that if such dispute relates to payment, the Cure
Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts), (C) it is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall
remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and (D) if it is finally and conclusively determined in accordance with Section 15.2 that the breaching Party committed such Material
Breach, then the breaching Party shall have the right to cure such Material Breach after such determination within the Cure Period (provided, that if such dispute relates to a failure to use Commercially Reasonable Efforts, such post-determination
Cure Period shall be strictly limited to thirty (30) days and any cure within such thirty (30) day period must fully cure such breach prior to the end of such thirty (30) day period). 

  
 85 

 (iv) If the Executive Officers are unable to resolve a dispute within such ten
(10) Business Day period after it is referred to them, the matter will be resolved as provided in Section 15.2. 
 (v)
Payments. No milestone payments by Celgene will be due on milestones achieved during the period between the notice of termination under Section 14.2(b) and the effective date of termination; provided, however, that,
if either Party provides notice of a dispute pursuant to Section 14.2(b) or otherwise and such dispute is resolved in a manner in which no termination of this Agreement occurs with respect to such breach or the breaching Party cures the
applicable breach during the Cure Period, then upon such resolution or cure Celgene will within five (5) Business Days pay to Vividion the applicable milestone payment for each milestone achieved during the period between the notice of
termination under Section 14.2(b) and the resolution of such dispute or cure of such breach, and if it was determined that Celgene wrongly asserted breach by Vividion under Section 14.2(b), then Celgene shall also pay interest on such
amount as provided in Section 9.12. 
 (c) Termination for Insolvency. To the extent permitted by Law, this Agreement may be
terminated by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to, or upon an assignment of a substantial portion of the assets for the benefit of creditors by, the other
Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding such right to terminate shall only become effective if the non-terminating Party
consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof. 

(d) Termination for Patent Challenge. Either Party shall have the right to terminate this Agreement solely on a Shared Product-by-Shared Product basis upon written notice if the other Party or any of its Affiliates challenges the validity, scope or enforceability of or otherwise opposes any
Patent (i) included in the Vividion Intellectual Property or Vividion Co-Co Collaboration Intellectual Property and that is licensed to Celgene under this Agreement in any action or proceeding, or
(ii) included in the Celgene Intellectual Property or Celgene Co-Co Collaboration Intellectual Property that is licensed to Vividion under this Agreement in any action or proceeding (subject to the
exceptions described in this Section 14.2(d), a “Challenge”) (other than as may be necessary or reasonably required to assert a defense, cross-claim or a counter¬claim in an action or proceeding asserted by either Party or
any of its Affiliates or Licensee Partners against the other Party or any of its Affiliates or to respond to a court request or order or administrative law, request or order) it being understood and agreed that either Party’s right to terminate
this Agreement under this Section 14.2(d) shall not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging Party”) that first becomes such an Affiliate as a result of a Change of Control involving
the Challenging Party, where such new Affiliate was undertaking any of the activities described in the foregoing clause prior to such Change of Control; provided that a Party’s right to terminate this Agreement under this
Section 14.2(d) shall apply to actions undertaken by such new Affiliate if the Challenging Party is the acquiror in such Change of Control and such new Affiliate does not terminate or otherwise cease participating in such action, proceeding,
challenge or opposition within thirty (30) days after the effective date of such Change of Control. If a Licensee Partner of either Party challenges the validity, scope or enforceability of or otherwise opposes any Patent included in any of the
intellectual property 

  
 86 

 described in this Section 14.2(d) under which such Licensee Partner is sublicensed in any action or
proceeding, then the Party that granted such sublicense shall, upon written notice from the other Party, terminate such sublicense. For the avoidance of doubt, an action by a Party or any of its Affiliates (collectively the “Pursuing
Party”) in accordance with this Agreement and the Master Agreement to amend claims within a pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application or in
defense of a Third Party proceeding, or to make a negative determination of patentability of claims of a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing Party’s
Prosecution of such pending patent application, shall not constitute a challenge under this Section 14.2(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any Confidential
Information of the other Party or any nonpublic information regarding the Prosecution or enforcement of any Vividion Patent, Celgene Co-Co Collaboration Patent or Vividion
Co-Co Collaboration Patent (including Joint Co-Co Patents and Joint Patents) to which a Party or any of its Affiliates or (sub)licensees are or become privy as a
consequence of the rights granted to such Party pursuant to Article X, in initiating, requesting, making, filing or maintaining, or in funding or otherwise assisting any other Person with respect to, any Challenge. 

Section 14.3 Effects Of Termination. 

(a) Effects of Celgene Termination for Convenience or Vividion Termination for Celgene Breach, Insolvency or Patent Challenge. Upon termination
of this Agreement by Celgene under Section 14.2(a) or by Vividion under Section 14.2 (b), Section 14.2(c) or Section 14.2(d), the following shall apply: 

(i) (A) all licenses granted by Vividion to Celgene under Section 8.1(a) shall terminate in their entirety if pursuant to
Section 14.2(a), Section 14.2(b) or Section 14.2(c), and (B) with respect to the corresponding Shared Product if pursuant to Section 14.2(d), and Celgene (x) shall grant to Vividion an exclusive (even as to Celgene and
its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene Co-Co Collaboration Intellectual Property and Celgene’s
interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared
Products and Companion Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly,
sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming or otherwise asserting that Vividion or its Affiliates or
their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective
(sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products; 

(ii) each Party shall be released from its Development, Manufacture and Commercialization obligations (except as set forth in
Section 14.3(a)(vii) and (viii) below with respect to Celgene’s transfer of Manufacturing to Vividion hereunder); 

  
 87 

 (iii) within [***] days after such termination, unless there has been a Vividion Opt-Out Date, each Party shall provide the other with a report of Net Sales, COGS and Allowable Expenses and other amounts incurred by such Party that are subject to the Parties’ cost-sharing obligations
through the effective date of termination for the purpose of calculating a final reconciliation of shared costs and payments in accordance with Section 9.1 and Section 9.6as applicable. Each Party shall submit any supporting information
reasonably requested by the other Party related to such Net Sales, COGS and Allowable Expenses and such other amounts included in such Party’s reconciliation report within [***] days after the other Party’s receipt of such request. The
Parties, with the assistance of the JCC, shall conduct a final reconciliation of such costs and payments within [***] days after receipt of all such supporting information, and an invoice shall be issued to the Party (if any) that owes the other
Party a payment to accomplish the cost sharing or payment envisioned under this Agreement pursuant to Section 9.1 and Section 9.6, as applicable. The paying Party shall pay all amounts payable under any such invoice within
[...***...)] days after its receipt of such invoice; provided, however, that, Celgene shall remain responsible for its applicable share of all COGS and Allowable Expenses committed prior to the effective date of
termination and not cancelable by Vividion, which Vividion shall reasonably seek to minimize, with respect to the Shared Products to the extent such COGS and Allowable Expenses (A) are within an approved Development Budget under an approved
Development Plan or Commercialization Budget under an approved U.S. Commercialization Plan, respectively, in place prior to termination and (B) are solely incurred by Vividion during the period ending [***] days after the effective date of
termination of this Agreement; 
 (iv) within [***] days after such termination, Celgene shall provide to Vividion a fair and accurate
summary report of the status of Development and Commercialization activities conducted by Celgene with respect to the Shared Products; 

(v) Celgene shall promptly transfer and assign to Vividion all of Celgene’s and its Affiliates’ rights, title and interests in and
to the product trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene and solely used for Shared Products; 

(vi) Celgene shall as soon as reasonably practicable transfer and assign to Vividion all Regulatory Approvals and Regulatory Documentation
with respect to the Shared Products and a copy of all of the data comprising the Global Safety Database; provided that Celgene may retain such data and a single copy of such Regulatory Approvals and Regulatory Documentation for its
records. Notwithstanding the foregoing, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development, Manufacture or Commercialization of any product other than the Shared Products, in place of transferring or
assigning the foregoing, Celgene shall instead grant Vividion a Right of Reference or Use with respect to such approvals or documentation with respect to the Shared Products; 

(vii) Vividion shall have the option, exercisable within [***] days following the effective date of such termination of this Agreement, to
obtain Celgene’s inventory of the Shared Products at a price equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs for such inventory of the Shared Products; provided that, if Celgene, its Affiliates or
(sub)licensees have outstanding orders, at Vividion’s election, either Vividion shall fulfill such orders or, notwithstanding Vividion’s option to purchase inventory, Celgene may retain 

  
 88 

 
sufficient inventory to fulfill such orders. Vividion may exercise such option by written notice to Celgene during such [***] day period; provided that, in the event Vividion
exercises such right to purchase such inventory, Celgene shall grant, and hereby does grant, a royalty-free right and license to any trademarks, names and logos of Celgene contained therein for a period of [***] months solely to permit the orderly
sale of such inventory, subject to Vividion meeting reasonable quality control standards imposed by Celgene on the use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 

(viii) to the extent that Celgene is responsible for Manufacturing the Shared Products immediately prior to such termination, at
Vividion’s written request: 
 (A) in exchange for a payment equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs and
upon other commercially reasonable terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable Efforts to supply Vividion and its Affiliates with comparable
quantities of the Shared Products in the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [***] months after the effective date of the termination and establishment by
Vividion of an alternative supply for such product(s); 
 (B) in the event Celgene was utilizing a Third Party manufacturer to Manufacture
the Shared Products, to the extent permitted by the terms of any applicable contract, Celgene shall promptly assign to Vividion the manufacturing agreements with such Third Party with respect to such product(s); and 

(C) Celgene shall transfer, or have transferred, to Vividion or its designee, pursuant to a technology transfer plan to be mutually agreed by
the Parties, all Manufacturing Technology Controlled by Celgene within Celgene Co-Co Collaboration Intellectual Property that is both necessary to Manufacture the Shared Products as Manufactured by or on
behalf of Celgene and its Affiliates prior to termination and has been incorporated in regulatory documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Shared Products (or is in the process of being
incorporated), and Celgene shall provide reasonable assistance in connection with the transfer of such Manufacturing Technology to Vividion or its designee, all of which shall be transferred or provided at Celgene’s Out-of-Pocket Costs; 
 (ix) separate transitional activities
shall be undertaken with respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How or Patents necessary for
the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other
Know-How or Patents otherwise associated with such Shared Products are transferred; 

  
 89 

 (x) notwithstanding anything to the contrary in Section 8.6, Vividion shall have the
right to pursue the Development, Manufacture and Commercialization of the Shared Products; and 
 (xi) the provisions of Article X (other
than Section 10.1) shall terminate, and Celgene shall, if applicable, provide reasonable assistance to Vividion and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Vividion with respect to
Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents then being
Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 
 (b) Effects of
Celgene Termination for Vividion Breach, Insolvency or Patent Challenge. Upon any termination of this Agreement by Celgene under Section 14.2(b), Section 14.2(c) or Section 14.2(d): 

(i) if Celgene has the right to terminate this Agreement pursuant to Section 14.2 (b), Section 14.2(c) or Section 14.2(d),
Celgene may elect, upon written notice to Vividion, to either: 
 (A) terminate this Agreement in its entirety, if pursuant to
Section 14.2(b) or Section 14.2(c), or with respect to the corresponding Shared Product, if pursuant to Section 14.2(d), in which case (1) all rights and obligations of the Parties under this Agreement or the corresponding Shared
Product, respectively, shall terminate, except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and (II) Section 14.3(d) shall, in each case
((I) and (II)), survive such termination, (2) Vividion shall return any Confidential Information of Celgene pursuant to Article VIII of the Master Agreement that is not necessary to practice any licenses retained by Vividion following such
termination under this Agreement, another Development & Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) Sections 14.3(a)(v), (vi) and (vii) shall apply and Celgene (x) shall grant
to Vividion an exclusive (even as to Celgene and its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene Co-Co
Collaboration Intellectual Property and Celgene’s interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer for
sale, sell, import and otherwise Commercialize the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective
successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case
claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation
involves Vividion or its Affiliates or their respective (sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely
for use in connection with the Shared Products; or 

  
 90 

 (B) maintain this Agreement in full force and effect (foregoing, for the avoidance of
doubt, the right to terminate this Agreement for such occurrence of such breach) and, with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion: (1) all future milestones and royalty obligations in respect
of such Shared Products payable by Celgene under this Agreement following such election shall be subject to a reduction of [***] percent ([***]%) and (2) the Profit & Loss Share shall be terminated. 

(ii) if Celgene has made the election set forth in Section 14.3(b)(i)(B), from and after such election: 

(A) if the Vividion Opt-Out Date has not occurred before the effective date of termination, then
Celgene shall pay Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination pursuant to Article IX (subject to the [***] percent ([***]%) reduction described in Section 14.3(b)(i)(B) above),
substituting “ROW Territory” for “Territory”, with the Vividion Opt-Out Date, as used therein, deemed to be the effective date of termination, or 

(B) if the Vividion Opt-Out Date has occurred before the effective date of termination, then Celgene
shall continue to pay to Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination (subject to the [***] percent ([***]%) reduction described in Section 14.3(b)(i) above). 

(iii) all licenses granted by Celgene to Vividion under Section 8.1(b) with respect to the Shared Products shall terminate if Celgene has
made the election set forth in Section 14.3(b)(i)(B) and all licenses granted by Vividion to Celgene under Section 8.1(a) with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion shall convert to
worldwide licenses and otherwise remain in effect; 
 (iv) Vividion shall be released from its Development, Manufacture and
Commercialization obligations; 
 (v) each Party shall provide the other with a report of the COGS and Allowable Expenses incurred by such
Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination for the purpose of calculating a final reconciliation of shared costs in accordance with Section 9.1 and Section 9.6; 

(vi) if Celgene has made the election set forth in Section 14.3(b)(i)(B) within [***] days after such termination, Vividion shall provide
to Celgene a fair and accurate summary report of the status of Development and Commercialization activities conducted by Vividion with respect to the Shared Products; 

(vii) if Celgene has made the election set forth in Section 14.3(b)(i)(B), notwithstanding anything to the contrary in Section 8.5
or Section 9.7, Celgene shall be solely responsible for any payments owed to any Third Party licensors of Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property or Celgene Co-Co Collaboration Intellectual Property (without deduction under Section 9.3(d)) and shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in either
case, directly related to Celgene’s exercise of such license; and 

  
 91 

 (viii) if Celgene has made the election set forth in Section 14.3(b)(i)(B), the rights
of Vividion in Article X (other than Section 10.1) shall be terminated and Vividion shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with the transition of Prosecution and enforcement responsibilities
to Celgene with respect to Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and
Joint Patents then being Prosecuted or enforced by Vividion, including execution of such documents as may be necessary to effect such transition; and 

(ix) if Celgene has made the election set forth in Section 14.3(b)(i)(A), separate transitional activities shall be undertaken with
respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents necessary for the Development,
Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How
or Patents otherwise associated with such Shared Products are transferred. 
 (c) In the case of any termination of this Agreement, if any
Clinical Trials (including any Additional Studies) are then being conducted at the time of such termination with respect to any Shared Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials
(including any Additional Studies), and (ii) notwithstanding anything to the contrary contained herein, to grant to the Party that retains global Commercialization rights to such Shared Product following such termination (A) free of
charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address issues
relating to: (1) the safety of such Shared Product in the Territory, including data that is related to adverse effects experienced with such Shared Product or (2) all activities relating to CMC regarding such Shared Product and in each of
(1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available, and (B) copies of and rights of reference to and use of all Shared Product Data (other than
the Shared Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address the Development and
Commercialization of such Shared Product promptly following the generation of such Shared Product Data if, but only if, as to such Shared Product Data described in this subclause (B), such Party that retains global Commercialization rights to such
Shared Product following such termination promptly pays for all Development costs incurred following any such termination of this Agreement with respect to such Clinical Trials (including any Additional Studies). 

(d) Survival. Upon any termination or expiration of this Agreement, unless otherwise specified in this Agreement and except for any
rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and obligations of each Party under this Agreement shall terminate in whole or with respect to the Shared Products, as the case may be;
provided, however, that Section 2.1, Section 3.7(b), Section 8.7, Section 8.8, Section 9.8, Section 9.9, Section 9.10, Section 9.11, Section 9.12, Section 10.1,
Section 11.5, Section 11.6, Section 12.5, Section 13.1, Section 13.2, Section 13.3, Section 13.4, Section 13.5, Section 13.6, Section 14.3 and Sections
15.2-15.20, as well as any other provision which by its terms or by the context thereof is intended to survive, shall survive any such termination or expiration of this Agreement. 

  
 92 

 (e) Equitable Relief. Termination of this Agreement shall be in addition to, and
shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the
reason for the termination. 
 (f) Accrued Liabilities. Except as otherwise specifically provided herein, termination of this
Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective terms
for obligations or undertakings following the expiration of the term of this Agreement. 
 Article XV 

Miscellaneous 

Section 15.1 Dispute Resolution. Except for any disagreements that are within the authority of any Committee as provided in
Article II (which disagreements shall be resolved in accordance with Section 2.2), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement (each, a
“Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this Section 15.1 after
in-person discussions between the Executive Officers within [***] Business Days after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter
in accordance with Section 15.2. 
 Section 15.2 Submission to Court for Resolution. Subject to Section 15.1, the
Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this
Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any
action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any
such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.8
shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. Notwithstanding anything to the contrary in this Section 15.2, each Party shall have the right to institute
judicial proceedings against the other Party or anyone acting by, through or under such other Party, in any court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific
performance, injunction or similar equitable relief. 

  
 93 

 Section 15.3 Governing Law. This Agreement and all questions regarding its
validity or interpretation, or the performance or breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

Section 15.4 Assignment. 

(a) Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by either Party (whether by
operation of law or otherwise) without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s written consent, assign this Agreement and its rights and obligations hereunder in
whole or in part to (i) an Affiliate of such Party or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the
subject matter of this Agreement relates; provided that the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement. The assigning Party will remain responsible for the performance by its
assignee of this Agreement or any obligations hereunder so assigned. 
 (b) In the event the Implementation Date for this Agreement has not
occurred within [***] days following the Execution Date, Celgene shall be entitled to assign this Agreement to any pharmaceutical company or any Affiliate thereof if required to comply with any Antitrust Law; provided that the right to
assign set forth in this Section 15.4(b) shall not apply if a breach by Celgene of its obligations under Section 8.6(a) is a material cause of the failure to obtain clearance under Antitrust Laws. 

Section 15.5 All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit
of the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of Section 15.4 will be null and void ab initio. 

Section 15.6 Change of Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual
property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of either Party, such
intellectual property rights shall not be included in the technology and intellectual property rights licensed to the other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant Party to this Agreement or any
Affiliate of a Party immediately before such Change of Control) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration, Shared Products, or related
Companion Diagnostics. The Vividion Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the Collaboration,
Shared Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement. 

  
 94 

 Section 15.7 Force Majeure. If the performance of any part of this Agreement by
a Party is prevented, restricted, interfered with or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood,
embargo, power shortage or failure, acts of war or terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure
event”), such Party shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use
its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

Section 15.8 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices required or permitted to
be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing
evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or (c) above), to
the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 
  

			
	 To Vividion
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Chief Executive
Officer
 Telephone:
	  	 To Celgene
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Senior Vice President Business

Development
 Telephone:

Facsimile:
  

	With a copy to:	  	With a copy to:
		
	 Vividion Therapeutics, Inc.
 3565 General
Atomics Ct., Suite 100
 San Diego, CA 92121
 Attention: Legal
Department
 Telephone:
	  	 Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Legal Department

Telephone:
 Facsimile:

		
	and	  	and
		
	 WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Steven D. Barrett
 Telephone:

Facsimile:
	  	 Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone:
 Facsimile:

  
 95 

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.9 Waiver. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a
written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s
rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or
term. 
 Section 15.10 Severability. If any provision of this Agreement should be invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect
in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal or unenforceable provision
of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not
have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 Section 15.11 Entire Agreement.
This Agreement (including the Exhibits attached hereto), together with the Master Agreement, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all prior and contemporaneous agreements,
representations or understandings, either written or oral, between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written,
between the Parties other than as set forth herein and therein. 
 Section 15.12 Modification. No modification, amendment or
addition to this Agreement, or any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral
agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.13 Independent Contractors; No Intended Third Party Beneficiaries. This Agreement is not intended nor shall be deemed
or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any
liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor to bind the other Party to any contract, agreement or
undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2 and (b) except for any licensor under any Existing
Third Party Agreement, to the extent described in Exhibit C. Notwithstanding the provisions of this Section 15.13, the provisions of Section 15.17 shall control for US federal income tax purposes, as applicable. 

  
 96 

 Section 15.14 Interpretation; Construction. The captions to the several Articles
and Sections of this Agreement are included only for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires
otherwise, (a) the words “including,” “include,” “includes,” “such as” and “e.g.” shall be deemed to be followed by the phrase “without limitation” or like
expression, whether or not followed by the same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words
“herein” or “hereunder” relate to this Agreement; (e) the word “or” is used in the inclusive sense that is typically associated with the phrase “and/or”; (f) the word
“will” shall be construed to have the same meaning and effect as the word “shall”; and (g) all references to “dollars” or “$” herein shall mean US Dollars and (h) a
capitalized term not defined herein but reflecting a different part of speech from that of a capitalized term which is defined herein shall be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel
in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which
drafted such terms and provisions. 
 Section 15.15 Performance by Affiliates. A Party may perform any obligation this Agreement
imposes on such Party through any of such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

Section 15.16 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an
original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an
“Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in
person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or defense with
respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

Section 15.17 Certain US Federal Income Tax Treatment. Pursuant to Section 15.13, this Agreement is not intended nor shall be
deemed or construed to create any relationship of employer and employee, agent and principal, legal partnership, or joint venture between the Parties; provided, however, that the Parties hereby acknowledge and agree that this
Agreement shall be treated as a partnership with respect to the US Territory for US federal and state income tax purposes only pursuant to Section 7701(a)(2) of the Code and the Treasury Regulations thereunder, and each of Vividion and Celgene
shall be treated as partners in such partnership for all taxable periods during which this Agreement is effective and no Vividion Opt-Out Date has occurred. Vividion and Celgene agree that each will take no
position inconsistent with partnership tax treatment for US federal and state income tax purposes for such time. Exhibit E of this Agreement sets forth the Parties’ intentions regarding allocations and other tax matters related to the
tax partnership. Exhibit E shall be interpreted in a manner consistent with this Section 15.17. For the avoidance of doubt, the tax partnership referred to in this Section 15.17 shall be treated as separate from any other
partnership entered into by, or deemed to exist between, the Parties. 

  
 97 

 Section 15.18 HSR Clearance; Cooperation. For the avoidance of doubt, the
Parties shall continue to comply with Section 3.2 of the Master Agreement. 
 Section 15.19 Equitable Relief.
Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the
exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at law or equity. 

Section 15.20 Further Assurances. Each Party shall execute, acknowledge and deliver such further instruments, and do all such
other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Remainder of page intentionally left blank] 

  
 98 

 IN WITNESS WHEREOF, the Parties have executed this US
Co-Development and Co-Commercialization Agreement as of the Execution Date. 
  

			
	VIVIDION THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	CELGENE CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	

 [Signature Page to US Co-Development and Co-Commercialization Agreement] 

 Exhibit A 

Co-Co Target and Co-Co Candidate(s) 

  
 A-1 

 Exhibit B 

Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

  
 C-1 

 Exhibit D 

Profit & Loss Share 
 This
Exhibit D to this Agreement covers financial planning, accounting policies and procedures to be followed in determining the Profit & Loss Share for U.S. Administration. The Profit & Loss Share is not a legal entity and has
been defined for identification purposes only. 
 1. Principles of Reporting. 

(a) The presentation of results of operation of the Parties with respect to Shared Products and Companion Diagnostics for U.S. Administration
will be based on each Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: 
  

					
	 	  	 Celgene
	  	 Vividion

	Total	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	

 (b) It is the intention of the Parties to interpret definitions to be consistent with this Exhibit D
and Accounting Standards, it being understood and agreed that “Operating Profits or Losses” shall be calculated in accordance with Celgene’s or Vividion’s, as applicable, then current Accounting Standards practices (and
the Parties hereby agree that Celgene, in its sole discretion, may adopt the same cost methodology as adopted by Vividion in accordance with its then current Accounting Standards practices solely for purposes of recording costs incurred by Celgene
under this Exhibit D). Where such costs will be determined based on either Party’s system of cost or project accounting, each Party agrees to provide reasonable supporting documentation, as may be requested by the other Party, to ensure
that each Party’s methodologies are reasonable and consistently applied. To the extent that such costs are not readily determinable based on the respective Party’s system of cost or project accounting, the JSC (or such other Committee
designated by the JSC) will develop a reasonable methodology for determining such costs. Reasonable methodologies may include a standard rate or some other appropriate basis for allocating costs. For billing and reporting, the statement of
operations will be translated into U.S. Dollars in accordance with this Agreement. 

  
 D-1 

 (c) If necessary, a Party will make the appropriate adjustments to the financial information
it supplies under this Exhibit D to conform to the above format of reporting results of operation. 
 (d) The Parties agree that all
Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics in the US Territory will be booked by Celgene. 
 (e) There
shall be no double counting of any expenses or income in determining the Operating Profits or Losses under this Exhibit D. 
 (f) All
employee Commercialization expenses shall be calculated in accordance with the Commercialization FTE Rate. 
  

	1.	 Frequency of Reporting. 

(a) The fiscal year for the purposes of reporting and other activities undertaken by the Parties pursuant to this Exhibit D will be a
Calendar Year. Unless the schedule of such reporting is altered by the JSC, reporting by each Party for revenues and expenses will be as set forth in this Paragraph 2 of this Exhibit D. 

(b) Unless otherwise directed by the JCC, the Finance Working Group will prepare, for sales of Shared Products and Companion Diagnostics, a
consolidated reporting of the activities undertaken by the Parties hereunder (including Operating Profits or Losses), the calculation of the Profit & Loss Share, and determination of the cash settlement as between the Parties. Unless
otherwise directed by the JCC, the Finance Working Group will provide the Parties within [***] days after the end of each Calendar Quarter, a detailed statement showing the consolidated results and calculations of the Profit & Loss Share
and cash settlement required in a format agreed to by the Parties (each, a “Report”). Each Party will cooperate as appropriate and provide the other Party with financial statements, within [***] days after the end of each
Calendar Quarter, with respect to Shared Products and Companion Diagnostics (if any), prepared in accordance with the terms contained in the financial planning, accounting and reporting procedures set forth in this Exhibit D in order for each
Party to prepare the consolidated reports, including in reasonable detail the following costs and expenses incurred by each Party (if any) in such Calendar Quarter: (i) Cost of Goods Sold, (ii) Marketing Costs, (iii) Sales Costs,
(iv) Distribution Costs, (v) Other Operating Income/Expense and (vi) Manufacturing Costs. 
 (c) On a quarterly basis, Celgene
will supply the JCC and Vividion with an estimate of Annual Net Sales for such Calendar Quarter of Shared Products and, as applicable, Companion Diagnostics in the US Territory, in units, local currency and U.S. dollars (using the conversion method
set forth in this Agreement) according to Celgene’s sales reporting system, which will be consistent with the financial planning, accounting and reporting procedures set forth in this Exhibit D. Each Party shall also provide to the other
Party (and the JCC if then in existence) information regarding the gross sales and gross-to-net sales for all Shared Products and Companion Diagnostics for such Calendar
Quarter. Each such report will be provided as early as possible, but no later than [***] days after the last day of the Calendar Quarter in question, and will separately provide quarterly and year-to-date cumulative figures. Celgene will provide Vividion (and the JCC if then in existence), together with the next Calendar Quarter estimate under this

  
 D-2 

 
Section 2(c), an updated report for the immediately preceding Calendar Quarter providing a reconciliation of the estimated amounts for such preceding Calendar Quarter against the actual
Annual Net Sales during such Calendar Quarter of all such Shared Products and Companion Diagnostics in the US Territory within [***] days after the last day of such Calendar Quarter. 

Summary of Reporting Obligations 
  

					
	Financial statements provided by each Party	  	Quarterly	  	[***] days after each Calendar Quarter
	Gross sales & gross-to-net sales report	  	Quarterly	  	[***] days after each Calendar Quarter
	The Report	  	Quarterly	  	[***] days after each Calendar Quarter
	Quarterly estimate of Annual Net Sales and reconciliation	  	Quarterly	  	[***] days after each Calendar Quarter

 2. Financial Records. With respect to all financial records and reports required by this Exhibit D, each Party to
the extent applicable hereunder will keep financial records in accordance with its Accounting Standards. All cost reporting will be based on the appropriate costs definitions stated in Paragraph 7 of this Exhibit D or elsewhere in this
Agreement, and each Party will report costs in a manner consistent with a mutually agreed standard. 
 3. Operating Profits and Loss Sharing. 

(a) The Parties agree that Celgene will bear (and be entitled to) [***] percent ([***]%), and Vividion will bear (and be entitled to) [***]
percent ([***]%) of Operating Profits or Losses with respect to (i) any Phase IV Studies of Shared Products and Companion Diagnostics conducted following Regulatory Approval in the US Territory for U.S. Administration (“US Phase IV
Studies”) and (ii) Commercialization of Shared Products and Companion Diagnostics in the US Territory. 
 (b) Celgene shall
either invoice Vividion, or pay to Vividion, at the time each Report is delivered to Vividion, an amount such that Vividion will be bearing its Profit & Loss Share (as defined in Section 9.6(a)of this Agreement) for the relevant sales
of Shared Products and Companion Diagnostics. Either (i) Vividion shall make payment in full to Celgene of the amount of any such invoice, within [***] days after the date of such invoice, or (ii) Celgene shall pay Vividion [***] the
delivery of the applicable Report to Vividion, an amount such that Vividion will bear or receive its Profit & Loss Share. Such amounts will be invoiced and paid (whether before or after Regulatory Approval is received) pursuant to this
Paragraph 4(b) of this Exhibit D. All payments to be made by either Party hereunder will be made in U.S. Dollars by wire transfer to such bank account as such Party may designate. 

  
 D-3 

 (c) In the event any payment is made after the date specified in Paragraph 4(b) of this
Exhibit D, the paying Party will pay the past-due amounts with interest from the date originally due as provided in Section 9.12 of this Agreement (subject to the proviso therein regarding disputed
payments). In the event any overpayment of any amounts specified in Paragraph 4(b) of this Exhibit D is made, the Party receiving such overpayment will refund such overpayment amounts to the paying Party. 

4. Start of Operations and Effective Accounting Date Termination. 

(a) Operation of the Profit & Loss Share will be deemed to have commenced as of the Effective Date. Except as otherwise provided
herein, costs and expenses incurred prior to such date are not chargeable to the Profit & Loss Share. 
 (b) Unless otherwise set
forth in this Agreement, for reporting and accounting purposes with respect to the Profit & Loss Share, the effective termination date of the Agreement with regard to the last detailing year for all Shared Products and Companion Diagnostics
will be the end of the month in which such termination takes place. 
 5. Audits. Each Party will keep, and will cause its Affiliates and
(sub)licensees, as applicable, to keep, accurate books and records of accounting as required under its Accounting Standards for the purpose of calculating all amounts payable by either Party to the other Party under the Profit & Loss Share,
including with respect to the calculation of Allowable Expenses, Gross Profit and Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics for U.S. Administration, subject further to the audit rights and obligations granted to
each Party in Section 9.9 of this Agreement. In the event of a dispute regarding any applicable books and records, including the amounts owed to a Party under Section 9.6of this Agreement or the calculation of the Profit & Loss
Share, Allowable Expenses, Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics or Gross Profit or Operating Profits or Losses, the Parties will work in good faith to resolve the disagreement. If the Parties are unable to
reach a mutually acceptable resolution of any such dispute within thirty (30) days, such dispute will be resolved in accordance with Section 12.1 of the Master Agreement. 

5. Definitions. 
 (a)
“Allocable Overhead” means the following costs, attributable to the Profit & Loss Share, all of which will be consistent with Accounting Standards in accordance with each Party’s then-current practices and
reported in a manner consistent with a standard mutually agreed upon by the Parties: 
 (i) indirect supplies and department overhead, such
as indirect labor and other department expenses; and 
 (ii) facility overhead, such as rent, depreciation, utilities and facility support.

 (b) “Allowable Expenses” means the sum of the following costs and expenses incurred during the term the
Profit & Loss Share is applicable, as set forth in Paragraph 5 of this Exhibit D, which will coincide with the Term, except as otherwise set forth in this Agreement, by the Parties, their Affiliates or Licensee Partners, pursuant to
the Commercialization, including Manufacturing, of Shared Products and Companion Diagnostics in accordance with this Agreement, during the applicable Calendar Quarter or the applicable Calendar Year: (i) Marketing Costs, (ii) Sales Costs
and (iii) Distribution Costs, and (iv) Other Operating Income/Expense, in each case that are incurred in accordance with the U.S. Commercialization Budget, as applicable, and the terms and conditions of this Agreement. 

  
 D-4 

 (c) “Costs of Goods Sold” or “COGS” means
the sum of [***]. For clarity, these would exclude [***]. 
 (d) “Distribution Costs” means the costs, including
[***], in each case for the end use by a Party, including [***]. 
 (e) “Gross Profit” means Annual Net Sales of
Shared Products and Companion Diagnostics for U.S. Administration less Cost of Goods Sold for sales of such Shared Products and Companion Diagnostics for U.S. Administration. 

(f) “Manufacturing Costs” means costs to supply applicable therapeutic ingredients, finished Shared Products and
Companion Diagnostics, or related components or inputs and services for the Commercialization of Shared Products and Companion Diagnostics (i) [***], or (ii) [***] 

  
 D-5 

 [***]. Overhead included in Manufacturing Costs incurred with respect to [***]. 

(g) “Marketing Costs” means Direct Costs incurred by the Parties or their Affiliates or Licensee Partners, arising from
[***]. Marketing Costs will also include activities related to [***]. Marketing Costs will specifically exclude [***]. 
 (h)
“Operating Profits or Losses” means Gross Profit for Shared Products and Companion Diagnostics for U.S. Administration less the Allowable Expenses for such Shared Products and Companion Diagnostics. The Parties agree that
Operating Profits or Losses will not include costs or expenses of a Party or its Affiliates or Licensee Partners that are: (i) [***], or (ii) [***]. 

(i) “Other Operating Income/Expense” means the following items, to the extent incurred with respect to and reasonably
related to the Commercialization of Shared Products for U.S. Administration: 
 (i) [***] 

(ii) [***] 

  
 D-6 

 (iii) [***] 

(iv) [***] 
 (v) [***]. 

(j) “Pharmacovigilance Expenses” means those expenses incurred by either Party or its Affiliates in performing
pharmacovigilance activities related to each Shared Product or Companion Diagnostic in the US Territory. 
 (k) “Product Recall
Expenses” means all costs associated with the recall of each Shared Product and Companion Diagnostic. 
 (l)
“Regulatory Expenses” means all costs incurred, with respect to Shared Products and Companion Diagnostics in any relevant country to obtain or comply with all Regulatory Approvals and requirements of all regulatory agencies,
including FDA user and other fees, reporting, and other regulatory affairs activities recorded as an expense in accordance with GAAP, by or on behalf of a Party or any of its Affiliates during the Term and pursuant to this Agreement, that are
specifically identifiable or reasonably allocable to the preparation of Regulatory Filings for, and the obtaining and maintenance of reimbursement for, and Regulatory Approval of, Shared Products for U.S. Administration, including without limitation
compliance with requirements of such Regulatory Authorities, adverse event recordation and reporting, regulatory affairs activities, and all Product Recall Expenses. 

(m) “Sales Costs” means costs, arising from activities expressly set forth in the U.S. Commercialization Plan which are
specifically and directly identifiable, attributable and allocable to the sales efforts for Shared Products (including the managed care market), including costs arising from applicable medical affairs activities. “Sales Costs” will
include [***]. 
 (n) “Sublicense Revenues” means all revenues or other consideration (including milestones and
royalties) received by either Party or its Affiliates from a Licensee Partner as consideration for the grant of a sublicense under the licenses granted with respect to any Shared Products. 

  
 D-7 

 Exhibit E 

PARTNERSHIP TAX MATTERS 

Section 1.1 Constructive Partnership. Celgene and Vividion (the “Partners,” and each a
“Partner”) acknowledge that the rights and obligations imposed on each of them pursuant to this US Co-Development and Co-Commercialization Agreement
(the “Co-Co Agreement”) that relate to the sharing of profits and losses from the development and commercialization of the US Rights (as defined below), and the collaborative relationship
formed between them in connection therewith, give rise to a partnership for U.S. federal (and, to the extent applicable, state) income tax purposes (the “Partnership”), which will commence upon the Effective Date. The activities of
the Partners in respect of the development and commercialization of a Shared Product in the US Territory, and the rights related thereto (the “US Rights”), shall be deemed to be conducted in and held by the Partnership. The
Partnership, and the rights and obligations set forth in this Exhibit E, shall remain in existence for so long as this Co-Co Agreement remains in full force and effect and no Vividion Opt-Out Date has occurred. The parties further acknowledge that the arrangement described in this Co-Co Agreement (including this Exhibit E) shall be treated by the
parties as a partnership solely for U.S. federal (and applicable state) income tax purposes and is not intended to constitute a partnership for any non-tax or non-U.S.
purpose. 
 Section 1.2 Definitions. Capitalized terms used, but not defined, herein will have the meanings ascribed to them in
the Co-Co Agreement. For purposes of this Exhibit E: 
 “Book” means the method of
accounting prescribed for compliance with the capital account maintenance rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations, as distinguished from any accounting method which the
Company may adopt for other purposes such as financial reporting. 
 “Capital Account” has the meaning set forth in Section 1.4 of
this Exhibit E. 
 “Capital Contribution” means, for each Partner, such Partner’s cash or property contributed (or deemed
contributed) to the Partnership. 
 “Fiscal Year” means the calendar year. 

“Gross Asset Value” means, with respect to any asset of the Partnership, the asset’s adjusted basis for federal income tax purposes,
adjusted to reflect any adjustments required or permitted by Sections 1.704-1(b)(2)(iv)(d) through (g), (m) and (s) of the Treasury Regulations, as determined by the Tax Matters Partner in its reasonable
discretion; provided that, in the case of any asset contributed to the Partnership, the initial Gross Asset Value of such property shall be equal to the fair market value of such asset as of the date of contribution, as determined by
the Tax Matters Partner in its reasonable discretion. 
 “Net Income” and “Net Losses” mean the Book income, gain, loss,
deductions and credits of the Partnership in the aggregate or separately stated, as appropriate, as of the close of each Taxable Year on the Partnership’s tax return filed for federal income tax purposes (or other allocation period). 

  
 E-1 

 “Tax Matters Partner” has the meaning set forth in Section 1.7(a) of this Exhibit
E. 
 “Taxable Year” means the Partnership’s Fiscal Year or such other year as may be required by Section 706 of the Code.

 “Treasury Regulations” means regulations (whether in final, proposed or temporary form) promulgated by the U.S. Department of the
Treasury under the Code, as amended. 
 “US Asset Allocation” shall mean 0.6. 

“US Profit Share” means, with respect to a Partner, the Profit & Loss Share (as defined in Section 9.6(a) of the body of this Co-Co Agreement) applicable to such Partner. 
 “US Rights” has the meaning set forth in Section 1.1
of this Exhibit E. 
 1.3 Capital Contributions. 

(a) The amount of any Capital Contributions contributed (or deemed contributed) by each Partner to the Partnership shall be determined by the
Tax Matters Partner in its reasonable discretion unless specifically addressed in Sections 1.3(b) – (d) of this Exhibit E below. 

(b) Upon the Effective Date, the Partners shall be deemed to have completed the following steps: 

(i) Celgene shall be deemed to have acquired from Vividion, pursuant to the exercise of an Opt-In
Right (as defined in the Master Agreement), an interest in the US Rights equal to Celgene’s US Profit Share, with Vividion retaining an interest in the US Rights equal to Vividion’s US Profit Share. The parties agree that, for U.S. federal
income tax purposes, Celgene’s purchase price for its interest in the US Rights with respect to a Program equals the product of the Opt-In Right exercise payment set forth in Section 6.5 of the
Master Agreement with respect to such Program multiplied by the US Asset Allocation. 
 (ii) Immediately following the deemed acquisition by
Celgene of its interest in the US Rights, as described in Section 1.3(b)(i) of this Exhibit E, the Partners shall each own an interest in the US Rights, and each Partner shall be deemed to immediately contribute its interests in the US
Rights to the Partnership in a tax-free transaction described in Section 721 of the Code. The Capital Accounts of Celgene and Vividion shall each be increased following such contributions by an amount
equal to the fair market values of such contributed interests. 
 (c) Upon the payment of any milestone payment to Vividion pursuant to
Section 9.2 of the Co-Co Agreement (each a “Milestone Payment”), the following steps shall be deemed to have occurred: 

(i) The Milestone Payment shall be deemed to reflect an increase in the fair market value of the US Rights as of the Effective Date. 

  
 E-2 

 (ii) As a result of the Milestone Payment, Celgene shall be deemed, as of the Effective
Date, to have paid additional consideration to Vividion for the acquisition of its interests in the US Rights (the “Added Consideration”), which shall be treated by the Partners as an adjustment to purchase price of the purchase
described in Section 1.3(b)(i) of this Exhibit E. The portion of the Milestone Payment treated as Added Consideration shall be determined by the Tax Matters Partner in its reasonable discretion. 

(iii) Celgene shall be deemed to have made an additional contribution to the Partnership equal to the Added Consideration in a transaction
qualifying under Section 721 of the Code, and Vividion’s Capital Account shall be booked up to reflect the increased value of the US Rights. 

(d) The payment by each Partner of its respective share of any costs or expenses on behalf of the Partnership (including Worldwide Development
Costs and any costs and expenses included in the Profit & Loss Share) shall, to the extent determined by the Tax Matters Partner in its reasonable discretion, be deemed to be Capital Contributions made by each such Partner to the
Partnership. 
 Section 1.4 Capital Accounts. 

(a) The Partnership shall maintain a separate capital account for each Partner according to the rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations (a “Capital Account”). 
 (b)
Each Partner’s Capital Account: 
 (i) shall be increased by (A) the Capital Contributions by such Partner to the Partnership
after the date hereof, as determined by the Tax Matters Partner and mutually agreed upon by the Partners (net of liabilities secured by the contributed property that the Partnership is considered to assume or take subject to under Section 752
of the Code), and (B) such Partner’s distributive share of Net Income and other items of income and gain allocated to such Partner after the date hereof, and 

(ii) shall be decreased by (A) the amount of money distributed (or deemed distributed) to such Partner by the Partnership after the date
hereof, (B) the fair market value of property (as determined by the Tax Matters Partner and mutually agreed upon by the Partners) distributed (or deemed distributed) to such Partner by the Partnership (net of liabilities secured by the
distributed property that the Partner is considered to assume or take subject to under Section 752 of the Code) after the date hereof and (C) such Partner’s distributive share of Net Losses and other items of loss and deduction
allocated to such Partner after the date hereof. 
 (iii) Other adjustments shall be made to the Capital Accounts of the Partners to accord
with the regulations promulgated under Section 704(b) of the Code as determined by the Tax Matters Partner in its reasonable discretion. 

(c) As of the Effective Date, the initial Capital Account of each Partner shall be equal to the initial Capital Contribution of each such
Partner. 

  
 E-3 

 Section 1.5 Distributions. 

(a) Non-Liquidating Distributions. In the event that assets of the Partnership are deemed to be
distributed other than in liquidation of the Partnership, such assets shall be deemed to be distributed in accordance with the US Profit Shares (unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 

(b) Liquidating Distribution. In the event that the Partnership is terminated pursuant to Section 708(b)(1)(A) of the Code (or
otherwise) and the assets of the Partnership are required to be distributed (or are deemed to be distributed) in liquidation of the Partnership, then such assets shall be distributed (or deemed to be distributed) in accordance with the US Profit
Shares (unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 
 (c) Withholding for Taxes. Subject to
the provisions of Section 9.10(b) of the body of this Co-Co Agreement, any Partner is authorized to withhold from distributions described in Section 1.5(a) or (b) of this Exhibit E to the
Partners, and with respect to allocations pursuant to Section 1.6 of this Exhibit E to the Partners, and to pay over to any federal, state, local or foreign government, any such taxes as are required to be deducted or withheld under any
provision of applicable Law. Any amounts so withheld shall be treated as distributed pursuant to Section 1.5(a) or (b) of this Exhibit E, to the extent applicable. 

Section 1.6 Allocations; Section 704(c). 

(a) Except as required by Section 1.6(b) or 1.6(c) of this Exhibit E, the Net Income or Net Loss for any Taxable Year shall be
allocated to the Partners in such a manner so that the Capital Account of each Partner equals (as of the end of such allocation period and to the fullest extent possible) the amount that would be distributed to such Partner if all properties of the
Partnership, including cash, were sold for cash equal to their respective Gross Asset Values, all liabilities allocable to such properties were then due and were satisfied according to their terms, all minimum gain chargebacks required by this Co-Co Agreement and the Treasury Regulations were made, and all obligations of Partners to contribute additional capital to the Partnership were satisfied and all remaining proceeds from such sale were distributed
pursuant to the order and priority of Section 1.5(b) of this Exhibit E. 
 (b) Special Allocations. Notwithstanding
Section 1.6(a) of this Exhibit E, any Worldwide Development Costs shall be specially allocated among Celgene and Vividion in accordance with the Development Cost Share, pursuant to Section 9.1(a) of the body of this Co-Co Agreement. 
 (c) Regulatory Allocations. In the event any Partner unexpectedly receives any
adjustments, allocations or distributions described in Sections 1.704-1(b)(2)(ii)(d)(4), 1.704-1(b)(2)(ii)(d)(5) or
1.704-1(b)(2)(ii)(d)(6) of the Treasury Regulations, items of income (including gross income) and gain shall be specially allocated to such Partner in an amount and manner sufficient to eliminate the deficit
balance in such Partner’s Capital Account (in excess of (i) the amount such Partner is obligated to restore upon liquidation of the Partnership or upon liquidation of such Partner’s interest in the Partnership and (ii) such
Partner’s share of the Minimum Gain (as defined in Section 1.704-2 of the Treasury Regulations)) created by such 

  
 E-4 

 
adjustments, allocations or distributions as quickly as possible. Additionally, there are hereby incorporated herein such special allocation provisions governing the allocation of income,
deduction, gain, and loss for U.S. federal income tax purposes as may be necessary under, and in the manner required by, the Treasury Regulations to ensure that this Exhibit E complies with all requirements of
Section 1.704-2 of the Treasury Regulations relating to “minimum gain” and “partner nonrecourse debt minimum gain” and the allocation and chargeback of
so-called “nonrecourse deductions” and “partner nonrecourse deductions”, including a “qualified income offset”. 

(d) Except as otherwise provided in this Section 1.6(d) and in Section 1.6(e) of this Exhibit E, for U.S. federal income tax
purposes, all items of income gain, loss deduction and credit shall be allocated among the Partners in the same manner the corresponding Book item was allocated pursuant to Section 1.6(a) or (b) of this Exhibit E. In the case of
contributed property, items of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated first in a manner consistent with the requirements of Section 704(c) of the Code to take into account the
difference between the Gross Asset Value of such property and its adjusted tax basis at the time of contribution. If the Gross Asset Value of any asset of the Partnership is adjusted pursuant to the terms of this Exhibit E, then subsequent
allocations of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated with respect to such assets so as to take into account such adjustment in the same manner as under Section 704(c) of the
Code and the Treasury Regulations promulgated thereunder. 
 (e) The method under Section 704(c) of the Code and the Treasury
Regulations promulgated thereunder shall be the “traditional method with curative allocations” (as described in Section 1.704-3 of the Treasury Regulations), unless otherwise determined
by the Tax Matters Partner. For the sake of clarity, the allocations required by Section 1.6(d) and this Section 1.6(e) of this Exhibit E are solely for purposes of federal, state and local income taxes and will not affect the
allocation of Net Income or Net Losses as between the Partners or any Partner’s Capital Account. 
 Section 1.7 Tax Reports,
Tax Elections and Tax Matters Partner. 
 (a) The Partnership hereby designates Celgene to act as the “tax matters
partner” (as defined in Section 6231(a)(7) of the Code) and the “partnership representative” of the Partnership for any tax period subject to the provisions of Section 6223 of the Code, as amended by the
Bipartisan Budget Act of 2015, and any corresponding designation (the “Tax Matters Partner”) in accordance with Sections 6221 through 6233 of the Code. The Tax Matters Partner is authorized and required to represent the Partnership
(at the Partnership’s expense) in connection with all examinations of the Partnership’s affairs by U.S. federal (and any applicable state) income tax authorities, including resulting administrative and judicial proceedings, to make any
elections in connection therewith, and to expend Partnership funds for professional services and costs associated therewith; provided, that the Tax Matters Partner shall notify the Vividion of any such administrative and judicial proceedings
involving the Partnership and upon request shall provide Vividion the opportunity to participate in any such matters if requested by Vividion. Vividion agrees to cooperate with the Tax Matters Partner as reasonably requested by the Tax Matters
Partner with respect to the conduct of such proceedings. The Tax Matters Partner will, in its reasonable discretion, determine whether the Partnership (either on its own behalf or on behalf of 

  
 E-5 

 
the Partners) will contest or continue to contest any tax deficiencies assessed or proposed to be assessed by any taxing authority provided, however, that the Tax Matters
Partner shall not agree or consent to compromise or settle such matters without the prior written consent of Vividion, which consent shall not be unreasonably delayed, conditioned or withheld. Any deficiency for taxes imposed on any Partner
(including penalties, additions to tax or interest imposed with respect to such taxes) will be paid by such Partner, and if paid by another Partner, will be recoverable from the Partner on which such deficiency was imposed (including by offset
against distributions otherwise payable to such Partner). The Partners agree to cooperate in good faith to notify each other regarding any tax notices or audits relating to the Partnership. 

(b) The Tax Matters Partner shall prepare and file, or cause to be prepared and filed, all necessary U.S. federal, state or local income tax
returns for the Partnership. At least [***] days before the due date of such tax return, the Tax Matters Partner shall submit a copy of such tax return to Vividion for its review and comment. The Tax Matters Partner shall consider in good faith any
comments and incorporate any reasonable comments submitted by Vividion no fewer than [***] days prior to the due date of such tax return. Within [***] days after the end of each Taxable Year, the Tax Matters Partner shall cause the Partnership to
furnish Vividion with an IRS Form K-1 a (“K-1”) for such Taxable Year. In addition, the Partnership shall deliver or cause to be delivered not later
than the [***] day after the end of each Taxable Year to Vividion all information necessary for the preparation of Vividion’s federal income tax returns and any state, local and foreign income tax returns that such Partner is required to file.
Furthermore, the Tax Matters Partner shall consider in good faith any comments from Vividion regarding any matter for which the Tax Matters Partner is responsible or over which the Tax Matters Partner has discretion under this Exhibit E,
including without limitation the preparation of any tax return or the making of any election hereunder. 
 (c) The Tax Matters Partner will
determine whether to make or revoke any available election pursuant to the Code, provided, however, that any action (or the failure to take any action known to the Tax Matters Partner to be reasonably necessary) on the part of
the Tax Matters Partner with respect to such election in its capacity as Tax Matters Partner shall require the prior written consent of Vividion if such action or failure, as applicable, would reasonably be expected to have a material adverse impact
on Vividion. Each Partner will, upon request, use reasonable efforts to supply the information necessary to give proper effect to any such election. The Partners hereby agree to cooperate in good faith regarding any matters related to any tax
elections or tax reporting positions of the Partnership. 
 Section 1.8 Tax Position. Unless otherwise required by applicable
Law, no Partner will take a position on such Partner’s federal income tax return, in any claim for refund or in any administrative or legal proceedings that is inconsistent with this Co-Co Agreement
(including this Exhibit E) or with any information return filed by the Partnership. If any Partner believes that such a position is required by applicable Law, such Partner must immediately notify the other Partner in writing, citing such
applicable Law or any interpretation thereof. 
 Section 1.9 Termination of Partnership. The Partnership shall terminate upon
the earlier of (a) termination of this Co-Co Agreement, as determined in accordance with Article XIV of this Co-Co Agreement or (b) the Vividion Opt-Out Date. 

  
 E-6 

 SCHEDULE 6.5 

Minimum Vividion and Celgene Sales Representative Qualifications 

 Schedule 12.2(i) 

Patents 

 Schedule 12.2(j) 

Existing Third Party Agreements 

 APPENDIX A-2 

FORM OF GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION
AGREEMENT 
  

  
 [Appendix A-2]-1 

 EXECUTION VERSION 

EXHIBIT A-2 

FORM OF GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION

 AGREEMENT 
 GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 
 by and between

 VIVIDION THERAPEUTICS, INC. 

and 
 CELGENE CORPORATION 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
		
	 ARTICLE I DEFINITIONS
	  	 	1	 
		
	 ARTICLE II GOVERNANCE; COLLABORATION
	  	 	15	 
		
	 ARTICLE III DEVELOPMENT
	  	 	20	 
		
	 ARTICLE IV MANUFACTURE AND SUPPLY
	  	 	27	 
		
	 ARTICLE V REGULATORY MATTERS
	  	 	27	 
		
	 ARTICLE VI COMMERCIALIZATION
	  	 	30	 
		
	 ARTICLE VII DILIGENCE
	  	 	36	 
		
	 ARTICLE VIII GRANT OF RIGHTS; EXCLUSIVITY
	  	 	36	 
		
	 ARTICLE IX FINANCIAL PROVISIONS
	  	 	48	 
		
	 ARTICLE X INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	56	 
		
	 ARTICLE XI CONFIDENTIALITY
	  	 	64	 
		
	 ARTICLE XII REPRESENTATIONS AND WARRANTIES
	  	 	70	 
		
	 ARTICLE XIII INDEMNIFICATION; PRODUCT LIABILITIES
	  	 	75	 
		
	 ARTICLE XIV TERM AND TERMINATION
	  	 	78	 
		
	 ARTICLE XV MISCELLANEOUS
	  	 	89	 

  
 -i- 

 Exhibits 
  

			
	Exhibit A	  	Co-Co Target, Co-Co Candidate(s) and Lead US Party
		
	Exhibit B	  	Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents (as of the Execution Date)
		
	Exhibit C	  	Existing Third Party Agreements
		
	Exhibit D	  	Profit & Loss Share
		
	Exhibit E	  	Partnership Tax Matters
		
	Schedules	  	
		
	Schedule 6.5	  	Minimum Vividion and Celgene Sales Representative Qualifications
		
	Schedule 12.2(i)
	  	Patents
		
	Schedule 12.2(j)	  	Existing Third Party Agreements

  
 -ii- 

 EXECUTION VERSION 

GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

 This Global Co-Development and Co-Commercialization
Agreement (this “Agreement”) is entered into as of [•] (the “Execution Date”), by and between Vividion Therapeutics, Inc., a Delaware corporation (“Vividion”) and Celgene Corporation, a
Delaware corporation (“Celgene”). Celgene and Vividion are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”. 

INTRODUCTION 
  

	1.	 Vividion and Celgene are parties to the Master Research and Collaboration Agreement, dated as of March 1,
2018 (the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Vividion has discovered and has been developing the Co-Co Candidates(s) identified on Exhibit A, each of which the Parties believe to be Directed against the Co-Co Target identified on Exhibit A.

  

	3.	 Pursuant to the terms of the Master Agreement, upon exercise by Celgene of its
Opt-In Right (as defined in the Master Agreement) with respect to a Shared Global Program (as defined in the Master Agreement), the Parties shall enter into this Agreement with respect to such Shared Global
Program. 

  

	4.	 Pursuant to this Agreement, Vividion grants to Celgene under a
co-development and co-commercialization structure, co-exclusive rights in the Territory with respect to the development,
manufacture and commercialization of the Shared Products, on the terms and subject to the conditions set forth herein. 

NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and for other
valuable consideration, the receipt and adequacy of which are hereby acknowledged, Vividion and Celgene hereby agree as follows: 

Article I 
 Definitions

 When used in this Agreement, each of the following terms shall have the meanings set forth in this Article I. Terms used but not
defined herein shall have the meaning set forth in the Master Agreement. 
 Section 1.1 “Annual Net Sales” means,
[***]. 
 Section 1.2 “Calendar Quarter” means a calendar quarter ending on the last day of March, June, September or
December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the last day of the calendar quarter during which the Effective Date occurs. 

 Section 1.3 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31; provided, however, that the first Calendar Year shall begin on the Effective Date and end on December 31 of the calendar year during which the Effective Date occurs.

 Section 1.4 “Celgene Co-Co Collaboration Intellectual Property” means
Celgene Co-Co Collaboration Know-How and Celgene Co-Co Collaboration Patents, collectively. 

Section 1.5 “Celgene Co-Co Collaboration
Know-How” means, collectively, (a) Know-How within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that was discovered,
developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Know-How (as defined in the
Master Agreement) that was discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Know-How Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Know-How and Joint Inventions), in each case that
is necessary or useful for the Development, Manufacture or Commercialization of any Shared Products. 
 Section 1.6 “Celgene Co-Co Collaboration Patents” means, collectively, (a) Patents within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that Cover
Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Patents (as
defined in the Master Agreement) that Cover Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Patents Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Patents and Joint Patents), in each case that are necessary or
useful for the Development, Manufacture or Commercialization of any Shared Products. Celgene Co-Co Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.7 “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively. 
 Section 1.8 “Celgene Know-How” means any Know-How that is (a) Controlled by Celgene as of the Execution Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products; and
(c) contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Know-How. 
 Section 1.9 “Celgene Patents” means any Patents that (a) are
Controlled by Celgene as of the Execution Date or during the Term; (b) Cover the Shared Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from
Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Patents. Celgene Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.10 “Clinical Trial” means a Phase I Study, a Phase II Study, a Phase III Study, a Pivotal Clinical Trial, a
Phase IV Study or a combination of any of the foregoing studies. 

  
 - 2 - 

 Section 1.11 “Code” means the United States Internal Revenue Code of
1986, as amended. 
 Section 1.12 “Co-Co Candidate” means (a) any Program
Compound that is listed on Exhibit A and (b) to the extent Directed against the Co-Co Target, any salt, fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates,
anhydride, ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of any such
Program Compound identified in the foregoing clause (a) or in this clause (b). 
 Section 1.13 “Co-Co Collaboration Intellectual Property” means Co-Co Collaboration Know-How and
Co-Co Collaboration Patents, collectively. 
 Section 1.14 “Co-Co Collaboration Know-How” means any Know-How or interest therein that is discovered, developed, generated or invented on
or after the Execution Date, either (a) solely by or on behalf of Celgene or its Affiliates, (b) solely by or on behalf of Vividion or its Affiliates or (c) jointly by or on behalf of Persons described in the foregoing clauses
(a) and (b), in the conduct of the Collaboration activities pursuant to this Agreement, including Joint Co-Co Know-How and Joint Inventions. 

Section 1.15 “Co-Co Collaboration Patents” means any Patents or interest therein
that: (a) result from the conduct of the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date, (c) are Controlled solely by Celgene or Vividion or Controlled jointly by any of such Persons
and (d) Cover Co-Co Collaboration Know-How, including Joint Co-Co Patents and Joint Patents. 

Section 1.16 “Co-Co Target” means the Program Target set forth as the “Co-Co Target” on Exhibit A; it being understood and agreed that (i) in the case of Co-Co Candidates in a Deal Target Program described in clause
(b) of Section 1.1.36 of the Master Agreement, the “Co-Co Target” shall be the Selected Target and (ii) in the case of Co-Co Candidates in an E3
Ligase Program described in clause (b) of Section 1.1.46 of the Master Agreement, the “Co-Co Target” shall be the Selected Target. 

Section 1.17 “Collaboration” means the activities performed or to be performed by a Party or Parties, as the case may
be, relating to the Development, Manufacture or Commercialization of the Shared Products under this Agreement or the Master Agreement, including in the exercise of any license granted under this Agreement or the Master Agreement relating to the
Shared Products. 
 Section 1.18 “Companion Diagnostic” means a biomarker or diagnostic test that is developed by or
on behalf of a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Shared Product in accordance with the Regulatory Approval(s) therefor to generate a result for the purposes of diagnosing a
disease or condition, or to facilitate the application of any Shared Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a specific patient will contract
a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy using a Shared Product. 

  
 - 3 - 

 Section 1.19 “Confidential Information” means, subject to Sections
11.1(a), 11.1(b), 11.1(c) and 11.1(d), (a) all confidential or proprietary information relating to the Collaboration, and (b) all other confidential or proprietary documents, technology, Know-How or other
information (whether or not patentable) actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement or the Master Agreement relating to the Shared Products and all proprietary
biological materials of a Party. 
 Section 1.20 “Data” means any and all research data, results, pharmacology data,
medicinal chemistry data, preclinical data, market research, clinical data (including investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, safety and other electronic databases), in any and all forms,
including files, reports, raw data, source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the like, in each case directed
to, or used in, the Development, Manufacture or Commercialization of the Shared Products. 
 Section 1.21 “Development
Plan” means a development plan and the related Development Budget approved by the JSC, as amended from time to time pursuant to Section 3.1(a). 

Section 1.22 “Direct Cost” means, with respect to certain activities hereunder, [***]. 

Section 1.23 “Effective Date” means the date on or after the Execution Date that is the Implementation Date (as defined
in the Master Agreement) with respect to this Agreement. 
 Section 1.24 “Executive Officers” means Celgene’s
Chief Executive Officer (or the officer or employee of Celgene then serving in a substantially equivalent capacity) or his designee and Vividion’s Chief Executive Officer (or the officer or employee of Vividion then serving in a substantially
equivalent capacity) or his designee; provided that any such designee must have decision-making authority on behalf of the applicable Party. 

Section 1.25 “Existing Third Party Agreement” means any agreement listed on Exhibit C to this Agreement. 

Section 1.26 “Field” means the diagnosis, prevention, palliation or treatment of diseases in humans or animals. 

  
 - 4 - 

 Section 1.27 “First Commercial Sale” means the first commercial sale
of a Shared Product by the applicable Lead Party, its Affiliates, or Licensee Partners in a country in an arms’ length transaction to a Third Party following receipt of applicable Regulatory Approval of such product in such country. Sales for
test marketing or Clinical Trial purposes shall not constitute a First Commercial Sale. 
 Section 1.28 “FTE” means
the equivalent of the work of one (1) full-time employee of a Party or its Affiliates for one (1) year (consisting of 1840 hours per year) in directly conducting Development, Manufacturing or Commercialization activities hereunder. Any
Party’s employee who devotes fewer than 1840 hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, calculated by dividing the actual number of hours worked by such
employee on such activities by 1840. Any employee who devotes more than 1840 hours per year on the applicable activities shall be treated as one (1) FTE. For the avoidance of doubt, FTE shall not include the work of general corporate or
administrative personnel, except for the portion of such personnel’s work time actually spent on conducting scientific, technical or commercial activities directly related to the Development, Manufacture or Commercialization of Shared Products.

 Section 1.29 “FTE Rate” means, during the Term: (a) with respect to Development activities, $[***] per FTE and
(b) with respect to Commercialization activities, $[***] per FTE. On January 1, 2019 and on January 1st of each subsequent Calendar Year, the foregoing rate shall be increased for the Calendar Year then commencing by [***]. As used in this
definition, [***]. The FTE Rate includes the applicable employee’s wages, bonuses, Incentive Compensation, equity incentive compensation, employer paid taxes, benefits, perks and other forms of compensation that would otherwise be considered
the cost of an employee. 
 Section 1.30 “Generic Competition” means, with respect to a Shared Product in a given
country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.31 “Generic Product” means, as to a Shared Product, in any country, any pharmaceutical product sold by a Third
Party not authorized by or on behalf of Celgene, its Affiliates or Licensee Partners, that (a) contains, as an active pharmaceutical ingredient, the same Co-Co Candidate contained in the applicable Shared
Product, (b) is approved by the applicable Regulatory Authority in such country for one or more of the same Indications as the applicable Shared Product; and (c) is AB rated in the United States or is comparably rated in any jurisdiction
outside the United States (including pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001) with respect to the applicable Shared Product. 

Section 1.32 “IIT” means any investigator initiated Clinical Trial sponsored and conducted by an investigator at a
research institution for which a Party or its Affiliate provides drug supplies. 

  
 - 5 - 

 Section 1.33 “Joint Co-Co IP”
means, collectively: 
 “Joint Co-Co
Know-How” which means all Know-How, including physical embodiments of Shared Product(s) and Companion Diagnostic(s), that is discovered, developed, generated or
invented by or on behalf of both Parties or their respective Affiliates, whether solely or jointly with any Third Party, pursuant to the conduct of activities under the Collaboration at any time during the Term, including Joint Inventions; and 

“Joint Co-Co Patents” which means Patents that: (a) result from the conduct of
the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date and (c) Cover any Joint Co-Co Know-How, including Joint
Patents. 
 Section 1.34 “Lead Party” means (a) with respect to the US Territory, the Lead US Party and
(b) with respect to the ROW Territory, Celgene. Notwithstanding the foregoing, (a) Celgene shall be the Lead Party for the entire Territory from and after the Vividion Opt-Out Date, if any, and
(b) Celgene shall be the Lead Party for the entire Territory after any Change of Control of Vividion; provided, however, that, if Vividion was the Lead US Party prior to such Change of Control, Vividion shall retain the
right to book all sales of the Shared Products in the US Territory. 
 Section 1.35 “Lead US Party” means the Party
designated as the Lead US Party in Exhibit A of this Agreement; provided, however, that, (a) following the Vividion Opt-Out Date, if any, Celgene shall become (if it is not
already) the Lead US Party and (b) following any Change of Control of Vividion, Celgene shall become (if it is not already) the Lead US Party; provided, however, that, if Vividion was the Lead US Party prior to such Change
of Control, Vividion shall retain the right to book all sales of the Shared Products in the US Territory. 
 Section 1.36
“Licensee Partner” means any Third Party to whom a Party or any of its Affiliates or any other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Shared Products in
the Field under rights to Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration
Intellectual Property or Joint Co-Co IP, as the case may be, granted to such Party or Affiliate hereunder, in each case excluding (a) Third Party Contractors and (b) wholesale distributors or any
other Third Party that purchases any Shared Product in an arm’s-length transaction, where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize any Shared Product except for
a limited sublicense to the extent required to enable such Third Party to perform final packaging for such Shared Product for local distribution. 

Section 1.37 “Major Market” means each of the US Territory, France, Germany, Italy, Spain, the United Kingdom, and
Japan. 
 Section 1.38 “Manufacturing Technology” means copies of all Celgene
Know-How, Vividion Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co-Co Collaboration Know-How or Joint Co-Co Know-How, as applicable, which are necessary or
useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Shared Products, including specifications, assays, batch records, quality control data, and transportation and storage requirements. 

  
 - 6 - 

 Section 1.39 “Manufacturing Transition Costs” means the Direct Costs
associated with the transfer by Vividion, following the Effective Date, of responsibility for Manufacturing and CMC activities to Celgene or a Third Party selected by Celgene, including [***]. 

Section 1.40 “NDA” means an application submitted to a Regulatory Authority for the marketing approval of a Shared
Product, including (a) a New Drug Application (as such capitalized term is used in C.F.R Title 21) filed with FDA or any successor applications or procedures, (b) a foreign equivalent of a US New Drug Application or any successor
applications or procedures, including a Marketing Authorization Application in the European Union, and (c) all supplements and amendments that may be filed with respect to the foregoing. 

Section 1.41 “Net Sales” means, with respect to any Shared Product, the gross amounts invoiced by the applicable Lead
Party, its Affiliates and Licensee Partners (each, a “Selling Party”) to Third Parties (that are not Licensee Partners) for sales or other commercial dispositions of such Shared Product, less the following deductions actually
incurred, allowed, paid, accrued or specifically allocated in its financial statements and calculated in accordance with the Accounting Standards as consistently applied, for: 

(a) [***]; 
 (b) [***]; 

(c) [***]; 
 (d) [***]; 

(e) [***]; and 
 (f) [***]. 

  
 - 7 - 

 There should be no double counting in determining the foregoing deductions from gross amounts invoiced to
calculate “Net Sales” hereunder. The calculations set forth in this definition shall be determined in accordance with Accounting Standards consistently applied. 

If non-monetary consideration is received by a Selling Party for any Shared Product in the relevant country, Net Sales
will be [***]. Notwithstanding the foregoing, Net Sales shall [***]. 
 Net Sales shall be determined on, [***], the [***] by a Selling Party or any of its
Affiliates or (sub)licensees to a non-(sub)licensee Third Party. 
 If a Shared Product is sold as part of a
Combination Product (as defined below), Net Sales will be the product of (i) [***] and (ii) the fraction (A/(A+B)), where: 
 “A” is [***];
and 
 “B” is [***]. 
 If “A” or
“B” cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated as above, but [***]. 

As used in this definition of “Net Sales,” “Combination Product” means a Shared Product that contains one or more additional
active ingredients (whether co-formulated or co-packaged) that are neither Co-Co Candidates nor generic or other non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall be deemed not to be “active ingredients.” 

Section 1.42 “Out-of-Pocket Costs”
means, with respect to certain activities hereunder, [***]. 

  
 - 8 - 

 Section 1.43 “Partnership Agreement” means an agreement pursuant to
which a Party or its Affiliate provides funding to a Third Party to research and develop pharmaceutical compounds or products and which may include the grant of an option for such Party or Affiliate to obtain rights to, but not (in the absence of
the exercise of such option) a license to Commercialize or other rights to Commercialize, such pharmaceutical compounds or products. 

Section 1.44 “Phase IV Study” means a human clinical trial of a product which is (a) conducted to satisfy a
requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has been obtained from an appropriate Regulatory Authority for enhancing marketing or
scientific knowledge of an approved Indication. 
 Section 1.45 “Product Liabilities” means all losses, damages, fees,
costs and other liabilities incurred by a Party, its Affiliate(s) or its Licensee Partner(s) and resulting from or relating to the use of a Shared Product in a human (including clinical trials or Commercialization) in the Territory incurred after
the Effective Date. For the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party, its Affiliate(s), or its Licensee Partner(s) and all
losses, damages, fees and costs associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of any Shared Product. 

Section 1.46 “Regulatory Documentation” means, with respect to the Collaboration, all INDs, NDAs and other regulatory
applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug dossiers, master files (including Drug Master Files, as
defined in 21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials relating to Development or Regulatory Approval of the
Shared Products, or required to Manufacture, distribute or sell the Shared Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls data, batch records, safety and efficacy, and any safety
database. 
 Section 1.47 “Regulatory Exclusivity” means, with respect to a Shared Product in a country, that the
Shared Product has been granted (a) data exclusivity afforded approved drug products pursuant to Section 505(c), 505(j), or 505A of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or their equivalent in
a country other than the United States, (b) market exclusivity pursuant to the orphan drug provisions governing approved drugs designated for rare diseases or conditions under Sections 526 and 527 of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (c) any other data exclusivity or market exclusivity pursuant to any future Law. 

Section 1.48 “Right of Reference or Use” means a “Right of Reference or Use” as that term is defined in
21 C.F.R. §314.3(b), and any non-United States equivalents. 
 Section 1.49 “ROW
Administration” means administration of Shared Products to a patient when such patient is located in the ROW Territory. 

  
 - 9 - 

 Section 1.50 “ROW Territory” means all countries in the world other
than the US Territory. 
 Section 1.51 “Shared Product” means (a) a Co-Co
Candidate or (b) any product that contains a Co-Co Candidate as an active ingredient. 

Section 1.52 “Shared Product Data” means all relevant Data included in the
Know-How Controlled by either Party in relation to Shared Products or Companion Diagnostics for use in the Field either: (a) as of the Execution Date; or (b) generated from activities conducted by or
on behalf of a Party under the Development Plan or that otherwise specifically relates to Shared Products or Companion Diagnostics and in each case is necessary or useful for applications for Regulatory Approval, or Regulatory Approvals, for Shared
Products in the Field and in the Territory. 
 Section 1.53 “Shared Program” means the Program that is the subject of
this Agreement. 
 Section 1.54 “Territory” means the US Territory and the ROW Territory. 

Section 1.55 “Third Party Agreement” means (a) each Existing Third Party Agreement and (b) each Subsequent
Third Party Agreement. 
 Section 1.56 “Third Party Rights” means, with respect to a Party, any rights of, and any
limitations, restrictions or obligations imposed by, Third Parties pursuant to any Third Party Agreements. 
 Section 1.57
“U.S. Administration” means administration of Shared Products to a patient when such patient is located in the US Territory. 

Section 1.58 “US Territory” means the United States of America, including its territories, possessions and Puerto Rico.

 Section 1.59 “Valid Claim” means (a) a claim of any issued, unexpired patent that has not been revoked or held
unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been
disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or subject matter of a claim thereof filed by a Person in good faith that has not been cancelled, withdrawn or
abandoned, nor been pending for more than six (6) years from the earliest filing date to which such patent application or claim is entitled. 

Section 1.60 “Vividion Co-Co Collaboration Intellectual Property” means the Co-Co Collaboration Intellectual Property Controlled by Vividion. 
 Section 1.61 “Vividion Co-Co Collaboration Know-How” means the Co-Co Collaboration Know-How Controlled by
Vividion (including Vividion’s interest in the Joint Co-Co Know-How and Joint Inventions). 

  
 - 10 - 

 Section 1.62 “Vividion Co-Co
Collaboration Patents” means the Co-Co Collaboration Patents Controlled by Vividion (including Vividion’s interest in the Joint Co-Co Patents and Joint
Patents). 
 Section 1.63 “Vividion Intellectual Property” means Vividion
Know-How and Vividion Patents, collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion
and The Scripps Research Institute, dated as of January 6, 2016. 
 Section 1.64 “Vividion
Know-How” means any Know-How that is (a) Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Know-How, as defined under the Master Agreement) or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products, but excluding (y) Co-Co Collaboration Know-How and (z) any Know-How licensed to Vividion under the License Agreement by and between
Vividion and The Scripps Research Institute, dated as of January 6, 2016. 
 Section 1.65 “Vividion Patents”
means any Patents that (a) are Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Patents, as defined under the Master Agreement) or during the Term, and (b) Cover, or are useful for, the
Development, Manufacture or Commercialization of the Shared Products (including the composition of matter, manufacture or any use thereof); but excluding (y) Co-Co Collaboration Patents and
(z) any Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. Vividion Patents as of the Execution Date are as set forth on Exhibit B to
this Agreement. 
 Section 1.66 Additional Definitions. Each of the following definitions is set forth in the section of this
Agreement indicated below: 
  

			
	 DEFINITION
	  	 SECTION

		
	 35 U.S.C. § 102(c) Patent
	  	 Section 10.7

		
	 Academic Essential Provisions
	  	 Section 8.6(b)(iii)

		
	 Accounting Standards
	  	 Master Agreement

		
	 Acquirer Program
	  	 Section 8.6(b)(v)(D)

		
	 Additional Study
	  	 Section 3.3

		
	 Additional Study Approval
	  	 Section 3.3(c)

		
	 Affiliate
	  	 Master Agreement

		
	 Agreement
	  	 Preamble

		
	 Allocable Overhead
	  	 Exhibit D

		
	 Allowable Expenses
	  	 Exhibit D

		
	 Allowed Indication
	  	 Section 8.6(b)(viii)

		
	 Antitrust Law
	  	 Master Agreement

		
	 Audit Team
	  	 Section 9.7(a)

		
	 Audit Rights Holder
	  	 Section 9.7(e)

		
	 Auditee
	  	 Section 9.7(e)

  
 - 11 - 

			
	 DEFINITION
	  	 SECTION

		
	 Bankruptcy Code
	  	 Section 8.8

		
	 Barred Indication
	  	 Section 8.6(b)(vii)

		
	 Business Day
	  	 Master Agreement

		
	 CCB Program MTA
	  	 Master Agreement

		
	 Celgene
	  	 Preamble

		
	 Celgene Indemnified Parties
	  	 Section 13.2

		
	 Celgene Independent Product
	  	 Master Agreement

		
	 Challenge
	  	 Section 14.3(d)

		
	 Challenging Party
	  	 Section 14.3(d)

		
	 Change of Control
	  	 Master Agreement

		
	 Clinically Develop
	  	 Section 8.6(a)

		
	 Co-Co
Buy-In
	  	 Section 3.4

		
	 Combination Product
	  	 Section 1.41

		
	 Commercialization/Commercialize
	  	 Master Agreement

		
	 Commercialization Budget
	  	 Section 6.2(c)

		
	 Commercialization Costs
	  	 Section 6.5(c)

		
	 Commercialization Plan
	  	 Section 6.2(a)

		
	 Commercially Reasonable Efforts
	  	 Master Agreement

		
	 Competitive Infringement
	  	 Section 10.3(b)

		
	 Competitive Program
	  	 Section 8.6(b)(iv)

		
	 Competitive Program Party
	  	 Section 8.6(b)(iv)

		
	 Control/Controlled
	  	 Master Agreement

		
	 Cooperating Party
	  	 Section 11.3(b)(iii)

		
	 Costs of Goods Sold or COGS
	  	 Exhibit D

		
	 Cover/Covering/Covered
	  	 Master Agreement

		
	 CPI
	  	 Section 1.29

		
	 Cure Period
	  	 Section 14.3(b)(i)

		
	 Damages
	  	 Master Agreement

		
	 Deemed Buy-In
	  	 Section 3.3(c)

		
	 Develop/Development
	  	 Master Agreement

		
	 Development Budget
	  	 Section 3.1(a)(i)

		
	 Directed
	  	 Master Agreement

		
	 Disclosing Party
	  	 Section 11.1

		
	 Dispute
	  	 Section 15.1

		
	 [Distinct Product
	  	 Master Agreement]

		
	 [Distinct Product Catch-Up Payments
	  	 Section 9.2(a)(iii)]

		
	 Distribution Costs
	  	 Exhibit D

		
	 Earlier Patent
	  	 Section 10.7

		
	 Electronic Delivery
	  	 Section 15.16

		
	 Enabling Manufacturing
	  	 Section 8.6(a)

		
	 Execution Date
	  	 Preamble

		
	 FDA
	  	 Master Agreement

		
	 FDCA
	  	 Master Agreement

		
	 Finance Working Group
	  	 Section 2.2(f)

		
	 force majeure event
	  	 Section 15.7

  
 - 12 - 

			
	 DEFINITION
	  	 SECTION

		
	 Functional Phenotypic Assay Similarity Criteria
	  	 Master Agreement

		
	 Global Safety Database
	  	 Section 5.3

		
	 Gross Profit
	  	 Exhibit D

		
	 Incentive Compensation
	  	 Section 6.5(b)(v)

		
	 IND
	  	 Master Agreement

		
	 Indemnified Party
	  	 Section 13.3

		
	 Indemnitor
	  	 Section 13.3

		
	 Indirect Taxes
	  	 Section 9.8(b)(i)

		
	 Indication
	  	 Master Agreement

		
	 Information Request
	  	 Section 6.5(b)(vii)

		
	 Initial Enforcement Party
	  	 Section 10.3(b)

		
	 Joint Inventions
	  	 Section 10.1(c)

		
	 Joint Patents
	  	 Section 10.1(c)

		
	 Know-How
	  	 Master Agreement

		
	 Law
	  	 Master Agreement

		
	 Licensed Branding
	  	 Section 6.6(c)

		
	 Licensing Party
	  	 Section 8.5(c)

		
	 Lump Sum
	  	 Section 3.3(c)

		
	 Manufacture/Manufacturing
	  	 Master Agreement

		
	 Manufacturing Costs
	  	 Exhibit D

		
	 Marketing Costs
	  	 Exhibit D

		
	 Master Agreement
	  	 Introduction

		
	 Material Breach
	  	 Section 14.3(b)(i)

		
	 Non-Proposing Party
	  	 Section 3.3

		
	 Operating Profits or Losses
	  	 Exhibit D

		
	 Opt-In Right
	  	 Master Agreement

		
	 Other Operating Income/Expense
	  	 Exhibit D

		
	 Party or Parties
	  	 Preamble

		
	 Patent Officers
	  	 Master Agreement

		
	 Patent Prosecution Expenses
	  	 Section 10.2(c)

		
	 Patent
	  	 Master Agreement

		
	 Payee Party
	  	 Section 9.8(b)(i)

		
	 Paying Party
	  	 Section 9.8(b)(i)

		
	 Permitted Indication
	  	 Section 8.6(b)(vii)

		
	 Person
	  	 Master Agreement

		
	 Pharmacovigilance Agreement
	  	 Section 5.3

		
	 Pharmacovigilance Expenses
	  	 Exhibit D

		
	 Phase I Study
	  	 Master Agreement

		
	 Phase II Study
	  	 Master Agreement

		
	 Phase III Study
	  	 Master Agreement

		
	 Pivotal Clinical Trial
	  	 Master Agreement

		
	 Product Recall Expenses
	  	 Exhibit D

		
	 Product Trademarks
	  	 Section 6.6(a)

		
	 Profit & Loss Share
	  	 Section 9.3(a)

		
	 Program Assets
	  	 Section 12.4(a)

  
 - 13 - 

			
	 DEFINITION
	  	 SECTION

		
	DEFINITION	  	SECTION
		
	 Program Compound
	  	 Master Agreement

		
	 Program Product
	  	 Master Agreement

		
	 Program Target
	  	 Master Agreement

		
	 Proposing Party
	  	 Section 3.3

		
	 Prosecuting Party
	  	 Section 10.2(d)(ii)

		
	 Prosecution/Prosecute
	  	 Master Agreement

		
	 Publication
	  	 Master Agreement

		
	 Pursuing Party
	  	 Section 14.3(d)

		
	 Receiving Party
	  	 Section 11.1

		
	 Redacted Version
	  	 Section 11.3(b)(i)

		
	 Regulatory Approval
	  	 Master Agreement

		
	 Regulatory Authority
	  	 Master Agreement

		
	 Regulatory Expenses
	  	 Exhibit D

		
	 Regulatory Interactions
	  	 Section 5.1(b)

		
	 Report
	  	 Exhibit D

		
	 Requesting Party
	  	 Section 11.3(b)(iii)

		
	 Royalty Rate
	  	 Section 9.4(a)

		
	 Royalty Term
	  	 Section 9.4(b)

		
	 Sales Costs
	  	 Exhibit D

		
	 Sales Milestone Condition
	  	 Section 9.2(b)

		
	 SEC
	  	 Section 11.3(b)(i)

		
	 Selected Target
	  	 Master Agreement

		
	 Selling Party
	  	 Section 1.41

		
	 Separate Program
	  	 Master Agreement

		
	 Separate Program Product
	  	 Section 8.6(b)(vii)

		
	 Step-In Enforcement Party
	  	 Section 10.3(d)

		
	 Sublicense Revenues
	  	 Exhibit D

		
	 Subsequent Third Party Agreement
	  	 Section 9.5(b)

		
	 Term
	  	 Section 14.1

		
	 Third Party Contractors
	  	 Section 8.2(a)(ii)

		
	 Third Party Infringement
	  	 Section 10.3(a)

		
	 Third Party Infringement Action
	  	 Section 10.4

		
	 Third Party Products Liability Action
	  	 Section 13.5(a)

		
	 Vividion
	  	 Preamble

		
	 Vividion Indemnified Parties
	  	 Section 13.1

		
	 Vividion Opt-Out Notice
	  	 Section 2.3(a)

		
	 Vividion Opt-Out Date
	  	 Section 2.3(b)

  
 - 14 - 

 Article II 

Governance; Collaboration 

Section 2.1 Certain Interactions with and Effects on the Master Agreement. Upon and after the Effective Date, notwithstanding
anything to the contrary in the Master Agreement: 
 (a) During the Term, the Committees shall remain established as set forth in Article IV
of the Master Agreement to perform the functions set forth therein with respect to the Parties’ activities under this Agreement. 
 (b)
Except as otherwise set forth in this Agreement, all activities regarding Development and Manufacturing of Shared Products shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 

(c) None of the Parties’ activities performed in accordance with this Agreement (including those activities specifically permitted upon
and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 
 Section 2.2 Decision Making.

 (a) Committee Voting. All decisions of a Committee with respect to the Parties’ activities under this Agreement shall be
attempted to be made by unanimous vote, with each Party’s representatives collectively having one (1) vote, and each such decision (if made) shall be set forth in minutes approved by both Parties’ representatives on the Committee.
Upon [***] Business Days prior written notice, either Party may convene a special meeting of a Committee for the purpose of resolving any failure to reach agreement on a matter within the scope of the authority and responsibility of such Committee.
No Committee shall have the authority to resolve any dispute involving the breach or alleged breach of this Agreement or to amend or modify this Agreement or the Parties’ respective rights and obligations hereunder. 

(b) Referrals from JDC or JCC to JSC. If the JDC or JCC is unable to decide, by unanimous vote, on any matter so referred to it for
resolution by one or both Parties within [***] Business Days after the matter is so referred to it, the chairperson of the JDC or JCC, as applicable, shall refer such matter to the JSC for attempted resolution by unanimous vote. 

(c) Referrals from the JSC to Executive Officers. If the JSC is unable to decide, by unanimous vote, on any such matter referred to it
by the JDC or the JCC or on any other matter specified in this Agreement to be decided by the JSC, within [***] Business Days after the matter is referred to it or first considered by it, the chairperson of the JSC shall submit such matter for
attempted resolution by agreement of the Executive Officers. 
 (d) Decision-Making Authority. If the Executive Officers are unable to
resolve any matter referred to them by the chairperson of the JSC within [***] Business Days after the matter is referred to them, then, subject to Section 2.2(g): 

(i) if the [***] the right to decide any such unresolved matter that relates solely to the US Territory, (B) Celgene shall have the right
to decide any such unresolved matter that relates solely to the ROW Territory, and (C) if Vividion is the Lead US Party and such unresolved matter relates to both the US Territory and the ROW Territory, Vividion shall have the right to decide
such unresolved matter with respect to the US Territory and Celgene shall have the right to decide such unresolved matter with respect to the ROW Territory; provided, however, that, in each case ((A), (B) and (C)), the resolving
Party shall give due, good faith consideration to any comments or preferences expressed by the other Party with respect to any such matter; 

  
 - 15 - 

 (ii) if the unresolved matter relates to Commercialization of the Shared Products:
(A) the Lead US Party shall have the right to decide the unresolved matter for the US Territory and (B) Celgene shall have the right to decide the unresolved matter for the ROW Territory; provided, however, that the
resolving Party shall give due consideration to any comments or preferences expressed by the other Party with respect to such matter; and 

(iii) if the unresolved matter relates to Manufacture of the Shared Products, Celgene shall have the right to decide the unresolved matter for
the Territory; provided, however, that Celgene shall give due, good faith consideration to any comments or preferences expressed by Vividion with respect to any such matter; 

(e) JPC. If the JPC is unable to decide, by unanimous vote, on any matter within [***] Business Days after the matter is first raised
with the JPC, then the matter will be referred to the Patent Officers for resolution. If such matter is not resolved by the Patent Officers of the Parties within [***] Business Days after the matter was referred to them, then, subject to
Section 2.2(g), the applicable Prosecuting Party (as set forth in Article X) may decide the matter. Notwithstanding the foregoing, but subject to Section 2.2(g), if at any time the Party who has decision-making rights for such matter under
Article X reasonably believes that the delay in decision resulting from such procedure will create a risk that any rights to Know-How or Patents will be lost or otherwise diminished, then such Party may
exercise such decision-making rights immediately, provided that such resolving Party shall give due, good faith consideration to any comments or preferences expressed by the other Party with respect to such matter. 

(f) Formation of Finance Working Group. Promptly after the Effective Date, Celgene and Vividion shall establish a joint Finance Working
Group (the “Finance Working Group”), which shall report to the JDC with respect to the Development of the Shared Products, to the JCC with respect to the Commercialization of the Shared Products and to the JSC with respect to the
preparation and approval of the Reports and other related financial information in accordance with Exhibit D and the terms and conditions of this Agreement, and operate in coordination with the various committees. The Finance Working Group
shall include individuals from each Party with reasonable expertise in the areas of accounting, cost allocation, budgeting and financial reporting. The Finance Working Group shall be responsible for: (i) coordinating and conducting the
accounting, reporting, reconciliation and other related activities set forth in this Agreement and Exhibit D; (ii) advising and providing support to the JSC and the other committees with respect to financial, accounting, budgeting,
reporting and other issues that may arise in connection with the various plans and corresponding budgets for activities thereunder; (iii) reviewing relevant FTE costs and other costs included in the Profit & Loss Share incurred by the
Parties and their Affiliates hereunder; (iv) recommending for approval by the JSC any changes to reporting procedures; (v) coordinating or performing the budgeting, consolidation, completion and review of the Reports and other related
financial information statements in accordance with the terms and conditions of this Agreement and Exhibit D, including budgeting and calculation of Allowable Expenses not covered in the Development Budget or the Commercialization Budget;
(vi) performing and reviewing calculations for the reconciliation of payments, and controlling and performing such other accounting functions as provided in the terms and conditions of this Agreement and Exhibit D;
(vii) coordinating audits pursuant to Section 9.7, by Third Party audit firms, and discussing and attempting to resolve discrepancies or issues arising from such audits; (viii) performing such other functions as are specifically
delegated to the 

  
 - 16 - 

 Finance Working Group in this Agreement or Exhibit D, or as the Parties otherwise agree are
appropriate to further the purposes of this Agreement; (ix) working with the JSC and the committees to assist in financial, budgeting and planning matters, and providing periodic updates to the JSC, JDC and JCC on financial matters relating to
this Agreement, and perform such other financial matters as are delegated to it under this Agreement or by the JSC, JDC and JCC; and (x) making such decisions and determinations as are assigned to it under this Agreement. If the Finance Working
Group is unable to decide, by unanimous vote, on any matter so referred to it for resolution by one or both Parties within [***] Business Days after the matter is so referred to it, the Finance Working Group shall refer such matter to the JDC, JCC
or JSC, as applicable, for attempted resolution by unanimous vote. 
 (g) Exceptions. 

(i) This Section 2.2 is subject to the applicable terms and conditions of Article IV of the Master Agreement. 

(ii) No Party shall have the right to finally resolve a dispute pursuant to Section 2.2(d), without agreement of the other Party, in a
manner that would impose any obligations on such other Party beyond those for which such other Party is responsible, or diminish such other Party’s rights, under this Agreement or the then-current Development Plan or Development Budget or
Commercialization Plan or Commercialization Budget, as applicable, (including by increasing such other Party’s financial obligations hereunder). 

(iii) Notwithstanding anything to the contrary contained herein, the Parties understand and agree that, from and after the date that Vividion
provides the Vividion Opt-Out Notice, the Committees shall no longer have any decision-making authority, but shall continue to function for information sharing purposes until the Vividion Opt-Out Date. 
 (h) All “Confidential Information” disclosed under the Master Agreement that
solely relates to any Shared Product shall, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), be deemed to be Confidential Information disclosed under this Agreement and not the Master Agreement. All “Confidential
Information” disclosed under the Master Agreement that relates to, but does not solely relate to, any Shared Product shall be deemed “Confidential Information” disclosed under the Master Agreement and also, subject to
Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), Confidential Information disclosed under this Agreement; provided, however, that any disclosure of such information that is permitted under the Master Agreement shall not be deemed
a breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be deemed a breach of the Master Agreement. 

Section 2.3 Vividion Opt-Out. 

(a) Opt-Out Notice. Without it being a breach of Article VII, Vividion shall have the right to
elect to opt out of its Development, Manufacturing and Commercialization rights and the sharing of Operating Profits or Losses under this Agreement by written notice to Celgene (such notice, the “Vividion
Opt-Out Notice”); provided, however, that Vividion may not, without consent of Celgene, provide any such notice (x) within [***] months after any Regulatory Authority or the
other Party has provided to any Committee or Vividion any notification under 

  
 - 17 - 

 Section 5.4 that a recall, market withdrawal or similar action may be required with respect to any Shared
Product or (y) within [***] months after any Committee or Vividion receives knowledge of any Third Party Products Liability Action. After Vividion provides such Vividion Opt-Out Notice, Celgene shall have
sole discretion with respect to any matters regarding further Development, Manufacturing and Commercialization (including any sales force activities and designation of sales representatives) hereunder, provided that, (i) during the period
between such Vividion Opt-Out Notice and the applicable Vividion Opt-Out Date, Celgene shall use Commercially Reasonable Efforts to continue such activities in
accordance with the plans and budgets therefor in effect as of such Vividion Opt-Out Notice and (ii) after the applicable Vividion Opt-Out Date, Celgene shall use
Commercially Reasonable Efforts to Develop and Commercialize the Shared Products as provided in Article VII. 
 (b) Opt-Out Date. Vividion’s opt-out shall be effective [***] months after the Vividion Opt-Out Notice is given; provided
that, if Vividion exercises its right to opt-out at any time during the [***] month period prior to the anticipated First Commercial Sale in the US Territory of any Shared Product, then such notice
period shall commence on the date of the Vividion Opt-Out Notice and continue until [***] months after the actual First Commercial Sale of such Shared Product in the US Territory (the “Vividion Opt-Out Date”). 
 (c) Effects of Vividion Opt-Out
Notice or Vividion Opt-Out Date. Following the Vividion Opt-Out Notice: 

(i) the license and sublicense granted to Vividion under Section 8.1(b) shall terminate effective as of the Vividion Opt-Out Date and all licenses granted by Vividion to Celgene under Section 8.1(a) with respect to the Shared Product(s) shall convert to exclusive worldwide licenses and otherwise remain in effect; 

(ii) effective as of the Vividion Opt-Out Date, the Committees shall not oversee or review any of the
matters under this Agreement; 
 (iii) neither Party shall have any further obligations under the Development Plan or Commercialization Plan
effective as of the Vividion Opt-Out Date (and such plans, for clarity, shall terminate); 
 (iv)
effective as of the Vividion Opt-Out Date, Celgene (but not Vividion) shall continue to have obligations under Section 7.1(b) and Section 7.2, but neither Party shall have any obligations under
Section 7.1(a); 
 (v) [***] shall be solely responsible for all COGS and Allowable Expenses for the Shared Products incurred after the
Vividion Opt-Out Date, except as provided in this Section 2.3(c) and as provided in Section 5.4, Section 13.4 and Section 13.5; 

(vi) effective as of the Vividion Opt-Out Date, Vividion shall cease to conduct any further
Development or Commercialization activities (including marketing activities) with respect to any Shared Products, cease to have any obligations to use Commercially Reasonable Efforts with respect to Article III (Development) and Article VI
(Commercialization), and cease to incur any further COGS or Allowable Expenses except as approved by Celgene or as provided in Section 5.4, Section 13.4 and Section 13.5; 

  
 - 18 - 

 (vii) within [***] days after the Vividion Opt-Out
Date, Vividion shall provide to Celgene a reasonably detailed accounting of all COGS and Allowable Expenses incurred by Vividion under the Collaboration prior to the Vividion Opt-Out Date for the purpose of
calculating a final reconciliation of shared costs through the Vividion Opt-Out Date in accordance with Section 9.1 and Section 9.3; 

(viii) within [***] days after the Vividion Opt-Out Notice, Vividion shall provide to Celgene a
reasonably detailed summary of Development and Commercialization activities performed by Vividion under the Collaboration, including any Clinical Trials committed but not yet completed as of such date; 

(ix) within [***] days after the Vividion Opt-Out Date, Vividion shall provide to Celgene an update to
the summary provided pursuant to subsection (viii) above; 
 (x) Vividion shall undertake, and coordinate with Celgene with respect to,
any wind-down or transitional activities reasonably necessary to transfer to Celgene all Development and Commercialization responsibility for the Shared Products throughout the Territory, at [***] sole expense, and Vividion shall use Commercially
Reasonable Efforts to complete such activities before the Vividion Opt-Out Date; provided that the Parties shall reasonably cooperate in seeking to minimize the costs of such wind-down or
transitional activities; provided further that, (A) if Celgene requests that any contracts or agreements that extend beyond the Vividion Opt-Out Date be terminated, Vividion and
Celgene shall share all costs associated with such termination, and, (B) if Celgene requests that any such contract or agreement remain in effect, Celgene shall be responsible for all costs, expenses and Product Liabilities incurred under such
contract or agreement following the Vividion Opt-Out Date or, if Celgene requests assignment of such contract or agreement prior to the Vividion Opt-Out Date, incurred
following such assignment (whichever is earlier); it being understood and agreed that, notwithstanding anything to the contrary contained herein, Vividion shall continue to be responsible with Celgene pursuant to the terms and conditions of this
Agreement for all costs, expenses and Product Liabilities incurred or otherwise arising prior to the assignment of such contract or agreement to Celgene (including liability arising following the Vividion
Opt-Out Date to the extent based on facts and circumstances first arising prior to such assignment), under such contract or agreement as if no such Vividion Opt-Out Date
had occurred; 
 (xi) effective as of the Vividion Opt-Out Date, each Shared Product shall be
subject to the royalty provisions of Section 9.4 from and after the Vividion Opt-Out Date, in lieu of the sharing of Development Costs under Section 9.1 and Operating Profits or Losses under
Section 9.3; 
 (xii) following the Vividion Opt-Out Date, Celgene shall provide to Vividion an
annual written progress report during the Term on the status of its material Development activities with respect to the Shared Program under this Agreement; and 

(xiii) as quickly as reasonably possible, as and to the extent applicable, Vividion shall transition to Celgene (if not previously
transitioned) Vividion’s Prosecution and enforcement responsibilities (if any) with respect to Vividion Patents, Vividion Co-Co 

  
 - 19 - 

 Collaboration Patents, Joint Inventions and Joint Co-Co Patents,
which transition Vividion shall use Commercially Reasonable Efforts to complete prior to the Vividion Opt-Out Date, and thereafter provide reasonable assistance to Celgene and cooperation in connection
therewith, including execution of such documents as may be necessary to effect such transition, provided that Vividion shall retain step-in rights (in the event that Celgene elects not to
Prosecute) on Prosecution matters relating to Joint Co-Co Patents, Vividion Patents and Vividion Co-Co Collaboration Patents that are not Joint Co-Co Patents comparable to the non-Lead US Party’s step-in rights under Section 10.2(a). 

(d) No Reversion. For purposes of clarity, except as provided in this Agreement, after the Vividion
Opt-Out Date, Celgene shall be responsible for all costs and expenses for the Shared Program and Vividion shall not have any option or right to buy back into any
co-Development or co-Commercialization rights with respect to the Shared Program. 

Article III 
 Development

 Section 3.1 Development of Shared Products. 

(a) Development Plan. 
 (i)
Initial Plan. Subject to Section 2.2 and Section 2.3, Development of Shared Products shall be governed by the Development Plan for each of the US Territory and the ROW Territory that, collectively, describe the Development
activities to be undertaken with respect to the Shared Products in the Territory, which shall include an annual budget of Development Costs and related Manufacturing Costs and other Allowable Expenses pursuant to Section 3.1(b)
(“Development Budget”) and anticipated timelines for performance. Promptly after the Effective Date, but in any event within [***] days thereafter, the Lead US Party (with respect to Development of the Shared Products in the US
Territory) and Celgene (with respect to Development of the Shared Product in the ROW Territory) shall each prepare and submit to the JDC for review the applicable portions of a Development Plan for inclusion in an initial global Development Plan for
Shared Products, including any activities to be performed by Vividion for U.S. Administration, and such initial global Development Plan for Shared Products shall be subject to review and approval by the JSC. The JDC will review the required form and
contents of the Development Plan (which shall be subject to review and approval by the JSC), and will review each Development Plan in accordance with Section 3.1(c). The Development Plan may be amended from time to time by the JDC. The Direct
Costs of conducting Development activities in both the ROW Territory and the US Territory in relation to a Shared Product shall be reflected in the Development Budget and allocated and paid as set forth in Section 3.2. 

(ii) Updates. Following the initial preparation of the Development Plan as set forth in Section 3.1(a)(i), the JDC will update,
and the JSC will review approve, the Development Plan at least once in each Calendar Year during the Term prior to the grant of Regulatory Approval for the applicable Shared Products, with (A) the Lead US Party proposing the updates for the
Development Plan with respect to Shared Products for U.S. Administration and (B) Celgene proposing the updates for the Development Plan with respect to Shared Products for ROW Administration. In addition, either Party may reasonably request at
any time that the JDC 

  
 - 20 - 

 consider, and the JSC review and approve, other updates to the Development Plan for Development activities
to support Regulatory Approval on a global basis, including any Additional Study pursuant to Section 3.3. Neither Party (itself or by or through any others, including any Affiliates or (sub)licensees) will take any material action regarding the
Development of the Shared Products unless described in the Development Plan or mutually agreed upon in writing by the Parties or, with respect to Additional Studies, in accordance with Section 3.3, or as required by applicable Laws or
applicable Regulatory Authorities or independent monitoring boards for Clinical Trials. 
 (b) Development Budgets. Promptly after the
Effective Date, but in any event within [***] days thereafter, and concurrently with the preparation of the Development Plan pursuant to Section 3.1(a), the Parties shall cooperate to prepare the initial Development Budget, which shall be
reviewed and approved by the JSC. The Lead US Party shall be responsible for the preparation of the applicable portion of the budget for the Development activities, including all Clinical Trials, to be conducted solely to support Regulatory Approval
of Shared Products in the US Territory, and Celgene shall be responsible for the preparation of the portion of the budget for the Development activities, including all Clinical Trials, to be conducted solely to support Regulatory Approval of Shared
Products in the ROW Territory. All reasonable Direct Costs incurred by either Party or its Affiliates in conducting (i) Development activities pursuant to the Development Plan, or (ii) Additional Studies that the Parties agree to conduct
pursuant to Section 3.3 following the Agreement Effective Date shall be considered Development Costs or Manufacturing Costs or other Allowable Expenses, as applicable, and shall be included in Allowable Expenses for the purposes of calculating
the Profit & Loss Share. For Development Costs and related Manufacturing Costs and other Allowable Expenses to be incurred from and after the Effective Date, the JSC will review and approve the Development Budget reasonably in advance of
the applicable Development Costs or Manufacturing Costs or other Allowable Expenses being incurred (with the intent being to obtain such approval at least [***] months in advance of such costs being incurred, where practicable). Thereafter, the JSC
will update and provide the JDC with a copy of the Development Budget, including the budgeted Development Costs and related Manufacturing Costs and other Allowable Expenses, each Calendar Year at a meeting of the JDC sufficiently in advance of the
next Calendar Year so as to provide the Parties with an opportunity to budget accordingly, but in any event no later than November 1st of each Calendar Year during the Term. The JSC will review and approve any such update or any other amendment to
the Development Budget. In addition, either Party may request at any time that the JDC consider, and the JSC approve, other updates to the Development Budget. The Parties understand and agree that, if the
Non-Proposing Party does not elect to participate in an Additional Study as set forth in Section 3.3, the Proposing Party shall have the sole right to amend the Development Budget to account for the
Direct Costs of such Additional Study (but, for clarity, shall not have the right to impose any additional payment obligations on the Non-Proposing Party for expenses related to such Additional Study, unless
and until a Co-Co Buy-In occurs as set forth in Section 3.4, or a Deemed Buy-In occurs pursuant to Section 3.3(c)),
after which time any changes to the Development Budget shall be run through the procedures described in this Section 3.1(b). Each Party shall use Commercially Reasonable Efforts to perform the activities assigned to it in the Development Plan.

  
 - 21 - 

 (c) General Development Principles. It is the intent of the Parties that Development
of the Shared Products will be conducted in accordance with the following principles, except as otherwise mutually agreed by the Parties. The JDC (or the JSC or the Executive Officers as applicable) shall take into account and attempt to implement
the following principles in its decision-making, including preparation, review and approval of any updates to and amendments of the Development Plan: 

(i) Regardless of the specific division of responsibility between the Parties for particular activities at any particular time, the JDC (and
JSC) shall serve as a conduit for sharing information, knowledge and expertise relating to the Development of the Shared Products. 
 (ii)
Clinical Development of the Shared Products should be performed according to a single, integrated global program (with, for the avoidance of doubt, allowance of Additional Studies as provided in Section 3.3). 

(iii) The Development Plan should include an allocation of responsibilities between the Parties reasonably determined after taking into
consideration each Party’s expertise, capabilities, staffing and available resources to take on such activities. 
 (iv) After receipt
of Regulatory Approval of a Shared Product in any Major Market, the Development Plan should (absent special circumstances or significant changes in circumstances) include pursuit of Regulatory Approval for such Shared Product in the other Major
Markets and such other countries as the applicable Lead Party deems appropriate. 
 (d) Coordination and Reports. Each Party shall
coordinate with, and keep the JDC informed with respect to, activities assigned to such Party under the Development Plan, including the conduct of any applicable Clinical Trials. Each Party shall provide the JDC with regular quarterly written
reports on such Party’s Development activities relating to the Collaboration, including a summary of results, information, and data generated, any activities planned with respect to Development going forward (including, for example, updates
regarding regulatory matters and Development activities for the next Calendar Quarter), challenges anticipated and updates regarding intellectual property issues (including a disclosure of Co-Co Collaboration
Intellectual Property discovered, developed, generated or invented since the last written report) relating to the Collaboration. Such written reports may be discussed by telephone or video-conference, or may be provided at each JDC meeting;
provided that, reasonably in advance of the meeting of the JDC, the Party providing the written report will deliver to the JDC an agenda setting forth what will be discussed during the meeting. The Party receiving such written report
shall have the right to reasonably request, and to receive in a timely manner at or after the JDC meeting, clarifications and answers to questions with respect to such reports. 

Section 3.2 Development Costs and Related Manufacturing Costs. The Parties will share all Development Costs and related
Manufacturing Costs incurred from and after the Effective Date in accordance with Section 9.1. 
 Section 3.3 Additional
Development Activities. If, following the Effective Date, the Lead Party in the US Territory or the ROW Territory, as applicable (any such Party, the “Proposing Party”) wishes (i) to conduct a Clinical Trial or other study
(including to repeat any Clinical Trial previously conducted under the Development Plan that failed to meet its primary endpoints) of 

  
 - 22- 

 Shared Products not contemplated by the Development Plan, (ii) to Develop Shared Products for a
territory in which it is the Lead Party for any Indication in the Field other than an Indication for which such Shared Products are being Developed pursuant to the Development Plan, (iii) to Develop a dosage form or formulation of Shared
Products for a territory for which the Proposing Party is the Lead Party other than that being studied in the Development Plan, or (iv) to conduct any other Clinical Trial of a Shared Product in the Field for a territory for which the Proposing
Party is the Lead Party, or any Clinical Trial or study that is not otherwise set forth in the Development Plan, or any Clinical Trial that the Proposing Party believes may have utility to support Regulatory Approval in the Proposing Party’s
territory, including any Phase IV Study or any combination of pharmaceutical products (each such study or activity in (i)-(iv) not already included in the then-current Development Plan, an “Additional Study”), then Parties
understand and agree that this Section 3.3 shall apply and, accordingly, (A) the Proposing Party shall first provide the proposed trial design and protocol for such Additional Study to the other Party (the “Non-Proposing Party”), through its members on the JSC for review and approval as to the clinical and regulatory aspects of such Additional Study, and shall incorporate reasonable comments from the Non-Proposing Party’s JSC members into such Additional Study design and protocol, and (B) following such review by the Non-Proposing Party’s JSC members, the
Proposing Party shall provide the final proposed design and projected costs of such Additional Study to the Non-Proposing Party’s JSC members. In any such case the following shall apply: 

(a) If the Non-Proposing Party, through its members of the JSC, agrees to co-fund such Additional Study or subsequently elects to exercise a Co-Co Buy-In pursuant to Section 3.4, the Parties shall amend
the Development Plan and the Development Budget to include such Additional Study, and, subject to Section 3.4, the Direct Costs of such Additional Study that constitute Development Costs, Manufacturing Costs or other Allowable Expenses shall be
included for the purposes of calculating the Profit & Loss Share. 
 (b) If the
Non-Proposing Party does not wish to include costs incurred with respect to such proposed Additional Study as Development Costs, Manufacturing Costs and other Allowable Expenses subject to the
Profit & Loss Share, but the Non-Proposing Party has no material objection to such Additional Study, the Proposing Party may proceed with such Additional Study and would be solely responsible for the
conduct and costs of such study, subject to Section 3.3(c) and Section 3.4. In such case, the Non-Proposing Party would have no rights to use any resulting data (including any Shared Product Data),
except as set forth in Section 3.5(b) with respect to safety information required to be filed with the applicable Regulatory Authorities, in any such filings with Regulatory Authorities in the territory for which such non-funding Party is the Lead Party, unless and until a Co-Co Buy-In occurs as set forth in Section 3.4, or a Deemed Buy-In occurs pursuant to Section 3.3(c). In the event that Celgene is the Non-Proposing Party, Celgene agrees to sell to Vividion sufficient quantities of the Shared
Product to conduct the applicable Additional Study at a price equal to Celgene’s cost pursuant to the terms of a supply arrangement to be mutually agreed between the Parties. 

(c) If (i) the Non-Proposing Party does not wish to
co-fund an Additional Study, include an Additional Study as a Development Cost, Manufacturing Cost or other Allowable Expense (for the purposes of calculating the Profit & Loss Share), or to exercise
a Co-Co Buy-In for such Additional Study pursuant to Section 3.4 prior to the initiation of (A) a Pivotal Clinical Trial or (B) a Phase III Study of such
Shared Product for the Indication, formulation, dosage form 

  
 - 23 - 

 or other attribute of such Shared Product that was the subject of such Additional Study and if the data from
such Additional Study thereafter is included as primary efficacy data (and not solely safety data) in the Regulatory Approval for such Indication, formulation, dosage form or other attribute of such Shared Product, or informs a reimbursement
decision, in Australia, Austria, Belgium, Brazil, Bulgaria, Croatia, Canada, China, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Latvia, Lithuania,
Luxembourg, Malta, the Netherlands, New Zealand, Norway, Poland, Portugal, Russia, San Marino, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, the United Kingdom or the United States (each, an “Additional Study
Approval”), then such Non-Proposing Party shall be deemed to have elected to buy in to such Additional Study (a “Deemed Buy-In”), and shall pay
to the Proposing Party for such Additional Study a lump sum payment (“Lump Sum”) equal to [***] percent ([***]%) of the Direct Costs that otherwise would have been apportioned to the
Non-Proposing Party as Development Costs, Manufacturing Costs or other Allowable Expenses had such Non-Proposing Party originally
opted-in, to conduct such Additional Study prior to the Deemed Buy-In. For example, [***]. The Non-Proposing Party
shall pay to the Proposing Party the Deemed Buy-In amounts set forth in this Section 3.3(c) within [***] days after the Proposing Party notifies the Non-Proposing
Party in writing that the Proposing Party has received Additional Study Approval. 
 (d) If the
Non-Proposing Party elects to co-fund an Additional Study, or elects to exercise a Co-Co
Buy-In pursuant to Section 3.4, or is subject to a Deemed Buy-In as set forth in Section 3.3(c), then following the
Non-Proposing Party’s decision to co-fund, or following such Co-Co Buy-In, or Deemed
Buy-In, as applicable, all data resulting from such Additional Study (including any Shared Product Data) shall be available for use (i) by the Non-Proposing Party
in any territory for which it is the Lead Party, and (ii) by both Parties in the Territory to perform activities allocated to each such Party in the Development Plan or otherwise as set forth in this Agreement. 

(e) For clarity, the costs of any Additional Study shall never be included as Development Costs, Manufacturing Costs or other Allowable
Expenses or be subject to the Profit & Loss Share (and the Non-Proposing Party shall have no rights to any Shared Product Data arising from any such Additional Study) unless and until (i) the Non-Proposing Party agrees to pay such costs pursuant to Section 3.3(a); (ii) a Co-Co Buy-In occurs pursuant to Section 3.4;
or (iii) a Deemed Buy-In occurs pursuant to Section 3.3(c). 
 Section 3.4 Buy-In Right. Notwithstanding Section 3.3(b) above, and subject to Section 3.3(c), at any time prior to the initiation of the earlier of (a) a Pivotal Clinical Trial or (b) a Phase III Study
of an applicable Shared Product for the Indication, formulation, dosage form or other attribute of such Shared Product that was the subject of an Additional Study which the Non-Proposing Party declined
previously to co-fund or for which a Deemed Buy-In has not yet occurred, the Non-Proposing Party shall have the right to elect by
written notice to the Proposing Party to include Development Costs, Manufacturing Costs and other Allowable Expenses, for the 

  
 - 24 - 

 purposes of calculating the Profit & Loss Share, incurred in conducting any Additional Study for
Shared Products for which the Non-Proposing Party declined previously to co-fund and for which a Deemed Buy-In has not yet
occurred (the “Co-Co Buy-In”). In such case, (x) the Parties shall include within the Development Costs, Manufacturing Costs or other Allowable
Expenses (subject to the Profit & Loss Share) from the day of such notice onward [***], and (y) the Non-Proposing Party shall reimburse the Proposing Party an amount equal to [***] percent
([***]%) of the Direct Costs that otherwise would have been apportioned to the Non-Proposing Party if the Non-Proposing Party had originally opted-in, to conduct such Additional Study prior to the Co-Co Buy-In. For example, [***]. Upon any such Co-Co Buy-In, the Parties shall have the rights with respect to such Clinical Trial or studies and the data arising therefrom as set forth in Section 3.3(d) and
Section 3.5. If the Non-Proposing Party elects a Co-Co Buy-In, it shall pay to the Proposing Party the Co-Co Buy-In amounts set forth in subsection (y) within [***] days after the Non-Proposing Party notifies the Proposing Party in
writing that the Non-Proposing Party is exercising its right to effect the Co-Co Buy-In pursuant to this Section 3.4 and,
for clarity, from and after any Co-Co Buy-In, the ongoing Direct Costs incurred for such Additional Study that constitute Development Costs, Manufacturing Costs or other
Allowable Expenses shall be subject to the Profit & Loss Share. 
 Section 3.5 Rights to Use Shared Product Data. 

(a) Each Party, in a given country for Development or Commercialization of Shared Products in such country, shall keep accurate records of all
Shared Product Data generated as a result of all activity by or on behalf of such Party in performing Development and Commercialization in relation to Shared Products and Companion Diagnostics, including any data generated pursuant to the
Party’s activities under Section 3.3. Except as provided in Section 3.3(b) and Section 3.3(e), each Party shall provide the other Party with copies of all such Shared Product Data Controlled by the Party during the Term that is
necessary for or reasonably related to the Development and Commercialization of Shared Products and Companion Diagnostics promptly following the generation of such Shared Product Data. Shared Product Data Controlled by the applicable Lead Party
(other than that to which the Non-Proposing Party does not have rights pursuant to Section 3.3(b) and Section 3.3(e)) shall be included in the license grant to the
non-Lead Party pursuant to Section 8.1(a) or Section 8.1(b), as applicable, and Shared Product Data Controlled by the non-Lead Party shall be included in the
license grant to the Lead Party pursuant to Section 8.1(a) or Section 8.1(b), as applicable. 
 (b) Notwithstanding anything to the
contrary in this Agreement, each Party shall promptly provide to the other Party, free of charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party, and that is relevant to or necessary to
address issues relating to: (i) the safety of Shared Products in the Territory, including data that is related to adverse effects experienced with Shared Products, or (ii) all activities relating to CMC regarding Shared Products, and in
each of (i) and (ii), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available. 

  
 - 25 - 

 Section 3.6 Companion Diagnostics. 

(a) Development of Companion Diagnostic. The Parties may mutually agree to Develop or Commercialize a Companion Diagnostic for use with
the Shared Products; provided that, in the event the Parties do not agree to jointly Develop or Commercialize a Companion Diagnostic, the JDC may permit a Party to Develop, Manufacture or Commercialize a Companion Diagnostic for use
with Shared Products in the Territory, directly or indirectly through a Third Party Contractor. In such event, all costs and profits with respect to such Development, Manufacturing or Commercialization of the Companion Diagnostic (as Developed,
Manufactured and Commercialized in accordance with this Section 3.6(a)) shall be shared by the Parties in accordance with the Profit & Loss Share, pursuant to a mechanism agreed to by the Parties at the time the Parties agree or the
JCD permits a Party to Develop, Manufacture or Commercialize the applicable Companion Diagnostic. 
 (b) Separate Obligations. No
payments shall be owed by Celgene to Vividion pursuant to Section 9.2 or Section 9.4 or by either Party pursuant to Section 14.4 with respect to any Companion Diagnostic. Upon termination of this Agreement, or reversion of rights to a
Party with respect to the Shared Products, in addition to the effects of such termination or reversion set forth in Section 14.4, separate transitional activities shall be undertaken with respect to the Companion Diagnostics to ensure that the
appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostics shall be transferred to the
Party to whom the rights to the Shared Products are transferred to the same extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Shared Products
are transferred. 
 (c) No Other Diagnostics. For purposes of clarity, unless otherwise mutually agreed by the Parties, neither Party
shall have any right, under the licenses granted to such Party pursuant to Section 8.1 and notwithstanding the definition of “Field” hereunder, to Develop, Manufacture or Commercialize any biomarker or diagnostic product for
use with the Shared Products, other than a Companion Diagnostic pursuant to this Section 3.6. 
 Section 3.7 Records; Tech
Transfer. 
 (a) Maintenance of Records. Each Party shall maintain in all material respects, and shall require its Licensee
Partners and Third Party Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted in furtherance of the Collaboration and all results, data and developments made in
conducting such activities. Such records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.
Each Party shall require the applicable study sites to maintain original source documents from Clinical Trials of the Shared Products for at least [***] years (or such longer period as is commercially reasonable under the circumstances, taking into
account maintenance requirements under applicable Law) following completion of the Development activities undertaken by such Party or its Licensee Partners or Third Party Contractors; provided that Celgene or Vividion shall be entitled
to obtain copies of such source documents at the end of such [***]-year period. 

  
 - 26 - 

 (b) Inspection. Each Party shall have the right, during normal business hours and
upon reasonable notice, to inspect and copy (or request the other Party to copy) all records of the other Party or its Licensee Partners or Third Party Contractors, as applicable, maintained in connection with the work done and results achieved in
the performance of Development activities under the Collaboration, but solely to the extent access to such records is necessary for such Party to exercise its rights under this Agreement. 

(c) Tech Transfer. As soon as reasonably practical after the Effective Date and thereafter upon Celgene’s reasonable request during
the Term, Vividion shall transfer to Celgene, at no cost to Celgene, copies of all Vividion Know-How, Vividion Co-Co Collaboration
Know-How and Vividion’s interest in the Joint Co-Co Know-How related to the Shared Products, to the extent not previously
transferred to Celgene. Upon Vividion’s reasonable request during the Term, Celgene shall transfer to Vividion, at no cost to Vividion, copies of all Celgene Know-How, Celgene Co-Co Collaboration Know-How and Celgene’s interest in the Joint Co-Co Know-How related to
the Shared Products, to the extent not previously transferred to Vividion. In addition, each Party shall provide reasonable assistance, including making its personnel reasonably available for meetings or teleconferences to answer questions and
provide technical support to the other Party with respect to the use of such transferred Know-How in the Development, Manufacture and Commercialization of Shared Products. The costs and expenses incurred by
either Party in connection with such assistance shall constitute Allowable Expenses. 
 Article IV 

Manufacture and Supply 

Section 4.1 Generally. Subject to the terms and conditions of this Agreement, Celgene will assume sole responsibility for
Manufacture of the Shared Products and Companion Diagnostics for Development and Commercialization in the Territory for both U.S. Administration and ROW Administration. 

Section 4.2 Manufacturing Transition Costs. All Manufacturing Costs associated with Manufacturing Shared Products (including
Manufacturing Transition Costs) shall be shared by the Parties in accordance with the Profit & Loss Share. 
 Article V 

Regulatory Matters 

Section 5.1 Lead Responsibility for Regulatory Interactions. Except as may otherwise be mutually agreed by the Parties or the JSC,
JDC or JCC, as applicable, and subject to oversight by the JSC, JDC or JCC: 
 (a) Lead Responsibility. 

(i) US Territory. The Lead US Party shall have lead responsibility for all Regulatory Interactions with Regulatory Authorities in the
US Territory for each Shared Product. 

  
 - 27 - 

 (ii) ROW Territory. Celgene shall have lead responsibility for all Regulatory
Interactions with Regulatory Authorities in the ROW Territory for each Shared Product. 
 (b) Regulatory Interactions Defined. For
purposes of this Agreement, “Regulatory Interactions” means (i) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory
Authorities with respect to the Shared Products and (ii) interfacing, corresponding and meeting with the Regulatory Authorities with respect to the Shared Products. 

(c) Transfer of Regulatory Responsibility. Celgene shall become the Lead Party for Regulatory Interactions for any Shared Product upon a
Vividion Opt-Out Notice being delivered to Celgene. 
 (d) Regulatory Responsibilities. Upon
and after such time that Celgene becomes the Lead Party for Regulatory Interactions for any Shared Product pursuant to Section 5.1(a) or 5.1(c): 

(i) Vividion shall (A) at Celgene’s option, either close or inactivate Vividion’s IND(s) for each Shared Product, or transfer
such IND(s) to Celgene, and (B) with Celgene input, complete all relevant activities related to such IND(s) as required for Celgene to assume regulatory ownership, as applicable, all as soon as practicable (but, in the case of the transfer of
any IND(s), in no event later than [***] days after Celgene’s notice unless otherwise agreed by the Parties); 
 (ii) Celgene shall be
responsible for the preparation and filing of all regulatory filings with respect to any subsequent Development, Manufacturing or Commercialization for Shared Products after such activities described in clause (i) above are completed; and 

(iii) subject to Section 3.3 and Section 3.4, Vividion shall provide Celgene with all relevant clinical and non-clinical data reasonably requested by Celgene or a Regulatory Authority, including CMC, pharmacology and toxicology generated by Vividion with respect to each Shared Product. 

Section 5.2 Participation Rights. 

(a) Review of Regulatory Documentation. Each Party shall keep the JDC reasonably informed in connection with all Regulatory
Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, Regulatory Approvals, annual reports, including annual safety reports to the respective health authorities, annual re-assessments, and any subsequent variations and changes to labeling, in each case with respect to the Shared Products. Each Party shall respond within a reasonable time frame to all reasonable inquiries by the
other Party with respect to any information provided pursuant to this Section 5.2(a) (and sufficiently promptly for the other Party to provide meaningful input with respect to responses to Regulatory Authorities). 

  
 - 28 - 

 (b) Participation in Meetings. The Party not having the lead responsibility for
Regulatory Interactions in a country with respect to the Shared Products shall have the right to have up to two (2) senior, experienced employees reasonably acceptable to the responsible Party participate as observers in material or scheduled face-to-face meetings, video conferences and teleconferences with all applicable Regulatory Authorities relating to any Shared Product, and shall be provided with advance
access to the responsible Party’s material documentation prepared for such meetings. 
 (c) Review. Prior to submission of
material correspondence to any Regulatory Authority with respect to the Shared Products, the Party having the lead responsibility for Regulatory Interactions shall, sufficiently in advance for the other Party to review and comment, provide the other
Party any material correspondence with the Regulatory Authority related to such meetings. The responsible Party shall also provide the other Party with copies of any material correspondence with Regulatory Authorities relating to Development of, or
the process of obtaining Regulatory Approval for, the Shared Products and respond within a reasonable time frame to all reasonable inquiries by the other Party with respect thereto. 

Section 5.3 Global Safety Database; Pharmacovigilance Agreement. At a time to be mutually agreed by the Parties, the Lead US Party
shall establish, hold and maintain a single electronic system for the collection and storage of all safety information for the Shared Products in the Territory (the “Global Safety Database”). Such database shall comply in all
material respects with all Laws reasonably applicable to pharmacovigilance anywhere where the Shared Products are being or have been Developed or Commercialized. Unless the Parties otherwise agree in the Pharmacovigilance Agreement, the Lead US
Party shall initially be responsible for the Global Safety Database for the Shared Products and the other Party shall assume control on a Shared Product-by-Shared
Product basis following the transfer, if any, of lead responsibility for Regulatory Interactions in the US Territory for such Shared Product to the other Party. The Party not maintaining the Global Safety Database may hold and maintain a parallel
safety database for the Shared Products as needed or required according to applicable Laws. The Parties will use Commercially Reasonable Efforts to negotiate a pharmacovigilance agreement (the “Pharmacovigilance Agreement”) to
govern cooperation among the Parties that will enable each of them to comply with its respective obligations under applicable Laws and to satisfy its duty of care with respect to the Shared Products, including with regard to ownership of the Global
Safety Database, adverse event data collection, analysis and reporting. The Pharmacovigilance Agreement will be entered among the Parties no later than [***] days following the Effective Date. 

Section 5.4 Recalls, Market Withdrawals or Corrective Actions. 

(a) In the event that any Regulatory Authority issues or requests a recall, market withdrawal or similar action in connection with a Shared
Product in any portion of the Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall, market withdrawal or similar action in any country in the Territory, the
Party notified of such recall, market withdrawal or similar action, or the Party that desires such recall, market withdrawal or similar action, shall within twenty-four (24) hours advise the other Party thereof by telephone. The Lead Party
shall, after reasonable consultation with the other Party, decide whether to conduct a recall, market withdrawal or similar action in its applicable portion of the Territory and the manner in which any such recall, market withdrawal or similar
action shall be conducted. Each Party will make available to the other Party, upon request, all of such Party’s (and its Affiliates’) pertinent records that such other Party may reasonably request to assist such other Party in effecting
any recall, market withdrawal or similar action. 

  
 - 29 - 

 (b) The costs and expenses incurred before the Vividion
Opt-Out Date relating to a recall, market withdrawal or similar action of any Shared Product(s) in the Territory shall be taken into account in determining the Profit & Loss Share (as, and to the
extent, provided in Section 9.1, Section 9.3 and Exhibit D). The costs and expenses incurred after the Vividion Opt-Out Date for any recall, market withdrawal or similar action of any Shared
Product(s) in the Territory shall be borne solely by Celgene if and only to the extent (i) such recall, market withdrawal or similar action was caused by the occurrence after the Vividion Opt-Out Date of
the event, incident or circumstance that led to the recall, market withdrawal or similar action and (ii) the event, incident or circumstance and the costs and expenses for such recall, market withdrawal or similar action are not the subject of
an indemnity obligation of Vividion under Section 13.2. The costs and expenses incurred after the Vividion Opt-Out Date relating to any recall, market withdrawal or similar action of any Shared Product(s)
shall be borne by the Parties in accordance with the Profit & Loss Share to the extent (A) such recall, market withdrawal or similar action was caused by the occurrence before the Vividion
Opt-Out Date of the event, incident or circumstance that led to the recall, market withdrawal or similar action and (B) such event, incident or circumstance and such costs and expenses are not the subject
of an indemnity obligation of either Party under Section 13.1 or Section 13.2. If Vividion is invoiced for its portion of such costs and expenses incurred after the Vividion Opt-Out Date, payment is
due within [***] days of receipt of invoice. 
 Article VI 

Commercialization 

Section 6.1 Commercialization Responsibilities for Shared Products. 

(a) Responsibility. Subject to the terms and conditions of this Agreement, each Party shall have the responsibilities for the
Commercialization of Shared Products as specified in the Commercialization Plan. Subject to the foregoing and the remainder of this Article VI, the applicable Lead Party in each of the US Territory and the ROW Territory shall have primary
responsibility and final decision-making authority for Commercialization of Shared Products in the US Territory and the ROW Territory, respectively, in accordance with Section 2.2. The non-Lead Party
(itself or by or through any others, including any Affiliates or (sub)licensees), will not take any action regarding the Commercialization of Shared Products unless (i) described in the Commercialization Plan or (ii) otherwise approved by
the JCC. 
 (b) Sales. The applicable Lead Party will book all sales of the Shared Products in the US Territory and the ROW Territory,
respectively, and will have the sole responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Shared Products throughout the US Territory and the ROW Territory, respectively, associated therewith. 

  
 - 30 - 

 Section 6.2 Commercialization Plan. 

(a) Initial Commercialization Plan. No later than [***] months prior to the anticipated submission of the first NDA for the first Shared
Product (as set forth in the Development Plan) for Regulatory Approval from the FDA in the US Territory or any other Regulatory Authority in the ROW Territory, as applicable, the applicable Lead Party (after good faith consultation with the other
party) will prepare its portion of an initial Commercialization plan for the US Territory and ROW Territory (the “Commercialization Plan”) for Shared Products covering the first [***] years after First Commercial Sale of any Shared
Product in such Party’s territory, and the JCC will review and approve such initial Commercialization Plan. Thereafter, the Lead Party (after good faith consultation with the other Party) will update the applicable portion of the
Commercialization Plan (for the current Calendar Year and the [***] succeeding Calendar Years) each Calendar Year, and the JCC will review and approve any such update or other amendment to the Commercialization Plan. Either Party may request at any
time that the JCC consider and approve other updates to the Commercialization Plan. 
 (b) Additional Terms. In addition: 

(i) The JCC will set the required form and contents of the Commercialization Plan. The Commercialization Plan will specify, as applicable,
among other things, the number of sales representatives in the US Territory for each Party, creation of marketing and promotional materials, planning for conferences, the number, type (e.g., first position, second position) and frequency of details
to be conducted by sales representatives for Shared Products in each Calendar Year, the allocation of sales details across geographies between the Parties, sales forecasts, strategies for compensation packages for sales representatives, Shared
Product pricing strategy, strategy for managed care and reimbursement plans; it being understood and agreed that, pursuant to Section 6.3, Celgene shall specify the form and contents of the Commercialization Plan for the ROW Territory. The non-Lead Party will have the right to provide up to [***] percent ([***]%) of the total sales representatives and medical science liaisons in the US Territory, calculated on an FTE basis (with the calculation of
costs of engaging such FTEs for purposes of calculating Operating Profits or Losses being based on the FTE Rate), such basis to be used by both Parties for promotion of Shared Products for U.S. Administration. The Commercialization Plan will set
forth the precise number of non-Lead Party sales representatives and medical science liaisons in the US Territory consistent with the foregoing. 

(ii) The Commercialization Plan will attempt to provide that marketing activities in the US Territory are distributed equitably (with respect
to geography and prescriber opportunities) between the Parties. 
 (iii) Neither Party (itself or by or through any others, including any
Affiliates or (sub)licensees) will take any material action regarding the Commercialization of Shared Products unless described in the Commercialization Plan or approved by the JCC. 

(iv) All Commercialization of Shared Products will be conducted pursuant to the overview of the JCC and pursuant to the Commercialization
Plan. 
 (c) Commercialization Budget. At such times as the JCC will deem appropriate, and concurrently with the preparation of the
initial Commercialization Plan, each Lead Party (after good faith consultation with the non-Lead Party) will prepare its portion of an 

  
 - 31 - 

 initial Commercialization budget (collectively, the “Commercialization Budget”), and the
JCC will review and approve such initial Commercialization Budget; it being understood and agreed that, pursuant to Section 6.3, Celgene shall specify the form and contents of the Commercialization Budget for the ROW Territory. Thereafter, the
applicable Lead Party (after good faith consultation with the non-Lead Party) will update its portion of the Commercialization Budget at least once in each Calendar Year, (but in any event no later than
November 30 of each Calendar Year during the Term) and the JCC will review and approve any such update or any other amendment to the Commercialization Budget. In addition, either Party may request at any time that the JCC consider and approve
other updates to the Commercialization Budget. 
 Section 6.3 ROW Commercialization; Celgene Reports. For the avoidance of
doubt, and notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that Celgene has the sole right and responsibility for the Commercialization of the Shared Products for the ROW Territory and, except as
expressly set forth in this Agreement, and subject to the terms and conditions of this Agreement and the Master Agreement, nothing will restrict Celgene from taking any action regarding the Commercialization of the Shared Products in the ROW
Territory. As part of the JCC, Celgene shall provide to Vividion updates on the status of its material Commercialization activities with respect to Shared Products and related Companion Diagnostics in the ROW Territory, and Celgene’s plans with
respect to Commercialization of Shared Products and related Companion Diagnostics. Notwithstanding the foregoing, following any Vividion Opt-Out Date, Celgene shall instead provide to Vividion an [***] written
progress report on the status of its material Commercialization activities with respect to Shared Products and related Companion Diagnostics in the Territory, and Celgene’s plans with respect to Commercialization of Shared Products and related
Companion Diagnostics in the Territory. 
 Section 6.4 Acknowledgement. Vividion hereby acknowledges and agrees that (a) it
has rights with respect to the Commercialization of Shared Products for U.S. Administration solely as set forth herein; (b) it will not convey, transfer, license or lease any of its rights or obligations under this Agreement, except as
expressly permitted in this Agreement, including as set forth in Section 8.2, Section 12.4 or Section 15.4. 

Section 6.5 Commercialization Activities. 

(a) Training. In the US Territory and pursuant to the overview of the JCC, the Lead US Party shall, and in the ROW Territory, Celgene
shall (i) direct the training of sales representatives (together with the first line managers who oversee such sales representatives) with respect to Shared Products, and will prepare and implement a training program and training materials for
such sales representatives therefor, and (ii) specify the conduct and content of details (including detail scripts) for the Shared Products. Each Party will cause each of its sales representatives assigned to promote the Shared Products to
attend and complete the training program developed as provided above for the Shared Products to assure a consistent, focused promotional strategy and message as and to the extent consistent with applicable Law. 

(b) Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to
Commercialization of Shared Products: 

  
 - 32 - 

 (i) Conduct of Sales Representatives. Each Party will be solely responsible for
recruiting, hiring and maintaining its sales force of sales representatives for promotion of the Shared Products in accordance with its standard procedures, the requirements of this Agreement and the minimum qualifications set forth on Schedule
6.5. Each Party will be responsible for the activities of its sales representatives, including compliance by its sales representatives with training and detailing requirements. In particular, each Party will provide its sales representatives
assigned to promote the Shared Products in the US Territory and the other Major Markets with the level of oversight, management, direction and sales support with respect to the promotion of Shared Products necessary to effectively and efficiently
promote the Shared Products in accordance with the terms of this Agreement and applicable Law. Each Party agrees that none of its sales representatives involved in the promotion of the Shared Products will have any legal or regulatory
disqualifications, bars or sanctions. 
 (ii) Third Party Contract Sales Force. Notwithstanding the foregoing and solely with respect
to the US Territory, the non-Lead US Party will not have the right to use any Third Party contract sales force to fulfill its activities under this Agreement, except with the prior written consent of the Lead
US Party, not to be unreasonably withheld or delayed (provided that the Lead US Party may withhold or revoke its consent, with respect to all Shared Products, for any reason during the [***] months following First Commercial Sale in the US Territory
upon reasonable written notice to the non-Lead US Party). 
 (iii) Detailing. The
Commercialization Plan will set forth (A) the precise number of each Party’s sales representatives for Shared Products in the US Territory, (B) policies and processes for the creation of marketing and promotional materials,
(C) planning for conferences, (D) the number, type (e.g., first position, second position, etc.) and frequency of details to be conducted by sales representatives for Shared Products in each Calendar Year, (E) the allocation of sales
details between the Parties, (F) development of sales forecasts, and (G) coordinating strategies for compensation packages for sales representatives. 

(iv) Shortfall. If the non-Lead US Party does not initially provide in the US Territory or at
any particular time after the commencement of such detailing does not provide in the US Territory, for any reason, the number of sales representatives specified in the Commercialization Plan to be provided for the US Territory, then the Lead US
Party will have the right to make up such shortfall using its sales representatives until such time as the non-Lead US Party is able to provide its agreed upon number of sales representatives and for a period
of one hundred eighty (180) days thereafter, and, for clarity, all costs incurred by the Lead US Party related to its making up such shortfall shall be included in the calculation of Operating Profits or Losses. 

(v) Cost Calculation. The calculation of costs of engaging sales representatives in the Territory for purposes of calculating Operating
Profits or Losses shall be based on the FTE Rate, and such FTE Rate shall be used by both Parties for promotion of Shared Products in the Territory; provided, however, that (A) if the costs of engaging a sales
representative (whether or not as an employee) is (x) above the FTE Rate, the costs shall be capped at the FTE Rate and (y) below the FTE Rate, the actual costs shall be used instead of the FTE Rate; and (B) with respect to any sales
representative who is detailing pharmaceutical products other than Shared Products, the applicable Party shall allocate costs of engaging such sales representative with 

  
 - 33 - 

 respect to such pharmaceutical products and Shared Products based on the weighted Incentive Compensation of
such sales representative. For purposes of this Section 6.5(b)(v), “Incentive Compensation” means, with respect to a sales representative, the variable, periodic target compensation (not including equity compensation) the sales
representative earned based on such sales representative’s performance. 
 (vi) Promotional Materials. Each Party’s sales
representatives assigned to promote the Shared Products in the US Territory will utilize only promotional materials that have been reviewed by the JCC and approved by the Lead US Party. All detailing activities conducted by each Party’s sales
representatives will be consistent in all material respects with the promotional materials so approved. Each Party will train and instruct their respective sales representatives to make only those statements and claims regarding the Shared Products,
including as to efficacy and safety, that are consistent with the Shared Product labeling and accompanying inserts and the approved promotional materials. For clarity, all marketing and promotional materials used in the US Territory must be approved
by the Lead US Party prior to use. 
 (vii) Medical Affairs; Information. For Shared Products in the US Territory, the Parties will
discuss the implementation of medical and scientific affairs and programs, including for professional symposia and other educational activities, and medical affairs studies based upon approved protocols, medical information support and medical
communications and publishing activities, and the allocation of each Party to such activities in the US Territory, provided that the Lead US Party, following consultation with the JCC, shall have the final decision-making authority to the conduct of
such activities in the US Territory (it being understood and agreed that [***] shall be permitted to contribute [***] percent ([***]%) of the medical science liaisons on an equitable basis in the US Territory). The Parties acknowledge that in the US
Territory each Party may receive requests for medical information concerning any Shared Product from members of the medical professions and consumers. Celgene will have the exclusive right to respond to questions and requests for information about
Shared Products received from Persons in the Territory that warrant a response beyond the understanding of the sales representatives or that are beyond the scope of the Shared Product labels and inserts (each such request, an “Information
Request”) and that are solely applicable to Shared Products for ROW Administration. Any Information Request that is applicable to Shared Products for U.S. Administration or throughout the Territory shall be referred to the JCC. 

(viii) Market Access Activities. The Lead US Party, in the US Territory, and Celgene, in the ROW Territory, will have sole authority,
following consultation with the JCC, to develop plans for market access activities. For Shared Products in the US Territory, each Party shall have the right to participate in the foregoing activities in accordance with the Commercialization Plan,
which shall provide for an equitable distribution of such activities between the Parties. The costs related to such market access activities shall be included, to the extent they constitute Allowable Expenses, in the calculation of Operating Profits
or Losses. 
 (ix) Reporting. Each Party will provide the JCC with a report, as soon as practicable but in no event later than [***]
days following the end of each Calendar Quarter commencing as of the date upon which the first Shared Product has received Regulatory Approval in the Territory, or at such other time as the JCC deems appropriate, and continuing thereafter for each
Calendar Quarter for the remainder of the Term, setting forth the 

  
 - 34 - 

 number of details made by its sales representatives of Shared Products during such Calendar Quarter. Costs
and expenses for sales representatives will be charged to the Profit & Loss Share on an FTE Rate basis consistent with the Commercialization Budget. 

(x) Records. Each Party will maintain records and otherwise establish procedures to ensure compliance with all applicable Laws and
professional requirements that apply to the promotion and marketing of Shared Products, including compliance with the PhRMA Code on Interactions with Healthcare Professionals. 

(c) Commercialization Costs. During the Term, all Commercialization costs in the Territory that constitute Allowable Expenses and are
incurred pursuant to the Commercialization Plan and Commercialization Budget (the “Commercialization Costs”) shall be included in the Profit & Loss Share. 

Section 6.6 Trademarks. 

(a) Selection of Trademarks. The applicable Lead Party, following consultation with the JCC and JPC, shall select the trademark(s) to be
used in connection with the marketing and sale of the Shared Products in the Territory (such marks, together with registrations, applications for registration and common law rights therein, collectively, “Product Trademarks”). Any
dispute over the selection of a Product Trademarks shall be presented to the JSC for resolution. The Parties shall adhere to the use of the Product Trademark(s) in their Commercialization of the Shared Products in the Territory hereunder, to the
extent permitted by Law. 
 (b) Ownership. The applicable Lead Party shall own all Product Trademarks for any Shared Product in its
portion of the Territory. Effective as of the Vividion Opt-Out Date, if Vividion is the Lead US Party under this Agreement, it hereby assigns to Celgene all right, title and interest in and to the Product
Trademarks in the Territory that are owned by Vividion and its Affiliates free and clear of any liens and encumbrances. Vividion will execute and deliver any further document reasonably requested by Celgene to further document or record such
assignment. 
 (c) Branding. At such time as the JCC deems appropriate, the Parties shall discuss in good faith any branding or co-branding of the Shared Products (the “Licensed Branding”), and the Parties will enter into appropriate trademark licensing agreements to achieve the foregoing. For the avoidance of doubt, nothing
in this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s trademarks, tradenames, logos, or other marks (other than Product Trademarks), including use thereof, absent a separate trademark licensing
agreement entered into by the Parties. Notwithstanding the foregoing, subject to any restrictions on the form or content of the Licensed Branding imposed by any Regulatory Authority, unless the Parties mutually agree otherwise in writing, the
Licensed Branding used with respect to Shared Products shall feature the logos of Vividion and Celgene with approximately equal sizing and similar prominence, with the Lead Party’s name first, on all packaging and materials used for
Commercialization of such Shared Products, to the extent permitted by applicable Law. 

  
 - 35 - 

 Article VII 

Diligence 

Section 7.1 Collaboration Activities. 

(a) General. Each Party shall use Commercially Reasonable Efforts to perform all Development, Manufacturing and Commercialization
activities for which such Party is responsible hereunder and, as applicable, shall perform such activities in compliance with the applicable Development Plan or Commercialization Plan, including any budget(s) and timeframe(s) set forth therein and
including making available those resources set forth in any applicable Development Plan or Commercialization Plan, and the terms of this Agreement. 

(b) Compliance with Laws. Each Party shall: 

(i) perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and 

(ii) carry out all work done in the course of the Collaboration in compliance with all applicable Laws governing the conduct of such work.

 Section 7.2 Diligence Obligations. In addition to the diligence obligations set forth in Section 7.1, the Parties
(directly or through one or more Affiliates or Licensee Partners) shall, as applicable, use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Shared Products in each of the Major Markets and, following such
Regulatory Approval, to Commercialize such Shared Products in each of the Major Markets. 
 Section 7.3 Day-to-Day Responsibility. Each Party shall be responsible for day-to-day implementation of
the Development, Manufacturing and Commercialization activities for which it (or its Affiliate) has been, or otherwise is, assigned responsibility under this Agreement or the applicable Development Plan or Commercialization Plan and shall keep the
other Party reasonably informed as to the progress of such activities, as determined by the JDC and JCC. 
 Article VIII 

Grant of Rights; Exclusivity 

Section 8.1 License Grants. Subject to the terms and conditions of this Agreement: 

(a) License Granted to Celgene. During the Term, subject to the terms and the conditions set forth in this Agreement and the Master
Agreement, Vividion hereby grants to Celgene the following licenses: 
 (i) in the Territory, a
co-exclusive (with Vividion and its Affiliates and (sub)licensees) license, with the right to grant sublicenses (subject to Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and Vividion’s interest in the Manufacturing Technology to Develop, use, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion
Diagnostics; provided, however, that, as to Companion Diagnostics, such license grant shall be limited to Developing, using, offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as
companion diagnostics with Shared Products under this Agreement; and 

  
 - 36 - 

 (ii) in the Territory, an exclusive (even as to Vividion and its Affiliates) license, with
the right to grant sublicenses (subject to Section 8.2 and Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and Vividion’s
interest in the Manufacturing Technology to Manufacture and have Manufactured the Shared Products and Companion Diagnostics; provided, however, that, as to Companion Diagnostics, such license grant shall be limited to
Manufacturing and having Manufactured Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

(b) License Granted to Vividion. During the Term, subject to the terms and the conditions set forth in this Agreement and the Master Agreement,
Celgene hereby grants to Vividion the following licenses (in addition to the covenant not to sue contained in Section 12.7): 
 (i) a non-exclusive, worldwide, royalty-free, fully-paid right and license, with the right to grant sublicenses (subject to Section 8.3), under the Celgene Co-Co Collaboration
Intellectual Property, solely (A) in the event Celgene requests Vividion to perform activities with respect to the Shared Products or Companion Diagnostics (including pursuant to Section 3.1), and in the event Vividion agrees to perform
such activities, in accordance with the terms and conditions of this Agreement and (B) to the extent required to permit Vividion to conduct such activities (if any); provided, however, that, as to Companion Diagnostics,
such license grant shall be limited to performing such activities with respect to Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement; and 

(ii) in the Territory, a co-exclusive (with Celgene and its Affiliates and (sub)licensees),
royalty-free, fully-paid right and license, with the right to grant sublicenses (subject to Section 8.2 and Section 8.3) under and to the Celgene Co-Co Collaboration Intellectual Property to Develop
and use the Shared Products and Companion Diagnostics and to offer for sale, sell, import, and otherwise Commercialize the Shared Products and Companion Diagnostics for U.S. Administration; provided, however, that, as to
Companion Diagnostics, such license grant shall be limited to Developing, offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

Section 8.2 Sublicense Rights. Subject to Section 8.3, the Parties have the following sublicensing rights. 

(a) Sublicenses to Affiliates and Subcontractors. Each Party shall have the right to grant sublicenses within the scope of the licenses
and sublicense under Section 8.1: 
 (i) to such Party’s Affiliates; and 

(ii) to Third Parties for the purpose of (X) with respect to Celgene, Commercializing, outside of the US Territory, France, Germany,
Italy, Spain and the United Kingdom, any Shared Product or related Companion Diagnostic or (Y) engaging Third Parties as contract research organizations, contract manufacturers, contract sales forces, consultants, 

  
 - 37 - 

 academic researchers and the like (“Third Party Contractors”) in connection with
Development, Manufacturing or Commercialization activities throughout the Territory (to the extent such Party is permitted to engage in such activities in any applicable country) on behalf of such Party or its Affiliates with respect to the
Collaboration under this Agreement, subject to the following: 
 (A) unless otherwise mutually agreed by the Parties, each Party shall
require any such Third Party to whom such Party discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of confidentiality and restrictions on use of such Confidential
Information that are no less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in compliance with the terms of this Agreement (including approval
by the JDC or JCC, as applicable, pursuant to the approved publication plan, and the obligations set forth in Section 11.4, except that Publications by academic collaborators shall be permitted (without JDC or JCC consent, as applicable) if the
academic collaborator (i) provides an advance copy of the proposed Publication (under the same time periods as described in Section 11.4(a)), which must be shared with the other Party, (ii) agrees to delay such Publication
sufficiently long enough to permit the timely preparation and filing of a patent application, and (iii) upon the request of either Party, removes from such Publication any Confidential Information of such Party); 

(B) unless otherwise mutually agreed by the Parties, each Party will obligate such Third Party to agree in writing to assign ownership of, or
grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to the extent related to Development, Manufacturing or
Commercialization with respect to the Shared Products in the Field; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party inventions to the other Party pursuant to
Section 8.1 (including permitting such other Party to grant further sublicenses); provided that, in connection with any academic collaborator performing research work with respect to the
Co-Co Target or Shared Products that is not reasonably expected by the applicable Party to result in inventions related to composition of matter or methods of use, it shall be sufficient for such Party to
obtain a non¬exclusive, worldwide, royalty-free, perpetual license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses, to, any inventions resulting from such research
work, which sublicensing rights must permit sublicensing to the other Party pursuant to Section 8.1 (including permitting such other Party to grant further sublicenses); 

(C) each Party shall notify the JDC or JCC, as applicable, at a regular meeting of the JDC or JCC, as applicable, of the execution of any such
agreement with any such Third Party and, if requested, shall provide the other Party with a copy of such agreement, which copy may be redacted with respect to matters that do not relate to the Collaboration; and 

(D) unless otherwise mutually agreed by the Parties, each Party will require any such Third Party to grant to the other Party access to all
confidential protocols and data generated by such Third Party’s work with respect to the Shared Products to the same extent as such other Party’s grant of licenses under Section 8.1, and grant the other Party the right to audit the
records of such Third Party. 

  
 - 38 - 

 (b) Other Sublicenses. Except as provided in Section 8.2(a), any other
sublicense by either Party under the licenses and sublicenses set forth in Section 8.1 shall require the prior written approval of the other Party. 

Section 8.3 Sublicense Requirements. Any sublicense granted by a Party pursuant to this Agreement shall be subject to the
following: 
 (a) each sublicense granted hereunder by a Party or its Affiliates shall be consistent with the requirements of this Agreement;

 (b) any transfer of rights between a Party and its Affiliates shall not be deemed a sublicense by such Party but shall be deemed a direct
license by the other Party to such Party’s Affiliate; it being understood and agreed that such Party shall remain responsible for the activities of its Affiliate; 

(c) a Party’s or its Affiliates’ Licensee Partners or Third Party Contractors shall have no right to grant further sublicenses
without the other Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 
 (d) such
Party shall be primarily liable for any failure by its Affiliates and Licensee Partners and Third Party Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement; and 

(e) such sublicense must be granted pursuant to a written sublicense agreement and, with respect to any sublicense other than a sublicense by a
Party to an Affiliate of such Party, such Party must provide the other Party with a copy of any sublicense agreement entered into under Section 8.2 above within thirty (30) days after the execution of such sublicense agreement;
provided that any such copy may be reasonably redacted to remove any confidential, proprietary or competitive information, but such copy shall not be redacted to the extent that it impairs the other Party’s ability to ensure
compliance with this Agreement. Such sublicense agreement shall be treated as Confidential Information of the sublicensing Party and no copies are required with respect to sublicense agreements with Third Party Contractors. 

Section 8.4 Affiliates and Third Party Contractors. Either Party may exercise its rights and perform its obligations hereunder
itself or through its Affiliates and (sub)licensees. Each Party shall be primarily liable for any failure by its Affiliates and (sub)licensees (including Third Party Contractors) to comply with all relevant restrictions, limitations and obligations
in this Agreement. If either Party desires to use any Person to conduct any of its Development, Commercialization, Manufacture or other Collaboration activities hereunder, such Party must comply with the obligations of Section 8.2(a)(ii)(A)
through (D), even to the extent no sublicense of rights is granted to such Third Party. 
 Section 8.5 Third Party Agreements.

 (a) Acknowledgement. Except as provided in Section 8.5(b) and Section 9.5, each Party acknowledges that Vividion is
responsible for the fulfillment of its obligations under each Existing Third Party Agreement, and each Party is responsible for the fulfillment of its obligations under any Subsequent Third Party Agreement that it enters into, and each Party agrees

  
 - 39 - 

 to fulfill the same obligations, including any provisions necessary to maintain in effect any rights
sublicensed to the other Party hereunder and the exclusive or non-exclusive nature of such rights, as applicable, subject to the other Party’s compliance with its obligations hereunder. 

(b) Incorporation of Certain Provisions. Each Party agrees and acknowledges that Vividion is required to provide to licensors under the
Existing Third Party Agreements, and either Party may be required to provide to licensors under any Subsequent Third Party Agreements, periodic reports relating to the gross sales and Net Sales of Shared Products. Each Party shall keep true and
accurate records and books of account, and open such books and records for inspection by such licensors, for a duration of [***] years from the date of origination of such books or records. Furthermore, each Party acknowledges that the other Party
may be required to share certain reports and copies of sublicense agreements provided hereunder with any licensor under an Existing Third Party Agreement or Subsequent Third Party Agreement, and each Party consents to the sharing of such reports and
such copies of such sublicense agreements to the extent required under such Existing Third Party Agreement or Subsequent Third Party Agreement to the same extent as disclosures are permitted under Section 11.3(b) hereunder; provided
that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party Agreement or Subsequent Third Party Agreement. In addition, each Party acknowledges that the Prosecution, enforcement and
other intellectual property management rights under this Agreement with respect to Patents and other intellectual property licensed under Existing Third Party Agreements or Subsequent Third Party Agreements shall be subject to the terms and
conditions of the applicable Existing Third Party Agreements or Subsequent Third Party Agreements and, in the case of Existing Third Party Agreements or Subsequent Third Party Agreements in which the licensor is an academic institution, other
provisions of such Existing Third Party Agreements or Subsequent Third Party Agreements that are customarily required to be imposed on sublicensees in academic licenses (in no event to include any exclusivity covenant). 

(c) Covenants Regarding Third Party Agreements. Each Party that has entered into an Existing Third Party Agreement or Subsequent Third
Party Agreement (the “Licensing Party”) agrees that during the Term: 
 (i) The Licensing Party shall not modify or amend
any Existing Third Party Agreement or Subsequent Third Party Agreement in any way that adversely affects the other Party’s rights hereunder without the other Party’s prior written consent; 

(ii) The Licensing Party shall not terminate any Existing Third Party Agreement or Subsequent Third Party Agreement, in whole or in part,
without the other Party’s prior written consent; 
 (iii) Subject to Section 9.5, the Licensing Party shall be solely responsible
for, and shall make, all royalty payments, milestone payments, yearly fees, sublicensee fees, Prosecution fees, and all other payments owed to any licensor under and pursuant to any Existing Third Party Agreement or Subsequent Third Party Agreement;

 (iv) The Licensing Party shall not exercise or fail to exercise any of its rights, or fail to perform any of its obligations, under any
Existing Third Party Agreement or 

  
 - 40 - 

 Subsequent Third Party Agreement, where such exercise or failure to exercise or perform would adversely
affect the other Party’s rights hereunder, without the prior written consent of the other Party, including rights with respect to including applicable improvements within the licenses granted under such Existing Third Party Agreement or
Subsequent Third Party Agreement; and, at the reasonable request of the other Party, the Licensing Party shall exercise such rights and make such requests described above as are permitted under such Existing Third Party Agreement or Subsequent Third
Party Agreement; 
 (v) The Licensing Party shall promptly furnish the other Party with copies of all reports and other communications that
the Licensing Party furnishes to any licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent that such reports relate to this Agreement; 

(vi) The Licensing Party shall promptly furnish the other Party with copies of all reports and other communications that the Licensing Party
receives from any licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement that relate to this Agreement (including notices relating to applicable improvements under such Existing Third Party Agreement or Subsequent
Third Party Agreement); 
 (vii) The Licensing Party shall furnish the other Party with copies of all notices received by the Licensing
Party relating to any alleged breach or default by the Licensing Party under any Existing Third Party Agreement or Subsequent Third Party Agreement within [***] Business Days after the Licensing Party’s receipt thereof; in addition, if the
Licensing Party should at any time breach an Existing Third Party Agreement or subsequent Third Party Agreement or become unable to timely perform its obligations thereunder, the Licensing Party shall immediately notify the other Party; and 

(viii) If the Licensing Party cannot or chooses not to cure or otherwise resolve any alleged breach or default under any Existing Third Party
Agreement or Subsequent Third Party Agreement, (A) the Licensing Party shall so notify the other Party within [***] Business Days of such decision, which shall not be less than [***] Business Days prior to the expiration of the cure period
under such Existing Third Party Agreement or Subsequent Third Party Agreement; provided that the Licensing Party shall use Commercially Reasonable Efforts to cure any such breach or default; and (B) the other Party, in its sole
discretion, shall be permitted (but shall not be obligated), on behalf of the Licensing Party, to cure any breach or default under such Existing Third Party Agreement or Subsequent Third Party Agreement in accordance with the terms and conditions of
such Existing Third Party Agreement or Subsequent Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such Existing Third Party Agreement or Subsequent Third Party Agreement; and (C) if the Lead
Party pays any such licensor any amounts owed by the Licensing Party (where the Licensing Party is the non-Lead Party) under such Existing Third Party Agreement or Subsequent Third Party Agreement, then,
provided that such amounts have not arisen as a result of the Lead Party’s failure to comply with the terms and conditions of such Existing Third Party Agreement or Subsequent Third Party Agreement within the categories described in
Section 8.5(b) applicable to the Lead Party as a sublicensee, the Lead Party may deduct the Licensing Party’s (where the Licensing Party is the non-Lead Party) share of such amounts from payments the
Lead Party is required to make thereafter to the Licensing Party (where the Licensing Party is the non-Lead Party) hereunder or, 

  
 - 41 - 

 at the Lead Party’s election, may otherwise seek reimbursement of such amounts from the Licensing Party
(where the Licensing Party is the non-Lead Party). 
 (d) Survival of Rights Following Termination
of Third Party Agreement. The Parties agree that in the event of any termination of any Existing Third Party Agreement or Subsequent Third Party Agreement with respect to any intellectual property rights licensed to a Party hereunder, such Party
shall have any rights available under such Existing Third Party Agreement or Subsequent Third Party Agreement to become a direct licensee of the Third Party licensor(s) under such Existing Third Party Agreement or Subsequent Third Party Agreement
and the Licensing Party shall use Commercially Reasonable Efforts to assist the other Party in exercising such rights, in each case solely with respect to Shared Products; provided that the other Party has not breached this Agreement,
or breached the applicable Third Party Rights under such Existing Third Party Agreement or Subsequent Third Party Agreement. In addition, notwithstanding the foregoing, in the event of such termination, the other Party may in any event approach any
licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement for a direct license. 
 (e) Termination of Third
Party Agreements. The Parties agree that termination, without both Parties’ prior written consent, of any Existing Third Party Agreement with respect to any Patent or Know-How that is necessary to
Develop, Manufacture or Commercialize the Shared Products shall be deemed a breach of this Agreement by the Licensing Party; provided that (i) if the other Party’s breach of this Agreement results in a breach of any Existing
Third Party Agreement, such other Party agrees to use Commercially Reasonable Efforts to assist the Licensing Party in curing such breach of such Existing Third Party Agreement, and (ii) if the other Party’s breach of this Agreement
results in a termination of any Existing Third Party Agreement, such termination of such Existing Third Party Agreement shall not be deemed a breach by the Licensing Party of this Agreement. 

Section 8.6 Exclusivity. 

(a) Exclusivity Obligations. From the Effective Date until the end of the Term, each of the Parties covenants and agrees, solely on
behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program MTA or any other Development &
Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or Commercialization (“Enabling
Manufacturing”) or Commercialize (A) the Co-Co Candidate, (B) any molecule in the Field that is Directed against the Co-Co Target or (C) any
pharmaceutical product (including any Diagnostic Product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Co-Co Target, or (ii) license,
authorize, appoint or otherwise willfully or intentionally enable, whether directly or indirectly, a Third Party to conduct any of the activities described in clause (i). 

(b) Exceptions. 
 (i)
Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly (whether such activities are conducted internally or with or through a Third Party), 

  
 - 42 - 

 Developing, Manufacturing or Commercializing in violation of the provisions of Section 8.6(a) as a
result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a molecule resulting from such research program or discovery effort) that has as its specified and primary goal, as evidenced by items such
as laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to discover or Develop any compound that is Directed against a target other than the Co-Co Target. 

(ii) Celgene Exception. It is agreed and understood by the Parties that, (A) solely prior to the enrollment of the first patient
in the first Phase II Study of the first Shared Product under this Agreement: (x) any Celgene research, Development, discovery, manufacturing and commercialization activities existing as of the Effective Date or (y) any commercialization
activities commenced following the Effective Date, where the applicable compound or product was the subject of ongoing research, Development, discovery, or manufacturing or commercialization activities as of the Effective Date, whether in either
case such activities are undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators, are expressly excluded from the provisions of this Section 8.6, and (B) at any time during the
Term, Celgene research, discovery, and commercialization activities related to (i) the glutarimide class of drugs, including but not limited to lenalidomide, pomalidomide, and thalidomide; (ii) the activation or inhibition through direct
binding to PDE4 (apremilast); (iii) romidepsin drugs; (iv) Celgene’s cell-based therapies; or (v) any drug or program owned or controlled by Celgene on or before the Effective Date that has commenced a Phase III Study or has been
Commercialized on or before the Effective Date are expressly excluded from the provisions of this Section 8.6. 
 (iii) Academic
Collaborations. Notwithstanding the provisions of Section 8.6(a), and without limiting Section 8.2(a)(ii), each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in
relation to the Co-Co Target, if such activities are (A) the subject of an existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective
date of the Master Agreement, provided that such Party shall not be permitted to amend any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the
Master Agreement with respect to (1) ownership and licenses of pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of
activities under such agreement, (2) rights regarding publication of the results arising pursuant to the conduct of activities under such agreement, and (3) confidentiality obligations (collectively, (1) through (3), the
“Academic Essential Provisions”), or (B) the subject of a new agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic
Essential Provisions consistent with the terms and conditions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement; provided that, if
any Academic Essential Provisions of an amendment described in (A) or an agreement described in (B) would not be consistent with the Academic Essential Provisions of the agreements between such Party and an academic institution or academic
collaborator entered into prior to the effective date of the Master Agreement, such Party shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of the other Party. 

  
 - 43 - 

 (iv) Competitive Programs. Section 8.6(a) shall not apply to the applicable
Party if, during the Term, such Party or any of its Affiliates (other than in a Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would
otherwise constitute a breach of this Section 8.6 by such Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a
Competitive Program (the “Competitive Program Party”) shall, within [***] days after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant
Affiliate to terminate, the Competitive Program or (B) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [***] day
period that it intends to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program as quickly as possible, and in
any event within [***] days (unless applicable Law requires a longer termination period) after the Competitive Program Party delivers such notice to the other Party; and (Y) confirm to the other Party when such termination has been completed,
and the Competitive Program Party’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations
under Section 8.6(a). If the Competitive Program Party notifies the other Party within such [***] day period that it intends to divest such Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable
efforts to effect such divestiture as quickly as possible, and in any event within [***] days after the Competitive Program Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed.
If the Competitive Program Party or its relevant Affiliate fails to complete such divestiture within such [***] day period, but has used reasonable efforts to effect such divestiture within such [***] day period, then, unless otherwise required by
applicable Law, such [***] day period shall be extended for such additional reasonable period thereafter as is necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided,
however, that such additional [***] day period shall be extended for such period as is necessary to obtain any governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant
Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s
exclusivity obligations under Section 8.6(a). 
 (v) Certain Permitted Activities. 

(A) The supply by either Party or its Affiliates of drug for use in any IIT shall not constitute a breach of Section 8.6(a) by such
Party. Each Party shall report to the JSC on a Calendar Quarterly basis all IITs for which it or its Affiliates supply drug and that would otherwise breach Section 8.6(a). For clarity, providing at market price any supply of any biological or
pharmaceutical product owned or controlled by a Party or any of its Affiliates that is then being commercialized without violation of Section 8.6(a) to a Third Party conducting a human Clinical Trial with respect to a compound that is Directed
against the Co-Co Target in the Field for the Territory shall not constitute Development in violation of such Party’s exclusivity obligations under this Section 8.6 as long as neither such Party nor
any of its Affiliates receives any other monetary consideration with respect to any product other than such product that is the subject of such Clinical Trial. 

  
 - 44 - 

 (B) The entry into any Partnership Agreement by Celgene or its Affiliates, either before or
after the Effective Date, and the performance by Celgene or its Affiliates of any obligations thereunder shall not constitute a breach of Section 8.6(a); provided that any exercise of any options by Celgene or its Affiliates
thereunder shall be subject to Section 8.6(a) and such exercise, in and of itself, shall not be permitted under this Section 8.6(b)(v). 

(C) The restrictions set forth in Section 8.6(a) shall not be deemed to prevent either Party or its respective Affiliates from
(1) fulfilling its obligations under this Agreement, or (2) engaging any subcontractors in accordance with Section 8.2(a)(ii) of this Agreement. 

(D) If a Change of Control occurs with respect to either Party with a Third Party and the Third Party already is conducting or is planning to
conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such initiation or
continuation will not constitute a violation of Section 8.6(a); provided that (1) none of the Celgene Co-Co Collaboration Intellectual Property, Vividion
Co-Co Collaboration Intellectual Property or Joint Co-Co IP will be used in any Acquirer Program, (2) none of the other Patents or
Know-How licensed by either Party to the other Party pursuant to this Agreement will be used in any Acquirer Program, (3) no Confidential Information of the other Party will be used in any such Acquirer
Program, and (4) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program, including by the maintenance of separate lab notebooks and records
(password-protected to the extent kept on a computer network) and the use of separate personnel working on each of the activities under this Agreement, and the activities covered under such Acquirer Program (except that this requirement shall not
apply to personnel who have senior research management roles and not project level research roles, provided such personnel in senior research management roles are not directly involved in the day-to-day activities under such Acquirer Program). 
 (vi) Clinical Combinations. Notwithstanding
anything to the contrary in this Agreement, for purposes of this Section 8.6, either Party shall, at all times, have the right to conduct clinical Development of Shared Products, alone or with Third Parties, in which the Shared Products are
used in combination with other therapeutic products, and to grant to any such Third Parties the right to use and reference either Party’s regulatory filings for purposes of enabling such Party and such Third Party to include the relevant use of
Shared Products in combination with such other therapeutic product in the approved label for such Shared Products or such other therapeutic product, respectively, provided that neither Party may grant to any such Third Party the right to sell, offer
for sale or otherwise commercially exploit such Shared Products. 
 (vii) Separate Programs under the Collaboration1. Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or 

 

	1 	 Only insert for E3 Ligase Programs. 

  
 - 45 - 

 Commercialization of any Program Product in a Separate Program Directed against the Co-Co Target by or on behalf of Vividion (a “Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement: (x) such
Separate Program Product is no longer subject to Celgene’s Opt-In Right under the Master Agreement and is not the subject of any Development & Commercialization Agreement as a Licensed Product or
Shared Product; and (y) such proposed Separate Program Product demonstrates utility in distinct Indications where such Separate Program Product could not be substituted by any Shared Product for such distinct Indication(s), based upon distinct
substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty (30) days, as determined by a
Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any of such one or more distinct Indications for which the Separate Program Product demonstrates utility, a “Permitted
Indication”); and (z) such Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or Commercialization, or Commercialized by or on behalf of Vividion or its Affiliates for one or more Permitted
Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(vii) may be convened at any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject
to Section 2.3.4(d) of the Master Agreement). Vividion covenants and agrees, on behalf of itself and its Affiliates, as a condition to granting a license or sublicense to Develop, Manufacture or Commercialize such Separate Program Product, or
otherwise transferring, assigning, conveying or otherwise granting rights to such Separate Program Product, Vividion shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene)
to only Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such Separate Program Product in one or more Permitted Indications. 

(viii) Non-Collaboration Separate
Programs.2 [Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any molecule outside of the Collaboration by or on
behalf of either Party or its Affiliates (a “Non-Collaboration Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this
Agreement with respect to such Party or its Affiliates: (x) such Non-Collaboration Separate Program Product is Directed to the Co-Co Target; (y) such Non-Collaboration Separate Program Product demonstrates utility in distinct Indications where such Non-Collaboration Separate Program Product could not be substituted by any Shared Product for such distinct
Indication(s), based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty
(30) days, as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any such one or more distinct Indications for which the
Non-Collaboration Separate Program Product demonstrates utility, an “Allowed Indication”), where such Non-Collaboration Separate Program Product could
not be substituted for any Shared Product for any Allowed Indication; and (z) such Non-Collaboration Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or
Commercialization, or Commercialized by or on behalf of such Party or its Affiliates for one or more Allowed Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(viii) 

 

	2 	 Only insert for E3 Ligase Programs. 

  
 - 46 - 

 
may be convened at any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Each Party
covenants and agrees, on behalf of itself and its Affiliates, as a condition to granting a license or sublicense to Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such
Non-Collaboration Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Non-Collaboration Separate Program
Product, such Party shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Enabling Manufacture or Commercialize such Non-Collaboration Separate Program Product in one or more Allowed Indications.] 
 Section 8.7
Retained Rights. 
 (a) No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and subject to
Section 8.6, all rights in and to the Vividion Intellectual Property, Vividion’s and its Affiliates’ interests in Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP and any other Patents or Know-How of Vividion and its Affiliates, are hereby retained by Vividion and its Affiliates. Except as expressly provided in
Section 8.1, and subject to Section 8.6, all rights in and to the Celgene Intellectual Property, Celgene’s and its Affiliates’ interests in Celgene Co-Co Collaboration Intellectual Property
and any other Patents or Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 

(b) Other Retained Rights. The Parties acknowledge that the licenses granted hereunder are subject to any rights retained by any
licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement, as identified in Exhibit C; provided that, upon Celgene’s reasonable request, Vividion shall cooperate
fully in requesting and obtaining any waiver with respect to the requirement, if applicable under such agreements, that the Shared Products used or sold in the US Territory be manufactured substantially in the US Territory. 

Section 8.8 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this
Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, US Code), as amended (the “Bankruptcy Code”), licenses of rights to “intellectual
property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. The Parties agree that each Party, as licensee of such
rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the US Territory that provide similar protection for “intellectual
property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or analogous provisions of applicable Law outside the US Territory, the Party that is not
subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in the
non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof. Any agreements supplemental hereto will
be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 

  
 - 47 - 

 Article IX 

Financial Provisions 

Section 9.1 Sharing of Certain Costs. Subject to Section 3.3 and Section 3.4, during the Term, all reasonable Direct
Costs incurred by either Party or its Affiliates in conducting (i) Additional Studies for which (A) the Non-Proposing Party has agreed to share such costs pursuant to Section 3.3; (B) a Co-Co Buy-In has occurred pursuant to Section 3.4; or (C) a Deemed Buy-In has occurred pursuant to Section 3.3 and
(ii) Development activities pursuant to the Development Plan (including Manufacturing related thereto and any Clinical Trials, including any Phase IV Studies conducted following Regulatory Approval) in accordance with terms and conditions of
this Agreement that constitute Development Costs, Manufacturing Costs or other Allowable Expenses shall be included for the purposes of calculating the Profit & Loss Share. Development Costs shall initially be borne by the Party incurring
the cost or expense, subject to reimbursement in accordance with the Profit & Loss Share. 
 Section 9.2 Milestone
Payments. 
 (a) Development and Regulatory Milestones. Celgene shall pay Vividion the following amounts after the first
achievement by or on behalf of Celgene (or Vividion, solely if achieved in accordance with a Development Plan approved by Celgene or if Celgene requests (and Vividion, in its sole discretion, subject to Section 2.3, accepts) that Vividion
Develop the Shared Product for the applicable development and regulatory milestone events set forth below) or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the
first Shared Product to achieve such milestone events. 
  

			
	 Milestones
	  	Payment
(in US Dollars)
	 (1) [***]
	  	$[***]
	 (2) [***]
	  	$[***]

 (i) Each milestone payment under this Section 9.2(a) shall be made within [***] days after the
achievement of the applicable milestone by either Party or any of its Affiliates or Licensee Partners. 
 (ii) [Subject to
Section 9.2(a)(iii) below] [include as applicable], the milestone payments set forth in the table above in this Section 9.2(a) (to the extent payable) shall be paid only once, regardless of the number of Shared Products to
achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

  
 - 48 - 

 (iii) [Parties to include in execution version solely where the Program under this
Agreement is an E3 Ligase Program] [Solely for purposes of this Section 9.2, in the event that the Shared Program produces two (2) or more Distinct Products (as determined pursuant to Section 2.3.4 of the Master Agreement),
the Parties understand and agree that, following Regulatory Approval of the first Shared Product in the United States under this Agreement, each subsequent Distinct Product to receive Regulatory Approval in the United States shall be eligible to
receive the Milestone Payments set forth in the table above (the “Distinct Product Catch-Up Payments”). Celgene will make any Distinct Product Catch-Up
Payments within [***] days after such Distinct Product receives Regulatory Approval in the United States. 
 (b) Sales Milestones.
Celgene shall make a one-time sales milestone payment to Vividion of [***] U.S. Dollars ($[***]) the first time aggregate Annual Net Sales of Shared Products in a given Calendar Year in the ROW Territory
exceed [***] U.S. Dollars ($[***]) (the “Sales Milestone Condition”); it being understood and agreed that (i) Celgene shall notify Vividion of the achievement of such Sales Milestone Condition within [***] days after the end of
the applicable Calendar Quarter in which such Sales Milestone Condition is achieved; and (ii) Vividion shall deliver to Celgene an invoice for such [***] U.S. Dollars ($[***]) payment; and (iii) Celgene shall pay to Vividion such [***]
U.S. Dollars ($[***]) payment within [***] days following receipt of such invoice. For clarity, the sales milestone payment set forth in this Section 9.2(b) (to the extent payable) shall be paid only once, regardless of the number of Shared
Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

Section 9.3 Profit & Loss Share. 

(a) Profit & Loss Share. The Parties will share in (and bear) Operating Profits or Losses with respect to Shared
Product(s) as follows: [***] will bear (and be entitled to) [***] percent ([***]%) of such Operating Profits or Losses, and Celgene will bear (and be entitled to) [***] percent ([***]%) of such Operating Profits or Losses (collectively, the
“Profit & Loss Share”). 
 (b) Quarterly Reconciliation and Payments. Unless the
Parties otherwise agree in advance in writing, reconciliation and payments of the Profit & Loss Share shall be conducted as set forth in Exhibit D. 

Section 9.4 Royalty Payments Following Vividion Opt-Out. Following any Vividion Opt-Out Date: 
 (a) Royalty Rate. Subject to Section 9.4(b), Celgene shall pay to Vividion
royalties on worldwide Annual Net Sales of Shared Products following any Vividion Opt-Out Date at the applicable royalty rate set forth below (each, a “Royalty Rate”) on a Shared Product-by-Shared Product basis (in no event to include Companion Diagnostics): 

  
 - 49 - 

			
	 Per Shared Product Annual Net Sales in the Territory
	  	Royalty Rate
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in
the aggregate, up to and including [***] U.S. Dollars ($[***]).
	  	[***]%
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in
the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).
	  	[***]%
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in
the aggregate, greater than [***] U.S. Dollars ($[***]).
	  	[***]%

 Each Royalty Rate set forth in the table above will apply only to that portion of the worldwide Annual Net Sales of a given
Shared Product in the Territory during a given Calendar Year that falls within the indicated portion. 
 For example, if worldwide Annual Net Sales of a
given Shared Product in the Territory by Celgene and its Affiliates and Licensee Partners was $[***], then the royalties payable with respect to such worldwide Annual Net Sales, subject to adjustment as set forth in this Section 9.4, would be:

 [***] 
 (b) Royalty
Term. Royalties payable under this Section 9.4 shall be paid by Celgene on a Shared Product-by-Shared Product and country-by-country basis from the later of (i) the Vividion Opt-Out Date and (ii) the date of First Commercial Sale of each Shared Product in a country with
respect to which royalty payments are due, until the latest of: 
 (i) the last to expire of any Valid Claim of Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents or Joint Co-Co Patents Covering such Shared Product in such country;

 (ii) [***] years following the date of First Commercial Sale in such country; and 

(iii) the expiration of Regulatory Exclusivity for such Shared Product in such country; 

(each such term with respect to a Shared Product and a country, a “Royalty Term”). 

  
 - 50 - 

 Notwithstanding the foregoing, in the event that the Royalty Term for a Shared Product in a country
continues solely due to Section 9.4(b)(ii) above (i.e., the Shared Product is not Covered by a Valid Claim of Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene
Co-Co Collaboration Patents or Joint Co-Co Patents in the applicable country, and such Shared Product is not subject to Regulatory Exclusivity in such country) then, in
such event, the Royalty Rate for such Shared Product in such country will be reduced to [***] percent ([***]%) of the applicable Royalty Rate in Section 9.4(a) for such Shared Product in such country. 

Upon the expiration of the Royalty Term with respect to a Shared Product in a country, the license granted by Vividion to Celgene pursuant to
Section 8.1(a) shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Shared Product in such country; provided that, notwithstanding Section 8.5 or 9.5,
Celgene shall assume and be solely responsible (without deduction under Section 9.4(d)) for any amounts payable to Third Party licensors and Celgene shall be responsible for complying with the terms of any license agreements with such Third
Party licensors, in each case, with respect to Celgene’s exercise of such rights as to such Shared Product in such country following the expiration of such Royalty Term. 

(c) Royalty Reduction for Generic Competition. If, on a Shared
Product-by-Shared Product, country-by-country and Calendar
Quarter-by-Calendar Quarter basis, 
 (i) A Generic
Product(s) has a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%); or 
 (ii) A Generic
Product(s) has a market share of more than [***] percent ([***]%); 
 then, subject to Section 9.4(f), the royalties payable with respect to Annual Net
Sales of such Shared Product pursuant to Section 9.4(a) in such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies,
respectively, of the royalties otherwise payable pursuant to Section 9.4(a). Market share shall be based on the aggregate market in such country of such Shared Product and all applicable Generic Products (based on sales of units of such Shared
Product and such Generic Product(s) in the aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

(d) Deduction for Third Party Payments after Vividion Opt-Out. In the event that, following the
Vividion Opt-Out Date, royalties are payable by Celgene to Vividion with respect to any Shared Product under this Section 9.4, the Parties shall continue to be responsible for amounts payable to Third
Party licensors under Existing Third Party Agreements as set forth in Section 8.5 (which amounts shall not be deductible from royalties as set forth in this Section 9.4(d)) and Celgene shall have the right to deduct from royalty payments
otherwise due and payable by Celgene to Vividion under this Section 9.4, on a Shared Product-by-Shared Product and country-by-country basis, a maximum of [***] percent ([***]%) of any royalties or other amounts actually paid by Celgene to a Third Party from and after the Vividion
Opt-Out Date with respect to such Shared Product in such country(ies) under any Subsequent Third Party Agreement, but only to the extent that the Patents or Know-How
licensed under such Subsequent Third Party Agreement are necessary for the Development, Manufacture or Commercialization of such Shared Product in such country(ies). 

  
 - 51 - 

 (e) Royalty Reports; Payments. Within [***] days after the end of each Calendar
Quarter following the Vividion Opt-Out Date, Celgene with respect to each Shared Product shall provide Vividion with a report stating the sales in units and in value of such Shared Product made by Celgene, its
Affiliates, and Licensee Partners, as applicable, on a country-by- country basis, together with the calculation of the royalties due to Vividion, including the method
used to calculate the royalties, the exchange rates used, and itemized deductions. Payments of all amounts payable under this Section 9.4 shall be made by Celgene to the bank account indicated by Vividion within [***] days from the end of each
Calendar Quarter in which such payment accrues. 
 (f) Cumulative Effect of Royalty Reductions. In no event shall the royalty
reductions described in this Section 9.4, alone or together, reduce the royalties payable by Celgene for a Shared Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts otherwise payable by Celgene
for such Shared Product in such country in such Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation
set forth above in this Section 9.4(f), to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until
fully deducted, in all cases subject to the limitation set forth above in this Section 9.4(f). 
 Section 9.5 Third Party
Payments. After the Effective Date, if either Party at any time believes that a license under Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, could be necessary
or useful to Develop, Manufacture or Commercialize the Shared Products, then such Party shall notify (A) the JDC if such notice is provided during Development or Manufacturing of Shared Products for Development or (B) the JCC if such
notice is provided during Commercialization of Shared Products, and the following shall apply: 
 (a) If the JDC or JCC, as applicable,
agrees by unanimous vote to obtain such license, and if so, which of the Parties will do so, then the Parties will proceed as determined by the JDC or JCC, as applicable. If the JDC or JCC, as applicable, cannot agree on whether to obtain such
license or which Party will do so, then the matter will be escalated to the JSC for resolution in accordance with Section 2.2; provided that, if the JSC cannot agree on which Party should obtain such license, then the Lead Party
in the applicable Territory shall have the first right to obtain such license and if the applicable Lead Party does not promptly exercise such right then the other Party shall have the right to do so; provided, further, that,
after a Vividion Opt-Out Notice, Celgene shall have the sole right, but not the obligation, to obtain such license throughout the Territory. 

(b) The costs of each license obtained pursuant to Section 9.5(a) (each, a “Subsequent Third Party Agreement”) to the
extent such costs directly relate to the Shared Products and constitute COGS shall be included for purposes of calculating the Profit & Loss Share and, in the event of a Vividion Opt-Out Date, shall
be borne solely by Celgene to the extent incurred after the Vividion Opt-Out Date, subject to deduction from royalties in accordance with Section 9.4(d). 

(c) For purposes of this Agreement, the Third Party Patents and Third Party Know-How licensed under a
Subsequent Third Party Agreement shall be deemed “Co-Co Collaboration Intellectual Property” of the Party obtaining such license. 

  
 - 52 - 

 (d) (i) The Party designated to pursue the Subsequent Third Party Agreement shall keep the
other Party fully informed of the status of the negotiations with the applicable Third Party and provide the other Party with copies of all draft agreements; (ii) the other Party may provide comments and suggestions with respect to the
negotiation of the agreement with such Third Party, and the Party seeking the Subsequent Third Party Agreement shall reasonably consider all comments and suggestions reasonably recommended by the other Party; and (iii) the Party seeking the
Subsequent Third Party Agreement shall obtain a license that is sublicensable to the other Party in accordance with the terms of this Agreement, treating (unless otherwise agreed by the Parties) the Third Party intellectual property as Co-Co Collaboration Intellectual Property hereunder and treating the agreement licensing such Third Party intellectual property in the same way as the Existing Third Party Agreements (including as provided in
Section 8.5), except for payment obligations, which will be treated as provided in this Section 9.5. 
 Section 9.6
Financial Records. The Parties shall keep, and shall require their respective Affiliates and (sub)licensees to keep, complete and accurate books and records in accordance with the applicable Accounting Standards. The Parties shall keep, and
shall require their respective Affiliates and (sub)licensees to keep, such books and records for at least [***] years following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of
business of the financial personnel with responsibility for preparing and maintaining such records. With respect to royalties, such records shall be in sufficient detail to support calculations of royalties due to Vividion. Prior to any Vividion Opt-Out Date, Celgene and Vividion shall also keep, and require their respective Affiliates and (sub)licensees to keep, complete and accurate records and books of accounts containing all data reasonably required for
the calculation and verification of Annual Net Sales, COGS and Allowable Expenses, including internal FTEs utilized by either Party, and the Profit & Loss Share. 

Section 9.7 Audits. 

(a) Audit Team. Each Party may, upon request and at its expense (except as provided for herein), cause an internationally recognized
independent accounting firm selected by it (except one to whom the Auditee has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of the other Party and the correctness of any
payment made or required to be made to or by such Party, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this Agreement, the Audit Team shall enter into an
appropriate confidentiality agreement with the Auditee obligating the Audit Team to be bound by obligations of confidentiality and restrictions on use of confidential information that are no less restrictive than the obligations set forth in Article
XI. 
 (b) Limitations. In respect of each audit of the Auditee’s books and records: (i) the Auditee may be audited only
once per year, (ii) no records for any given year for an Auditee may be audited more than once; provided that the Auditee’s records shall still be made available if such records impact another financial year which is being
audited, and (iii) the Audit Rights Holder shall only be entitled to audit books and records of an Auditee from the three (3) Calendar Years prior to the Calendar Year in which the audit request is made. 

  
 - 53 - 

 (c) Audit Notice. In order to initiate an audit for a particular Calendar Year, the
Audit Rights Holder must provide written notice to the Auditee. The Audit Rights Holder exercising its audit rights shall provide the Auditee with notice of one or more proposed dates of the audit not less than sixty (60) days prior to the
first proposed date. The Auditee will reasonably accommodate the scheduling of such audit. The Auditee shall provide such Audit Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate with such
audit. 
 (d) Payments. If the audit shows any under-reporting or underpayment, or overcharging or overpayment by any Party, that
under-reporting, underpayment, overpayment or overcharging shall be reported to the Audit Rights Holder and the underpaying or overcharging Party shall remit the applicable underpayment amount or reimburse the applicable overpayment amount (together
with interest at the rate set forth in Section 9.10) to the underpaid or overcharged Party within [***] days after receiving the audit report. Further, if the audit for an annual period shows an under-reporting or underpayment or an overcharge
by any Party for that period in excess of [***] percent ([***]%) of the amounts properly determined, the underpaying or overcharging Party, as the case may be, shall reimburse the applicable underpaid or overcharged Audit Rights Holder conducting
the audit, for its respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [***] days after
receiving appropriate invoices and other support for such audit-related costs. 
 (e) Definitions. For the purposes of the audit
rights described herein, an individual Party subject to an audit in any given year will be referred to as the “Auditee” and the other Party who has certain and respective rights to audit the books and records of the Auditee will be
referred to as the “Audit Rights Holder.” 
 Section 9.8 Tax Matters. 

(a) General. The Parties acknowledge that the rights and obligations imposed on each of them pursuant to this Agreement that relate to
the sharing of profits from the development and commercialization of the Shared Products in the Territory to the Shared Products and Companion Diagnostics and the collaborative relationship formed between them in connection therewith, gives rise to
a partnership for US federal (and, to the extent applicable, state) income tax purposes (but not for any non-tax or non-US purpose) that solely relates to the Territory,
and the Parties shall act in accordance with Exhibit E. 
 (b) Withholding and Indirect Taxes. 

(i) Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement (or allocable to another Party pursuant
to Section 1.6 of Exhibit E) such taxes as are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will:
(A) deduct those taxes from such payment, (B) timely remit the taxes to the proper taxing authority, and (C) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee
Party”) on a timely basis following that tax payment; provided, however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction
or withholding (and such notice, which shall set forth in 

  
 - 54 - 

 reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding,
shall be given at least a reasonable period of time before such deduction or withholding is required, in order for such Payee Party to obtain reduction of or relief from such deduction or withholding). Each Party agrees to cooperate with the other
Parties in claiming refunds or exemptions from, or reductions in, such deductions or withholdings under any applicable Law or treaty to ensure that any amounts required to be withheld pursuant to this Section 9.8(b)(i) are reduced to the
fullest extent permitted by applicable Law. 
 (ii) Each Party, for itself and, if applicable, in its capacity as “Tax Matters
Partner” of such partnership (as defined in Exhibit E), agrees to cooperate with the other Parties in claiming refunds or exemptions from, or reductions in, any deductions or withholdings, including pursuant to Code
Section 1446(f), required to be withheld or deducted by an acquirer of an interest in the partnership described in Section 9.8(a) and in reducing or eliminating such withholdings to the fullest extent permitted by applicable Law. 

(iii) The Parties shall cooperate to minimize value added tax, sales an use tax, consumption tax and other similar taxes (“Indirect
Taxes”) imposed in connection with this Agreement, as applicable. 
 (iv) Each Party has provided a properly completed and duly
executed IRS Form W-9 Form W-8, as applicable, to the other Party. Each Party and any other recipient of payments described in this Section 9.8(b) shall provide to
the other Party (including where the other Party is acting in its capacity as Tax Matters Partner (as defined in Exhibit E)), at the time or times reasonably requested by such other Parties or as required by applicable Law, such other
properly completed and duly executed documentation as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made without (or at a reduced rate of)
withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 
 Section 9.9 Currency
Exchange; Blocked Payments; Prohibitions on Payments. 
 (a) Currency Exchange. Unless otherwise expressly stated in this
Agreement, all amounts specified in, and all payments made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts payable under this Agreement, such
conversion shall be performed in a manner consistent with the paying Party’s normal practices used to prepare its audited financial statements for internal and external reporting purposes. For clarity, Celgene sets currency transaction rates
for the month on the last business day of the month prior. Vividion has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month prior. 

(b) Blocked Payments. In the event that, by reason of applicable Law in any country, it becomes impossible or illegal for the paying
Party (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed the other Party hereunder, the paying Party will promptly notify the other Party of the conditions preventing such transfer and such
payments will be deposited in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is 

  
 - 55 - 

 designated by the other Party within a period of [***] days, in a recognized banking institution selected by
the paying Party or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to the other Party. 

(c) Prohibitions on Payments. When in any country in the Territory applicable Law prohibits both the transmittal and the deposit of
royalties on sales in such country, royalty payments due on Net Sales shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in effect, all royalties that Celgene would have been under an
obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent allowable. The Parties shall cooperate in good faith to overcome, to the extent reasonably possible, any prohibition described in
this Section 9.9(c) within a reasonable period of time. 
 Section 9.10 Late Payments. Any payments that are not paid on or
before the date such payments are due under this Agreement shall bear interest at an annual rate equal to the lesser of (x) [***] or [***]; provided that, [***]. 

Article X 
 Intellectual
Property Ownership, Protection and Related Matters 
 Section 10.1 Ownership of Inventions. 

(a) Non-Co-Co Collaboration
Know-How. Any Know-How discovered, developed, generated or invented by Celgene or its Affiliates or Vividion or its Affiliates prior to or outside the Collaboration
shall remain the sole property of such Party or its applicable Affiliate(s), except as otherwise agreed by the Parties. 
 (b) Sole
Inventions. All Co-Co Collaboration Know-How discovered, developed, generated or invented solely by employees, agents and consultants of a Party or its Affiliates
shall be owned exclusively by such Party or its applicable Affiliate(s). 
 (c) Joint Inventions. All
Co-Co Collaboration Know-How discovered, developed, generated or invented jointly by employees, agents and consultants of Celgene or its Affiliates, on the one hand, and
employees, agents and consultants of Vividion or its Affiliates, on the other hand, in the conduct of activities under this Agreement (“Joint Inventions” and, any Patents Covering such Joint Inventions, “Joint
Patents”) shall be owned jointly on the basis of each Party (or its applicable Affiliate(s)) having an undivided interest without a duty to account to the other Party (or its applicable Affiliate(s)) and shall be deemed to be Controlled by
each Party. Each Party shall have the right to use such Joint Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell or otherwise transfer its interest in such Joint Inventions to its Affiliates or a Third Party,
in each case without the consent of the other Party or its applicable Affiliate(s) (and, to the extent that applicable Law requires the consent of the other Party or applicable Affiliate(s), this Section 10.1(c) shall constitute such consent),
so long as such use, sale, license or transfer is subject to Section 8.6 and the licenses granted pursuant to this Agreement and is otherwise consistent with this Agreement. 

  
 - 56 - 

 (d) Notice. Each Party agrees to provide, at the request of the other Party and no
more than once per Calendar Quarter, reports disclosing to the other Party all Co-Co Collaboration Intellectual Property discovered, developed, generated or invented by employees, agents and consultants of
such Party and all Vividion Intellectual Property and Celgene Intellectual Property that becomes subject to this Agreement, which disclosures may be made in connection with the updates made in accordance with Section 3.1(d). 

(e) Inventorship. For purposes of determining ownership hereunder, the determination of inventorship shall be made in accordance with
United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually acceptable independent patent counsel not regularly employed by either Party to
resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(f) Further Actions and Assignments. Each Party shall take all further actions and execute all assignments requested by the other Party
and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 
 Section 10.2
Prosecution of Patents. Subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Vividion Patents, Vividion
Co-Co Collaboration Patents, Celgene Patents or Celgene Co-Co Collaboration Patents, the following provisions shall apply with respect to the Vividion Patents, Celgene
Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the
Territory: 
 (a) Lead US Party. Subject to the provisions of Section 10.2(f) and coordination with the JPC, the Lead US Party
(or, in the event of any Vividion Opt-Out, Celgene) shall have the initial right and option to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents,
Celgene Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the Territory. In the event that the Lead US Party declines to Prosecute such Patents, it
shall give the non-Lead US Party reasonable notice to this effect, sufficiently in advance to permit the non-Lead US Party to undertake such Prosecution in any
applicable country without a loss of rights, and thereafter the non-Lead US Party may, upon written notice to the Lead US Party and receipt of the Lead US Party’s prior written consent (not to be
unreasonably withheld), Prosecute such Patents in the owning Party(ies)’s name(s) subject to coordination with the JPC. 
 (b)
Celgene. Celgene shall have the sole right and option to Prosecute the Celgene Patents. 
 (c) Costs and Expenses. The Parties
shall jointly bear as part of the Profit & Loss Share all costs and expenses in Prosecuting Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene
Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents 

  
 - 57 - 

 (collectively, “Patent Prosecution Expenses”) as Allowable Expenses for the purposes of
calculating the Profit & Loss Share; provided, however, that, (A) in the event of a Vividion Opt-Out Date, all such Patent Prosecution Expenses incurred by [***] following
the Vividion Opt-Out Date shall be borne solely by [***] and (B) all such Patent Prosecution Expenses paid to a Third Party in connection with an Existing Third Party Agreement shall be borne as set forth
in the Master Agreement. 
 (d) Strategy; Failure of JPC to Agree; Diligence and Cooperation. 

(i) The JPC shall attempt to agree upon a strategy (which may be updated from time to time) for Prosecution of Vividion Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents, including the scope and
priority of the claims to be pursued within such Patents and to maximize the value of such Patents, on a global basis. As part of such strategy, the JPC shall discuss and consider in good faith filing separate Patents that include claims that Cover
Shared Products specifically or generically and claims that Cover only other compounds. Any failure by the JPC to agree by unanimous vote with respect to such strategy or any other Prosecution matter will be attempted to be resolved as specified in
Section 2.2(e), and if such attempt fails, then the Prosecuting Party may resolve such matter. The Prosecuting Party with respect to any such Patent shall follow such strategy in connection with all Prosecution of such Patent unless the JPC
approves of a divergence from such strategy (with any failure by the JPC to agree by unanimous vote to be resolved in accordance with Section 2.2(e) and the foregoing sentence). 

(ii) The Party authorized to conduct prosecution pursuant to Section 10.2(a) or Section 10.2(b) at the relevant time (as applicable,
the “Prosecuting Party”) shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including
in-house patent counsel as well as outside patent counsel) for the Prosecution of the Patents subject to Section 10.2(a) and Section 10.2(b). Each Party agrees to cooperate with the other with
respect to the Prosecution of such Patents pursuant to this Section 10.2, including (X) executing all such documents and instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake
any Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a) and Section 10.2(b) and (Y) giving consideration to the proper scope of Patents. In addition, Vividion
agrees that, if it is the non-Prosecuting Party, then Vividion, from time to time at the direction of the Prosecuting Party, shall Prosecute the Patents together with its external Patent counsel. The
Prosecuting Party shall: 
 (A) use Commercially Reasonable Efforts to regularly provide the JPC in advance with reasonable information
relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings
and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with sufficient time for the non-Prosecuting
party to provide meaningful input; 

  
 - 58 - 

 (B) use Commercially Reasonable Efforts to consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 
 (C) use Commercially
Reasonable Efforts to Prosecute additional claims substantially similar to those suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 
 (D) consult with the JPC and
non-Prosecuting Party before taking any action that would have a material adverse impact on the scope of claims within the Vividion Patents, Celgene Co-Co Collaboration
Patents or Vividion Co-Co Collaboration Patents (including the Joint Co-Co Patents and Joint Patents), as applicable. 

(iii) The applicable Prosecuting Party, in consultation with the JPC, shall determine the countries in which Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents (including Joint Co-Co Patents and Joint Patents) shall be
Prosecuted. 
 (iv) The Prosecuting Party may abandon the subject matter of a claim in a Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent in response to an office action from the applicable patent office if, in the
Prosecuting Party’s reasonable judgment after consultation with the non-Prosecuting Party, such Patent requires such abandonment; provided, however, that, prior to such abandonment,
if feasible, the Parties will cooperate to file divisional or continuation applications to separate such claim. The Prosecuting Party agrees not to otherwise abandon any Vividion Patent, Celgene Co-Co
Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent without filing a divisional or continuation application in respect thereof unless it provides the non-Prosecuting Party with reasonable notice to this effect, sufficiently in advance to permit the non-Prosecuting Party to undertake such Prosecution of such Vividion Patent,
Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent, and thereafter such
non-Prosecuting Party may, upon written notice to the Prosecuting Party and, in the case of the non-Lead US Party, receipt of the Lead US Party’s prior written
consent (not to be unreasonably withheld), Prosecute such Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration
Patent at [***] expense with counsel of its choice. 
 (e) Third Party Rights. Vividion covenants and agrees that it shall not grant
any Third Party any right to control the Prosecution of the Vividion Patents or Vividion Co-Co Collaboration Patents or to approve or consult with respect to any Patents licensed to Celgene hereunder, in any
case, that is more favorable to the Third Party than the rights granted to Celgene hereunder or that otherwise conflicts with Celgene’s rights hereunder. Celgene covenants and agrees that it shall not grant any Third Party any right to control
the Prosecution of the Celgene Co-Co Collaboration Patents or to approve or consult with respect to the Celgene Co-Co Collaboration Patents licensed to Vividion
hereunder, in any case, that is more favorable to the Third Party than the rights granted to Vividion hereunder or that otherwise conflicts with Vividion’s rights hereunder. 

  
 - 59 - 

 (f) Third Party Agreements. Each Party acknowledges that, pursuant to an Existing
Third Party Agreement or Subsequent Third Party Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents covered by such agreement, and that Vividion or Celgene, as applicable, may have certain rights to assume Prosecution under such agreement. Vividion and Celgene, as applicable, each
agrees to keep the other Party fully informed of these rights, as well as provide to the other Party all information and copies of documents received from the licensor(s) under any such Existing Third Party Agreement or Subsequent Third Party
Agreement, or their patent counsel, relating to the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents covered by such
agreement. To the extent that Vividion or Celgene, as applicable, is permitted to proceed with Prosecution or provide comments or suggestions to patent documents under an Existing Third Party Agreement or Subsequent Third Party Agreement, then the
Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party
Agreement shall be treated, to the extent possible, in the same manner as other Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration
Patents under this Section 10.2, and Vividion or Celgene, as applicable, shall exercise all such rights with respect to such Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents pursuant to the instructions of the other Party, if the other Party is given the right to act under this Section 10.2 (provided that all such decisions shall be subject to the
applicable Prosecuting Party’s final decision-making authority). 
 Section 10.3 Third Party Infringement and Challenges of
Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents. Subject to the terms and conditions of any Existing Third Party
Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co
Collaboration Patents, the following provisions shall apply with respect to the Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration
Patents, Joint Co-Co Patents, Joint Patents, Vividion Know-How, Vividion Co-Co Collaboration
Know-How, Celgene Co-Co Collaboration Know-How, Joint Co-Co Know-How and Joint Inventions: 
 (a) Notice. Each Party shall immediately provide the other Party
with written notice reasonably detailing any (i) known or alleged infringement of any Vividion Patents, Celgene Patents, Celgene Co-Co Collaboration Patents, Vividion
Co-Co Collaboration Patents, Joint Co-Co Patents or Joint Patents or known or alleged misappropriation of any Vividion Know-How,
Celgene Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co-Co Collaboration Know-How, Joint Co-Co Know-How or Joint Inventions, by a Third Party, (ii) “patent certification” filed in the US Territory
under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions, and (iii) any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any such intellectual property rights (collectively “Third Party Infringement”). 

(b) First Right to Initiate Infringement Actions. Each Party shall have the initial right throughout that part of the Territory (i.e.
the US Territory or the ROW Territory, as applicable) for which it is the Lead Party, but not the obligation, to initiate a suit or take other appropriate action that such Party believes is reasonably required to protect the Vividion Intellectual
Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co 

  
 - 60 - 

 Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents,
or Joint Inventions against any infringement or challenge (including any Third Party Infringement), unauthorized use or misappropriation by a Third Party that relates to a Shared Product in such part of the Territory, which, in the case of a
Companion Diagnostic, shall mean Third Party Infringement, unauthorized use or misappropriation in connection with such Companion Diagnostic in the Field (“Competitive Infringement”). The Party having such initial right under the
preceding sentence (the “Initial Enforcement Party”) shall give the other Party advance notice of the Initial Enforcement Party’s intent to file any such suit or take any such action and the reasons therefor, and shall provide
the other Party with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, the Initial Enforcement Party shall keep the other Party promptly informed, and shall from time to time consult with the other Party
regarding the status of any such suit or action and shall provide the other Party with copies of all material documents (e.g., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs,
interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or
otherwise relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall discuss in good faith the Initial Enforcement Party’s intended response to a Competitive Infringement. For clarity, Celgene shall
have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products. 

(c) Preparation to Enforce. After the First Commercial Sale of a Shared Product in the US Territory or the ROW Territory, as applicable,
subject to coordination with the JPC, the Initial Enforcement Party for such part of the Territory shall use reasonable efforts to prepare for the possibility of suit for Competitive Infringement starting [***] years after such First Commercial
Sale. 
 (d) Step-in Rights. If the Initial Enforcement Party fails to initiate a suit or take
such other appropriate action under Section 10.3(b) above within [***] days after becoming aware of any Competitive Infringement, then the other Party may, in its discretion, provide the Initial Enforcement Party with written notice of such
Party’s intent to initiate a suit or take other appropriate action to combat such Competitive Infringement); provided, however, that (i) such period will be more than [***] days to the extent applicable Law prevents
earlier enforcement of the applicable Patent(s) and provided further that if such period is extended because applicable Law prevents earlier enforcement, the Initial Enforcement Party shall have until the date that is [***] days following the date
upon which applicable Law first permits such enforcement proceeding to elect to so enforce the applicable Patent(s), and (ii) the Initial Enforcement Party shall have less than [***] days (or, as applicable, less than the [***] day period
described in clause(i)) to elect to so enforce the applicable Patent(s) to the extent that a delay in bringing such enforcement proceeding against such alleged Third Party infringer would limit or compromise the remedies (including monetary relief
and stay of regulatory approval) available against such alleged Third Party infringer. If the Party with such step-in rights under the preceding sentence
(“Step-In Enforcement Party”) provides such notice and the Initial Enforcement Party fails to initiate a suit or take such other appropriate action within [***] days after receipt of such
notice from the Step-In Enforcement Party (or such earlier time as is required to avoid limiting or compromising the remedies (including monetary relief and stay of regulatory approval) available against such
alleged Third Party infringer), then the Step-In 

  
 - 61 - 

 Enforcement Party shall have the right, but not the obligation, to initiate a suit or initiate or take such
other appropriate action that it believes is reasonably required to protect the applicable Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual Property,
Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or Joint Inventions. The Step-In Enforcement
Party shall give the Initial Enforcement Party advance notice of the Step-In Enforcement Party’s intent to file any such suit or take any such action and the reasons therefor and shall provide the Initial
Enforcement Party with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, the Step-In Enforcement Party shall keep the Initial Enforcement Party promptly informed and
shall from time to time consult with the Initial Enforcement Party regarding the status of any such suit or action and shall provide the Initial Enforcement Party with copies of all material documents (e.g., complaints, answers, counterclaims,
material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings
and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Notwithstanding anything in this Section 10.3 to the contrary: (x) Celgene shall have final decision-making authority as to
representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products, (y) if the Initial Enforcement Party has a reasonable, good faith concern that the
Step-In Enforcement Party’s exercise of its backup enforcement or defense rights with respect to any Patent would be detrimental to the overall patent protection of the Shared Products or related
Companion Diagnostics, then the Step-In Enforcement Party shall not be permitted to enforce or defend such Patent without the prior consent of the Initial Enforcement Party, and (z) in no event shall
Vividion ever be entitled to enforce or defend any Celgene Intellectual Property. 
 (e) Conduct of Action. The Party initiating suit
shall have the sole and exclusive right to select counsel for any suit initiated by it under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate
or maintain such suit, the other Party shall join as a party to the suit. If requested by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party
except that the initiating Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The
Party initiating suit shall assume and pay all of its own Out-of-Pocket Costs incurred in connection with any litigation or proceedings described in this
Section 10.3, including the fees and expenses of the counsel selected by it, provided that, prior to the Vividion Opt-Out Date, if any, such fees and expenses shall be shared in accordance with the
Profit & Loss Share. The other Party shall have the right to participate and be represented in any such suit by its own counsel at its own expense (which shall not be included in the calculation of the Profit & Loss Share). 

(f) Recoveries. Any damages or other monetary awards recovered in any action, suit or proceeding brought under this Section 10.3
shall be shared as follows: 
 (i) Initial Allocation. Such damages or other sums recovered shall first be applied to reimburse each
Party for all of the costs and expenses it incurred in connection with such action, and if such recovery is insufficient to cover all such costs and expenses of both Parties, it shall [***]; and 

  
 - 62 - 

 (ii) Remaining Proceeds. Any remaining proceeds in case of suits with respect to an
enforcement proceeding relating to any Shared Product or Companion Diagnostic under this Section 10.3, shall be shared by the Parties in accordance with the Profit & Loss Share or, if obtained on or after the Vividion Opt-Out Date, the Party bringing suit under this Section 10.3 shall retain [***] percent ([***]%) and the other Party shall retain [***] percent ([***]%) of such amount. 

(g) Third Party Agreements. In the event that (i) a Patent covered by an Existing Third Party Agreement or Subsequent Third Party
Agreement is at issue in an action under this Section 10.3 or Section 10.4, (ii) Vividion or Celgene, as applicable, has a right to enforce or defend, as applicable, the Vividion Patents, Vividion
Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party Agreement, and (iii) Celgene
or Vividion, respectively, desires to enforce or defend, as applicable, such Patent in accordance with the procedures under this Section 10.3 or Section 10.4, as applicable, then Vividion or Celgene, respectively, shall either
(A) obtain the licensor(s)’ consent under such Existing Third Party Agreement or Subsequent Third Party Agreement so that Celgene or Vividion, respectively, may file such an action in its own name or (B) shall undertake such an action
on Celgene’s behalf and at [***] expense or on Vividion’s behalf and at [***] expense, respectively. 
 Section 10.4
Claimed Infringement. Each Party shall promptly notify the other Party in writing of any allegation by a Third Party that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or misappropriates,
or may infringe or misappropriate, the intellectual property rights of such Third Party. If a Third Party asserts or files against a Party or its Affiliates any claim of infringement or misappropriation of the intellectual property rights of such
Third Party or other action relating to alleged infringement or misappropriation of such intellectual property rights (“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 

(a) Notice and Defense. If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization
of any Shared Product or Companion Diagnostic infringes or misappropriates the intellectual property rights of any Third Party, such Party shall promptly notify the other Party. In any such instance, the Parties shall as soon as practicable
thereafter meet (which may be through the JSC) to discuss in good faith regarding the best response to such notice. With respect to any such claim by a Third Party described in this Section 10.4(a), the applicable Lead Party shall have the sole
right, but not the obligation, to defend and dispose (including through settlement or license) such claim in the applicable portion(s) of the Territory; it being understood and agreed that the applicable
non-Lead Party shall be entitled to defend itself with respect to any such Third Party claim in the applicable portion(s) of the Territory to the extent that such
non-Lead Party’s responses and admissions in conducting such defense do not interfere with the ability of the Lead Party to defend such Third Party claim. 

(b) Costs. Prior to the Vividion Opt-Out Date, the costs and expenses incurred by the Parties in
connection with defense of any claim described in Section 10.4(a) in the Territory shall be shared by the Parties in accordance with the Profit & Loss Share. For clarity, this Section 10.4(b) is intended to address the
Parties’ defense costs in such claim, and if as a result of any 

  
 - 63 - 

 such defense of such claim, a Party obtains a license under Third Party intellectual property rights,
Section 9.5 shall apply to the amounts due to any such Third Party pursuant to such license. 
 Section 10.5 Patent Term
Extensions. The JPC shall, as necessary and appropriate, use reasonable efforts to agree upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions for Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents Joint Co-Co Patents and Joint Patents that Cover Shared Products. If
the JPC is unable to agree upon which of such Patents should be extended, and the matter remains unresolved after the procedure described in Section 2.2(e), then the Lead Party with respect to the portion of the Territory as to which such
patent term extension relates shall have the right to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to such
Vividion Patent, Vividion Co-Co Collaboration Patent or Celgene Co-Co Collaboration Patent. 

Section 10.6 Patent Marking. Each Party shall comply with the patent marking statutes in each country in which any Shared Product
is Manufactured or Commercialized by or on behalf of a Party or their respective Affiliates or (sub)licensees, as applicable, hereunder. 

Section 10.7 Application of 35 U.S.C. § 102(c). It is agreed and acknowledged that this Agreement establishes a qualifying
collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C. § 102(c). Neither Party shall invoke the provisions of 35 U.S.C.
§ 102(c), or file this Agreement, in connection with the prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without the prior written consent of the other Party. In the event that a Party,
during the course of prosecuting a patent application claiming a 35 U.S.C. § 102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it necessary to file a terminal disclaimer to overcome an obviousness type
double patenting rejection in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall coordinate the filing of such terminal disclaimer in good faith, and, to the
extent required under 35 U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce 35 U.S.C. § 102(c) Patent independently from the Earlier Patent. To this end, to the extent required
under 35 U.S.C. § 102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to 35 U.S.C. § 102(c) Patent. 

Article XI 

Confidentiality 

Section 11.1 Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its
Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its Affiliates shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (b) not disclose such Confidential Information to any Third Party without the prior written
consent of the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement, the Master Agreement or any other Development &
Commercialization Agreement (it being 

  
 - 64 - 

 
understood that this clause (c) shall not create or imply any rights or licenses not expressly granted under this Agreement). No Confidential Information of the Disclosing Party or any of
its Affiliates shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights explicitly granted to the Receiving Party under this Agreement. “Confidential
Information” shall exclude any information that: 
 (a) was known by the Receiving Party or any of its Affiliates prior to its date of
disclosure to the Receiving Party or any of its Affiliates by or on behalf of the Disclosing Party or any of its Affiliates, as established by written evidence; or 

(b) is lawfully disclosed to the Receiving Party or any of its Affiliates by sources other than the Disclosing Party or any of its Affiliates
rightfully in possession of the Confidential Information; or 
 (c) is or becomes published or generally known to the public through no fault
or omission on the part of the Receiving Party or any of its Affiliates or (sub)licensees; or 
 (d) is independently developed by or for the
Receiving Party or any of its Affiliates without reference to or reliance upon such Confidential Information, as established by written records. 

Section 11.2 Permitted Disclosure. The Receiving Party may provide the Disclosing Party’s or any of the Disclosing
Party’s Affiliates’ Confidential Information: 
 (a) to the Receiving Party’s employees, consultants and advisors, and to the
employees, consultants and advisors of such Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such
information and materials as confidential under obligations of confidentiality and non-use no less stringent than those set forth in this Article XI (provided that legal counsel shall not be required to
execute any written confidentiality agreements); 
 (b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in
order to seek or obtain approval to conduct Clinical Trials or to gain Regulatory Approval with respect to the Shared Products as contemplated by this Agreement; provided that such disclosure may be made only following reasonable
notice to the Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 
 (c) if
such disclosure is required by judicial order or applicable Law or to defend or prosecute litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the
Disclosing Party of such requirement, cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its
applicable Affiliates’) Confidential Information that the Receiving Party is legally required to furnish. 

  
 - 65 - 

 Section 11.3 Publicity; Terms of this Agreement;
Non-Use of Names. 
 (a) Public Announcements. Except as required by judicial order or
applicable Law (in which case, Section 11.3(b) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other
Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would like to
make the public announcement (or, in extraordinary circumstances, such shorter period as required to comply with applicable Law). Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or
news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure
relating to this Agreement if the contents of such press release, public announcement or disclosure (i) (A) does not consist of financial information and has previously been made public other than through a breach of this Agreement by the
issuing Party or its Affiliates, (B) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or (C) is contained in the a redacted version of this Agreement, and (ii) is material
to the event or purpose for which the new press release or public announcement is made. 
 (b) Notwithstanding the terms of this Article XI:

 (i) Either Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the reasonable
opinion of such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other Governmental Authority. Notwithstanding the foregoing, before
disclosing this Agreement or any of the terms hereof pursuant to this Section 11.3(b)(i), the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all
exhibits and schedules) with respect to any filings with the US Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which
securities issued by a Party or a Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by
the other Party, and the Parties will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(ii) Notwithstanding Section 11.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of
its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary
in the following instances: 
 (A) complying with applicable Laws (including the rules and regulations of the SEC or any national securities
exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

  
 - 66 - 

 (B) disclosure, solely on a “need to know basis,” to (1) Affiliates,
subcontractors, advisors (including attorneys and accountants), (2) subject to Section 11.3(b)(ii)(C), investment bankers, and (3) in each case of (1) and (2), such Affiliates’, subcontractors’, advisors’ and investment
bankers’, and each of the Parties’, respective directors, employees, contractors and agents; provided that, in all cases of (1), (2) and (3), prior to any such disclosure, each disclosee must be bound by written obligations
of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this Article XI (provided, however, that in the
case of prospective investment bankers, the term of confidentiality may be shortened to three (3) years from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt,
will not permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any
failure by any Person who receives Confidential Information pursuant to this Section 11.3(b)(ii)(B) or Section 11.3(b)(ii)(C) to treat such Confidential Information as required under this Article XI; and 

(C) in the case of any disclosure of this Agreement to any actual or potential acquirer, assignee, licensee, licensor, investment banker,
institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted Version, in each case, which version shall be agreed upon by the Parties in good faith; it being understood and agreed that, in connection
with a proposed Change of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is in the final round of negotiations with such
Third Party regarding execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement as applicable, to such Third Party; provided
that a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under obligations of confidentiality not to disclose
the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such licensors and lenders. 

(iii) The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results and significant developments
regarding the Shared Program and other activities in connection with this Agreement, the Master Agreement and each Development & Commercialization Agreement that may include information that is not otherwise permitted to be disclosed under
this Article XI, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and regulatory process, commercialization activities and the like. A Party (the
“Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory process and commercialization activities, and in such event it shall first
notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business Days in advance of issuing such press release or making such public
announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as possible under the circumstances
if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement without such prior review by the other Party if (A) the
contents of such press release or public announcement 

  
 - 67 - 

 have previously been made public other than through a breach of this Agreement by the issuing Party and
(B) such press release or public announcement does not materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or
suggestions that the Cooperating Party may have regarding the proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles
to be observed in such disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep
investors informed regarding the Requesting Party’s business. 
 Section 11.4 Publications. The Parties agree that
decisions regarding the timing and content of Publications shall be subject to the oversight and approval of the JDC and JPC and neither Party nor its Affiliates shall have the right to make Publications pertaining to the Collaboration except as
provided herein. If a Party or its Affiliates desire to make a Publication, such Party must comply with the following procedure: 
 (a)
JDC Review. The publishing Party shall provide the JDC and the non-publishing Party with an advance copy of the proposed Publication, and the JDC shall then have [***] days prior to submission for any
Publication [***] days in the case of an abstract or oral presentation) in which to determine whether the Publication may be published and under what conditions, including (i) delaying sufficiently long to permit the timely preparation and
filing of a patent application or (ii) specifying changes the JDC reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or license, including under
this Agreement) in whole or in part to the non-publishing Party. 
 (b) Removal of Confidential
Information. In addition, if the non-publishing Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment,
discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential
Information of the non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c) Scientific Conferences. Each Party shall have the right to present its Publications approved pursuant to this Section 11.4 at
scientific conferences, including at any conferences in any country in the world, subject to any conditions imposed by the JDC in its approval. 

(d) Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to
Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to
restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement,
exercise such rights after consultation with Celgene. 

  
 - 68 - 

 (e) Delegation. For purposes of convenience, the JDC may delegate its
responsibilities under this Section 11.4 to one or more representatives of Vividion and Celgene. 
 Section 11.5 Term. All
obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall survive termination or expiration of this Agreement and shall expire five (5) years following termination or expiration of this Agreement. 

Section 11.6 Return of Confidential Information. 

(a) Obligations to Return or Destroy. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the
Disclosing Party all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy:

 (i) any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information
of the Disclosing Party or any of its Affiliates; and 
 (ii) any Confidential Information of the Disclosing Party or any of its Affiliates
(and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 
 (b)
Destruction. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its
Affiliates (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any
requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

(c) Limitation. Nothing in this Section 11.6 shall require the alteration, modification, deletion or destruction of archival tapes
or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations
under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d) Exceptions. Notwithstanding the foregoing, 

(i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 
 (ii) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents 

  
 - 69 - 

 (A) to the extent reasonably required (1) to exercise the rights and licenses of the
Receiving Party expressly surviving expiration or termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(B) to the extent it is impracticable to return or destroy such Confidential Information without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving Party shall
continue to be bound by its obligations of confidentiality and other obligations under this Article XI. 
 Article XII 

Representations and Warranties 

Section 12.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the
Execution Date, that: 
 (a) Authority. Each Party is duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as applicable. 

(b) Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder have been obtained, except for authorizations and consents that may be necessary
under Antitrust Law. 
 (c) No Conflict. Notwithstanding anything to the contrary in this Agreement, the execution and delivery of
this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of
applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to which it is a party or by
which it or any of its Affiliates is bound, existing as of the Execution Date. 
 (d) Enforceability. This Agreement has been duly
executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e) Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in the
Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 

  
 - 70 - 

 Section 12.2 Additional Vividion Representations. Vividion represents, warrants
and covenants to Celgene, as of the Execution Date, as follows: [Note: The representations and warranties marked by an asterisk (*) below may be qualified by Vividion with a schedule of exceptions prior to the Execution Date] 

(a) Vividion has all rights, authorizations and consents necessary to grant all rights and licenses it purports to grant to Celgene under this
Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 
 (b) Vividion has not used, and during the
Term will not knowingly use, any Know-How in the Shared Program that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses
granted or to be granted to Celgene hereunder; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(b)
with respect to any Patents or Know-How licensed to Vividion under the Scripps License is as set forth in Section 12.4(b). 

(c) Vividion has not granted, and during the Term Vividion will not grant, any right or license, to any Third Party relating to any of the
intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d) There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings or governmental
investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion to consummate the
transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or the Co-Co
Target or any Shared Product.* 
 (e) To Vividion’s knowledge, the practice of the Vividion Intellectual Property as contemplated under
this Agreement does not (i) infringe any claims of any Patents of any Third Party (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including
any safe harbor, research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (ii) misappropriate any
Know-How of any Third Party, and, in particular, the practice of the Vividion Intellectual Property by or on behalf of Celgene or any of its Affiliates or Licensee Partners as contemplated under this Agreement
does and will not (A) infringe any claims of any Patents licensed to Vividion pursuant to the License Agreement dated as of January 6, 2016 by and between by The Scripps Research Institute (“Scripps”) and Vividion (the
“Scripps License”) (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including any safe harbor, research exemption, government or
executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (B) misappropriate any Know-How
licensed to Vividion pursuant to the Scripps License; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under 

  
 - 71 - 

 law or at equity, Celgene’s only remedy for any breach of this Section 12.2(e) solely with respect
to the Scripps License is as set forth in Section 12.4(b).* 
 (f) None of (i) the Vividion Patents owned by Vividion or both
Controlled by and Prosecuted by Vividion and (ii) to Vividion’s knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination, opposition,
interference or litigation proceedings or inter partes reviews, post grant reviews or covered business methods reviews.* 
 (g) To the
knowledge of Vividion, the Vividion Patents Controlled by Vividion or any of its Affiliates pursuant to any Existing Third Party Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing Third
Party Agreements. 
 (h) Vividion has and, to Vividion’s knowledge, the applicable licensor under each Existing Third Party Agreement
has, if applicable, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patents or Know-How licensed thereunder.* Neither Vividion nor any of its Affiliates has
granted any liens or security interests on the Vividion Intellectual Property and the Vividion Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind,
except in each case with respect to licenses, covenants not to sue, immunities from suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration. 

(i) Schedule 12.2(i) contains a complete and accurate list of all Patents owned or licensed by Vividion or its Affiliates as of the Execution
Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 12.2(i), Vividion and its Affiliates do not own and have not licensed any
Patent that is necessary or, to Vividion’s reasonable belief as of the Execution Date, reasonably useful to Develop, Manufacture or Commercialize any Shared Products; it being understood and agreed that, notwithstanding anything to the contrary
in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(i) with respect to any Patents or Know-How licensed to Vividion under the Scripps License
is as set forth in Section 12.4(b). 
 (j) Schedule 12.2(j) sets forth a complete and accurate list of all Existing Third Party
Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Vividion nor, to the knowledge of Vividion, any licensor under the Existing
Third Party Agreements is in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a material obligation under, the Existing
Third Party Agreements.* 
 (k) Except under the Scripps License (solely with respect to royalties for which Vividion shall be solely
responsible) and Existing Third Party Agreements in effect as of the Execution Date, and except as set forth on Schedule 12.2(j), Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or
performance of this Agreement. 

  
 - 72 - 

 Section 12.3 Covenants. 

(a) Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i) all employees of such Party or its Affiliates, Licensee Partners or Third Party subcontractors working under this Agreement will be under
appropriate confidentiality obligations at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries,
whether or not patentable, to such Party as the sole owner thereof; 
 (ii) to its knowledge, such Party will not (A) employ or use,
nor hire or use any contractor or consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any
Regulatory Authority outside the US Territory) or (B) employ any individual who, or entity that is, the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the US Territory), in
each of subclauses (A) and (B) in the conduct of its activities under this Agreement 
 (iii) neither such Party nor any of its
Affiliates shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder;
and 
 (iv) such Party and its Affiliates shall perform their activities pursuant to this Agreement in compliance (and shall ensure
compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP as applicable. 
 (b)
Third Party Agreement Covenants. Vividion hereby covenants to Celgene that Vividion shall maintain the Existing Third Party Agreements and each Party hereby covenants to the other Party that it shall maintain any Subsequent Third Party
Agreements to which it is a Party, and shall not amend or terminate such agreements entered into by such Party, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect the other Party’s
rights under this Agreement. 
 Section 12.4 Vividion Covenants During the Term. 

(a) Except to the extent expressly permitted under Section 15.4, during the Term, neither Vividion nor its Affiliates will, other than to
an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of
subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below)
or dispose of, any assets specifically related to this Agreement, including with respect to any Shared Product(s) and any then-identified Companion Diagnostic(s) developed therefor, or pre-clinical study or
Clinical Trial results or other data specifically related to the Shared Program, or any intellectual property specifically related to any of the foregoing (with respect to the Shared Program, the “Program Assets”) owned or
controlled by Vividion at any time, except to the extent such assignment, transfer, conveyance, encumbrance 

  
 - 73 - 

 or disposition would not fundamentally frustrate the purpose of this Agreement with respect to the Shared
Program, (b) license or grant to any Third Party, or agree to license or grant to any Third Party, any rights to any Program Assets owned or controlled by Vividion at any time if such license or grant would fundamentally frustrate the purpose
of this Agreement with respect to the Shared Program, or (c) disclose any Confidential Information relating to the Program Assets owned or controlled by Vividion at any time to any Third Party if such disclosure would fundamentally frustrate
the purpose of this Agreement with respect to the Shared Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to the Shared Program to any Affiliate of Vividion to the
extent permitted under Section 15.4. 
 (b) Vividion hereby covenants and agrees, subject to Section 13.3, that it will defend and
hold harmless Celgene and its Affiliates from any Damages resulting from any Claims that, as a result of any Development, Manufacturing or Commercialization, including any making, using, selling, offering for sale, or importing, of any Shared
Product in the Territory in accordance with this Agreement, Celgene or any other Selling Party has infringed or misappropriated (i) any Patents or Know-How that (A) are owned jointly or solely by
Scripps and/or its employees or consultants and (B) (I) arose from any Development by or on behalf of Vividion of any Shared Product and/or involved, to the extent provided by Vividion, the use of any Shared Product, Vividion Intellectual
Property and/or other Vividion materials or resources and/or (II) were discovered, developed, generated or invented by any employee or consultant of Scripps in the conduct of activities under a sponsored research or other agreement or any other
arrangement (whether formal or informal) with Vividion and (ii) any Patents or Know-How licensed to Vividion under the Scripps License (any such claims under clauses (i) or (ii) above, the
“Scripps Claims”). Notwithstanding anything to the contrary in this Agreement, in the event of any Scripps Claim, Vividion hereby covenants and agrees to sublicense to Celgene (with the right to sublicense in accordance with
Section 8.2 and Section 8.3) any Patents or Know-How that are the subject of such Scripps Claim, all as reasonably necessary or desirable in order to enable Celgene and its Selling Parties to
Develop, Manufacture, Commercialize, make, use, sell, offer for sale, or import the Shared Product throughout the Territory in accordance with this Agreement without any royalty or other financial obligation on account of such sublicense. 

Section 12.5 Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR
EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success of any study or test commenced under this Agreement; (b) the safety or usefulness for any
purpose of the technology or materials, including any Shared Product or Companion Diagnostic; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it provides or licenses to the other Party
under this Agreement. 
 Section 12.6 Additional Celgene Representations. Celgene represents and warrants to Vividion, as of the
Execution Date that Celgene possesses sufficient rights to enable Celgene to 

  
 - 74 - 

 grant all rights and licenses it purports to grant to Vividion under this Agreement as of the Execution
Date. 
 Section 12.7 Covenant Not to Sue. Celgene (on behalf of itself and its Affiliates and its and their respective
successors, assigns and transfers) covenants not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in
any case claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or
misappropriation involves Vividion or its Affiliates or their respective (sub)licensees (a) Developing, using, Manufacturing, or having Manufactured the Shared Products and Companion Diagnostics (solely for use in connection with the Shared
Products) in the Territory at the request of Celgene or, if Vividion is the Lead US Party, as otherwise contemplated by this Agreement or (b) offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion
Diagnostics (solely for use in connection with the Shared Products) in the US Territory as contemplated by this Agreement. 
 Article XIII

 Indemnification; Product Liabilities 

Section 13.1 Indemnification by Celgene. 

Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless Vividion and its Affiliates and their respective directors,
officers, employees and agents (the “Vividion Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(a) any breach by Celgene of any of its representations, warranties or obligations under this Agreement; 

(b) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee Partners or Third Party Contractors
in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; or 
 (c) any Development,
use, Manufacture or Commercialization of Shared Products by or on behalf of Celgene or any of its Affiliates following any Vividion Opt-Out Date, including any Product Liability Claims incurred following any
Vividion Opt-Out Date (except as contemplated by Section 2.3(c)) or any personal injury, property damage or other damage, in each case, resulting from any of the foregoing activities described in this
Section 13.1(c); provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this Section 13.1(c) from or against any Third Party Damages
arising out of or relating to, directly or indirectly, any Claim brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in his/her capacity as a director, officer, shareholder or employee of
Vividion, as applicable; it being understood and agreed that this Section 13.1(c) shall not require Celgene to pay to Vividion any amounts that [***] or [***]; in each case, provided, however, that such indemnity shall not
apply to the extent (i) Vividion has an indemnification obligation pursuant to Section 13.2 for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

  
 - 75 - 

 Section 13.2 Indemnification by Vividion. Vividion agrees, at Vividion’s
cost and expense, to defend, indemnify and hold harmless Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any
Claim relating to: 
 (a) any breach by Vividion of any of its representations, warranties or obligations under this Agreement (including
without limitation pursuant to Section 12.4(b)); 
 (b) the gross negligence, willful misconduct or violation of Law of Vividion or its
Affiliates, Licensee Partners or Third Party Contractors in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(c) any of the matters disclosed by Vividion in a disclosure schedule pursuant to Section 12.2, where the cause of action underlying such
Damages accrued prior to the Execution Date. For the avoidance of doubt, amounts payable under Subsequent Third Party Agreements entered into under Section 9.5 shall be borne by Celgene as set forth in Section 9.5, and shall not be subject
to indemnification under this Section 13.2; or 
 (d) any Development, use, Manufacture or Commercialization of Shared Products by or on
behalf of Vividion or any of its Affiliates following the reversion thereof to Vividion pursuant to Section 14.4(a), including any Product Liability Claims or any personal injury, property damage or other damage, in each case, resulting from
any of the foregoing activities described in this Section 13.2(d); provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the Celgene Indemnified Parties under this
Section 13.2(d) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim brought against Celgene Indemnified Parties by any director, officer, shareholder or employee of Celgene acting in his/her
capacity as a director, officer, shareholder or employee of Celgene, as applicable; it being understood and agreed that this Section 13.2(d) shall not require Vividion to pay Celgene any amounts that Vividion includes as an expense in, or has
previously paid pursuant to, Section 9.1 or Section 9.3, as applicable; 
 in each case, provided, however, that such
indemnity shall not apply to the extent (i) Celgene has an indemnification obligation pursuant to Section 13.1 for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

Section 13.3 Indemnification Procedures. In the event of any such Claim against any of the Celgene Indemnified Parties or Vividion
Indemnified Parties (each, an “Indemnified Party”), as applicable, by any Third Party, such Indemnified Party shall promptly, and in any event within [***] Business Days, notify the applicable indemnifying Party (the
“Indemnitor”) in writing of the Claim. The Indemnitor shall have the right, exercisable by notice to the Indemnified Party within [***] Business Days after receipt of notice from the Indemnified Party of the Claim, to assume
direction and control of the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and the Indemnitor agrees to 

  
 - 76 - 

 pay all Damages relating to such matter, as evidenced in a written confirmation delivered by the Indemnitor
to the Indemnified Party) with counsel selected by the Indemnitor and reasonably acceptable to the Indemnified Party; provided that the failure to provide timely notice of a Claim by a Third Party shall not limit an Indemnified
Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to the Indemnitor. The Indemnified Parties shall cooperate with the Indemnitor and may, at their option and expense, be separately
represented in any such action or proceeding. The Indemnitor shall not be liable for any litigation costs or expenses incurred by the Indemnified Parties without the Indemnitor’s prior written authorization for so long as the Indemnitor
controls such litigation. In addition, the Indemnitor shall not be responsible for the indemnification or defense of any Indemnified Party to the extent arising from any negligent or intentional acts by any Indemnified Party or the breach by such
Indemnified Party of any representation, obligation or warranty under this Agreement, or any Claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Article
XIII. 
 Section 13.4 Product Liability Costs. Except with respect to such portion (if any) of Product Liabilities that are
Claims entitled to indemnification under Section 13.1 or Section 13.2, the Parties jointly shall be responsible for all Product Liabilities, all Out-of-Pocket
Costs and FTE costs incurred by the controlling Party under Section 13.5 in connection with any litigation or proceeding related to any applicable Third Party Products Liability Action and all Out-of-Pocket Costs and FTE costs incurred by the non-controlling Party under Section 13.5 at the request of the controlling Party under Section 13.5, all of
which such costs and expenses shall (a) if relating to Shared Products distributed prior to the Vividion Opt-Out Date, be taken into account in determining the Profit & Loss Share as, and to the
extent, provided in Exhibit D or (b) be borne solely by [***] if and only to the extent such Product Liabilities arose from Shared Products distributed after the Vividion Opt-Out Date. 

Section 13.5 Conduct of Product Liability Claims. 

(a) Each Party shall promptly notify the other in the event that any Third Party asserts or files any products liability claim or other action
relating to alleged defects in any Shared Product (whether design defects, manufacturing defects or defects in sales or marketing) (“Third Party Products Liability Action”) against such Party. In the event of a Third Party Products
Liability Action against such a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to join or otherwise participate in such legal action with legal counsel selected by the unnamed Party and reasonably
acceptable to the named Party. The Party named in such Third Party Products Liability Action shall have the right to control the defense of the action, but shall notify and keep the unnamed Party apprised in writing of such action and shall consider
and take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action; provided, however, that, in the event of a Vividion
Opt-Out Notice, Celgene shall have the right to control the defense of all Third Party Product Liability Actions after the Vividion Opt-Out Date. In the event of a Third
Party Products Liability Action against both Parties, unless otherwise agreed by the Parties in writing, Celgene shall control the response to such Third Party Products Liability Action. 

(b) The non-controlling Party of a Third Party Products Liability Action shall reasonably cooperate
with the controlling Party in the preparation and formulation of a defense 

  
 - 77 - 

 to such Third Party Products Liability Action, and in taking other steps reasonably necessary to respond to
such Third Party Products Liability Action. The controlling Party shall have the right to select its counsel for the defense to such Third Party Products Liability Action, which counsel must be reasonably acceptable to the non-controlling Party. If required under applicable Law in order for the controlling Party to maintain a suit in response to such Third Party Products Liability Action, the
non-controlling Party shall join as a party to the suit. The non-controlling Party shall also have the right to participate and be represented in any such suit on a
voluntary basis by its own counsel at [***] expense. The controlling Party shall not settle or compromise any Third Party Products Liability Action without the consent of the other Party, which consent shall not be unreasonably withheld. 

Section 13.6 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF SECTION 8.6 OR ARTICLE XI, OR A PARTY’S LIABILITY
PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT
OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 

Section 13.7 Insurance. Beginning on the commencement of the first Clinical Trial of a Shared Product and thereafter during the
Term, each Party shall maintain commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least [***] US Dollars ($[***]) per claim and annual
aggregate. Celgene may elect to self-insure all or parts of the limits described above. Within [***] days following written request from the other Party, each Party shall furnish to the other Party a certificate of insurance evidencing such
coverage. If such coverage is modified or cancelled, the insured Party shall notify the other Party and promptly provide such other Party with a new certificate of insurance evidencing that such insured Party’s coverage meets the requirements
of this Section 13.7. 
 Article XIV 

Term and Termination 

Section 14.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and shall
continue, unless earlier terminated pursuant to Section 14.3 on a Shared Product-by-Shared Product and country-by-country basis, in full force and effect: 
 (a) as long as the Parties continue to
Develop or Commercialize Shared Products in accordance with the terms and conditions of this Agreement; or 
 (b) in the event of a Vividion Opt-Out Date, this Agreement shall expire: 
 (i) on a Shared Product-by-Shared Product and country-by-country basis, upon the expiration of the applicable Royalty Term with respect to such
Shared Product in such country; and 

  
 - 78 - 

 (ii) in its entirety upon the expiration of all applicable Royalty Terms under this
Agreement with respect to all Shared Products in all countries worldwide. 
 For the avoidance of doubt, this Agreement shall not be effective until the
Effective Date, and this Agreement may be subject to termination prior to the Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Program (as defined in the Master Agreement) that is the subject
of this Agreement shall revert to Vividion in accordance with Section 3.2 of the Master Agreement. 
 Section 14.2 Effect of
Expiration. Following any Vividion Opt-Out Date, after the expiration of the Term pursuant to Section 14.1(b) above, the following terms shall apply: 

(a) Licenses after Shared Product Expiration. After expiration of the Term (but not after early termination) with respect to any Shared
Product in a country in the world pursuant to Section 14.1(b)(i), Celgene’s rights and licenses hereunder under the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property
and Vividion’s rights in the Joint Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize such Shared Product and related Companion Diagnostics
in the Field in such country shall convert to exclusive, irrevocable, non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers; provided, however,
that, following such expiration and notwithstanding Section 8.5 or Section 9.5, (i) Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with
the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect to Celgene’s exercise of such rights. 

(b) Licenses after Expiration of Agreement. After expiration of the Term (but not after early termination) with respect to this
Agreement in its entirety pursuant to Section 14.1(b)(ii), Celgene’s rights and licenses hereunder under the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and
Vividion’ rights in the Joint Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize Shared Products and Companion Diagnostics in the Field
worldwide shall convert to exclusive, irrevocable, non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers; provided, however, that, following such
expiration and notwithstanding Section 8.5 or Section 9.5, (i) Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license
agreements with such Third Party licensors, in each case, ((i) and (ii)), solely with respect to Celgene’s exercise of such rights. 

Section 14.3 Termination. 

(a) Termination for Convenience. Celgene shall have the right to terminate this Agreement in its entirety for convenience upon ninety
(90) days’ prior written notice to Vividion; provided that Celgene shall not have the right to terminate this Agreement until twelve (12) months following the Effective Date (it being understood and agreed that Celgene
shall be entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

  
 - 79 - 

 (b) Termination for Material Breach. 

(i) Termination by Either Party for Breach. Subject to Section 14.3(b)(ii) (with respect to a Material Breach by either Party of
its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that fundamentally frustrates the transactions contemplated
by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such Material Breach within ninety (90) days after the date
of written notice to the breaching Party of such breach (or thirty (30) days, in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.3(b)(ii) with respect to a Material
Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section 14.3(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as to a
Material Breach under this Agreement will run from the date that written notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement under this
Section 14.3(b)(i) shall become effective at the end of the Cure Period, unless the breaching Party has cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within
the Cure Period, then, the non-breaching Party’s right of termination shall be suspended only if and for so long as the breaching Party has provided to the
non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits
to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five (225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the totality of the circumstances with respect to this Agreement will be taken into account and assessed as a whole for
purposes of determining whether a breach is a Material Breach under this Agreement. 
 (ii) Additional Procedures for Termination by
either Party for Failure of the Other Party to Use Commercially Reasonable Efforts. If either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.3(b)(i) for the other Party’s Material Breach of its
obligations to use Commercially Reasonable Efforts, it shall provide to such other Party a written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially
Reasonable Efforts,” and shall state the reasons and justification for such termination and recommending steps which such Party believes the other Party should take to cure such alleged breach. For any such notice of breach by a Party, the Cure
Period shall, subject to Section 14.3(b)(iii), be one hundred and eighty (180) days, and shall become effective in accordance with Section 14.3(b)(i). 

(iii) Disagreement as to Material Breach. If the Parties reasonably and in good faith disagree as to whether there has been a Material
Breach, then, subject to Section 15.1: (A) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within thirty (30) days following such notice of alleged Material Breach for
resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter, whether or not a Material Breach 

  
 - 80 - 

 has occurred pursuant to this Section 14.3(b); (B) the relevant Cure Period with respect thereto will
be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement (provided,
that if such dispute relates to payment, the Cure Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts), (C) it is understood and agreed that during the pendency of such dispute, all of
the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and (D) if it is finally and conclusively determined in accordance with Section 15.2
that the breaching Party committed such Material Breach, then the breaching Party shall have the right to cure such Material Breach after such determination within the Cure Period (provided, that if such dispute relates to a failure to use
Commercially Reasonable Efforts, such post-determination Cure Period shall be strictly limited to thirty (30) days and any cure within such thirty (30) day period must fully cure such breach prior to the end of such thirty (30) day
period). 
 (iv) If the Executive Officers are unable to resolve a dispute within such ten (10) Business Day period after it is
referred to them, the matter will be resolved as provided in Section 15.2. 
 (v) Payments. No milestone payments by Celgene
will be due on milestones achieved during the period between the notice of termination under Section 14.3(b) and the effective date of termination; provided, however, that, if either Party provides notice of a dispute
pursuant to Section 14.3(b) or otherwise and such dispute is resolved in a manner in which no termination of this Agreement occurs with respect to such breach or the breaching Party cures the applicable breach during the Cure Period, then upon
such resolution or cure Celgene will within five (5) Business Days pay to Vividion the applicable milestone payment for each milestone achieved during the period between the notice of termination under Section 14.3(b) and the resolution of
such dispute or cure of such breach, and if it was determined that Celgene wrongly asserted breach by Vividion under Section 14.3(b), then Celgene shall also pay interest on such amount as provided in Section 9.10. 

(c) Termination for Insolvency. To the extent permitted by Law, this Agreement may be terminated by either Party upon the filing or
institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however,
that, in the event of any involuntary bankruptcy or receivership proceeding such right to terminate shall only become effective if the non-terminating Party consents to the involuntary bankruptcy or
receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof. 
 (d) Termination for Patent
Challenge. Either Party shall have the right to terminate this Agreement solely on a Shared Product-by-Shared Product basis upon written notice if the other Party or
any of its Affiliates challenges the validity, scope or enforceability of or otherwise opposes any Patent (i) included in the Vividion Intellectual Property or Vividion Co-Co Collaboration Intellectual
Property and that is licensed to Celgene under this Agreement in any action or proceeding, or (ii) included in the Celgene Intellectual Property or Celgene Co-Co Collaboration Intellectual Property that
is licensed to Vividion under this Agreement in any action 

  
 - 81 - 

 
or proceeding (subject to the exceptions described in this Section 14.3(d), a “Challenge”) (other than as may be necessary or reasonably required to assert a defense,
cross-claim or a counter-claim in an action or proceeding asserted by either Party or any of its Affiliates or Licensee Partners against the other Party or any of its Affiliates or to respond to a court request or order or administrative law,
request or order) it being understood and agreed that either Party’s right to terminate this Agreement under this Section 14.3(d) shall not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging
Party”) that first becomes such an Affiliate as a result of a Change of Control involving the Challenging Party, where such new Affiliate was undertaking any of the activities described in the foregoing clause prior to such Change of
Control; provided that a Party’s right to terminate this Agreement under this Section 14.3(d) shall apply to actions undertaken by such new Affiliate if the Challenging Party is the acquiror in such Change of Control and such
new Affiliate does not terminate or otherwise cease participating in such action, proceeding, challenge or opposition within thirty (30) days after the effective date of such Change of Control. If a Licensee Partner of either Party challenges
the validity, scope or enforceability of or otherwise opposes any Patent included in any of the intellectual property described in this Section 14.3(d) under which such Licensee Partner is sublicensed in any action or proceeding, then the Party
that granted such sublicense shall, upon written notice from the other Party, terminate such sublicense. For the avoidance of doubt, an action by a Party or any of its Affiliates (collectively the “Pursuing Party”) in accordance
with this Agreement and the Master Agreement to amend claims within a pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application or in defense of a Third Party
proceeding, or to make a negative determination of patentability of claims of a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending
patent application, shall not constitute a challenge under this Section 14.3(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any Confidential Information of the other Party
or any nonpublic information regarding the Prosecution or enforcement of any Vividion Patent, Celgene Co-Co Collaboration Patent or Vividion Co-Co Collaboration Patent
(including Joint Co-Co Patents and Joint Patents) to which a Party or any of its Affiliates or (sub)licensees are or become privy as a consequence of the rights granted to such Party pursuant to Article X, in
initiating, requesting, making, filing or maintaining, or in funding or otherwise assisting any other Person with respect to, any Challenge. 

Section 14.4 Effects Of Termination. 

(a) Effects of Celgene Termination for Convenience or Vividion Termination for Celgene Breach, Insolvency or Patent Challenge. Upon
termination of this Agreement by Celgene under Section 14.3(a) or by Vividion under Section 14.3(b), 14.3(c) or 14.3(d), the following shall apply: 

(i) (A) all licenses granted by Vividion to Celgene under Section 8.1(a) shall terminate in their entirety if pursuant to
Section 14.3(a), Section 14.3(b) or Section 14.3(c), and (B) with respect to the corresponding Shared Product if pursuant to Section 14.3(d), and Celgene shall (x) grant to Vividion an exclusive (even as to Celgene and
its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene Co-Co Collaboration Intellectual Property and Celgene’s
interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop, use, Manufacture, have 

  
 - 82 - 

 Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion
Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or
counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming or otherwise asserting that Vividion or its Affiliates or their respective
(sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective (sub)licensees Developing,
using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products; 

(ii) each Party shall be released from its Development, Manufacture and Commercialization obligations (except as set forth in
Section 14.4(a)(vii) and (viii) below with respect to Celgene’s transfer of Manufacturing to Vividion hereunder); 
 (iii)
within [***] days after such termination, unless there has been a Vividion Opt-Out Date, each Party shall provide the other with a report of Net Sales, COGS and Allowable Expenses and other amounts incurred by
such Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination for the purpose of calculating a final reconciliation of shared costs and payments in accordance with Section 9.1 and
Section 9.3, as applicable. Each Party shall submit any supporting information reasonably requested by the other Party related to such Net Sales, COGS and Allowable Expenses and such other amounts included in such Party’s reconciliation
report within [***] days after the other Party’s receipt of such request. The Parties, with the assistance of the JCC, shall conduct a final reconciliation of such costs and payments within [***] days after receipt of all such supporting
information, and an invoice shall be issued to the Party (if any) that owes the other Party a payment to accomplish the cost sharing or payment envisioned under this Agreement pursuant to Section 9.1 and Section 9.3, as applicable. The
paying Party shall pay all amounts payable under any such invoice within [***] days after its receipt of such invoice; provided, however, that, Celgene shall remain responsible for its applicable share of all COGS and Allowable
Expenses committed prior to the effective date of termination and not cancelable by Vividion, which Vividion shall reasonably seek to minimize, with respect to the Shared Products to the extent such COGS and Allowable Expenses (A) are within an
approved Development Budget under an approved Development Plan or Commercialization Budget under an approved Commercialization Plan, respectively, in place prior to termination and (B) are solely incurred by Vividion during the period ending
[***] days after the effective date of termination of this Agreement; 
 (iv) within [***] days after such termination, Celgene shall
provide to Vividion a fair and accurate summary report of the status of Development and Commercialization activities conducted by Celgene with respect to the Shared Products; 

(v) Celgene shall promptly transfer and assign to Vividion all of Celgene’s and its Affiliates’ rights, title and interests in and
to the product trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene and solely used for Shared Products; 

  
 - 83 - 

 (vi) Celgene shall as soon as reasonably practicable transfer and assign to Vividion all
Regulatory Approvals and Regulatory Documentation with respect to the Shared Products and a copy of all of the data comprising the Global Safety Database; provided that Celgene may retain such data and a single copy of such Regulatory
Approvals and Regulatory Documentation for its records. Notwithstanding the foregoing, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development, Manufacture or Commercialization of any product other than
the Shared Products, in place of transferring or assigning the foregoing, Celgene shall instead grant Vividion a Right of Reference or Use with respect to such approvals or documentation with respect to the Shared Products; 

(vii) Vividion shall have the option, exercisable within [***] days following the effective date of such termination of this Agreement, to
obtain Celgene’s inventory of the Shared Products at a price equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs for such inventory of the Shared Products; provided that, if Celgene, its Affiliates or
(sub)licensees have outstanding orders, at Vividion’s election, either Vividion shall fulfill such orders or, notwithstanding Vividion’s option to purchase inventory, Celgene may retain sufficient inventory to fulfill such orders. Vividion
may exercise such option by written notice to Celgene during such [***] day period; provided that, in the event Vividion exercises such right to purchase such inventory, Celgene shall grant, and hereby does grant, a royalty-free right
and license to any trademarks, names and logos of Celgene contained therein for a period of [***] months solely to permit the orderly sale of such inventory, subject to Vividion meeting reasonable quality control standards imposed by Celgene on the
use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 
 (viii)
to the extent that Celgene is responsible for Manufacturing the Shared Products immediately prior to such termination, at Vividion’s written request: 

(A) in exchange for a payment equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs and upon other commercially reasonable
terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable Efforts to supply Vividion and its Affiliates with comparable quantities of the Shared Products in
the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [***] months after the effective date of the termination and establishment by Vividion of an alternative supply
for such product(s); 
 (B) in the event Celgene was utilizing a Third Party manufacturer to Manufacture the Shared Products, to the extent
permitted by the terms of any applicable contract, Celgene shall promptly assign to Vividion the manufacturing agreements with such Third Party with respect to such product(s); and 

(C) Celgene shall transfer, or have transferred, to Vividion or its designee, pursuant to a technology transfer plan to be mutually agreed by
the Parties, all Manufacturing Technology Controlled by Celgene within Celgene Co-Co Collaboration Intellectual Property that is both necessary to Manufacture the Shared Products as Manufactured by or on
behalf of Celgene and its Affiliates prior to termination and has been incorporated in 

  
 - 84 - 

 
regulatory documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Shared Products (or is in the process of being incorporated), and Celgene shall
provide reasonable assistance in connection with the transfer of such Manufacturing Technology to Vividion or its designee, all of which shall be transferred or provided at Celgene’s Out-of-Pocket Costs; 
 (ix) separate transitional activities shall be undertaken with respect to
any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or
Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents
otherwise associated with such Shared Products are transferred; 
 (x) notwithstanding anything to the contrary in Section 8.6,
Vividion shall have the right to pursue the Development, Manufacture and Commercialization of the Shared Products; and 
 (xi) the
provisions of Article X (other than Section 10.1) shall terminate, and Celgene shall, if applicable, provide reasonable assistance to Vividion and cooperation in connection with the transition of Prosecution and enforcement responsibilities to
Vividion with respect to Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint
Patents then being Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 

(b) Effects of Celgene Termination for Vividion Breach, Insolvency or Patent Challenge. Upon any termination of this Agreement by
Celgene under Section 14.3(b), 14.3(c) or 14.3(d): 
 (i) if Celgene has the right to terminate this Agreement pursuant to
Section 14.3(b), Section 14.3(c) or Section 14.3(d), Celgene may elect, upon written notice to Vividion, to either: 
 (A)
terminate this Agreement in its entirety, if pursuant to Section 14.3(b) or 14.3(c), or with respect to the corresponding Shared Product, if pursuant to Section 14.3(d), in which case (1) all rights and obligations of the Parties
under this Agreement or the corresponding Shared Product, respectively, shall terminate, except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and
(II) Section 14.4(d) shall, in each case (I) and (II), survive such termination, (2) Vividion shall return any Confidential Information of Celgene pursuant to Article VIII of the Master Agreement that is not necessary to practice
any licenses retained by Vividion following such termination under this Agreement, another Development & Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) Sections 14.4(a)(v), (vi) and
(vii) shall apply and Celgene (x) shall grant to Vividion an exclusive (even as to Celgene and its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene
Co-Co Collaboration Intellectual Property and Celgene’s interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop,

  
 - 85 - 

 use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared
Products and Companion Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly,
sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming or otherwise asserting that Vividion or its Affiliates or
their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective
(sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products; or 

(B) maintain this Agreement in full force and effect (foregoing, for the avoidance of doubt, the right to terminate this Agreement for such
occurrence of such breach) and, with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion: (1) all future milestones and royalty obligations in respect of such Shared Products payable by Celgene under this
Agreement following such election shall be subject to a reduction of [***] percent ([***]%) and (2) the Profit & Loss Share shall be terminated (and the Parties shall treat this Agreement as though a Vividion Opt-Out had occurred pursuant to Section 2.3). 
 (ii) if Celgene has made the election set forth in
Section 14.4(b)(i)(B), from and after such election: 
 (A) if the Vividion Opt-Out Date has
not occurred before the effective date of termination, then Celgene shall pay Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination pursuant to Article IX (subject to the [***] percent ([***]%) reduction
described in Section 14.4(b)(i) above), with the Vividion Opt-Out Date, as used therein, deemed to be the effective date of termination, or 

(B) if the Vividion Opt-Out Date has occurred before the effective date of termination, then Celgene
shall continue to pay to Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination pursuant to Article IX (subject to the [***] percent ([***]%) reduction described in Section 14.4(b)(i) above). 

(iii) all licenses granted by Celgene to Vividion under Section 8.1(b) with respect to the Shared Products shall terminate if Celgene has
made the election set forth in Section 14.4(b)(i)(B) and all licenses granted by Vividion to Celgene under Section 8.1(a) with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion shall convert to
worldwide licenses and otherwise remain in effect; 
 (iv) Vividion shall be released from its Development, Manufacture and
Commercialization obligations; 
 (v) each Party shall provide the other with a report of the COGS and Allowable Expenses incurred by such
Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination for the purpose of calculating a final reconciliation of shared costs in accordance with Section 9.1 and Section 9.3; 

  
 - 86 - 

 (vi) if Celgene has made the election set forth in Section 14.4(b)(i)(B) within [***]
days after such termination, Vividion shall provide to Celgene a fair and accurate summary report of the status of Development and Commercialization activities conducted by Vividion with respect to the Shared Products; 

(vii) if Vividion is the Lead US Party and Celgene has made the election set forth in Section 14.4(b)(i)(B) above: 

(A) Vividion shall promptly transfer and assign to Celgene all of Vividion’s and its Affiliates’ rights, title and interests in and
to the Product Trademark(s) (but not any Vividion house marks or composite marks including a house mark) owned by Vividion and solely used for Shared Products in the US Territory; 

(B) Vividion shall as soon as reasonably practicable transfer and assign to Celgene all Regulatory Approvals and Regulatory Documentation with
respect to the Shared Products for the US Territory and a copy of all of the data comprising the Global Safety Database for the US Territory; provided that Vividion may retain such data and a single copy of such Regulatory Approvals
and Regulatory Documentation for its records; and provided further that, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development, Manufacture or Commercialization of any product other
than the Shared Products, in place of transferring or assigning the foregoing, Vividion shall grant Celgene a Right of Reference or Use with respect to such approvals or documentation with respect to the Shared Products; and 

(C) Celgene shall have the option, exercisable within [***] days following the effective date of such termination of this Agreement, to obtain
Vividion’s inventory of the Shared Products at a price equal to [***] percent ([***]%) of the Manufacturing Costs for such inventory of the Shared Products; provided that, if Vividion, its Affiliates or (sub)licensees have
outstanding orders, at Celgene’s election, either Celgene shall fulfill such orders or, notwithstanding Celgene’s option to purchase inventory, Vividion may retain sufficient inventory to fulfill such orders. Celgene may exercise such
option by written notice to Vividion during such [***] day period; provided that, in the event Celgene exercises such right to purchase such inventory, Vividion shall grant, and hereby does grant, a royalty-free right and license to
any trademarks, names and logos of Vividion contained therein for a period of [***] months solely to permit the orderly sale of such inventory, subject to Celgene meeting reasonable quality control standards imposed by Vividion on the use of such
trademarks, names and logos, which shall be consistent with the standards used by Vividion prior to such termination. Unless Celgene exercises its option under the first sentence of this Section 14.4(b)(vii)(C) and Vividion, its Affiliates or
(sub)licensees at termination of this Agreement possess Shared Product, have started the manufacture thereof or have accepted orders therefor, Vividion, its Affiliates or (sub)licensees shall have the right, for up to [***] year following the date
of termination, to sell their inventories thereof, complete the manufacture thereof and Commercialize such fully-manufactured Shared Product, in order to fulfill such accepted orders or distribute such fully-manufactured Shared Product in the US
Territory, subject to the obligation of Vividion to pay Celgene any and all payments as provided in this Agreement. 

  
 - 87 - 

 (viii) if Celgene has made the election set forth in Section 14.4(b)(i)(B),
notwithstanding Section 8.5 or Section 9.5, Celgene shall be solely responsible for any payments owed to any Third Party licensors of Vividion Intellectual Property, Vividion Co-Co Collaboration
Intellectual Property or Celgene Co-Co Collaboration Intellectual Property (without deduction under Section 9.4(d)) and shall be responsible for complying with the terms of any license agreements with
such Third Party licensors, in either case, directly related to Celgene’s exercise of such license; and 
 (ix) if Celgene has made the
election set forth in Section 14.4(b)(i)(B), the rights of Vividion in Article X (other than Section 10.1) shall be terminated and Vividion shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with
the transition of Prosecution and enforcement responsibilities to Celgene with respect to Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents,
Joint Co-Co Patents and Joint Patents then being Prosecuted or enforced by Vividion, including execution of such documents as may be necessary to effect such transition; and 

(x) if Celgene has made the election set forth in Section 14.4(b)(i)(A), separate transitional activities shall be undertaken with
respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents necessary for the Development,
Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How
or Patents otherwise associated with such Shared Products are transferred. 
 (c) In the case of any termination of this Agreement, if any
Clinical Trials (including any Additional Studies) are then being conducted at the time of such termination with respect to any Shared Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials
(including any Additional Studies), and (ii) notwithstanding anything to the contrary contained herein, to grant to the Party that retains global Commercialization rights to such Shared Product following such termination (A) free of
charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address issues
relating to: (1) the safety of such Shared Product in the Territory, including data that is related to adverse effects experienced with such Shared Product or (2) all activities relating to CMC regarding such Shared Product and in each of
(1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available, and (B) copies of and rights of reference to and use of all Shared Product Data (other than
the Shared Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address the Development and
Commercialization of such Shared Product promptly following the generation of such Shared Product Data if, but only if, as to such Shared Product Data described in this subclause (B), such Party that retains global Commercialization rights to such
Shared Product following such termination promptly pays for all COGS and Allowable Expenses incurred following any such termination of this Agreement with respect to such Clinical Trials (including any Additional Studies). 

  
 - 88 - 

 (d) Survival. Upon any termination or expiration of this Agreement, unless otherwise
specified in this Agreement and except for any rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and obligations of each Party under this Agreement shall terminate in whole or with respect
to the Shared Products, as the case may be; provided, however, that Section 2.1, Section 3.6(b), Section 8.7, Section 8.8, Section 9.6, Section 9.7, Section 9.8, Section 9.9,
Section 9.10, Section 10.1, Section 11.5, Section 11.6, Section 12.5, Section 13.1, Section 13.2, Section 13.3, Section 13.4, Section 13.5, Section 13.6, Section 14.4 and Sections 15.2-15.20, as well as any other provision which by its terms or by the context thereof is intended to survive, shall survive any such termination or expiration of this Agreement. 

(e) Equitable Relief. Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law
or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for the termination. 

(f) Accrued Liabilities. Except as otherwise specifically provided herein, termination of this Agreement shall not relieve the Parties
of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective terms for obligations or undertakings following
the expiration of the term of this Agreement. 
 Article XV 

Miscellaneous 

Section 15.1 Dispute Resolution. Except for any disagreements that are within the authority of any Committee as provided in
Article II (which disagreements shall be resolved in accordance with Section 2.2), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement (each, a
“Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this Section 15.1 after
in-person discussions between the Executive Officers within [***] Business Days after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter
in accordance with Section 15.2. 
 Section 15.2 Submission to Court for Resolution. Subject to Section 15.1, the
Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this
Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any

  
 - 89 - 

 action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in
the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each
Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.8 shall be effective service of process for any action, suit or proceeding brought against it under this
Agreement in any such court. Notwithstanding anything to the contrary in this Section 15.2, each Party shall have the right to institute judicial proceedings against the other Party or anyone acting by, through or under such other Party, in any
court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific performance, injunction or similar equitable relief. 

Section 15.3 Governing Law. This Agreement and all questions regarding its validity or interpretation, or the performance or
breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

Section 15.4 Assignment. 

(a) Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by either Party
(whether by operation of law or otherwise) without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s written consent, assign this Agreement and its rights and obligations
hereunder in whole or in part to (i) an Affiliate of such Party or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party
to which the subject matter of this Agreement relates; provided that the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement. The assigning Party will remain responsible for the
performance by its assignee of this Agreement or any obligations hereunder so assigned. 
 (b) In the event the Implementation Date for this
Agreement has not occurred within [***] days following the Execution Date, Celgene shall be entitled to assign this Agreement to any pharmaceutical company or any Affiliate thereof if required to comply with any Antitrust Law; provided
that the right to assign set forth in this Section 15.4(b) shall not apply if a breach by Celgene of its obligations under Section 8.6(a) is a material cause of the failure to obtain clearance under Antitrust Laws. 

Section 15.5 All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit
of the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of Section 15.4 will be null and void ab initio. 

Section 15.6 Change of Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual
property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of either Party, such
intellectual property rights shall not be included in the technology and intellectual property rights licensed to 

  
 - 90 - 

 the other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant
Party to this Agreement or any Affiliate of a Party immediately before such Change of Control) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration,
Shared Products, or related Companion Diagnostics. The Vividion Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in
connection with the Collaboration, Shared Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement. 

Section 15.7 Force Majeure. If the performance of any part of this Agreement by a Party is prevented, restricted, interfered with
or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood, embargo, power shortage or failure, acts of war or
terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure event”), such Party shall, upon giving written
notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such
causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

Section 15.8 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices required or permitted to
be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing
evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or (c) above), to
the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 
  

			
	 To Vividion
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Chief Executive
Officer
 Telephone:
	  	 To Celgene:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Senior Vice President Business

Development
 Telephone:

Facsimile:

  
 - 91 - 

			
	 With a copy to:
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Legal Department

Telephone:
	  	 With a copy to:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Legal Department

Telephone: Facsimile:

		
	and	  	and
		
	 WilmerHale
 60 State Street

Boston, MA 02109
 Attention:Steven D. Singer

Steven D. Barrett
 Telephone:

Facsimile:
	  	 Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone:
 Facsimile:

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.9 Waiver. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a
written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s
rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or
term. 
 Section 15.10 Severability. If any provision of this Agreement should be invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect
in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal or unenforceable provision
of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not
have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 Section 15.11 Entire Agreement.
This Agreement (including the Exhibits attached hereto), together with the Master Agreement, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all prior and contemporaneous agreements,
representations or understandings, either written or oral, between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written,
between the Parties other than as set forth herein and therein. 

  
 - 92 - 

 Section 15.12 Modification. No modification, amendment or addition to this
Agreement, or any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of
dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.13 Independent Contractors; No Intended Third Party Beneficiaries. This Agreement is not intended nor shall be deemed
or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any
liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor to bind the other Party to any contract, agreement or
undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2 and (b) except for any licensor under any Existing
Third Party Agreement, to the extent described in Exhibit C. Notwithstanding the provisions of this Section 15.13, the provisions of Section 15.17 shall control for US federal income tax purposes, as applicable. 

Section 15.14 Interpretation; Construction. The captions to the several Articles and Sections of this Agreement are included only
for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires otherwise, (a) the words “including,”
“include,” “includes,” “such as” and “e.g.” shall be deemed to be followed by the phrase “without limitation” or like expression, whether or not followed by the same; (b) references to
the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words “herein” or “hereunder” relate to this Agreement;
(e) the word “or” is used in the inclusive sense that is typically associated with the phrase “and/or”; (f) the word “will” shall be construed to have the same meaning and effect as the word “shall”; and
(g) all references to “dollars” or “$” herein shall mean US Dollars and (h) a capitalized term not defined herein but reflecting a different part of speech from that of a capitalized term which is defined herein shall
be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms
and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

Section 15.15 Performance by Affiliates. A Party may perform any obligation this Agreement imposes on such Party through any of
such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

Section 15.16 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an
original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an
“Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall 

  
 - 93 - 

 be considered to have the same binding legal effect as if it were the original signed version thereof
delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or
defense with respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

Section 15.17 Certain US Federal Income Tax Treatment. Pursuant to Section 15.13, this Agreement is not intended nor shall be
deemed or construed to create any relationship of employer and employee, agent and principal, legal partnership, or joint venture between the Parties; provided, however, that the Parties hereby acknowledge and agree that this
Agreement shall be treated as a partnership with respect to the Territory for US federal and state income tax purposes only pursuant to Section 7701(a)(2) of the Code and the Treasury Regulations thereunder, and each of Vividion and Celgene
shall be treated as partners in such partnership for all taxable periods during which this Agreement is effective and no Vividion Opt-Out Date has occurred. Vividion and Celgene agree that each will take no
position inconsistent with partnership tax treatment for US federal and state income tax purposes for such time. Exhibit E of this Agreement sets forth the Parties’ intentions regarding allocations and other tax matters related to the
tax partnership. Exhibit E shall be interpreted in a manner consistent with this Section 15.17. For the avoidance of doubt, the tax partnership referred to in this Section 15.17 shall be treated as separate from any other
partnership entered into by, or deemed to exist between, the Parties. 
 Section 15.18 HSR Clearance; Cooperation. For the
avoidance of doubt, the Parties shall continue to comply with Section 3.2 of the Master Agreement. 
 Section 15.19 Equitable
Relief. Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be
the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at law or equity. 

Section 15.20 Further Assurances. Each Party shall execute, acknowledge and deliver such further instruments, and do all such
other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Remainder of page intentionally left blank] 

  
 - 94 - 

 IN WITNESS WHEREOF, the Parties have executed this Global
Co-Development and Co-Commercialization Agreement as of the Execution Date. 
  

			
	VIVIDION THERAPEUTICS, INC.
		
	By:	 	              

	Name:	 	              

	Title:	 	              

	
	CELGENE CORPORATION
		
	By:	 	              

	Name:	 	              

	Title:	 	              

 Exhibit A 

Co-Co Target, Co-Co Candidate(s) and Lead US Party 

  
 A - 1 

 Exhibit B 

Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

  
 C-1 

 Exhibit D 

Profit & Loss Share 
 This
Exhibit D to this Agreement covers financial planning, accounting policies and procedures to be followed in determining the Profit & Loss Share for the Territory. The Profit & Loss Share is not a legal entity and has been
defined for identification purposes only. 
 1. Principles of Reporting. 

(a) The presentation of results of operation of the Parties with respect to Shared Products and Companion Diagnostics will be based on each
Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: 
  

					
	 	  	 Celgene
	  	 Vividion

			
	 Total
	  	 	  	 
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	

 (b) It is the intention of the Parties to interpret definitions to be consistent with this Exhibit D and
Accounting Standards, it being understood and agreed that “Operating Profits or Losses” shall be calculated in accordance with Celgene’s or Vividion’s, as applicable, then current Accounting Standards practices (and the Parties
hereby agree that Celgene, in its sole discretion, may adopt the same cost methodology as adopted by Vividion in accordance with its then current Accounting Standards practices solely for purposes of recording costs incurred by Celgene under this
Exhibit D). Where such costs will be determined based on either Party’s system of cost or project accounting, each Party agrees to provide reasonable supporting documentation, as may be requested by the other Party, to ensure that each
Party’s methodologies are reasonable and consistently applied. To the extent that such costs are not readily determinable based on the respective Party’s system of cost or project accounting, the JSC (or such other Committee designated by
the JSC) will develop a reasonable methodology for determining such costs. Reasonable methodologies may include a standard rate or some other appropriate basis for allocating costs. For billing and reporting, the statement of operations will be
translated into U.S. Dollars in accordance with this Agreement. 

  
 D-1 

 (c) If necessary, a Party will make the appropriate adjustments to the financial information
it supplies under this Exhibit D to conform to the above format of reporting results of operation. 
 (d) The Parties agree that all
Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics in the Territory will be booked by the applicable Lead Party in the relevant portion of the Territory. 

(e) There shall be no double counting of any expenses or income in determining the Operating Profits or Losses under this Exhibit D.

 (f) All employee expenses shall be calculated in accordance with the applicable FTE Rate. 

2. Frequency of Reporting. 
 (a) The fiscal
year for the purposes of reporting and other activities undertaken by the Parties pursuant to this Exhibit D will be a Calendar Year. Unless the schedule of such reporting is altered by the JSC, reporting by each Party for revenues and
expenses will be as set forth in this Paragraph 2 of this Exhibit D. 
 (b) Unless otherwise directed by the JCC or JDC, as
applicable, the Finance Working Group will prepare, for sales or Development of Shared Products and Companion Diagnostics, a consolidated reporting of the activities undertaken by the Parties hereunder (including Operating Profits or Losses), the
calculation of the Profit & Loss Share, and determination of the cash settlement as between the Parties. Unless otherwise directed by the JCC or JDC, as applicable, the Finance Working Group will provide the Parties within [***] days after
the end of each Calendar Quarter, a detailed statement showing the consolidated results and calculations of the Profit & Loss Share and cash settlement required in a format agreed to by the Parties (each, a “Report”). Each
Party will cooperate as appropriate and provide the other Party with financial statements, within [***] days after the end of each Calendar Quarter, with respect to Shared Products and Companion Diagnostics (if any), prepared in accordance with the
terms contained in the financial planning, accounting and reporting procedures set forth in this Exhibit D in order for each Party to prepare the consolidated reports, including in reasonable detail the following costs and expenses incurred
by each Party (if any) in such Calendar Quarter: (i) Cost of Goods Sold, (ii) Marketing Costs, (iii) Sales Costs, (iv) Distribution Costs, (v) Development Costs, (vi) Manufacturing Costs and (vii) Other Operating
Income/Expense. 
 (c) On a quarterly basis, each applicable Lead Party will supply the JCC or JDC, as applicable, and the other Party with
an estimate of Annual Net Sales (for the applicable portion of the Territory for which such Party is the Lead Party) for such Calendar Quarter of Shared Products and, as applicable, Companion Diagnostics, in units, local currency and U.S. dollars
(using the conversion method set forth in this Agreement) according to such Lead Party’s sales reporting system, which will be consistent with the financial planning, accounting and reporting procedures set forth in this Exhibit D. Each
Party shall also provide to the other Party (and the JCC or JDC, as applicable, if then in existence) information regarding the gross sales and gross-to-net sales for
all Shared Products and Companion Diagnostics for such Calendar Quarter. Each 

  
 D-2 

 
such report will be provided as early as possible, but no later than [***] days after the last day of the Calendar Quarter in question, and will separately provide quarterly and year-to-date cumulative figures. Each applicable Lead Party will provide to the other Party (and the JCC or JDC, as applicable, if then in existence), together with the next
Calendar Quarter estimate under this Section 2(c), an updated report for the immediately preceding Calendar Quarter providing a reconciliation of the estimated amounts for such preceding Calendar Quarter against the actual Annual Net Sales
during such Calendar Quarter of all such Shared Products and Companion Diagnostics within [***] days after the last day of such Calendar Quarter. 

Summary of Reporting Obligations 
  

					
	 Financial statements provided by each Party
	  	 Quarterly
	  	 [***] days after each Calendar Quarter

			
	 Gross sales &
gross-to-net sales report
	  	 Quarterly
	  	 [***] days after each Calendar Quarter

			
	 The Report
	  	 Quarterly
	  	 [***] days after each Calendar Quarter

			
	 Quarterly estimate of Annual Net Sales and reconciliation
	  	Quarterly	  	[***] days after each Calendar Quarter

 3. Financial Records. With respect to all financial records and reports required by this Exhibit D, each Party
to the extent applicable hereunder will keep financial records in accordance with its Accounting Standards. All cost reporting will be based on the appropriate costs definitions stated in Paragraph 7 of this Exhibit D or elsewhere in this
Agreement, and each Party will report costs in a manner consistent with a mutually agreed standard. 
 4. Operating Profits and Loss Sharing. 

(a) The Parties agree that Celgene will bear (and be entitled to) [***] percent ([***]%), and Vividion will bear (and be entitled to) [***]
percent ([***]%) of Operating Profits or Losses with respect to Development and Commercialization of Shared Products and Companion Diagnostics in the Territory. 

(b) Celgene shall either invoice Vividion, or pay to Vividion, at the time each Report is delivered to Vividion, an amount such that Vividion
will be bearing its Profit & Loss Share (as defined in Section 9.3 of this Agreement) for the relevant sales of Shared Products and Companion Diagnostics. Either (i) Vividion shall make payment in full to Celgene of the amount of
any such invoice, within [***] days after the date of such invoice, or (ii) Celgene shall pay Vividion [***] the delivery of the applicable Report to Vividion, an amount such that Vividion will bear or receive its Profit & Loss Share.
Such amounts will be invoiced and paid (whether before or after Regulatory Approval is received) pursuant to this Paragraph 4(b) of this Exhibit D. All payments to be made by either Party hereunder will be made in U.S. Dollars by wire
transfer to such bank account as such Party may designate. 

  
 D-3 

 (c) In the event any payment is made after the date specified in Paragraph 4(b) of this
Exhibit D, the paying Party will pay the past-due amounts with interest from the date originally due as provided in Section 9.10 of this Agreement (subject to the proviso therein regarding disputed
payments). In the event any overpayment of any amounts specified in Paragraph 4(b) of this Exhibit D is made, the Party receiving such overpayment will refund such overpayment amounts to the paying Party. 

5. Start of Operations and Effective Accounting Date Termination. 

(a) Operation of the Profit & Loss Share will be deemed to have commenced as of the Effective Date. Except as otherwise provided
herein, costs and expenses incurred prior to such date are not chargeable to the Profit & Loss Share. 
 (b) Unless otherwise set
forth in this Agreement, for reporting and accounting purposes with respect to the Profit & Loss Share, the effective termination date of the Agreement with regard to the last detailing year for all Shared Products and Companion Diagnostics
will be the end of the month in which such termination takes place. 
 6. Audits. Each Party will keep, and will cause its Affiliates and
(sub)licensees, as applicable, to keep, accurate books and records of accounting as required under its Accounting Standards for the purpose of calculating all amounts payable by either Party to the other Party under the Profit & Loss Share,
including with respect to the calculation of Allowable Expenses, Gross Profit and Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics, which books and records may be audited in accordance with the audit rights and
obligations granted to each Party in Section 9.7 of this Agreement. In the event of a dispute regarding any applicable books and records, including the amounts owed to a Party under Section 9.3 of this Agreement or the calculation of the
Profit & Loss Share, Allowable Expenses, Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics, or Gross Profit or Operating Profits or Losses, the Parties will work in good faith to resolve the disagreement. If the
Parties are unable to reach a mutually acceptable resolution of any such dispute within thirty (30) days, such dispute will be resolved in accordance with Section 12.1 of the Master Agreement. 

7. Definitions. 
 (a) “Allocable
Overhead” means the following costs, attributable to the Profit & Loss Share, all of which will be consistent with Accounting Standards in accordance with each Party’s then-current practices and reported in a manner consistent
with a standard mutually agreed upon by the Parties: 
 (i) indirect supplies and department overhead, such as indirect labor and other
department expenses; and 
 (ii) facility overhead, such as rent, depreciation, utilities and facility support. 

(b) “Allowable Expenses” means the sum of the following costs and expenses incurred during the term the Profit & Loss
Share is applicable, as set forth in Paragraph 5 of this Exhibit D, which will coincide with the Term, except as otherwise set forth in this Agreement, by the Parties, their Affiliates or Licensee Partners, pursuant to the Development and

  
 D-4 

 
D-4 Commercialization, including Manufacturing, of Shared Products and Companion Diagnostics in accordance with this Agreement, during the applicable
Calendar Quarter or the applicable Calendar Year: (i) Development Costs, (ii) Marketing Costs, (iii) Sales Costs, (iv) Distribution Costs, and (v) Other Operating Income/Expense, in each case that are incurred in accordance
with the Development Budget or Commercialization Budget, as applicable, and the terms and conditions of this Agreement. 
 (c) “Costs
of Goods Sold” or “COGS” means the sum of [***]. For clarity, these would exclude [***]. 
 (d)
“Distribution Costs” means the costs, including [***], in each case for the end use by a Party, including [***]. 
 (e)
“Development Costs” means, on a Shared Product-by-Shared Product basis, the costs actually incurred by the Parties or their Affiliates, in accordance
with the Development Budget with respect to those Development activities performed pursuant to the Development Plan, from and after the Effective Date; it being understood that “Development Costs” chargeable under this Agreement
will, as applicable, be calculated using the FTE Rate. 
 (f) “Gross Profit” means Annual Net Sales of Shared Products and
Companion Diagnostics less Cost of Goods Sold for sales of such Shared Products and Companion Diagnostics. 
 (g) “Manufacturing
Costs” means costs to supply applicable therapeutic ingredients, finished Shared Products and Companion Diagnostics, or related components or inputs and services for the Development and Commercialization of Shared Products and Companion
Diagnostics (i) [***], or (ii) [***]. Overhead included in Manufacturing Costs incurred with respect to [***], will each be allocated on a reasonable basis that is mutually agreed upon by the Parties. As applicable, “Manufacturing Costs”
shall include Manufacturing Transition Costs. 
 (h) “Marketing Costs” means Direct Costs incurred by the Parties or their
Affiliates or Licensee Partners, arising from [***]. Marketing Costs will also include activities related to [***]. Marketing Costs will specifically exclude [***]. 

(i) “Operating Profits or Losses” means Gross Profit for Shared Products and Companion Diagnostics less the Allowable Expenses
for such Shared Products and Companion Diagnostics. The Parties agree that Operating Profits or Losses will not include costs or expenses of a Party or its Affiliates or Licensee Partners that are: (i) [***], or (ii) [***]. 

  
 D-5 

 (j) “Other Operating Income/Expense” means the following items, to the
extent incurred with respect to and reasonably related to the Development or Commercialization of Shared Products: 
 (i)
[***] 
 (ii) [***] 

(iii) [***] 

(iv) [***] 

(v) [***] 

(vi) [***] 
 (k)
“Pharmacovigilance Expenses” means those expenses incurred by either Party or its Affiliates in performing pharmacovigilance activities related to each Shared Product or Companion Diagnostic. 

(l) “Product Recall Expenses” means all costs associated with the recall of each Shared Product and Companion Diagnostic. 

(m) “Regulatory Expenses” means all costs incurred, with respect to Shared Products and Companion Diagnostics in any relevant
country to obtain or comply with all Regulatory Approvals and requirements of all regulatory agencies, including FDA user and other fees, reporting, and other regulatory affairs activities recorded as an expense in accordance with GAAP, by or on
behalf of a Party or any of its Affiliates during the Term and pursuant to this Agreement, that are specifically identifiable or reasonably allocable to the preparation of Regulatory Filings for, and the obtaining and maintenance of reimbursement
for, and Regulatory Approval of, Shared Products, including without limitation compliance with requirements of such Regulatory Authorities, adverse event recordation and reporting, regulatory affairs activities, and all Product Recall Expenses. 

(n) “Sales Costs” means costs, arising from activities expressly set forth in the Commercialization Plan which are
specifically and directly identifiable, attributable and allocable to the sales efforts for Shared Products (including the managed care market), including costs arising from applicable medical affairs activities. “Sales Costs” will
include [***]. 
 (o) “Sublicense Revenues” means all revenues or other consideration (including milestones and royalties)
received by either Party or its Affiliates from a Licensee Partner as consideration for the grant of a sublicense under the licenses granted with respect to any Shared Products. 

  
 D-6 

 Exhibit E 

PARTNERSHIP TAX MATTERS 

Section 1.1 Constructive Partnership. Celgene and Vividion (the “Partners,” and each a “Partner”)
acknowledge that the rights and obligations imposed on each of them pursuant to this Co-Development and Co-Commercialization Agreement (the “Co-Co Agreement”) that relate to the sharing of profits and losses from the development and commercialization of the Rights (as defined below), and the collaborative relationship formed between them in
connection therewith, give rise to a partnership for U.S. federal (and, to the extent applicable, state) income tax purposes (the “Partnership”), which will commence upon the Effective Date. The activities of the Partners in respect
of the development and commercialization of a Shared Product in the Territory, and the rights related thereto (the “Rights”), shall be deemed to be conducted in and held by the Partnership. The Partnership, and the rights and
obligations set forth in this Exhibit E, shall remain in existence for so long as this Co-Co Agreement remains in full force and effect and no Vividion Opt-Out
Date has occurred. The parties further acknowledge that the arrangement described in this Co-Co Agreement (including this Exhibit E) shall be treated by the parties as a partnership solely for U.S.
federal (and applicable state) income tax purposes and is not intended to constitute a partnership for any non-tax or non-U.S. purpose. 

Section 1.2 Definitions. Capitalized terms used, but not defined, herein will have the meanings ascribed to them in the body of
this Co-Co Agreement. For purposes of this Exhibit E: 
 “Book” means the method of
accounting prescribed for compliance with the capital account maintenance rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations, as distinguished from any accounting method which the
Company may adopt for other purposes such as financial reporting. 
 “Capital Account” has the meaning set forth in
Section 1.4 of this Exhibit E. 
 “Capital Contribution” means, for each Partner, such Partner’s cash
or property contributed (or deemed contributed) to the Partnership. 
 “Fiscal Year” means the calendar year. 

“Gross Asset Value” means, with respect to any asset of the Partnership, the asset’s adjusted basis for federal income tax purposes,
adjusted to reflect any adjustments required or permitted by Sections 1.704-1(b)(2)(iv)(d) through (g), (m) and (s) of the Treasury Regulations, as determined by the Tax Matters Partner in its reasonable
discretion; provided that, in the case of any asset contributed to the Partnership, the initial Gross Asset Value of such property shall be equal to the fair market value of such asset as of the date of contribution, as determined by the Tax
Matters Partner in its reasonable discretion. 
 “Net Income” and “Net Losses” mean the Book income, gain, loss,
deductions and credits of the Partnership in the aggregate or separately stated, as appropriate, as of the close of each Taxable Year on the Partnership’s tax return filed for federal income tax purposes (or other allocation period). 

  
 E-1 

 “Tax Matters Partner” has the meaning set forth in Section 1.7(a)
of this Exhibit E. 
 “Taxable Year” means the Partnership’s Fiscal Year or such other year as may be required by
Section 706 of the Code. 
 “Treasury Regulations” means regulations (whether in final, proposed or temporary form) promulgated by the
U.S. Department of the Treasury under the Code, as amended. 
 “Asset Allocation” shall mean 1.0. 

“Profit Share” means, with respect to a Partner, the Profit & Loss Share (as defined in Section 9.3(a) of the body of this Co-Co Agreement) applicable to such Partner. 
 “Rights” has the meaning set forth in
Section 1.1 of this Exhibit E. 
 Section 1.3 Capital Contributions. 

(a) The amount of any Capital Contributions contributed (or deemed contributed) by each Partner to the Partnership shall be determined by the
Tax Matters Partner in its reasonable discretion unless specifically addressed in Sections 1.3(b) – (d) of this Exhibit E below. 

(b) Upon the Effective Date, the Partners shall be deemed to have completed the following steps: 

(i) Celgene shall be deemed to have acquired from Vividion, pursuant to the exercise of an Opt-In
Right (as defined in the Master Agreement), an interest in the Rights equal to Celgene’s Profit Share, with Vividion retaining an interest in the Rights equal to Vividion’s Profit Share. The parties agree that, for U.S. federal income tax
purposes, Celgene’s purchase price for its interest in the Rights with respect to a Program equals the product of the Opt-In Right exercise payment set forth in Section 6.5 of the Master Agreement
with respect to such Program multiplied by the Asset Allocation. 
 (ii) Immediately following the deemed acquisition by Celgene of its
interest in the Rights, as described in Section 1.3(b)(i) of this Exhibit E, the Partners shall each own an interest in the Rights, and each Partner shall be deemed to immediately contribute its interests in the
Rights to the Partnership in a tax-free transaction described in Section 721 of the Code. The Capital Accounts of Celgene and Vividion shall each be increased following such contributions by an amount
equal to the fair market values of such contributed interests. 
 (c) Upon the payment of any milestone payment to Vividion pursuant to 9.2
of the body of this Co-Co Agreement (each a “Milestone Payment”), the following steps shall be deemed to have occurred: 

(i) The Milestone Payment shall be deemed to reflect an increase in the fair market value of the Rights as of the Effective Date. 

  
 E-2 

 (ii) As a result of the Milestone Payment, Celgene shall be deemed, as of the Effective
Date, to have paid additional consideration to Vividion for the acquisition of its interests in the Rights (the “Added Consideration”), which shall be treated by the Partners as an adjustment to purchase price of the purchase
described in Section 1.3(b)(i) of this Exhibit E. The portion of the Milestone Payment treated as Added Consideration shall be determined by the Tax Matters Partner in its reasonable discretion. 

(iii) Celgene shall be deemed to have made an additional contribution to the Partnership equal to the Added Consideration in a transaction
qualifying under Section 721 of the Code, and Vividion’s Capital Account shall be booked up to reflect the increased value of the Rights. 

(d) The payment by each Partner of its respective share of any costs or expenses on behalf of the Partnership (including Development Costs and
any other costs and expenses included in the Profit & Loss Share) shall, to the extent determined by the Tax Matters Partner in its reasonable discretion, be deemed to be Capital Contributions made by each such Partner to the Partnership.

 Section 1.4 Capital Accounts. 

(a) The Partnership shall maintain a separate capital account for each Partner according to the rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations (a “Capital Account”). 
 (b)
Each Partner’s Capital Account: 
 (i) shall be increased by (A) the Capital Contributions by such Partner to the Partnership
after the date hereof, as determined by the Tax Matters Partner and mutually agreed upon by the Partners (net of liabilities secured by the contributed property that the Partnership is considered to assume or take subject to under Section 752
of the Code), and (B) such Partner’s distributive share of Net Income and other items of income and gain allocated to such Partner after the date hereof, and 

(ii) shall be decreased by (A) the amount of money distributed (or deemed distributed) to such Partner by the Partnership after the date
hereof, (B) the fair market value of property (as determined by the Tax Matters Partner and mutually agreed upon by the Partners) distributed (or deemed distributed) to such Partner by the Partnership (net of liabilities secured by the
distributed property that the Partner is considered to assume or take subject to under Section 752 of the Code) after the date hereof and (C) such Partner’s distributive share of Net Losses and other items of loss and deduction
allocated to such Partner after the date hereof. 
 (iii) Other adjustments shall be made to the Capital Accounts of the Partners to accord
with the regulations promulgated under Section 704(b) of the Code as determined by the Tax Matters Partner in its reasonable discretion. 

(c) As of the Effective Date, the initial Capital Account of each Partner shall be equal to the initial Capital Contribution of each such
Partner. 

  
 E-3 

 Section 1.5 Distributions. 

(a) Non-Liquidating Distributions. In the event that assets of the Partnership are deemed to be
distributed other than in liquidation of the Partnership, such assets shall be deemed to be distributed in accordance with the Profit Shares (unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 

(b) Liquidating Distribution. In the event that the Partnership is terminated pursuant to Section 708(b)(1)(A) of the Code (or
otherwise) and the assets of the Partnership are required to be distributed (or are deemed to be distributed) in liquidation of the Partnership, then such assets shall be distributed (or deemed to be distributed) in accordance with the Profit Shares
(unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 
 (c) Withholding for Taxes. Subject to the
provisions of Section 9.8(b) of the body of this Co-Co Agreement, any Partner is authorized to withhold from distributions described in Section 1.5(a) or (b) of this
Exhibit E to the Partners, and with respect to allocations pursuant to Section 1.6 of this Exhibit E to the Partners, and to pay over to any federal, state, local or foreign government, any such taxes as are
required to be deducted or withheld under any provision of applicable Law. Any amounts so withheld shall be treated as distributed pursuant to Section 1.5(a) or (b) of this Exhibit E, to the extent
applicable. 
 Section 1.6 Allocations; Section 704(c). 

(a) Except as required by Section 1.6(c) of this Exhibit E, the Net Income or Net Loss for any Taxable Year
shall be allocated to the Partners in such a manner so that the Capital Account of each Partner equals (as of the end of such allocation period and to the fullest extent possible) the amount that would be distributed to such Partner if all
properties of the Partnership, including cash, were sold for cash equal to their respective Gross Asset Values, all liabilities allocable to such properties were then due and were satisfied according to their terms, all minimum gain chargebacks
required by this Co-Co Agreement and the Treasury Regulations were made, and all obligations of Partners to contribute additional capital to the Partnership were satisfied and all remaining proceeds from such
sale were distributed pursuant to the order and priority of Section 1.5(b) of this Exhibit E. 
 (b)
Regulatory Allocations. In the event any Partner unexpectedly receives any adjustments, allocations or distributions described in Sections 1.704-1(b)(2)(ii)(d)(4),
1.704-1(b)(2)(ii)(d)(5) or 1.704-1(b)(2)(ii)(d)(6) of the Treasury Regulations, items of income (including gross income) and gain shall be specially allocated to such
Partner in an amount and manner sufficient to eliminate the deficit balance in such Partner’s Capital Account (in excess of (i) the amount such Partner is obligated to restore upon liquidation of the Partnership or upon liquidation of such
Partner’s interest in the Partnership and (ii) such Partner’s share of the Minimum Gain (as defined in Section 1.704-2 of the Treasury Regulations)) created by such adjustments, allocations
or distributions as quickly as possible. Additionally, there are hereby incorporated herein such special allocation provisions governing the allocation of income, deduction, gain, and loss for U.S. federal income tax purposes as may be necessary
under, and in the manner required by, the Treasury Regulations to ensure that this Exhibit E complies with all requirements of Section 1.704-2 of the Treasury Regulations relating to “minimum
gain” and “partner nonrecourse debt minimum gain” and the allocation and chargeback of so-called “nonrecourse deductions” and “partner nonrecourse deductions”, including a
“qualified income offset”. 

  
 E-4 

 (c) Except as otherwise provided in this Section 1.6(c) and in
Section 1.6(d) of this Exhibit E, for U.S. federal income tax purposes, all items of income gain, loss deduction and credit shall be allocated among the Partners in the same manner the corresponding Book item was
allocated pursuant to Section 1.6(a) of this Exhibit E. In the case of contributed property, items of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated first
in a manner consistent with the requirements of Section 704(c) of the Code to take into account the difference between the Gross Asset Value of such property and its adjusted tax basis at the time of contribution. If the Gross Asset Value of
any asset of the Partnership is adjusted pursuant to the terms of this Exhibit E, then subsequent allocations of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated with respect to such
assets so as to take into account such adjustment in the same manner as under Section 704(c) of the Code and the Treasury Regulations promulgated thereunder. 

(d) The method under Section 704(c) of the Code and the Treasury Regulations promulgated thereunder shall be the “traditional method
with curative allocations” (as described in Section 1.704-3 of the Treasury Regulations), unless otherwise determined by the Tax Matters Partner. For the sake of clarity, the allocations required by
Section 1.6(c) and this Section 1.6(d) of this Exhibit E are solely for purposes of federal, state and local income taxes and will not affect the allocation of Net Income or Net Losses as
between the Partners or any Partner’s Capital Account. 
 Section 1.7 Tax Reports, Tax Elections and Tax Matters Partner.

 (a) The Partnership hereby designates Celgene to act as the “tax matters partner” (as defined in Section 6231(a)(7) of the
Code) and the “partnership representative” of the Partnership for any tax period subject to the provisions of Section 6223 of the Code, as amended by the Bipartisan Budget Act of 2015, and any corresponding designation (the
“Tax Matters Partner”) in accordance with Sections 6221 through 6233 of the Code. The Tax Matters Partner is authorized and required to represent the Partnership (at the Partnership’s expense) in connection with all
examinations of the Partnership’s affairs by U.S. federal (and any applicable state) income tax authorities, including resulting administrative and judicial proceedings, to make any elections in connection therewith, and to expend Partnership
funds for professional services and costs associated therewith; provided, that the Tax Matters Partner shall notify the Vividion of any such administrative and judicial proceedings involving the Partnership and upon request shall provide Vividion
the opportunity to participate in any such matters. Vividion agrees to cooperate with the Tax Matters Partner as reasonably requested by the Tax Matters Partner with respect to the conduct of such proceedings. The Tax Matters Partner will, in its
reasonable discretion, determine whether the Partnership (either on its own behalf or on behalf of the Partners) will contest or continue to contest any tax deficiencies assessed or proposed to be assessed by any taxing authority provided,
however, that the Tax Matters Partner shall not agree or consent to compromise or settle such matters without the prior written consent of Vividion, which consent shall not be unreasonably delayed, conditioned or withheld. Any
deficiency for taxes imposed on any Partner (including penalties, additions to tax or interest imposed with respect to such taxes) will be paid by such Partner, and if paid by another Partner, will be recoverable from the Partner on which such
deficiency was imposed (including by offset against distributions otherwise payable to such Partner). The Partners agree to cooperate in good faith to notify each other regarding any tax notices or audits relating to the Partnership. 

  
 E-5 

 (b) The Tax Matters Partner shall prepare and file, or cause to be prepared and filed, all
necessary U.S. federal, state or local income tax returns for the Partnership. At least [***] days before the due date of such tax return, the Tax Matters Partner shall submit a copy of such tax return to Vividion for its review and comment. The Tax
Matters Partner shall consider in good faith any comments and incorporate any reasonable comments submitted by Vividion no fewer than [***] days prior to the due date of such tax return. Within [***] days after the end of each Taxable Year, the Tax
Matters Partner shall cause the Partnership to furnish Vividion with an IRS Form K-1 a (“K-1”) for such Taxable Year. In addition, the Partnership shall
deliver or cause to be delivered not later than the [***] day after the end of each Taxable Year to Vividion all information necessary for the preparation of Vividion’s federal income tax returns and any state, local and foreign income tax
returns that such Partner is required to file. Furthermore, the Tax Matters Partner shall consider in good faith any comments from Vividion regarding any matter for which the Tax Matters Partner is responsible or over which the Tax Matters Partner
has discretion under this Exhibit E, including without limitation the preparation of any tax return or the making of any election hereunder. 

(p) The Tax Matters Partner will determine whether to make or revoke any available election pursuant to the Code, provided,
however, that any action (or the failure to take any action known to the Tax Matters Partner to be reasonably necessary) on the part of the Tax Matters Partner with respect to such election in its capacity as Tax Matters Partner shall
require the prior written consent of Vividion if such action or failure, as applicable, would reasonably be expected to have a material adverse impact on Vividion. Each Partner will, upon request, use reasonable efforts to supply the information
necessary to give proper effect to any such election. The Partners hereby agree to cooperate in good faith regarding any matters related to any tax elections or tax reporting positions of the Partnership. 

Section 1.8 Tax Position. Unless otherwise required by applicable Law, no Partner will take a position on such Partner’s
federal income tax return, in any claim for refund or in any administrative or legal proceedings that is inconsistent with this Co-Co Agreement (including this Exhibit E) or with any information return
filed by the Partnership. If any Partner believes that such a position is required by applicable Law, such Partner must immediately notify the other Partner in writing, citing such applicable Law or any interpretation thereof. 

Section 1.9 Termination of Partnership. The Partnership shall terminate upon the earlier of (a) the termination of this Co-Co Agreement, as determined in accordance with Article XIV of the body of this Co-Co Agreement or (b) the Vividion Opt-Out
Date. 

  
 E-6 

 Schedule 6.5 

Minimum Vividion and Celgene Sales Representative Qualifications 

 Schedule 12.2(i) 

Patents 

 Schedule 12.2(j) 

Existing Third Party Agreements 

 APPENDIX B-1 

FORM OF LICENSE AGREEMENT 
  

  
 [Appendix B-1]-1 

 EXECUTION VERSION 

EXHIBIT B-1 

FORM OF LICENSE AGREEMENT 

LICENSE AGREEMENT 
 by and between

 VIVIDION THERAPEUTICS, INC. 

and 
 CELGENE CORPORATION 

 

 TABLE OF CONTENTS 

 

					
	 	  	 Page
	 
	 ARTICLE I. DEFINITIONS
	  	 	1	 
	 ARTICLE II. GOVERNANCE
	  	 	11	 
	 ARTICLE III. DEVELOPMENT
	  	 	12	 
	 ARTICLE IV. MANUFACTURE AND SUPPLY
	  	 	14	 
	 ARTICLE V. REGULATORY MATTERS
	  	 	14	 
	 ARTICLE VI. COMMERCIALIZATION
	  	 	16	 
	 ARTICLE VII. DILIGENCE
	  	 	16	 
	 ARTICLE VIII. GRANT OF RIGHTS; EXCLUSIVITY
	  	 	17	 
	 ARTICLE IX. FINANCIAL PROVISIONS
	  	 	27	 
	 ARTICLE X. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	36	 
	 ARTICLE XI. CONFIDENTIALITY
	  	 	43	 
	 ARTICLE XII. REPRESENTATIONS AND WARRANTIES
	  	 	48	 
	 ARTICLE XIII. INDEMNIFICATION; PRODUCT LIABILITIES
	  	 	53	 
	 ARTICLE XIV. TERM AND TERMINATION
	  	 	56	 
	 ARTICLE XV. MISCELLANEOUS
	  	 	65	 

  
 - i - 

			
	
	 Exhibits and Schedules

		
	Exhibit A	  	 Licensed Target, Licensed Compound(s) and Licensed Program

		
	Exhibit B	  	 Vividion Patents and Celgene License Collaboration Patents

		
	Exhibit C	  	 Existing Third Party Agreements

		
	Schedules	  	
		
	Schedule 12.2(i)	  	 Patents

  
 - ii - 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is entered into as of [●] (the “Execution Date”), by and
between Vividion Therapeutics, Inc., a Delaware corporation (“Vividion”) and Celgene Corporation, a Delaware corporation (“Celgene”). Celgene and Vividion are each referred to herein by name or as a
“Party”, or, collectively, as the “Parties”. 
 INTRODUCTION 

 

	1.	 Vividion and Celgene are parties to the Master Research and Collaboration Agreement, dated as of March 1,
2018 (the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Vividion has discovered and has been developing the Licensed Compound(s) in
the Field identified on Exhibit A, which the Parties believe to be Directed against the Licensed Target identified on Exhibit A. 

  

	3.	 Pursuant to the terms of the Master Agreement, upon exercise by Celgene of its
Opt-In Right with respect to the First Program, any CCB Program, any Vividion Cereblon Program or any Program for which Vividion delivered a Vividion Opt-Out Notice
under the Master Agreement (each as defined in the Master Agreement) identified on Exhibit A, the Parties shall enter into this Agreement with respect to such Program (the “Licensed Program”). 

 

	4.	 Except as provided herein, the Parties have agreed that the further Development, Manufacturing and
Commercialization of the Licensed Compound(s) included in such Program should be conducted pursuant to the terms of this Agreement and that all further such activities related to the Licensed Compound(s) should cease under the Master Agreement.

 NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained
herein, and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Vividion and Celgene hereby agree as follows: 

Article I. 
 Definitions

 Terms used but not defined herein shall have the meaning set forth in the Master Agreement. When used in this Agreement, each of the
following terms shall have the meanings set forth in this Article I: 
 Section 1.1 “Annual Net Sales” means, on a
Licensed Product-by-Licensed Product basis, the total Net Sales of such Licensed Product by Celgene or its Affiliates or Licensee Partners in a particular Calendar Year
in the Territory. For clarity, “Annual Net Sales” does not include [***]. 
 Section 1.2 “Calendar
Quarter” means a calendar quarter ending on the last day of March, June, September or December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the last day of the calendar quarter
during which the Effective Date occurs. 

 Section 1.3 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31; provided, however, that the first Calendar Year shall begin on the Effective Date and end on December 31 of the calendar year during which the Effective Date occurs. 

Section 1.4 “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively. 
 Section 1.5 “Celgene Know-How” means any Know-How that is (a) Controlled by Celgene as of the Execution Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Licensed Products; and
(c) contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene License Collaboration
Know-How. 
 Section 1.6 “Celgene License Collaboration Intellectual Property”
means Celgene License Collaboration Know-How and Celgene License Collaboration Patents, collectively. 

Section 1.7 “Celgene License Collaboration Know-How” means, collectively, (a) Know-How within Celgene Collaboration Intellectual Property (as defined in the Master Agreement), (b) Celgene’s interest in the Joint Collaboration Know-How (as
defined in the Master Agreement) and (c) Know-How that is discovered, developed, generated or invented on or after the Execution Date by or on behalf of Celgene or its Affiliates in the conduct of the
Collaboration activities pursuant to this Agreement (including Celgene’s interest in the Joint Inventions), in each case that is necessary or useful for the Development, Manufacture or Commercialization of any Licensed Products. 

Section 1.8 “Celgene License Collaboration Patents” means, collectively, (a) Patents within Celgene Collaboration
Intellectual Property (as defined in the Master Agreement), (b) Celgene’s interest in the Joint Collaboration Patents (as defined in the Master Agreement) and (c) Patents that are, on or after the Execution Date, Controlled by Celgene and
that Cover any of the Celgene License Collaboration Know-How described in Section 1.7(c) (including Celgene’s interest in the Joint Patents), in each case that are necessary or useful for the
Development, Manufacture or Commercialization of any Licensed Products. Celgene License Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.9 “Celgene Patents” means any Patents that (a) are Controlled by Celgene as of the Execution Date or
during the Term; (b) Cover the Licensed Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene
License Collaboration Patents. 
 Section 1.10 “Clinical Trial” means a Phase I Study, a Phase II Study, a Phase III
Study, a Phase IV Study or a combination of any of the foregoing studies. 
 Section 1.11 “Code” means the United
States Internal Revenue Code of 1986, as amended. 

  
 - 2 - 

 Section 1.12 “Collaboration” means the activities performed or to be
performed by a Party or Parties, as the case may be, relating to the Development, Manufacture or Commercialization of the Licensed Products under this Agreement or the Master Agreement, including in the exercise of any license granted under this
Agreement or the Master Agreement for the Licensed Products. 
 Section 1.13 “Companion Diagnostic” means a biomarker
or diagnostic test that is developed by or on behalf of a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Licensed Product in accordance with the Regulatory Approval(s) therefor to generate
a result for the purpose of diagnosing a disease or condition, or to facilitate the application of any Licensed Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the
likelihood that a specific patient will contract a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy using a Licensed Product. 

Section 1.14 “Confidential Information” means, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), (a) all
confidential or proprietary information relating to the Collaboration, and (b) all other confidential or proprietary documents, technology, Know-How or other information (whether or not patentable)
actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement[, the Licensed Product MTA]1 or the Master Agreement relating to the
Licensed Products or any proprietary biological materials of a Party. 
 Section 1.15 “Data” means any and all
research data, results, pharmacology data, medicinal chemistry data, preclinical data, market research, clinical data (including investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, safety and other
electronic databases), in any and all forms, including files, reports, raw data, source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the
like, in each case directed to, or used in, the Development, Manufacture or Commercialization of the Licensed Products. 
 Section 1.16
“Early Opt-Out Program” means any Deal Target Program or E3 Ligase Program, as applicable, for which Vividion delivers a Vividion Opt-Out Notice to
Celgene pursuant to Section 3.1.1(d) of the Master Agreement. 
 Section 1.17 “Effective Date” means the date on
or after the Execution Date that is the Implementation Date (as defined in the Master Agreement) with respect to this Agreement. 

Section 1.18 “Executive Officers” means Celgene’s Chief Executive Officer (or the officer or employee of Celgene
then serving in a substantially equivalent capacity) or his designee and Vividion’s Chief Executive Officer (or the officer or employee of Vividion then serving in a substantially equivalent capacity) or his designee; provided that any
such designee must have decision-making authority on behalf of the applicable Party. 
  

	1 	 Insert only for CCB Programs. 

  
 - 3 - 

 Section 1.19 “Existing Third Party Agreement” means any agreement
listed on Exhibit C to this Agreement. 
 Section 1.20 “Field” means the diagnosis, prevention,
palliation or treatment of diseases in humans or animals. 
 Section 1.21 “First Commercial Sale” means the first
commercial sale of a Licensed Product by Celgene, its Affiliates or Licensee Partners in a country in an arms’ length transaction to a Third Party following receipt of applicable Regulatory Approval of such product in such country. Sales for
test marketing or Clinical Trial purposes shall not constitute a First Commercial Sale. 
 Section 1.22 “Generic
Competition” means, with respect to a Licensed Product in a given country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.23 “Generic Product” means, as to a Licensed Product, in any country, any pharmaceutical product sold by a
Third Party not authorized by or on behalf of Celgene, its Affiliates or Licensee Partners, that (a) contains, as an active pharmaceutical ingredient, the same Licensed Compound contained in the applicable Licensed Product, (b) is approved
by the applicable Regulatory Authority in such country for one or more of the same Indications as the applicable Licensed Product; and (c) is AB rated in the United States or is comparably rated in any jurisdiction outside the United States
(including pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001) with respect to the applicable Licensed Product. 

Section 1.24 “IIT” means any investigator initiated Clinical Trial sponsored and conducted by an investigator at a
research institution for which a Party or its Affiliate provides drug supplies. 
 Section 1.25 “Licensed Compound”
means (a) any Program Compound listed on Exhibit A, and (b) to the extent Directed against the Licensed Target, any salt, fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates, anhydride, ester,
chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of any such Program Compound
identified in the foregoing clause (a) or in this clause (b). 
 Section 1.26 “Licensed Product” means (a) a
Licensed Compound, or (b) any product that contains a Licensed Compound as an active ingredient. 
 Section 1.27
[“Licensed Product MTA” means the Material Transfer Agreement entered into by and between Vividion and Celgene, dated as of [ ].]2 

Section 1.28 “Licensed Target” means the Program Target set forth as the “Licensed Target” on
Exhibit A; it being understood and agreed that (i) in the case of Licensed Compounds in a Deal Target Program described in clause (b) of Section 1.1.36 of the Master Agreement, the “Licensed Target” shall be
the Selected Target and (ii) in the case of Licensed Compounds in a E3 Ligase Program described in clause (b) of Section 1.1.46 of the Master Agreement, the “Licensed Target” shall be the Selected Target. 

 

	2 	 Insert only for CCB Programs. 

  
 - 4 - 

 Section 1.29 “Licensee Partner” means any Third Party to whom Celgene
or any of its Affiliates or any other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Licensed Products in the Field under the rights to Vividion Intellectual Property granted to
Celgene or its Affiliate hereunder, in each case excluding (a) Third Party Contractors and (b) wholesale distributors or any other Third Party that purchases any Licensed Product in an
arm’s-length transaction, where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize any Licensed Product except for a limited sublicense to the extent required to enable
such Third Party to perform final packaging for such Licensed Product for local distribution. 
 Section 1.30 “Major European
Country” means each of France, Germany, Italy, Spain and the United Kingdom. 
 Section 1.31 “Major Market”
means each of the United States, each of the Major European Countries, and Japan. 
 Section 1.32 “Manufacturing
Technology” means copies of all Vividion Know-How, Celgene License Collaboration Know-How or Celgene Know-How, as
applicable, which are necessary or useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Licensed Products, including specifications, assays, batch records, quality control data, and transportation and storage
requirements. 
 Section 1.33 “NDA” means an application submitted to a Regulatory Authority for the marketing
approval of a Licensed Product, including (a) a New Drug Application (as such capitalized term is used in C.F.R Title 21) filed with FDA or any successor applications or procedures, (b) a foreign equivalent of a U.S. New Drug Application
or any successor applications or procedures, including a Marketing Authorization Application in the European Union, and (c) all supplements and amendments that may be filed with respect to the foregoing. 

Section 1.34 “Net Sales” means, with respect to any Licensed Product, the [***], less the following deductions actually
incurred, allowed, paid, accrued or specifically allocated in its financial statements and calculated in accordance with the Accounting Standards as consistently applied, for: 

(a) [***]; 

  
 - 5 - 

 (b) [***]; 

(c) [***]; 
 (d) [***]; 

(e) [***]; and 
 (f) [***]. 

There should be no double counting in determining the foregoing deductions from gross amounts invoiced to calculate “Net Sales” hereunder.
The calculations set forth in this definition shall be determined in accordance with Accounting Standards consistently applied. 
 If non-monetary consideration is received by a Selling Party for any Licensed Product in the relevant country, Net Sales will be [***]. Notwithstanding the foregoing, Net Sales shall [***]. 

Net Sales shall be determined on, and only on, the first sale by a Selling Party or any of its Affiliates or (sub)licensees to a non-(sub)licensee Third Party. 
 If a Licensed Product is sold as part of a Combination Product (as defined below), Net
Sales will be the product of (i) [***] and (ii) the fraction (A/(A+B)), where: 

  
 - 6 - 

 “A” is [***]; and 

“B” is [***]. 
 If “A” or “B”
cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated as above, [***]. 

As used in this definition of “Net Sales,” “Combination Product” means a Licensed Product that contains one or more
additional active ingredients (whether co-formulated or co-packaged) that are neither Licensed Compounds nor generic or other
non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall be deemed not to be “active ingredients.” 

Section 1.35 “Out-of-Pocket Costs”
means, with respect to certain activities hereunder, [***]. 
 Section 1.36 “Partnership Agreement” means an agreement
pursuant to which a Party or its Affiliate provides funding to a Third Party to research and develop pharmaceutical compounds or products and which may include the grant of an option for such Party or Affiliate to obtain rights to, but not (in the
absence of the exercise of such option) a license to Commercialize or other rights to Commercialize, such pharmaceutical compounds or products. 

Section 1.37 “Phase IV Study” means a human clinical trial of a product which is (a) conducted to satisfy a
requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has been obtained from an appropriate Regulatory Authority for enhancing marketing or
scientific knowledge of an approved Indication. 
 Section 1.38 “Product Liabilities” means all losses, damages, fees,
costs and other liabilities incurred by a Party, its Affiliate(s) or its Licensee Partner(s) and resulting from or relating to the use of a Licensed Product in a human (including clinical trials or Commercialization) in the Territory incurred after
the Execution Date. For the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party, its Affiliate(s), or its Licensee Partner(s) and all
losses, damages, fees and costs associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of any Licensed Product. 

  
 - 7 - 

 Section 1.39 “Regulatory Documentation” means, with respect to the
Licensed Products, all INDs, NDAs and other regulatory applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug
dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials
relating to Development or Regulatory Approval of the Licensed Products, or required to Manufacture, distribute or sell the Licensed Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls
data, batch records, safety and efficacy, and any safety database. 
 Section 1.40 “Regulatory Exclusivity” means,
with respect to a Licensed Product in a country, that the Licensed Product has been granted (a) data exclusivity afforded approved drug products pursuant to Section 505(c), 505(j), or 505A of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or their equivalent in a country other than the United States, (b) market exclusivity pursuant to the orphan drug provisions governing approved drugs designated for rare diseases or conditions under
Sections 526 and 527 of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (c) any other type of non-patent
exclusivity adopted as an amendment to the FDCA, or its equivalent in a country other than the United States, or (c) any other data exclusivity or market exclusivity pursuant to any future Law. 

Section 1.41 “Right of Reference or Use” means a “Right of Reference or Use” as that term is defined in 21
C.F.R. §314.3(b), and any non-United States equivalents. 
 Section 1.42
“Territory” means worldwide. 
 Section 1.43 “Third Party Agreement” means (a) each Existing
Third Party Agreement and (b) any other Third Party agreement that Celgene or any Selling Party may enter into, during the Term in accordance with the terms of this Agreement, to acquire or license Third Party Patents or Know-How that are necessary or useful for the Development, Manufacture or Commercialization of the Licensed Products. 

Section 1.44 “Third Party Rights” means, with respect to a Party, any rights of, and any limitations, restrictions or
obligations imposed by, Third Parties pursuant to any Third Party Agreements. 
 Section 1.45 “Valid Claim” means
(a) a claim of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an
appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or subject matter of a claim thereof filed
by a Person in good faith that has not been cancelled, withdrawn or abandoned, nor been pending for more than six (6) years from the earliest filing date to which such patent application or claim is entitled. 

Section 1.46 “Vividion Intellectual Property” means Vividion Know-How and
Vividion Patents, collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of
January 6, 2016. 

  
 - 8 - 

 Section 1.47 “Vividion
Know-How” means any Know-How that is (a) Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Know-How, as defined under the Master Agreement) or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the Licensed Products; but excluding any Know-How licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. 

Section 1.48 “Vividion Patents” means any Patents that (a) are Controlled by Vividion as of the Execution Date
(including its interest in any Joint Collaboration Patents, as defined under the Master Agreement) or during the Term, and (b) Cover, or are useful for, the Development, Manufacture or Commercialization of the Licensed Products (including the
composition of matter, manufacture or any use thereof); but excluding any Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. Vividion Patents
as of the Execution Date are as set forth on Exhibit B to this Agreement. 
 Section 1.49 Additional Definitions. Each of
the following definitions is set forth in the section of this Agreement indicated below: 
  

			
	 DEFINITION
	  	 SECTION

	35 U.S.C. § 102(c) Patent	  	Section 10.8
	Academic Essential Provisions	  	Section 8.6(b)(iii)
	Accounting Standards	  	Master Agreement
	Acquirer Program	  	Section 8.6(b)(v)(4)
	Affiliate	  	Master Agreement
	Agreement	  	Preamble
	Allowed Indication	  	Section 8.6(b)(viii)
	Antitrust Law	  	Master Agreement
	Audit Team	  	Section 9.5(a)
	Bankruptcy Code	  	Section 8.8
	Business Day	  	Master Agreement
	CCB Program	  	Master Agreement
	Celgene	  	Preamble
	Celgene Independent Product	  	Master Agreement
	Celgene Indemnified Parties	  	Section 13.2(a)
	Celgene Manufacturing Responsibilities	  	Section 4.1(a)
	Challenge	  	Section 14.3(d)
	Challenging Party	  	Section 14.3(d)
	Clinically Develop	  	Section 8.6(a)
	Combination Product	  	Section 1.34
	Commercialization/Commercialize	  	Master Agreement
	Commercially Reasonable Efforts	  	Master Agreement
	Competitive Infringement	  	Section 10.3(b)

  
 - 9 - 

			
	 DEFINITION
	  	 SECTION

	Competitive Program	  	Section 8.6(b)(iv)
	Competitive Program Party	  	Section 8.6(b)(iv)
	Compound	  	Master Agreement
	Control/Controlled	  	Master Agreement
	Cooperating Party	  	Section 11.3(b)(iii)
	Cover/Covering/Covered	  	Master Agreement
	Cure Period	  	Section 14.3(b)(i)
	Deal Target	  	Master Agreement
	Deal Target Program	  	Master Agreement
	Develop/Development	  	Master Agreement
	Directed	  	Master Agreement
	Disclosing Party	  	Section 11.1
	Dispute	  	Section 15.1
	Distinct Product	  	Master Agreement
	Distinct Product Catch-Up Payments	  	Section 9.1(a)(iv)
	Earlier Patent	  	Section 10.8
	Electronic Delivery	  	Section 15.14
	Enabling Manufacturing	  	Section 8.6(a)
	Execution Date	  	Preamble
	E3 Ligase Program	  	Master Agreement
	FDA	  	Master Agreement
	First Program	  	Master Agreement
	force majeure event	  	Section 15.5
	Functional Phenotypic Assay Similarity Criteria	  	Master Agreement
	Implementation Date	  	Master Agreement
	IND	  	Master Agreement
	Indication	  	Master Agreement
	Indirect Taxes	  	Section 9.6(a)
	Invalidity Claim	  	Section 10.4(b)
	Joint Inventions	  	Section 10.1(c)
	Joint Patents	  	Section 10.1(c)
	Know-How	  	Master Agreement
	Law	  	Master Agreement
	Licensed Branding	  	Section 6.2(c)
	Licensed Product Data	  	Section 14.4(c)
	Licensed Program	  	Introduction
	Manufacture/Manufacturing	  	Master Agreement
	Master Agreement	  	Introduction
	Material Breach	  	Section 14.3(b)(i)
	Opt-In Right	  	Master Agreement
	Party/Parties	  	Preamble
	Patent	  	Master Agreement
	Payee Party	  	Section 9.6(a)
	Paying Party	  	Section 9.6(a)
	Person	  	Master Agreement

  
 - 10 - 

			
	 DEFINITION
	  	 SECTION

	Permitted Indication	  	Section 8.6(b)(vii)
	Phase I Study	  	Master Agreement
	Phase II Study	  	Master Agreement
	Phase III Study	  	Master Agreement
	Product Trademarks	  	Section 6.2(a)
	Program Assets	  	Section 12.4
	Program Compound	  	Master Agreement
	Prosecution/Prosecute	  	Master Agreement
	Publication	  	Master Agreement
	Publication Purpose	  	Section 11.4(a)
	Pursuing Party	  	Section 14.3(d)
	Receiving Party	  	Section 11.1
	Redacted Version	  	Section 11.3(b)(i)
	Regulatory Approval	  	Master Agreement
	Regulatory Authority	  	Master Agreement
	Regulatory Interactions	  	Section 5.2
	Requesting Party	  	Section 11.3(b)(iii)
	Royalty Term	  	Section 9.2(b)
	SEC	  	Section 11.3(b)(i)
	Separate Program	  	Master Agreement
	Separate Program Product	  	Section 8.6(b)(vii)
	Selling Party	  	Section 1.34
	Target	  	Master Agreement
	Term	  	Section 14.1
	Third Party	  	Master Agreement
	Third Party Contractors	  	Section 8.2(b)
	Third Party Infringement	  	Section 10.3(a)
	Third Party Infringement Action	  	Section 10.4(a)
	Vividion	  	Preamble
	Vividion Cereblon Program	  	Master Agreement
	Vividion Indemnified Parties	  	Section 13.1(a)
	Vividion Opt-Out Notice	  	Master Agreement

 Article II. 

Governance 

Section 2.1 Meetings and Reports. During the Term: 

(a) Committees. The Committees shall not oversee or review any of the matters under this Agreement. 

(b) Status Reports. Celgene shall provide to Vividion a progress report in the form it prepares in the ordinary course of business
(including in the form of slides) every [***] months during the Term on the status of its material Development, Commercialization and Prosecution activities with respect to the Licensed Products. 

  
 - 11 - 

 (c) Meetings. At Vividion’s request, the Parties shall meet (whether in person
or by teleconference) not more than once every [***] months during the Term to discuss Celgene’s Development, Commercialization and Prosecution activities with respect to the Licensed Program under this Agreement; it being understood and agreed
that the Parties shall not be required to meet in person more than once per Calendar Year. 
 Section 2.2 Certain Interactions with
and Effects on the Master Agreement. Upon and after the Effective Date, notwithstanding anything to the contrary in the Master Agreement (with each quoted term below having the meaning given in the Master Agreement): 

(a) Except as provided herein, all activities regarding Development, Manufacturing and Commercialization of a Licensed Product or Companion
Diagnostic shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 
 (b) None
of the Parties’ activities performed in accordance with this Agreement (including those activities specifically permitted upon and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 

(c) No decision of any “Committee” or working group under the Master Agreement shall have any binding effect with respect to
Development, Manufacture or Commercialization of a Licensed Product under this Agreement. 
 (d) All “Confidential Information”
disclosed under the Master Agreement that solely relates to any Licensed Product shall, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), be deemed to be Confidential Information disclosed under this Agreement and not the Master Agreement.
All “Confidential Information” disclosed under the Master Agreement that relates to, but does not solely relate to, any Licensed Product shall be deemed “Confidential Information” disclosed under the Master Agreement and also,
subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), Confidential Information disclosed under this Agreement; provided, however, that any disclosure of such information that is permitted under the Master Agreement shall not be deemed a
breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be deemed a breach of the Master Agreement. 

Article III. 

Development 

Section 3.1 Development of Licensed Products. As of and after the Effective Date Celgene will assume sole responsibility for, and
control of, Developing, Manufacturing and Commercializing Licensed Products and Companion Diagnostics in the Field in the Territory, and, except as otherwise set forth in this Agreement, will have sole responsibility to pay for all costs and
expenses arising from the Development, Manufacture and Commercialization of Licensed Products and Companion Diagnostics in the Field in the Territory. 

Section 3.2 Companion Diagnostics. Celgene may, in its sole discretion, Develop, Manufacture or Commercialize a Companion
Diagnostic for use with the Licensed Products and may, in its sole discretion, use a Third Party Contractor to perform all Development, Manufacturing and Commercialization for the Companion Diagnostic, which activities may

  
 - 12 - 

 
include continued Development of a Companion Diagnostic for which Development was commenced under the Master Agreement. In no event shall any payments be owed by Celgene to Vividion (including
pursuant to Article IX) with respect to a Companion Diagnostic; provided, however, that [***] shall be solely responsible for all costs associated with the Development, Manufacture or Commercialization of any Companion Diagnostics and shall
reimburse [***] for any such costs incurred by [***] within [***] days after receipt of any invoice therefor. 
 Section 3.3
Records; Tech Transfer. 
 (a) Maintenance of Records. Celgene shall maintain in all material respects, and shall require its
Licensee Partners and Third Party Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted under this Agreement and all results, data and developments made in conducting
such activities. Such records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Celgene
shall require the applicable study sites to maintain original source documents from Clinical Trials of the Licensed Products for at least [***] years (or such longer period as is commercially reasonable under the circumstances, taking into account
maintenance requirements under applicable Law) following completion of the Development activities undertaken by Celgene or its Licensee Partners or Third Party Contractors; provided that Celgene or Vividion shall be entitled to obtain copies
of such source documents at the end of such [***] period, but solely to the extent access to such records are necessary for Vividion to exercise its rights under this Agreement. 

(b) Inspection. Vividion shall have the right (no more than once each Calendar Year), during normal business hours and upon reasonable
notice, to inspect and copy (or request Celgene to copy) all records of Celgene or its Licensee Partners or Third Party Contractors, as applicable, maintained in connection with the work done and results achieved in the performance of Development
activities under this Agreement, but solely to the extent access to such records is necessary for Vividion to exercise its rights under this Agreement; it being understood and agreed that, in the case of a CCB Program, the right of access in this
Section 3.3(b) with respect to the CCB Program shall only commence following commencement the first Clinical Trial for the Licensed Product under the CCB Program. 

(c) Tech Transfer. As soon as reasonably practical after the Effective Date and thereafter upon Celgene’s reasonable request during
the Term, Vividion shall transfer to Celgene, at no cost to Celgene, copies of all Vividion Know-How (including for the avoidance of doubt any Manufacturing Technology Controlled by Vividion) and any on-hand biological or chemical materials Controlled by Vividion that are related to the Licensed Program, to the extent not previously transferred to Celgene. In addition, Vividion shall provide reasonable
assistance, including making its personnel reasonably available for meetings or teleconferences to answer questions and provide technical support to Celgene with respect to regulatory and Manufacturing transition matters and the use of such
transferred Know-How in the Development, Manufacture and Commercialization of Licensed Products. The Out-of-Pocket Costs, as
indicated with reasonable supporting evidence of such incurred Out-of-Pocket Costs, incurred by Vividion in connection with such assistance shall be reimbursed by
Celgene within [***] days after receipt by Celgene of an invoice for such costs. 

  
 - 13 - 

 Article IV. 

Manufacture and Supply 

Section 4.1 Pre-Clinical, Clinical and Commercial Supply. 

(a) Celgene Responsibilities. Subject to the terms and conditions of this Agreement, Celgene will assume sole responsibility for
Manufacture of the Licensed Products and Companion Diagnostics for Development and Commercialization in the Territory (collectively, the “Celgene Manufacturing Responsibilities”). 

(b) Manufacturing Costs. Except as otherwise set forth herein, Manufacturing Costs associated with clinical and commercial supply of the
Licensed Products shall be borne by Celgene. 
 Section 4.2 Transfer of Manufacturing Responsibility. In order to assist Celgene
to perform the Celgene Manufacturing Responsibilities, Vividion shall (a) transfer, or have transferred, to Celgene or its designee all Manufacturing Technology Controlled by Vividion and used in Manufacturing Licensed Products at the time of
such transfer to the extent relevant to the Celgene Manufacturing Responsibilities and use Commercially Reasonable Efforts to complete such transfer within [***] days after the Effective Date, and (b) provide reasonable assistance in connection
with the transfer of such Manufacturing responsibility to Celgene or its designee. The Out-of-Pocket Costs incurred by Vividion in connection with such transfer shall be
reimbursed by Celgene within [***] days after receipt by Celgene of an invoice for such costs. 
 Section 4.3 Manufacturing
Efforts. Celgene shall use Commercially Reasonable Efforts to ensure adequate manufacturing capacity to meet forecast demand for each applicable Licensed Product, including the establishment of an alternative supply source. Celgene shall also
use Commercially Reasonable Efforts to ensure adequate pre-clinical, clinical and commercial supply of each applicable Licensed Product to Develop or Commercialize, as applicable, such Licensed Products. 

Article V. 
 Regulatory
Matters 
 Section 5.1 Transfer of Regulatory Documentation. Vividion shall transfer, as soon as practicable (but in the
case of any IND(s) in no event later than [***] days after the Effective Date unless otherwise agreed by the Parties), to Celgene any and all Regulatory Approvals and Regulatory Documentation (including the IND and any foreign counterparts thereof)
for all Licensed Products and Companion Diagnostics in the Territory, and thereafter Celgene (or its designee) shall file and hold title to all Regulatory Documentation and Regulatory Approvals and supplements thereto relating to Licensed Products
and Companion Diagnostics in the Territory. 
 Section 5.2 Responsibility for Regulatory Interactions. As of and after the date
upon which the transfer described in Section 5.1 is effected, Celgene shall have sole responsibility for all Regulatory Interactions with Regulatory Authorities with respect to each Licensed Product. As used herein, the term “Regulatory
Interactions” means (a) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory Authorities with respect to the Development,
Manufacture and Commercialization of Licensed Products and Companion Diagnostics and (b) interfacing, corresponding and meeting with the Regulatory Authorities with respect to the Licensed Products and Companion Diagnostics. 

  
 - 14 - 

 Section 5.3 Review of Regulatory Documentation. During the Term, Celgene shall
keep Vividion reasonably informed of all Regulatory Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, Regulatory Approvals, annual reports, including annual safety reports to the
respective health authorities, annual re-assessments, and any subsequent variations or changes to labeling, in each case with respect to the Licensed Products and Companion Diagnostics. Celgene shall respond
within a reasonable timeframe to all reasonable inquiries by Vividion with respect to any information provided pursuant to this Section 5.3 (and sufficiently promptly for Vividion to provide meaningful input with respect to responses to
Regulatory Authorities). 
 Section 5.4 Right of Reference or Use. In the event of failure to assign any applicable Regulatory
Documentation or Regulatory Approval to Celgene as required by Section 5.1, Vividion hereby consents and grants to Celgene a Right of Reference or Use (without any further action required on the part of Vividion, whose authorization to file
this consent with any Regulatory Authority is hereby granted) to any such Regulatory Documentation or Regulatory Approval (including all data contained or referenced therein) that are necessary for the Development, Manufacture or Commercialization
(as set forth in this Agreement) of the Licensed Products and Companion Diagnostics. 
 Section 5.5 Pharmacovigilance. Celgene
will deploy and administer any safety monitoring activity implemented for the Licensed Products in the Territory, and be responsible for all pharmacovigilance activities for the Licensed Products in the Territory. Further, Vividion will follow the
adverse event reporting requirements and processes set forth in the pharmacovigilance agreement described in this Section 5.5. In addition: 

(a) In accordance with the procedures established by the Parties under this Section 5.5, each Party shall cooperate with the other Party
and share information concerning the pharmaceutical safety of each Licensed Product. Each Party shall promptly advise the other Party of any information that comes to its knowledge that may affect the safety, effectiveness or labelling of such
Licensed Product and any actions taken in response to such information. Treatment of safety information, standard operating procedures and training, as well as a statement of respective regulatory obligations shall be agreed in a separate
pharmacovigilance agreement between Vividion and Celgene (or an Affiliate of Celgene, as designated by Celgene). 
 (b) Following the date on
which the transfer described in Section 5.1 is effected, Celgene shall be solely responsible for reporting all adverse drug experiences associated with the Licensed Products and Companion Diagnostics in the Territory, and for establishing,
holding and maintaining the global safety database for the Licensed Products and Companion Diagnostics. Each Party shall provide the other Party with all Licensed Product and Companion Diagnostic complaints, adverse event information and safety data
from clinical studies that are in its possession and control and that are necessary or desirable for the other Party to comply with all applicable Laws with respect to Licensed Products and Companion Diagnostics. 

  
 - 15 - 

 Article VI. 

Commercialization 

Section 6.1 Commercialization Responsibilities for Licensed Products. 

(a) Responsibility. Celgene shall have the sole responsibility for, and right to carry out, Commercialization of Licensed Products in
the Territory. 
 (b) Sales. Celgene will book all sales of the Licensed Products in the Territory and will have the sole
responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Licensed Products throughout the Territory associated therewith. 

Section 6.2 Trademarks. 

(a) Selection of Trademarks. Celgene shall select the trademark(s) to be used in connection with the marketing and sale of the Licensed
Products in the Territory (such marks, together with registrations, applications for registration and common law rights therein, collectively, “Product Trademarks”). 

(b) Ownership. Celgene shall own all Product Trademarks for any Licensed Product in the Territory. 

(c) Branding. Nothing in this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s
trademarks, tradenames, logos, or other marks, including use thereof, absent a separate trademark licensing agreement entered into between the Parties. Notwithstanding the foregoing, subject to any restrictions on the form or content of the branding
or co-branding of the Licensed Products (the “Licensed Branding”) imposed by any Regulatory Authority, unless the Parties mutually agree otherwise in writing, the Licensed Branding used with
respect to Licensed Products shall feature the logos of Vividion and Celgene with approximately equal sizing and similar prominence, with Celgene’s name first, on all packaging and materials used for Commercialization of such Licensed Products,
to the extent permitted by applicable Law. 
 Article VII. 

Diligence 

Section 7.1 Compliance with Laws. Celgene shall: 

(a) perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and 

(b) carry out all work done in the course of the Development, Manufacturing and Commercialization of Licensed Products in compliance with all
applicable Laws governing the conduct of such work. 
 Section 7.2 Diligence Obligations. Celgene, directly or through one or
more of its Affiliates or Licensee Partners, shall use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Licensed Products in each of the Major Markets, and, following such Regulatory Approval, to Commercialize such
Licensed Products in each of the Major Markets. 

  
 - 16 - 

 Section 7.3 No Representation. Subject to the foregoing obligation to use
Commercially Reasonable Efforts, neither Party makes any representation, warranty or guarantee that the Licensed Program will be successful, or that any other particular results will be achieved with respect to the Licensed Program, or any Licensed
Product or Companion Diagnostic hereunder. 
 Article VIII. 

Grant of Rights; Exclusivity 

Section 8.1 License Grants. Subject to the terms and conditions of this Agreement, Vividion hereby grants to Celgene an exclusive
(even as to Vividion and its Affiliates), worldwide right and license in the Field in the Territory, with the right to grant sublicenses as set forth in Section 8.2, under Vividion’s rights in Vividion Intellectual Property, Joint
Inventions, Joint Patents and Manufacturing Technology, to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Licensed Products and Companion Diagnostics; provided, however, that, as to
Companion Diagnostics, such license grant shall be limited to Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as companion diagnostics with
Licensed Products under this Agreement. 
 Section 8.2 Sublicense Rights. Subject to Section 8.3, Celgene shall have the
right to grant sublicenses within the scope of the licenses under Section 8.1: 
 (a) to its Affiliates; and 

(b) to Third Parties for the purpose of (a) Commercializing any Licensed Product or related Companion Diagnostic or (b) engaging
Third Parties as contract research organizations, contract manufacturers, contract sales forces, consultants, academic researchers and the like (“Third Party Contractors”) in connection with Development, Manufacture or
Commercialization activities on behalf of Celgene or its Affiliates under this Agreement, subject to the following: 
 (i) unless otherwise
agreed by mutual agreement of the Parties, Celgene shall require any such Third Party to whom Celgene discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of
confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in
compliance with the terms of this Agreement (except that Publications by academic collaborators shall be permitted if (A) the academic collaborator provides an advance copy of the proposed Publication under the time periods as described in
Section 11.4(a)), which may be shared with Vividion, (B) agrees to delay such Publication sufficiently long enough to permit the timely preparation and filing of a patent application, and (C) upon the request of either Party, removes
from such Publication any Confidential Information of such Party); 

  
 - 17 - 

 (ii) unless otherwise agreed by mutual agreement of the Parties, Celgene will obligate such
Third Party to agree in writing to assign ownership of, or grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to
the extent related to Development, Manufacture or Commercialization with respect to the Licensed Products in the Field in the Territory; and Celgene shall structure such assignment or exclusive license so as to enable it to sublicense such Third
Party inventions to Vividion pursuant to Section 14.4(a)(ii) or Section 14.4(b)(i)(A), as applicable, (including permitting Vividion to grant further sublicenses); provided that, in connection with any academic collaborator
performing research work with respect to the Licensed Target or Licensed Products that is not reasonably expected by Celgene to result in inventions related to composition of matter or methods of use, it shall be sufficient for Celgene to obtain a non-exclusive, worldwide, royalty-free, perpetual license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses, to, any inventions
resulting from such research work, which sublicensing rights must permit sublicensing to Vividion pursuant to Section 14.4(a)(ii) or Section 14.4(b)(i)(A), as applicable, (including permitting Vividion to grant further sublicenses); and

 (c) to any other sublicensee with the prior written approval of Vividion, which approval shall not be unreasonably withheld, conditioned
or delayed. 
 Section 8.3 Sublicense Requirements. Any sublicense granted by Celgene pursuant to this Agreement shall be
subject to the following: 
 (a) each sublicense granted hereunder by Celgene or its Affiliates shall be consistent with the requirements of
this Agreement; 
 (b) any transfer of rights between Celgene and its Affiliates shall not be deemed a sublicense by Celgene but shall be
deemed a direct license by Vividion to Celgene’s Affiliate; it being understood and agreed that Celgene shall remain responsible for the activities of its Affiliate; 

(c) Celgene’s or its Affiliates’ Third Party Licensee Partners shall have no right to grant further sublicenses without
Vividion’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 
 (d) Celgene shall be
primarily liable for any failure by its Affiliates and Licensee Partners and Third Party Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement; and 

(e) such sublicense must be granted pursuant to a written sublicense agreement and Celgene shall provide Vividion with a copy of any sublicense
agreement entered into under Section 8.2 above within [***] days after the execution of such sublicense agreement; provided that, any such copy may be reasonably redacted to remove any confidential, proprietary or competitive
information, but such copy shall not be redacted to the extent that it impairs Vividion’s ability to ensure compliance with this Agreement. Such sublicense agreement shall be treated as Confidential Information of Celgene and no copies are
required with respect to sublicense agreements with Third Party Contractors. 

  
 - 18 - 

 Section 8.4 Affiliates, Licensee Partners and Third Party Contractors. Celgene
may exercise its rights and perform its obligations hereunder itself or through its Affiliates, Licensee Partners and Third Party Contractors. Celgene shall be primarily liable for any failure by its Affiliates, Licensee Partners and Third Party
Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement. If Celgene desires to use any Person to conduct any of its Development, Manufacturing, Commercialization or other activities hereunder, Celgene must
comply with the obligations of Section 8.2(b)(i) and Section 8.2(b)(ii) even to the extent no sublicense of rights is granted to such Third Party. 

Section 8.5 Existing Third Party Agreements. 

(a) Acknowledgement. Except as otherwise expressly provided in this Agreement, including in Section 8.5(b) and Section 9.3,
Vividion acknowledges that it is responsible for the fulfillment of its obligations under each Existing Third Party Agreement and agrees to fulfill the same, including any provisions necessary to maintain in effect any rights sublicensed to Celgene
hereunder and the exclusive or non-exclusive nature of such rights, as applicable, subject to Celgene’s compliance with its obligations hereunder. 

(b) Incorporation of Certain Provisions. Celgene agrees and acknowledges that Vividion is required to provide to licensors under the
Existing Third Party Agreements periodic reports relating to the gross sales and Net Sales of Licensed Products. Celgene shall keep true and accurate records and books of account, and open such books and records for inspection by such licensors, for
a duration of [***] years from the date of origination of such books or records. Furthermore, Celgene acknowledges that Vividion may be required to share certain reports and copies of sublicense agreements provided by Celgene to Vividion hereunder
with any licensor under an Existing Third Party Agreement, and Celgene consents to the sharing of such reports and such copies of such sublicense agreements to the extent required under such Existing Third Party Agreement to the same extent as
disclosures are permitted under Section 11.3(b) hereunder; provided that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party Agreement. In addition, Celgene acknowledges that
the Prosecution, enforcement and other intellectual property management rights under this Agreement with respect to Patents and other intellectual property licensed under Existing Third Party Agreements shall be subject to the terms and conditions
of the applicable Existing Third Party Agreements and, in the case of Existing Third Party Agreements in which the licensor is an academic institution, other provisions of such Existing Third Party Agreements that are customarily required to be
imposed on sublicensees in academic licenses (in no event to include any exclusivity covenant). 
 (c) Covenants Regarding Existing Third
Party Agreements. Vividion agrees that during the Term: 
 (i) Vividion shall not modify or amend any Existing Third Party Agreement in
any way that adversely affects Celgene’s rights hereunder without Celgene’s prior written consent; 
 (ii) Vividion shall not
terminate any Existing Third Party Agreement, in whole or in part, without Celgene’s prior written consent; 

  
 - 19 - 

 (iii) Vividion shall not exercise or fail to exercise any of Vividion’s rights, or
fail to perform any of Vividion’s obligations, under any Existing Third Party Agreement, where such exercise or failure to exercise or perform would adversely affect Celgene’s rights hereunder, without the prior written consent of Celgene,
including rights with respect to including applicable improvements within the licenses granted under such Existing Third Party Agreement; and, at the reasonable request of Celgene, Vividion shall exercise such rights and make such requests described
above as are permitted under such Existing Third Party Agreement; 
 (iv) Vividion shall promptly furnish Celgene with copies of all reports
and other communications that Vividion furnishes to any licensor under any Existing Third Party Agreement to the extent that such reports relate to this Agreement; 

(v) Vividion shall promptly furnish Celgene with copies of all reports and other communications that Vividion receives from any licensor under
any Existing Third Party Agreement that relate to the subject of this Agreement (including notices relating to applicable improvements under such Existing Third Party Agreement); 

(vi) Vividion shall furnish Celgene with copies of all notices received by Vividion relating to any alleged breach or default by Vividion
under any Existing Third Party Agreement within [***] Business Days after Vividion’s receipt thereof; in addition, if Vividion should at any time breach an Existing Third Party Agreement or become unable to timely perform its obligations
thereunder, Vividion shall immediately notify Celgene; 
 (vii) If Vividion cannot or chooses not to cure or otherwise resolve any alleged
breach or default under any Existing Third Party Agreement, (A) Vividion shall so notify Celgene within [***] Business Days of such decision, which shall not be less than [***] Business Days prior to the expiration of the cure period under such
Existing Third Party Agreement; provided that Vividion shall use Commercially Reasonable Efforts to cure any such breach or default; and (B) Celgene, in its sole discretion, shall be permitted (but shall not be obligated), on behalf of
Vividion, to cure any breach or default under such Existing Third Party Agreement in accordance with the terms and conditions of such Existing Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such
Existing Third Party Agreement; and (C) if Celgene pays any such licensor any amounts owed by Vividion under such Existing Third Party Agreement, then, provided that such amounts have not arisen as a result of Celgene’s failure to
comply with the terms and conditions of such Existing Third Party Agreement applicable to Celgene as a sublicensee and Celgene may deduct Vividion’s share of such amounts from payments Celgene is required to make thereafter to Vividion
hereunder or, at Celgene’s election, may otherwise seek reimbursement of such amounts from Vividion; and 
 (viii) Vividion shall not
provide any Licensed Products to any licensor under any Existing Third Party Agreement without Celgene’s prior written consent. 
 (d)
Survival of Celgene’s Rights Following Termination of Existing Third Party Agreement. The Parties agree that in the event of any termination of any Existing Third Party Agreement with respect to any intellectual property rights licensed
to Celgene hereunder, Celgene shall have any rights available with respect to the rights under such Existing Third Party Agreement to become a direct licensee of the Third Party licensor(s) with respect to the rights

  
 - 20 - 

 
under such Existing Third Party Agreement and Vividion shall use Commercially Reasonable Efforts to assist Celgene in exercising such rights; provided that Celgene has not breached this
Agreement, or breached the applicable Third Party Rights under such Existing Third Party Agreement. In addition, notwithstanding the foregoing, in the event of such termination, Celgene may in any event approach any licensor under any Existing Third
Party Agreement for a direct license. In the event of any such direct license following any termination of an Existing Third Party Agreement without Celgene’s consent, Celgene shall be entitled to deduct from any payments owed to Vividion
hereunder the amounts paid by Celgene to such licensor under such direct license with respect to licenses within the scope of the licenses previously granted to Vividion under such Existing Third Party Agreement to the extent permitted under
Section 9.2(e); provided that such termination was not the result of Celgene breaching the applicable Existing Third Party Agreement. 

(e) Termination of Existing Third Party Agreements. The Parties agree that termination, without Celgene’s prior written consent, of
any Existing Third Party Agreement with respect to any Patent or Know-How that is necessary to Develop, Manufacture or Commercialize the Licensed Products shall be deemed a material breach of this Agreement by
Vividion; provided, however, that (i) if Celgene’s breach of this Agreement results in a breach of any Existing Third Party Agreement, Celgene agrees to use Commercially Reasonable Efforts to assist Vividion in curing such breach of
such Existing Third Party Agreement, and (ii) if Celgene’s breach of this Agreement results in a termination of any Existing Third Party Agreement, such termination of such Existing Third Party Agreement shall not be deemed a material
breach by Vividion of this Agreement. 
 Section 8.6 Exclusivity. Subject to the terms and conditions of this Agreement, each of
the Parties hereby agrees as follows: 
 (a) Exclusivity Obligations. 

[[Parties to include in execution version solely where the Licensed Target under this Agreement is not Cereblon] 

Solely in the case where the Licensed Target for the Licensed Products is not Cereblon, from the Effective Date until the end of the Term, each of the Parties
covenants and agrees, solely on behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program MTA or
any other Development & Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or
Commercialization (“Enabling Manufacturing”) or Commercialize (A) the Licensed Compound, (B) any molecule in the Field that is Directed against the Licensed Target or (C) any pharmaceutical product (including any
diagnostic product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Licensed Target or (ii) license, authorize, appoint or otherwise willfully or intentionally enable, whether
directly or indirectly, a Third Party to conduct any of the activities described in clause (i). 

  
 - 21 - 

 [Parties to include in execution version solely where the Licensed Target under this Agreement is
Cereblon] 
 Solely in the case where the Licensed Target for the Licensed Products is Cereblon, from the Effective Date until the end of the Term,
Vividion covenants and agrees, solely on behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program
MTA or any other Development & Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or
Commercialization (“Enabling Manufacturing”) or Commercialize (A) the Licensed Compound, (B) any molecule in the Field that is Directed against the Licensed Target or (C) any pharmaceutical product (including any
diagnostic product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Licensed Target or (ii) license, authorize, appoint or otherwise willfully or intentionally enable, whether
directly or indirectly, a Third Party to conduct any of the activities described in clause (i).] 
 (b) Exceptions. 

(i) Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly (whether such activities are conducted internally
or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions of Section 8.6(a) as a result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a
molecule resulting from such research program or discovery effort) that has as its specified and primary goal, as evidenced by items such as laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to discover or
Develop any compound that is Directed against a target other than the Licensed Target. 
 (ii) Celgene Exception. It is agreed and
understood by the Parties that: (A) solely prior to the enrollment of the first patient in the first Phase II Study of the first Licensed Product under this Agreement: (x) any Celgene research, Development, discovery, manufacturing and
commercialization activities existing as of the Effective Date or (y) any commercialization activities commenced following the Effective Date, where the applicable compound or product was the subject of ongoing research, Development, discovery,
or manufacturing or commercialization activities as of the Effective Date, whether in either case such activities are undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators, are expressly
excluded from the provisions of this Section 8.6, and (B) at any time during the Term, Celgene research, discovery, and commercialization activities related to (i) the glutarimide class of drugs, including but not limited to
lenalidomide, pomalidomide, and thalidomide; (ii) the activation or inhibition through direct binding to PDE4 (apremilast); (iii) romidepsin drugs; (iv) Celgene’s cell-based therapies; or (v) any drug or program owned or
controlled by Celgene on or before the Effective Date that has commenced a Phase III Study or has been Commercialized on or before the Effective Date are expressly excluded from the provisions of this Section 8.6. 

  
 - 22 - 

 (iii) Academic Collaborations. Notwithstanding the provisions of
Section 8.6(a), and without limiting Section 8.2(b), each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in relation to the Licensed Target, if such activities are
(A) the subject of an existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, provided that such Party shall not be permitted to amend
any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the Master Agreement with respect to (1) ownership and licenses of pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of activities under such agreement, (2) rights regarding publication of the
results arising pursuant to the conduct of activities under such agreement, and (3) confidentiality obligations (collectively, (1) through (3), the “Academic Essential Provisions”), or (B) the subject of a new
agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic Essential Provisions consistent with the terms and conditions of the agreements between
such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement; provided that, if any Academic Essential Provisions of an amendment described in (A) or an agreement
described in (B) would not be consistent with the Academic Essential Provisions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, such
Party shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of the other Party. 

(iv) Competitive Programs. Section 8.6(a) shall not apply to the applicable Party if, during the Term, such Party or any of its
Affiliates (other than in a Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this
Section 8.6 by such Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a Competitive Program (the
“Competitive Program Party”) shall, within [***] days after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant Affiliate to terminate,
the Competitive Program or (B) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [***] day period that it intends
to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program as quickly as possible, and in any event within [***]
days (unless applicable Law requires a longer termination period) after the Competitive Program Party delivers such notice to the other Party; and (Y) confirm to the other Party when such termination has been completed, and the Competitive
Program Party’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under
Section 8.6(a). If the Competitive Program Party notifies the other Party within such [***] day period that it intends to divest such Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable efforts
to effect such divestiture as quickly as possible, and in any event within [***] days after the Competitive Program Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed. If the
Competitive Program Party or its relevant Affiliate fails to complete such divestiture within such [***] day period, but has used reasonable efforts to 

  
 - 23 - 

 
effect such divestiture within such [***] day period, then, unless otherwise required by applicable Law, such [***] day period shall be extended for such additional reasonable period thereafter
as is necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided, however, that, such additional [***] day period shall be extended for such period as is necessary to obtain any
governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the
Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). 

(v) Certain Permitted Activities. 

(1) The supply by either Party or its Affiliates of drug for use in any IIT shall not constitute a breach of Section 8.6(a) by such
Party. Each Party shall report to the other Party on a Calendar Quarterly basis all IITs for which it or its Affiliates supplies drug and that would otherwise breach Section 8.6(a). For clarity, providing at market price any supply of any
biological or pharmaceutical product owned or controlled by a Party or any of its Affiliates that is then being commercialized without violation of Section 8.6(a) to a Third Party conducting a human Clinical Trial with respect to a compound
that is Directed against the Licensed Target in the Field for the Territory shall not constitute Development in violation of such Party’s exclusivity obligations under this Section 8.6 as long as neither such Party nor any of its
Affiliates receives any other monetary consideration with respect to any product other than such product that is the subject of such Clinical Trial. 

(2) The entry into any Partnership Agreement by Celgene or its Affiliates, either before or after the Effective Date, and the performance by
Celgene or its Affiliates of any obligations thereunder shall not constitute a breach of Section 8.6(a); provided that any exercise of any options by Celgene or its Affiliates thereunder shall be subject to Section 8.6(a) and such
exercise, in and of itself, shall not be permitted under this Section 8.6(b)(v). 
 (3) The restrictions set forth in
Section 8.6(a) shall not be deemed to prevent either Party or its respective Affiliates from (A) fulfilling its obligations under this Agreement, or (B) engaging any subcontractors in accordance with Section 8.2 of this
Agreement. 
 (4) If a Change of Control occurs with respect to either Party with a Third Party and the Third Party already is conducting or
is planning to conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such
initiation or continuation will not constitute a violation of Section 8.6(a); provided that, (A) none of the Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Inventions or Joint Patents will
be used in any Acquirer Program, (B) none of the other Patents or Know-How licensed by either Party to the other Party pursuant to this Agreement will be used in any such Acquirer Program, (C) no
Confidential Information of the other Party will be used in such Acquirer Program, and (D) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program,

  
 - 24 - 

 
including by the maintenance of separate lab notebooks and records (password-protected to the extent kept on a computer network) and the use of separate personnel working on each of the
activities under this Agreement, and the activities covered under any Acquirer Program (except that this requirement shall not apply to personnel who have senior research management roles and not project level research roles, provided such personnel
in senior research management roles are not directly involved in the day-to-day activities under such Acquirer Program). 

(vi) Clinical Combinations. Notwithstanding anything to the contrary in this Agreement, for purposes of this Section 8.6, either
Party shall, at all times, have the right to conduct clinical Development of Licensed Products, alone or with Third Parties, in which the Licensed Products are used in combination with other therapeutic products, and to grant to any such Third
Parties the right to use and reference either Party’s regulatory filings for purposes of enabling such Party and such Third Party to include the relevant use of Licensed Products in combination with such other therapeutic product in the
approved label for such Licensed Products or such other therapeutic product, respectively, provided that neither Party may grant to any such Third Party the right to sell, offer for sale or otherwise commercially exploit such Licensed
Products. 
 (vii) [Separate Programs under the Collaboration.3 Notwithstanding
the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any Program Product Directed against the Licensed Target in a Separate Program by or on behalf of Vividion (a “Separate Program
Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement: (x) such Separate Program Product is no longer subject to Celgene’s Opt-In
Right under the Master Agreement and is not the subject of any Development & Commercialization Agreement as a Licensed Product or Shared Product; and (y) such proposed Separate Program Product demonstrates utility in distinct
Indications where such Separate Program Product could not be substituted by any Licensed Product for such distinct Indication(s), based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results
(i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty (30) days, as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master
Agreement (any such one or more distinct Indications for which the Separate Program Product demonstrates utility, a “Permitted Indication”); and (z) such Separate Program Product is only Clinically Developed, Manufactured for
Clinical Development or Commercialization, or Commercialized by or on behalf of Vividion or its Affiliates for one or more Permitted Indications. The Parties understand and agree that any Scientific Panel appointed under this
Section 8.6(b)(vii) may be convened at any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Vividion covenants and agrees, on behalf
of itself and its Affiliates, as a condition to granting a license or sublicense to Develop, Manufacture or Commercialize such Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Separate
Program Product, Vividion shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Manufacture for Clinical Development or Commercialization, or
Commercialize such Separate Program Product in one or more Permitted Indications.] 
  

	3 	 Only insert for E3 Ligase Programs and Vividion Cereblon Programs. 

  
 - 25 - 

 (viii) Non-Collaboration Separate Programs.4 [Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any molecule outside of the Collaboration by or on behalf of either
Party or its Affiliates (a “Non-Collaboration Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement with respect
to such Party or its Affiliates: (x) such Non-Collaboration Separate Program Product is Directed to the Licensed Target; (y) such Non-Collaboration Separate
Program Product demonstrates utility in distinct Indications where such Non-Collaboration Separate Program Product could not be substituted by any Licensed Product for such distinct Indication(s), based upon
distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or, (ii) if the Parties are unable to mutually agree within thirty (30) days, as
determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any such one or more distinct Indications for which the Non-Collaboration Separate
Program Product demonstrates utility, an “Allowed Indication”), where such Non-Collaboration Separate Program Product could not be substituted for any Licensed Product for any Allowed
Indication; and (z) such Non-Collaboration Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or Commercialization, or Commercialized by or on behalf of such
Party or its Affiliates for one or more Allowed Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(viii) may be convened at any time during the Term (notwithstanding anything to the
contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Each Party covenants and agrees, on behalf of itself and its Affiliates, as a condition to granting a license or sublicense to Clinically
Develop, Enabling Manufacture or Commercialize such Non-Collaboration Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Non-Collaboration Separate Program Product, such Party shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop,
Manufacture for Clinical Development, or Commercialize such Non-Collaboration Separate Program Product in one or more Allowed Indications.] 

Section 8.7 Retained Rights. 

(a) No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and subject to Section 8.6, all rights in and
to the Vividion Intellectual Property and any other Patents or Know-How of Vividion and its Affiliates, are hereby retained by Vividion and its Affiliates. Except as expressly provided in Section 14.4,
and subject to Section 8.6, all rights in and to the Celgene Intellectual Property and any other Patents or Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 

(b) Other Retained Rights. The Parties acknowledge that the licenses granted hereunder are subject to any rights retained by any
licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement, provided that, upon Celgene’s reasonable request, Vividion shall cooperate fully in requesting and obtaining any waiver
with respect to the requirement, if applicable under such agreements, that the Licensed Products used or sold in the United States be manufactured substantially in the United States. 

 

	4 	 Only insert for E3 Ligase Programs and Vividion Cereblon Programs. 

  
 - 26 - 

 Section 8.8 Section 365(n) of the Bankruptcy Code. All rights
and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the “Bankruptcy
Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy
Code. The Parties agree that each Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable law outside the United
States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or analogous provisions of
applicable Law outside the United States, the Party that is not subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual
property, which, if not already in the non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof.
Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 

Article IX. 
 Financial
Provisions 
 Section 9.1 Milestone Payments. 

(a) Development and Regulatory Milestones. Celgene shall pay Vividion the following one-time
amounts after the first achievement by or on behalf of Celgene or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the first Licensed Product to achieve such
milestone events. 
 [Parties to include in execution version solely where the Licensed Program under this Agreement is a Vividion Cereblon Program,
any Early Opt-Out Program or the First Program] 
  

					
	 Milestones
	  	Payment
(in US Dollars)	 
	 (1) [***]
	  	$	[	***] 
	 (2) [***]
	  	$	[	***] 
	 (3) [***]
	  	$	[	***] 
	 (4) [***]
	  	$	[	***] 

  
 - 27 - 

 [Parties to include in execution version solely where the Licensed Program under this Agreement is a
CCB Program] 
  

					
	 Milestones
	  	Payment
(in US Dollars)	 
	 (1) [***]
	  	$	[	***] 
	 (2) [***]
	  	$	[	***] 
	 (3) [***]
	  	$	[	***] 
	 (4) [***]
	  	$	[	***] 

 (i) Each milestone payment under this Section 9.1(a) shall be made within [***] days after the
achievement of the applicable milestone by Celgene or any of its Affiliates or Licensee Partners. 
 (ii) For clarity and subject to
Section 9.1(a)(iii) [and Section 9.1(a)(iv)] [include as applicable] below, the milestone payments set forth in the table above in this Section 9.1(a) (to the extent payable) shall be paid only once, regardless of the
number of Licensed Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

(iii) Solely with respect to Milestones 3 and 4 in the table above, [***] percent ([***]%) of the corresponding milestone payment amount shall
be paid upon the achievement of the applicable milestone event by a Licensed Product for a different Indication than the Indication for which a Licensed Product first achieved such milestone event. For the avoidance of doubt, each distinct histology
shall qualify as a distinct Indication for purposes of this Section 9.1(a)(iii). For the further avoidance of doubt, if a Licensed Product achieves a milestone for an Indication and subsequently achieves the same milestone for an earlier or
different line setting in the same Indication, no milestone payment shall be due for such earlier or different line setting (e.g., if a Licensed Product received Regulatory Approval in the European Union as a third line therapy for an
Indication, no milestone payment would be due if such Licensed Product later received Regulatory Approval in the European Union as a second line therapy for such Indication). For the further avoidance of doubt, for purposes of this
Section 9.1(a)(iii), if a Licensed Product achieves a milestone for an Indication as part of a monotherapy or combination therapy and subsequently achieves the same milestone in the same Indication as part of a combination therapy or
monotherapy, respectively, no milestone payment shall be due for such subsequent milestone. 

  
 - 28 - 

 (iv) [Parties to include in execution version solely where the Licensed Program under
this Agreement is an E3 Ligase Program or a Vividion Cereblon Program] [Solely for purposes of this Section 9.1(a), in the event that the Licensed Program produces two (2) or more Distinct Products (as determined pursuant to
Section 2.3.4 of the Master Agreement), the Parties understand and agree, following Regulatory Approval of the first Licensed Product in the United States under this Agreement, each subsequent Distinct Product to receive Regulatory Approval in
the United States shall be eligible to receive the Milestone Payments set forth in the table above and Section 9.1(a)(iii) (the “Distinct Product Catch-Up Payments”). Celgene will make
any Distinct Product Catch-Up Payments within [***] days after such Distinct Product receives Regulatory Approval in the United States; provided, however, that, Milestone 4 above shall instead only be
payable [***] days after such Distinct Product receives Regulatory Approval in the European Union. For clarity, in the event that Celgene makes any Distinct Product Catch-Up Payment for a Distinct Product
pursuant to this Section 9.1(a)(iv), Vividion shall be entitled to additionally receive the milestone amounts under Section 9.1(a)(iii) for such Distinct Product if, but only if, such Distinct Product receives Regulatory Approval in the
United States for an additional Indication which is distinct from any of the Indications for which any of the Licensed Products have received Regulatory Approval.] 

(b) Sales Milestones. Celgene shall make a non-refundable,
non-creditable, one-time payment of [***] US Dollars ($[***]) to Vividion [***] days following the first time aggregate Annual Net Sales of Licensed Products in a given
Calendar Year in the Territory exceed [***] U.S. Dollars ($[***]). For clarity, the milestone payment set forth in this Section 9.1(b) shall be paid only once. 

Section 9.2 Royalty Payments. 

(a) Royalty Rate. Celgene shall pay to Vividion royalties on worldwide Annual Net Sales of Licensed Products, on a Licensed Product-by-Licensed Product basis (in no event to include Companion Diagnostics), as set forth below: 

[Parties to include in execution version solely where the Licensed Program under this Agreement is a Vividion Cereblon Program, an Early Opt-Out Program or the First Program, unless the First Program is a Deal Target Program or an E3 Ligase Program, the second Program for which Celgene exercises its Opt-In
Right under the Master Agreement is a Vividion Cereblon Program, and such second Program that is a Vividion Cereblon Program is the Licensed Program hereunder] 
  

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%

  
 - 29 - 

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

 [Parties to include in execution version solely where the First Program is a Deal Target Program or an E3 Ligase
Program, the second Program for which Celgene exercises its Opt-In Right under the Master Agreement is a Vividion Cereblon Program, and such second Program that is a Vividion Cereblon Program is the Licensed
Program hereunder] 
  

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including[ *** ] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

  
 - 30 - 

 [Parties to include in execution version solely where the Licensed Program under this Agreement is a
CCB Program] 
  

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

 Each royalty rate set forth in the table above will apply only to that portion of the worldwide Annual Net Sales of a given
Licensed Product in the Territory during a given Calendar Year that falls within the indicated portion. 
 [[Parties to fill in applicable
numbers based on the applicable Program] For example, if worldwide Annual Net Sales of a given Licensed Product by Celgene and its Affiliates and Licensee Partners was $900,000,000, then the royalties payable with respect to such
worldwide Annual Net Sales would be: 
 [***] 

(b) Royalty Term. Royalties payable under this Section 9.2 shall be paid by Celgene on a Licensed Product-by-Licensed Product and country-by-country basis from the date of First Commercial Sale of each Licensed Product in a
country with respect to which royalty payments are due, until the latest of: 
 (i) the last to expire of any Valid Claim of Vividion
Patents, Celgene License Collaboration Patents or Joint Patents Covering such Licensed Product in such country; 
 (ii) [***] years
following the date of First Commercial Sale of such Licensed Product in such country; and 
 (ii) the expiration of Regulatory Exclusivity
for such Licensed Product in such country; 
 (each such term with respect to a Licensed Product and a country, a “Royalty
Term”). 

  
 - 31 - 

 Notwithstanding the foregoing, in the event that the Royalty Term for a Licensed Product in
a country continues solely due to Section 9.2(b)(ii) above (i.e., the Licensed Product is not Covered by a Valid Claim of Vividion Patents, Celgene License Collaboration Patents or Joint Patents in the applicable country, and such
Licensed Product is not subject to Regulatory Exclusivity in such country), then, subject to Section 9.2(g), in such event, the royalty rate in such country will be reduced to [***] percent ([***]%) of the applicable rate in
Section 9.2(a)in such country. 
 (c) Expiration of Royalty Term. Upon the expiration of the Royalty Term with respect to a
Licensed Product in a country, the license granted by Vividion to Celgene pursuant to Section 8.1 shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Licensed Product in
such country; provided that, notwithstanding Section 9.3, Celgene shall assume and be solely responsible (without deduction under Section 9.2(e)) for any amounts payable to Third Party licensors and Celgene shall be responsible for
complying with the terms of any license agreements with such Third Party licensors, in each case, with respect to Celgene’s exercise of such rights as to such Licensed Product in such country following the expiration of such Royalty Term. 

(d) Royalty Reduction for Generic Competition. If, on a Licensed
Product-by-Licensed Product, country-by-country and Calendar Quarter-by-Calendar Quarter basis, 
 (i) a Generic Product(s) has
a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%); or 
 (ii) a Generic Product(s) has
a market share of more than [***] percent ([***]%); 
 then, subject to Section 9.2(g), the royalties payable with respect to Annual
Net Sales of such Licensed Product pursuant to Section 9.2(a) in such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies,
respectively, of the royalties otherwise payable pursuant to Section 9.2(a). Market share shall be based on the aggregate market in such country of such Licensed Product and all applicable Generic Products (based on sales of units of such
Licensed Product and such Generic Product(s) in the aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

(e) Deduction for Third Party Payments. In the event that royalties are payable by Celgene to Vividion with respect to any Licensed
Product in any country under this Section 9.2, then, subject to Section 9.2(g), Celgene shall have the right to deduct a maximum of [***] percent ([***]%) of any royalties or other amounts actually paid by Celgene to a Third Party with
respect to any license obtained pursuant to Section 9.3(b) with respect to such Licensed Product in such country, but only to the extent that the Patents or Know-How licensed under such other license are
necessary for the Development, Manufacture or Commercialization of such Licensed Product in such country, from royalty payments otherwise due and payable by Celgene to Vividion under this Section 9.2 with respect to such Licensed Product in
such country, on a Licensed Product-by-Licensed Product and country-by-country basis.

  
 - 32 - 

 (f) Royalty Reports; Payments. Celgene shall: (i) within [***] days following the end
of each Calendar Quarter in which a royalty payment accrues, provide to Vividion a report for each country in the Territory in which sales of any Licensed Product occurred in the Calendar Quarter covered by such statement, specifying for such
Calendar Quarter: the number of Licensed Products sold; the applicable royalty rate under this Agreement; the royalties payable in each country’s currency, including an accounting of deductions taken in the calculation of Annual Net Sales in
accordance with Celgene’s Accounting Standards; the applicable exchange rate to convert from each country’s currency to U.S. Dollars under Section 9.7; and the royalty calculation and royalties payable in U.S. Dollars, and (ii) make the
royalty payments owed to Vividion hereunder in accordance with such royalty report in arrears, within [***] days from the end of each Calendar Quarter in which such payment accrues. 

(g) Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in this Section 9.2, alone or together,
reduce the royalties payable by Celgene for a Licensed Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts otherwise payable by Celgene for such Licensed Product in such country in such Calendar
Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth above in this Section 9.2(g), to any subsequent
Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully deducted, in all cases subject to the limitation set forth
above in this Section 9.2(g). 
 Section 9.3 Third Party Payments. 

(a) Existing Third Party Agreements. Each Party acknowledges that Vividion is responsible for all amounts payable under the Existing
Third Party Agreements. 
 (b) Additional Agreements. After the Effective Date, if Celgene at any time believes that a license under
Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, is necessary or useful to Develop, Manufacture or Commercialize the Licensed Products, then Celgene shall have the
sole right make such determination, without escalation to the Executive Officers. The costs of each such license to the extent the costs directly relate to the Licensed Products shall be paid by Celgene, subject to deduction from royalties to the
extent set forth in Section 9.2(e). 
 Section 9.4 Financial Records. Celgene shall keep, and shall require its Affiliates
and Licensee Partners to keep, complete and accurate books and records in accordance with the applicable Accounting Standards. Celgene shall keep, and shall require its Affiliates and Licensee Partners to keep, such books and records for at least
[***] years following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing and maintaining such records. With respect
to royalties, such records shall be in sufficient detail to support calculations of royalties due to Vividion. 

  
 - 33 - 

 Section 9.5 Audits. 

(a) Audit Team. Vividion may, upon request and at [***] expense (except as provided for herein), cause an internationally recognized
independent accounting firm selected by it (except one to whom Celgene has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of Celgene and the correctness of any payment made
or required to be made, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this Agreement, the Audit Team shall enter into an appropriate confidentiality
agreement with Celgene obligating the Audit Team to be bound by obligations of confidentiality and restrictions on use of Celgene’s Confidential Information that are no less restrictive than the obligations set forth in Article XI. 

(b) Limitations. In respect of each audit of Celgene’s books and records: (i) Celgene may be audited only once per year,
(ii) no records for any given year for Celgene may be audited more than once; provided that Celgene’s records shall still be made available if such records impact another financial year which is being audited, and
(iii) Vividion shall only be entitled to audit books and records of Celgene from the [***] Calendar Years prior to the Calendar Year in which the audit request is made. 

(c) Audit Notice. In order to initiate an audit for a particular Calendar Year, Vividion must provide written notice to Celgene.
Vividion shall provide Celgene with notice of one or more proposed dates of the audit not less than [***] days prior to the first proposed date. Celgene will reasonably accommodate the scheduling of such audit. Celgene shall provide such Audit
Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate with such audit. 
 (d)
Payments. If the audit shows any under-reporting or underpayment, or overpayment by Celgene, that under-reporting, underpayment or overpayment shall be reported to Vividion and (x) Celgene shall remit such underpayment (together with
interest at the rate set forth in Section 9.8) to Vividion and (y) Vividion shall reimburse such overcompensation to Celgene, each within [***] days after receiving the audit report. Further, if the audit for an annual period shows an
under-reporting or underpayment or an overpayment by Celgene for that period in excess of [***] percent ([***]%) of the amounts properly determined, Celgene shall reimburse Vividion for its respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [***] days after receiving appropriate invoices and other support for such
audit-related costs. 
 Section 9.6 Tax Matters. 

(a) Withholding Taxes. Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement such taxes as
are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will: (i) deduct those taxes from such payment, (ii) timely
remit the taxes to the proper taxing authority, and (iii) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee Party”) on a timely basis following that tax payment; provided,
however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction or withholding (and such notice, which shall set forth in reasonable detail the authority,
basis and method of calculation for the proposed deduction or withholding, shall be given at least a reasonable period of time before such deduction or withholding is required, in order for such Payee Party to obtain reduction of or relief from such
deduction or withholding). Each Party agrees to 

  
 - 34 - 

 
cooperate with the other Parties in claiming refunds or exemptions from, or reductions in, such deductions or withholdings under any applicable Law or treaty to ensure that any amounts required
to be withheld pursuant to this Section 9.6(a) are reduced to the fullest extent permitted by applicable Law. In addition, the Parties shall cooperate to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other
similar taxes (“Indirect Taxes”)) in connection with this Agreement, as applicable. 
 (b) Tax Documentation. Each
Party has provided a properly completed and duly executed IRS Form W-9 or applicable Form W-8 to the other Parties. Each Party and any other recipient of payments under
this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Parties or as required by applicable Law, such properly completed and duly executed documentation (for example, IRS Forms W-8 or W-9) as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made
without (or at a reduced rate of) withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 

Section 9.7 Currency Exchange. Unless otherwise expressly stated in this Agreement, all amounts specified in, and all payments
made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts payable under this Agreement, such conversion shall be performed in a manner consistent with
Celgene’s normal practices used to prepare its audited financial statements for internal and external reporting purposes. For clarity, Celgene sets currency transaction rates for the month on the last business day of the month prior. Vividion
has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month prior. 

Section 9.8 Late Payments. Any payments that are not paid on or before the date such payments are due under this Agreement shall
bear interest at an annual rate equal to the lesser of (x) [***], or (y) [***]; provided that, [***]. 
 Section 9.9 Blocked
Payments. In the event that, by reason of applicable Law in any country, it becomes impossible or illegal for Celgene (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed Vividion
hereunder, Celgene will promptly notify Vividion of the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country to the credit of Vividion in a recognized banking institution designated by
Vividion or, if none is designated by Vividion within a period of [***] days, in a recognized banking institution selected by Celgene or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to
Vividion. 

  
 - 35 - 

 Section 9.10 Prohibitions on Payments. When in any country in the Territory
applicable Law prohibits both the transmittal and the deposit of royalties on sales in such country, royalty payments due on Net Sales shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in
effect, all royalties that Celgene would have been under an obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent allowable. The Parties shall cooperate in good faith to overcome, to the
extent reasonably possible, any prohibition described in this Section 9.10 within a reasonable period of time. 
 Article X. 

Intellectual Property Ownership, Protection and Related Matters 

Section 10.1 Ownership of Inventions. 

(a) Non-Collaboration Know-How. Any Know-How discovered, developed, generated or invented by Celgene or its Affiliates or Vividion or its Affiliates prior to or outside the Collaboration shall remain the sole property of such Party or its applicable
Affiliate(s), except as otherwise agreed by the Parties. 
 (b) Sole Inventions. All Know-How
discovered, developed, generated or invented solely by employees, agents and consultants of a Party or its Affiliates shall be owned exclusively by such Party or its applicable Affiliate(s). 

(c) Joint Inventions. All Know-How discovered, developed, generated or invented jointly by
employees, agents and consultants of Celgene or its Affiliates, on the one hand, and employees, agents and consultants of Vividion or its Affiliates, on the other hand, in the conduct of activities under this Agreement (“Joint
Inventions” and, any Patents Covering such Joint Inventions, “Joint Patents”) shall be owned jointly on the basis of each Party (or its applicable Affiliate(s)) having an undivided interest without a duty to account to the
other Party (other than as set forth in this Agreement) and shall be deemed to be Controlled by each Party. Each Party shall have the right to use such Joint Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell
or otherwise transfer its interest in such Joint Inventions to its Affiliates or a Third Party, in each case without the consent of the other Party or its applicable Affiliate(s) (and, to the extent that applicable Law requires the consent of the
other Party or its applicable Affiliate(s), this Section 10.1(c) shall constitute such consent), so long as such use, sale, license or transfer is subject to Section 8.6 and the licenses granted pursuant to this Agreement and is otherwise
consistent with this Agreement. 
 (d) Inventorship. For purposes of determining ownership hereunder, the determination of
inventorship shall be made in accordance with United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually acceptable independent patent
counsel not regularly employed by either Party to resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(e) Further Actions and Assignments. Each Party shall take all further actions and execute all assignments requested by the other Party
and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 

  
 - 36 - 

 Section 10.2 Prosecution of Patents. Subject to the terms and conditions of any
Existing Third Party Agreement to the extent such agreement applies to the Vividion Patents, the following provisions shall apply with respect to the Vividion Patents, Celgene Patents, Celgene License Collaboration Patents and Joint Patents: 

(a) Vividion Patents, Celgene License Collaboration Patents and Joint Patents. Subject to the provisions of Section 10.2(f) and
coordination with Vividion, Celgene shall have the initial right and option to Prosecute the Vividion Patents, Celgene License Collaboration Patents and Joint Patents. In the event that Celgene declines to Prosecute any such Patent(s), it shall give
Vividion reasonable notice to this effect, sufficiently in advance to permit Vividion to undertake Prosecution of such Patent(s) so declined in any applicable country without a loss of rights, and thereafter Vividion may, upon written notice to
Celgene and receipt of Celgene’s prior written consent (not to be unreasonably withheld), Prosecute such Patents in the owning Party(ies)’s name(s) subject to coordination with Celgene. 

(b) Celgene Patents. Celgene shall have the sole right and option, in its sole discretion and at [***] expense, to Prosecute the Celgene
Patents. 
 (c) Costs and Expenses. Each Prosecuting Party shall bear [***] costs and expenses in Prosecuting Vividion Patents,
Celgene License Collaboration Patents and Joint Patents. 
 (d) Strategy; Diligence and Cooperation. 

(i) The Party authorized to conduct Prosecution pursuant to Section 10.2(a) at the relevant time (as applicable, the “Prosecuting
Party”) with respect to a Vividion Patent, Celgene License Collaboration Patent or Joint Patent shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting
Party (including in-house patent counsel as well as outside patent counsel) for the Prosecution of the Patents subject to Section 10.2(a). Each Party agrees to cooperate with the other with respect to the
Prosecution of such Patents pursuant to this Section 10.2, including by (X) executing all such documents and instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake any
Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a), (Y) giving consideration to the proper scope of Patents and (Z) discussing with the other Party and considering in
good faith filing separate Patents that include, respectively, claims that Cover Licensed Products specifically or generically and claims that Cover only other compounds. The Prosecuting Party shall: 

(1) use Commercially Reasonable Efforts to regularly provide the non-Prosecuting Party in advance with
reasonable information relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and
copies of drafts of filings and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with sufficient time for the non-Prosecuting party to provide meaningful input; 
 (2) use Commercially Reasonable Efforts to consider
in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 

  
 - 37 - 

 (3) use Commercially Reasonable Efforts to Prosecute additional claims substantially
similar to those suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 

(4) consult with the non-Prosecuting Party before taking any action that would have a material adverse
impact on the scope of claims within the Vividion Patents, Celgene License Collaboration Patents or Joint Patents, as applicable. 
 (ii)
The Prosecuting Party shall determine the countries in which Vividion Patents, Celgene License Collaboration Patents and Joint Patents shall be Prosecuted. 

(iii) The Prosecuting Party agrees not to abandon any Vividion Patent, Celgene License Collaboration Patent or Joint Patent without filing a
divisional or continuation application in respect thereof unless it provides the non-Prosecuting Party with reasonable notice to this effect, sufficiently in advance to permit the non-Prosecuting Party to undertake such Prosecution of such Vividion Patent, Celgene License Collaboration Patent or Joint Patent, and thereafter such non-Prosecuting Party
may, upon written notice to the Prosecuting Party and, in the case of Vividion, receipt of Celgene’s prior written consent (not to be unreasonably withheld), Prosecute such Vividion Patent, Celgene License Collaboration Patent or Joint Patent
at [***] expense with counsel of its choice. 
 (e) Third Party Rights. Vividion covenants and agrees that it shall not grant any
Third Party any right to control the Prosecution of the Vividion Patents or to approve or consult with respect to any Patents licensed to Celgene hereunder, in any case, that is more favorable to the Third Party than the rights granted to Celgene
hereunder or that otherwise conflicts with Celgene’s rights hereunder. 
 (f) Existing Third Party Agreements. Each Party
acknowledges that, pursuant to an Existing Third Party Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Vividion Patents covered by such agreement, and that Vividion may have certain rights to assume Prosecution
under such agreement. Vividion agrees to keep Celgene fully informed of these rights, as well as provide to Celgene all information and copies of documents received from the licensor(s) under any such Existing Third Party Agreement or their patent
counsel relating to the Vividion Patents covered by such agreements. To the extent that Vividion is permitted to proceed with Prosecution or provide comments or suggestions to patent documents under an Existing Third Party Agreement, then the
Vividion Patents under such Existing Third Party Agreement shall be treated, to the extent possible, in the same manner as other Vividion Patents under this Section 10.2, and Vividion shall exercise all such rights with respect to such Vividion
Patents pursuant to the instructions of Celgene, if Celgene is given the right to act under this Section 10.2. 
 Section 10.3
Third Party Infringement of Vividion Patents, Celgene License Collaboration Patents and Joint Patents. Subject to the terms and conditions of the Existing Third Party Agreements to the extent such agreements apply to the Vividion Intellectual
Property, the following provisions shall apply with respect to the Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Patents and Joint Inventions: 

(a) Notice. Each Party shall immediately provide the other Party with written notice reasonably detailing any (i) known or alleged
infringement of any Vividion Patents, Celgene License Collaboration Patents or Joint Patents, or known or alleged misappropriation of any Vividion Know-How, Celgene License Collaboration Know-How or Joint Inventions, by a Third Party, (ii) “patent certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other
jurisdictions, or (iii) declaratory judgment, opposition or similar action alleging the invalidity, unenforceability or non-infringement of any such intellectual property rights (collectively
“Third Party Infringement”). 

  
 - 38 - 

 (b) First Right to Initiate Infringement Actions. Celgene shall have the initial
right, but not the obligation, to initiate a suit or take other appropriate action that Celgene believes is reasonably required to protect the Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Inventions and
Joint Patents against infringement in the Territory, including Third Party Infringement, unauthorized use or misappropriation by a Third Party that relates to a Licensed Product (“Competitive Infringement”). Celgene shall give
Vividion advance notice of Celgene’s intent to file any such suit or take any such action and the reasons therefor, and shall provide Vividion with an opportunity to make suggestions and comments regarding such suit or action. Thereafter,
Celgene shall keep Vividion promptly informed, and shall from time to time consult with Vividion regarding the status of any such suit or action and shall provide Vividion with copies of all material documents (e.g., complaints, answers,
counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts
of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall discuss in good faith Celgene’s intended
response to a Competitive Infringement. For clarity, Celgene shall have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products. 

(c) Step-in Rights. If Celgene fails to initiate a suit or take such other appropriate action
under Section 10.3(b) above within [***] days after becoming aware of the Competitive Infringement, then Vividion may, in its discretion, provide Celgene with written notice of its intent to initiate a suit or take other appropriate action to
combat such Competitive Infringement; provided, however, that (i) such period will be more than [***] days to the extent applicable Law prevents earlier enforcement of the applicable Patent(s) and provided further that if such period is
extended because applicable Law prevents earlier enforcement, then Celgene shall have until the date that is [***] days following the date upon which applicable Law first permits such enforcement proceeding to elect to so enforce the applicable
Patent(s), and (ii) Celgene shall have less than [***] days (or, as applicable, less than the [***] day period described in clause (i)) to elect to so enforce the applicable Patent(s) to the extent that a delay in bringing such enforcement
proceeding against such alleged Third Party infringer would limit or compromise the remedies (including monetary relief and stay of regulatory approval) available against such alleged Third Party infringer. If Vividion provides such notice and
Celgene fails to initiate a suit or take such other appropriate action within [***] days after receipt of such notice from Vividion (or such earlier time as is required to avoid limiting or compromising the remedies (including monetary relief and
stay of regulatory approval) available against such alleged Third Party infringer), then Vividion shall have the right, but not the obligation, to initiate a suit or take other appropriate action that it believes is reasonably required to protect
the applicable 

  
 - 39 - 

 
Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Inventions or Joint Patents from Competitive Infringement. Vividion shall give Celgene advance notice of
its intent to file any such suit or take any such action and the reasons therefor and shall provide Celgene with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, Vividion shall keep Celgene promptly informed
and shall from time to time consult with Celgene regarding the status of any such suit or action and shall provide Celgene with copies of all material documents (e.g., complaints, answers, counterclaims, material motions, orders of the court,
memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and
notices of appeal) filed in, or otherwise relating to, such suit or action. Notwithstanding anything in this Section 10.3 to the contrary, (i) Celgene shall have final decision-making authority as to representations made in any proceedings
under this Section 10.3 with respect to any Celgene Independent Products and (ii) if Celgene has a reasonable, good faith concern that Vividion’s exercise of its backup enforcement or defense rights with respect to any Patent would be
detrimental to the overall patent protection of the Licensed Products or related Companion Diagnostics, then Vividion shall not be permitted to enforce or defend such Patent without the prior consent of Celgene. 

(d) Conduct of Action; Costs. The Party initiating suit shall have the sole and exclusive right to select counsel for any suit initiated
by it under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate or maintain such suit, the other Party shall join as a party to the suit. If
requested by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party except that the initiating Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The Party initiating suit shall assume and pay [***] Out-of-Pocket Costs incurred in connection with any litigation or proceedings described in this Section 10.3, including the fees and expenses of the counsel selected by
it. The other Party shall have the right to participate and be represented in any such suit by its own counsel at [***] expense. 
 (e)
Recoveries. Any recovery obtained as a result of any proceeding described in this Section 10.3 or from any counterclaim or similar claim asserted in a proceeding described in Section 10.4, by settlement or otherwise, shall be
applied in the following order of priority: 
 (i) first, the Parties shall be reimbursed for all previously unreimbursed Out-of-Pocket Costs in connection with such proceeding; and 

(ii) second, any remainder shall be paid [***] percent ([***]%) to the Party initiating the suit or action, and [***] percent ([***]%) to the
other Party. 
 (f) Existing Third Party Agreements. In the event that (i) a Patent covered by an Existing Third Party Agreement
is at issue in an action under this Section 10.3 or Section 10.4, (ii) Vividion has a right to enforce the Vividion Patents under such Existing Third Party Agreement, and (iii) Celgene desires to enforce such Patent in accordance with
the procedures under this Section 10.3 or Section 10.4, as applicable, then Vividion shall either obtain the licensor(s)’ consent under such Existing Third Party Agreement so that Celgene may file such an action in its own name or
shall undertake such an action on Celgene’s behalf and at [***] expense. 

  
 - 40 - 

 Section 10.4 Claimed Infringement; Claimed Invalidity. 

(a) Infringement of Third Party Rights. Each Party shall promptly notify the other Party in writing of any allegation by a Third Party
that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or misappropriates, or may infringe or misappropriate, the intellectual property rights of such Third Party. If a Third Party asserts or files
against a Party or its Affiliates any claim of infringement or misappropriation of the intellectual property rights of such Third Party or other action relating to alleged infringement or misappropriation of such intellectual property rights
(“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 
 (i) In the event of a Third Party
Infringement Action against a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to participate in the defense of such legal action with legal counsel selected by the unnamed Party and reasonably
acceptable to the named Party. The Party named in such Third Party Infringement Action shall have the right to control the defense of the action, but shall notify and keep the unnamed Party apprised in writing of such action and shall consider and
take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action. In the event of a Third Party Infringement Action against both Parties, Celgene shall have the right to control the
defense of such Third Party Infringement Action. 
 (ii) The non-controlling Party of a Third Party
Infringement Action shall reasonably cooperate with the controlling Party in the preparation and formulation of a defense to such Third Party Infringement Action, and in taking other steps reasonably necessary to respond to such Third Party
Infringement Action. The controlling Party shall have the right to select its counsel for the defense to such Third Party Infringement Action, which counsel must be reasonably acceptable to the non-controlling
Party if both Parties have been named as defendants in the action. The non-controlling Party shall also have the right to participate and be represented in any such suit by its own counsel at [***] expense.
The controlling Party shall not (and shall cause its Affiliates and Licensee Partners not to) either (A) admit infringement, validity or enforceability of the asserted intellectual property rights, (B) pay any amount of money in settlement
thereof, or (C) enter into a license for the asserted intellectual property rights upon terms that would restrict either Party from fully exploiting such rights consistently with the scope of the rights and obligations of both Parties under
this Agreement, in each case (A) through (C), without the written consent of the non-controlling Party, which will not to be unreasonably withheld, conditioned or delayed. For the avoidance of doubt,
except as provided in the foregoing clause (B), the costs of such defense and settlement shall be borne by the controlling Party. 
 (iii)
If the Party entitled to control the defense under Section 10.4(a)(i) fails to proceed in a timely manner with respect to such defense, the other Party shall have the right to control the defense of such claim upon the same conditions set forth
therein. 

  
 - 41 - 

 (iv) If requested by the Party controlling the defense, the Parties shall enter into a
joint defense agreement that further outlines their rights and responsibilities consistent with the terms of this Section 10.4(a) or as otherwise mutually agreed. 

(b) Patent Invalidity Claim. If a Third Party at any time asserts a claim that any issued Vividion Patent, Celgene License Collaboration
Patent or Joint Patent is invalid or otherwise unenforceable, or if any such Patent is the subject of a post-grant proceeding or any European opposition proceeding whether as a pre-grant or post-grant
proceeding (each, an “Invalidity Claim”), whether as a defense in an infringement action brought by Vividion or Celgene pursuant to Section 10.3(b) or Section 10.3(c), in a declaratory judgment action or in a Third Party
Infringement claim brought against Vividion or Celgene, or otherwise, the Parties shall cooperate with each other in preparing and formulating a response to such Invalidity Claim; provided that, subject to the terms and conditions of any
Existing Third Party Agreement to the extent such agreement applies to such Vividion Patent, the Party who has (or would have) control over litigation pursuant to Section 10.3(b) or Section 10.3(c) shall have the sole right to control the
defense and settlement of any such Invalidity Claim as if it were litigation initiated therein. For the avoidance of doubt, any claim asserted against any Vividion Patent before any such Patent is issued (other than any European opposition
proceeding) is deemed a Prosecution matter that is the subject of Section 10.2. 
 Section 10.5 Patent Term Extensions. The
Parties shall, as necessary and appropriate, use reasonable efforts to agree upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions for Vividion Patents, Celgene License Collaboration Patents and
Joint Patents that Cover Licensed Products. If the Parties are unable to agree upon which of such Patents should be extended, and the matter remains unresolved after the procedure described in the Master Agreement, then Celgene shall have the right
to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement to the extent such agreement applies to an applicable Vividion Patent. 

Section 10.6 Patent Marking. Celgene shall comply with the patent marking statutes in each country in which any Licensed Product
is Manufactured or Commercialized by or on behalf of Celgene or its Affiliates or Licensee Partners, as applicable, hereunder. 

Section 10.7 Celgene Intellectual Property. Celgene shall have the sole right, but not the obligation, to initiate a suit or take
other appropriate action that it believes is reasonably required to protect the Celgene Intellectual Property without any obligation to consult with Vividion. Notwithstanding anything to the contrary in Section 10.3 or Section 10.4, all
recoveries with respect to any such action, by settlement or otherwise, shall be retained [***] percent ([***]%) by [***]. 

Section 10.8 Application of 35 U.S.C. § 102(c). It is agreed and acknowledged that this Agreement establishes a qualifying
collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C. § 102(c). Neither Party shall invoke the provisions of 35 U.S.C.
§ 102(c), or file this Agreement, in connection with the Prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without the prior written consent of the other Party. In the event that a Party,
during the course of Prosecuting a patent application claiming a 35 U.S.C. § 

  
 - 42 - 

 
102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it necessary to file a terminal disclaimer to overcome an obviousness type double patenting rejection
in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall coordinate the filing of such terminal disclaimer in good faith, and, to the extent required under 35
U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce the 35 U.S.C. § 102(c) Patent independently from the Earlier Patent. To this end, to the extent required under 35 U.S.C. §
102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to such 35 U.S.C. § 102(c) Patent. 

Article XI. 

Confidentiality 

Section 11.1 Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its
Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its Affiliates shall (x) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (y) not disclose such Confidential Information to any Third Party without the prior written
consent of the Disclosing Party, except for disclosures expressly permitted below, and (z) not use such Confidential Information for any purpose except those permitted by this Agreement, the Master Agreement or any other Development &
Commercialization Agreement (it being understood that this clause (z) shall not create or imply any rights or licenses not expressly granted under this Agreement). No Confidential Information of the Disclosing Party or any of its Affiliates
shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights explicitly granted to the Receiving Party under this Agreement. “Confidential Information” shall
exclude any information that: 
 (a) was known by the Receiving Party or any of its Affiliates prior to its date of disclosure to the
Receiving Party or any of its Affiliates by or on behalf of the Disclosing Party or any of its Affiliates, as established by written evidence; or 

(b) is lawfully disclosed to the Receiving Party or any of its Affiliates by sources other than the Disclosing Party or any of its Affiliates
rightfully in possession of the Confidential Information; or 
 (c) is or becomes published or generally known to the public through no fault
or omission on the part of the Receiving Party or any of its Affiliates or (sub)licensees; or 
 (d) is independently developed by or for the
Receiving Party or any of its Affiliates without reference to or reliance upon such Confidential Information, as established by written records. 

Section 11.2 Permitted Disclosure. The Receiving Party may provide the Disclosing Party’s or any of the Disclosing
Party’s Affiliates’ Confidential Information: 

  
 - 43 - 

 (a) to the Receiving Party’s employees, consultants and advisors, and to the employees,
consultants and advisors of such Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such information
and materials as confidential under obligations of confidentiality and non-use no less stringent than those set forth in this Article XI (provided that legal counsel shall not be required to execute any
written confidentiality agreements); 
 (b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in order to
seek or obtain approval to conduct Clinical Trials or to gain Regulatory Approval with respect to the Licensed Products as contemplated by this Agreement; provided that such disclosure may be made only following reasonable notice to the
Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 
 (c) if such disclosure
is required by judicial order or applicable Law or to defend or prosecute litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such
requirement, cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its applicable Affiliates’)
Confidential Information that the Receiving Party is legally required to furnish. 
 Section 11.3 Publicity; Terms of this
Agreement; Non-Use of Names. 
 (a) Public Announcements. Except as required by judicial
order or applicable Law (in which case, Section 11.3(b) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the
other Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would
like to make the public announcement (or, in extraordinary circumstances, such shorter period as required to comply with applicable Law). Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any
publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other
disclosure relating to this Agreement if the contents of such press release, public announcement or disclosure (i) (A) does not consist of financial information and has previously been made public other than through a breach of this Agreement
by the issuing Party or its Affiliates, (B) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or (C) is contained in the a redacted version of this Agreement, and (ii) is
material to the event or purpose for which the new press release or public announcement is made. 
 (b) Notwithstanding the terms of this
Article XI: 
 (i) Either Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the
reasonable opinion of such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the SEC or any other Governmental Authority. Notwithstanding the foregoing, before disclosing this Agreement or
any of the terms hereof pursuant to this Section 11.3(b)(i), the Parties will coordinate 

  
 - 44 - 

 
in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all exhibits and schedules) with respect to any filings with the US Securities
and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which securities issued by a Party or a Party’s Affiliate are traded (the
“Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other Party, and the Parties will use commercially reasonable efforts
to file redacted versions with any governing bodies which are consistent with the Redacted Version. 
 (ii) Notwithstanding
Section 11.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the
Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(1) complying with applicable Laws (including the rules and regulations of the SEC or any national securities exchange) and with judicial
process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 
 (2)
disclosure, solely on a “need to know basis,” to (A) Affiliates, subcontractors, advisors (including attorneys and accountants), (B) subject to Section 11.3(b)(ii)(3), investment bankers, and (C) in each case of (A) and
(B), such Affiliates’, subcontractors’ advisors’ and investment bankers’, and each of the Parties’, respective directors, employees, contractors and agents; provided that, in all cases of (A), (B) and (C), prior to
any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set
forth in this Article XI (provided, however, that in the case of prospective investment bankers, the term of confidentiality may be shortened to three (3) years from the date of disclosure and in the case of legal advisors, no written
agreement shall be required), which for the avoidance of doubt, will not permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the
Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 11.3(b)(ii)(2) or Section 11.3(b)(ii)(3) to treat such Confidential Information as required under this
Article XI; and 
 (3) in the case of any disclosure of this Agreement to any actual or potential acquirer, assignee, licensee, licensor,
investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted Version, in each case, which version shall be agreed upon by the Parties in good faith; it being understood and agreed
that, in connection with a proposed Change of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is in the final round of
negotiations with such Third Party regarding execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement as applicable, to such Third
Party; provided that, a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under obligations of confidentiality
not to disclose the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such licensors and lenders. 

  
 - 45 - 

 (iii) The Parties acknowledge the importance of supporting each other’s efforts to
publicly disclose results and significant developments regarding the Licensed Program and other activities in connection with this Agreement, the Master Agreement and each Development & Commercialization Agreement that may include
information that is not otherwise permitted to be disclosed under this Article XI, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and
regulatory process, commercialization activities and the like. A Party (the “Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory
process and commercialization activities, and in such event it shall first notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business
Days in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including
NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement
without such prior review by the other Party if (A) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the issuing Party and (B) such press release or
public announcement does not materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the Cooperating
Party may have regarding the proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles to be observed in such disclosures
shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the
Requesting Party’s business. 
 Section 11.4 Publications. The Parties agree that neither Party nor its Affiliates shall
have the right to make Publications pertaining to the Licensed Products except as provided herein. If a Party or its Affiliates desire to make a Publication, such Party or its Affiliates must comply with the following procedure: 

(a) Review by the Non-Publishing Party. The publishing Party shall provide the non-publishing Party with an advance copy of the proposed Publication, and the non-publishing Party shall then have [***] days prior to submission for any Publication [***]
days in the case of an abstract or oral presentation) in which to review and provide comments on such Publication, including (i) delaying sufficiently long to permit the timely preparation and filing of a patent application or
(ii) specifying changes the non-publishing Party reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or
license, including under this Agreement) in whole or in part to the non-publishing Party (the “Publication Purpose”), and the publishing Party shall implement all reasonable and timely
comments provided by the non-publishing Party with respect to the Publication Purpose; it being understood and agreed that Celgene shall always have final decision-making authority over any Publication. 

  
 - 46 - 

 (b) Removal of Confidential Information. In addition, if the non-publishing Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential Information of the
non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c) Scientific Conferences. Each Party shall have the right to present its Publications approved pursuant to this Section 11.4 at
scientific conferences, including at any conferences in any country in the world, subject to any reasonable conditions imposed by the non-publishing Party in its comments. 

(d) Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to
Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to
restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement, exercise such
rights after consultation with Celgene. 
 Section 11.5 Term. All obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall
survive termination or expiration of this Agreement and shall expire five (5) years following termination or expiration of this Agreement. 

Section 11.6 Return of Confidential Information. 

(a) Obligations to Return or Destroy. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the
Disclosing Party all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy:

 (i) any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information
of the Disclosing Party or any of its Affiliates; and 
 (ii) any Confidential Information of the Disclosing Party or any of its Affiliates
(and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 
 (b)
Destruction. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its
Affiliates (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any
requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

  
 - 47 - 

 (c) Limitation. Nothing in this Section 11.6 shall require the alteration,
modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its
obligations of confidentiality and other obligations under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d) Exceptions. Notwithstanding the foregoing, 

(i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 
 (ii) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents: 

(A) to the extent reasonably required (1) to exercise the rights and licenses of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(B) to the extent it is impracticable to return or destroy such Confidential Information without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving Party shall
continue to be bound by its obligations of confidentiality and other obligations under this Article XI. 
 Article XII. 

Representations and Warranties 

Section 12.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the
Execution Date, that: 
 (a) Authority. Each Party is duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as applicable. 

(b) Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder have been obtained, except for authorizations and consents that may be necessary
under Antitrust Law. 

  
 - 48 - 

 (c) No Conflict. Notwithstanding anything to the contrary in this Agreement, the
execution and delivery of this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or
violate any requirement of applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to
which it is a party or by which it or any of its Affiliates is bound, existing as of the Execution Date. 
 (d) Enforceability. This
Agreement has been duly executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e) Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in the
Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 
 Section 12.2 Additional Vividion
Representations. Vividion represents, warrants and covenants to Celgene, as of the Execution Date, as follows: [Note: The representations and warranties marked by an asterisk (*) below may be qualified by Vividion with a schedule of
exceptions prior to the Execution Date] 
 (a) Vividion has all rights, authorizations and consents necessary to grant all rights and
licenses it purports to grant to Celgene under this Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 

(b) Vividion has not used, and during the Term will not knowingly use, any Know-How in the Licensed
Program that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder; it being understood and agreed that, notwithstanding
anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(b) with respect to any Patents or Know-How licensed to Vividion
under the Scripps License is as set forth in Section 12.4(b). 
 (c) Vividion has not granted, and during the Term Vividion will not
grant, any right or license, to any Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d) There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings or governmental
investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion to consummate the
transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or the Licensed Target or Licensed Compound.* 

  
 - 49 - 

 (e) To Vividion’s knowledge, the practice of the Vividion Intellectual Property as
contemplated under this Agreement does not (i) infringe any claims of any Patents of any Third Party (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the
United States, including any safe harbor, research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or
(ii) misappropriate any Know-How of any Third Party, and, in particular, the practice of the Vividion Intellectual Property by or on behalf of Celgene or any of its Affiliates or Licensee Partners as
contemplated under this Agreement does and will not (A) infringe any claims of any Patents licensed to Vividion pursuant to the License Agreement (the “Scripps License”) dated as of January 6, 2016 by and between by The
Scripps Research Institute (“Scripps”) and Vividion (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including any safe harbor,
research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (B) misappropriate any Know-How licensed to Vividion pursuant to the Scripps License; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy
for any breach of this Section 12.2(e) solely with respect to the Scripps License is as set forth in Section 12.4(b).* 
 (f) None
of (i) the Vividion Patents owned by Vividion or both Controlled by and Prosecuted by Vividion and (ii) to Vividion’s knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination, opposition, interference or litigation proceedings or inter partes reviews, post grant reviews or covered business methods reviews.* 

(g) To the knowledge of Vividion, the Vividion Patents Controlled by Vividion or any of its Affiliates pursuant to any Existing Third Party
Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing Third Party Agreements. 
 (h)
Vividion has and, to Vividion’s knowledge, the applicable licensor under each Existing Third Party Agreement has, if applicable, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patents or Know-How licensed thereunder. Neither Vividion nor any of its Affiliates has granted any liens or security interests on the Vividion Intellectual Property and the Vividion Intellectual Property is free and clear of
any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind, except in each case with respect to licenses, covenants not to sue, immunities from suit, standstills, releases and options which would not,
in the aggregate, fundamentally frustrate the purposes of the Collaboration. 
 (i) Schedule 12.2(i) contains a complete and accurate
list of all Patents owned or licensed by Vividion or its Affiliates as of the Execution Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth
on Schedule 12.2(i), Vividion and its Affiliates do not own and have not licensed any Patent that is necessary 

  
 - 50 - 

 
or, to Vividion’s reasonable belief as of the Execution Date, reasonably useful to Develop, Manufacture or Commercialize any Licensed Products; it being understood and agreed that,
notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(i) with respect to any Patents or Know-How
licensed to Vividion under the Scripps License is as set forth in Section 12.4(b). 
 (j) Exhibit C sets forth a complete and
accurate list of all Existing Third Party Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Vividion nor, to the knowledge of
Vividion, any licensor under the Existing Third Party Agreements is in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a
material obligation under, the Existing Third Party Agreements. 
 (k) Except under the Scripps License (solely with respect to royalties for
which Vividion shall be solely responsible) and Existing Third Party Agreements in effect as of the Execution Date, Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance
of this Agreement. 
 Section 12.3 Covenants. 

(a) Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i) all employees of such Party or its Affiliates, Licensee Partners or Third Party subcontractors working under this Agreement will be under
appropriate confidentiality obligations at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries,
whether or not patentable, to such Party as the sole owner thereof; 
 (ii) to its knowledge, such Party will not (A) employ or use,
nor hire or use any contractor or consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any
Regulatory Authority outside the United States) or (B) employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in
each of subclauses (A) and (B) in the conduct of its activities under this Agreement; 
 (iii) neither such Party nor any of its
Affiliates shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder;
and 
 (iv) such Party and its Affiliates shall perform their activities pursuant to this Agreement in compliance (and shall ensure
compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP, as applicable. 

  
 - 51 - 

 (b) Existing Third Party Agreement Covenants. Vividion hereby covenants to Celgene
that Vividion shall maintain the Existing Third Party Agreements, and shall not amend or terminate such agreements, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect Celgene’s
rights under this Agreement. 
 Section 12.4 Vividion Covenants During the Term. 

(a) Except to the extent expressly permitted under Section 15.4, during the Term, neither Vividion nor its Affiliates will, other than to
an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection
(b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, any assets
specifically related to this Agreement, including with respect to the Licensed Product(s) and any then-identified Companion Diagnostic(s) developed therefor, or pre-clinical study or Clinical Trial results or
other data specifically related to the Licensed Program, or any intellectual property specifically related to any of the foregoing (with respect to the Licensed Program, the “Program Assets”) owned or controlled by Vividion at any
time, except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this Agreement with respect to the Licensed Program, (b) license or grant to any Third Party, or agree
to license or grant to any Third Party, any rights to any Program Assets owned or controlled by Vividion at any time if such license or grant would fundamentally frustrate the purpose of this Agreement with respect to the Licensed Program, or
(c) disclose any Confidential Information relating to the Program Assets owned or controlled by Vividion at any time to any Third Party if such disclosure would fundamentally frustrate the purpose of this Agreement with respect to the Licensed
Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to the Licensed Program to any Affiliate of Vividion to the extent permitted under Section 15.4. 

(b) Vividion hereby covenants and agrees, subject to Section 13.2(b), that it will defend and hold harmless Celgene and its Affiliates in
the Territory from any Damages resulting from any Claims that, as a result of any Development, Manufacturing or Commercialization, including any making, using, selling, offering for sale, or importing, of any Licensed Product, Celgene or any other
Selling Party has infringed or misappropriated (i) any Patents or Know-How that (A) are owned jointly or solely by Scripps and/or its employees or consultants and (B) (I) arose from any
Development by or on behalf of Vividion of any Licensed Product and/or involved, to the extent provided by Vividion, the use of any Licensed Product, Vividion Intellectual Property and/or other Vividion materials or resources and/or (II) were
discovered, developed, generated or invented by any employee or consultant of Scripps in the conduct of activities under a sponsored research or other agreement or any other arrangement (whether formal or informal) with Vividion and (ii) any
Patents or Know-How licensed to Vividion under the Scripps License (any such claims under clauses (i) or (ii) above, the “Scripps Claims”). Notwithstanding anything to the contrary in
this Agreement, in the event of any Scripps Claim, Vividion hereby covenants and agrees to sublicense to Celgene (with the right to sublicense in accordance with Section 8.2 and Section 8.3) any Patents or
Know-How that are the subject of such Scripps Claim, all as reasonably necessary or desirable in order to enable Celgene and its Selling Parties to Develop, Manufacture, Commercialize, make, use, sell, offer
for sale, or import the Shared Product throughout the Territory in accordance with this Agreement without any royalty or other financial obligation on account of such sublicense. 

  
 - 52 - 

 Section 12.5 Disclaimer. Except as otherwise expressly set forth in this
Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success
of any study or test commenced under this Agreement; (b) the safety or usefulness for any purpose of the technology or materials, including any Licensed Product or Companion Diagnostic; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. 

Article XIII. 

Indemnification; Product Liabilities 

Section 13.1 By Celgene. 

(a) Celgene Indemnification Obligation. Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless
Vividion and its Affiliates and their respective directors, officers, employees and agents (the “Vividion Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Celgene of any of its representations, warranties or obligations under this Agreement; 

(ii) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee Partners or Third Party
Contractors in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; or 
 (iii) any
Development, use, Manufacture or Commercialization of Licensed Products by or on behalf of Celgene or any of its Affiliates or Licensee Partners, including all Product Liabilities Claims arising from Licensed Products distributed by or on behalf of
Celgene or any of its Affiliates or Licensee Partners or Third Party Contractors; provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this
Section 13.1(a)(iii) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in
his/her capacity as a director, officer, shareholder or employee of Vividion, as applicable; 
 in each case, provided, however, that such indemnity
shall not apply to the extent Vividion has an indemnification obligation pursuant to Section 13.2 for such Damages. 

  
 - 53 - 

 (b) Indemnification Procedures. In the event of any such Claim against any of the
Vividion Indemnified Parties by any Third Party, Vividion shall promptly, and in any event within [***] Business Days, notify Celgene in writing of the Claim. Celgene shall have the right, exercisable by notice to Vividion within [***] Business Days
after receipt of notice from Vividion of the Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Celgene agrees
to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by Celgene to Vividion) with counsel selected by Celgene and reasonably acceptable to Vividion; provided, however, that the failure to provide timely
notice of a Claim by a Third Party shall not limit a Vividion Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to Celgene. The Vividion Indemnified Parties shall cooperate
with Celgene and may, at their option and expense, be separately represented in any such action or proceeding. Celgene shall not be liable for any litigation costs or expenses incurred by the Vividion Indemnified Parties without Celgene’s prior
written authorization for so long as Celgene controls such litigation. In addition, Celgene shall not be responsible for the indemnification or defense of any Vividion Indemnified Party to the extent arising from any negligent or intentional acts by
any Vividion Indemnified Party or the breach by Vividion of any representation, obligation or warranty under this Agreement, or any Claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate
Damages indemnified under this Section 13.1. 
 Section 13.2 By Vividion. 

(a) Vividion Indemnification Obligation. Vividion agrees, at Vividion’s cost and expense, to defend, indemnify and hold harmless
Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Vividion of any of its representations, warranties or obligations under this Agreement (including without limitation
pursuant to Section 12.4(b)); 
 (ii) the gross negligence, willful misconduct or violation of Law of Vividion or its Affiliates, or
following termination of this Agreement where Section 14.4(a) is applicable, its Licensee Partners, in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any Development, use, Manufacture or Commercialization of Licensed Products by or on behalf of Vividion or any of its Affiliates or
(sub)licensees following any reversion of rights to Vividion pursuant to Section 14.4, including all Product Liabilities Claims arising from Licensed Products distributed by or on behalf of Vividion or any of its Affiliates or (sub)licensees
following any reversion of rights to Vividion pursuant to Section 14.4; provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the Celgene Indemnified Parties under this Section 13.2(a)(iii)
from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim brought against Celgene Indemnified Parties by any director, officer, shareholder or employee of Celgene acting in his/her capacity as a
director, officer, shareholder or employee of Celgene, as applicable; or 

  
 - 54 - 

 (iv) any of the matters disclosed by Vividion in a disclosure schedule pursuant to
Section 12.2, where the cause of action underlying such Damages accrued prior to the Execution Date. For the avoidance of doubt, amounts payable under Third Party licenses entered into under Section 9.3(b) shall be borne by Celgene as set
forth in Section 9.3(b), and shall not be subject to indemnification under this Section 13.2; 
 in each case, provided, however, that such
indemnity shall not apply to the extent Celgene has an indemnification obligation pursuant to Section 13.1 for such Damages. 
 (b)
Indemnification Procedures. In the event of any such Claim against any of the Celgene Indemnified Parties by any Third Party, Celgene shall promptly, and in any event within [***] Business Days, notify Vividion in writing of the Claim.
Vividion shall have the right, exercisable by notice to Celgene within [***] Business Days after receipt of notice from Celgene of the Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Claim (provided that such Claim is solely for monetary damages and Vividion agrees to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by Vividion to Celgene) with counsel selected by Vividion and
reasonably acceptable to Celgene; provided, however, that the failure to provide timely notice of a Claim by a Third Party shall not limit a Celgene Indemnified Party’s right for indemnification hereunder except to the extent such
failure results in actual prejudice to Vividion. The Celgene Indemnified Parties shall cooperate with Vividion and may, at their option and expense, be separately represented in any such action or proceeding. Vividion shall not be liable for any
litigation costs or expenses incurred by the Celgene Indemnified Parties without Vividion’s prior written authorization for so long as Vividion controls such litigation. In addition, Vividion shall not be responsible for the indemnification or
defense of any Celgene Indemnified Party to the extent arising from any negligent or intentional acts by any Celgene Indemnified Party or the breach by Celgene of any representation, obligation or warranty under this Agreement, or any Claims
compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 13.2. 

Section 13.3 Product Liability Costs. Except with respect to such portion (if any) of Product Liabilities that are Claims entitled
to indemnification under Section 13.1 or Section 13.2, all Damages (including all Product Liabilities) incurred in connection with any litigation or proceeding relating to any Third Party products liability claim or other action relating
to alleged defects in any Licensed Product (whether design defects, manufacturing defects or defects in sales or marketing) shall be borne solely by [***]. 

Section 13.4 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF SECTION 8.6 OR ARTICLE XI, OR A PARTY’S LIABILITY
PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT
OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 

  
 - 55 - 

 Section 13.5 Insurance. Beginning on the commencement of the first Clinical
Trial of a Licensed Product and thereafter during the Term, Celgene shall maintain, at [***] cost, a program of insurance and/or self-insurance against liability and other risks associated with its activities and obligations under this Agreement,
including as applicable Celgene’s Clinical Trials, the Commercialization of any Licensed Product, and Celgene’s indemnification obligations hereunder, in such amounts, subject to such deductibles and on such terms as are customary for
Celgene for the activities to be conducted by it under this Agreement. 
 Article XIV. 

Term and Termination 

Section 14.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to
Section 14.3, shall remain in effect until it expires (the “Term”) as follows: 
 (a) on a Licensed Product-by-Licensed Product and country-by-country basis, this Agreement shall expire on the
date of the expiration of the Royalty Term with respect to such Licensed Product in such country; and 
 (b) this Agreement shall expire in
its entirety upon the expiration of all applicable Royalty Terms under this Agreement with respect to all Licensed Products in all countries in the Territory. 

For the avoidance of doubt, this Agreement shall not be effective until the Effective Date, and this Agreement may be subject to termination prior to the
Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Licensed Program shall revert to Vividion in accordance with Section 3.2 of the Master Agreement. 

Section 14.2 Effect of Expiration. After the expiration of the Term pursuant to Section 14.1 above, the following terms shall
apply: 
 (a) Licenses after Licensed Product Expiration. After expiration of the Term (but not after early termination) with respect
to any Licensed Product in a country in the Territory pursuant to Section 14.1(a), the rights and licenses granted to Celgene hereunder to the Vividion Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology to
Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize such Licensed Product and related Companion Diagnostics in the Field in such country shall convert to irrevocable,
non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers, in such country; provided, however, that, following such expiration and notwithstanding Section 9.3,
(i) Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and
(ii)), solely with respect to Celgene’s exercise of such rights. 
 (b) Licenses after Expiration of Agreement. After expiration
of the Term (but not after early termination) with respect to this Agreement in its entirety pursuant to Section 14.1(b), the rights and licenses granted to Celgene hereunder to the Vividion Intellectual Property, Joint Inventions, Joint
Patents and Manufacturing Technology to Develop, use, Manufacture, have 

  
 - 56 - 

 
Manufactured, offer for sale, sell, import and otherwise Commercialize Licensed Products and Companion Diagnostics in the Field worldwide shall convert to irrevocable, non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers; provided, however, that, following such expiration and notwithstanding Section 9.3, (i) Celgene shall be
solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect
to Celgene’s exercise of such rights. 
 Section 14.3 Termination. 

(a) Termination for Convenience. Celgene shall have the right to terminate this Agreement in its entirety for convenience upon ninety
(90) days’ prior written notice to Vividion; provided that Celgene shall not have the right to terminate this Agreement until twelve (12) months following the Effective Date (it being understood and agreed that Celgene shall be
entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

(b) Termination for Material Breach. 

(i) Termination by Either Party for Breach. Subject to Section 14.3(b)(ii) (with respect to a Material Breach by either Party of
its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that fundamentally frustrates the transactions contemplated
by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such Material Breach within ninety (90) days after the date of
written notice to the breaching Party of such breach (or thirty (30) days, in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.3(b)(ii) with respect to a Material
Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section 14.3(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as to a
Material Breach under this Agreement will run from the date that written notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement under this
Section 14.3(b)(i) shall become effective at the end of the Cure Period, unless the breaching Party has cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within
the Cure Period, then, the non-breaching Party’s right of termination shall be suspended only if and for so long as the breaching Party has provided to the
non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits
to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five (225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the totality of the circumstances with respect to this Agreement will be taken into account and assessed as a whole for
purposes of determining whether a breach is a Material Breach under this Agreement. 

  
 - 57 - 

 (ii) Additional Procedures for Termination by either Party for Failure of the Other
Party to Use Commercially Reasonable Efforts. If either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.3(b)(i) for the other Party’s Material Breach of its obligations to use Commercially
Reasonable Efforts, it shall provide to such other Party a written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially Reasonable Efforts,” and shall
state the reasons and justification for such termination and recommending steps which such Party believes the other Party should take to cure such alleged breach. For any such notice of breach by a Party, the Cure Period shall, subject to
Section 14.3(b)(iii), be one hundred and eighty (180) days, and shall become effective in accordance with Section 14.3(b)(i). 

(iii) Disagreement as to Material Breach. If the Parties reasonably and in good faith disagree as to whether there has been a Material
Breach, then, subject to Section 15.1: (A) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within thirty (30) days following such notice of alleged Material Breach for
resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter, whether or not a Material Breach has occurred pursuant to this
Section 14.3(b); (B) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such
dispute in accordance with the applicable provisions of this Agreement (provided that, if such dispute relates to payment, the Cure Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed
amounts), (C) it is understood and agreed that, during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and
(D) if it is finally and conclusively determined in accordance with Section 15.2 that the breaching Party committed such Material Breach, then the breaching Party shall have the right to cure such Material Breach after such determination
within the Cure Period (provided, that if such dispute relates to a failure to use Commercially Reasonable Efforts, such post-determination Cure Period shall be strictly limited to thirty (30) days and any cure within such thirty (30) day
period must fully cure such breach prior to the end of such thirty (30) day period). 
 (iv) If the Executive Officers are unable to
resolve a dispute within such ten (10) Business Day period after it is referred to them, the matter will be resolved as provided in Section 15.2. 

(v) Payments. No milestone payments by Celgene will be due on milestones achieved during the period between the notice of termination
under this Section 14.3(b) and the effective date of termination; provided, however, that (A) if either Party provides notice of a dispute pursuant to Section 14.3(b)(iii) or otherwise and such dispute is resolved in a manner
in which no termination of this Agreement occurs with respect to such breach or (B) the breaching Party cures the applicable breach during the Cure Period, then upon such resolution or cure Celgene will within five (5) Business Days pay to
Vividion the applicable milestone payment for each milestone achieved during the period between the notice of termination under Section 14.3(b) and the resolution of such dispute or cure of such breach, and if it was determined that Celgene
wrongly asserted breach by Vividion under Section 14.3(b)(iii), then Celgene shall also pay interest on such amount as provided in Section 9.8. 

  
 - 58 - 

 (c) Termination for Insolvency. To the extent permitted by Law, this Agreement may be
terminated by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to, or upon an assignment of a substantial portion of the assets for the benefit of creditors by, the other
Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding, such right to terminate shall only become effective if the non-terminating Party consents to the
involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof. 
 (d)
Termination for Patent Challenge. Either Party shall have the right to terminate this Agreement solely on a Licensed Product-by-Licensed Product basis upon
written notice if the other Party or any of its Affiliates challenges the validity, scope or enforceability of or otherwise opposes any Patent (i) included in the Vividion Intellectual Property and that is licensed to Celgene under this
Agreement in any action or proceeding, or (ii) included in the Celgene Patents or Celgene License Collaboration Patents under this Agreement in any action or proceeding (subject to the exceptions described in this Section 14.3(d), a
“Challenge”) (other than as may be necessary or reasonably required to assert a defense, cross-claim or a counter-claim in an action or proceeding asserted by either Party or any of its Affiliates or Licensee Partners against the
other Party or any of its Affiliates or to respond to a court request or order or administrative law, request or order), it being understood and agreed that either Party’s right to terminate this Agreement under this Section 14.3(d) shall
not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging Party”) that first becomes such an Affiliate as a result of a Change of Control involving the Challenging Party, where such new Affiliate was
undertaking any of the activities described in the foregoing clause prior to such Change of Control; provided that, a Party’s right to terminate this Agreement under this Section 14.3(d) shall apply to actions undertaken by such new
Affiliate if the Challenging Party is the acquiror in such Change of Control and such new Affiliate does not terminate or otherwise cease participating in such action, proceeding, challenge or opposition within thirty (30) days after the
effective date of such Change of Control. If a Licensee Partner of Celgene challenges the validity, scope or enforceability of or otherwise opposes any Patent included in any of the intellectual property described in this Section 14.3(d) under
which such Licensee Partner is sublicensed in any action or proceeding, then Celgene shall, upon written notice from Vividion, terminate such sublicense. For the avoidance of doubt, an action by a Party or any of its Affiliates (collectively the
“Pursuing Party”) in accordance with this Agreement or the Master Agreement to amend claims within a pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent
application or in defense of a Third Party proceeding, or to make a negative determination of patentability of claims of a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing
Party’s Prosecution of such pending patent application, shall not constitute a challenge under this Section 14.3(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any
Confidential Information of the other Party or any nonpublic information regarding the Prosecution or enforcement of any Vividion Patents, Celgene License Collaboration Patents or Joint Patents to which a Party or any of its Affiliates or Licensee
Partners are or become privy as a consequence of the rights granted to Celgene pursuant to Article X, in initiating, requesting, making, filing or maintaining, or in funding or otherwise assisting any other Person with respect to, any Challenge.

 Section 14.4 Effects of Termination. 

(a) Effects of Celgene Termination for Convenience or Vividion Termination for Celgene Breach, Insolvency or Patent Challenge. Upon
termination of this Agreement by Celgene under Section 14.3(a) or by Vividion under Section 14.3(b), 14.3(c) or 14.3(d), the following shall apply: 

  
 - 59 - 

 (i) all licenses granted by Vividion to Celgene under Section 8.1 shall terminate
(A) in their entirety if pursuant to Section 14.3(a), (b) or (c), and (B) with respect to the corresponding Licensed Product if pursuant to Section 14.3(d); 

(ii) Celgene shall (x) grant to Vividion an exclusive (even as to Celgene and its Affiliates), worldwide right and license in the Field,
with the right to grant sublicenses (in accordance with Section 8.3, mutatis mutandis), under Celgene’s rights in the Celgene License Collaboration Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology
to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the terminated Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products, and (y) covenants (on
behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion
or its Affiliates or their respective (sub)licensees, in any case claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating Celgene Intellectual Property,
but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective (sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise
Commercializing the Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products; 
 (iii) Celgene
shall be released from its Development, Manufacture and Commercialization obligations (except as set forth in Section 14.4(a)(vii) and Section 14.4(a)(viii) below with respect to Celgene’s transfer of Manufacturing to Vividion
hereunder); 
 (iv) within [***] days after such termination, Celgene shall provide to Vividion a fair and accurate summary report of the
status of Development and Commercialization activities conducted by Celgene with respect to the Licensed Products; 
 (v) Celgene shall
promptly transfer and assign to Vividion all of Celgene’s and its Affiliates’ rights, title and interests in and to the Product Trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene and
solely used for Licensed Products in the Territory; 
 (vi) Celgene shall as soon as reasonably practicable transfer and assign to Vividion
all Regulatory Approvals and Regulatory Documentation with respect to the Licensed Products in the Territory and a copy of all of the data comprising the global safety database for the Licensed Products and any related Companion Diagnostics;
provided that Celgene may retain such data and a single copy of such Regulatory Approvals and Regulatory Documentation for its records; and provided further that, if such Regulatory Approvals or Regulatory Documentation are necessary or
useful for the Development, Manufacture or Commercialization of any product other than the Licensed Products, in place of transferring or assigning the foregoing, Celgene shall instead grant Vividion a Right of Reference or Use with respect to such
approvals or documentation with respect to the Licensed Products in the Territory; 

  
 - 60 - 

 (vii) Vividion shall have the option, exercisable within [***] days following the effective
date of such termination of this Agreement, to obtain Celgene’s inventory of the Licensed Products at a price equal to [***] percent ([***]%) of Celgene’s Manufacturing costs for such inventory of the Licensed Products; provided
that, if Celgene, its Affiliates or Licensee Partners have outstanding orders, at Vividion’s election, either Vividion shall fulfill such orders or, notwithstanding Vividion’s option to purchase inventory, Celgene may retain sufficient
inventory to fulfill such orders. Vividion may exercise such option by written notice to Celgene during such [***]-day period; provided that, in the event Vividion exercises such right to purchase such
inventory, Celgene shall grant, and hereby does grant, a royalty-free right and license to any trademarks, names and logos of Celgene contained therein for a period of [***] months solely to permit the orderly sale of such inventory, subject to
Vividion meeting reasonable quality control standards imposed by Celgene on the use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 

(viii) at Vividion’s written request: 

(1) in exchange for a payment equal to [***] percent ([***]%) of Celgene’s Manufacturing costs and upon other commercially reasonable
terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable Efforts to supply Vividion and its Affiliates with comparable quantities of the Licensed Products in
the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [***] months after the effective date of the termination and establishment by Vividion of an alternative supply
for such product(s); 
 (2) in the event Celgene was utilizing a Third Party manufacturer to Manufacture the Licensed Products, to the
extent permitted by the terms of such contract, Celgene shall promptly assign to Vividion the manufacturing agreements with such Third Party with respect to such product(s); and 

(3) Celgene shall transfer, or have transferred, to Vividion or its designee, pursuant to a technology transfer plan to be mutually agreed by
the Parties, all Manufacturing Technology Controlled by Celgene that is both necessary to Manufacture the Licensed Products as Manufactured by or on behalf of Celgene and its Affiliates prior to termination and has been incorporated in regulatory
documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Licensed Products (or is in the process of being incorporated), and Celgene shall provide reasonable assistance in connection with the transfer
of such Manufacturing Technology to Vividion or its designee, all of which shall be transferred or provided at [***] cost; 
 (ix) separate
transitional activities shall be undertaken with respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How
or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed Products are transferred; 

  
 - 61 - 

 (x) notwithstanding anything to the contrary in Section 8.6, Vividion shall have the
right to pursue the Development, Manufacture and Commercialization of the Licensed Products; and 
 (xi) the provisions of Article X (other
than Section 10.1) shall terminate, and Celgene shall, if applicable, provide reasonable assistance to Vividion and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Vividion with respect to
Vividion Patents, Celgene License Collaboration Patents and Joint Patents then being Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 

(xii) Sell-Down. Unless Vividion exercises its option under Section 14.4(a)(vii), if Celgene, its Affiliates or Licensee Partners
at termination of this Agreement possess Licensed Products, have started the Manufacture thereof or have accepted orders therefor, Celgene, its Affiliates or Licensee Partners shall have the right, for up to [***] year following the date of
termination, to sell their inventories thereof, complete the Manufacture thereof and Commercialize such fully-Manufactured Licensed Product, in order to fulfill such accepted orders or distribute such fully-Manufactured Licensed Product, subject to
the obligation of Celgene to pay Vividion any and all related milestone and royalty payments as provided in this Agreement. 
 (b) Effects
of Celgene Termination for Vividion Breach, Insolvency or Patent Challenge. Upon any termination of this Agreement by Celgene under Section 14.3(b), 14.3(c) or 14.3(d): 

(i) if Celgene has the right to terminate this Agreement pursuant to Section 14.3(b), Section 14.3(c) or Section 14.3(d),
Celgene may elect upon written notice to Vividion, to either: 
 (A) terminate this Agreement in its entirety, if pursuant to
Section 14.3(b) or Section 14.3(c), or with respect to the corresponding Licensed Product, if pursuant to Section 14.3(d), in which case (1) all rights and obligations of the Parties under this Agreement or the corresponding
Licensed Product, respectively, shall terminate, except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and (II) Section 14.4(d), shall
survive such termination, (2) Vividion shall return any Confidential Information of Celgene pursuant to Section 11.6 that is not necessary to practice any licenses retained by Vividion following such termination under this Agreement,
another Development & Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) Sections 14.4(a)(v), (vi) and (vii) shall apply and Celgene (x) shall grant to Vividion an exclusive (even as
to Celgene and its Affiliates), worldwide right and license in the Field, with the right to grant sublicenses (in accordance with Section 8.3, mutatis mutandis), under Celgene’s rights in Celgene License Collaboration Intellectual
Property, Joint Inventions, Joint Patents and Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer 

  
 - 62 - 

 
for sale, sell, import and otherwise Commercialize the terminated Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products, and (y) covenants (on
behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion
or its Affiliates or their respective (sub)licensees, in any case claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating Celgene Intellectual Property,
but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective (sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise
Commercializing the Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products; or 
 (B) maintain
this Agreement in full force and effect (foregoing, for the avoidance of doubt, the right to terminate this Agreement for such occurrence of such breach) and, with respect to the Licensed Product(s) that are the subject of the applicable breach by
Vividion, all future milestones and royalty obligations in respect of such Licensed Products payable by Celgene under this Agreement following such election shall be subject to a reduction of [***] percent ([***]%). 

(ii) If Celgene has made the election set forth in Section 14.4(b)(i)(B), each Party shall be released from its Development, Manufacture
and Commercialization obligations; 
 (iii) If Celgene has made the election set forth in Section 14.4(b)(i)(B), the license granted by
Vividion to Celgene in Section 8.1 shall convert to an exclusive, irrevocable, non-terminable license, with the right to grant sublicenses; provided that, notwithstanding Section 9.3, (A)
Celgene shall be solely responsible for all payments owed to any Third Party licensors (without any right to offset any such amounts against royalties payable to Vividion hereunder) and (B) Celgene shall be responsible for complying with the
terms of any license agreements with such Third Party licensors, in each case ((A) and (B)), solely with respect to Celgene’s exercise of such rights. 

(iv) If Celgene has made the election set forth in Section 14.4(b)(i)(B), the rights of Vividion in Article X (other than
Section 10.1) shall be terminated and Vividion shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Celgene with respect to Vividion
Patents, including execution of such documents as may be necessary to effect such transition. 
 (v) If Celgene has made the election set
forth in Section 14.4(b)(i)(A), separate transitional activities shall be undertaken with respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory
Documentation, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed Products are transferred. 

  
 - 63 - 

 (c) In the case of any termination of this Agreement, if any Clinical Trials are then being
conducted at the time of such termination with respect to any Licensed Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials, and (ii) notwithstanding anything to the contrary contained
herein, to grant to the Party that retains global Commercialization rights to such Licensed Product following such termination (A) free of charge, copies of and a Right of Reference or Use to all Licensed Product Data that is Controlled by such
Party and generated pursuant to such Clinical Trials that are relevant to or necessary to address issues relating to: (1) the safety of such Licensed Product in the Territory, including data that is related to adverse effects experienced with
such Licensed Product or (2) all activities relating to CMC regarding such Licensed Product and in each of (1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data
become available, and (B) copies of and a Right of Reference or Use to all Licensed Product Data (other than the Licensed Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such
Clinical Trials that are relevant to or necessary to address the Development and Commercialization of such Licensed Product promptly following the generation of such Licensed Product Data if, but only if, as to such Licensed Product Data described
in this subclause (B), such Party that retains global Commercialization rights to such Licensed Product following such termination promptly pays for all Development costs incurred following any such termination of this Agreement with respect to such
Clinical Trials. For purposes of this Section 14.4(c), “Licensed Product Data” means all relevant Data included in the Know-How Controlled by either Party in relation to Licensed Products
for use in the Field either: (x) as of the Execution Date; or (y) generated from the applicable Clinical Trials. 
 (d)
Survival. Upon any termination or expiration of this Agreement, unless otherwise specified in this Agreement and except for any rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and
obligations of each Party under this Agreement shall terminate in whole or with respect to the terminated Licensed Product(s), as the case may be; provided, however, that Section 2.2, Section 8.7, Section 8.8,
Section 9.2(c), Section 9.4, Section 9.5, Section 9.6, Section 9.7, Section 9.8, Section 9.9, Section 9.10, Section 10.1, Section 11.5, Section 11.6, Section 12.5, Section 13.1,
Section 13.2, Section 13.3, Section 13.4, Section 14.4, and Sections 15.2-15.17, as well as any other provision which by its terms or by the context thereof is intended to survive, shall
survive any such termination or expiration of this Agreement. 
 (e) Equitable Relief. Termination of this Agreement shall be in
addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such
breach was the reason for the termination. 
 (f) Accrued Liabilities. Except as otherwise specifically provided herein, termination
of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective
terms for obligations or undertakings following the expiration of the term of this Agreement. 

  
 - 64 - 

 (g) Relationship to Other Agreements. Termination or expiration of this Agreement
shall not affect in any way the terms or provisions of the Master Agreement or any other then-existing executed Development & Commercialization Agreement. 

Article XV. 

Miscellaneous 

Section 15.1 Dispute Resolution. The Parties agree that any disputes arising with respect to the interpretation, enforcement,
termination or invalidity of this Agreement (each, a “Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this
Section 15.1 after discussions between the Executive Officers within ten (10) Business Days after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter in accordance with
Section 15.2. 
 Section 15.2 Submission to Court for Resolution. Subject to Section 15.1, the Parties hereby
irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and
agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or
proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit
or proceeding brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.6 shall be effective
service of process for any action, suit or proceeding brought against it under this Agreement in any such court. Notwithstanding anything to the contrary in this Section 15.2, each Party shall have the right to institute judicial proceedings
against the other Party or anyone acting by, through or under such other Party, in any court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific performance,
injunction or similar equitable relief. 
 Section 15.3 Governing Law. This Agreement and all questions regarding its validity
or interpretation, or the performance or breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

Section 15.4 Assignment. 

(a) Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by either Party
(whether by operation of law or otherwise) without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s written consent, assign this Agreement and its rights and obligations
hereunder in whole or in part to (i) an Affiliate of such Party or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party
to which the subject matter of this Agreement relates; provided that the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement. The assigning Party will remain responsible for the performance
by its assignee of this Agreement or any obligations hereunder so assigned. 

  
 - 65 - 

 (b) In the event the Implementation Date for this Agreement has not occurred within [***]
days following the Execution Date, Celgene shall be entitled to assign this Agreement to any pharmaceutical company or any Affiliate thereof if required by any Antitrust Law; provided that, the right to assign set forth in this
Section 15.4(b) shall not apply if a breach by Celgene of its obligations under Section 8.6(a) is a material cause of the failure to obtain clearance under Antitrust Laws. 

(c) All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit of the
successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of this Section 15.4 will be null and void ab initio. 

(d) Change of Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual property rights
controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of either Party, such intellectual
property rights shall not be included in the technology and intellectual property rights licensed to the other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant Party to this Agreement or any Affiliate of
a Party immediately before such Change of Control) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration, Licensed Products, or related Companion
Diagnostics. The Vividion Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the Collaboration, Licensed
Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement. 

Section 15.5 Force Majeure. If the performance of any part of this Agreement by a Party is prevented, restricted, interfered with
or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood, embargo, power shortage or failure, acts of war or
terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure event”), such Party shall, upon giving written notice to the
other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

Section 15.6 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices required or permitted to
be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing
evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or (c) above), to
the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 

  
 - 66 - 

			
	 To Vividion:
 Vividion Therapeutics, Inc.

3565 General Atomics Ct., Suite 100
 San Diego, CA 92121

Attention: Chief Executive Officer
 Telephone:
	  	 To Celgene:
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Senior Vice President Business Development

Telephone:
 Facsimile:

	  
 With a copy to:

 
 Vividion Therapeutics, Inc.

3565 General Atomics Ct., Suite 100
 San Diego, CA 92121

Attention: Legal Department
 Telephone:
	  	  
 With a copy to:

 
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Legal Department
 Telephone:

Facsimile:

	  
 and

 
 WilmerHale

60 State Street
 Boston, MA 02109

Attention:     Steven D. Singer

                     Steven D. Barrett

Telephone:
 Facsimile:
	  	  
 and

 
 Dechert LLP

1900 K St. NW
 Washington, DC 20006

Attention: David E. Schulman
 Telephone:

Facsimile:

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.7 Waiver. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a
written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s
rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or
term. 
 Section 15.8 Severability. If any provision of this Agreement should be held invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect
in such jurisdiction and 

  
 - 67 - 

 
shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal
or unenforceable provision of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed
that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 Section 15.9
Entire Agreement. This Agreement (including the Exhibits attached hereto), together with the Master Agreement and the CCB Program MTA, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all
prior and contemporaneous agreements, representations or understandings, either written or oral, between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or
understandings, either oral or written, between the Parties other than as set forth herein and therein. 
 Section 15.10
Modification. No modification, amendment or addition to this Agreement, or any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall
be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.11 Independent Contractors; No Intended Third Party Beneficiaries. This Agreement is not intended nor shall be deemed
or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any
liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor to bind the other Party to any contract, agreement or
undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2, and (b) except for any licensor under any Existing
Third Party Agreement. 
 Section 15.12 Interpretation; Construction. The captions to the several Articles and Sections of this
Agreement are included only for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires otherwise, (a) the
words “including,” “include,” “includes,” “such as” and “e.g.” shall be deemed to be followed by the phrase “without limitation” or like expression, whether or not followed by the
same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words “herein” or
“hereunder” relate to this Agreement; (e) the word “or” is used in the inclusive sense that is typically associated with the phrase “and/or”; (f) the word “will” shall be construed to have the same
meaning and effect as the word “shall”; and (g) all references to “dollars” or “$” herein shall mean U.S. Dollars and (h) a capitalized term not defined herein but reflecting a different part of speech from
that of a capitalized term which is defined herein shall be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the
drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

  
 - 68 - 

 Section 15.13 Performance by Affiliates. A Party may perform any obligation this
Agreement imposes on such Party through any of such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

Section 15.14 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an
original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an
“Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in
person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or defense with
respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

Section 15.15 HSR Clearance; Cooperation. For the avoidance of doubt, the Parties shall continue to comply with Section 3.2
of the Master Agreement. 
 Section 15.16 Equitable Relief. Notwithstanding anything to the contrary herein, the Parties shall
be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition
to all other remedies available at law or equity. 
 Section 15.17 Further Assurances. Each Party shall execute, acknowledge and
deliver such further instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Remainder of page intentionally left blank] 

  
 - 69 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Execution Date. 

 

			
	VIVIDION THERAPEUTICS, INC.

 
			
		
	By:	 	  

 
			
	Name:	 	  

 
			
	Title:	 	  

 
			
	
	CELGENE CORPORATION

 
			
		
	By:	 	  

 
			
	Name:	 	  

 
			
	Title:	 	  

 Exhibit A 

Licensed Target, Licensed Compound(s) and Licensed Program 

  
 A-1 

 Exhibit B 

Vividion Patents and Celgene License Collaboration Patents 

Vividion Patents 
 (as of
the Execution Date) 
 Celgene License Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

[Parties to identify each applicable Existing Third Party Agreement referenced in the Opt-In Data Package and
each provision thereof that must be included in this Agreement, including for Third Party Programs and Third Party Licenses] 

  
 C-1 

 Schedule 12.2(i) 

Patents 

 APPENDIX B-2 

FORM OF E3 LIGASE BINDER PROGRAM LICENSE AGREEMENT 

  
 [Appendix B-2]-1 

 APPENDIX C 

FORM OF CCB PROGRAM MTA 
  

  
 Appendix C-1 

 APPENDIX D 

FORM OF COMMON INTEREST AGREEMENT 

  
 Appendix D-1 

 APPENDIX E 

FORM OF PRESS RELEASE 
  

  
 Appendix E-1 

 APPENDIX F 

FORM OF E3 LIGASE BINDER PROGRAM MTA 
  

  
 Appendix F-1 

 SCHEDULE 1.1.32 

DATA 

  
 1.1.32-1 

 SCHEDULE 1.1.34 

DEAL E3 LIGASES 

  
 1.1.34-1 

 SCHEDULE 1.1.35 

DEAL TARGETS 

  
 1.1.35-1 

 SCHEDULE 1.1.56 

FUNCTIONAL PHENOTYPIC ASSAY SIMILARITY CRITERIA 

  
 1.1.56-1 

 SCHEDULE 1.1.91 

PUBLICATION GUIDELINES 
  

  
 1.1.91-1 

 SCHEDULE 9.2.9 

VIVIDION PATENTS 

  
 9.2.9-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]